0001681622-19-000083.txt : 20191220 0001681622-19-000083.hdr.sgml : 20191220 20191220172454 ACCESSION NUMBER: 0001681622-19-000083 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 127 CONFORMED PERIOD OF REPORT: 20190927 FILED AS OF DATE: 20191220 DATE AS OF CHANGE: 20191220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Varex Imaging Corp CENTRAL INDEX KEY: 0001681622 STANDARD INDUSTRIAL CLASSIFICATION: ELECTRONIC COMPONENTS, NEC [3679] IRS NUMBER: 813434516 STATE OF INCORPORATION: DE FISCAL YEAR END: 0927 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37860 FILM NUMBER: 191302762 BUSINESS ADDRESS: STREET 1: 1678 S. PIONEER ROAD CITY: SALT LAKE CITY STATE: UT ZIP: 84104 BUSINESS PHONE: 801-972-5000 MAIL ADDRESS: STREET 1: 1678 S. PIONEER ROAD CITY: SALT LAKE CITY STATE: UT ZIP: 84104 10-K 1 varex10k2019.htm 10-K Document
false--09-27FY201900016816220.010.0115000000015000000038026597383713053802659738371305P5Y00300000000.010.012000000020000000000P12M01000000.10.0750.0750.0537.6022.6337.6022.6337.6022.6331.0831.0827.7722.8431.4231.42 0001681622 2018-09-29 2019-09-27 0001681622 2019-11-18 0001681622 2019-03-29 0001681622 2017-09-30 2018-09-28 0001681622 2016-10-01 2017-09-29 0001681622 2018-09-28 0001681622 2019-09-27 0001681622 2017-09-29 0001681622 2016-09-30 0001681622 us-gaap:CommonStockMember 2018-09-29 2019-09-27 0001681622 us-gaap:CommonStockMember 2017-09-30 2018-09-28 0001681622 us-gaap:CommonStockMember 2017-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-09-29 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2017-09-30 2018-09-28 0001681622 us-gaap:ParentMember 2017-09-30 2018-09-28 0001681622 us-gaap:RetainedEarningsMember 2017-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2017-09-29 0001681622 us-gaap:CommonStockMember 2016-10-01 2017-09-29 0001681622 us-gaap:NoncontrollingInterestMember 2018-09-29 2019-09-27 0001681622 us-gaap:ParentMember 2016-10-01 2017-09-29 0001681622 var:NetParentInvestmentMember 2016-09-30 0001681622 us-gaap:RetainedEarningsMember 2016-10-01 2017-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 2018-09-28 0001681622 us-gaap:CommonStockMember 2016-09-30 0001681622 us-gaap:RetainedEarningsMember 2017-09-30 2018-09-28 0001681622 var:NetParentInvestmentMember 2016-10-01 2017-09-29 0001681622 var:NetParentInvestmentMember 2018-09-28 0001681622 us-gaap:RetainedEarningsMember 2018-09-29 2019-09-27 0001681622 us-gaap:AdditionalPaidInCapitalMember 2017-09-29 0001681622 var:NetParentInvestmentMember 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:ParentMember 2016-09-30 0001681622 us-gaap:RetainedEarningsMember 2019-09-27 0001681622 us-gaap:CommonStockMember 2018-09-28 0001681622 us-gaap:ParentMember 2018-09-29 2019-09-27 0001681622 us-gaap:ParentMember 2018-09-28 0001681622 us-gaap:ParentMember 2019-09-27 0001681622 us-gaap:RetainedEarningsMember 2016-09-30 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 2018-09-28 0001681622 us-gaap:AdditionalPaidInCapitalMember 2016-10-01 2017-09-29 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-10-01 2017-09-29 0001681622 us-gaap:RetainedEarningsMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-29 2019-09-27 0001681622 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:CommonStockMember 2019-09-27 0001681622 var:NetParentInvestmentMember 2017-09-29 0001681622 us-gaap:NoncontrollingInterestMember 2016-09-30 0001681622 us-gaap:ParentMember 2017-09-29 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-29 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-09-30 2018-09-28 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-09-29 2019-09-27 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2016-10-01 2017-09-29 0001681622 srt:MinimumMember 2018-09-29 2019-09-27 0001681622 us-gaap:LandImprovementsMember 2018-09-29 2019-09-27 0001681622 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2018-09-29 2019-09-27 0001681622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-28 0001681622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-03-29 0001681622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-09-27 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-09-30 2018-09-28 0001681622 var:VarianMedicalSystemsInc.Member 2017-01-28 0001681622 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2018-09-29 2019-09-27 0001681622 srt:MaximumMember 2018-09-29 2019-09-27 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-09-29 2019-09-27 0001681622 us-gaap:BuildingMember 2018-09-29 2019-09-27 0001681622 srt:RestatementAdjustmentMember 2017-09-30 2018-09-28 0001681622 us-gaap:MachineryAndEquipmentMember 2019-09-27 0001681622 us-gaap:MachineryAndEquipmentMember 2018-09-28 0001681622 var:BuildingsandLeaseholdImprovementsMember 2019-09-27 0001681622 us-gaap:ConstructionInProgressMember 2019-09-27 0001681622 us-gaap:LandMember 2019-09-27 0001681622 var:BuildingsandLeaseholdImprovementsMember 2018-09-28 0001681622 us-gaap:LandMember 2018-09-28 0001681622 us-gaap:ConstructionInProgressMember 2018-09-28 0001681622 var:PerkinElmerInc.Member 2017-05-01 0001681622 var:PerkinElmerInc.Member 2017-05-01 2017-05-01 0001681622 var:DirectConversionABMember us-gaap:DevelopedTechnologyRightsMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:CustomerRelationshipsMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:CustomerRelationshipsMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:DevelopedTechnologyRightsMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:TradeNamesMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:OrderOrProductionBacklogMember 2019-04-29 0001681622 var:DirectConversionABMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:OrderOrProductionBacklogMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:TradeNamesMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:InProcessResearchAndDevelopmentMember 2019-04-29 0001681622 var:DirectConversionABMember 2019-04-29 2019-04-29 0001681622 var:PerkinElmerInc.Member 2016-10-01 2017-09-29 0001681622 var:PerkinElmerInc.Member var:IndustrialMember 2017-05-01 2017-09-29 0001681622 var:PerkinElmerInc.Member 2017-05-01 2017-09-29 0001681622 var:PerkinElmerInc.Member var:MedicalMember 2017-05-01 2017-09-29 0001681622 var:VirtualMediaIntegrationLtd.Member 2018-08-31 2018-08-31 0001681622 var:PerkinElmerInc.Member us-gaap:ForeignCountryMember 2017-05-01 0001681622 var:DirectConversionABMember 2019-04-30 0001681622 var:PerkinElmerInc.Member us-gaap:LeaseAgreementsMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:OrderOrProductionBacklogMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:LeaseAgreementsMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:TradeNamesMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:OrderOrProductionBacklogMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:CustomerRelationshipsMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:DevelopedTechnologyRightsMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:DevelopedTechnologyRightsMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:TradeNamesMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:CustomerRelationshipsMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2017-05-01 0001681622 var:VirtualMediaIntegrationLtd.Member 2018-08-31 0001681622 var:DirectConversionABMember 2019-04-30 2019-09-27 0001681622 var:DirectConversionABMember var:IndustrialMember 2019-04-30 2019-09-27 0001681622 var:DirectConversionABMember var:MedicalMember 2019-04-30 2019-09-27 0001681622 var:VECImagingGmbHCo.KGMember 2018-11-01 2019-09-27 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2019-09-27 0001681622 var:VECImagingGmbHCo.KGMember srt:ScenarioForecastMember 2019-12-17 2019-12-17 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2018-09-29 2019-09-27 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2013-10-01 2013-10-31 0001681622 var:DpiXHoldingMember 2019-09-27 0001681622 var:DpiXHoldingMember 2018-09-29 2019-09-27 0001681622 var:DpiXLLCMember 2019-09-27 0001681622 var:CETTEENGmbHMember var:VECImagingGmbHCo.KGMember 2019-09-27 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2018-09-28 0001681622 var:DpiXHoldingMember 2016-10-01 2017-09-29 0001681622 var:DpiXHoldingMember 2017-09-30 2018-09-28 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2016-10-01 2017-09-29 0001681622 var:VECImagingGmbHCo.KGMember 2019-09-27 0001681622 var:DpiXHoldingMember var:FixedCostCommitmentsMember 2018-09-29 2019-09-27 0001681622 var:DpiXHoldingMember 2018-09-28 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2017-09-30 2018-09-28 0001681622 var:LondonFacilityClosingMember 2017-09-30 2018-09-28 0001681622 var:SantaClaraFacilityRelocationMember 2017-09-30 2018-09-28 0001681622 var:SantaClaraFacilityRelocationMember 2018-09-29 2019-09-27 0001681622 srt:MinimumMember var:SantaClaraFacilityRelocationMember 2019-09-27 0001681622 srt:MaximumMember var:SantaClaraFacilityRelocationMember 2019-09-27 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 currency:CHF us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 currency:CHF us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-10-01 2017-09-29 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 2018-09-28 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-29 2019-09-27 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-29 2019-09-27 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 2018-09-28 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-10-01 2017-09-29 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2018-09-29 2019-09-27 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-10-10 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:BaseRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodOneMember 2017-05-01 2017-05-01 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:BaseRateMember 2017-05-01 2017-05-01 0001681622 var:RevolvingCreditFacilityMay2017Member 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodThreeMember 2017-05-01 2017-05-01 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 var:RevolvingCreditFacilityMay2017Member us-gaap:SubsequentEventMember 2019-10-08 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodFiveMember 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 var:RevolvingCreditFacilityMay2017Member us-gaap:SubsequentEventMember 2019-10-08 2019-10-08 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-10-10 2018-10-10 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:FederalFundsEffectiveSwapRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember 2019-09-27 0001681622 var:OtherDebtMember 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-09-29 2019-09-27 0001681622 us-gaap:SecuredDebtMember 2018-09-29 2019-09-27 0001681622 us-gaap:SecuredDebtMember 2018-09-28 0001681622 us-gaap:SecuredDebtMember 2017-09-30 2018-09-28 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-09-30 2018-09-28 0001681622 var:OtherDebtMember 2018-09-28 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-09-28 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodTwoMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodFourMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodFourMember 2017-01-25 2017-01-25 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodTwoMember 2017-01-25 2017-01-25 0001681622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-27 0001681622 us-gaap:FairValueMeasurementsRecurringMember 2019-09-27 0001681622 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-27 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-27 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-28 0001681622 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-28 0001681622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-28 0001681622 us-gaap:FairValueMeasurementsRecurringMember 2018-09-28 0001681622 var:MedicalMember 2018-09-29 2019-09-27 0001681622 var:IndustrialMember 2018-09-29 2019-09-27 0001681622 var:IndustrialMember 2019-09-27 0001681622 var:MedicalMember 2018-09-28 0001681622 var:IndustrialMember 2018-09-28 0001681622 var:MedicalMember 2019-09-27 0001681622 us-gaap:IntellectualPropertyMember 2018-09-28 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2019-09-27 0001681622 us-gaap:DevelopedTechnologyRightsMember 2018-09-28 0001681622 us-gaap:IntellectualPropertyMember 2019-09-27 0001681622 us-gaap:DevelopedTechnologyRightsMember 2019-09-27 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2018-09-28 0001681622 var:JointVentureInSaudiArabiaMember 2018-09-28 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-04-30 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2019-09-27 0001681622 var:MeVisMedicalSolutionsAGMeVisMember var:MeVisMedicalSolutionsAGMeVisMember 2019-09-27 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-10-31 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-10-01 2015-10-31 0001681622 us-gaap:CostOfSalesMember 2016-10-01 2017-09-29 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2017-09-30 2018-09-28 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-09-29 2019-09-27 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-10-01 2017-09-29 0001681622 us-gaap:CostOfSalesMember 2018-09-29 2019-09-27 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-09-30 2018-09-28 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2016-10-01 2017-09-29 0001681622 us-gaap:CostOfSalesMember 2017-09-30 2018-09-28 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2018-09-29 2019-09-27 0001681622 us-gaap:EmployeeStockMember 2018-09-29 2018-12-28 0001681622 us-gaap:EmployeeStockMember 2018-09-29 2019-09-27 0001681622 us-gaap:EmployeeStockOptionMember 2018-09-29 2019-09-27 0001681622 us-gaap:EmployeeStockOptionMember 2017-09-30 2017-12-29 0001681622 us-gaap:EmployeeStockOptionMember 2018-09-29 2018-12-28 0001681622 us-gaap:EmployeeStockMember 2017-09-30 2017-12-29 0001681622 us-gaap:EmployeeStockMember var:A2017ESPPMember 2017-01-01 2017-01-31 0001681622 us-gaap:EmployeeStockOptionMember var:A2017ESPPMember 2019-09-27 0001681622 us-gaap:EmployeeStockOptionMember var:A2017OmnibusStockPlanMember 2019-09-27 0001681622 us-gaap:EmployeeStockOptionMember 2019-09-27 0001681622 us-gaap:EmployeeStockMember var:A2017ESPPMember 2018-09-29 2019-09-27 0001681622 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-09-29 2019-09-27 0001681622 us-gaap:EmployeeStockMember var:A2017ESPPMember 2017-01-31 0001681622 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:MajorityShareholderMember 2016-10-01 2017-09-29 0001681622 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-09-29 2019-09-27 0001681622 srt:MaximumMember 2019-09-27 0001681622 srt:MinimumMember 2019-09-27 0001681622 srt:MaximumMember 2018-09-28 0001681622 srt:MinimumMember 2018-09-28 0001681622 us-gaap:OperatingSegmentsMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2018-09-28 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2018-09-28 0001681622 us-gaap:OperatingSegmentsMember 2018-09-28 0001681622 srt:LatinAmericaMember 2018-09-29 2019-09-27 0001681622 us-gaap:EMEAMember 2018-09-29 2019-09-27 0001681622 us-gaap:EMEAMember 2018-09-28 0001681622 srt:LatinAmericaMember 2017-09-30 2018-09-28 0001681622 srt:AsiaPacificMember 2018-09-29 2019-09-27 0001681622 srt:AsiaPacificMember 2016-10-01 2017-09-29 0001681622 srt:AsiaPacificMember 2019-09-27 0001681622 country:US 2019-09-27 0001681622 us-gaap:EMEAMember 2019-09-27 0001681622 country:US 2018-09-29 2019-09-27 0001681622 srt:LatinAmericaMember 2018-09-28 0001681622 country:US 2016-10-01 2017-09-29 0001681622 srt:LatinAmericaMember 2016-10-01 2017-09-29 0001681622 srt:LatinAmericaMember 2019-09-27 0001681622 us-gaap:EMEAMember 2016-10-01 2017-09-29 0001681622 country:US 2018-09-28 0001681622 country:US 2017-09-30 2018-09-28 0001681622 srt:AsiaPacificMember 2018-09-28 0001681622 us-gaap:EMEAMember 2017-09-30 2018-09-28 0001681622 srt:AsiaPacificMember 2017-09-30 2018-09-28 0001681622 var:IndustrialMember 2017-09-30 2018-09-28 0001681622 var:MedicalMember 2017-09-30 2018-09-28 0001681622 var:IndustrialMember 2016-10-01 2017-09-29 0001681622 var:MedicalMember 2016-10-01 2017-09-29 0001681622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-29 2019-09-27 0001681622 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-09-29 2019-09-27 0001681622 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-28 0001681622 2018-09-29 0001681622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-09-29 0001681622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-29 2019-09-27 0001681622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-09-27 0001681622 2019-09-28 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:SubsequentEventMember 2019-10-08 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:SubsequentEventMember 2019-10-08 2019-10-08 var:derivative iso4217:USD iso4217:USD xbrli:shares xbrli:pure var:member xbrli:shares var:entity var:employee var:segment iso4217:EUR xbrli:shares


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ____________________________________________________________
FORM 10-K
 ____________________________________________________________
☒
ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the year ended September 27, 2019
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to
Commission File Number 001-37860
 ____________________________________________________________
varex10k2017draft0image1a02.jpg
VAREX IMAGING CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
 
 
81-3434516
(State or other jurisdiction of
incorporation or organization)
 
 
(I.R.S. Employer
Identification Number)
 
 
 
 
1678 S. Pioneer Road
Salt Lake City
Utah
84104
(Address of principal executive offices)
(Zip Code)
(801) 972-5000
(Registrant’s telephone number, including area code)
 ____________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
VREX
The Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No ý
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨ No ý

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   ý No   ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes   ý     No   ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth



company” in Rule 12b-2 of the Exchange Act.
 
 
 
 
 
 
 
 
Large Accelerated filer
 
☒
 
Accelerated filer
 
☐
 
 
 
 
 
 
 
Non-Accelerated filer
 
☐  
 
Smaller reporting company
 
☐
 
 
 
 
 
 
 
 
 
 
 
Emerging growth company
 
☐
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  ☐  No  ☒

As of March 29, 2019, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of shares of the registrant’s common stock held by non-affiliates of the registrant (based upon the closing sale price of such shares on the NASDAQ Global Select Market on March 29, 2019) was approximately $1,160.4 million. Shares of the registrant’s common stock held by the registrant’s executive officers and directors and by each entity that owned 10% or more of the registrant’s outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of November 18, 2019, there were 38,494,349 shares of the registrant’s common stock outstanding.
Documents Incorporated by Reference

Portions of registrant’s proxy statement relating to registrant’s 2020 annual meeting of stockholders have been incorporated by reference in Part III of this annual report on Form 10-K.




VAREX IMAGING CORPORATION
INDEX

 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



1

Forward-Looking Statements
This Annual Report on Form 10-K (this “Annual Report”), including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”) contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a safe harbor for statements about future events, products and financial performance that are based on the beliefs of, estimates made by, and information currently available to the management of Varex Imaging Corporation (“we,” “our,” “us,” the “Company,” “Varex,” or “Varex Imaging”). Actual results and the outcome or timing of certain events described in these forward-looking statements are subject to risk and uncertainties and may differ significantly from those projected in these forward-looking statements. Important factors that could cause our actual results and financial condition to differ significantly from those projections or expectations include, among other things, the following:
•
reduction in or loss of business to key customers;
•
changes in, or our inability to predict and meet, demand for our products;
•
loss of business to, and inability to compete with, competitors;
•
changes in macroeconomic and global geopolitical factors, including changes in regulatory regimes, import and export controls and restrictions (such as tariffs) and global or regional economic stability;
•
our ability to meet the payment and other requirements of our existing bank debt and other contractual obligations;
•
our ability to develop new products and enhance existing products;
•
the ability to identify and remediate significant deficiencies and material weaknesses in internal controls;
•
disruption at our manufacturing facilities and fluctuations in manufacturing costs;
•
changes in our effective tax rate;
•
our inability to source components and raw materials of our products
•
disruption or breach of our critical information technology systems;
•
the results of any product liability or product defect claims, product recalls and other litigation and regulatory investigations;
•
risks related to intellectual property;
•
our ability to hire and retain qualified personnel;
•
the impact of natural and other disasters, power loss, strikes and other events beyond our control; and
•
other factors cited in the Risk Factors listed under Part I, Item 1A of this Annual Report, MD&A and other factors described from time to time in our other filings with the U.S. Securities and Exchange Commission (the “SEC”), or other reasons.
Statements concerning industry or market segment outlook; market acceptance of or transition to new products or technology such as advanced X-ray tube and digital flat panel detector products; growth drivers; future orders, revenues, backlog, earnings or other financial results; and any statements using the terms “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intended,” “potential,” and “possible” or similar statements are forward-looking statements.
Any forward-looking statement made in this Annual Report (including in any exhibits or documents incorporated by reference) is based only on information currently available to Varex and its management and speaks only as of the date on which it is made. We have not assumed any obligation to, and you should not expect us to, update or revise those statements because of new information, future events or otherwise.

PART I

Item 1. Business
Overview

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components including X-ray tubes, digital detectors, linear accelerators and other image processing solutions, which are key components of X-ray imaging systems. Our components are used in medical imaging as well as in industrial and security imaging applications. Global original equipment manufacturers (“OEM”) incorporate our X‑ray imaging components in their systems to detect, diagnose, protect and inspect. As of September 27, 2019, we had approximately 2,000 full-time equivalents employees, located at manufacturing and service center sites in North America, Europe, and Asia. For more information about us, visit vareximaging.com.

Founded as a Delaware corporation in July 2016, Varex was established as an independent publicly-traded company in January 2017 as a result of its spin-off from Varian Medical Systems, Inc. (“Varian”). We expanded our business in May 2017, when we acquired the medical imaging business (“Acquired Detector Business”) of PerkinElmer, Inc. (“PKI”) for $273.3 million. In the transaction, we acquired PerkinElmer Medical Holdings, Inc. and Dexela Limited, together with certain assets of PKI and its direct and indirect subsidiaries relating to digital detectors that serve as components for medical and industrial X-ray imaging systems. In

2

April 2019, we acquired Direct Conversion AB, a manufacturer and marketer of linear array digital detectors utilizing direct conversion and photon counting technology.

Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, Russia, the Middle East, India and Africa. APAC includes Asia and Australia. Revenues by region are based on the known final destination of products sold.

Our success depends, among other things, on our ability to anticipate and respond to changes in our markets, the direction of technological innovation and the demands of our customers. We continue to invest in research and development and employ over 500 engineers. Combining this focus on innovation and product performance with strong long-term customer relationships allows us to partner with our customers to bring industry-leading products to the X-ray imaging market. We continue to work to improve the life and quality of our imaging components and leverage our scale as the largest X-ray imaging component supplier to provide cost-effective solutions for our customers. Demand for our products can also be impacted by geo-political factors, including tariffs on key imported materials used in manufacturing our products and also on X-ray imaging products we sell to customers outside the United States. The escalation of trade conflicts between the United States and China has negatively impacted our business and are expected to continue.

Operating Segments and Products

Our Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), evaluates our product groupings and measures our business performance in two reportable operating segments: Medical and Industrial. The segments align our products and service offerings with customer use in medical and industrial markets and are consistent with how the CODM evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin.
Medical

In our Medical business segment, we design, manufacture, sell and service X-ray imaging components for use in a range of radiographic or fluoroscopic imaging applications including computed tomography (“CT”), mammography, oncology, cardiac, surgery, dental, and computer-aided detection. We provide a broad range of X-ray imaging components for Medical customers, including X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers and buckys.

A significant portion of our revenues come from the sales of high-end X-ray tubes used in CT imaging and high-end dynamic digital detectors used in fluoroscopic and 3D dental imaging applications. These upper-tier imaging components are characterized by increased levels of technological complexity, engineering and intellectual property that typically allow these products to have a higher sales price and gross margin.

The digital detector market continues to mature from initial product introductions that were made approximately 15 years ago. For the past few years, we have experienced price erosion for these products, predominantly in the highly-competitive market for radiographic detectors. We anticipate this trend will continue in the foreseeable future.

Our X-ray imaging components are primarily sold to OEM customers that incorporate our products into their X-ray imaging systems for a variety of medical modalities and industrial applications. To a much lesser extent, we also sell our X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.

In China, the government is broadening the availability of healthcare services throughout the country. As a result, the number of diagnostic X-ray imaging systems, including CT, has grown significantly. We are developing CT tubes and related subsystems for Chinese OEMs as they introduce new CT imaging systems in China. Over the long-term, we anticipate that China-based revenues will increase as a percentage of our revenues. For fiscal year 2019, revenues from X-ray imaging components shipped to China-based OEMs and distributors declined to approximately 8% of total company revenues from 10% in the prior year. This decrease reflects a tariff-related decline in sales of radiographic digital detectors in China as well as lower non-OEM aftermarket sales, which more than offset an increase in sales of CT tubes to OEM customers.

To mitigate the impact of the trade war between the United States and China, we have implemented changes to secure more non-China sources of supply of parts and materials used to manufacture our X-ray imaging products, and in September 2019, we received from the United States Trade Representative a temporary exclusion from Section 301 tariffs on certain parts and components

3

imported from China into the United States. We continue to expand manufacturing capabilities at our facilities in China, Germany and the Philippines.
Industrial

In our Industrial business segment, we design, manufacture, sell and service X-ray imaging products for use in a number of markets, including security applications, such as cargo screening at ports and borders and baggage screening at airports, and nondestructive testing and inspection applications used in a number of other markets. Our industrial products include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors and high voltage connectors. In addition, we provide proprietary image-processing and detection software designed to work with these other Varex products to provide package solutions to our Industrial customers.

The security market primarily consists of airport security for carry-on baggage, checked baggage and palletized cargo, as well as cargo security for the screening of trucks, trains and cargo containers at ports and borders. The end customers for border protection systems are typically government agencies, many of which are in oil-based economies and war zones where there has been significant year over year variation in buying patterns.

The non-destructive testing market utilizes X-ray imaging to scan items for inspection of manufacturing defects and product integrity in a wide range of industries including the aerospace, automotive, oil and gas, food packaging, metal castings and 3D printing industries. We provide X-ray sources, digital detectors, high voltage connectors and image processing software to OEM customers, system integrators and manufacturers. In addition, new applications for X-ray sources are being developed, such as sterilization of food and its packaging.
Customers

Our customers are primarily large OEMs. Our top five customers, measured by revenue, are Canon Medical Systems Corporation (“Canon”), General Electric Company, Elekta AB, Varian Medical Systems, Inc. and Hologic, Inc., which collectively accounted for approximately 38% in fiscal year 2019. Our largest customer, Canon, accounted for approximately 17%, 18% and 19% of our total revenues for fiscal years 2019, 2018, and 2017, respectively, while our ten largest customers as a group accounted for approximately 51%, 49% and 48% of our revenue for fiscal years 2019, 2018 and 2017, respectively. The loss of one or more of our top customers would have a material and adverse effect on our business. For more information, see “Risk Factors-Varex sells its products and services to a limited number of OEM customers, many of which are also its competitors, and a reduction in or loss of business of one or more of these customers may materially reduce its sales.”

Competition

The imaging components market is highly competitive. OEMs may choose to develop and manufacture X-ray imaging components in-house or they may choose to out-source to a supplier such as us or other providers of imaging components. Our success depends upon our ability to anticipate changes in our markets, the direction of technological innovation and the demands of our customers. To remain competitive, we must continue to invest in research and development focused on innovation, improve product performance and quality, and reduce the cost of our imaging components. Significant capital investment is required for imaging component manufacturers. We believe we have sufficient manufacturing scale to leverage our high volume to reduce overall costs by spreading fixed costs over more units.

Medical

We often compete with the in-house X-ray tube manufacturing operations of major diagnostic imaging systems companies, which are the primary OEM customers for our Medical products. To effectively compete with these in-house capabilities, we must have a competitive advantage in one or more significant areas, such as innovative technology and greater product performance, better product quality or lower product price. We sell a significant volume of our X-ray tubes to OEM customers that have in-house X‑ray tube production capability. In addition, we compete with some OEM customers, such as Canon, Philips Healthcare and other companies who sell X-ray tubes to smaller OEMs and other manufacturers, such as Industria Applicazioni Elettroniche S.p.A, as well as emerging X-ray tube manufacturers in China. High capital costs and mastery of complex manufacturing processes that drive production yield and product life are significant characteristics of the X-ray tubes business.

The market for digital detectors is also highly competitive. We sell our digital detectors to a number of OEM customers that incorporate our detectors into their medical diagnostic, oncology, 3D dental and veterinary imaging systems. Our amorphous silicon based digital detector technology, our photon counting technology and our complementary metal-oxide-semiconductor technology

4

competes with other detector technologies, such as amorphous selenium, charge-coupled devices and variations of amorphous silicon scintillators. We believe that our products provide a competitive advantage due to product quality and performance and lower overall product lifecycle costs. In the digital flat panel detector market, we primarily compete against Trixell S.A.S., Canon, Vieworks Co., Ltd., Hamamatsu Corporation, iRay Technology (Shanghai) Limited and Jiangsu CareRay Medical Systems Co., Ltd.

Industrial

In the low-energy market of the Industrial segment, we compete with other OEM suppliers, such as General Electric, Canon, Nuctech Company Limited (“Nuctech”) and Comet AG. While there are other manufacturers of low-energy X-ray tubes and digital detectors for specialized and niche industrial applications, our products are designed for a broad range of applications in inspection, analysis, and testing. In the high-energy market, we compete against technologies from Nuctech, Siemens AG, and Foton Ltd., whose X-ray sources are used in applications that include cargo and container scanning, border security, aerospace applications, castings and pressure vessel inspections.

Customer Services and Support

We generally warranty our products for 12 to 24 months. In certain cases, the warranty also may be specified by usage metrics such as number of scans. We provide technical advice and consultation to major OEM customers from our U.S. offices in Utah, California, Nevada, South Carolina, New York and Illinois; and internationally in the Philippines, China, the Netherlands, Germany, France, Sweden, Switzerland, the United Kingdom, Italy and Japan. Our application specialists and engineers make recommendations to meet the customer’s technical requirements within the customer’s budgetary constraints. We often develop specifications for a unique product that will be designed and manufactured to meet a specific customer’s requirements.

Manufacturing and Supplies

We manufacture our products at facilities located in Salt Lake City, Utah; Santa Clara, California; Las Vegas, Nevada; Liverpool, New York; Franklin Park, Illinois; Dinxperlo and Heerlen, the Netherlands; Walluf and Bremen, Germany; Espoo, Finland and Calamba City, Philippines. These facilities employ state-of-the-art manufacturing techniques and several have been recognized by the press, governments and trade organizations for their commitment to quality improvement. Each of these manufacturing facilities are certified by International Standards Organization (“ISO”) under ISO 9001 (for industrial products) or ISO 13485 (for medical devices). In addition, we have regional service centers in North Charleston, South Carolina; Willich, Germany; and Wuxi, China. The combined medical and industrial manufacturing infrastructure enable us to leverage production scale to achieve productivity and low cost advantage as well as research and development synergies.

Manufacturing processes at our various facilities include machining, fabrication, subassembly, system assembly and final testing. We have invested in various automated and semi-automated equipment for the fabrication and machining of the parts and assemblies that we incorporate into our products. We may, from time to time, invest further in such equipment. Our quality assurance program includes various quality control measures from inspection of raw materials, purchased parts and assemblies through in-line inspection. In some cases, we may outsource the manufacturing of sub-assemblies while still performing system design, final assembly and testing in-house. In such cases, we believe outsourcing enables us to reduce or maintain fixed costs and capital expenditures, while also providing the flexibility to increase production capacity. We purchase material and components from various suppliers that are either standard products or customized to our specifications. Some of the components included in our products may be sourced from a limited group of suppliers or from a single source supplier, such as the wave guides for linear accelerators; transistor arrays and cesium iodide coatings for digital detectors and specialized integrated circuits, X-ray tube targets, housings, bearings and various other components. We require certain raw materials, such as copper, lead, tungsten, iridium, rhenium, molybdenum zirconium, and various high grades of steel alloy for X-ray tubes and industrial products. Worldwide demand, availability and pricing of these raw materials have been volatile, and we expect that availability and pricing will continue to fluctuate in the future.

In the fourth quarter of 2019, we announced the closure of the remainder of our Santa Clara facility and that we would relocate production to other existing facilities. We expect operations at the Santa Clara facility to cease by the end of December 2020 and all activities related to the closure of the facility to be completed by the end of March 2021.


5

Research and Development

Innovation and developing products, systems and services based on advanced technology is essential to our ability to compete effectively in the marketplace. We maintain a research and development and engineering staff responsible for product design and engineering.

Research and development are primarily conducted domestically at our facilities in Salt Lake City, Utah; San Jose and Santa Clara, California; Las Vegas, Nevada; Liverpool, New York; and Franklin Park, Illinois and internationally at our facilities in the Netherlands, Sweden and Germany. Our research and development activities are primarily focused on developing and improving imaging component technology. Current X-ray source development areas include smaller footprint linear accelerators, improvements to tube life and tube stability, reductions of tube noise and tube designs that will enable OEMs to continue to reduce dose delivered, and improve image resolution, cost effectively. Research in digital detector imaging technology is aimed at developing new panel technologies with better dose utilization, improved image quality and materials discrimination, lower product costs and new image processing tools for advanced applications.

Industrial products share some of the same base technology competencies and platforms as medical products and our medical and industrial development teams are therefore co-located in Salt Lake City, San Jose, Santa Clara, Dinxperlo, Danderyd and Walluf. One of our competitive advantages is that some of the foundational technologies and software components developed for medical applications may also be applicable in industrial components, and vice versa. In addition to these product development synergies, we are also able to realize sourcing, production, service center, and logistics synergies across the different products and market sectors.

Product and Other Liabilities

Our business exposes us to potential product liability claims that are inherent in the manufacture, sale, installation, servicing and support of X-ray imaging devices, related software and other devices that contain hazardous material or deliver radiation. Because our products are involved in the intentional delivery of radiation to the human body and other situations where people may come in contact with radiation (for example, when our Industrial products are being used to scan cargo) as well as the detection, planning and treatment of medical problems, the possibility for significant injury or death exists if our products fail to work or are not used properly. We may face substantial liability to patients, our customers and others for damages resulting from the faulty, or allegedly faulty, design, manufacture, installation, servicing, support, testing or interoperability of our products and our customers’ products, or their misuse or failure. We may also be subject to claims for property damages or economic loss related to or resulting from any errors or defects in our products, or the installation, servicing and support of our products. Any accident or mistreatment could subject us to legal costs, litigation, adverse publicity and damage to our reputation, whether or not our products or services were a factor. In addition, if a product we design or manufacture were defective (whether due to design, labeling or manufacturing defects, improper use of the product or other reasons), or found to be so by a regulatory authority, we may be required to correct or recall the product and notify other regulatory authorities. We maintain limited product liability, professional liability and omissions liability insurance coverage.

Government Regulation

U.S. Regulations

Laws governing marketing a medical device. In the United States, as a manufacturer and seller of medical devices and devices emitting radiation or utilizing radioactive by-product material, we and some of our suppliers and distributors are subject to extensive regulation by federal governmental authorities, such as the U.S. Food and Drug Administration (the “FDA”), Nuclear Regulatory Commission (“NRC”), and state and local regulatory agencies, to ensure the devices are safe and effective and comply with laws governing products which emit, produce or control radiation. Similar international regulations apply overseas. These regulations, which include the U.S. Food, Drug and Cosmetic Act (the “FDC Act”) and regulations promulgated by the FDA, govern, among other things, the design, development, testing, manufacturing, packaging, labeling, distribution, import/export, sale and marketing and disposal of medical devices, post market surveillance and reporting of serious injuries and death, repairs, replacements, recalls and other matters relating to medical devices, radiation emitting devices and devices utilizing radioactive by-product material. State regulations are extensive and vary from state to state. Our X-ray tube products, imaging workstations and flat panel detectors are considered medical devices. Under the FDC Act, each medical device manufacturer must comply with quality system regulations that are strictly enforced by the FDA.

Unless an exception applies, the FDA requires that the manufacturer of a new medical device or a new indication for use of, or other significant change in, existing currently marketed medical device obtain 510(k) pre-market notification clearance before it can

6

market or sell those products in the United States. The 510(k) clearance process is applicable when the device introduced into commercial distribution is substantially equivalent to a legally marketed device. The obtaining 510(k) clearance generally takes at least six months from the date an application is filed, but could take significantly longer, and generally requires submitting supporting testing data. After a product receives 510(k) clearance, any modifications or enhancements to a product that could significantly affect its safety or effectiveness, or that would constitute a major change in the intended use of the device, technology, materials, labeling, packaging, or manufacturing process, may require a new 510(k) clearance. The FDA requires each manufacturer to make this determination in the first instance, but the FDA can review any such decision. If the FDA disagrees with the manufacturer’s decision, it may retroactively require the manufacturer to submit a request for 510(k) pre-market notification clearance and may require the manufacturer to cease marketing and recall the product until 510(k) clearance is obtained. The FDA adopted guidance in September 2019 that we expect will increase the number and frequency of clearances for changes made to legally marketed devices. Most of our products are non-classified or Class I medical devices, which do not require 510(k) clearance.

Quality systems. Our manufacturing operations for medical devices, and those of our third-party manufacturers, are required to comply with the FDA’s Quality System Regulation (“QSR”), which addresses a company’s responsibility for product design, testing, and manufacturing quality assurance, and the maintenance of records and documentation. The QSR requires that each manufacturer establish a quality systems program by which the manufacturer monitors the manufacturing process and maintains records that show compliance with FDA regulations and the manufacturer’s written specifications and procedures relating to the devices. QSR compliance is necessary to receive and maintain FDA clearance or approval to market new and existing products. The FDA makes announced and unannounced periodic and ongoing inspections of medical device manufacturers to determine compliance with the QSR. If in connection with these inspections the FDA believes the manufacturer has failed to comply with applicable regulations and/or procedures, it may issue observations that would necessitate prompt corrective action. If FDA inspection observations are not addressed and/or corrective action taken in a timely manner and to the FDA’s satisfaction, the FDA may issue a warning letter (which would similarly necessitate prompt corrective action) and/or proceed directly to other forms of enforcement action. Failure to respond timely to FDA inspection observations, a warning letter or other notice of noncompliance and to promptly come into compliance could result in the FDA bringing enforcement action against us, which could include the total shutdown of our production facilities, denial of importation rights to the United States for products manufactured in overseas locations and denial of export rights for U.S. products and criminal and civil fines.

The FDA and the Federal Trade Commission (the “FTC”) regulate advertising and promotion of our products to ensure that the claims we make are consistent with our regulatory clearances, that we have adequate and reasonable scientific data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading. We may not promote or advertise our products for uses not within the scope of our intended use statement in our clearances or approvals or make unsupported safety and effectiveness claims.

It is also important that our products comply with electrical safety and environmental standards, such as those of Underwriters Laboratories (“UL”), the Canadian Standards Association (“CSA”), and the International Electrotechnical Commission (“IEC”). In addition, the manufacture and distribution of medical devices utilizing radioactive material requires a specific radioactive material license. For the United States, manufacture and distribution of these radioactive sources and devices also must be in accordance with a model-specific certificate issued by either the NRC or by an Agreement State. In essentially every country and state, installation and service of these products must be in accordance with a specific radioactive materials license issued by the applicable radiation control agency. Service of these products must be in accordance with a specific radioactive materials license. We are also subject to a variety of additional environmental laws regulating our manufacturing operations and the handling, storage, transport and disposal of hazardous substances, and which impose liability for the cleanup of any contamination from these substances.

Other applicable U.S. regulations. As a participant in the healthcare industry, we are also subject to extensive laws and regulations protecting the privacy and integrity of patient medical information that we receive, including the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), “fraud and abuse” laws and regulations, including physician self-referral prohibitions, and false claims laws. From time to time, these laws and regulations may be revised or interpreted in ways that could make it more difficult for our customers to conduct their businesses, such as recent proposed revisions to the laws prohibiting physician self-referrals, and such revisions could have an adverse effect on the demand for our products, and therefore our business and results of operations. We also must comply with numerous federal, state and local laws of more general applicability relating to such matters as environmental protection, safe working conditions, manufacturing practices, fire hazard control and other matters.

The laws and regulations and their enforcement are constantly undergoing change, and we cannot predict what effect, if any, changes to these laws and regulations may have on our business. For example, national and state laws regulate privacy and may regulate our use of data. Furthermore, HIPAA was amended by the HITECH Act to provide that business associates who have access

7

to patient health information provided by hospitals and healthcare providers are now directly subject to HIPAA, including the associated enforcement scheme and inspection requirements.

Medicare and Medicaid Reimbursement

The federal and state governments of the United States establish guidelines and pay reimbursements to hospitals and free-standing clinics for diagnostic examinations and therapeutic procedures under Medicare at the federal level and Medicaid at the state level. Private insurers often establish payment levels and policies based on reimbursement rates and guidelines established by the government.

The federal government and Congress review and adjust rates annually, and from time to time consider various Medicare and other healthcare reform proposals that could significantly affect both private and public reimbursement for healthcare services in hospitals and free-standing clinics. In the past, we have seen demand for our customers’ systems (in which our products are incorporated) negatively impacted by the uncertainties surrounding reimbursement rates in the United States. State government reimbursement for services is determined pursuant to each state’s Medicaid plan, which is established by state law and regulations, subject to requirements of federal law and regulations.

Various healthcare reform proposals have also emerged at the state level, and we are unable to predict which, if any, of these proposals will be enacted. In addition, it is possible that changes in federal health care law and policy could result in additional proposals and/or changes to health care system legislation which could have a material adverse effect on our business. Uncertainty created by healthcare reform complicates our customers’ decision-making process and, therefore, impacts our business, and may continue to do so.

The sale of medical devices, the referral of patients for diagnostic examinations and treatments utilizing such devices, and the submission of claims to third-party payors (including Medicare and Medicaid) seeking reimbursement for such services, are subject to various federal and state laws pertaining to healthcare “fraud and abuse.” Anti-kickback laws make it illegal to solicit, induce, offer, receive or pay any remuneration in exchange for the referral of business, including the purchase of medical devices from a particular manufacturer or the referral of patients to a particular supplier of diagnostic services utilizing such devices. False claims laws prohibit anyone from knowingly and willfully presenting, or causing to be presented, claims for payment to third-party payors (including Medicare and Medicaid) that are false or fraudulent, for services not provided as claimed, or for medically unnecessary services. The Office of the Inspector General prosecutes violations of fraud and abuse laws and any violation may result in criminal and/or civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal healthcare programs such as Medicare and Medicaid, which may negatively impact the demand for our products.

Foreign Regulations
Our operations, sales and service of our products outside the United States are subject to regulatory requirements that vary from country to country and may differ significantly from those in the United States. In general, our products are regulated outside the United States as medical devices by foreign governmental agencies similar to the FDA.

Marketing a medical device internationally. For us to market our products internationally, we must obtain clearances or approvals for products and product modifications. We are required to affix the CE mark to our products to sell them in member countries of the European Union (“EU”). The CE mark is an international symbol of adherence to certain essential principles of safety and effectiveness, which once affixed enables a product to be sold in member countries of the EEA. The CE mark is also recognized in many countries outside the EU, such as Switzerland and Norway and can assist in the clearance process. To receive permission to affix the CE mark to our medical devices products, we must obtain Quality System certification, e.g., ISO 13485, through an accredited Notified Body and must otherwise have a quality management system that complies with the EU Medical Device Directive to be superseded by the EU MDR-Medical Device Regulations in May 2020. The ISO promulgates standards for certification of quality assurance operations. We are certified as complying with the ISO 9001 for our security and inspection products and ISO 13485 for our medical devices. Several Asian countries, including Japan and China, have adopted regulatory schemes that are comparable, and in some cases more stringent, than the EU scheme. To import medical devices into Japan, the requirements of Japan’s New Medical Device Regulation must be met and an approval to sell medical products in Japan, must be obtained. Similarly, a registration certification issued by the National Medical Products Administration and a China Compulsory Certification mark for certain products are required to sell medical devices in China. Obtaining such certifications on our products can be time-consuming and can cause us to delay marketing or sales of certain products in such countries. Similarly, prior to selling a device in Canada, manufacturers of Class II devices must obtain a medical device license in Canada. Additionally, many countries have laws and regulations relating to radiation and radiation safety that apply to our products. In most countries, radiological regulatory agencies require some form of licensing or

8

registration by the facility prior to acquisition and operation of an X-ray generating device or a radiation source. The handling, transportation and recycling of radioactive metals and source materials are also highly regulated.

A number of countries, including the members of the EU, have implemented or are implementing regulations that would require manufacturers to dispose, or bear certain disposal costs, of products at the end of a product’s useful life and restrict the use of some hazardous substances in certain products sold in those countries.

Manufacturing and selling a device internationally. We are subject to laws and regulations outside the United States applicable to manufacturers of radiation-producing devices and products utilizing radioactive materials, and laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, manufacturing practices and other matters, in each case that are often comparable to, if not more stringent than, regulations in the United States. In addition, our sales of products in foreign countries are subject to regulation of matters such as product standards, packaging requirements, labeling requirements, import restrictions, environmental and product recycling requirements, tariff regulations, duties and tax requirements. In some countries, we rely on our foreign distributors and agents to assist us in complying with foreign regulatory requirements.

Other applicable international regulations. In addition to the U.S. laws regarding the privacy and integrity of patient medical information, we are subject to similar laws and regulations in foreign countries covering data privacy and other protection of health and employee information. Particularly within Europe, data protection legislation is comprehensive and complex and there has been a recent trend toward more stringent enforcement of requirements regarding protection and confidentiality of personal data, as well as enactment of stricter legislation. We are also subject to international “fraud and abuse” laws and regulations, as well as false claims and misleading advertisement laws. We also must comply with numerous international laws of more general applicability relating to such matters as environmental protection, safe working conditions, manufacturing practices, fire hazard control and other matters.

On June 23, 2016, the United Kingdom (the “U.K.”) held a referendum in which voters approved an exit from the E.U., commonly referred to as “Brexit”. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replace or replicate. Given the lack of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the U.K. from the E.U. would have and how such withdrawal would affect us. We currently have UK based Notified Bodies that must be transferred to an EU Member State recognized Notified Body.

Anti-Corruption Laws and Regulations
We are subject to the U.S. Foreign Corrupt Practices Act and anti-corruption laws, and similar laws in foreign countries, such as the U.K. Bribery Act of 2010, which became effective on July 1, 2011, and the law “On the Fundamentals of Health Protection in the Russian Federation,” which became effective in January 2012. In general, there is a worldwide trend to strengthen anti-corruption laws and their enforcement, and the healthcare industry and medical equipment manufacturers have been particular targets of these investigation and enforcement efforts. Any violation of these laws by us or our agents or distributors could create a substantial liability for us, subject our officers and directors to personal liability and also cause a loss of reputation in the market.

Transparency International’s 2015 Corruption Perceptions Index measured the degree to which public sector corruption is perceived to exist in 168 countries/territories around the world, and found that two-thirds of the countries in the index, including many that we consider to be high-growth areas for our products, such as China and India, scored below 50, on a scale from 100 (very clean) to 0 (highly corrupt). We currently operate in many countries where the public sector is perceived as being more or highly corrupt and our strategic business plans include expanding our business in regions and countries that are rated as higher risk for corruption activity by Transparency International.

Increased business in higher-risk countries could subject us and our officers and directors to increased scrutiny and increased liability. In addition, becoming familiar with and implementing the infrastructure necessary to comply with laws, rules and regulations applicable to new business activities and mitigating and protecting against corruption risks could be quite costly. Failure by us or our agents or distributors to comply with these laws, rules and regulations could delay our expansion into high-growth markets and could materially and adversely affect our business.

Competition and Trade Compliance Laws

We are subject to various competition and trade compliance laws in the jurisdictions where we operate. Regulatory or government authorities where we operate may have enforcement powers that can subject us to sanctions and can impose changes or conditions in the way we conduct our business. For example, local authorities may disagree with how we classify our products, and we may be required to change our classifications, which could increase our operating costs or subject us to increased taxes or fines and

9

penalties. In addition, an increasing number of jurisdictions also provide private rights of action for competitors or consumers to seek damages asserting claims of anti-competitive conduct. Increased government scrutiny of our actions or enforcement or private rights of action could materially and adversely affect our business or damage our reputation. In addition, we may conduct, or we may be required to conduct, internal investigations or face audits or investigations by one or more domestic or foreign government or regulatory agencies, which could be costly and time-consuming, and could divert our management and key personnel from our business operations. An adverse outcome under any such investigation or audit could subject us to increased costs, fines or criminal or other penalties, which could materially and adversely affect our business and financial results. Furthermore, competition laws may prohibit or increase the cost of future acquisitions that we may desire to undertake.

International sales of certain of our Linatron® X-ray accelerators are subject to U.S. export licenses that are issued at the discretion of the U.S. government. Orders and revenues for our security and inspection products have been and may continue to be unpredictable as governmental agencies may place large orders with us or with our customers over a short period of time and then may not place additional orders until complete deployment and installation of previously ordered products. We have seen domestic and international governments postpone purchasing decisions and delay installations of products for security and inspection systems. Furthermore, tender awards in this business may be subject to challenge by third parties, as we have previously encountered, which can make the conversion of orders to revenues unpredictable for some security and inspection products. The market for border protection systems has slowed significantly and end customers, particularly in oil-based economies and war zones in which we have a significant customer base, are delaying system deployments or tenders and have considered moving to alternative sources.

Intellectual Property

We place considerable importance on obtaining and maintaining patent, copyright and trade secret protection for significant new technologies, products and processes, because of the length of time and expense associated with bringing new products through the development process and to the marketplace.

We generally rely on a combination of patents, copyrights, trademarks, trade secret and other laws, and contractual restrictions on disclosure, copying and transferring title, including confidentiality agreements with vendors, strategic partners, co-developers, employees, consultants and other third parties, to protect our proprietary rights in the developments, improvements and inventions that we have originated and which are incorporated in our products or that fall within our fields of interest. As of September 27, 2019, we own over 290 patents issued in the United States, over 370 patents issued throughout the rest of the world and had approximately another 160 patent applications pending with various patent agencies worldwide. The patents and patents issuing from the pending applications generally expire between 2019 and 2037. We intend to file additional patent applications as appropriate. We have trademarks, both registered and unregistered, that are maintained and enforced to provide customer recognition for our products in the marketplace. We also have agreements with third parties that provide for licensing of patented or proprietary technology, including royalty-bearing licenses and technology cross-licenses. These licenses generally can only be terminated for breach. See “Risk Factors-Protecting our intellectual property can be costly, and we may not be able to maintain licensed rights, and, in either case, our competitive position would be harmed if we are not able to do so.”

In conjunction with the January 2017 separation from Varian, we entered into an Intellectual Property Matters Agreement with Varian, pursuant to which, among other things, we each granted the other licenses to use certain intellectual property.

Environmental Matters

Our operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, we are obligated to indemnify Varian for 20% of the cleanup liabilities related to prior corporate restructuring activities while a division of Varian and fully indemnify Varian for other liabilities arising from the operations of the business transferred to it as part of those activities. Those include facilities sold as part of Varian’s electron devices business in 1995 and thin film systems business in 1997. The U.S. Environmental Protection Agency (“EPA”) or third parties have named Varian as a potentially responsible party under the amended Comprehensive Environmental Response Compensation and Liability Act of 1980 (“CERCLA”), at sites to which Varian or the facilities of the businesses sold in 1995 and 1997 were alleged to have shipped waste for recycling or disposal (the “CERCLA sites”). We anticipate that we will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these CERCLA sites (after adjusting for any insurance proceeds or tax benefits received by Varian). In connection with the CERCLA sites, to date Varian has been required to pay only a small portion of the total cleanup costs and we anticipate that any reimbursement to Varian in the future will not be material. As of September 27, 2019, we had an existing environmental liability of approximately $0.9 million related to the CERCLA sites.


10

Working Capital

Our working capital needs and our credit practices are comparable to those of other companies manufacturing and selling similar products in similar markets. We endeavor to carry sufficient levels of inventory to meet the product delivery needs of our customers. We also provide payment terms to customers in the normal course of business. The product warranty obligations contained in our standard terms and conditions typically range from 12 to 24 months, depending on the product.

Employees

As of September 27, 2019, we had approximately 2,000 full-time and part-time employees worldwide. None of our employees based in the United States are unionized or subject to collective bargaining agreements. Employees based in some foreign countries may, from time to time, be represented by works councils or unions or subject to collective bargaining agreements. We currently consider our relations with our employees to be good.

Information Available to Investors

The Securities and Exchange Commission (“SEC”) maintains an internet site, www.sec.gov, that contains reports, proxy and information statements, and other information regarding the Company and other issuers that file electronically with the SEC. As soon as reasonably practicable after filing with or furnishing to the SEC, we also make the following reports and information available free of charge on the Investors page of our website www.vareximaging.com:
•
our annual reports on Form 10-K;
•
quarterly reports on Form 10-Q;
•
current reports on Form 8-K (including any amendments to those reports); and
•
proxy statements.

Additionally, our Code of Conduct, Corporate Governance Guidelines and the charters of the Audit Committee, Compensation and Management Development Committee, and Nominating and Corporate Governance Committee are also available on the Investors page of our website. Investors and others should note that we announce material financial and operational information to our investors using our investor relations website (http://investors.vareximaging.com/), press releases, SEC filings and public conference calls and webcasts. Please note that information on, or that can be accessed through, our website is not deemed “filed” with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Executive Officers of the Registrant
The biographical summaries of our executive officers are as follows:

Sunny S. Sanyal, 55, has served as President, Chief Executive Officer, and Director since January 2017. Prior to the separation of Varex from Varian, Sunny served as senior vice president and president of Varian’s Imaging Components business for Varian since February 2014. Prior to joining Varian in 2014, Sunny was chief executive officer of T-System, a privately held company providing information technology solutions and services to hospitals and urgent care facilities. He also served as president of McKesson Provider Technologies, where he led the company to significant market expansion with its clinical software, medical imaging technology, and services solutions. Sunny has held executive positions at GE Healthcare, Accenture, and IDX Systems. He received a Master of Business Administration from Harvard Business School, a Master of Science in industrial engineering from Louisiana State University, and a Bachelor of Engineering in electrical engineering from the University of Bombay.

Clarence R. Verhoef, 64, has served as Chief Financial Officer, and Senior Vice President since January 2017. Prior to the separation of Varex from Varian, Clarence served as senior vice president, chief accounting officer and corporate controller for Varian since August 2012. He joined Varian in 2006 and served as the divisional controller of Varian’s Imaging Components business until 2012. Prior to joining Varian, Clarence served in numerous executive management roles, including chief financial officer of Techniscan Medical Systems, and chief financial officer and vice president of marketing for GE OEC Medical Systems. He holds a bachelor’s degree in finance from the University of Utah.

Kimberley E. Honeysett, 48, has served as Senior Vice President, General Counsel, and Corporate Secretary since January 2017. Prior to the separation of Varex from Varian, Kim served vice president and assistant general counsel and assistant corporate secretary for Varian, where she advised Varian’s Board of Directors, executive management and corporate functions, including business development, investor relations, human resources, information technology and was responsible for corporate governance,

11

general compliance matters, litigation and global subsidiary governance. Prior to joining Varian in 2005, Kim served as group director, legal affairs at Siebel Systems, Inc., an enterprise software company, and as an associate with the law firm Brobeck, Phleger & Harrison LLP. Kim holds juris doctor degree from Cornell Law School and a bachelor’s degree in communications from the University of California, Los Angeles.

Brian W. Giambattista, 60, has served as Senior Vice President, and General Manager - X-ray Detectors since May 2017 and joined Varex after the acquisition of the PerkinElmer Medical Imaging business. He has nearly 30 years of experience in the industry, having held various management and engineering roles at PerkinElmer and General Electric, and received his doctorate degree in physics from the University of Virginia.

Mark S. Jonaitis, 58, has served as Senior Vice President and General Manager - X-Ray Sources since 2017. Prior to the separation of Varex from Varian, Mark served in various management positions at Varian, including most recently vice president and general manager, X‑ray Tube Products and global manufacturing. Mark joined Varian’s predecessor, Varian Associates, in 1983, where he served in various product and engineering positions. Mark received his Bachelor of Science in physics from the University of Utah.
Item 1A. Risk Factors
The following risk factors and other information included in this Annual Report on Form 10-K should be carefully considered. Although the risk factors described below are the ones management deems significant, additional risks and uncertainties not presently known to us or that we presently deem less significant may also adversely affect our business operations. If any of the following risks or additional risks and uncertainties actually occur, our business, operating results, and financial condition could be adversely affected.
Varex sells its products and services to a limited number of OEM customers, many of which are also its competitors, and a reduction in or loss of business of one or more of these customers may materially reduce its sales.
Varex had one customer during fiscal year 2019 that accounted for 17% of its revenue. Varex’s ten largest customers as a group accounted for approximately 51%, 49% and 48% of its revenue for fiscal years 2019, 2018 and 2017, respectively.
Varex sells its products to a limited number of OEM customers, many of which are also its competitors with in-house X-ray component manufacturing operations. Although Varex seeks to broaden its customer base, it will continue to depend on sales to a relatively small number of major customers. Because it often takes significant time to replace lost business, it is likely that Varex’s operating results would be materially and adversely affected if one or more of its major OEM customers were to cancel, delay, or reduce orders in the future.
Furthermore, Varex generates significant accounts receivables from the sale of its products and the provision of services directly to its major customers. If one or more of these customers were to cancel a product order or service contract (whether in accordance with its terms or otherwise), become insolvent or otherwise be unable or fail to pay for Varex products and services, Varex’s operating results and financial condition could be materially and adversely affected.
Varex may not be able to accurately predict the demand for its products by its customers.
End-user product demand, economic uncertainties, natural disasters, and other matters beyond Varex’s control make it difficult for its customers to accurately forecast and plan future business activities; which makes it difficult for Varex to accurately predict the demand for its products. Because the manufacture of our products requires some lead-time, changes in customer purchasing forecasts have previously impacted Varex’s business, resulting in excess inventory and slowdowns in sales. Similar inventory adjustments and slowdowns in sales are likely to occur in the future. Changes to customer forecasts can occur on short notice. Varex’s customers also face inherent competitive issues and new product introduction delays which can result in changes in forecasts. The market and regulatory risks faced by Varex’s customers also ultimately impact Varex’s ability to forecast future business. Varex’s agreements for imaging components, such as its three-year pricing agreement with Canon Medical Systems, may contain purchasing estimates that are based on its customers’ historical purchasing patterns rather than firm commitments, and actual purchasing volumes under the agreements may vary significantly from these estimates. The variation from forecasted purchasing volume may be due, in part, to the increasing life of X-ray tubes, which can result in reduced demand for replacement X-ray tubes in ways Varex may not be able to accurately forecast. Reductions in purchasing patterns have in the past and may in the future materially and adversely affect Varex’s operating results.

12

Varex competes in highly competitive markets, and it may lose business to its customers or other companies with greater resources or the ability to develop more effective technologies, or it could be forced to reduce its prices.
Rapidly-evolving technology, intense competition and pricing pressure characterize the market in which Varex competes. Varex often competes with companies that have greater financial, marketing and other resources than Varex. Some of the major diagnostic imaging systems companies, which are the primary OEM customers for Varex’s X-ray components, also manufacture X-ray components, including X-ray tubes, for use in their own imaging systems products. Varex must compete with these in-house manufacturing operations for business. If these customers manufacture a greater percentage of their components in-house or otherwise decrease purchases from external sources, which may occur for a number of reasons, including a strong U.S. Dollar, or a general economic slowdown, Varex could experience reductions in purchasing volume by, or loss of, one or more of these customers. Such a reduction or loss may have a material and adverse effect on its business. In addition, Varex competes against other stand-alone, independent X-ray tube manufacturers for both the OEM business of major diagnostic imaging equipment manufacturers and the independent servicing business for X-ray tubes.
The market for flat panel detectors is also very competitive, and Varex faces intense competition from over a dozen smaller competitors. As a result of these competitive dynamics, to effectively retain the business of its customers and compete with its competitors Varex must have an advantage in one or more significant areas, such as lower product cost, better product quality and/or superior technology and/or performance. Varex has made price concessions to maintain existing customers and attract new customers, and may have to make additional price concessions in the future.
In its industrial segment, Varex competes with other OEM suppliers, primarily outside of the United States. The market for its X-ray tube and flat panel products used for nondestructive testing in industrial applications is small and highly fragmented. Some of Varex’s competitors outside the United States may have resources and support from their governments that Varex does not, such as preferences for local manufacturers, and may not be subject to the same trade compliance regulations as Varex. Therefore, Varex’s ability to compete in certain high-growth markets may be limited compared to its competitors.
Varex’s competitors could develop technologies and products that are more effective than those Varex currently uses or produces or that could render its products obsolete or noncompetitive. In addition, the timing of Varex’s competitors’ introduction of products into the market could affect the market acceptance and sales of Varex’s products. Some competitors offer specialized products that provide, or may be perceived by customers to provide, an advantage over Varex’s products. Also, some of Varex’s non-U.S. competitors may not be subject to the same standards, regulatory and/or other legal requirements to which Varex is subject and, therefore, they could have a competitive advantage in developing, manufacturing and marketing products and services. Any inability to develop, gain regulatory approval for and supply commercial quantities of competitive products to the market as quickly and effectively as Varex’s competitors could limit market acceptance of Varex’s products and reduce its sales. Any of these competitive factors could negatively and materially affect Varex’s pricing, sales, revenues, market share and gross margins and its ability to maintain or increase its operating margins.
Changes in import/export regulatory regimes and tariffs could continue to negatively impact our business.
Tariffs and changes in international trade agreements or trade-related laws and regulations may have an indirect adverse impact on our business. As a component manufacturer, our products are integrated into the systems and products of our OEM customers. If the United States, China or other countries levy tariffs, duties or other additional taxes or restrictions on our customer’s products, the demand for such products, and our components included in such products, could decrease, which could have a material adverse effect on our business. Uncertainty over tariffs and trade wars could also cause our customers to delay or cancel orders for our products.
In 2018 and 2019, the United States has imposed tariffs on items imported from China that are incorporated into our products. Tariffs on items imported by us from China and other countries have increased our costs and has increased prices and lowered gross margins on some of our products. These tariffs have had a direct adverse impact on our business and results of operations, and future tariffs could have a more significant impact on our business. China has imposed retaliatory tariffs that impact a number of Varex products including U.S. origin X-ray tubes, heat exchange units, and certain flat panel detectors. The tariffs levied by China have increased our customers’ costs for products imported into China, which has caused us to make price concessions on some products and has caused some customers to stop purchasing products from us. We expect that tariffs will continue to have a negative effect on our business and results of operations, including the possibility of continued price concessions or loss of business. Tariffs could limit our ability to compete for increased market share in China, which could cause our long-term prospects in China to suffer. The imposition of additional tariffs by the United States could result in the adoption of additional tariffs by China and other countries,

13

as well as further retaliatory actions by any affected country, which could negatively impact the global market for imaging equipment and could have a significant adverse effect on our business.
Varex’s success depends on the successful development, introduction, and commercialization of new generations of products and enhancements to or simplifications of existing product lines.
Rapid change and technological innovation characterize the markets in which Varex operates, particularly with respect to flat panel technology. Varex’s customers use its products in their medical diagnostic, security, and industrial imaging systems, and Varex must continually introduce new products at competitive costs while also improving existing products with higher quality, lower costs, and increased features. To be successful, Varex must anticipate its customers’ needs and demands, as well as potential shifts in market preferences. Varex’s failure to do so has in the past resulted, and may in the future result, in the loss of customers and an adverse impact to its financial performance. With a relatively strong U.S. Dollar, Varex’s ability to meet its customers’ pricing expectations is particularly challenging and may result in erosion of product margin and market share.
Varex has in the past spent, and in the future may need to spend, more time and money than it expects to develop, market and introduce new products or enhancements, and, even if Varex succeeds, Varex may not be able to recover all or a meaningful part of its investment. Once introduced, new products may materially and adversely impact sales of Varex’s existing products or make them less desirable or even obsolete, which could materially and adversely impact Varex’s revenues and operating results. In addition, certain costs, including installation and warranty costs, associated with new products may be proportionately greater than the costs associated with other products and may therefore disproportionately, materially, and adversely affect Varex’s gross and operating margins. If Varex is unable to lower these costs over time, Varex’s operating results could be materially and adversely affected. Some of the electronic components and integrated circuits used in Varex’s flat panel detectors are susceptible to discontinuance and obsolescence risks, which may force Varex to incorporate newer generations of these components, resulting in unplanned additional R&D expenses, delays in the launch of new products, supply disruption, or inventory write downs.
Varex’s ability to successfully develop and introduce new products and product enhancements and simplifications, and the revenues and costs associated with these efforts, are affected by Varex’s ability to, among other things:
•
properly identify customer needs or long-term customer demands;
•
prove the feasibility of new products;
•
properly manage and control research and development costs;
•
limit the time required from proof of feasibility to routine production;
•
timely and efficiently comply with internal quality assurance systems and processes;
•
limit the timing and cost of regulatory approvals;
•
accurately predict and control costs associated with inventory overruns caused by the phase-in of new products and the phase-out of old products;
•
price its products competitively and profitably, which can be particularly difficult with a strong U.S. Dollar;
•
manufacture, deliver, and install its products in sufficient volumes on time and accurately predict and control costs associated with manufacturing installation, warranty, and maintenance of the products;
•
appropriately manage its supply chain;
•
manage customer acceptance and payment for products; and
•
anticipate, respond to, and compete successfully with competitors.

Furthermore, as discussed in greater detail elsewhere in this “Risk Factors” section, Varex cannot be sure that it will be able to successfully develop, manufacture, or introduce new products or enhancements, the roll-out of which involves compliance with complex quality assurance processes, including the Quality System Regulation of the U.S. Food and Drug Administration (“FDA”). Failure to complete these processes timely and efficiently could result in delays that could affect Varex’s ability to attract and retain customers or cause customers to delay or cancel orders, which would materially and adversely affect Varex’s revenues and operating results.
More than half of Varex’s revenues are generated from customers located outside the United States, and economic, political, and other risks associated with international sales and operations could materially and adversely affect Varex’s sales or make them less predictable.
Varex conducts business globally. Revenues generated from customers located outside the United States accounted for approximately 65%%, 65% and 66% of Varex’s total revenues during fiscal years 2019, 2018, and 2017, respectively. As a result,

14

Varex must provide significant service and support globally. Varex intends to continue to expand its presence in international markets and expects to expend significant resources in doing so. Varex cannot be sure that it will be able to meet its sales, service, and support objectives or obligations in these international markets or recover its investment in these international markets. Varex’s future results could be harmed by a variety of factors, including:
•
currency fluctuations, and in particular the strength of the U.S. Dollar (which is our functional and reporting currency) relative to many currencies, which have and may in the future adversely affect Varex’s financial results and cause some customers to delay purchasing decisions or move to in-sourcing supply or migrate to lower cost alternatives or ask for additional discounts;
•
the longer payment cycles associated with many customers located outside the United States;
•
difficulties in interpreting or enforcing agreements and collecting receivables through many foreign countries’ legal systems;
•
changes in restrictions on trade between the United States and other countries or unstable regional political and economic conditions;
•
changes in the political, regulatory, safety or economic conditions in a country or region
•
the imposition by governments of additional taxes, tariffs, global economic sanctions programs, or other restrictions on foreign trade such as the tariffs recently put into place by both China and the United States;
•
any inability to obtain required export or import licenses or approvals, including the inability to obtain required export licenses during a U.S. government shutdown;
•
failure to comply with export laws and requirements, which may result in civil or criminal penalties and restrictions on Varex’s ability to export its products, particularly its industrial linear accelerator products;
•
risks unique to the Chinese market, including import barriers and preferences for local manufacturers;
•
failure to obtain proper business licenses or other documentation or to otherwise comply with local laws and requirements regarding marketing, sales, service, or any other business Varex conducts in a foreign jurisdiction, which may result in civil or criminal penalties and restrictions on its ability to conduct business in that jurisdiction; and
•
difficulties in protecting Varex’s intellectual property in foreign countries.
Although Varex’s sales fluctuate from period to period, in recent years Varex’s international operations have represented a larger share of its business. The more Varex depends on international sales, the more vulnerable Varex becomes to these factors.
A change in the percentage of Varex’s total earnings from international sales or additional changes in tax laws could increase Varex’s effective tax rate.     
Varex’s effective tax rate is impacted by tax laws in both the United States and in foreign countries. Earnings from Varex’s international subsidiaries are generally taxed at rates that differ from U.S. rates. A change in the percentage of Varex’s total earnings from the international subsidiaries, a change in the mix of particular tax jurisdictions between the international subsidiaries, or a change in currency exchange rates could cause Varex’s effective tax rate to increase. The Tax Cuts and Jobs Act of 2017 (“U.S. Tax Reform”) was signed into law on December 22, 2017. Prior to the enactment of U.S. Tax Reform, Varex was not taxed in the United States on certain undistributed earnings of certain foreign subsidiaries. While U.S. Tax Reform imposed a current tax on cumulative undistributed earnings, these earnings could also become subject to incremental foreign withholding or U.S. state taxes should they be actually remitted to the United States, in which case Varex’s financial results could be materially and adversely affected.
The changes included in U.S. Tax Reform are broad, complex, and subject to change and interpretation. Additional statutory changes or interpretive guidance issued by Federal or local authorities could have a material impact on income tax expense, the effective rate, or the value of deferred tax assets and liabilities. In addition, significant judgments and estimates are required to evaluate our tax position and the impact of the new tax law. If these judgments and estimates are incorrect, or if the underlying assumptions are modified by subsequent guidance or are different from what we expect, our tax liability could differ significantly from our current estimates.  Changes in the valuation of Varex’s deferred tax assets or liabilities, additional changes in tax laws or rates, changes in the interpretation of tax laws in other jurisdictions, or other changes beyond Varex’s control could materially and adversely affect its financial position and results of operations.
Varex has entities in certain jurisdictions with cumulative net operating losses for which no income tax benefit can be recorded due to full valuation allowance positions. There could be additional future losses in these and other jurisdictions that would negatively impact Varex's effective tax rate.

15

Our secured revolving credit facility and secured term loan credit facility (collectively the “Credit Facility”) restrict certain activities, and failure to comply with the terms of this facility may have an adverse effect on our business, liquidity and financial position.
Varex is party to a secured revolving credit facility and a secured term loan credit facility, each of which contains restrictive financial covenants, including financial covenants that require Varex to comply with specified financial ratios. If we do not increase our earnings, we are at risk of not being in compliance with certain of our financial covenants, including our consolidated total leverage ratio and our consolidated senior secured leverage ratio. Varex may have to curtail some of its operations to comply with these covenants. In addition, its credit facilities contain other affirmative and negative covenants that could restrict its operating and financing activities. These provisions limit its ability to, among other things, incur future indebtedness, contingent obligations or liens, guarantee indebtedness, make certain investments and capital expenditures, sell stock or assets, pay dividends and consummate certain mergers or acquisitions. Failure to comply with the credit facility requirements, including the requirement to timely deliver financial statements within applicable grace periods, could result in an event of default under our credit facility. Upon an event of default, if the credit facility documents are not amended or the event of default is not waived, the lender could declare all amounts then outstanding, together with accrued interest, to be immediately due and payable. If this happens, Varex may not be able to make those payments or borrow sufficient funds from alternative sources to make those payments. Even if Varex were to obtain additional financing, that financing may be on unfavorable terms.
Varex has significant debt obligations that could adversely affect its business, profitability and ability to meet its obligations.
As of September 27, 2019, Varex’s total combined indebtedness, net of deferred loan costs, was approximately $395.1 million. The borrowings under Varex’s credit facilities bear interest at floating interest rates. As part of its overall risk management practices, Varex entered into financial derivatives, particularly interest rate swaps designed as cash flow hedges, to hedge the floating LIBOR interest rate on $264.4 million of its debt. As a result, Varex will be exposed to fluctuations in interest rates to the extent of the balance of its borrowings under the LIBOR-based portion of its credit facilities.
Varex's debt could potentially have important consequences to Varex and its investors, including:
•
requiring that a portion of Varex’s cash flow from operations be used to make principal and interest payments on this debt, which would reduce cash flow available for other corporate purposes;
•
increasing Varex’s vulnerability to shifts in interest rates and to general adverse economic and industry conditions;
•
limiting Varex’s flexibility in planning for, or reacting to, changes in its business and the industry; and
•
limiting Varex’s ability to borrow additional funds as needed or increasing the costs of any such borrowing.
In addition, Varex’s actual cash requirements in the future may be greater than expected. Varex’s cash flow from operations may not be sufficient to repay all of the outstanding debt as it becomes due, and Varex may not be able to borrow money, sell assets, or otherwise raise funds on acceptable terms, or at all, to refinance Varex’s debt.
Fulfilling obligations incidental to being a public company place significant demands on Varex’s management, administrative, and operational resources, including accounting and information technology resources.
As a public company, Varex is subject to the reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”), and is required to prepare its financial statements according to the rules and regulations required by the SEC. The Exchange Act requires that Varex file annual, quarterly, and current reports. Varex’s failure to prepare and disclose this information in a timely manner or to otherwise comply with applicable law could subject it to penalties under federal securities laws, cause it to be out of compliance with applicable stock exchange listing requirements, and expose it to lawsuits and restrict its ability to access financing. For example, as a result of the delayed filing of this Annual Report on Form 10-K, we received a notification letter from Nasdaq advising us that we were not in compliance with Nasdaq listing requirements.  While with the filing of our Form 10-K we will regain compliance with the Nasdaq listing requirements, if we had failed to regain compliance in a timely manner, it would have negatively impacted Varex.
Varex must, among other things, establish and maintain effective internal controls and procedures for financial reporting and disclosure purposes. Internal control over financial reporting is complex and may be revised over time to adapt to changes in Varex’s business or changes in applicable accounting rules. As described in the following risk factor, Varex has identified material weaknesses in its internal control over financial reporting. Varex cannot assure that its internal control over financial reporting will be effective in the future or that additional material weaknesses will not be discovered with respect to a prior period for which it had previously believed that internal controls were effective.

16

Matters impacting Varex’s internal controls may cause Varex to be unable to report its financial information on a timely basis or may cause Varex to restate previously-issued financial information, thereby subjecting Varex to adverse regulatory consequences, including sanctions or investigations by the SEC or in respect of violations of applicable stock exchange listing rules. There could also be a negative reaction in the financial markets due to a loss of investor confidence in Varex and the reliability of its financial statements, which could affect Varex’s stock price.
The delayed filing of some of this Annual Report has made Varex currently ineligible to use a registration statement on Form S-3 to register the offer and sale of securities, which could adversely affect its ability to raise future capital or complete acquisitions.

As a result of the delayed filing of this Annual Report on Form 10-k, Varex will not be eligible to register the offer and sale of our securities using a registration statement on Form S-3 until one year from the date it regained and maintains its status as a current filer. Should Varex wish to register the offer and sale of its securities to the public prior to the time it is eligible to use Form S-3, both the transaction costs and the amount of time required to complete the transaction could increase, making it more difficult to execute any such transaction successfully and potentially harming our financial condition.

Varex identified material weaknesses in its internal control over financial reporting which, if not remediated appropriately or timely, could result in loss of investor confidence and adversely impact our stock price.

As further described in Item 9A of this report, at the end of each of fiscal year 2019 and 2018, management determined that Varex’s internal control over financial reporting and its disclosure controls and procedures were not effective and that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified material weaknesses within our risk assessment process and control environment. Management also identified business process control deficiencies which resulted in material weaknesses in the business processes for revenue, inventory and financial close. These material weaknesses resulted in immaterial audit adjustments and out of period adjustments to the Company’s consolidated financial statements. Until remediated, these material weaknesses could result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected on a timely basis. There can be no assurance that the remedial measures being implemented by Varex's management will be successful. If Varex is unable to remediate the material weaknesses, or is otherwise unable to maintain effective internal control over financial reporting or disclosure controls and procedures, Varex's ability to record, process and report financial information accurately, and to prepare financial statements within required time periods, could be adversely affected, which could subject Varex to litigation or investigations requiring management resources and payment of legal and other expenses, including civil penalties, negatively affect investor confidence in our financial statements and adversely impact our stock price.

Varex may face additional risks from the acquisition or development of new lines of business.
From time to time, Varex may acquire or develop new lines of business. There are substantial risks and uncertainties associated with new lines of business, particularly in instances where the markets are not fully developed. Risks include developing knowledge of and experience in the new business, recruiting market professionals, increasing research and development expenditures, and developing and capitalizing on new relationships with experienced market participants. This may mean significant investment and involvement of Varex’s senior management to acquire or develop, then integrate, the business into its operations. Timelines for integration of new businesses may not be achieved, and price and profitability targets may not prove feasible, as new products can carry lower gross margins than existing products. External factors, such as compliance with regulations, competitive alternatives, and shifting market preferences may also impact whether implementation of a new business will be successful. Failure to manage these risks could have a material and adverse effect on Varex’s business, results of operations, and/or financial condition.
Varex may be unable to complete future acquisitions or realize expected benefits from acquisitions of or investments in new businesses, products, or technologies, which could harm Varex’s business.
Varex’s ability to identify and take advantage of attractive acquisitions or other business development opportunities is an important component in implementing its overall business strategy. Varex must grow its businesses in response to changing technologies, customer demands, and competitive pressures. In some circumstances, Varex may decide to grow its business through the acquisition of complementary businesses, products, or technologies, rather than through internal development; however, there is no guarantee that these acquisitions will be successful or that Varex will realize a return on its investment.
Identifying suitable acquisition candidates can be difficult, time consuming, and costly, and Varex may not be able to identify suitable candidates or successfully complete or finance identified acquisitions, including as a result of failing to obtain regulatory or competition clearances, which could impair Varex’s growth and ability to compete. In addition, completing an acquisition can divert

17

Varex’s management and key personnel from its current business operations, which could harm its business and affect its financial results. Even if Varex completes an acquisition, Varex may not be able to successfully integrate newly-acquired organizations, products, technologies, or employees into its operations or may not fully realize some of the expected synergies.
Integrating an acquisition can also be expensive and time consuming and may strain Varex’s resources. It may cost Varex more to commercialize new products than originally anticipated or cause Varex to increase its expenses related to research and development, either of which could materially and adversely impact its results of operations. In many instances, integrating a new business will also involve implementing or improving internal controls appropriate for a public company into a business that lacks them. It is also possible that an acquisition could increase Varex’s risk of litigation, as a third party may be more likely to assert a legal claim following an acquisition because of perceived deeper pockets or a perceived greater value of a claim. In addition, Varex may be unable to retain the employees of acquired companies or the acquired company’s customers, suppliers, distributors, or other partners for a variety of reasons, including the fact that these entities may be Varex’s competitors or may have close relationships with its competitors.
Further, Varex may find that it needs to restructure or divest acquired businesses or assets of those businesses. Even if it does so, an acquisition may not produce the full efficiencies, growth, or benefits that were expected. If Varex decides to sell assets or a business, it may be difficult to identify buyers or alternative exit strategies on acceptable terms, in a timely manner, or at all, which could delay the accomplishment of its strategic objectives. Varex may be required to dispose of a business at a lower price or on less advantageous terms, or to recognize greater losses than it had anticipated.
If Varex acquires a business, it allocates the total purchase price to the acquired business’ tangible assets and liabilities, identifiable intangible assets, and liabilities based on their fair values as of the date of the acquisition and records the excess of the purchase price over those values as goodwill. If it fails to achieve the anticipated growth from an acquisition, or if it decides to sell assets or a business, it may be required to recognize an impairment loss on the write down of its assets and goodwill, which could materially and adversely affect its financial results. In addition, acquisitions can result in potentially dilutive issuances of equity securities or the incurrence of debt, contingent liabilities or expenses, or other charges, any of which could harm Varex’s business and affect its financial results.
Additionally, Varex participates in joint ventures and has investments in privately-held companies (for example, its 40% ownership in dpiX LLC, its major supplier of its amorphous silicon-based thin film transistor arrays (flat panels used in its digital detectors) that are subject to risk of loss of investment capital. These investments are inherently risky, in some instances because the markets for the technologies or products these companies have under development may never materialize. If these companies do not succeed, Varex could lose some or all of its investment in these companies.
A disruption at Varex’s manufacturing facilities, as well as fluctuating manufacturing costs, could materially and adversely affect its business.
The majority of Varex’s products are manufactured at its facility in Salt Lake City, Utah. Varex’s manufacturing operations are subject to potential power failures, the breakdown, failure, or substandard performance of equipment, the improper installation or operation of equipment, and natural or other disasters. Loss or damage to its manufacturing facility due to any of these factors or otherwise could materially and adversely affect Varex’s ability to manufacture sufficient quantities of its products or otherwise deliver products to meet customer demand or contractual requirements, which may result in a loss of revenue and other adverse business consequences. Because of the time required to obtain regulatory approval and licensing of a manufacturing facility, Varex may not be available on a timely basis to replace any lost manufacturing capacity. The occurrence of these or any other operational issues at Varex’s manufacturing facilities could have a material and adverse effect on Varex’s business, financial condition, and results of operations.
Some of Varex’s products are manufactured in Wuxi, China; Walluf, Germany; Heerlen and Dinxperlo, the Netherlands; and Calamba City, Philippines, which are subject to similar risks but may also face additional regulatory and political risks, which could impact Varex’s ability to manufacture and ship products in a timely manner or at all. Varex manufactures its security products in Las Vegas, Nevada, and certain flat panels in Santa Clara, California, and these operations are also subject to potential power failures, the breakdown, failure, or substandard performance of equipment, the improper installation or operation of equipment, earthquakes, and other disasters, all of which could materially and adversely affect Varex’s ability to deliver products to meet customer demand. In addition, Varex’s costs associated with manufacturing its products can vary significantly from quarter to quarter, and fluctuations thereof may adversely affect its business, operating results, and/or financial condition.

18

Varex’s results have been and may continue to be affected by continuing worldwide economic instability, including changes in foreign currency exchange rates and fluctuations in the price of crude oil and other commodities.
The global economy has been impacted by a number of economic and political factors. In many markets, these conditions have shrunk capital equipment budgets, slowed decision-making and made it difficult for Varex’s customers and vendors to accurately forecast and plan future business activities. This, in turn, has caused Varex’s customers to be more cautious with, and sometimes freeze, delay, or dramatically reduce purchases and capital project expenditures. Some countries have adopted and may in the future adopt austerity or stimulus programs that could negatively affect Varex’s results from period to period. In addition, actions taken by the current U.S. administration and the pending withdrawal of the United Kingdom from the European Union (“EU”) may also create global economic uncertainty, which may cause our customers to reduce their spending, which, in turn, could adversely affect our business, financial condition, operating results, and cash flows. An uncertain economic environment may also disrupt supply or affect our service business, as customers’ constrained budgets may result in pricing pressure, extended warranty provisions, and even cancellation of service contracts.
In addition, concerns over continued economic instability could make it more difficult for Varex to collect outstanding receivables. A weak or deteriorating healthcare market would inevitably materially and adversely affect Varex’s business, financial conditions, and results of operations.
Because Varex’s products are generally priced in U.S. Dollars, the strengthening of the U.S. Dollar in the last several years has caused, and could continue to cause, some customers to ask for discounts, delay purchasing decisions, or consider moving to in-sourcing such components or migrating to lower cost alternatives. Further, because Varex’s business is global and some payments may be made in local currency, fluctuations in foreign currency exchange rates can impact its results by affecting product demand, revenues and expenses, and/or the profitability in U.S. Dollars of products and services that Varex provides in foreign markets.
Changes in monetary or other policies here and abroad, including as a result of economic and/or political instability or in reaction thereto, would also likely affect foreign currency exchange rates. Furthermore, if one or more European countries were to replace the Euro with another currency, Varex’s sales in these countries, or in Europe generally, would likely be materially and adversely affected until stable exchange rates are established.
Additionally, fluctuations in commodities prices could materially and adversely affect Varex’s performance. Rising commodities prices will increase Varex’s costs and those of Varex’s medical OEM customers, which could in turn result in reduced demand for Varex’s products. Further, Varex’s security product revenues from oil-producing countries, in which Varex has a significant customer base, have in the past suffered as a result of volatility in oil prices and remain sensitive to fluctuations in the future.
The loss of a supplier or any inability to obtain supplies of important components could restrict Varex’s ability to manufacture products, cause delays in its ability to deliver products, or significantly increase its costs.
Varex obtains from a limited group of suppliers or from sole-source suppliers some of the components included in its products, such as wave guides for industrial linear accelerators, transistor arrays, cesium iodide coatings and specialized integrated circuits for flat panel detectors, X-ray tube targets, housings, glass frames, high-voltage cable, bearings and various other components. For example, Varex’s major supplier of its amorphous silicon-based thin film transistor arrays (flat panels) used in its digital image detectors is dpiX LLC. Although Varex holds a 40% ownership interest in dpiX, Varex does not have majority voting rights and does not have the power to direct the activities of dpiX. In addition, Varian is Varex’s sole source supplier for a key component in linear accelerators used in Varex’s security and inspection products subsystems, which are specially made for Varex. If current suppliers cease producing these components, there can be no assurance that the components will be available from other suppliers on reasonable terms or at all.
If Varex loses any of these limited- or sole-source suppliers, if their operations are substantially interrupted, or if any of them fail to meet performance or quality specifications or delivery deadlines, Varex may be required to obtain and qualify one or more replacement suppliers. Such an event (1) may then also require Varex to redesign or modify its products to incorporate new parts and/or further require Varex to obtain clearance, qualification, or certification of these products, including by the FDA, or obtain other applicable regulatory approvals in other countries, or (2) could significantly increase costs for the affected products and cause material delays in delivery of those and other related products. In addition, manufacturing capacity limitations of any of Varex’s suppliers or other inability of these suppliers to meet increasing demand or delivery deadlines could limit growth opportunities for the affected product lines and damage customer relationships. Shortage of, and greater demand for, components and subassemblies could also

19

increase manufacturing costs if the supply/demand imbalance increases the price of the components and subassemblies. Any of these events could materially and adversely affect Varex’s business and financial results.
A shortage or change in source of, or increase in price of, raw materials could restrict Varex’s ability to manufacture products, cause delays, or significantly increase its cost of goods.
Varex relies on the supplies of certain raw materials such as tungsten, lead, iridium, and copper for security and inspection products and copper, lead, tungsten, rhenium, molybdenum zirconium, and various high grades of steel alloy for X-ray tubes. Worldwide demand, availability, and pricing of these raw materials have been volatile, and Varex expects that availability and pricing will continue to fluctuate in the future. If supplies are restricted or become unavailable or if prices increase, this could constrain Varex’s manufacturing of affected products, reduce its profit margins, or otherwise materially and adversely affect its business.
Varex is required to disclose (1) the presence in a company’s products of certain metals known as “conflict minerals,” which are metals mined from the Democratic Republic of the Congo and adjoining countries, and (2) procedures regarding a manufacturer’s efforts to identify the sourcing of those minerals from this region. Varex’s complex supply chain may inhibit Varex’s ability to sufficiently verify the origins of the relevant minerals used in its products through the due diligence procedures that it implements, which may harm Varex’s reputation. In addition, Varex may encounter challenges in satisfying customers who require that all of the components of Varex products are certified as conflict-free, which could place Varex at a competitive disadvantage if it is unable to do so. Moreover, complying with these rules requires investigative efforts, which has and will continue to cause Varex to incur associated costs and could materially and adversely affect the sourcing, supply, and pricing of materials used in Varex’s products or result in process or manufacturing modifications, all of which could materially and adversely affect its results of operations.

The trading price of Varex’s common stock may decline or fluctuate significantly and fluctuations in Varex’s operating results, including quarterly revenues, and margins, may cause its stock price to be volatile, which could cause losses for its stockholders.

In the past year, Varex's stock price has ranged from a low of $21.57 to a high of $35.00. Varex cannot guarantee that an active trading market will be sustained for its common stock. Nor can Varex predict the prices at which shares of its common stock may trade. Varex has experienced and expects in the future to experience fluctuations in its operating results, including revenues and margins, from period to period. These fluctuations may cause Varex’s stock price to be volatile, which could cause losses for its stockholders.
Varex’s quarterly and annual operating results, including its revenues and margins, may be affected by a number of other factors, including:
•
the introduction and timing of announcement of new products or product enhancements by Varex and its competitors;
•
change in its or its competitors’ pricing or discount levels;
•
changes in foreign currency exchange rates and other economic uncertainty;
•
changes in import/export regulatory regimes including the imposition of tariffs on our products or those of our customers;
•
changes in the relative portion of its revenues represented by its various products, including the relative mix between higher margin and lower-margin products;
•
the ability to identify and remediate significant deficiencies and material weaknesses in internal controls;
•
changes in the relative portion of its revenues represented by its international region as a whole and by regions within the overall region, as well as by individual countries (notably, those in emerging markets);
•
fluctuation in its effective tax rate, which may or may not be known to Varex in advance;
•
the availability of economic stimulus packages or other government funding, or reductions thereof;
•
disruptions in the supply or changes in the costs of raw materials, labor, product components or transportation services;
•
changes to its organizational structure, which may result in restructuring or other charges;
•
disruptions in its operations, including its ability to manufacture products, caused by events such as earthquakes, fires, floods, terrorist attacks or the outbreak of epidemic diseases;
•
the unfavorable outcome of any litigation or administrative proceeding or inquiry, including governmental audits, as well as ongoing costs associated with legal proceedings and governmental audits; and
•
accounting changes and adoption of new accounting pronouncements.
Because many of Varex’s operating expenses are based on anticipated capacity levels, and a high percentage of these expenses are fixed for the short term, a small variation in the timing of revenue recognition can cause significant variations in operating results from quarter to quarter. If Varex’s gross margins fall below the expectation of securities analysts and investors, the trading price of Varex common stock may decline.

20

Compliance with foreign laws and regulations applicable to the marketing, manufacture, and distribution of Varex’s products may be costly, and failure to comply may result in significant penalties and other harm to Varex’s business.
Regulatory requirements affecting Varex’s operations and sales outside the United States vary from country to country, often differing significantly from those in the United States. In general, outside the United States, some of Varex’s products are regulated as medical devices by foreign governmental agencies similar to the FDA.
For Varex to market its products internationally, Varex must obtain clearances or approvals for products and product modifications. These processes (including, for example, in the EU, the European Economic Area (“EEA”), Switzerland, Brazil, Australia, China, Japan and Canada) can be time consuming, expensive and uncertain, which can delay Varex’s ability to market products in those countries. Delays in the receipt of or failure to receive regulatory approvals, the inclusion of significant limitations on the indicated uses of a product, the loss of previously obtained approvals or failure to comply with existing or future regulatory requirements could restrict or prevent Varex from doing business in a country or subject Varex to a variety of enforcement actions and civil or criminal penalties, which would materially and materially and adversely affect its business. In addition, compliance with changing regulatory schemes, such as what may occur in connection with Brexit, may add additional complexity, cost and delays in marketing or selling Varex’s products. The Brexit process has caused legal uncertainty and will likely lead to divergent national laws and regulations. While the full financial, regulatory and legal effects of Brexit are unknown, if the United Kingdom’s regulatory scheme is materially different from the current EU regulatory process, Varex’s regulatory compliance burden will likely increase.
Within the EU/EEA, Varex must obtain, and in turn affix, a CE mark certification, which is a European marking of conformity that indicates that a product meets the essential requirements of the Medical Device Directive. Compliance with the Medical Device Directive is done through a self-certification process that is then verified by an independent certification body called a “Notified Body,” which is an organization empowered by the legislature to conduct this verification. Once the CE mark is affixed, the Notified Body will regularly audit Varex to ensure that it remains in compliance with the applicable European laws and Medical Device Directive. By affixing the CE mark to its product, Varex is certifying that its products comply with the laws and regulations required by the EU/EEA countries, thereby allowing the free movement of its products within these countries and others that accept CE mark standards. If Varex cannot support its performance claims and demonstrate compliance with the applicable European laws and the Medical Device Directive, Varex would lose its right to affix the CE mark to its products, which would prevent Varex from selling its products within the EU/EEA/Switzerland territory and in other countries that recognize the CE mark. In April 2017, the European Commission adopted two new regulations on medical devices. These new regulations impose stricter requirements for placing medical devices in the EU market, as well as for Notified Bodies. These new regulations have resulted in the limited availability of recognized Notified Bodies, which could delay our ability to obtaining CE marks. Varex may be subject to risks associated with additional testing, modification, certification, or amendment of its existing market authorizations, or Varex may be required to modify products already installed at its customers’ facilities to comply with the official interpretations of these revised regulations.
Varex is also subject to international laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, and manufacturing practices, as well as others. These are often comparable to, if not more stringent than, the equivalent regulations in the United States. Sales overseas are also affected by regulation of matters such as product standards, packaging, labeling, environmental and product recycling requirements, import and export restrictions, tariffs, duties, and taxes.
In addition, Varex is required to timely file various reports with international regulatory authorities similar to the reports it is required to timely file with U.S. regulatory authorities, including reports required by international adverse event reporting regulations. If these reports are not timely filed, regulators may impose sanctions, including temporarily suspending Varex’s market authorizations or CE mark, and sales of its products may suffer.
Further, as Varex enters new businesses or pursues new business opportunities internationally, or as regulatory schemes change, Varex may become subject to additional laws, rules, and regulations. Becoming familiar with and implementing the infrastructure necessary to comply with these laws, rules, and regulations is costly. Additionally, in some countries, Varex relies or may rely in the future on foreign distributors and agents to assist in complying with foreign regulatory requirements, and Varex cannot be sure that they will always do so. The failure of Varex or its agents to comply with these laws, rules, and regulations could delay the introduction of new products, cause reputational harm, or result in investigations, fines, injunctions, civil penalties, criminal prosecution, or an inability to sell Varex’s products in or to import its products into certain countries, which could materially and adversely affect Varex’s business.

21

Compliance with U.S. laws and regulations applicable to the marketing, manufacture, and distribution of Varex’s products may be costly, and failure or delays in obtaining regulatory clearances or approvals or failure to comply with applicable laws and regulations could prevent Varex from distributing its products, require Varex to recall its products, or result in significant penalties or other harm to Varex’s business.
Some of Varex’s products and those of OEMs that incorporate Varex’s products are subject to extensive and rigorous government regulation in the United States. Compliance with these laws and regulations is expensive and time-consuming, and failure to comply with these laws and regulations could materially and adversely affect Varex’s business.
Generally, Varex’s manufacturing operations for medical devices, and those of its third-party manufacturers, are required to comply with the Quality System Regulations (“QSR”) of the FDA, as well as other federal and state regulations for medical devices and radiation-emitting products. The FDA makes announced and unannounced periodic and on-going inspections of medical device manufacturers to determine compliance with QSR and, in connection with these inspections, issues reports known as Form FDA 483 reports when the FDA believes the manufacturer has failed to comply with applicable regulations and/or procedures. If observations from the FDA issued on Form FDA 483 reports are not addressed and/or corrective action is not taken in a timely manner and to the FDA’s satisfaction, the FDA may issue a warning letter and/or proceed directly to other forms of enforcement action. Similarly, if a warning letter were issued, prompt corrective action to come into compliance would be required. Failure to respond in a timely manner to Form FDA 483 observations, a warning letter, or any other notice of noncompliance and to promptly come into compliance could result in the FDA bringing an enforcement action, which could include the total shutdown of Varex’s production facilities, denial of importation rights to the United States for products manufactured in overseas locations, adverse publicity, and criminal and civil fines. The expense and costs of any corrective actions that Varex may take, which may include product recalls, correction and removal of products from customer sites, and/or changes to its product manufacturing and quality systems, could materially and adversely impact Varex’s financial results and may also divert management resources, attention, and time. Additionally, if a warning letter were issued, customers could delay purchasing decisions or cancel orders, and Varex could face increased pressure from its competitors, who could use the warning letter against Varex in competitive sales situations, either of which could materially and adversely affect Varex’s reputation, business, and stock price.
In addition, Varex is required to timely file various reports with the FDA, including reports required by the medical device reporting regulations (“MDRs”), that require Varex report to regulatory authorities if its devices may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If Varex initiates a correction or removal of a device to reduce a risk to health posed by the device, Varex would be required to submit a publicly-available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall, which could lead to increased scrutiny by the FDA, other international regulatory agencies, and Varex’s customers regarding the quality and safety of Varex’s devices. If these MDRs or correction and removal reports are not filed on a timely basis, regulators may impose sanctions, sales of Varex’s products may suffer, and Varex may be subject to product liability or regulatory enforcement actions, all of which could harm its business.
Government regulation may also cause significant delays or even prevent the marketing and full commercialization of future products or services that Varex may develop and/or may impose costly requirements on Varex’s business. Further, as Varex enters new businesses or pursues new business opportunities, Varex will become subject to additional laws, rules, and regulations, including FDA and foreign rules and regulations. Becoming familiar with and implementing the infrastructure necessary to comply with these laws, rules, and regulations is costly and time consuming. In addition, failure to comply with these laws, rules and regulations could delay the introduction of new products and could materially and adversely affect Varex’s business.
If Varex or any of its suppliers, distributors, agents, or customers fail to comply with FDA, Federal Trade Commission, or other applicable U.S. regulatory requirements or are perceived to have failed to comply with regulations, Varex may face:
•
adverse publicity affecting both Varex and its customers;
•
increased pressures from competitors;
•
investigations by governmental authorities;
•
fines, injunctions, civil penalties, and criminal prosecution;
•
partial suspension or total shutdown of production facilities or the imposition of operating restrictions;
•
increased difficulty in obtaining required clearances or approvals or losses of clearances or approvals already granted;
•
seizures or recalls of Varex products or those of its customers;
•
delays in purchasing decisions by customers or cancellation of existing orders;
•
the inability to sell Varex products; and
•
difficulty in obtaining product liability or operating insurance at a reasonable cost, or at all.

22

Varex is also subject to federal and state laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, manufacturing practices, and other matters. Insurance coverage is not commercially available for violations of law, including the fines, penalties, or investigatory costs that Varex may incur as the consequence of regulatory violations. Consequently, Varex does not have insurance that would cover this type of liability.
Varex sells certain X-ray tube products as replacements which are subject to medical device certification and product registration laws and regulations, which vary by country and are subject to change, and Varex may be unable to receive registration approval or renewal of existing registrations if it fails to meet regulatory approval requirements or if the approval process becomes commercially infeasible or impractical.

Varex markets and distributes certain X-ray tubes through distributors and third-party/multi-vendor service organizations that are used as equivalent replacements for specific OEM tubes. Varex is subject to medical device certification and product registration laws, which vary by country and are subject to periodic reviews and changes by regulatory authorities in those countries. For example, to sell X-ray tubes for replacement applications in China, product registrations must be approved by the new National Medical Products Administration (“NMPA”). Varex must comply with the requirements of the NMPA, and Varex may not be able to receive registration approval or renewal of existing registrations if it fails to meet regulatory approval requirements or if the process of gaining approval becomes commercially infeasible or impractical. Certain of these local laws and regulations have the effect of serving as a barrier to trade and can be difficult to navigate predictably.
In addition, certain countries in which Varex products are sold require products to undergo re-registration if the product is altered in any significant way, and it may be determined that the separation of Varex from Varian, including Varex’s new name, will require these products to be re-registered as Varex products, even if they are physically unchanged.
These registration processes can be costly and time consuming, and customers may decide to purchase products from Varex’s competitors that do not have to be involved in a re-registration process. In addition, Varex’s inability to receive or renew product registrations may prevent Varex from marketing and/or distributing those particular products for replacement applications in the specific country.
Existing and future healthcare reforms, including the Affordable Care Act and changes to reimbursement rates, may indirectly have a material adverse effect on Varex’s business and results of operations.
Sales of Varex’s products to OEMs in the medical sector indirectly depend on whether adequate reimbursement is available for its customers’ products from a variety of sources, such as government healthcare insurance programs, including U.S. Medicare and Medicaid programs, foreign government programs, private insurance plans, health maintenance organizations, and preferred provider organizations. Without adequate reimbursement, the demand for Varex’s customers’ products, and therefore indirectly Varex’s products, may be limited.
Healthcare reform proposals and medical cost containment measures in the United States and in many foreign countries could limit the use of both Varex’s and its customers’ products, reduce reimbursement available for such use, further tax the sale or use of Varex’s products, and further increase the administrative and financial burden of compliance. These reforms and measures, including the uncertainty in the medical community regarding their nature and effect, could have a material and adverse effect on Varex’s and its customers’ purchasing decisions regarding its products and treatments and could harm Varex’s business, results of operations, financial condition, and prospects. Varex cannot predict the specific healthcare programs and regulations that will be ultimately implemented by local, regional, and national governments globally. However, any changes that lower reimbursements for Varex’s or its customers’ products and/or procedures using these products, including, for example, existing reimbursement incentives to convert from analog to digital X-ray systems, or changes that reduce medical procedure volumes or increase cost containment pressures on Varex or others in the healthcare sector could materially and adversely affect Varex’s business and results of operations.
Varex is subject to federal, state, and foreign laws governing its business practices which, if violated, could result in substantial penalties. Additionally, challenges to or investigations into Varex’s practices could cause adverse publicity and be costly to respond to and thus could harm its business.
Anti-corruption laws and regulations. Varex is subject to the U.S. Foreign Corrupt Practices Act and anti-corruption laws, as well as similar laws in foreign countries, such as the U.K. Bribery Act and the Law On the Fundamentals of Health Protection in the Russian Federation. In general, there is a worldwide trend to strengthen anti-corruption laws and their enforcement, and the healthcare industry and medical equipment manufacturers have been particular targets of these investigation and enforcement efforts. Any violation of these laws by Varex or its agents or distributors could create substantial liability for Varex, subject its officers and

23

directors to personal liability, and cause a loss of reputation in the market. Varex operates in many countries, including India and China, where the public sector is perceived as being corrupt. Varex’s strategic business plans include expanding its business in regions and countries that are rated as higher risk for corruption activity by Transparency International e.V., an international non-profit that publishes an annual corruption perception index. Becoming familiar with and implementing the infrastructure necessary to comply with laws, rules, and regulations applicable to new business activities and mitigating and protecting against corruption risks could be costly. Failure by Varex or its agents or distributors to comply with these laws, rules, and regulations could delay its expansion into high-growth markets and could materially and adversely affect its business. Varex will likely do more business, directly and potentially indirectly, in countries where the public sector is perceived to be corrupt. Increased business in higher-risk countries could subject Varex and its officers and directors to increased scrutiny and increased liability from its business operations.
Competition and trade compliance laws. Varex is subject to various competition and trade compliance laws in the jurisdictions where it operates. Regulatory authorities in those jurisdictions may have the power to subject Varex to sanctions and impose changes or conditions in the way Varex conducts its business. An increasing number of jurisdictions provide private rights of action for competitors or consumers to assert claims of anti-competitive conduct and seek damages. Increased government scrutiny of Varex’s actions or enforcement or private rights of action could materially and adversely affect its business or damage its reputation. Varex may be required to conduct internal investigations or face audits or investigations by one or more domestic or foreign government agencies, which could be costly and time consuming and could divert its management and key personnel from its business operations. An adverse outcome under any such investigation or audit could subject Varex to fines and/or or criminal or other penalties, which could materially and adversely affect Varex’s business and financial results. Furthermore, competition laws may prohibit or increase the cost of future acquisitions that Varex may desire to undertake.
Laws and ethical rules governing interactions with healthcare providers. Varex does not generally sell its products directly to healthcare providers, but may occasionally sell its products to healthcare providers through distributors. The U.S. Medicare and Medicaid “anti-kickback” laws, and similar state laws, prohibit payments or other remuneration that is intended to induce hospitals, physicians, or others either to refer patients or to purchase, lease, or order, or to arrange for or recommend the purchase, lease, or order of healthcare products or services for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. These laws affect Varex’s sales, marketing, and other promotional activities by limiting the kinds of financial arrangements Varex may have with hospitals, physicians, or other potential purchasers of its products. They particularly impact how Varex structures its sales offerings, including discount practices, customer support, education and training programs, physician consulting, research grants, and other fee-for-service arrangements. These laws are broadly written, and it is often difficult to determine precisely how these laws will be applied to specific circumstances.
Federal and state “false claims” laws generally prohibit knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government payors that are false or fraudulent, or for items or services that were not provided as claimed. Although Varex does not submit claims directly to payors, manufacturers can be, and have been, held liable under these laws if they are deemed to “cause” the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers or through certain other activities, including promoting products for uses not approved or cleared by the FDA, which is called off-label promotion. Violating “anti-kickback” and “false claims” laws can result in civil and criminal penalties, which can be substantial, as well as potential mandatory or discretionary exclusion from healthcare programs for noncompliance. Even an unsuccessful challenge or investigation into Varex’s practices could cause adverse publicity and be costly to defend and thus could harm its business and results of operations. Additionally, several recently-enacted state and federal laws, including laws in Massachusetts and Vermont, and the federal Physician Payment Sunshine Act, now require, among other things, extensive tracking and maintenance of databases regarding the disclosure of equity ownership and payments to physicians, healthcare providers, and hospitals. These laws may require Varex to implement the necessary and costly infrastructure to track and report certain payments to healthcare providers. Failure to comply with these new tracking and reporting laws could subject Varex to significant civil monetary penalties.
Varex is subject to similar laws in foreign countries where it conducts business. For example, within the EU, the control of unlawful marketing activities is a matter of national law in each of the member states. The member states of the EU closely monitor perceived unlawful marketing activity by companies. Varex could face civil, criminal, and administrative sanctions if any member state determines that Varex has breached its obligations under such state’s national laws. Industry associations also closely monitor the activities of member companies. If these organizations or authorities name Varex as having breached its obligations under their regulations, rules, or standards, its reputation would suffer, and its business and financial condition could be materially and adversely affected.

24

Warranty claims may materially and adversely affect Varex’s business.
Varex could experience an increase in warranty claims as a result of issues with product quality or product failures as a direct result of Varex’s design, manufacturing, or issues in its supply chain. Such an occurrence may damage Varex’s market reputation, cause sales to decline, or require repairs or voluntary remedial measures to enhance customer satisfaction, which could materially and adversely impact Varex’s financial results. Increased warranty claims on any given product could cause Varex to halt production on that product and significantly impair Varex’s liquidity and profitability, and cause reputational harm to Varex. Because some categories of products tend to experience higher numbers of warranty claims than others, a shift in the types of products that Varex’s customers purchase could lead to an increase in warranty claims. If actual levels of warranty claims are greater than the level of claims Varex estimates, cost of sales could increase, and Varex’s financial condition could be materially and adversely affected. In addition, product quality issues could result in significant follow-on effects for Varex, including, among other things, reputational harm to Varex and its customers, loss of customers, and liability as a result of product quality issues. These outcomes would materially and adversely affect Varex’s business and financial condition.
If Varex is not able to match its manufacturing capacity with demand for its products, its financial results may suffer.
Many of Varex’s products have a long production cycle, and Varex must anticipate demand for its products to ensure adequate manufacturing or testing capacity. If Varex is unable to anticipate demand, and its manufacturing or testing capacity does not keep pace with product demand, Varex will not be able to fulfill orders in a timely manner, which may negatively impact its financial results and overall business. Conversely, if demand for Varex’s products decreases, the fixed costs associated with excess manufacturing capacity may harm its financial results, including by decreasing gross margins and increasing research and development costs as a percentage of revenue.    
Delivery schedules for Varex’s security, industrial, and inspection products tend to be unpredictable.
Varex designs, manufactures, sells, and services Linatron® X-ray accelerators, image-processing software, and image detection products for security and inspection, such as cargo screening at ports and borders and nondestructive examination for a variety of applications, as well as industrial applications. Varex generally sells security and inspection products to OEMs who incorporate its products into their inspection systems, which are then sold to customs and other government agencies, as well as to commercial organizations in the casting, power, aerospace, chemical, petro-chemical, and automotive industries. Varex believes growth in its security and inspection products will be driven by security cargo screening and border protection needs, as well as by the needs of customs agencies to verify shipments for assessing duties and taxes. This business is heavily influenced by domestic and international government policies on border and port security, political change, and government budgets. In addition, Varex believes growth in this product line may be driven in part by industrial customers engaged in 3-D printing, which, as a developing market, may be difficult to predict. Orders for Varex’s security and inspection products have been and may continue to be unpredictable, as governmental agencies may place large orders with Varex or its OEM customers in a short time period and then may not place any orders for a long time period thereafter. Because it is difficult to predict Varex’s OEM customer delivery, the actual timing of sales and revenue recognition varies significantly. The market for border protection systems has slowed significantly, and end customers, particularly in oil-based economies and war zones in which Varex has a significant customer base, are delaying system deployments or tenders and considering moving to alternative sources, resulting in a decline in the demand for security and inspection products.
The demand for Varex’s security and inspection products is heavily influenced by U.S. and foreign governmental policies on national and homeland security, border protection, and customs activities, which depend upon government budgets and appropriations that are subject to economic conditions, as well as political changes and oil prices. Varex has seen customers freeze or dramatically reduce purchases and capital project expenditures, delay projects, or act cautiously as governments around the world wrestle with spending priorities. As economic growth remains sluggish in various jurisdictions and appears to be deteriorating in others, and as concerns about levels of government employment and government debt continue, Varex expects that these effects will also continue. Bid awards in this business may be subject to challenge by third parties, as Varex has previously encountered with a large government project. These factors make this business more unpredictable and could cause volatility in Varex’s revenues and earnings.
Varex’s international manufacturing operations subject it to volatility and other risks, including high security risks, which could result in harm to its employees and contractors or substantial costs.
Varex conducts certain manufacturing operations internationally to reduce costs and streamline its manufacturing operations. There are administrative, legal, and governmental risks to operating internationally that could increase operating expenses or hamper the development of these operations. The risks from operating internationally that could increase Varex’s operating expenses and

25

materially and adversely affect its operating results, financial condition, and ability to deliver its products and grow its business include, among others:
•
difficulties in staffing and managing employee relations and foreign operations, particularly in attracting and retaining personnel qualified to design, sell, test, and support its products;
•
fluctuations in currency exchange rates;
•
difficulties in coordinating its operations globally and in maintaining uniform standards, controls, procedures, and policies across its operations;
•
difficulties in enforcing contracts and protecting intellectual property;
•
diversion of management attention;
•
imposition of burdensome governmental regulations, including changing laws and regulations with respect to collection and maintenance of personally identifiable data;
•
regional and country-specific political and economic instability, as discussed in greater detail below; and
•
inadequacy of the local infrastructure to support its operations.
Varex’s international locations expose it to higher security risks compared to its United States locations, which could result in both harm to its employees and contractors or substantial costs. Some of its services are performed in or adjacent to high-risk locations where the country or location and surrounding area is suffering from political, social, or economic turmoil, war or civil unrest, or has a high level of criminal or terrorist activity. In those locations where Varex has employees or operations, Varex may incur substantial costs to maintain the safety of its personnel. Despite these precautions, the safety of its personnel in these locations may continue to be at risk, and Varex may in the future suffer the loss of employees and contractors, which could harm its business reputation and operating results.
Varex’s competitive position would be harmed if it is not able to maintain its intellectual property rights and protecting Varex’s intellectual property can be costly.

Varex files applications as appropriate for patents covering new products and manufacturing processes. Varex cannot be sure, however, that patents will be issued from any of Varex’s pending or future patent applications. Varex also cannot be sure that its current patents, the claims allowed under its current patents, or patents for technologies licensed to Varex will be sufficiently broad to protect its technology position against competitors. Issued patents owned by, or licensed to, Varex may be challenged, invalidated, or circumvented, or the rights granted under the patents may not provide Varex with competitive advantages. Asserting Varex’s patent rights against others in litigation or other legal proceedings is costly and diverts managerial resources. For example, during fiscal year 2019, Varex initiated litigation asserting claims of patent infringement against a third party. Varex intends to prosecute its claims vigorously, and Varex has experienced, and will continue to experience, increased legal expenses related to this litigation that could adversely affect its financial results. An adverse finding in this or similar patent infringement litigation could adversely impact Varex’s competitive position. In addition, Varex may not be able to detect patent infringement by others or may lose its competitive position in the market before Varex is able to do so.
Varex also relies on a combination of copyright, trade secret, and other laws, and contractual restrictions on disclosure, copying and transferring title (including confidentiality agreements with vendors, strategic partners, co-developers, employees, consultants, and other third parties), to protect its proprietary, and other confidential rights. These protections may prove to be inadequate, since agreements may still be breached, and Varex may not have adequate remedies for a breach. Varex’s trade secrets may become known to or be independently developed by others, including as a result of misappropriation by unauthorized access to Varex’s technology systems. If Varex’s proprietary or confidential information is misappropriated, its business and financial results could be materially and adversely impacted. Varex has trademarks, both registered and unregistered, that are maintained and enforced to provide customer recognition for its products in the marketplace, but unauthorized parties may still use them. Varex also licenses certain patented or proprietary technologies from others. In some cases, products with substantial revenues may depend on these license rights. If Varex were to lose the rights to license these technologies, or its costs to license these technologies were to materially increase, its business would suffer. As Varex expands its manufacturing capabilities outside of the United States, more of Varex’s intellectual property may be held in jurisdictions that do not have robust intellectual property protections, which may make it harder for Varex to adequately protect its Intellectual Property.
Third parties may claim that Varex is infringing upon their intellectual property, and Varex could suffer significant litigation or licensing expenses or be prevented from selling its products.
There is a substantial amount of litigation over patent and other intellectual property rights in the industries in which Varex competes. Varex’s competitors, like companies in many high technology businesses, continually review other companies’ activities for

26

possible conflicts with their own intellectual property rights. In addition, non-practicing entities may review Varex’s activities for conflicts with their patent rights. Determining whether a product infringes on a party’s intellectual property rights involves complex legal and factual issues, and the outcome of this type of litigation is often uncertain. Parties may claim that Varex is infringing upon their intellectual property rights. Varex may not be aware of intellectual property rights of others that relate to its products, services, or technologies. From time to time, Varex has received notices from parties asserting infringement, and Varex has been subject to lawsuits alleging infringement of patent or other intellectual property rights. Any dispute regarding patents or other intellectual property could be costly and time consuming and could divert Varex’s management and key personnel from its business operations. Varex may not prevail in a dispute. Varex does not maintain insurance for intellectual property infringement, so costs of defense, whether or not Varex is successful in defending an infringement claim, will be borne by Varex and could be significant. If Varex is unsuccessful in defending or appealing an infringement claim, Varex may be subject to significant damages, and its combined financial position, results of operations, or cash flows could be materially and adversely affected. Varex may also be subject to injunctions against development and sale of its products, the effect of which could be to materially reduce its revenues. Furthermore, a third party claiming infringement may not be willing to license its rights to Varex, and even if a third-party rights holder is willing to do so, the amounts Varex might be required to pay under the associated royalty or license agreement could be significant. Varex could decide to alter its business strategy or voluntarily cease the allegedly infringing actions rather than face litigation or pay a royalty, which could materially and adversely impact its business and results of operations.
Product defects or misuse may result in material product liability or professional errors and omissions claims, litigation, investigation by regulatory authorities, or product recalls that could harm Varex’s future revenues and require it to pay material uninsured claims.
Varex’s business exposes it to potential product liability claims that are inherent in the manufacture, sale, installation, servicing, and support of components that are used in medical devices and other devices that deliver radiation. Because Varex’s products, through incorporation in OEMs’ systems, are involved in the intentional delivery of radiation to the human body and other situations where people may come into contact with radiation (for example, when Varex’s security and inspection products are being used to scan cargo or in the diagnosis of medical problems), the possibility for significant personal injury or loss of life exists. Although Varex’s products are incorporated into OEMs’ systems, and thus only perform pursuant to the design and operating systems of OEMs, Varex may also be subject to claims for property damage, personal injury, or economic loss related to or resulting from any errors or defects in its products or the installation, servicing, or support of its products. Any accident or mistreatment could subject Varex to legal costs, litigation, adverse publicity, and damage to its reputation, whether or not its products or services were a factor.
If Varex’s X-ray inspection systems fail to detect the presence of bombs, explosives, weapons, contraband, or other threats to personal safety, Varex could be subject to product and other liability claims or negative publicity, which could result in increased costs, reduced sales, and a decline in the market price of Varex’s common stock. There are many factors beyond Varex’s control that could result in the failure of its products to detect the presence of bombs, explosives, weapons, contraband, or other threats to personal safety, including operator error and misuse of or malfunction of Varex equipment. The failure of Varex’s systems to detect the presence of these dangerous materials may lead to personal injury, loss of life, and extensive property damage and may result in potential claims against Varex.
Product liability actions are subject to uncertainty and may be expensive, time consuming, and disruptive to Varex’s operations. For these and other reasons, Varex may choose to settle product liability claims against it regardless of their actual merit. A product liability action determined against Varex could result in adverse publicity or significant damages, including the possibility of punitive damages, and Varex’s combined financial position, results of operations, or cash flows could be materially and adversely affected.
If a product Varex designs or manufactures were defective (whether due to design, labeling or manufacturing defects, improper use of the product, or other reasons), Varex may be required to correct or recall the product and notify regulatory authorities. The adverse publicity resulting from a correction or recall could damage Varex’s reputation and cause customers to review and potentially terminate their relationships with Varex. A product correction or recall could consume management time and have an adverse financial impact on its business, including incurring substantial costs, losing revenues, and accruing losses.
Varex maintains limited product liability insurance coverage. Varex’s product liability insurance policies are expensive and have high deductible amounts and self-insured retentions. Varex’s insurance coverage may prove to be inadequate, and future policies may not be available on acceptable terms or in sufficient amounts, if at all. If a material claim is not insured or is in excess of Varex’s insurance coverage, Varex could have to pay substantial damages, which could have a material and adverse effect on its financial position and/or results of operations.

27

Certain of Varex’s products are subject to regulations relating to use of radioactive material, compliance with which may be costly, and a failure to comply therewith may materially and adversely affect Varex’s business.
As a manufacturer and seller of medical devices and devices emitting radiation or utilizing radioactive by-product material, Varex and some of its suppliers and distributors are subject to extensive regulation by United States governmental authorities, such as the FDA, the Nuclear Regulatory Commission (“NRC”), and state and local regulatory agencies, which is intended to ensure the devices are safe and effective and comply with laws governing products which emit, produce, or control radiation. These regulations govern, among other things, the design, development, testing, manufacturing, packaging, labeling, distribution, import/export, sale, and marketing and disposal of Varex’s products. Varex is also subject to international laws and regulations that apply to manufacturers of radiation-emitting devices and products utilizing radioactive materials. These are often comparable to, if not more stringent than, the equivalent regulations in the United States.
Varex’s industrial and medical devices utilizing radioactive material are subject to NRC clearance and approval requirements, and the manufacture and sale of these products are subject to extensive federal and state regulation that varies from state to state and among regions. Varex’s manufacture, distribution, installation, service, and removal of industrial devices utilizing radioactive material or emitting radiation also requires Varex to obtain a number of licenses and certifications for these devices and materials. Service of these products must also be in accordance with a specific radioactive materials licenses. Obtaining licenses and certifications may be time consuming, expensive, and uncertain.
The handling and disposal of radioactive materials resulting from the manufacture, use, or disposal of Varex’s products may impose significant costs and requirements. Disposal sites for the lawful disposal of materials generated by the manufacture, use, or decommissioning of Varex’s products may no longer accept these substances in the future or may accept them on unfavorable terms.
If Varex is unable to obtain required FDA clearances or approvals for a product or is unduly delayed in doing so, or the uses of that product were limited, Varex’s business could suffer.
Typically, Varex’s OEM customers are responsible for obtaining 510(k) pre-market notification clearance on their systems that integrate Varex products. A substantial majority of Varex’s products are “Class I” devices that do not require 510(k) clearance, but Varex does produce software that is classified as a Class II device subject to 510(k) clearance. Unless an exception applies, Varex may be required by FDA regulations to obtain a 510(k) pre-market notification clearance in connection with the manufacture of a new medical device or a new indication for use of, or other significant change in, an existing currently marketed medical device before it can market or sell those products in the United States. Modifications or enhancements to a product that could significantly affect its safety or effectiveness, or that would constitute a major change in the intended use of the device, technology, materials, labeling, packaging, or manufacturing process also require a new 510(k) clearance. Although manufacturers make the initial determination whether a change to a cleared device requires a new 510(k) clearance, Varex cannot ensure that the FDA will agree with its decisions not to seek additional approvals or clearances for particular modifications to its products or that Varex will be successful in obtaining new 510(k) clearances for modifications. Obtaining clearances or approvals is time consuming, expensive, and uncertain. Varex may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, which could harm its business. Furthermore, even if Varex is granted regulatory clearances or approvals, they may include significant limitations on the indicated uses of the product, which may limit the market for the product. If Varex is unable to obtain required FDA clearance or approval for a product or is unduly delayed in doing so, or the uses of that product were limited, Varex’s business could suffer.
Disruption of critical information systems or material breaches in the security of Varex’s systems may materially and adversely affect its business and customer relations.
Information technology (including technology from third party providers) helps Varex operate efficiently, interface with and support its customers, maintain financial accuracy and efficiency, and produce its financial statements. In the ordinary course of its business, Varex collects, processes and stores sensitive data, including intellectual property, proprietary business information and that of customers, suppliers and business partners, third parties accessing its website, patient data and personally identifiable information of customers and employees, in Varex’s data centers, and on its networks, as well as third party off-site infrastructure. Despite security measures, there is an increasing threat of information security attacks, including from computer viruses or other malicious codes, unauthorized access attempts, and cyber-attacks that pose risks to companies, including Varex. Because the techniques used to obtain unauthorized access, or to sabotage systems, change frequently, have become increasingly sophisticated and generally are not recognized until launched against a target, Varex may be unable to anticipate these techniques or to implement adequate preventative measures, which could result in data leaks or otherwise compromise our confidential or proprietary information and disrupt our operations. If Varex does not allocate and effectively manage the resources necessary to build and sustain the proper technology infrastructure, Varex could be subject to, among other things, transaction errors, processing inefficiencies, the loss of customers,

28

business disruptions, or the loss of or damage to intellectual property through a security breach or misappropriation of intellectual property. Such security breaches could expose Varex to a risk of loss of information, litigation, and possible liability to employees, customers, and/or regulatory authorities. If Varex’s data management systems do not effectively collect, secure, store, process, and report relevant data for the operation of its business, whether due to equipment malfunction or constraints, software deficiencies, or human error, Varex’s ability to effectively plan, forecast, and execute its business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect Varex’s financial condition, results of operations, cash flows, and the timeliness with which Varex reports its operating results internally and externally.
Varex uses certain cloud-based software. A security breach, whether of Varex’s products, of Varex’s customers’ network security and systems, or of third-party hosting services could disrupt access to Varex’s customers’ stored information and could lead to the loss of, damage to or public disclosure of Varex’s customers’ stored information, including patient health information. Such an event could have serious negative consequences, including possible patient injury, regulatory action, fines, penalties and damages, reduced demand for Varex’s solutions, an unwillingness of its customers to use its solutions, harm to its reputation and brand, and time-consuming and expensive litigation, any of which could have a material and adverse effect on Varex’s financial results.
Unfavorable results of legal proceedings could materially and adversely affect Varex’s financial results.
From time to time, Varex is a party to or otherwise involved in legal proceedings, claims, government inspections, audits or investigations, and other legal matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. Legal proceedings are often lengthy, taking place over a period of years with interim motions or judgments subject to multiple levels of review (such as appeals or rehearings) before the outcome is final. Litigation and other legal proceedings, claims, government inspections, audits and investigations are subject to significant uncertainty and may be expensive, time consuming, and disruptive to Varex’s operations. For these and other reasons, Varex may choose to settle legal proceedings and claims, regardless of their actual merit.
If a legal proceeding were ultimately resolved against Varex, it could result in significant compensatory damages, and, in certain circumstances, punitive damages, disgorgement of revenue or profits, remedial corporate measures, or injunctive relief imposed on Varex. If Varex’s existing insurance does not cover the amount or types of damages awarded, or if other resolution or actions taken as a result of such legal proceeding were to restrain its ability to market one or more of its material products or services, its combined financial position, results of operations, or cash flows could be materially and adversely affected. In addition, legal proceedings, and any adverse resolution thereof, can result in adverse publicity and damage to Varex’s reputation, which could materially and adversely impact its business.
Varex’s business may suffer if it is not able to hire and retain qualified personnel.
Varex’s future success depends, to a great degree, on its ability to retain, attract, expand, integrate, and train its management team and other key personnel, such as qualified engineering, service, sales, marketing, and other staff. Varex competes for key personnel with other medical equipment and software manufacturers and technology companies, as well as universities and research institutions. Because this competition is intense, particularly in Utah, where unemployment rates are relatively low, compensation-related costs could increase significantly if the supply of qualified personnel decreases or demand increases. If Varex is unable to hire and train qualified personnel, Varex may not be able to maintain or expand its business. Additionally, if Varex is unable to retain key personnel, Varex may not be able to replace them readily or on terms that are reasonable, which also could hurt its business.
Changes in interpretation or application of generally accepted accounting principles may materially and adversely affect Varex’s operating results.
Varex prepares its financial statements in accordance with GAAP. These principles are subject to interpretation by the FASB, American Institute of Certified Public Accountants, the SEC, and various other regulatory and/or accounting bodies. A change in interpretations of, or its application of, these principles can have a significant effect on Varex’s reported results and may even affect its reporting of transactions completed before a change is announced. In addition, when Varex is required to adopt new accounting standards, Varex’s methods of accounting for certain items may change, which could cause its results of operations to fluctuate from period to period and make it more difficult to compare its financial results to prior periods.
As its operations evolve over time, Varex may introduce new products and/or new technologies that require Varex to apply different accounting principles, including ones regarding revenue recognition, than Varex has applied in past periods. The application of different types of accounting principles and related potential changes may make it more difficult to compare its financial results from quarter to quarter, and the trading price of Varex common stock could suffer or become more volatile as a result.

29

Environmental laws impose compliance costs on Varex’s business and may also result in liability.
Varex is subject to environmental laws around the world. These laws regulate many aspects of its operations, including its handling, storage, transport, and disposal of hazardous substances, such as the chemicals and materials that Varex uses in the course of its manufacturing operations. They can also impose cleanup liabilities, including with respect to discontinued operations. As a consequence, Varex can incur significant environmental costs and liabilities, some recurring and others not recurring. Although its follows procedures intended to comply with existing environmental laws, Varex, like other businesses, may mishandle or inadequately manage hazardous substances used in its manufacturing operations and can never completely eliminate the risk of contamination or injury from certain materials that it uses in its business and, therefore, it cannot completely eliminate the prospect of resulting claims and damage payments. Varex may also be assessed fines and/or other penalties for failure to comply with environmental laws and regulations. Insurance has provided coverage for portions of cleanup costs resulting from historical occurrences, but Varex does not expect to maintain insurance coverage for costs or claims that might result from any future contamination.
Future changes in environmental laws could also increase its costs of doing business, perhaps significantly. Several countries, including some in the EU, now require medical equipment manufacturers to bear certain disposal costs of products at the end of the product’s useful life, increasing its costs. The EU has also adopted directives that may lead to restrictions on the use of certain hazardous substances or other regulated substances in some of its products sold there. These directives, along with another that requires substance information to be provided upon request, could increase Varex’s operating costs in order to maintain its access to certain markets. All of these costs, and any future violations or liabilities under environmental laws or regulations, could have a material adverse effect on its business.
Varex’s operations are vulnerable to interruption or loss due to natural or other disasters, power loss, strikes, and other events beyond its control.

Varex conducts some of its activities, including manufacturing, research and development, administration, and data processing at facilities located in areas that have in the past experienced or may in the future experience natural disasters. Varex’s insurance coverage for such disasters may not be adequate or continue to be available at commercially-reasonable terms, or at all. A major disaster (such as a major fire, hurricane, earthquake, flood, tsunami, volcanic eruption or terrorist attack) affecting Varex’s facilities, or those of its suppliers, could significantly disrupt its operations and delay or prevent product manufacture and shipment during the time required to repair, rebuild, or replace its or its suppliers’ damaged manufacturing facilities. These delays could be lengthy and costly. If any of Varex’s customers’ facilities are adversely affected by a disaster, shipments of its products could be delayed. Additionally, customers may delay purchases of Varex’s products until its operations return to normal. For example, following the earthquake and tsunami disasters in Japan in 2011, the operations of Canon Medical Systems, our largest customer, were impacted, and, as a consequence, orders to and product shipment from our business were delayed for several months. Even if Varex's suppliers or customers are able to quickly respond to a disaster, the ongoing effects of the disaster could create some uncertainty in the operations of its business. In addition, Varex’s facilities may be subject to a shortage of available electrical power and other energy supplies. Any shortages may increase its costs for power and energy supplies or could result in blackouts, which could disrupt the operations of its affected facilities and harm its business. Further, Varex’s products are typically shipped from a limited number of ports, and any disaster, strike, or other event blocking shipment from these ports could delay or prevent shipments and harm its business. In addition, concerns about terrorism, the effects of a terrorist attack, political turmoil, or an outbreak of epidemic diseases could have a negative effect on Varex’s business operations, those of its suppliers and customers, and the ability to travel, resulting in adverse consequences on its revenues and financial performance.

Certain provisions in Varex’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, and of Delaware law, may prevent or delay an acquisition of Varex, which could decrease the trading price of Varex’s common stock.
Varex’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws contain, and Delaware law contains, provisions that are intended to deter coercive takeover practices and inadequate takeover bids by making such practices or bids unacceptably expensive to the bidder and to encourage prospective acquirers to negotiate with Varex’s board of directors rather than to attempt a hostile takeover. These provisions include, among others:
•
the inability of Varex’s stockholders to call a special meeting;
•
the inability of Varex’s stockholders to act without a meeting of stockholders;
•
rules regarding how stockholders may present proposals or nominate directors for election at stockholder meetings;
•
the right of Varex’s board of directors to issue preferred stock without stockholder approval;

30

•
the division of Varex’s board of directors into three classes of directors, with each class serving a staggered three-year term, and this classified board provision could have the effect of making the replacement of incumbent directors more time-consuming and difficult, until the 2022 annual meeting of stockholders, after which directors will be elected annually;
•
a provision that stockholders may only remove directors with cause while the board is classified;
•
the ability of Varex’s directors, and not stockholders, to fill vacancies on Varex’s board of directors; and,
•
the requirement that the affirmative vote of stockholders holding at least 66 2/3% of Varex’s voting stock is required to amend certain provisions in Varex’s Amended and Restated Certificate of Incorporation (relating to the term and removal of its directors, the filling of its board vacancies, the calling of special meetings of stockholders, stockholder action by written consent, the elimination of liability of directors to the extent permitted by Delaware law and indemnification of directors and officers), although this requirement will expire on the completion of the 2021 annual meeting of stockholders, after which Varex's Amended and Restated Certificate of Incorporation may be amended by the affirmative vote of the holders of at least a majority of the outstanding voting stock.
In addition, because Varex did not elect to be exempt from Section 203 of the Delaware General Corporation Law (the “DGCL”), this provision could also delay or prevent a change of control that stockholders may favor. Section 203 provides that, subject to limited exceptions, persons that acquire, or who are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation (an “interested stockholder”) shall not engage in any business combination with that corporation, including by merger, consolidation, or acquisitions of additional shares, for a three-year period following the date on which the person became an interested stockholder, unless: (1) prior to such time, the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (2) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced; or (3) on or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock of such corporation not owned by the interested stockholder.
Varex believes these provisions will protect its stockholders from coercive or otherwise unfair takeover tactics by requiring potential acquirers to negotiate with Varex’s board of directors and by providing Varex’s board of directors with more time to assess any acquisition proposal. These provisions are not intended to make Varex immune from takeovers. However, these provisions will apply even if the offer may be considered beneficial by some stockholders and could delay or prevent an acquisition that Varex’s board of directors determines is not in the best interests of Varex and Varex’s stockholders. These provisions may also prevent or discourage attempts to remove and replace incumbent directors.
Potential indemnification liabilities to Varian could materially and adversely affect Varex’s business, financial condition, results of operations, and cash flows.
Varex entered into a Separation and Distribution Agreement when it spun off from Varian. The agreement provides for, among other things, indemnification obligations designed to make Varex financially responsible for any Varex liabilities; the failure of Varex to pay, perform, or otherwise promptly discharge any Varex liabilities or contracts in accordance with their respective terms; any guarantee, indemnification obligation, surety bond or other credit support agreement, arrangement, commitment, or understanding by Varian for the benefit of Varex, unless related to Varian liabilities; any breach by Varex of the Separation and Distribution Agreement or any of the ancillary agreements; any action by Varex in contravention of its Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws; and, any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, with respect to all information contained in the Registration Statement on Form 10 (as amended or supplemented) or any other disclosure document that describes the separation, the distribution, Varex and its subsidiaries, or the transactions contemplated by the Separation and Distribution Agreement, subject to certain exceptions. If Varex is required to indemnify Varian under the circumstances set forth in the Separation and Distribution Agreement, Varex may be subject to substantial liabilities.
In connection with Varex’s spin-off from Varian, Varian has agreed to indemnify Varex for certain liabilities. However, there can be no assurance that the indemnity will be sufficient to insure Varex against the full amount of such liabilities or that Varian’s ability to satisfy its indemnification obligation will not be impaired in the future.
Pursuant to the Separation and Distribution Agreement and certain other agreements with Varian, Varian agreed to indemnify Varex for certain liabilities. However, third parties could also seek to hold Varex responsible for any of the liabilities that Varian retained, and there can be no assurance that the indemnity from Varian will be sufficient to protect Varex against the full amount of such liabilities or that Varian will be able to fully satisfy its indemnification obligations. In addition, Varian’s insurers may attempt to deny coverage to Varex for liabilities associated with certain occurrences of indemnified liabilities prior to the separation. Moreover,

31

even if Varex ultimately succeeds in recovering from Varian or such insurance providers any amounts for which Varex is held liable, Varex may be temporarily required to bear these losses. Each of these risks could negatively affect Varex’s business, financial position, results of operations, and/or cash flows.
Potential liabilities may arise due to fraudulent transfer considerations, which could materially and adversely affect Varex’s financial condition and its results of operations.
In connection with the spin-off, Varian completed several corporate restructuring transactions, which, along with the separation and distribution, may be subject to federal and state fraudulent conveyance and transfer laws. If, under these laws, a court were to determine that, at the time of the separation and distribution, any entity involved in these restructuring transactions or the separation and distribution:
•
was insolvent;
•
was rendered insolvent by reason of the separation and distribution;
•
had remaining assets constituting unreasonably small capital; or,
•
intended to incur, or believed it would incur, debts beyond its ability to pay these debts as they matured,
then the court could void the separation and distribution, in whole or in part, as a fraudulent conveyance or transfer. The court could then require Varex’s stockholders to return to Varian some or all of the shares of Varex common stock issued in the distribution or require Varian or Varex, as the case may be, to fund liabilities of the other company for the benefit of creditors. The measure of insolvency will vary depending upon the jurisdiction whose law is being applied. Generally, however, an entity would be considered insolvent if the fair value of its assets was less than the amount of its liabilities or if it incurred debt beyond its ability to repay the debt as it matures.

Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
Our business is primarily located in Salt Lake City, Utah, where we own approximately 37 acres of land and approximately 494,000 square feet of space used for manufacturing, administrative functions and research and development, for both our Medical and Industrial segments. We also own or lease 34 other facilities throughout North America, Europe and Asia (located in 8 states and 17 foreign countries) that comprise over 2 million square feet of manufacturing facilities, warehouses, sales and service, research and development and office space, which are used for our Medical and/or Industrial segments, depending on the location.
In addition to our location in Salt Lake City, Utah, our other primary owned facilities are located in Las Vegas, Nevada and Franklin Park, Illinois. Our Las Vegas, Nevada, facility has approximately 5 acres of land and 94,000 square feet of space used for manufacturing, administrative functions and research and development, for our Industrial segments. Our Franklin Park, Illinois, facility has approximately 3 acres of land and approximately 61,000 square feet of space used for manufacturing, administrative functions and research and development, for both our Medical and Industrial segments.
Primary leased facilities include approximately 144,000 square feet in Laguna, Philippines, approximately 73,000 square feet in Santa Clara, California, approximately 46,000 square feet in Wuxi, China, approximately 47,000 square feet in Dinxperlo, the Netherlands, approximately 34,000 square feet in Bremen, Germany and approximately 34,000 of square feet in Walluf, Germany, all of which are used for manufacturing and administrative functions for our Medical and Industrial segments.
Item 3. Legal Proceedings
From time to time, we are involved in legal proceedings arising in the ordinary course of business or otherwise. We do not believe that any material liability will be imposed as a result of these matters. If actual liabilities significantly exceed the estimates made, our combined financial position, results of operations, comprehensive earnings or cash flows could be materially and adversely affected. Legal expenses relating to legal matters are expensed as incurred. See “Risk Factors- Unfavorable results of legal proceedings could materially and adversely affect Varex's financial results.”

32



Item 4. Mine Safety Disclosures
Not applicable.

33


PART II
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Varex's common stock is traded on the NASDAQ Global Select Market (the “NASDAQ”) under the symbol “VREX.”
Since our inception, we have not paid any cash dividends and have no current plan to pay cash dividends on Varex common stock. As of November 18, 2019, there were 1,662 holders of record of Varex common stock.
This graph shows the total return on VREX common stock since listing on NASDAQ on January 20, 2017, with comparative total returns for the Russell 2000 Index (“RUT”) and the Dow Jones Medical Equipment Index (“DJUSAM”). The graph below assumes that $100.00 was invested on January 20, 2017 in our common stock and the companies listed in the RUT and the DJUSAM, as well as a reinvestment of dividends paid on such investments throughout the period.
chart-60e2d95fbd6683f2865.jpg
Item 6. Selected Financial Data
In January 2017, we separated from Varian. Prior to the date of separation, the financial statements were prepared on a stand-alone basis and derived from Varian’s consolidated financial statements as we operated as part of Varian.
The following data, in so far as it relates to each of the fiscal years from 2015 through 2019, has been derived from annual consolidated financial statements, including the consolidated balance sheets at September 27, 2019 and September 28, 2018 and the related consolidated statements of earnings, of comprehensive earnings, and of cash flows for the fiscal years 2019, 2018 and 2017 and notes thereto appearing elsewhere herein. In addition, the following financial data should be read in conjunction with our consolidated financial statements and the accompanying notes and the MD&A included elsewhere herein.

34


Summary of Operations:
Fiscal Years
(In millions, except per share amounts)
2019
 
2018
 
2017(1)
 
2016
 
2015
Revenues
$
780.6

 
$
773.4

 
$
698.1

 
$
620.1

 
$
632.3

Gross margin
$
256.7

 
$
253.9

 
$
253.5

 
$
248.4

 
$
250.6

Earnings before taxes
21.5

 
25.7

 
74.8

 
105.0

 
127.6

Taxes on earnings
5.7

 
(2.6
)
 
22.8

 
36.0

 
46.8

Net earnings
15.8

 
28.3

 
52.0

 
69.0

 
80.8

Less: Net earnings attributable to noncontrolling interests
0.3

 
0.8

 
0.4

 
0.5

 
0.8

Net earnings attributable to Varex
$
15.5

 
$
27.5

 
$
51.6

 
$
68.5

 
$
80.0

Net earnings per share attributable to Varex
 
 
 
 
 
 
 
 
 
Net earnings per share - basic
$
0.41

 
$
0.73

 
$
1.37

 
$
1.83

 
$
2.14

Net earnings per share - diluted
$
0.40

 
$
0.72

 
$
1.36

 
$
1.82

 
$
2.12

Financial Position at Fiscal Year End:
 
 
 
 
 
 
 
 
 
Working capital
$
263.3

 
$
306.1

 
$
343.5

 
$
282.1

 
$
237.5

Total assets
1,038.9

 
987.9

 
1,040.1

 
622.4

 
583.6

Total debt (excluding current maturities, net of deferred costs)
364.4

 
364.8

 
464

 
—

 
—

(1)
The summary of operations for fiscal year 2017 includes operating results from the Acquired Detector Business for the period from May 1, 2017 through September 29, 2017.

Selected Quarterly Financial Data (Unaudited)
The following table sets forth selected financial data from our unaudited quarterly consolidated statements of earnings for the eight quarters ended fiscal year 2019. The information for each quarter has been derived from unaudited financial statements and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the unaudited interim periods and includes certain reclassifications and rounding differences. The quarterly data should be read together with our consolidated financial statements and related notes appearing elsewhere in this annual report.
 
Fiscal Year 2019 (1)
(In millions, except per share amounts, unaudited)
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
Total Year
Total revenues
$
185.7

 
$
195.8

 
$
196.7

 
$
202.4

 
$
780.6

Gross margin
$
60.0

 
$
64.4

 
$
60.7

 
$
71.6

 
$
256.7

Net earnings
$
3.0

 
$
5.9

 
$
(1.3
)
 
$
8.2

 
$
15.8

Net earnings attributable to Varex
$
3.0

 
$
5.8

 
$
(1.4
)
 
$
8.1

 
$
15.5

Net earnings per share - basic
$
0.08

 
$
0.15

 
$
(0.04
)
 
$
0.21

 
$
0.41

Net earnings per share - diluted
$
0.08

 
$
0.15

 
$
(0.04
)
 
$
0.21

 
$
0.40


(1)
During fiscal year 2019, the Company identified errors that originated in prior periods and were corrected for as out of period adjustments in the quarters of fiscal year 2019. Management has determined that such errors and out of period adjustments, which primarily related to inventory accounting, revenue recognition and intercompany transactions, were not material to any of the unaudited interim financial statements. The impact of these errors and out of period adjustments on total revenues, gross margin, net earnings and net earnings per diluted share was as follows:
•
Q1 2019 - $(0.6) million, $(1.1) million, $0.4 million and $0.01 per diluted share, respectively;
•
Q2 2019 - $0.1 million, $0.0 million, $(1.2) million and $(0.03) per diluted share respectively;
•
Q3 2019 -  $0.0 million, $(0.9) million, $(0.6) million and $(0.02) per diluted share respectively;
•
Q4 2019 - $0.0 million, $2.2 million, $1.6 million and $0.04 per diluted share, respectively.


35

 
Fiscal Year 2018
(In millions, except per share amounts, unaudited)
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
Total Year
Total revenues
$
176.2

 
$
201.2

 
$
191.2

 
$
204.8

 
$
773.4

Gross margin
$
61.5

 
$
70.1

 
$
63.0

 
$
59.3

 
$
253.9

Net earnings
$
11.4

 
$
12.3

 
$
3.9

 
$
0.7

 
$
28.3

Net earnings attributable to Varex
$
11.3

 
$
12.2

 
$
3.8

 
$
0.2

 
$
27.5

Net earnings per share - basic
$
0.30

 
$
0.32

 
$
0.10

 
$
0.01

 
$
0.73

Net earnings per share - diluted
$
0.30

 
$
0.32

 
$
0.10

 
$
0.01

 
$
0.72



36

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Basis of Presentation
We became an independent publicly-traded company in January 2017 following our separation from Varian and subsequent distribution of shares of our common stock to Varian shareholders.
Prior to the spin-off, we operated as a division of Varian. Accordingly, for part of fiscal year 2017, certain shared costs have been allocated to us and are reflected as expenses in the accompanying financial statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the related expenses attributable to us for purposes of the carve-out financial statements; however, the expenses reflected in these financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if we had operated as a separate stand-alone entity. The allocation methods include revenue, headcount, actual usage of services, and others. In addition, the expenses reflected in the financial statements may not be indicative of expenses that will be incurred by us in the future.
Our Business
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components including X-ray tubes, digital detectors, linear accelerators and other image processing solutions, which are key components of X-ray imaging systems. Our components are used in medical imaging as well as in industrial and security imaging applications. Global original equipment manufacturers (“OEM”) incorporate our X‑ray imaging components in their systems to detect, diagnose, protect and inspect. As of September 27, 2019, we had approximately 2,000 full-time equivalents employees, located at manufacturing and service center sites in North America, Europe, and Asia. 

Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, Russia, the Middle East, India and Africa. APAC includes Asia and Australia. Revenues by region are based on the known final destination of products sold.

Our success depends, among other things, on our ability to anticipate and respond to changes in our markets, the direction of technological innovation and the demands of our customers. We continue to invest in research and development and employ over 500 engineers. Combining this focus on innovation and product performance with strong long-term customer relationships allows us to partner with our customers to bring industry-leading products to the X-ray imaging market. We continue to work to improve the life and quality of our imaging components and leverage our scale as the largest X-ray imaging component supplier to provide cost-effective solutions for our customers. Demand for our products can also be impacted by geo-political factors, including tariffs on key imported materials used in manufacturing our products and also on X-ray imaging products we sell to customers outside the United States. The escalation of trade conflicts between the United States and China has negatively impacted our business and are expected to continue.

Operating Segments and Products

Our Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), evaluates our product groupings and measures our business performance in two reportable operating segments: Medical and Industrial. The segments align our products and service offerings with customer use in medical and industrial markets and are consistent with how the CODM evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin.
Medical

In our Medical business segment, we design, manufacture, sell and service X-ray imaging components for use in a range of radiographic or fluoroscopic imaging applications including, computed tomography (“CT”), mammography, oncology, cardiac, surgery, dental, and computer-aided detection. We provide a broad range of X-ray imaging components for Medical customers, including X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers and buckys.

A significant portion of our revenues come from the sales of high-end X-ray tubes used in CT imaging and high-end dynamic digital detectors used in fluoroscopic and 3D dental imaging applications. These upper-tier imaging components are characterized by increased levels of technological complexity, engineering and intellectual property that typically allow these products to have a higher sales price and gross margin.

37


The digital detector market continues to mature from initial product introductions that were made approximately 15 years ago. For the past few years, we have experienced price erosion for these products, predominantly in the highly-competitive market for radiographic detectors. We anticipate this trend will continue in the foreseeable future.

Our X-ray imaging components are primarily sold to OEM customers that incorporate our products into their X-ray imaging systems for a variety of medical modalities and industrial applications. To a much lesser extent, we also sell our X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.

In China, the government is broadening the availability of healthcare services throughout the country. As a result, the number of diagnostic X-ray imaging systems, including CT, has grown significantly. We are developing CT tubes and related subsystems for Chinese OEMs as they introduce new CT imaging systems in China. Over the long-term, we anticipate that China-based revenues will increase as a percentage of our revenues. For fiscal year 2019, revenues from X-ray imaging components shipped to China-based OEMs and distributors declined to approximately 8% of total company revenues from 10% in the prior year. This decrease reflects a tariff-related decline in sales of radiographic digital detectors in China as well as lower non-OEM aftermarket sales, which more than offset an increase in sales of CT tubes to OEM customers.

We have taken certain actions to help us mitigate the impact of the trade war between the United States and China. We have implemented changes to secure more non-China sources of supply of parts and materials used to manufacture our X-ray imaging products, and in September 2019, we received from the United States Trade Representative a temporary exclusion from Section 301 tariffs on certain parts and components imported from China into the United States. We continue to expand manufacturing capabilities at our facilities in China, Germany and the Philippines.
Industrial

In our Industrial business segment, we design, manufacture, sell and service X-ray imaging products for use a number of markets, including security applications, such as cargo screening at ports and borders and baggage screening at airports, as well as nondestructive testing and inspection applications used in a number of other markets. Our industrial products include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors and high voltage connectors. In addition, we provide proprietary image-processing and detection software designed to work with these other Varex products to provide package solutions to our Industrial customers.

The security market primarily consists of airport security for carry-on baggage, checked baggage and palletized cargo, as well as cargo security for the screening of trucks, trains and cargo containers at ports and borders. The end customers for border protection systems are typically government agencies, many of which are in oil-based economies and war zones where there has been significant year over year variation in buying patterns.

The non-destructive testing market utilizes X-ray imaging to scan items for inspection of manufacturing defects and product integrity in a wide range of industries including the aerospace, automotive, oil and gas, food packaging, metal castings and 3D printing industries. We provide X-ray sources, digital detectors, high voltage connectors and image processing software to OEM customers, system integrators and manufacturers. In addition, new applications for X-ray sources are being developed, such as sterilization of food and its packaging.
Fiscal Year
Our fiscal year is the 52- or 53-week period ending on the Friday nearest September 30. Fiscal year 2019 was the 52-week period that ended September 27, 2019, fiscal year 2018 was the 52-week period that ended September 28, 2018, and fiscal year 2017 was the 52-week period ended September 29, 2017. Set forth below is a discussion of our results of operations for fiscal years 2019, 2018 and 2017.

38

Discussion of Results of Operations for Fiscal Year 2019 and 2018
Revenues, net
 
Fiscal Years
 
 
 
 
(In millions)
2019
 
2018
 
$ Change
 
% Change
Medical
$
596.8

 
$
602.0

 
$
(5.2
)
 
(1)%
Industrial
183.8

 
171.4

 
12.4

 
7%
Total revenues, net
$
780.6

 
$
773.4

 
$
7.2

 
1%
Medical as a percentage of total revenues
76
%
 
78
%
 
 
 
 
Industrial as a percentage of total revenues
24
%
 
22
%
 
 
 
 
Medical revenues decreased $5.2 million primarily due to decreased sales of radiographic digital detectors in China and non-OEM aftermarket X-ray tubes, partially offset by increased sales of digital detectors and X-ray tubes for oncology applications, OEM X-ray tubes for CT applications and the addition of revenues from the acquisition of Direct Conversion AB (publ) (“Direct Conversion”).
Industrial revenues increased $12.4 million due to increased sales of X-ray tubes for airport security, digital detectors for
inspection applications and the addition of revenues with the acquisition of Direct Conversion.

Revenues by Region
 
Fiscal Years
 
 
 
 
(In millions)
2019
 
2018
 
$ Change
 
% Change
Americas
$
282.6

 
$
275.8

 
$
6.8

 
2
 %
EMEA
269.0

 
254.5

 
14.5

 
6
 %
APAC
229.0

 
243.1

 
(14.1
)
 
(6
)%
Total revenues, net
$
780.6

 
$
773.4

 
$
7.2

 
1
 %
Americas as a percentage of total revenues
36
%
 
36
%
 
 
 
 
EMEA as a percentage of total revenues
34
%
 
33
%
 
 
 
 
APAC as a percentage of total revenues
29
%
 
31
%
 
 
 
 
The Americas revenues increased $6.8 million primarily due to increased sales of X-ray tubes partially offset by lower sales of digital detectors and computer-aided detection software. EMEA revenues increased $14.5 million primarily due to increased sales of digital detectors, the addition of revenues from the acquisition of Direct Conversion in April of 2019 and higher sales of high voltage cables partially offset by lower sales of X-ray tubes. APAC revenues decreased $14.1 million primarily due to decreased sales of radiographic digital detectors in China partially offset by the addition of revenues with the acquisition of Direct Conversion.
Gross Margin
 
Fiscal Years
 
 
 
 
(In millions)
2019
 
2018
 
$ Change
 
% Change
Medical
$
188.9

 
$
190.5

 
$
(1.6
)
 
(1
)%
Industrial
67.8

 
63.4

 
4.4

 
7
 %
Total gross margin
$
256.7

 
$
253.9

 
$
2.8

 
1
 %
Medical gross margin %
31.7
%
 
31.6
%
 
 
 
 
Industrial gross margin %
36.9
%
 
37.0
%
 
 
 
 
Total gross margin %
32.9
%
 
32.8
%
 
 
 
 
Gross margin percentage increased for fiscal year 2019 compared to 2018. The gross margin for fiscal year 2019 included $9.4 million of restructuring charges and purchase price accounting adjustments and the gross margin for fiscal year 2018 included

39

$7.3 million of restructuring charges. The industrial gross margin percentage decreased primarily due to higher manufacturing costs and unfavorable product mix.
Operating Expenses
 
Fiscal Years
 
 
 
 
(In millions)
2019
 
2018
 
$ Change
 
% Change
Research and development
$
78.1

 
$
83.0

 
$
(4.9
)
 
(6
)%
As a percentage of total revenues
10.0
%
 
10.7
%
 
 
 
 
Selling, general and administrative
$
128.1

 
$
123.4

 
$
4.7

 
4
 %
As a percentage of total revenues
16.4
%
 
16.0
%
 
 
 
 
Impairment of intangible assets
$
4.8

 
$
3.0

 
$
1.8

 
60
 %
As a percentage of total revenues
0.6
%
 
0.4
%
 
 
 
 
Operating expenses
$
211.0

 
$
209.4

 
$
1.6

 
1
 %
As a percentage of total revenues
27.0
%
 
27.1
%
 
 
 
 
Research and Development
Research and development costs for fiscal year 2019 decreased to 10% of revenues due to lower personnel costs and prototype material costs. We are committed to investing in the business to support long-term growth and believe long-term research and development expenses of approximately 8% to 10% of annual revenues is the appropriate range that will allow us to innovate and bring new products to market for our global OEM customers.
Selling, General and Administrative
Selling, general and administrative expenses as a percentage of total revenues increased to 16.4% for fiscal year 2019 from 16.0% for fiscal year 2018 due to higher audit and consulting fees associated with the remediation of internal control deficiencies and increased legal fees for patent litigation. These were offset by reductions in personnel costs and other consulting fees.
Impairment of intangible assets
Impairment of intangible assets increased for fiscal year 2019 to $4.8 million as compared to $3.0 million for fiscal year 2018. In connection with the July 2019 announcement of the Santa Clara facility shut down we made the decision to discontinue further efforts on certain in-process research and development intangible assets. As a result, we recorded a corresponding impairment charge of $4.8 million in fiscal year 2019. See Note 4. Restructuring included in the notes to our consolidated financial statements for further information.
Interest and Other Income (Expense), Net
The following table summarizes our interest and other income (expense), net:
 
Fiscal Years
 
 
(In millions)
2019
 
2018
 
$ Change
Interest income
$
0.1

 
$
0.2

 
$
(0.1
)
Interest expense
(21.1
)
 
(21.7
)
 
0.6

Other income (expense), net
(3.2
)
 
2.7

 
(5.9
)
Interest and other expenses, net
$
(24.2
)
 
$
(18.8
)
 
$
(5.4
)
Interest and other expense, net increased in fiscal year 2019 compared to fiscal year 2018, primarily due to a other expense from equity method investments compared to other income from equity method investments in the prior fiscal year. A new joint venture investment was established in fiscal year 2019.
Taxes on Earnings
 
Fiscal Years
 
2019
 
2018
Effective tax rate
26.5
%
 
(10.1
)%

40

     We had an income tax expense of $5.7 million and an income tax benefit of $2.6 million, for effective rates of 26.5% and (10.1)%, for fiscal years 2019 and 2018, respectively.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (U.S. Tax Reform) was enacted in the U.S. which significantly revised the U.S. corporate income tax structure. Among the revisions impacting our effective tax rate are a lower U.S. corporate statutory rate going from 35% to 21% effective January 1, 2018 and changes to the way foreign earnings are taxed. As a September fiscal year filer, the lower corporate income tax rate was phased in with a U.S. statutory federal rate of 24.5% in fiscal year ended September 28, 2018, and a rate of 21% for the fiscal year ended September 27, 2019.
During fiscal year 2019, our effective tax rate varied from the U.S. federal statutory rate of 21.0% primarily because of the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform, U.S. research and development tax credits, and tax windfalls for share-based compensation. These favorable U.S. tax items are offset by increases resulting from losses in certain foreign jurisdictions for which no benefit is recognized and earnings in other foreign jurisdictions that are taxed at higher rates.
During fiscal year 2018, our effective tax rate varied from the U.S. federal statutory rate primarily because of the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform. The effective tax rate also differs from the U.S. federal statutory rate due to increases resulting from U.S. state income tax expense, losses in certain foreign jurisdictions for which no benefit is recognized, earnings in other foreign jurisdictions that are taxed at higher rates, and limitations on the deductibility of officers' compensation. These are offset by decreases due to U.S. research and development credits, tax windfalls for share-based compensation, and the release of a valuation allowance against loss carryforwards in certain foreign jurisdictions.
The SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) that allows for reasonable estimated amounts to be recorded and a measurement period of up to one year from the date of enactment to revise these provisional amounts as new information is obtained and additional guidance is issued. During the three months ended December 28, 2018, the Company completed its analysis of U.S. Tax Reform, and the accounting for the income tax effects has been finalized for the measurement period under SAB 118, with no significant adjustments from the provisional amounts. During fiscal year 2019, additional U.S. Tax Reform provisions, including GILTI (global intangible low-taxed income), BEAT (base-erosion anti-abuse tax), FDII (foreign-derived intangible income), limitations on interest expense deductions (if certain conditions apply), and other components became effective for us and, if applicable, have been included in the calculation of our fiscal year 2019 tax provision. The determination of the tax effects of U.S. Tax Reform may change following future legislation or further interpretation of U.S. Tax Reform from various U.S. Federal and state tax authorities.
The guidance for accounting for U.S. Tax Reform requires taxpayers to make an election regarding the accounting for GILTI. This policy election is to either: (1) treat GILTI as a period cost if and when incurred, or (2) recognize deferred taxes for basis differences that are expected to reverse as GILTI in future years. During fiscal year 2019, we made the accounting policy election to account for GILTI under the period cost method.
Discussion of Results of Operations for Fiscal Year 2018 and 2017
Revenues, net
 
Fiscal Years
 
 
 
 
(In millions)
2018
 
2017
 
$ Change
 
% Change
Medical
$
602.0

 
$
556.9

 
$
45.1

 
8
%
Industrial
171.4

 
141.2

 
30.2

 
21
%
Total revenues, net
$
773.4

 
$
698.1

 
$
75.3

 
11
%
Medical as a percentage of total revenues
78
%
 
80
%
 
 
 
 
Industrial as a percentage of total revenues
22
%
 
20
%
 
 
 
 
Medical revenues increased $45.1 million primarily due to an increase in sales of high-end radiographic digital detectors with the addition of revenues from the acquisition of the medical imaging business (“Acquired Detector Business”) of PerkinElmer, Inc., and from increased sales of X-ray tubes, including CT tubes to our OEM customers in China, and high voltage cables. These increases in medical revenues were partially offset by a decrease in sales of 3-D dental digital detectors and low-end radiographic.
Industrial revenues increased $30.2 million due to increased sales of digital detectors from the addition of the Acquired Detector Business, and from increased sales of high-voltage industrial cables. These increases were partially offset by a decrease of industrial digital detectors.

41

Revenues by Region
 
Fiscal Years
 
 
 
 
(In millions)
2018
 
2017
 
$ Change
 
% Change
Americas
$
275.8

 
$
239.8

 
$
36.0

 
15
%
EMEA
254.5

 
219.5

 
35.0

 
16
%
APAC
243.1

 
238.8

 
4.3

 
2
%
Total revenues, net
$
773.4

 
$
698.1

 
$
75.3

 
11
%
Americas as a percentage of total revenues
36
%
 
34
%
 
 
 
 
EMEA as a percentage of total revenues
33
%
 
31
%
 
 
 
 
APAC as a percentage of total revenues
31
%
 
34
%
 
 
 
 
The Americas revenues increased $36.0 million primarily due to increased sales of digital detectors from the addition of the Acquired Detector Business. EMEA revenues increased $35.0 million primarily due to increased sales of digital detectors from the addition of the Acquired Detector Business partially offset by lower sales of security and inspection products and digital detectors. APAC revenues increased $4.3 million due to increased sales of digital detectors from the addition of the Acquired Detector Business and higher sales of X-ray tubes, partially offset by lower sales of digital detectors.
Gross Margin
 
Fiscal Years
 
 
 
 
(In millions)
2018
 
2017
 
$ Change
 
% Change
Medical
$
190.5

 
$
193.6

 
$
(3.1
)
 
(2
)%
Industrial
63.4

 
59.9

 
3.5

 
6
 %
Total gross margin
$
253.9

 
$
253.5

 
$
0.4

 
—
 %
Medical gross margin %
31.6
%
 
34.8
%
 
 
 
 
Industrial gross margin %
37.0
%
 
42.4
%
 
 
 
 
Total gross margin %
32.8
%
 
36.3
%
 
 
 
 
The decrease in total gross margin percentage was due primarily to a product mix shift to lower margin products, restructuring charges of $7.3 million, including inventory markdowns of $3.1 million, higher digital detector product and indirect costs in our Santa Clara facility and the impact of tariffs in the fourth quarter. The decrease in medical gross margin percentage were primarily due to product mix shifts towards lower margin X-ray tubes and higher digital detector unit products costs in our Santa Clara facility. The decrease in industrial gross margin percentage were primarily due to product mix shifts towards lower margin cargo scanning products and price erosion in this same product category.
Operating Expenses
 
Fiscal Years
 
 
 
 
(In millions)
2018
 
2017
 
$ Change
 
% Change
Research and development
$
83.0

 
$
67.3

 
$
15.7

 
23
%
As a percentage of total revenues
10.7
%
 
9.6
%
 
 
 
 
Selling, general and administrative (1)
$
123.4

 
$
102.5

 
$
20.9

 
20
%
As a percentage of total revenues
16.0
%
 
14.7
%
 
 
 
 
Impairment of intangible assets
$
3.0

 
$
—

 
$
3.0

 
n/a

As a percentage of total revenues
0.4
%
 
$
—

 
 
 
 
Operating expenses
$
209.4

 
$
169.8

 
$
39.6

 
23
%
As a percentage of total revenues
27.1
%
 
24.3
%
 
 
 
 
(1)
Selling, general and administrative expenses include $12.4 million of corporate costs allocated to us by Varian in fiscal year 2017.

42

Research and Development
The increase in research and development expenses as a percentage of revenue was due to the continued acceleration and development of digital detector projects and prototype materials costs for CT X-ray tubes.
Selling, General and Administrative
Selling, general and administrative expenses as a percentage of total revenues increased primarily as a result of restructuring and impairment charges related to the Acquired Detector Business, increased amortization of intangible assets, increased share-based compensation expense and an increase in costs related to implementation of certain productivity initiatives.
Impairment of intangible assets
Impairment of intangible assets for fiscal year 2018 were $3.0 million, while there was no impairment of intangible assets for fiscal year 2017. In connection with the restructuring plan that was announced in July 2018 we recorded an impairment charge of $3.0 million related to certain intangible assets. See Note 4. Restructuring included in the notes to our consolidated financial statements for further information.
Interest and Other Income (Expense), Net
The following table summarizes our interest and other income (expense), net:
 
Fiscal Years
 
 
(In millions)
2018
 
2017
 
$ Change
Interest income
$
0.2

 
$
0.2

 
$
—

Interest expense
(21.7
)
 
(12.3
)
 
(9.4
)
Other income (expense), net
2.7

 
3.2

 
(0.5
)
Interest and other expenses, net
$
(18.8
)
 
$
(8.9
)
 
$
(9.9
)
The increase in interest and other income (expense), net was primarily due to higher interest expense as a result of higher weighted average interest rates and higher weighted average outstanding borrowings under our credit agreement and foreign currency translation losses, partially offset by income from equity method investments.
Taxes on Earnings
 
Fiscal Years
 
2018
 
2017
Effective tax rate
(10.1
)%
 
30.5
%
     We had an income tax benefit of $2.6 million and an income tax expense of $22.8 million for the year ended September 28, 2018 and September 29, 2017, respectively, for effective rates of (10.1)% and 30.5%, respectively.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (“U.S. Tax Reform”) was enacted in the U.S. which significantly revised the U.S. corporate income tax structure. Among the revisions impacting our effective tax rate are a lower U.S. corporate statutory rate going from 35% to 21% effective January 1, 2018 and changes to the way foreign earnings are taxed. As a September fiscal year filer, the lower corporate income tax rate has been phased in resulting in a U.S. statutory federal rate of 24.5% for the fiscal year ended September 28, 2018.
During fiscal year 2018, our effective tax rate varied from the U.S. federal statutory rate of 24.5% primarily because of the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform. The effective tax rate also differs from the U.S. federal statutory rate due to increases resulting from U.S. state income tax expense, losses in certain foreign jurisdictions for which no benefit is recognized, earnings in other foreign jurisdictions that are taxed at higher rates, and limitations on the deductibility of officers' compensation. These are offset by decreases due to U.S. research and development credits, tax windfalls for share-based compensation, and the release of a valuation allowance against loss carryforwards in certain foreign jurisdictions.
During fiscal year 2017, our effective tax rate varied from the U.S. federal statutory rate of 35% primarily because of a difference in the mix of earnings by jurisdiction, and overall global tax structure for Varex as a stand-alone company compared to the prior year when it was part of Varian. It was also impacted by the benefit of adjustments to certain deferred tax assets and the release of valuation allowances in jurisdictions where increased earnings allowed for the utilization of net operating loss carryforwards.

43

During fiscal year 2018, as a result of U.S. Tax Reform, we recorded income tax expense of $3.7 million for the tax on the deemed repatriation of deferred foreign earnings offset by a tax benefit of $10.9 million due to the revaluation of net deferred taxes.
Liquidity and Capital Resources
We assess our liquidity in terms of our ability to generate cash to fund our operating, including working capital and investing activities. We continue to generate sufficient cash from operating activities and believe that our operating cash flow, availability under our existing credit facility, current working capital and other sources of liquidity will be sufficient to allow us to continue to invest in our existing businesses, consummate strategic acquisitions and manage our capital structure on a short and long-term basis. Availability under our credit facility was $91.0 million as of September 27, 2019, although on October 8, 2019, we permanently reduced the revolving credit commitment under the credit facility by $25.0 million to $125.0 million. Although we believe that our future cash from operations, together with our access to banking and capital markets, will provide adequate resources to fund our operating and financing needs, our access to, and the availability of, financing on acceptable terms in the future will be affected by many factors, including: (i) the liquidity of the overall capital markets and (ii) the current state of the economy. There can be no assurances that we will continue to have access to these markets on terms acceptable to us. See “Risk Factors” for a further discussion. Subsequent to fiscal year 2019 we did not comply with the covenant under the Credit Agreement to timely deliver our fiscal year 2019 annual financial statements. However, upon the filing of this Annual Report with the SEC, we will be able to deliver the fiscal year 2019 annual financial statements within the 30-day cure period set forth in the Credit Agreement and consequently no event of default will occur. At September 27, 2019 we had $364.4 million in long-term debt and $30.7 million of current maturities of long-term debt, net of deferred issuance costs of $5.7 million. See Note 8. Borrowings in the notes to our consolidated financial statements for more information regarding our existing credit facility.
Cash and Cash Equivalents
The following table summarizes our cash and cash equivalents:
(In millions)
September 27, 2019
 
September 28, 2018
 
$ Change
 
% Change
Cash and cash equivalents
$
29.9

 
$
51.9

 
$
(22.0
)
 
(42.4
)%
Borrowings
The following table summarizes the changes in our debt outstanding:
(In millions)
September 27, 2019
 
September 28, 2018
 
$ Change
 
% Change
Current portion of Term Facility
$
29.4

 
$
25.0

 
$
4.4

 
17.6
 %
Current portion of other long-term debt
1.3

 
—

 
1.3

 
n/a

Revolving Credit Facility
59.0

 
28.0

 
31.0

 
110.7
 %
Long-Term portion of Term Facility
308.6

 
345.0

 
(36.4
)
 
(10.6
)%
Long-term portion of other debt
2.5

 
—

 
2.5

 
n/a

Total debt outstanding, gross
400.8

 
398.0

 
2.8

 
0.7
 %
Debt issuance costs
(5.7
)
 
(8.2
)
 
2.5

 
(30.5
)%
Total debt outstanding, net
$
395.1

 
$
389.8

 
$
5.3

 
1.4
 %

44

Cash Flows
 
Fiscal Years
(In millions)
2019
 
2018
 
2017
Net cash flow provided by (used in):
 
 
 
 
 
Operating activities
$
71.9

 
$
85.3

 
$
75.2

Investing activities
(93.2
)
 
(25.2
)
 
(292.0
)
Financing activities
(0.1
)
 
(90.4
)
 
263.3

Effects of exchange rate changes on cash and cash equivalents
(0.7
)
 
(0.5
)
 
0.9

Net increase (decrease) in cash and cash equivalents
$
(22.1
)
 
$
(30.8
)
 
$
47.4

Net Cash Provided by Operating Activities. Cash from operating activities consists primarily of net earnings adjusted for certain non-cash items, including share-based compensation, depreciation, amortization and impairment of intangible assets, inventory write-downs deferred income taxes, amortization of deferred loan costs, income and loss from equity investments and the effect of changes in operating assets and liabilities.
For fiscal year 2019, compared to fiscal year 2018, net cash provided by operating activities were as follows:
•
Net earnings were $15.8 million compared to $28.3 million,
•
Non-cash adjustments to net earnings of $51.4 million compared to $51.0 million,
•
Operating assets and liabilities activity:
◦
Accounts receivable decreased by $14.8 million compared to $9.0 million,
◦
Inventories increased by $11.1 million compared to $2.4 million,
◦
Prepaid expenses and other assets decreased $4.3 million compared to $2.0 million,
◦
Accounts payable decreased by $9.0 million compared to an increase of $5.2 million,
◦
Accrued liabilities and other long-term operating liabilities increased by $10.9 million compared to a decrease of $10.2 million, and
◦
Deferred revenues decreased by $5.2 million compared to an increase of $2.4 million.
For fiscal year 2017, net cash provided by operating activities was $75.2 million and consisted of net earnings of $52.0 million, increases from non-cash items of $29.2 million and decreases from operating assets and liabilities activities of $6.0 million.
Net cash used in investing activities. Cash used in investing activities was $93.2 million, $25.2 million, and $292.0 million for the fiscal years 2019, 2018 and 2017, respectively. Net cash used in investing activities for fiscal year 2019 related primarily to the April 2019, acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion for $69.5 million in cash, net of cash acquired, and capital expenditures for property plant and equipment of $19.8 million. Net cash used in investing activities for fiscal year 2018 related primarily to an acquisition of an industrial imaging solutions provider for $4.8 million, and capital expenditures for property plant and equipment of $20.4 million. Net cash used in investing activities for fiscal year 2017 related to the Acquired Detector Business for $271.8 million (net of cash acquired) and capital expenditures for property plant and equipment of $20.2 million.
Net Cash Provided by (Used in) Financing Activities. Financing activities for the fiscal year 2019 primarily consisted of borrowings under our credit agreements of $85.4 million, repayments of borrowings of $87.0 million, and net proceeds from equity plans of $2.5 million. Financing activities for the fiscal year 2018 primarily consisted of borrowings under our credit agreements of $10.0 million, repayments of borrowings of $106.0 million, and net proceeds from equity plans of $4.8 million. Financing activities for the fiscal years 2017 primarily consisted of borrowings under our credit agreements of $749.0 million and net transfers from Varian of $5.0 million, partially offset by distributions to Varian of $227.1 million, repayments of borrowings of $255.0 million and payment of debt issuance costs of $11.9 million.
Days Sales Outstanding
Trade accounts receivable days sales outstanding (“DSO”) was 63 days and 68 days at September 27, 2019 and September 28, 2018, respectively. Our accounts receivable and DSO are impacted by a number of factors, primarily including the timing of product shipments, collections performance, payment terms, the mix of revenues from different regions and the effects of economic instability.

45

Contractual Obligations
The following table summarizes, as of September 27, 2019, the total amount of future payments due in various future periods:
 
Payments Due by Period
(In millions)
Total
 
Fiscal Year 2020
 
Fiscal Years 2021-2022
 
Fiscal Years 2023-2024
 
Beyond
Operating lease obligations
$
20.5

 
$
7.5

 
$
10.1

 
$
2.7

 
$
0.2

Principal payments on borrowings
400.8

 
30.7

 
370.1

 
—

 
—

DpiX fixed cost commitment
3.7

 
3.7

 
—

 
—

 
—

Dividends to redeemable interest
4.2

 
0.6

 
1.2

 
1.2

 
1.2

Total
$
429.2

 
$
42.5

 
$
381.4

 
$
3.9

 
$
1.4

We lease office space under non-cancelable operating leases. The leases expire at various dates through 2025, excluding extensions at our option, and contain provisions for rental adjustments, including in certain cases, adjustments based on increases in the Consumer Price Index. The leases generally contain renewal provisions for varying periods of time.
For further discussion regarding our borrowings, see Note 8. Borrowings included in the notes to our consolidated financial statements.
In October 2013, we entered into an amended agreement with dpiX and other parties that, among other things, provides us with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires us to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. For the remainder of calendar year 2019, we estimate that we have fixed cost commitments of $3.7 million related to this amended agreement. The fixed cost commitment for future periods will be determined and approved by the dpiX board of directors at the beginning of each calendar year. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).
In October 2015, we committed to grant the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of €0.95 per MeVis share; and, (2) a put right for their MeVis shares at €19.77 per MeVis share. As of September 27, 2019, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares.
Contingencies
From time to time, we are a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duty audits and other matters both inside and outside the United States, arising in the ordinary course of our business or otherwise. Such matters are subject to many uncertainties and outcomes are not predictable with assurance.
See Part 1, Item 3 of this Annual Report for additional information regarding legal proceedings and Note 11, Commitments and Contingencies in the notes to our consolidated financial statements for further information regarding certain of our contractual obligations and contingencies, which discussion is incorporated herein by reference.
Off-Balance Sheet Arrangements
In conjunction with the sale of our products in the ordinary course of business, and consistent with industry practice, we provide standard indemnification of business partners and customers for losses suffered or incurred for property damages, death and injury and for patent, copyright or any other intellectual property infringement claims by any third parties with respect to our products. The terms of these indemnification arrangements are generally perpetual. Except for losses related to property damages, the maximum potential amount of future payments we could be required to make under these arrangements is unlimited. As of September 27, 2019, we have not incurred any material costs to defend lawsuits or settle claims related to these indemnification arrangements. As a result, we believe the estimated fair value of these arrangements is minimal.
We also have indemnification obligations to our directors and officers and certain of our employees that serve as officers or directors of our foreign subsidiaries that may require us to indemnify our directors and officers and those certain employees against liabilities that may arise by reason of their status or service as directors or officers, and to advance their expenses incurred as a result of any legal proceeding against them as to which they could be indemnified.

46

Critical Accounting Policies and Estimates
The preparation of our consolidated financial statements and related disclosures in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on historical experience and on various other factors that we believe are reasonable under the circumstances. Our critical accounting policies that are affected by accounting estimates require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates. For a discussion of how these estimates and other factors may affect our business, see “Risk Factors.”
We periodically review our accounting policies, estimates and assumptions and make adjustments when facts and circumstances dictate. Such accounting policies require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates. For a discussion of how these estimates and other factors may affect our business, see Item 1A, “Risk Factors.”
Inventories
Inventories are valued at the lower of cost or net realizable value. Costs include materials, labor and manufacturing overhead
and is computed using standard cost (which approximates actual cost) on a first-in-first-out basis. We evaluate the carrying
value of our inventories taking into consideration such factors as historical and anticipated future sales compared to quantities on hand
and the prices we expect to obtain for products in our various markets. We adjust excess and obsolete inventories to net realizable value and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues.
Goodwill and Intangible Assets
Goodwill is initially recorded when the purchase price paid for a business acquisition exceeds the estimated fair value of the net identified tangible and intangible assets acquired. Our future operating performance will be impacted by the future amortization of these acquired intangible assets and potential impairment charges related to these intangibles or to goodwill if indicators of impairment exist. The allocation of the purchase price from business acquisitions to goodwill and intangible assets could have a material impact on our future operating results. In addition, the allocation of the purchase price of the acquired businesses to goodwill and intangible assets requires us to make significant estimates and assumptions, including estimates of future cash flows expected to be generated by the acquired assets and the appropriate discount rate for those cash flows. Should conditions differ from management’s estimates at the time of the acquisition, material write-downs of intangible assets and/or goodwill may be required, which would adversely affect our operating results.
We evaluate goodwill for impairment at least annually or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The evaluation includes consideration of qualitative factors including industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. If we determine that a quantitative analysis is necessary, the impairment test for goodwill is a two-step process. Step one consists of a comparison of the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit. We determine the fair value of our reporting units based on a combination of income and market approaches. The income approach is based on the present value of estimated future cash flows of the reporting units and the market approach is based on a market multiple calculated for each reporting unit based on market data of other companies engaged in similar business. If the carrying amount of the reporting unit is in excess of its fair value, step two requires the comparison of the implied fair value of the reporting unit’s goodwill against the carrying amount of the reporting unit’s goodwill. Any excess of the carrying value of the reporting unit’s goodwill over the implied fair value of the reporting unit’s goodwill is recorded as an impairment loss.
In fiscal years 2019, 2018 and 2017, we performed the annual goodwill impairment test for our two reporting units and found no impairment. We performed the annual goodwill analysis as of the first day of the fourth quarter of each fiscal year (using balances as of the end of the third quarter of that fiscal year). For both reporting units, based upon the annual goodwill analysis that we performed as of the first day of the fourth quarter of the respective fiscal years, either step one of the impairment test was not completed based on evaluation of qualitative factors or, if step one was completed, the fair value was substantially in excess of carrying value. However, significant changes in our projections about our operating results or other factors could cause us to make interim assessments of impairments in any quarter that could result in some or all of the goodwill being impaired.
We will continue to make assessments of impairment on an annual basis or more frequently if indicators of potential impairment arise.

47

Impairment of Investments
We have investments in privately held companies that are accounted for under the equity method of accounting as we hold at least a 20% ownership interest or have the ability to exercise significant influence in these investments. We monitor these investments for events or circumstances indicative of potential impairment, and we make appropriate reductions in carrying values if we determine that an impairment charge is required, based primarily on the financial condition, near-term prospects and recent financing activities of the investee.
Taxes on Earnings
Current income tax expense is the amount of income taxes expected to be payable for the current year. Deferred income tax liabilities or assets are established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. In addition, we provide reserves for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance for accounting for income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense.
On December 22, 2017, the U.S. Government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (“U. S. Tax Reform”). U.S. Tax Reform significantly revised the U.S. corporate income tax structure including a lower corporate statutory rate and changes to the way foreign earnings are taxed. U.S. GAAP requires that the impact of tax legislation be recognized in the period in which the law is enacted. In accordance with these rules, we are including the impact of certain provisions of U.S. Tax Reform to the extent they are effective during the current reporting period.
Backlog
Backlog is the accumulation of all orders for which revenues have not been recognized and are still considered valid. Backlog also includes a small portion of billed service contracts that are included in deferred revenue. Our total backlog at September 27, 2019 was $265.2 million, a decrease of 13.9% from the backlog of $308.1 million at September 28, 2018.
Orders may be revised or canceled, either according to their terms or as customers’ needs change. Consequently, it is difficult to predict with certainty the amount of backlog that will result in revenues. We perform a quarterly review to verify that outstanding orders in the backlog remain valid. Aged orders that are not expected to be converted to revenues are deemed dormant and are reflected as a reduction in the backlog amounts in the period identified.
In addition to orders for which revenues have not been recognized and are still considered valid, we have pricing agreements with many of our established customers that span multi-year periods. These pricing agreements include volume ranges under which orders are placed.
Recent Accounting Standards or Updates Not Yet Effective
See Note 1, Summary of Significant Accounting Policies of the notes to the consolidated financial statements for a description of recent accounting standards, including the expected dates of adoption and the estimated effects on our consolidated financial statements.
Item 7A. Quantitative and Qualitative Disclosures about Market Risks
We are exposed to four primary types of market risks: foreign currency exchange rate risk, credit and counterparty risk, interest rate risk and commodity price risk.
Foreign Currency Exchange Rate Risk
A significant portion of our customers are outside the United States, while our financial statements are denominated, and our products are generally priced in U.S. Dollars. A strong U.S. Dollar may result in pricing pressure for our customers that are located outside the United States and that conduct their businesses in currencies other than the U.S. Dollar. Such pricing pressure has caused, and could continue to cause, some of our customers to ask for discounted prices, delay purchasing decisions, consider moving to in-sourcing supply of components or migrating to lower cost alternatives. In addition, because our business is global and some payments may be made in local currency, fluctuations in foreign currency exchange rates can impact our revenues and expenses and/or the profitability in U.S. Dollars of products and services that we provide in foreign markets.

48



We may enter into foreign currency forward and option contracts with financial institutions to protect against foreign exchange risks associated with certain existing assets and liabilities, and net investments in foreign subsidiaries. We generally hedge portions of forecasted foreign currency, typically for one month. In addition, we hold a cross-currency swap between the Euro and U.S. Dollar as a Net Investment Hedge of our recent acquisition of Direct Conversion. Depending on the spot rate between the Euro and U.S. Dollar at the time of settlement and whether we have sufficient Euros available, we may have to borrow incrementally in U.S. Dollars to settle this obligation. However, we may choose not to hedge certain foreign exchange exposures for a variety of reasons including, but not limited to, accounting considerations or the prohibitive economic cost of hedging particular exposures.
Credit and Counterparty Risk
We use a centralized approach to manage substantially all of our cash and to finance our operations. Our cash and cash equivalents may be exposed to a concentration of credit risk and we may also be exposed to credit risk and interest rate risk to the extent that we enter into credit facilities.
We perform ongoing credit evaluations of our customers and we maintain what we believe to be strong credit controls in evaluating and granting customer credit, including performing ongoing evaluations of our customers’ financial condition and creditworthiness and often using letters of credit and requiring industrial customers to provide a down payment.
Interest Rate Risk
At September 27, 2019, we had total borrowings of $395.1 million (net of deferred loan costs). Borrowings under our credit facilities bear interest at floating interest rates. As a result, we are exposed to fluctuations in interest rates to the extent of our borrowings under the credit facilities. As part of our overall risk management program, we entered into several interest rate swaps designed as cash flow hedges, to hedge the floating LIBOR components of our interest rate which represented a notional value of $264.4 million of our debt as of September 27, 2019. Excluding the amount of our borrowings that is subject to fixed interest rates under our interest rate swaps, and assuming the current level of borrowings remained the same, we estimate that our interest expense would change by approximately $1.3 million annually for each one percentage point change in the average interest rate under our borrowings.
See Note 7. Financial Derivatives and Hedging Activities and Note 8. Borrowings of the notes to our consolidated financial statements for further information on interest rate hedging activities and borrowings.
Commodity Price Risk
We are exposed to market risks related to volatility in the prices of raw materials used in our products. The prices of these raw materials fluctuate in response to changes in supply and demand fundamentals and our product margins and level of profitability tend to fluctuate with changes in these raw materials prices. We try to protect against such volatility through various business strategies. During the fiscal year ended September 27, 2019, we did not have any commodity derivative instruments in place to manage our exposure to price changes.
Item 8. Financial Statements and Supplementary Data.
The Consolidated Financial Statements and Schedules listed in the Index to Financial Statements, Schedules and Exhibits on page F-1 are filed as part of this Annual Report and incorporated in this Item 8 by reference.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None. 
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that such information required to be disclosed is accumulated and communicated to management, including

49


our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have evaluated the effectiveness of our disclosure controls and procedures as of September 27, 2019 and, based on their evaluation, the CEO and CFO have concluded that the disclosure controls and procedures were not effective as of such date due to the material weaknesses in internal control over financial reporting described below.

To address the material weaknesses described below, and prior to filing this Annual Report on Form 10-K, we performed additional analysis and other post-closing procedures to determine our consolidated financial statements are prepared in accordance with generally accepted accounting principles. Based on these procedures, management has concluded that our consolidated financial statements included in this Form 10-K have been prepared in accordance with generally accepted accounting principles and our CEO and CFO have certified that, based on their knowledge, the consolidated financial statements, and other financial information included in this Form 10-K, fairly present in all material respects the financial condition, results of operations and cash flows for the periods presented. PricewaterhouseCoopers LLP, an independent registered public accounting firm, has issued an unqualified opinion on our consolidated financial statements, which appears herein.

Management's Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

(1)
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and the dispositions of our assets;
(2)
provide reasonable assurance that our transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that our receipts and expenditures are being made only in accordance with appropriate authorizations; and
(3)
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, we assessed the effectiveness of our internal control over financial reporting as of September 27, 2019, using the criteria described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

We have identified the following control deficiencies that constituted material weaknesses in our internal control over financial reporting as of September 27, 2019:

•
We did not design and maintain an effective risk assessment process to identify and assess the risks in our business processes, specifically, we did not adequately identify new and evolving risks of material misstatement and design and implement controls to address those risks as a result of changes to our business operating environment including adoption of new accounting principles. We also did not maintain an effective control environment as we had an insufficient complement of resources with the requisite knowledge and experience to create the proper environment for effective internal control over financial reporting such that corrective activities to our internal control over financial reporting are appropriately applied, prioritized, and implemented in a timely manner. Although these deficiencies did not result in adjustments to our consolidated financial statements, until remediated, they could result in material misstatements potentially impacting all financial statement accounts and disclosures in our annual or interim consolidated financial statements that would not be prevented or detected. These material weaknesses contributed to the following control deficiencies, which are also considered to be material weaknesses:

50


◦
We did not design and maintain effective controls related to accounting for revenue, deferred revenue and related accounts receivable, including maintaining effective business process controls to prevent or detect misstatements in the processing of customer transactions. Specifically, we did not design and maintain effective controls related to the review of the completeness and accuracy of customer order entry, quantity and pricing. Additionally, we did not design and maintain effective controls for the effect of the adoption of and continuous accounting for Revenue from Contracts with Customers (“ASC 606”) to prevent and detect misstatements.
◦
We did not design and maintain effective controls related to accounting for inventory and cost of revenues, including maintaining effective business process controls to prevent or detect misstatements in the accuracy and valuation of inventory. Specifically, we did not maintain effective controls related to inventory count procedures, the valuation of inventory at lower of cost and net realizable value and presentation and disclosure of inventory classifications.
◦
We did not design and maintain effective controls over our financial reporting close process to prevent or detect material misstatements in our financial statements. Specifically, we did not maintain an effective business performance monitoring review control at our international entities, maintain effective controls related to the elimination of intercompany balances, design and maintain controls to identify post-close events which occur before the financial statements are available to be issued and design and maintain effective control over the review of the statement of cash flows.

The deficiencies in revenue, inventory and financial reporting close process resulted in immaterial audit adjustments and out of period adjustments to the Company’s consolidated financial statements for the fiscal years ended and as of September 27, 2019 and September 28, 2018 and respective interim periods. Additionally, until remediated, these deficiencies could result in a material misstatement impacting the aforementioned accounts and disclosures in our annual or interim consolidated financial statements that would not be prevented or detected. Accordingly, our management has determined these deficiencies constitute material weaknesses.

Because of the material weaknesses described above, management concluded that we did not maintain effective internal control over financial reporting as of September 27, 2019.

A subsidiary of Varex acquired Direct Conversion AB on April 29, 2019. Management has excluded Direct Conversion AB from its evaluation of the effectiveness of internal control over financial reporting as of September 27, 2019. The total assets and total revenues of Direct Conversion represent approximately 0.8% and 0.8%, respectively, of the related consolidated financial statements amounts as of and for the fiscal year ended September 27, 2019.

Our independent registered public accounting firm, PricewaterhouseCoopers LLP, has issued an adverse audit report on the effectiveness of our internal control over financial reporting as of September 27, 2019, which appears herein.

Status of Remediation Efforts

Remediation of Material Weaknesses Reported in Fiscal Year 2018 Form 10-K

We have devoted substantial effort to remediating the areas of material weakness identified in fiscal year 2018 and continue to perform a risk assessment process to identify, design, implement, and re-evaluate the control activities. While we continue to enhance our risk assessment process to ensure that it is comprehensive, management concluded that certain material weaknesses identified in fiscal year 2018 and reported in our Annual Report on Form 10-K as of September 28, 2018, were remediated in fiscal year 2019. Specifically, material weaknesses were remediated in the areas of:
1)
information technology general controls (ITGCs) around user access and program change controls; and
2)
accounting for our operations in Germany, including maintaining effective business process controls and segregation of duties related to the authorization of transactions and journal entries, and the cutoff, completeness and accuracy of transactions.

Implementation of improvements in ITGCs around user access and program change controls included the following: 
•
Performance of Control Environment Review - As part of the overall risk assessment process, we identified relevant applications and tools to enhance overall controls compliance.
•
Implementation of Control Design Review - We made significant changes to the control environment by redesigning certain controls to be aligned with the Control Objectives for Information and Related Technology (COBIT) framework and designing additional controls to ensure all identified risks were addressed. The result is effectively designed information technology general controls in the areas of change management, computer operations, backup and recovery, and security were subject to review. Security controls were reviewed by application.

51


•
Performance of Deficiency Specific Remediation Plans - We implemented remediation plans for each of the deficiencies, categorized by remediation actions, process implementation, and control rationalization.  Our remediation plans were focused on identifying and mitigating the risk, and our design effectiveness and operational testing were performed.

•
User Access:
◦
Sensitive access identified as being inappropriate was removed from our users of in-scope systems.
◦
Implemented real time monitoring in the form of reports and e-mail notifications. This monitoring acts as an alert whenever sensitive access has been executed. 
◦
Sensitive access can now only be used through a specific defined process and requires a service ticket in advance. We review sensitive access for appropriateness quarterly. 
◦
Implemented a specific segregation of duties rule-set, ensuring conflict-free roles are maintained, and user level segregation of duty conflicts are identified for remediation or mapping to certified mitigating controls.
◦
Enhanced the provisioning process by adding a preventative control for new and updated user access by incorporating our specific segregation of duties rule-set to ensure on-going compliance is maintained, and sensitive access and segregation of duty conflicts are not re-introduced into the environment.
◦
Completed a user access review for all accounts within our ERP system.

•
Change Management:
◦
We implemented an updated change management process and policy, including documented pre-approvals, testing procedures, and post approvals, as needed.
◦
Appropriate segregation of duties were implemented over making source code changes and migrating changes to the production environment.  Our users with developer access do not have access to push code to production.

Improved Germany Control Environment - We engaged outside consultants in Germany to perform a detailed review of business process control documentation, including segregation of duties, authorization of transactions, journal entries, cutoff, completeness and accuracy of transactions, key controls to execute remediation activities, and to implement appropriate controls, assess design and test operating effectiveness, and formalize our corporate-level review and approval.

Ongoing Remediation Efforts

Management has been implementing, and continues to implement, measures designed to ensure (a) that control deficiencies contributing to the remaining material weaknesses in the areas of risk assessment, control environment, revenue, inventory, and financial reporting close are remediated, and (b) that these controls are designed, implemented, and operating effectively. Specifically, we are implementing the following changes:
•
Risk Assessment Process - We are devoting substantial effort in performing a comprehensive risk assessment process to identify, design, implement, and re-evaluate our control activities related to the above mentioned material weakness in our internal control over financial reporting, including monitoring controls related to the design and operating effectiveness of certain control activities pertaining to our business process environment, as more fully discussed below.
•
Control Environment - We are committed to and are developing plans to attract, develop, and retain additional competent individuals in alignment with our objectives to remediate areas of material weakness, and to create the proper environment for effective internal control over financial reporting such that corrective activities to our internal control over financial reporting are appropriately applied, prioritized, and implemented in a timely manner. In addition, we are reviewing our oversight and supervision of our outside consultants that assist in our evaluation of internal controls and improving project management over internal controls
•
Revenue Processes - We are implementing controls over (i) standard contract reviews, (ii) customer invoice reviews, (iii) review of monthly sales order changes and (iv) an addition of a management review control that reviews and approves the summary of service billings for the period. We revised the revenue recognition controls due to the transition to ASC 606 and will continue to improve our review controls around the completeness and accuracy of customer order entry, quantity and pricing, and the continuing accounting for ASC 606.
•
Inventory Processes - We are implementing controls over (i) review of inventory adjustments and approvals and (ii) review over variance analysis. We continue to improve our inventory count procedures, review and valuation controls over inventory.
•
Financial Close Processes - To be consistent with our consolidated monthly closing financial statement review meetings, we continue to enhance controls over international business performance reviews to include improved documentation of items for follow-up and resolution, expand our review over completeness and accuracy of intercompany balances, design controls

52


to identify post-close events which occur before the financial statements are available to be issued and enhance controls over the review of the statement of cash flows.

The following represent ongoing remediation efforts related to implemented enhancements to our control environment that we believe will support our ongoing remediation efforts of any remaining material weaknesses:

Formal ICOFR Function - We are enhancing our control environment to include a formal internal control over financial reporting (ICOFR) compliance project management office (PMO) and ICOFR execution function. The roles and responsibilities of the PMO include the management of overall ICOFR timelines, coordination and communication with external and internal audit, process owner working sessions and related follow-up activities, coordination with international operations, and oversight of Company's remediation efforts. The Company has supplemented its internal resources with outside consultants recognized as experts in ICOFR program execution and have augmented process owner awareness and accountability with various training protocols as well as an ICOFR execution and monitoring program application.

Risk Management Committee - We formed an executive Risk Management Committee, which meets regularly, to review risk management and internal audit status updates, ICOFR status, and other compliance areas of focus. A detailed remediation and compliance plan, related timeline and critical milestones were developed, and reviewed with the committee on a regular basis.

Monthly / Quarterly Financial Process - We are implementing an improved financial close process and reporting process that includes;
i.
Monthly closing calendar supplementing the existing quarterly close calendar.
ii.
Monthly closing financial statement review meetings with process owners and financial reporting leadership.
iii.
Disclosure committee meetings, which include formal documented quarterly meetings with relevant business unit heads and other corporate functions to ensure all potential issues are escalated and resolved prior to finalizing the financial statements.
iv.
The financial statements are reviewed and approved by the disclosure committee, key financial management, legal department, the audit committee and other relevant process owners prior to filing.
v.
We have implemented controls to ensure the appropriate foreign currency rates are utilized in the financial reporting close process.
vi.
Quarterly, account reconciliations are reviewed and approved in accordance with our Account Reconciliation Policy.
vii.
We have implemented controls to ensure the segment and geographic reporting is correct.

We believe that these actions will remediate the remaining material weaknesses, although additional changes and improvements may be identified and adopted as we continue to evaluate and implement our remediation plans. The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that the controls are operating effectively. In particular, the material weakness for risk assessment and control environment will not be considered remediated until the material weaknesses within revenue, inventory and financial reporting close have been remediated. As a result, until remediated, these material weaknesses could result in material misstatements potentially impacting all financial statement accounts and disclosures in our annual or interim consolidated financial statements that would not be prevented or detected.

Changes in Internal Control Over Financial Reporting
During the quarter ended September 27, 2019, we determined that there was an additional material weakness related to our control environment, as well as additions to the material weakness in the financial reporting close process, as described above.
The remediation activities described below are changes in internal control over financial reporting during the quarter ended September 27, 2019 that have materially affected, or are reasonably likely to materially affect, our ICOFR.

Improvements to Entity Level Controls - We operated entity and corporate-level controls to support the overall control environment over financial reporting, including enhanced training and development activities around control ownership and operation, improved technologies to facilitate certifications, ongoing documentation and testing efforts, and increased accountability and overall communication.

Specific Analysis of Deficiencies and Identification of Remediation Activities - We implemented a systematic risk-based approach for identifying and implementing remediation efforts to address the six (6) material weaknesses disclosed in fiscal year 2018. We performed a detailed review of all deficiencies that were previously disclosed as material weaknesses: risk assessment, ITGC / user access, revenue, inventory, Germany operations, and the financial reporting close process.

53


Item 9B. Other Information
None.

54

PART III
Item 10. Directors, Executive Officers and Corporate Governance
Directors and Executive Officers
The information required by this item with respect to our executive officers is set forth in Part I of this Annual Report on Form 10-K and information relating to the availability of our code of conduct for executive officers and directors is set out below. The other information required by this item is incorporated by reference from our definitive proxy statement for the 2020 Annual Meeting of Stockholders under the captions “Proposal One — Election of Directors.” and “Stock Ownership-Section 16(a) Beneficial Ownership Reporting Compliance.” Our definitive proxy statement for the 2020 Annual Meeting of Stockholders will be filed with the SEC no later than 120 days after September 27, 2019.
Code of Conduct
We have adopted a Code of Conduct that applies to all of our executive officers and directors. The Code of Conduct is available on our website at http://www.vareximaging.com, and may be found as follows:
1.    From our main web page, first click “Investors.”
2.    Next click on “Governance Highlights” under “Corporate Governance” in the drop-down menu.
3.    Finally, click on “Code of Conduct.”
We intend to satisfy the disclosure requirements under Item 5.05(c) of Form 8-K regarding an amendment to, or waiver from, a provision of the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions by posting such information on our website, specified above.
Item 11. Executive Compensation.
The information required by this item is incorporated by reference from our definitive proxy statement for the 2020 Annual Meeting of Stockholders under the caption “Executive Compensation.”
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item is incorporated by reference from our definitive proxy statement for the 2020 Annual Meeting of Stockholders under the caption “Stock Ownership” and “Executive Compensation.”
Item 13. Certain Relationships and Related Transactions and Director Independence.
The information required by this item with respect to certain relationships and related transactions is incorporated by reference from our definitive proxy statement for the 2020 Annual Meeting of Stockholders under the caption “Certain Relationships and Related Transactions.” The information required by this item with respect to director and committee member independence is incorporated by reference from our definitive proxy statement for the 2020 Annual Meeting of Stockholders under the caption “Proposal One-Election of Directors.”
Item 14. Principal Accountant Fees and Services.
The information required by this item is incorporated by reference from our definitive proxy statement for the 2020 Annual Meeting of Stockholders under the caption “Proposal Four-Ratification of the Appointment of Our Independent Registered Public Accounting Firm.”

55

PART IV 
Item 15. Exhibits, Consolidated Financial Statements and Financial Statement Schedules.
Documents filed as part of this annual report include:
2.
Financial Statement Schedules and Other. All financial statement schedules have been omitted because they are not applicable, or not material or the required information is shown in the consolidated financial statements or the notes thereto.
3.
Exhibits. The exhibits listed below are filed as part of this annual report on Form 10-K.
Exhibit Number
 
Description
2.1*
 
 
 
 
2.2*
 
 
 
 
2.3*
 
 
 
 
2.4*
 
 
 
 
2.5*
 
 
 
 
3.1*
 
 
 
 
3.2*
 
 
 
 
4.1**
 
 
 
 
10.1*
 
 
 
 
10.2*
 
 
 
 
10.3*
 
 
 
 
10.4*
 
 
 
 

56

10.5*
 
 
 
 
10.6*++
 
 
 
 
10.7*
 
 
 
 
10.8*†
 
 
 
 
10.9*†
 
 
 
 
10.10*†
 
 
 
 
10.11*†
 
 
 
 
10.12*†
 
 
 
 
10.13*†
 
 
 
 
10.14*†
 
 
 
 
10.15*†
 
 
 
 
10.16*†
 
 
 
 
10.17*†
 
 
 
 
10.18*†
 
 
 
 
10.19*
 
 
 
 
10.20*
 
 
 
 
10.21*
 
 
 
 
10.22*
 
 
 
 
10.23*
 
 
 
 

57

21.1**
 
 
 
 
23.1**
 
 
 
 
31.1**
 
 
 
 
31.2**
 
 
 
 
32.1**
 
 
 
 
32.2**
 
 
 
 
101.INS**
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
101.SCH**
 
XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL**
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF**
 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB**
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE**
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
*
 
Incorporated herein by reference
 
 
 
**
 
Filed herewith
 
 
 
†
 
Management contract or compensatory agreement.
 
 
 
++
 
Portions of this exhibit have been omitted pursuant to a confidential treatment request filed pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Item 16. Form 10-K Summary
None


58



SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
 
 
VAREX IMAGING CORPORATION
 
 
 
 
Date:
December 20, 2019
By:
/s/ CLARENCE R. VERHOEF
 
 
 
Clarence R. Verhoef
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Duly Authorized Officer and Principal Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
 
Capacity
 
Date
/s/ SUNNY S. SANYAL
 
President and Chief Executive Officer and Director (Principal Executive Officer)
 
December 20, 2019
Sunny S. Sanyal
 
 
 
 
 
 
 
 
 
/s/ CLARENCE R. VERHOEF
 
Senior Vice President and Chief Financial Officer (Principal Financial Officer)
 
December 20, 2019
Clarence R. Verhoef
 
 
 
 
 
 
 
 
 
/s/ KEVIN B. YANKTON
 
Corporate Controller and Chief Accounting Officer (Principal Accounting Officer)
 
December 20, 2019
Kevin B. Yankton
 
 
 
 
 
 
 
 
 
/s/ RUEDIGER NAUMANN-ETIENNE
 
Chairman of the Board
 
December 20, 2019
Ruediger Naumann-Etienne
 
 
 
 
 
 
 
 
 
/s/ JOCELYN D. CHERTOFF
 
Director
 
December 20, 2019
Jocelyn D. Chertoff
 
 
 
 
 
 
 
 
 
/s/ CHRISTINE A. TSINGOS
 
Director
 
December 20, 2019
Christine A. Tsingos
 
 
 
 
 
 
 
 
 
/s/ JAY K. KUNKEL
 
Director
 
December 20, 2019
Jay K. Kunkel
 
 
 
 
 
 
 
 
 
/s/ ERICH R. REINHARDT
 
Director
 
December 20, 2019
Erich R. Reinhardt
 
 
 
 
 
 
 
 
 
/s/ WALTER M ROSEBROUGH, JR.
 
Director
 
December 20, 2019
Walter M Rosebrough, Jr.
 
 
 
 


59



INDEX TO CONSOLIDATED FINANCIAL STATEMENTS



60



Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Varex Imaging Corporation

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Varex Imaging Corporation and its subsidiaries (the “Company”) as of September 27, 2019 and September 28, 2018, and the related consolidated statements of earnings, of comprehensive earnings, of equity and of cash flows for each of the three years in the period ended September 27, 2019, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of September 27, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of September 27, 2019 and September 28, 2018, and the results of its operations and its cash flows for each of the three years in the period ended September 27, 2019 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company did not maintain, in all material respects, effective internal control over financial reporting as of September 27, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO because material weaknesses in internal control over financial reporting existed as of that date related to (i) ineffective risk assessment process to identify and assess the risks in the Company’s business processes, (ii) ineffective control environment as the Company had an insufficient complement of resources with the requisite knowledge and experience to create the proper environment for effective internal control over financial reporting such that corrective activities to the Company’s internal control over financial reporting are appropriately applied, prioritized, and implemented in a timely manner, (iii) ineffective controls related to accounting for revenue, deferred revenue and related accounts receivable, including maintaining effective business process controls to prevent or detect misstatements in the processing of customer transactions, and the effect of the adoption of and continuous accounting for Revenue from Contracts with Customers, (iv) ineffective controls related to accounting for inventory and cost of revenues, including maintaining effective business process controls to prevent or detect misstatements in the accuracy, valuation, presentation and disclosure of inventory, and (v) ineffective controls over the Company’s financial reporting close process to prevent or detect misstatements in the financial statements, including ineffective business performance monitoring review control over the Company’s international entities, ineffective controls related to elimination of intercompany balances, ineffective controls to identify post-close events which occur before the financial statements are available to be issued, and ineffective controls over the review of the statement of cash flows.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses referred to above are described in Management’s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. We considered these material weaknesses in determining the nature, timing, and extent of audit tests applied in our audit of the September 27, 2019 consolidated financial statements, and our opinion regarding the effectiveness of the Company’s internal control over financial reporting does not affect our opinion on those consolidated financial statements.

Change in Accounting Principle
As discussed in Note 18 to the consolidated financial statements, the Company changed the manner in which it accounts for revenue effective September 29, 2018.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in management's report referred to above. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.


F-1



We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As described in Management’s Annual Report on Internal Control Over Financial Reporting, management has excluded Direct Conversion AB from its assessment of internal control over financial reporting as of September 27, 2019 because it was acquired by the Company in a purchase business combination during the fiscal year ended September 27, 2019. We have also excluded Direct Conversion AB from our audit of internal control over financial reporting. Direct Conversion AB is a wholly-owned subsidiary whose total assets and total revenues excluded from management’s assessment and our audit of internal control over financial reporting represent 0.8% and 0.8%, respectively, of the related consolidated financial statement amounts as of and for the year ended September 27, 2019.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Consolidated Financial Statements - Impact of Resources and Controls Related to Risk Assessment and Financial Reporting
 
The completeness and accuracy of the consolidated financial statements, including the financial condition, results of operations and cash flows, is dependent on, in part, (i) designing and maintaining monitoring controls related to the identification and assessment of risk in the business process environment, (ii) designing and maintaining financial reporting controls, including information technology general controls, and financial reporting close controls related to review of international operations, intercompany balances, post-close events and the statement of cash flows, and (iii) maintaining sufficient resources to create the proper environment for effective internal control over financial reporting.


F-2



The principal considerations for our determination that performing procedures relating to the consolidated financial statements - impact of resources and controls related to risk assessment and financial reporting is a critical matter are there was a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence related to information systems and businesses processes, which affect substantially all financial statement account balances and disclosures. As described above in the “Opinions on the Financial Statements and Internal Control over Financial Reporting” section, material weaknesses were identified as of September 27, 2019 related to (i) ineffective risk assessment, (ii) ineffective control environment, and (iii) the financial reporting close process. Additionally, as previously disclosed by management, material weaknesses related to (i) information technology general controls and (ii) accounting for the Company’s operations in Germany existed during the year ended September 27, 2019.
 
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included, among others, evaluating the nature and extent of audit procedures performed and evidence obtained. These procedures also included manually testing the completeness and accuracy of system reports or other information generated by the Company's Information Technology (IT) systems.

Revenue Recognition, including Adoption of the New Revenue Accounting Standard
 
As described in Notes 1 and 18 to the consolidated financial statements, the Company’s consolidated revenue was $780.6 million for the year ended September 27, 2019. Effective September 29, 2018, the Company adopted the new revenue accounting standard. The Company determines revenue recognition through the following steps: identification of the contract, or contracts, with a customer, identification of the performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the performance obligations in the contract, and recognition of revenue when, or as, a performance obligation is satisfied. The Company’s revenues are derived primarily from the sale of hardware and services and are recognized net of any value-added or sales tax and net of sales discounts.
The principal considerations for our determination that performing procedures relating to revenue recognition, including adoption of the new revenue accounting standard, is a critical audit matter are there was a high degree of auditor judgment, subjectivity and effort in performing procedures and in evaluating the audit evidence obtained related to revenue recognition, including the adoption of the new revenue accounting standard. As described above in the “Opinions on the Financial Statements and Internal Control over Financial Reporting” section, a material weakness was identified as of September 27, 2019 related to the accounting for revenue, deferred revenue and related accounts receivable, specifically including the review of the completeness and accuracy of customer order entry, quantity and pricing, and the effect of the adoption of and continuous accounting for revenue from contracts with customers.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, evaluating management’s process for determining the application of the new revenue accounting standard to the Company’s revenue, evaluating the reasonableness of management’s judgments, and evaluating the impacts of adoption identified by management. Testing management’s application of the new revenue accounting standard included examining revenue arrangements on a test basis, including assessing the terms and conditions of the arrangement and performing procedures to test the adjustments recorded upon adoption. These procedures also included (i) manually testing the completeness and accuracy of system reports or other information generated by the Company’s IT systems and (ii) evaluating the nature and extent of audit procedures performed and evidence obtained.
Inventories
As described in Note 1 to the consolidated financial statements, the Company’s consolidated inventory balance was $248.2 million as of September 27, 2019. The Company values inventories at the lower of cost or net realizable value. Costs include materials, labor and manufacturing overhead and is computed using standard cost (which approximates actual cost) on a first-in-first-out basis. The Company evaluates the carrying value of its inventories taking into consideration such factors as historical and anticipated future sales compared to quantities on hand and the prices the Company expects to obtain for products in its various markets. The Company adjusts excess and obsolete inventories to net realizable value and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues.
The principal considerations for our determination that performing procedures relating to inventories is a critical audit matter are there was a high degree of auditor judgment, subjectivity and effort in performing procedures and in evaluating audit evidence related to the existence and valuation of inventory. As described above in the “Opinions on the Financial Statements and Internal Control over Financial Reporting” section, a material weakness was identified as of September 27, 2019 related to accounting for inventory and

F-3



cost of revenue, specifically including maintaining effective controls related to inventory count procedures, the valuation of inventory at lower of cost and net realizable value, and presentation and disclosure of inventory classifications.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, performing procedures to test the existence of inventories and evaluating and testing management’s process for determining the valuation of inventories. These procedures also included (i) manually testing the completeness and accuracy of system reports or other information generated by the Company’s IT systems and (ii) evaluating the nature and extent of audit procedures performed and evidence obtained.
Acquisition of Direct Conversion AB - Intangible Assets

As described in Note 2 to the consolidated financial statements, the Company completed the acquisition of Direct Conversion AB for net consideration of $79.4 million in 2019, which resulted in $32.9 million of intangible assets being recorded. Those intangible assets were comprised primarily of developed technology of $18.4 million and customer relationships of $9.0 million. Intangibles were valued primarily using a discounted cash flow, which included estimated revenue growth and discount rate.
The principal considerations for our determination that performing procedures relating to the intangible assets recorded with the acquisition of Direct Conversion AB is a critical audit matter are there was a high degree of auditor judgment and subjectivity in applying procedures relating to the fair value measurement of intangible assets acquired due to the significant judgment by management when developing the fair value of the intangible assets. Significant audit effort was required in performing procedures to evaluate the discounted cash flow, the estimated revenue growth, and the discount rate. The audit effort also involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included testing the effectiveness of controls relating to the acquisition accounting, including controls over management’s valuation of intangible assets and controls over development of the assumptions related to the valuation of intangible assets, including discounted cash flow, estimated revenue growth, and the discount rate. These procedures also included, among others (i) reading the purchase agreement, (ii) testing management’s process for estimating the fair value of intangible assets, and (iii) testing the completeness and accuracy of the data used in the discounted cash flow and evaluating the reasonableness of significant assumptions, including the discounted cash flow, the estimated revenue growth and the discount rate. Evaluating the reasonableness of the discounted cash flow, including the revenue growth, involved considering the past performance of the acquired business, as well as economic and industry forecasts, and considering whether they were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating the appropriateness of the valuation methods and evaluating significant assumptions, including the discount rate.



/s/ PricewaterhouseCoopers LLP

Salt Lake City, Utah
December 20, 2019

We have served as the Company’s auditor since 2016.



F-4

VAREX IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF EARNINGS


 
Fiscal Years
(In millions, except per share amounts)
2019
 
2018
 
2017
Revenues, net
$
780.6

 
$
773.4

 
$
698.1

Cost of revenues
523.9

 
519.5

 
444.6

Gross margin
256.7

 
253.9

 
253.5

Operating expenses:
 
 
 
 
 
Research and development
78.1

 
83.0

 
67.3

Selling, general and administrative
128.1

 
123.4

 
102.5

Impairment of intangible assets
4.8

 
3.0

 
—

Total operating expenses
211.0

 
209.4

 
169.8

Operating earnings
45.7

 
44.5

 
83.7

Interest income
0.1

 
0.2

 
0.2

Interest expense
(21.1
)
 
(21.7
)
 
(12.3
)
Other (expense) income, net
(3.2
)
 
2.7

 
3.2

Interest and other expenses, net
(24.2
)
 
(18.8
)
 
(8.9
)
Earnings before taxes
21.5

 
25.7

 
74.8

Taxes (benefit) on earnings
5.7

 
(2.6
)
 
22.8

Net earnings
15.8

 
28.3

 
52.0

Less: Net earnings attributable to noncontrolling interests
0.3

 
0.8

 
0.4

Net earnings attributable to Varex
$
15.5

 
$
27.5

 
$
51.6

Net earnings per common share attributable to Varex
 
 
 
 
 
Basic
$
0.41

 
$
0.73

 
$
1.37

Diluted
$
0.40

 
$
0.72

 
$
1.36

Weighted average common shares outstanding
 
 
 
 
 
Basic
38.2

 
37.9

 
37.6

Diluted
38.6

 
38.4

 
38.0


See accompanying notes to the consolidated financial statements.


F-5


VAREX IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS


 
Fiscal Years
(In millions)
2019
 
2018
 
2017
Net earnings
$
15.8

 
$
28.3

 
$
52.0

Other comprehensive (loss) earnings, net of tax:
 
 
 
 
 
Unrealized (loss) gain on interest rate swap contracts
(6.2
)
 
5.2

 
0.6

Unrealized (loss) gain on defined benefit obligations
(1.3
)
 
(0.2
)
 
0.2

Other comprehensive (loss) earnings, net of tax
(7.5
)
 
5.0

 
0.8

Comprehensive earnings
8.3

 
33.3

 
52.8

Less: Comprehensive earnings attributable to noncontrolling interests
0.3

 
0.8

 
0.4

Comprehensive earnings attributable to Varex
$
8.0

 
$
32.5

 
$
52.4




See accompanying notes to the consolidated financial statements.


F-6

VAREX IMAGING CORPORATION
CONSOLIDATED BALANCE SHEETS

(In millions, except share amounts)
September 27, 2019
 
September 28, 2018
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
29.9

 
$
51.9

Accounts receivable, net of allowance for doubtful accounts of $1.0 and $0.6 at September 27, 2019 and September 28, 2018, respectively
141.0

 
154.0

Inventories
248.2

 
235.1

Prepaid expenses and other current assets
19.3

 
17.1

Total current assets
$
438.4

 
$
458.1

Property, plant and equipment, net
142.3

 
144.9

Goodwill
290.8

 
243.6

Intangibles assets, net
86.3

 
73.8

Investments in privately-held companies
53.6

 
51.0

Other assets
27.5

 
16.5

Total assets
$
1,038.9

 
$
987.9

Liabilities, redeemable noncontrolling interests and stockholders' equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
58.2

 
$
66.3

Accrued liabilities
75.7

 
47.5

Current maturities of long-term debt
30.7

 
25.0

Deferred revenues
10.5

 
13.2

Total current liabilities
$
175.1

 
$
152.0

Long-term debt, net
364.4

 
364.8

Deferred tax liabilities
8.2

 
23.2

Other long-term liabilities
32.5

 
8.5

Total liabilities
$
580.2

 
$
548.5

Commitments and contingencies (Note 11)

 

Redeemable noncontrolling interests
10.5

 
11.1

Equity:
 
 
 
Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued
—

 
—

Common stock, $.01 par value: 150,000,000 shares authorized
 
 
 
Shares issued and outstanding: 38,371,305 and 38,026,597 at September 27, 2019 and September 28, 2018, respectively
0.4

 
0.4

Additional paid-in capital
371.8

 
357.6

Accumulated other comprehensive (loss) income
(1.7
)
 
5.8

Retained earnings
74.4

 
62.4

Total Varex stockholders' equity
$
444.9

 
$
426.2

Noncontrolling interests
3.3

 
2.1

Total stockholders' equity
$
448.2

 
$
428.3

Total liabilities, redeemable noncontrolling interests and stockholders' equity
$
1,038.9

 
$
987.9

See accompanying notes to the consolidated financial statements.

F-7

VAREX IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
Fiscal Years
(In millions)
2019
 
2018
 
2017
Cash flows from operating activities:
 
 
 
 
 
Net earnings
$
15.8

 
$
28.3

 
$
52.0

Adjustments to reconcile net earnings to net cash provided by operating activities:
 
 
 
 
 
Share-based compensation expense
11.7

 
10.0

 
8.4

Depreciation
23.5

 
26.0

 
16.9

Amortization of intangible assets
15.7

 
16.2

 
10.5

Impairment of intangible assets
4.8

 
3.0

 
—

Other assets impairment charges
—

 
1.3

 
—

Inventory write-down
3.1

 
3.1

 
—

Deferred taxes
(12.9
)
 
(7.7
)
 
(8.9
)
Amortization of deferred loan costs
2.4

 
2.3

 
1.8

Loss (gain) from equity method investments, net of dividends received
2.3

 
(3.9
)
 
(1.3
)
Other, net
0.8

 
0.7

 
1.8

Changes in assets and liabilities, net of effects of acquisitions:
 
 
 
 
 
Accounts receivable
14.8

 
9.0

 
(23.1
)
Inventories
(11.1
)
 
(2.4
)
 
(4.2
)
Prepaid expenses and other assets
4.3

 
2.0

 
(10.1
)
Accounts payable
(9.0
)
 
5.2

 
4.9

Accrued operating liabilities and other long-term operating liabilities
10.9

 
(10.2
)
 
28.1

Deferred revenues
(5.2
)
 
2.4

 
(1.6
)
Net cash provided by operating activities
71.9

 
85.3

 
75.2

Cash flows from investing activities:
 
 
 
 
 
Purchases of property, plant and equipment
(19.8
)
 
(20.4
)
 
(20.2
)
Acquisitions of businesses, net of cash acquired
(69.5
)
 
(4.8
)
 
(271.8
)
Investments in privately-held companies
(3.9
)
 
—

 
—

Net cash used in investing activities
(93.2
)
 
(25.2
)
 
(292.0
)
Cash flows from financing activities:
 
 
 
 
 
Net transfers from parent
—

 
—

 
5.0

Distributions to Varian Medical Systems, Inc.
—

 
—

 
(227.1
)
Taxes related to net share settlement of equity awards
(2.1
)
 
(2.3
)
 
(1.9
)
Borrowings under credit agreements
85.4

 
10.0

 
749.0

Repayments of borrowing under credit agreements
(87.0
)
 
(106.0
)
 
(255.0
)
Proceeds from exercise of stock options
0.8

 
3.8

 
2.8

Proceeds from shares issued under employee stock purchase plan
3.8

 
3.3

 
—

Excess tax benefits from share-based compensation
—

 
—

 
2.4

Payment of debt issuance costs
(0.5
)
 
(0.4
)
 
(11.9
)
Contributions from noncontrolling partner
—

 
1.8

 
—

Dividends paid to redeemable noncontrolling interest
(0.5
)
 
(0.6
)
 
—

Net cash (used in) provided by financing activities
(0.1
)
 
(90.4
)
 
263.3

Effects of exchange rate changes on cash and cash equivalents and restricted cash
(0.7
)
 
(0.5
)
 
0.9

Net (decrease) increase in cash and cash equivalents and restricted cash
(22.1
)
 
(30.8
)
 
47.4

Cash and cash equivalents and restricted cash at beginning of period
53.4

 
84.2

 
36.8

Cash and cash equivalents and restricted cash at end of period
$
31.3

 
$
53.4

 
$
84.2

Supplemental cash flow information:
 
 
 
 
 
Cash paid for interest
$
19.9

 
$
19.3

 
$
9.8

Cash paid for income tax
8.2

 
13.8

 
6.0

Supplemental non-cash activities:
 
 
 
 
 
Purchases of property, plant and equipment financed through accounts payable
$
1.8

 
$
2.0

 
$
4.0

Transfers of property, plant and equipment from Varian Medical Systems, Inc.
—

 
—

 
15.0

Other non-cash transfers to Varian Medical Systems, Inc.
—

 
—

 
1.6

See accompanying notes to the consolidated financial statements.

F-8

VAREX IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF EQUITY

 
 
Common Stock
 
Additional Paid-in Capital
 
Net Parent Investment
 
Accumulated Other Comprehensive Income (Loss)
 
Retained Earnings
 
Total Varex Equity
 
Noncontrolling Interests
 
Total Stockholders' Equity
(In millions)
 
Shares
 
Amount
 
 
 
 
 
 
 
September 30, 2016
 
—

 
—

 
—

 
526.0

 
—

 
—

 
526.0

 
—

 
526.0

Net earnings
 
—

 
—

 
—

 
16.5

 
—

 
35.1

 
51.6

 
—

 
51.6

Net transfers from parent
 
—

 
—

 
—

 
18.4

 
—

 
—

 
18.4

 
—

 
18.4

Distribution to Varian Medical Systems
 
—

 
—

 
—

 
(227.1
)
 
—

 
—

 
(227.1
)
 
—

 
(227.1
)
Conversion of net parent investment into common stock
 
37.4

 
0.4

 
333.4

 
(333.8
)
 
—

 
—

 
—

 
—

 
—

Exercise of stock options
 
0.1

 
—

 
2.8

 
—

 
—

 
—

 
2.8

 
—

 
2.8

Common stock issued upon vesting of restricted shares
 
0.2

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

Shares withheld on vesting of restricted stock
 
(0.1
)
 
—

 
(1.9
)
 
—

 
—

 
—

 
(1.9
)
 
—

 
(1.9
)
Share-based compensation
 
—

 
—

 
6.2

 
—

 
—

 
—

 
6.2

 
—

 
6.2

Unrealized gain on interest rate swap contracts, net of tax
 
—

 
—

 
—

 
—

 
0.6

 
—

 
0.6

 
—

 
0.6

Unrealized gain on defined benefit obligations, net of tax
 
—

 
—

 
—

 
—

 
0.2

 
—

 
0.2

 
—

 
0.2

Tax impacts to APIC related to share-based award activity
 
—

 
—

 
2.4

 
—

 
—

 
—

 
2.4

 
—

 
2.4

Other
 
—

 
—

 
(0.2
)
 
—

 
—

 
—

 
(0.2
)
 
—

 
(0.2
)
September 29, 2017
 
37.6

 
0.4

 
342.7

 
—

 
0.8

 
35.1

 
379.0

 
—

 
379.0

Net earnings
 
—

 
—

 
—

 
—

 
—

 
27.5

 
27.5

 
0.3

 
27.8

Exercise of stock options
 
0.2

 
—

 
3.8

 
—

 
—

 
—

 
3.8

 
—

 
3.8

Common stock issued upon vesting of restricted shares
 
0.2

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

Shares withheld on vesting of restricted stock
 
(0.1
)
 
—

 
(2.2
)
 
—

 
—

 
—

 
(2.2
)
 
—

 
(2.2
)
Common stock issued under employee stock purchase plan
 
0.1

 
 
 
3.3

 
—

 
—

 
—

 
3.3

 
—

 
3.3

Share-based compensation
 
—

 
—

 
10.0

 
—

 
—

 
—

 
10.0

 
—

 
10.0

Unrealized gain on interest rate swap contracts, net of tax
 
—

 
—

 
—

 
—

 
5.2

 
—

 
5.2

 
—

 
5.2

Unrealized loss on defined benefit obligations, net of tax
 
—

 
—

 
—

 
—

 
(0.2
)
 
—

 
(0.2
)
 
—

 
(0.2
)
Capital contribution by noncontrolling interest
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
1.8

 
1.8

Other
 
—

 
—

 
—

 
—

 
—

 
(0.2
)
 
(0.2
)
 
—

 
(0.2
)
September 28, 2018
 
38.0

 
$
0.4

 
$
357.6

 
$
—

 
$
5.8

 
$
62.4

 
$
426.2

 
$
2.1

 
$
428.3

Effect of adoption of ASC 606
 
—

 
—

 
—

 
—

 
—

 
(3.5
)
 
(3.5
)
 
—

 
(3.5
)
Net earnings
 
—

 
—

 
—

 
—

 
—

 
15.5

 
15.5

 
(0.2
)
 
15.3

Exercise of stock options
 
—

 
—

 
0.8

 
—

 
—

 
—

 
0.8

 
—

 
0.8

Common stock issued upon vesting of restricted shares
 
0.2

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

Shares withheld on vesting of restricted stock
 
—

 
—

 
(2.1
)
 
—

 
—

 
—

 
(2.1
)
 
—

 
(2.1
)
Common stock issued under employee stock purchase plan
 
0.2

 
—

 
3.8

 
—

 
—

 
—

 
3.8

 
—

 
3.8

Share-based compensation
 
—

 
—

 
11.7

 
—

 
—

 
—

 
11.7

 
—

 
11.7

Unrealized loss on interest rate swap contracts, net of tax
 
—

 
—

 
—

 
—

 
(6.2
)
 
—

 
(6.2
)
 
—

 
(6.2
)
Unrealized loss on defined benefit obligations, net of tax
 
—

 
—

 
—

 
—

 
(1.3
)
 
—

 
(1.3
)
 
—

 
(1.3
)
Noncontrolling interest acquired/consolidated
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
1.4

 
1.4

September 27, 2019
 
38.4

 
$
0.4

 
$
371.8

 
$
—

 
$
(1.7
)
 
$
74.4

 
$
444.9

 
$
3.3

 
$
448.2


See accompanying notes to the consolidated financial statements.


F-9

VAREX IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
Varex Imaging Corporation (the “Company,” “Varex” or “Varex Imaging”) designs, manufactures, sells and services a broad range of Medical products, which include X-ray imaging components, including X-ray tubes, digital detectors and accessories, high voltage connectors, image processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys, for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, computed tomography, oncology and computer-aided detection. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary, to independent service companies, distributors and directly to end-users for replacement purposes.
The Company also designs, manufacturers, sells and services industrial products, which include Linatron® X-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection systems. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.
Varex Imaging Corporation was incorporated in Delaware on July 18, 2016 for the purpose of holding the assets and liabilities associated with the Company's business and separated from Varian Medical Systems, Inc. (“Varian”) on January 28, 2017, upon which Varian completed the distribution of 100% of the outstanding common stock of Varex to Varian stockholders. Following the separation and distribution, Varex became an independent publicly-traded company and is listed on the NASDAQ Global Select Market under the ticker “VREX.”
Basis of Presentation and Principle of Consolidation
The accompanying consolidated financial statements are audited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Prior to January 28 2017, the date of separation and distribution, the financial statements were prepared on a stand-alone basis and were derived from Varian’s consolidated financial statements and records as it operated as part of Varian prior to the distribution, in conformity with GAAP. Prior to the separation and distribution, the consolidated financial statements included allocations of certain Varian corporate expenses these costs were allocated to the Company on the basis of direct usage when identifiable or other systematic measures that reflect utilization of services provided to or benefits received by the Company.
All transactions between the Company and Varian prior to the separation have been included in the accompanying consolidated financial statements. All intercompany transactions while the Company operated as part of Varian were considered to be effectively settled for cash and are reflected as a component of financing activities as net transfers from (to) Varian in the consolidated statements of cash flows at the time the transactions were recorded.
Prior to the separation, the Company was dependent upon Varian for its working capital and financing requirements, as Varian uses a centralized approach to cash management and financing of its operations. Financial transactions relating to the Company were accounted for through the net parent investment account. Cash and cash equivalents held by Varian were not allocated to the Company.
Net parent investment in the consolidated statements of equity represents Varian’s historical investment in the Company, the net effect of transactions with and allocations from Varian and the Company’s accumulated earnings.
Reclassification
The Company has reclassified $3.0 million from selling, general and administrative expense to impairment of intangible assets for the year ended September 28, 2018, to conform to the current year's presentation. Such reclassifications had no impact on net earnings as previously reported.

F-10

Segment Reporting
The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its CEO, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. See Note 15. Segment Information, included in this report, for further information on the Company’s segments.
Fiscal Year
The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2019 was the 52-week period that ended on September 27, 2019. Fiscal year 2018 was the 52-week period that ended on September 28, 2018. Fiscal year 2017 was the 52-week period that ended on September 29, 2017.
Variable Interest Entities
For entities in which the Company has variable interests, the Company focuses on identifying which entity has the power to direct the activities that most significantly impact the variable interest entity’s economic performance and which enterprise has the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities and results of operations of the variable interest entity will be included in the Company’s consolidated financial statements. As of September 27, 2019, the Company had two variable interest entities neither of which were consolidated.
 Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.
Cash and Cash Equivalents
The Company considers currency on hand, demand deposits, time deposits and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.
Restricted Cash
Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is
included in other assets on the consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within
the consolidated statements of cash flows consisted of the following:
 
Twelve Months Ended September 27, 2019
 
Twelve Months Ended September 28, 2018
 
Beginning of Period
 
End of Period
 
Beginning of Period
 
End of Period
Cash and cash equivalents
$
51.9

 
$
29.9

 
$
83.3

 
$
51.9

Restricted cash
1.5

 
1.4

 
0.9

 
1.5

Cash and cash equivalents and restricted cash as reported per statement of cash flows
$
53.4

 
$
31.3

 
$
84.2

 
$
53.4


Fair Value
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. There is a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
Level 1—Quoted prices in active markets for identical assets or liabilities.

F-11

Level 2—Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or, other inputs that are observable or can be corroborated by observable market data.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Derivative instruments and hedging activities
The Company records all derivatives on the balance sheet at fair value. Derivatives designated as a hedge are recorded on the Consolidated Balance Sheets at fair value as of the reporting date. For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss and reclassified from accumulated other comprehensive loss into earnings when the hedged transaction affects earnings.  For derivatives that are designated and qualify as net investment hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss. Time value is excluded and the cash payments are recognized as an adjustment to interest expense. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.
Concentration of Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.
Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, which is as follows:
 
Fiscal Year
 
2019
 
2018
 
2017
Canon Medical Systems Corporation
17.3
%
 
18.1
%
 
19.3
%

Canon Medical Systems Corporation accounted for 10.1% and 9.8% of the Company’s accounts receivable as of September 27, 2019 and September 28, 2018, respectively.
Inventories
Inventories are valued at the lower of cost or net realizable value. Costs include materials, labor and manufacturing overhead
and is computed using standard cost (which approximates actual cost) on a first-in-first-out basis. The Company evaluates the carrying
value of its inventories taking into consideration such factors as historical and anticipated future sales compared to quantities on hand
and the prices the Company expects to obtain for products in its various markets. The Company adjust excess and obsolete
inventories to net realizable value and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues.
The following table summarizes the Company’s inventories, net:
(In millions)
September 27, 2019
 
September 28, 2018
Raw materials and parts
$
160.1

 
$
149.9

Work-in-process
27.9

 
25.4

Finished goods
60.2

 
59.8

Total inventories
$
248.2

 
$
235.1



F-12

Property, Plant and Equipment, net
Property, plant and equipment are stated at cost, net of accumulated depreciation. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation are computed using the straight-line method over the estimated useful lives of the assets. Land is not subject to depreciation, but land improvements are depreciated over fifteen years. Land leasehold rights and leasehold improvements are depreciated over the lesser of their estimated useful lives or remaining lease terms. Buildings are depreciated over twenty years. Machinery and equipment are depreciated over their estimated useful lives, which range from three years to seven years. Assets subject to lease are depreciated over the lesser of their estimated useful lives or remaining lease terms. Estimated useful lives are periodically reviewed and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted, and an impairment assessment may be performed on the recoverability of the carrying amounts. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts.
The following table summarizes the Company’s property, plant and equipment, net:
(In millions)
September 27, 2019
 
September 28, 2018
Land
$
8.3

 
$
8.3

Buildings and leasehold improvements
134.4

 
138.1

Machinery
170.7

 
166.1

Construction in progress
28.5

 
23.1

 
$
341.9

 
$
335.6

Accumulated depreciation and amortization
(199.6
)
 
(190.7
)
Property, plant, and equipment, net
$
142.3

 
$
144.9


The Company recorded depreciation expense of $23.5 million, $26.0 million and $16.9 million, in fiscal years 2019, 2018 and 2017, respectively. During fiscal year 2019 the company recorded accelerated depreciation of $4.5 million on the machinery and equipment used in the fabrication of amorphous silicon glass at its facility in Santa Clara, CA. See Note 4. Restructuring, included in this report, for further information. During fiscal year 2018 the company recorded accelerated depreciation of $4.2 million on the machinery and equipment used in the fabrication of amorphous silicon glass at its facility in Santa Clara, CA. See Note 4. Restructuring, included in this report, for further information.
Investments
The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in these investments. Distributions received from an equity method investment are classified using the cumulative earnings approach. Under the cumulative earnings approach, distributions up to the amount of cumulative equity in earnings recognized will be treated as returns on investment as operating cash flows and those in excess of that amount will be treated as returns of investment as investing cash flows. The Company monitors these equity investments for impairment and makes appropriate reductions in carrying values if the Company determines that impairment charges are required based primarily on the financial condition and near-term prospects of these companies.
Goodwill and Intangible Assets
Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. Purchased intangible assets are carried at cost, net of accumulated amortization, and are included in intangible assets in the Company's consolidated balance sheets. Intangible assets with finite lives are amortized over their estimated useful lives of primarily two years to seven years using the straight-line method.
Impairment of Long-lived Assets, Intangible Assets and Goodwill
The Company reviews long-lived assets and identifiable intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. The Company assesses these assets for impairment based on their estimated undiscounted future cash flows. If the carrying value of the assets exceeds the estimated future undiscounted cash flows, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets.

F-13

The Company evaluates goodwill and indefinite lived intangible assets for impairment at least annually at the beginning of the fourth quarter of each fiscal year or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company performs a step one analysis, which consists of a comparison of the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit. The Company determines the fair value of its reporting units based on a combination of income and market approaches. The income approach is based on the present value of estimated future cash flows of the reporting units, and the market approach is based on a market multiple calculated for each reporting unit based on market data of other companies engaged in similar business. If the carrying amount of the reporting unit is in excess of its fair value, step two requires the comparison of the implied fair value of the reporting unit’s goodwill against the carrying amount of the reporting unit’s goodwill. Any excess of the carrying value of the reporting unit’s goodwill over the implied fair value of the reporting unit’s goodwill is recorded as an impairment loss. The impairment test for intangible assets with indefinite useful lives, if any, consists of a comparison of fair value to carrying value, with any excess of carrying value over fair value being recorded as an impairment loss.
During the fiscal year ended September 27, 2019 and 2018, the Company recognized $4.8 million and $3.0 million of impairments of intangible assets related to the restructuring activities see Note 4. Restructuring, included in this report. No goodwill impairment charges were recognized for any of the prior periods presented. No impairment charges were recognized in fiscal year 2017.
Loss Contingencies
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits and other loss contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent an unfavorable outcome is determined to be probable and the losses can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss.
Product Warranty
The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
The following table reflects the changes in the Company’s accrued product warranty:
 
Fiscal Years
(In millions)
2019
 
2018
Accrued product warranty, at beginning of period
$
7.3

 
$
7.0

Charged to cost of revenues
12.9

 
11.6

Actual product warranty expenditures
(12.1
)
 
(11.3
)
Accrued product warranty, at end of period
$
8.1

 
$
7.3


Revenue Recognition
Effective September 29, 2018, the Company adopted the requirements of Accounting Standards Update (“ASU”) 2014-09 and related amendments, Revenue from Contracts with Customers (“ASC 606”), which superseded all prior revenue recognition methods and industry-specific guidance. See “Recently Adopted Accounting Pronouncements” below.
The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts.
The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the

F-14

Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products.
The Company determines revenue recognition through the following steps:
•
Identification of the contract, or contracts, with a customer
•
Identification of the performance obligations in the contract
•
Determination of the transaction price
•
Allocation of the transaction price to the performance obligations in the contract
•
Recognition of revenue when, or as, a performance obligation is satisfied
Deferred Revenues
Deferred revenue primarily represents (i) the amount received applicable to non-software products for which parts
and services under the warranty contracts have not been delivered, and (ii) the amount received for service contracts for
which the services have not been rendered.
Allowance for Doubtful Accounts
The Company evaluates the creditworthiness of customers prior to authorizing shipment for all major sale transactions. On a quarterly basis, the Company evaluates aged items in the accounts receivable aging report and provide an allowance in an amount deemed adequate for doubtful accounts. If the evaluation of customers’ financial conditions does not reflect a future ability to collect outstanding receivables, additional provisions may be needed. We had an allowance for doubtful accounts of $1.0 million and $0.6 million as of September 27, 2019 and September 28, 2018, respectively.
Share-Based Compensation Expense
The Company has an equity-based incentive plan that provides for the grant of nonqualified stock options and restricted stock units to directors, officers and other employees. The Company also permits employees to purchase shares under the Varex employee stock purchase plan. Prior to the separation, the Company’s employees historically participated in Varian’s equity-based incentive plans. Share-based compensation expense through the date of separation included allocations to the Company based on the awards and terms previously granted to its employees as well as an allocation of Varian’s corporate and shared functional employee expenses.
The Company values stock options granted and the option component of the shares of common stock purchased under the equity-based incentive plans and stock purchased under the employee stock purchase plan using the Black-Scholes option-pricing model. Share-based compensation expense for restricted stock units is measured using the fair value of the Company’s stock on the date of grant and is amortized over the award’s respective service period. The Black-Scholes option-pricing model requires the input of certain assumptions, and changes in the assumptions can materially affect the fair value estimates of share-based payment awards.
The Company measures and recognizes expense for all share-based payment awards based on their fair values. Share-based compensation expense recognized in the consolidated statements of earnings includes compensation expense for the share-based payment awards based on the grant date fair value estimated in accordance with the guidance on share-based compensation. Share-based compensation expense recognized is based on the value of the portion of share-based payment awards that is ultimately expected to vest. The Company attributes the value of share-based compensation to expense using the straight-line method. The Company considers only the direct tax impacts of share-based compensation awards when calculating the amount of tax windfalls or shortfalls. For additional information, see Note 13. Employee Stock Plans, included in this report.
Shipping and Handling Costs
Shipping and handling costs are included as a component of cost of revenues.
Research and Development
Research and development costs have been expensed as incurred. These costs primarily include employees’ compensation, consulting fees and material costs.

F-15

Software Development Costs
Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized, as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility.
Taxes on Earnings
Current income tax expense is the amount of income taxes expected to be payable for the current year. Deferred income tax liabilities or assets are established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. In addition, we provide reserves for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance for accounting for income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense.
On December 22, 2017, the U.S. Government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (“U. S. Tax Reform”). U.S. Tax Reform significantly revised the U.S. corporate income tax structure including a lower corporate statutory rate and changes to the way foreign earnings are taxed. U.S. GAAP requires that the impact of tax legislation be recognized in the period in which the law is enacted. In accordance with these rules, we are including the impact of certain provisions of U.S. Tax Reform to the extent they are effective during the current reporting period.
Foreign Currency Translation
The Company uses the U.S. Dollar predominately as the functional currency of its foreign operations. Gains and losses from remeasurement of foreign currency balances into U.S. Dollars are included in the consolidated statements of earnings. For the foreign subsidiary where the local currency is the functional currency, translation adjustments of foreign currency financial statements into U.S. dollars are recorded to a separate component of accumulated other comprehensive (loss) earnings.
Accounting Standards Recently Adopted
In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which requires that the statement of cash flows explain the change in the total amount of restricted cash during the period and other additional disclosures. The Company adopted ASU 2016-18 in the first quarter of 2019 using the retrospective transition method and the Company's consolidated statements of cash flows have been retrospectively adjusted to reflect restricted cash balances. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-18.
The Company adopted ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which was issued to reduce the diversity in practice in how certain transactions are classified in the statement of cash flows. The Company adopted ASU 2016-15 in the first quarter of 2019 retrospectively. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-15.

The Company adopted ASC 606 as of September 29, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. The Company recorded a net reduction to retained earnings of $4.1 million, net of tax, as of September 29, 2018 due to the impact of adopting ASC 606. During the second quarter of 2019 the Company recorded an increase to retained earnings of $0.6 million, net of tax, to correct an error that was not quantitatively or qualitatively material to the current period, related to the adoption of ASC 606. The net cumulative impact of adopting ASC 606 was $3.5 million, net of tax. Refer to Note 18. Revenue Recognition, included in this report report for the detailed impact of adopting ASC 606.

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which amends the application of hedge accounting and improves financial reporting of hedging relationships to more accurately present the economic effects of risk management activities in the financial statements. The ASU is effective for public companies for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company early adopted the provisions of ASU 2017-12 during the quarter ended September 27, 2019, using the modified retrospective method. The adoption did not have an impact on the consolidated financial statements.

F-16

Recent Accounting Standards Updates Not Yet Effective
In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from U.S. federal tax legislation commonly referred to as the Tax Cuts and Jobs Act, which was enacted in December 2017 (the “2017 Tax Act”). ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021, and must be applied on a modified retrospective basis. The Company is currently evaluating the potential impact of this standard.
In February 2016, the FASB issued ASU 2016-02 on accounting for leases. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new standard will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of earnings. The new standard is required to be adopted using a modified retrospective method to each prior reporting period presented with various optional practical expedients. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2020 with early adoption permitted. The Company has not completed its assessment of the new standard, but anticipate that the most substantial change to its consolidated financial statements will be a gross-up of its total assets and liabilities. The adoption is not expected to materially impact our results of operations in the upcoming fiscal years and interim periods. The Company will continue to monitor the overall impact of adoption and update our disclosures as appropriate.
2. BUSINESS COMBINATIONS
Acquisition of Direct Conversion AB (publ)
On April 29, 2019, Varex completed the acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion AB (publ) (“Direct Conversion”) for $69.5 million in cash, net of cash acquired, the assumption of Direct Conversion's debt of $4.5 million and deferred consideration equal to $9.9 million or 0.3 million shares of the Company’s common stock (subject to reduction to settle indemnity claims) to be paid on the first anniversary of the closing with a mixture of cash and shares of Varex common stock. The acquisition of Direct Conversion expands our detector product portfolio to include photon counting technology.  This technology will allow Varex to expand its range of imaging applications and offer new solutions to both Medical and Industrial customers.

F-17

The following table summarizes the preliminary purchase price allocation:
(In millions)
Fair Value
Allocation of the purchase consideration:
 
Accounts receivable
$
2.4

Inventories
5.7

Prepaid expenses and other current assets
0.7

Property, plant, and equipment
0.9

Goodwill
47.2

Intangible assets
32.9

Total assets acquired
89.8

Accounts payable
(1.0
)
Accrued liabilities
(1.5
)
Current maturities of long-term debt
(1.0
)
Deferred revenues
(0.9
)
Long-term debt
(3.5
)
Other long-term liabilities
(1.1
)
Total liabilities assumed
(9.0
)
Noncontrolling interest
(1.4
)
Net assets acquired, less noncontrolling interest
$
79.4

Net cash paid
$
69.5

Deferred consideration
9.9

Total consideration
$
79.4



The Company recorded the assets acquired and liabilities assumed at their preliminary estimated fair values. Intangibles were valued primarily using a discounted cash flow, which included estimated revenue growth and discount rate. Due to the complexity of this transaction as of September 27, 2019, the Company had not finalized the determination of the fair values allocated to various assets and liabilities, including, but not limited to, inventory; deferred tax assets and liabilities; intangible assets and the residual amount allocated to goodwill. The fair value assigned to goodwill is primarily attributable to expected synergies. The goodwill related to the Direct Conversion acquisition is not tax deductible.
The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:
(In millions)
Fair Value
 
Estimated Weighted Average
Useful Life
(In Years)
Backlog
$
0.2

 
1
Trade names
2.5

 
5
Developed technology
18.4

 
10
In-process research and development
2.8

 
indefinite
Customer relationships
9.0

 
10
Total intangible assets acquired
$
32.9

 
 


F-18

The following amounts represent revenues by reporting segment from Direct Conversion from the acquisition date of April 29, 2019, through September 27, 2019:
(In millions)
Direct Conversion Revenue
Medical
$
4.5

Industrial
1.8

Total Direct Conversion revenues
$
6.3



The acquisition of Direct Conversion did not have a significant impact on our consolidated results of operations on a pro forma basis for the current or prior years.
Acquisition of Virtual Media Integration
On August 31, 2018, the Company completed the acquisition of Virtual Media Integration, Ltd. (“VMI”) from MISTRAS Group, Inc for $4.8 million. VMI is a provider of computed and digital radiography and X-ray film digitizer systems for industrial non-destructive testing. The acquired assets and liabilities of the VMI business were allocated to the Industrial reporting segment. The acquisition related costs were included in the consolidated statements of earnings under selling, general and administrative expenses.
The following table summarizes the purchase price allocation:
(In millions)
Fair Value
Allocation of the purchase consideration:
 
Accounts Receivable
$
0.2

Inventories
1.0

Other assets
0.2

Intangibles
1.6

Goodwill
1.5

Other liabilities
(0.2
)
Net assets acquired
4.3

Post-closing adjustments
0.5

Total cash consideration
$
4.8


Acquisition of PerkinElmer’s Medical Imaging Business
On May 1, 2017, the Company completed the acquisition of the medical imaging business (“Acquired Detector Business”) of PerkinElmer, Inc. (“PKI”) for $277.4 million, or $273.2 million after post-closing working capital adjustments. The acquisition consisted of PerkinElmer Medical Holdings, Inc. and Dexela Limited, together with certain assets of PKI and its direct and indirect subsidiaries relating to digital flat panel X-ray detectors that serve as components for industrial, medical, dental and veterinary X-ray imaging systems. The Acquired Detector Business included about 280 employees, with operations in Santa Clara, California as well as operations in Germany, the Netherlands, China and the United Kingdom. The acquisition of the Acquired Detector Business was pursuant to the Master Purchase and Sale Agreement, dated December 21, 2016 (the “Purchase Agreement”), by and between PKI and Varian and the subsequent Assignment and Assumption Agreement, dated January 27, 2017, by and between Varian and Varex, pursuant to which Varian assigned and conveyed all of its rights, obligations, title and interest in the Purchase Agreement to Varex.

F-19

The following amounts represent the determination of the fair value of identifiable assets acquired and liabilities for the Acquired Detector Business:
(In millions)
Fair Value
Total cash consideration
$
273.2

Allocation of the purchase consideration:
 
Cash
1.4

Accounts Receivable
18.7

Inventory
34.7

Prepaids and other current assets
0.6

Property, plant, and equipment
21.4

Other assets, non-current
2.0

Intangibles
81.1

Goodwill
167.3

Total assets acquired
$
327.2


 
 
Current liabilities
$
(17.2
)
Other liabilities, non-current
(36.8
)
Total liabilities assumed
(54.0
)
Net assets acquired
$
273.2


The fair value assigned to goodwill is attributable to expected cost synergy opportunities. Included in the goodwill recorded for the Acquired Detector Business is approximately $35 million that will be deductible for income tax purposes in Germany, China and the Netherlands. The remaining goodwill related to the stock acquisition in the United States is not tax deductible. Also, as a result of the acquisition, non-current deferred income tax liability increased by approximately $31 million related to basis differences for both tangible and intangible assets acquired as part of the stock purchases in the United States and the United Kingdom, and asset purchases in Germany, the Netherlands and China.
The following amounts represent the determination of the fair value of identifiable intangible assets for the Acquired Detector Business, which are amortized straight-line:
(In millions)
Fair Value
 
Estimated
Useful Life
(In Years)
Favorable leasehold interests
$
3.8

 
16
Backlog
1.2

 
1
Trade names
1.4

 
5
Developed technology
37.7

 
7
In-process research and development
4.0

 
indefinite
Customer relationships
33.0

 
7
Total intangible assets acquired
$
81.1

 
 

The following amounts represent revenues by reporting segment from the Acquired Detector Business from the acquisition date of May 1, 2017 through September 29, 2017:
(In millions)
May 1, 2017 through September 29, 2017
Acquired Detector Business
 
Medical
$
41.1

Industrial
20.2

Total Acquired Detector Business revenues
$
61.3



F-20

Unaudited Pro Forma Information
The unaudited pro-forma amounts presented below for the fiscal year 2017 are presented for informational purposes only. In addition to the Company's results for the periods presented, the amounts below also include effects of the Acquired Detector Business as if it had been consummated on October 1, 2016. These unaudited pro-forma results include effects that are directly attributable to the acquisition which include the amortization of intangible assets, interest expense, and other adjustments, including estimated tax effects. The unaudited pro-forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the Acquired Detector Business and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations or results that might have been achieved had the acquisition been consummated as of October 3, 2015.
 
Fiscal Year
(In millions)
2017
Revenue
$
777.8

Operating earnings
$
84.7

Net earnings
$
43.1

Net earnings per share, basic
$
1.15

Net earnings per share, diluted
$
1.13


3. RELATED-PARTY TRANSACTIONS
Investment in Privately-Held Companies
The Company has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a four-member consortium that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon based thin film transistor arrays for digital flat panel image detectors. In accordance with the dpiX Holding Agreement, net profits or losses are allocated to the members, in accordance with their ownership interests.
The equity investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated until realized by the Company. In fiscal years 2019, 2018 and 2017, the Company recorded (loss) and income on the equity investment in dpiX Holding of $(1.1) million, $3.4 million and $0.8 million, respectively. Income and loss on the equity investment in dpiX Holding is included in other (expense) income, net in the consolidated statements of earnings. The carrying value of the equity investment in dpiX Holding, which was included in investments in privately-held companies on the consolidated balance sheets, was $48.1 million and $48.9 million at September 27, 2019 and September 28, 2018, respectively.
In fiscal years 2019, 2018 and 2017, the Company purchased glass transistor arrays from dpiX totaling $23.5 million, $19.3 million and $24.7 million, respectively. These purchases of glass transistor arrays are included as a component of inventories on the consolidated balance sheets or cost of revenues in the consolidated statements of earnings for these fiscal years.
As of September 27, 2019 and September 28, 2018, the Company had accounts payable to dpiX totaling $3.6 million and $3.7 million, respectively.
In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides the Company with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires the Company to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of September 27, 2019, the Company estimated it has fixed cost commitments of $3.7 million related to this amended agreement through the remainder of calendar year 2019. The fixed cost commitment for future periods will be determined and approved by the dpiX board of directors at the beginning of each calendar year. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).
The Company has determined that dpiX is a variable interest entity because at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to direct the activities of dpiX and therefore is not the primary beneficiary of dpiX. The Company’s exposure to loss as a result of its involvement with dpiX is limited to the carrying value of the Company’s investment of $48.1 million and fixed cost commitments of $3.7 million.

F-21

In November 2018, the Company and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging Verwaltungsgesellschaft GmbH (“VEC”), a joint venture formed to develop technology to be used in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members, in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method. The Company has made contributions totaling $2.9 million, and has committed to contribute an additional $2.2 million, as milestones are achieved, and to provide certain full time employees to support prototyping and manufacturing activities in exchange for a 50% interest in VEC. CETTEEN made contributions of certain assets including intellectual property in exchange for a 50% interest in VEC. The Company's investment in VEC was $2.0 million as of September 27, 2019.
4. RESTRUCTURING
Following the acquisition of the medical imaging business from PKI in May of 2017, management began a multiyear program to consolidate the acquired operations, reduce costs, improve productivity and realize synergies.
In March 2018, the Company made the decision to transfer the complementary metal oxide semiconductor (“CMOS”) research and development capability from the U.K. to the U.S. and to permanently close the operation of the acquired detector business in London. The company will continue to develop the CMOS technology in the U.S. due to its competitive advantages, product differentiation and future economic benefit. In connection with this initiative, we recorded $1.7 million in restructuring charges during fiscal year 2018.
In July 2018, the Company committed to a plan to relocate the production of amorphous silicon glass for digital detectors, from its Santa Clara facility, to the jointly owned dpiX fabrication facility in Colorado. In July 2019, the Company committed to close its Santa Clara facility and to relocate the remaining production to its other existing facilities. The Company expects operations at the Santa Clara facility to cease by the end of December 2020 and all activities related to the closure of the facility to be complete by the end of March 2021. In connection with the relocation of the glass production and site closure the Company recorded $16.1 million and $14.2 million of restructuring and impairment charges during fiscal year 2019 and 2018, respectively. Fiscal year 2019 intangible asset impairment charges consisted of in-process research and development related to certain projects that were discontinued as a result of the Santa Clara facility closure. Fiscal year 2018 intangible asset impairment charges were related to a favorable leasehold interest that was impaired as a result of the amorphous silicon glass relocation. The Company expects to incur an additional $8.1 million to $12.1 million of restructuring charges through March 2021.
The Company also incurred approximately $2.8 million and $0.8 million of other unrelated restructuring expenses during fiscal years 2019 and 2018, respectively.
Cash outflows associated with these restructuring charges are limited to employee termination expenses, facility closure and equipment sales and disposals. Below is a detail of restructuring charges incurred during the 2019 and 2018 fiscal years, which predominately relate to the Company's Medical segment:
(In millions)
Location of Restructuring Charges in Consolidated Statements of Earnings
 
September 27, 2019
 
September 28, 2018
Other assets impairment charges
Selling, general and administrative
 
$
—

 
$
1.3

Inventory write downs
Cost of revenues
 
3.1

 
3.1

Intangible assets impairment
Impairment of intangible assets
 
4.8

 
3.0

Accelerated depreciation
Cost of revenues
 
4.5

 
4.2

Severance costs
Selling, general and administrative
 
6.2

 
4.3

Facility closure costs
Selling, general and administrative
 
0.3

 
0.8

Total restructuring charges
 
 
$
18.9

 
$
16.7



F-22

5. OTHER FINANCIAL INFORMATION
     The following table summarizes the Company’s accrued liabilities:
(In millions)
September 27, 2019
 
September 28, 2018
Accrued compensation and benefits
$
32.1

 
$
27.0

Product warranty
8.1

 
7.3

Income taxes payable
10.7

 
1.4

Payable to Varian Medical Systems
—

 
2.3

Right of return liability
6.9

 
—

Deferred consideration
8.9

 
—

Other
9.0

 
9.5

Total accrued liabilities
$
75.7

 
$
47.5


The following table summarizes the Company’s other long-term liabilities:
(In millions)
September 27, 2019
 
September 28, 2018
Long-term income tax payable
$
3.9

 
$
3.5

Environment liabilities
0.9

 
1.3

Defined benefit obligation liability
5.5

 
3.3

Long-term right of return liability
19.5

 
—

Long-term other
2.7

 
0.4

Total other long-term liabilities
$
32.5

 
$
8.5

The following table summarizes the Company’s other income (expense), net:
 
Fiscal Years
(In millions)
2019
 
2018
 
2017
Income (loss) from equity method investments
$
(2.3
)
 
$
3.9

 
$
1.3

Change in fair value of deferred consideration
1.0

 
—

 
—

Realized income (loss) on foreign currencies
(1.9
)
 
(1.2
)
 
1.9

Total other income (expense), net
$
(3.2
)
 
$
2.7

 
$
3.2


6. NET EARNINGS PER SHARE
Basic net earnings per common share is computed by dividing the net earnings for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net earnings per common share reflects the effects of potentially dilutive securities, which is computed by dividing net earnings by the sum of the weighted average number of common shares outstanding and dilutive common shares, which consists of stock options and unvested restricted stock.

F-23


A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per common share is as follows:
 
Fiscal Year
(In millions, except per share amounts)
2019
 
2018
 
2017
Net earnings attributable to Varex
$
15.5

 
$
27.5

 
$
51.6

Weighted average shares outstanding - basic
38.2

 
37.9

 
37.6

Dilutive effect of potential common shares
0.4

 
0.5

 
0.4

Weighted average shares outstanding - diluted
38.6

 
38.4

 
38

Net earnings per share attributable to Varex - basic
$
0.41

 
$
0.73

 
$
1.37

Net earnings per share attributable to Varex - diluted
$
0.40

 
$
0.72

 
$
1.36

Anti-dilutive employee shared based awards, excluded
1.9

 
1.2

 
1.0


The Company excludes potentially dilutive common shares (consisting of shares underlying stock options and the employee stock purchase plan) from the computation of diluted weighted average shares outstanding if the inclusion of the shares underlying these stock awards would be anti-dilutive to earnings per share.
7. FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.
The Company records all derivatives on the consolidated balance sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.    The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. The Company does not offset fair value amounts recognized for derivative instruments in its consolidated balance sheets for presentation purposes.
Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.
Derivatives Designated as Hedging Instruments - Cash Flow Hedges
The Company uses interest rate swap contracts as cash flow hedges to manage its exposure to fluctuations in LIBOR interest rates. Interest rate swap contracts hedging variable rate debt effectively fix the LIBOR component of its interest rate for a specific period of time.
As of September 27, 2019, the Company had the following outstanding derivatives designated as cash flow hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Interest Rate Swap Contracts
6
 
$
264.4


The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for cash flow hedges:

F-24

 
Amount of Gain or (Loss) Recognized in OCI on Derivative
Fiscal Year Ended
 
Location of Gain or (Loss) Reclassified from Accumulated OCI into Income
 
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income
Fiscal Year Ended
(In millions)
2019
 
2018
 
2017
 
 
2019
 
2018
 
2017
Interest Rate Swap Contracts
$
(6.3
)
 
$
6.9

 
$
0.6

 
Interest expense
 
$
1.9

 
$
0.1

 
$
(0.3
)
The Company expects that $0.1 million of the accumulated other comprehensive (loss) income related to cash flow hedges will be realized in pre-tax earnings over the next 12 months, but the amount will vary depending on interest rates.
These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded.
 
Derivative Assets
 
Derivative Liabilities
(In millions)
 
 
September 27, 2019
 
September 28, 2018
 
 
 
September 27, 2019
 
September 28, 2018
Derivatives designated as cash flow hedges
Balance sheet location
 
 
 
 
 
Balance sheet location
 
 
 
 
Interest rate swap contracts
Other current assets
 
$
—

 
$
2.2

 
Other current liabilities
 
$
—

 
$
—

Interest rate swap contracts
Other non-current assets
 
—

 
5.5

 
Other non-current liabilities
 
(0.5
)
 
—

 
 
 
$
—

 
$
7.7

 
 
 
$
(0.5
)
 
$
—


Derivatives Designated as Hedging Instruments - Net Investment Hedges
The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly-owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive (loss) income along with the foreign currency translation adjustments on those investments. As of September 27, 2019, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Cross Currency Swap Contracts
4
 
$
77.7


The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
 
Amount of Gain or (Loss) Recognized in OCI on Derivative
Fiscal Year Ended
 
Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
 
Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
(In millions)
2019
 
2018
 
2017
 
 
2019
 
2018
 
2017
Cross Currency Swap Contracts
$
(0.2
)
 
$
—

 
$
—

 
Interest expense
 
$
0.2

 
$
—

 
$
—

These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:
 
Derivative Assets
 
Derivative Liabilities
(In millions)
 
 
September 27, 2019
 
September 28, 2018
 
 
 
September 27, 2019
 
September 28, 2018
Derivatives designated as net investment hedges
Balance sheet location
 
 
 
 
 
Balance sheet location
 
 
 
 
Cross currency swap contracts
Other current assets
 
—

 
—

 
Other current liabilities
 
(0.2
)
 
—

 
 
 
$
—

 
$
—

 
 
 
$
(0.2
)
 
$
—



F-25

Balance Sheet Hedges
The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily cash, third-party accounts receivable, accounts payable, and intercompany receivables and payables. These forward contracts expire within 30 days. These forward contracts are not designated for hedge accounting treatment, therefore, the change in fair value of these derivatives is recorded as a component of other income (expense) and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense). The effect of derivative instruments not designated as hedges for fiscal year 2019 was a loss of $1.5 million, which was primarily related to the purchase price hedge established following the announcement of the Company's planned acquisition of Direct Conversion. The Company does not, and does not intend to use derivative financial instruments for speculative or trading purposes.
The following table shows the notional amounts of outstanding foreign currency contracts entered into under its balance sheet hedge program as of September 27, 2019:
 
Notional Value of Derivatives not Designated as Hedging Instruments:
In millions
Buy contracts
 
Sell contract
Japanese yen
$
0.9

 
$
—

Swiss franc
—

 
(1.0
)
Chinese renminbi
1.8

 
—

Euro
8.8

 
—

 
$
11.5

 
$
(1.0
)


8. BORROWINGS
The following table summarizes the Company's short-term and long-term debt:
 
September 27, 2019
 
September 28, 2018
(In millions, except for percentages)
Amount
 
Weighted-Average Interest Rate
 
Amount
 
Weighted-Average Interest Rate
Current maturities of long-term debt
 
 
 
 
 
 
 
Term facility
$
29.4

 
5.6
%
 
$
25.0

 
4.2
%
Other debt
1.3

 
 
 
—

 
 
Total current maturities of long-term debt
$
30.7

 
 
 
$
25.0

 
 
 
 
 
 
 
 
 
 
Non-current maturities of long-term debt:
 
 
 
 
 
 
 
Revolving credit facility
$
59.0

 
5.6
%
 
$
28.0

 
4.2
%
Term facility
308.6

 
5.6
%
 
345.0

 
4.2
%
Other debt
2.5

 
 
 
—

 
 
Debt issuance costs
(5.7
)
 
 
 
(8.2
)
 
 
Non-current maturities of long-term debt
364.4

 
 
 
364.8

 
 
Total long-term debt, net
$
395.1

 
 
 
$
389.8

 
 

Existing Credit Facility
On May 1, 2017 and in connection with the Acquired Detector Business, the Company entered into a new secured revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal amount of up to $200.0 million with a five-year term, and a secured term facility (the “Term Facility” and together with the Revolving Credit Facility, the “Credit Agreement”) in an aggregate principal amount of $400.0 million. The Term Facility will be repaid over five years, with 5.0% payable in quarterly installments

F-26

during each of the first two years of the term thereof, 7.5% payable in quarterly installments during the third and fourth years of the term thereof, and 10% payable in quarterly installments in the fifth year of the term thereof, with the remaining amount due at maturity. Varex used the net proceeds from the Term Facility, and the net proceeds from approximately $97.0 million drawn on the Revolving Credit Facility, to pay the purchase price for the Acquired Detector Business, plus related credit facility fees, and to repay all of Varex’s obligations under the Previous Credit Agreement. Both the Term Facility and Revolving Credit Facility expire on May 1, 2022.
The Credit Agreement contains various customary restrictive covenants that limits, among other things, the incurrence of indebtedness by Varex and its subsidiaries, the grant or incurrence of liens by Varex and its subsidiaries, the entry into sale and leaseback transactions by Varex and its subsidiaries, and the entry into certain fundamental change transactions by Varex and its subsidiaries. It also contains customary events of default and certain financial covenants. The Company agreed to maintain financial covenants, which include maximum consolidated total leverage ratio, maximum senior secured leverage ratio, maximum capital expenditures and a minimum consolidated fixed charge coverage ratio. The Company was in compliance with all financial covenants under the Credit Agreement as of September 27, 2019.
The Credit Agreement is secured by the stock and assets of Varex’s material subsidiaries. The Credit Agreement has several borrowing and interest rate options including the following indices: (a) LIBOR rate, or (b) the base rate (equal to the greater of the prime rate, the federal funds rate plus 0.50% or the LIBOR rate for a one-month period plus 1.00%). Loans under the Credit Agreement bear interest at a rate per annum using the applicable indices plus a varying interest rate margin of between 1.75% and 2.75% (for LIBOR rate loans) and 0.75%-1.75% (for base rate loans). The Credit Agreement also provides for fees applicable to amounts available to be drawn under outstanding letters of credit of 0.125%, and a fee on unused commitments which ranges from 0.25% to 0.40%.
On October 3, 2018, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of October 10, 2018, the Company had permanently reducing the revolving credit commitment under the Credit Agreement by $50.0 million to $150.0 million. The reduction in the revolving credit commitment reduced the fees paid by the Company in connection with such commitment.
Subsequent to fiscal year 2019, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of October 8, 2019, the Company was permanently reducing the revolving credit commitment under the Credit Agreement by $25.0 million to $125.0 million.
Subsequent to fiscal year 2019, the Company did not comply with the covenant under the Credit Agreement to timely deliver the Company's fiscal year 2019 annual financial statements. However, upon the filing of this Annual Report with the SEC, the Company will be able to deliver the fiscal year 2019 annual financial statements within the 30-day cure period set forth in the Credit Agreement and consequently no event of default will occur.
At September 27, 2019, the Company had $364.4 million in non-current maturities of long-term debt outstanding, net of deferred debt issuance costs of $5.7 million, and $30.7 million of current maturities of long-term debt outstanding.
Future principal payments of the long-term debt outstanding as of September 27, 2019 are as follows:
(In millions)
 
Fiscal years:
 
2020
$
30.7

2021
34.3

2022
335.8

Total debt outstanding
400.8

Less: current maturities of long-term debt
(30.7
)
Non-current portion of long -term debt
$
370.1



F-27

9. FAIR VALUE
Assets/Liabilities Measured at Fair Value on a Recurring Basis
In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
(In millions)
Fair Value Measurements at September 27, 2019
 
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - money market funds
$
—

 
$
8.8

 
$
—

 
$
8.8

Total assets measured at fair value
$
—

 
$
8.8

 
$
—

 
$
8.8

Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
0.7

 
$
—

 
$
0.7

Deferred consideration
8.9

 
—

 
—

 
8.9

Total liabilities measured at fair value
$
8.9

 
$
0.7

 
$
—

 
$
9.6


As of September 27, 2019, the total outstanding borrowings under the Company's credit agreement were $395.1 million, net of deferred loan costs, which approximated its fair value because it is carried at a market observable interest rate that resets periodically and is categorized as Level 2 in the fair value hierarchy. The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable and accounts payable, also approximate their fair values due to their short maturities.
There were no financial assets or liabilities measured on a recurring basis using significant unobservable inputs (Level 3) and there were no transfers in or out of Level 1, 2 or 3 during fiscal year 2018.
At September 28, 2018, the Company determined the following levels of inputs for the following assets or liabilities:
(In millions)
Fair Value Measurements at September 28, 2018
 
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - Money market funds
$
—

 
$
18.4

 
$
—

 
$
18.4

Derivative assets
—

 
7.7

 
—

 
7.7

Total assets measured at fair value
$
—

 
$
26.1

 
$
—

 
$
26.1

Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
—

 
$
—

 
$
—



F-28

10. GOODWILL AND INTANGIBLE ASSETS
The following table reflects goodwill by reportable operating segment:
(In millions)
Medical
 
Industrial
 
Total
Balance at September 28, 2018
$
147.0

 
$
96.6

 
$
243.6

Business combination
26.0

 
21.2

 
47.2

Balance at September 27, 2019
$
173.0

 
$
117.8

 
$
290.8


The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the consolidated balance sheets:
 
September 27, 2019
 
September 28, 2018
(In millions)
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Acquired existing technology
$
74.1

 
$
(28.4
)
 
$
45.7

 
$
57.9

 
$
(21.8
)
 
$
36.1

Patents, licenses and other
12.7

 
(8.4
)
 
4.3

 
9.9

 
(7.4
)
 
2.5

Customer contracts and supplier relationship
50.7

 
(17.2
)
 
33.5

 
42.6

 
(11.4
)
 
31.2

Total intangible assets with finite lives
137.5

 
(54.0
)
 
83.5

 
110.4

 
(40.6
)
 
69.8

In-process R&D with indefinite lives
2.8

 
0.0

 
2.8

 
4.0

 
0.0

 
4.0

Total intangible assets
$
140.3

 
$
(54.0
)
 
$
86.3

 
$
114.4

 
$
(40.6
)
 
$
73.8

 
 
 
 
 
 
 
 
 
 
 
 

Amortization expense for intangible assets was $15.7 million, $16.2 million and $10.5 million in fiscal years 2019, 2018 and 2017, respectively. The Company recognized an impairment loss of $4.8 million and $3.0 million in fiscal years 2019 and 2018, respectively. These impairment costs were included in the consolidated statements of earnings under impairment of intangible assets.
As of September 27, 2019, the estimated future amortization expense of intangible assets with finite lives is as follows:
(In millions)
 
Fiscal years:
 
2020
$
17.2

2021
16.3

2022
14.7

2023
13.7

2024
9.1

Thereafter
12.5

Total
$
83.5


11. COMMITMENTS AND CONTINGENCIES
Lease Commitments
At September 27, 2019, the Company was committed to minimum rentals under non-cancelable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and thereafter, as follows: $7.5 million, $5.4 million, $4.7 million, $1.8 million, $0.9 million, and $0.2 million, respectively. Rental expenses were $5.1 million, $5.3 million, and $4.0 million for fiscal years 2019, 2018 and 2017, respectively.
Other Commitments
See Note 3. Related Party Transactions, included in this report, for additional information about the Company’s commitments to dpiX.

F-29


See Note 12. Redeemable Noncontrolling Interests & Noncontrolling Interests, included in this report, for additional information about the Company’s commitment to the noncontrolling shareholders of MeVis.
The Company has an environmental liability of approximately $0.9 million as of September 27, 2019.
 Contingencies
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duty audits, other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. The Company did not have any contingent liabilities as of September 27, 2019 and September 28, 2018. Legal expenses are expensed as incurred.
12. REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS
In April 2019, a subsidiary of Varex completed the acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion. As the Company has majority voting rights it has consolidated Direct Conversion's operations in its consolidated financial statements and recorded the noncontrolling interest. The noncontrolling interest related to Direct Conversion is included in noncontrolling interest in the equity section of the Company's consolidated balance sheet. Earnings representing the noncontrolling interest's portion of Direct Conversion's income from operations is included in the Company's consolidated statements of earnings.
In September 2018, the Company entered into a partnership in Saudi Arabia. The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in our consolidated financial statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s 25% interest in the joint venture is included in noncontrolling interest in the equity section of the Company’s consolidated balance sheet. Earnings representing the noncontrolling partner's share of income from operations is included in the Company's consolidated statements of earnings.
In April 2015, the Company completed the acquisition of 73.5% of the then outstanding shares of MeVis Medical Solutions AG (“MeVis”), a public company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a domination and profit and loss transfer agreement (the “DPLTA”) with MeVis. In October 2015, the DPLTA became effective upon its registration at the local court of Bremen, Germany. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all of its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of €0.95 per MeVis share starting from January 1, 2015 and (2) a put right for their MeVis shares at €19.77 per MeVis share. Upon effectiveness of the DPLTA, the noncontrolling interests in MeVis became redeemable as a result of the put right and were reclassified to temporary equity. As of September 27, 2019, the redemption value of redeemable noncontrolling interests in MeVis was $10.5 million.
During fiscal year 2018, an immaterial number of MeVis’ shares were purchased under the put right. As of September 27, 2019, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares.

F-30

Changes in redeemable noncontrolling interests and noncontrolling interests were as follows: 
 
Fiscal Years
 
2019
 
2018
(In millions)
Redeemable
Noncontrolling
Interests
 
Noncontrolling
Interests
 
Redeemable
Noncontrolling
Interests
 
Noncontrolling Interest
Balance at beginning of period
$
11.1

 
$
2.1

 
$
11.2

 
$
—

Net earnings attributable to noncontrolling interests
0.5

 
(0.2
)
 
0.5

 
0.3

Contributions from noncontrolling interests
—

 
1.4

 
—

 
1.8

Dividend distributions
(0.5
)
 
—

 
(0.6
)
 
—

Other
(0.6
)
 
—

 
—

 
—

Balance at end of period
$
10.5

 
$
3.3

 
$
11.1

 
$
2.1


13. EMPLOYEE STOCK PLANS
Employee Stock Plans
The Company's employees participate in Varex Imaging Corporation 2017 Omnibus Stock Plan (the “2017 Stock Plan”) and Varex Imaging Corporation 2017 Employee Stock Purchase Plan (the “2017 ESPP”) which allows the grants of stock options, restricted stock units and performance shares among other types of awards.
In January 2017, Varex stockholders approved the 2017 ESPP, which provides eligible employees with an opportunity to purchase shares of Varex common stock at 85% of the lower of its fair market value at the start and end of a six months purchase period. The 2017 ESPP provides for the purchase of up to one million shares of Varex common stock.
Share-Based Compensation Expense
Share-based compensation expense recognized in the consolidated statements of earnings is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees. Prior to the separation, Varian also charged the Company for the allocated share-based compensation costs of certain employees of Varian who provided selling, general and administrative services on the Company’s behalf.
The table below summarizes the effect of recording share-based compensation expense and for the option component of the employee stock purchase plan shares:
 
Fiscal Year
(In millions)
2019
 
2018
 
2017
Cost of revenues
$
1.2

 
$
1.3

 
$
0.9

Research and development
2.2

 
1.8

 
1.5

Selling, general and administrative (1)
8.3

 
6.9

 
6.0

Total share-based compensation expense
$
11.7

 
$
10.0

 
$
8.4

(1) Includes allocated share-based compensation of $0.8 million for fiscal year 2017 and represents charges by Varian to the Company for certain Varian employees who provided general and administrative services on the Company’s behalf.
The unrecognized share-based compensation cost as of September 27, 2019 was $23.1 million, and is expected to be recognized in the next 3 to 4 fiscal years. As of September 27, 2019, there were approximately 1.2 million and 0.7 million shares of common stock available for future issuances under the 2017 Stock Plan and the 2017 ESPP, respectively.

F-31

The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of ESPP grants. The Company calculated the fair value of option grants and option component of ESPP grants on the respective dates of grant using the following weighted average assumptions:
 
Employee Stock Option Plan
 
Employee Stock Purchase Plans
 
Fiscal Year
 
Fiscal Year
 
2019
 
2018
 
2017
 
2019
 
2018
 
2017
Expected term (in years)
4.6

 
4.8

 
4.2

 
0.5

 
0.5

 
0.5

Risk-free interest rate
2.5
%
 
2.6
%
 
1.6
%
 
2.5
%
 
2.0
%
 
1.0
%
Expected volatility
33.9
%
 
31.8
%
 
23.6
%
 
43.9
%
 
34.1
%
 
28.0
%
Expected dividend
0.0
%
 
0.0
%
 
0.0
%
 
0.0
%
 
0.0
%
 
0.0
%
Weighted average fair value at grant date
$10.19
 
$11.57
 
$8.08
 
$7.81
 
$8.92
 
$7.81

Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.
Risk-Free Interest Rate
The interest rates used are based on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award.
Expected Term
Options granted generally vest over a period of 36 to 48 months and expire 7 to 10 years from date of grant. Employee stock purchase plan offering periods are 6 months and provides eligible employees with an opportunity to purchase shares of Varex common stock at 85% of the lower of its fair market value at the start and end of a six-month purchase period.
Expected Dividend Yield
The dividend rate used is zero as the Company has never paid any cash dividends on its common stock and does not anticipate doing so in the foreseeable future. The Company is also restricted from paying dividends on common stock under its credit facility.
Expected Volatility
Authoritative accounting guidance on stock-based compensation indicates that companies should consider volatility over a period generally commensurate with the expected or contractual term of the stock option. Adequate Company-specific data does not exist for this time period as the Company began trading in January 2017. The volatility variable used is a blended approach by using the Company's historic data for the years it has been publicly traded and a benchmark of other comparable companies’ volatility rates for the prior years.

F-32

Stock Option Activity
The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company’s employees:
(In thousands, except per share amounts and the remaining term)
Options
 
Price range
 
Weighted Average
Exercise Price
 
Weighted Average Remaining Term (in years)
 
Aggregate Intrinsic Value (1)
Outstanding at September 28, 2018
2,011
 
$22.63 — $37.60
 
$
30.35

 
 
 
 
Granted
297
 
$31.42 — $31.42
 
31.42

 
 
 
 
Canceled, expired or forfeited
(4)
 
$31.08 — $31.08
 
31.08

 
 
 
 
Exercised
(35)
 
$22.84 — $27.77
 
23.38

 
 
 
 
Outstanding at September 27, 2019
2,269
 
$22.63 — $37.60
 
$
30.60

 
4.1
 
$
1,220.3

Exercisable at September 27, 2019
1,477
 
$22.63 — $37.60
 
$
29.67

 
3.4
 
$
1,220.3

(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $28.28 as of September 27, 2019, the last trading date of the Company's respective fiscal years, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
The weighted-average grant-date fair value of options granted during fiscal years 2019, 2018 and 2017 was $3.0 million, $3.1 million and $9.2 million respectively. The total intrinsic value of the options exercised during the years ended September 27, 2019, September 28, 2018 and September 29, 2017 was $0.2 million, $1.7 million and $1.4 million respectively
Restricted Stock Units, Restricted Stock Awards and Deferred Stock Units
The following table summarizes the activity for restricted stock units, restricted stock awards and deferred stock units under Varex’s employee incentive plans for the Company’s employees:
(In thousands, except per share amounts)
Number of Shares
 
Weighted Average
Grant-Date Fair
Value
Balance at September 28, 2018
641
 
$
33.60

Granted
288
 
31.29

Vested
(201)
 
31.56

Canceled or expired
(50)
 
34.13

Balance at September 27, 2019
678
 
$
33.18

The total grant-date fair value of shares granted in fiscal year was $9.0 million, $10.1 million and $11.4 million for fiscal years 2019, 2018 and 2017, respectively. Shares outstanding at September 27, 2019, September 28, 2018 and September 29, 2017 had an estimated market value of $19.2 million, $18.4 million and $17.8 million, respectively.
14. TAXES ON EARNINGS
Income tax expense is based on reported income or loss before income taxes. Deferred income taxes reflect the effect of temporary differences between asset and liability amounts that are recognized for financial reporting purposes and the amounts that are recognized for income tax purposes. These deferred taxes are measured by applying currently enacted tax laws. Valuation allowances are recognized to reduce deferred tax assets to the amount that is more likely than not to be realized.

F-33

Taxes on earnings were as follows:
 
Fiscal Years
(In millions)
2019
 
2018
 
2017
Current provision:
 
 
 
 
 
Federal
$
9.2

 
$
(2.1
)
 
$
24.8

State and local
1.3

 
(0.3
)
 
1.6

Foreign
6.8

 
7.5

 
5.3

Total current
17.3

 
5.1

 
31.7

Deferred provision (benefit):
 
 
 
 
 
Federal
(10.0
)
 
(7.0
)
 
(7.0
)
State and local
(1.6
)
 
0.7

 
(1.0
)
Foreign
—

 
(1.4
)
 
(0.9
)
Total deferred
(11.6
)
 
(7.7
)
 
(8.9
)
Taxes on earnings
$
5.7

 
$
(2.6
)
 
$
22.8


Earnings before taxes are generated from the following geographic areas:
 
Fiscal Years
(In millions)
2019
 
2018
 
2017
United States
$
5.9

 
$
3.7

 
$
55.5

Foreign
15.6

 
22.0

 
19.3

Earnings before taxes
$
21.5

 
$
25.7

 
$
74.8


The effective tax rate differs from the U.S. federal statutory tax rate as a result of the following:
 
Fiscal Years
 
2019
 
2018
 
2017
Federal statutory income tax rate
21.0
 %
 
24.5
 %
 
35.0
 %
State and local taxes, net of federal tax benefit
(0.9
)%
 
1.1
 %
 
1.3
 %
Revaluation of deferred tax liabilities for US statutory change
—
 %
 
(41.8
)%
 
—
 %
Mandatory repatriation tax on foreign earnings
1.9
 %
 
13.0
 %
 
—
 %
Domestic production activities deduction
—
 %
 
(0.8
)%
 
(2.4
)%
Research and development credit
(10.2
)%
 
(11.1
)%
 
(2.6
)%
Prior year deferred tax adjustments
4.7
 %
 
1.9
 %
 
(4.0
)%
Foreign Rate Difference
6
 %
 
0.8
 %
 
—
 %
Change in valuation allowance
11.2
 %
 
(1.9
)%
 
3.8
 %
US Tax Reform - International Provisions
(4.7
)%
 
—
 %
 
—
 %
Other
(2.5
)%
 
4.2
 %
 
(0.6
)%
Effective tax rate
26.5
 %
 
(10.1
)%
 
30.5
 %

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (U.S. Tax Reform) was enacted in the U.S. which significantly revised the U.S. corporate income tax structure. Among the revisions impacting our effective tax rate are a lower U.S. corporate statutory rate going from 35% to 21% effective January 1, 2018 and changes to the way foreign earnings are taxed. As a September fiscal year filer, the lower corporate income tax rate is phased in from a U.S. statutory federal rate of 24.5% in fiscal year ending September 28, 2018 to a rate of 21% for the fiscal year ending September 27, 2019.
During fiscal year 2019, the Company’s effective tax rate varied from the U.S. federal statutory rate of 21% primarily because of the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform, and U.S. research and development tax credits. These favorable U.S. tax items are offset by losses in certain foreign jurisdictions for which no benefit is recognized and earnings in other foreign jurisdictions that are taxed at higher rates.

F-34

During fiscal year 2018, the Company’s effective tax rate varied from the U.S. federal statutory rate primarily because the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform. During fiscal years 2018 and 2017, the effective tax rate also differs from the U.S. federal statutory rate due to increases resulting from U.S. state income tax expense, losses in certain foreign jurisdictions for which no benefit is recognized, earnings in other foreign jurisdictions that are taxed at higher rates, and limitations on the deductibility of officers' compensation. These are offset by decreases due to U.S. research and development credits, tax windfalls for share-based compensation, and the release of a valuation allowance against loss carryforwards in certain foreign jurisdictions.
The SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) that allows for reasonable estimated amounts to be recorded and a measurement period of up to one year from the date of enactment to revise these provisional amounts as new information is obtained and additional guidance is issued. During the three months ended December 28, 2018, the Company completed its analysis of U.S. Tax Reform, and the accounting for the income tax effects has been finalized for the measurement period under SAB 118, with no significant adjustments from the provisional amounts. During fiscal year 2019, additional U.S. Tax Reform provisions, including GILTI (global intangible low-taxed income), BEAT (base-erosion anti-abuse tax), FDII (foreign-derived intangible income), limitations on interest expense deductions (if certain conditions apply), and other components became effective for the Company and, if applicable, have been included in the calculation of the fiscal year 2019 tax provision. The determination of the tax effects of U.S. Tax Reform may change following future legislation or further interpretation of U.S. Tax Reform from U.S. Federal and state tax authorities.
The guidance for accounting for U.S. Tax Reform requires taxpayers to make an election regarding the accounting for GILTI. This policy election is to either: (1) treat GILTI as a period cost if and when incurred, or (2) recognize deferred taxes for basis differences that are expected to reverse as GILTI in future years. During the first quarter of fiscal year 2019, the Company has made the accounting policy election to account for GILTI under the period cost method.
Significant components of deferred tax assets and liabilities are as follows:
(In millions)
September 27, 2019
 
September 28, 2018
Deferred Tax Assets:
 
 
 
Inventory adjustments
$
5.6

 
$
4.2

Share-based compensation
3.1

 
0.8

Product warranty
1.6

 
1.4

Deferred compensation
1.1

 
0.9

Net operating loss carryforwards
24.3

 
3.3

Accrued vacation
1.0

 
1.3

Credit carryforwards
1.9

 
1.8

Other
7.5

 
4.7

 
46.1

 
18.4

Valuation allowance
(18.8
)
 
(4.0
)
Total deferred tax assets
27.3

 
14.4

Deferred Tax Liabilities:
 
 
 
Acquired intangibles
(19.3
)
 
(15.2
)
Property, plant and equipment
(10.6
)
 
(14.3
)
Investments in privately held companies
(3.3
)
 
(4.1
)
Other
(2.3
)
 
(4.0
)
Total deferred tax liabilities
(35.5
)
 
(37.6
)
Net deferred tax liabilities
$
(8.2
)
 
$
(23.2
)
Reported As:
 
 
 
Deferred tax assets
$
27.3

 
$
14.4

Deferred tax liabilities
(35.5
)
 
(37.6
)
Net deferred tax liabilities
$
(8.2
)
 
$
(23.2
)

As a result of the changes to the U.S. taxation of foreign earnings included in U.S. Tax Reform, the Company reevaluated its previous indefinite reinvestment assertion with respect to these earnings during fiscal year 2018, which resulted in the Company revoking its assertion for current and future earnings for all countries, while maintaining the assertion that historic earnings are

F-35

indefinitely reinvested outside the U.S. The Company has modified this prior assertion for the year ended September 27, 2019 with respect to the acquisition of Direct Conversion. The modification was to assert that all earnings for Direct Conversion, located primarily in Sweden and Finland, are indefinitely reinvested in those countries. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable U.S. tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for U.S. State income taxes and foreign withholding taxes that would apply if the foreign earnings were actually repatriated in the form of a dividend.
As of September 27, 2019, the Company has net operating loss carryforwards of approximately $24.3 million with $4.4 million expiring between 2020 and 2030 and $19.9 million carried forward indefinitely.
The valuation allowance relates primarily to net operating losses in certain foreign jurisdictions where, based on the weight of available evidence, it is more likely than not that the tax benefit of the net operating losses will not be realized. The valuation allowance increased by $14.8 million during fiscal year 2019 and decreased by $0.3 million during fiscal year 2018. The increase during the current year was primarily related to the acquisition of Direct Conversion that included deferred tax assets subject to a valuation allowance as of acquisition. Changes in the Company's valuation allowance for deferred tax assets were as follows:
 
Fiscal Years
(In millions)
2019
 
2018
 
2017
Valuation allowance balance–beginning of fiscal year
$
4.0

 
$
4.3

 
$
2.5

Increases resulting from business combinations
12.0

 
—

 
—

Other increases
2.8

 
2.2

 
2.5

Other decreases
—

 
(2.5
)
 
(0.7
)
Valuation allowance balance—end of fiscal year
$
18.8

 
$
4.0

 
$
4.3


During fiscal year 2019, the Company paid U.S and foreign taxes of approximately $8.2 million. In fiscal year 2018, the Company paid U.S. and foreign taxes of approximately $13.8 million.
The Company accounts for uncertainty in income taxes following a two-step approach for recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether the weight of available evidence indicates that it is more likely than not that, based on the technical merits, the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.
Changes in the Company’s unrecognized tax benefits were as follows:
 
Fiscal Years
(In millions)
2019
 
2018
Unrecognized tax benefits balance–beginning of fiscal year
$
0.6

 
$
0.5

Subtractions based on tax positions related to a prior year
(0.2
)
 
—

Additions based on tax positions related to the current year
0.2

 
0.1

Unrecognized tax benefits balance—end of fiscal year
$
0.6

 
$
0.6


As of September 27, 2019 and September 28, 2018, the total amount of gross unrecognized tax benefits was $0.6 million and $0.6 million, respectively, all of which would affect the effective tax rate if recognized.
The Company includes interest and penalties related to income taxes within taxes on earnings on the Combined Statements of Earnings. For the year ended September 27, 2019, $0.1 million interest and penalties have been included for this period. For the year ended September 28, 2018 any interest or penalties related to unrecognized tax benefits are minimal and have been included in the balance for that period.
The Company files U.S. Federal and state income tax returns and non-U.S. income tax returns in various jurisdictions. All of these returns are subject to examination by their respective taxing jurisdictions from the date of filing through each applicable statute of limitation period. The Company’s significant operations up to the date of separation have historically been included in Varian’s U.S. federal and state income tax returns and non-U.S. jurisdiction tax returns. Material liabilities arising related to the pre-spin operations

F-36

would be the responsibility of Varian. Other periods for entities acquired are still open and subject to examination. Generally, periods prior to 2009 are no longer subject to examination.
15. SEGMENT INFORMATION
The Company has two reportable operating segments Medical and Industrial. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, who is also its CODM, evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin. The operating and reportable segment structure provides alignment between business strategies and operating results.
Description of Segments
The Medical segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy and computer-aided detection. The Company provides a broad range of X-ray imaging components for Medical customers including X-ray tubes, digital flat panel detectors, generators, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys. The Company’s X-ray imaging components are primarily sold to imaging system OEM customers that incorporate them into their medical diagnostic, radiation therapy, dental, veterinary and industrial imaging systems. The Company also sells its X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.
The Industrial segment designs, manufactures, sells and services products for use in the security and industrial inspection applications, such as airport security, cargo screening at ports and borders and nondestructive examination in a variety of applications. The products include Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high voltage connectors and image processing software that we generally sell to OEM customers that incorporate these products into their inspection systems.
Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.
Information related to the Company’s segments is as follows:
 
Fiscal Year
(In millions)
2019
 
2018
 
2017
Revenues
 
 
 
 
 
Medical
$
596.8

 
$
602.0

 
$
556.9

Industrial
183.8

 
171.4

 
141.2

Total revenues
780.6

 
773.4

 
698.1

Gross margin
 
 
 
 
 
Medical
188.9

 
190.5

 
193.6

Industrial
67.8

 
63.4

 
59.9

Total gross margin
256.7

 
253.9

 
253.5

Total operating expenses
211.0

 
209.4

 
169.8

Interest and other expenses, net
(24.2
)
 
(18.8
)
 
(8.9
)
Earnings before taxes
21.5

 
25.7

 
74.8

Taxes (benefit) on earnings
5.7

 
(2.6
)
 
22.8

Net earnings
15.8

 
28.3

 
52.0

Less: Net earnings attributable to noncontrolling interests
0.3

 
0.8

 
0.4

Net earnings attributable to Varex
$
15.5

 
$
27.5

 
$
51.6



F-37

The following table summarizes the Company’s total assets by its reportable segments:
(In millions)
September 27, 2019
 
September 28, 2018
Identifiable assets:
 
 
 
Medical
$
794.3

 
$
770.6

Industrial
244.6

 
217.3

Total reportable segments
$
1,038.9

 
$
987.9


Geographic Information
 
Revenues
 
Property, plant and equipment, net
 
Fiscal Years
 
Fiscal Years
(In millions)
2019
 
2018
 
2017
 
2019
 
2018
United States
$
275.3

 
$
268.8

 
$
231.9

 
$
122.6

 
$
127.9

Latin America
7.3

 
7.0

 
7.9

 
—

 
—

EMEA
269.0

 
254.5

 
219.5

 
11.4

 
8.7

APAC
229.0

 
243.1

 
238.8

 
8.3

 
8.3

Total company
$
780.6

 
$
773.4

 
$
698.1

 
$
142.3

 
$
144.9


The Company operates various manufacturing and marketing operations outside the United States. Latin America includes Brazil and Mexico. EMEA includes Europe, Russia, the Middle East, India and Africa. APAC includes Asia and Australia. Revenues by region are based on the known final destination of products sold.
16. EMPLOYEE BENEFIT PLANS
Varex’s 401(k) plan became effective on January 1, 2017. Varex’s 401(k) plan is intended to be qualified under Section 401(a) of the Code with the 401(k) plan’s related trust intended to be tax exempt under Section 501(a) of the Code and intended for all full-time employees in the United States. This plan allows employees to contribute a portion of their pretax salary up to the maximum dollar limitation prescribed by the Internal Revenue Service. Prior to Varex's 401(k) plan becoming effective, Company employees participated in Varian's 401(k) plan. The Company made matching contributions to the plan totaling $6.7 million, $6.5 million and $4.3 million in fiscal years 2019, 2018 and 2017, respectively.
The Company also maintains defined benefit plans for employees located outside the US. The net pension liability is included in non-current liability on the Company's consolidated balance sheets and totaled $5.5 million and $3.3 million as of September 27, 2019 and September 28, 2018, respectively. The Company’s net periodic benefit costs for the Company’s defined benefit plans was not material for fiscal years 2019, 2018 and 2017.
17. OTHER COMPREHENSIVE INCOME
The following table presents the changes in the accumulated balances for each component of other comprehensive income (loss):
(In millions)
Unrealized Gain (Loss) on Derivative Financial Instruments
 
Unrealized Gain on Defined Benefit Obligations
 
Accumulated Other Comprehensive Income
Balance at September 28, 2018
$
5.8

 
$
—

 
$
5.8

Other comprehensive loss before reclassifications
(8.3
)
 
(1.9
)
 
(10.2
)
Income tax benefit
2.1

 
0.6

 
2.7

Balance at September 27, 2019
$
(0.4
)
 
$
(1.3
)
 
$
(1.7
)
 
 
 
 
 
 

No amounts were reclassified out of accumulated other comprehensive income during fiscal years 2019 and 2018.


F-38

18. REVENUE RECOGNITION
The Company adopted ASC 606 on September 29, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for fiscal year 2019 reflect the application of ASC 606 guidance while the reported results for fiscal year 2018 were prepared under the guidance of ASC 605, “Revenue Recognition.” The primary impacts of the adoption include: (1) recording a separate contract liability and contract asset related to the sale of X-ray tubes that were sold with an option for the customer to require the Company to repurchase specific parts of the X‑ray tube at a specific price; and (2) recording a liability related to the deferral of revenue for service type warranties that are provided to certain customers who purchase Linatron® X-ray accelerators.
The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component, if, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are included as a component of cost of revenues; and (5) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.
Transaction price and allocation to performance obligations
Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available.
The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.
The beginning net cumulative-effect adjustment to the balance sheet for the adoption of ASC 606 is as follows:
 
Balance at
 
Adjustment Due to
 
Balance at
(In millions)
September 28, 2018
 
ASC 606
 
September 29, 2018
Assets:
 
 
 
 
 
Prepaid expenses and other current assets
$
17.1

 
$
6.4

 
$
23.5

Other assets
16.5

 
18.0

 
34.5

Liabilities and Equity:
 
 
 
 
 
Deferred revenues
13.2

 
0.3

 
13.5

Accrued liabilities
47.5

 
7.1

 
54.6

Deferred tax liabilities
23.2

 
(0.8
)
 
22.4

Other long-term liabilities
8.5

 
21.3

 
29.8

Retained earnings
62.4

 
(3.5
)
 
58.9


F-39


The following tables compare the reported consolidated balance sheet and statement of operations for fiscal year ended September 27, 2019, to the amounts that would have been reported if ASC 605 had been in effect:
 
September 27, 2019
(In millions)
Balance without Adoption
 
As Reported
Assets:
 
 
 
Prepaid expenses and other current assets
$
13.1

 
$
19.3

Other assets
$
10.0

 
$
27.5

Liabilities and equity:
 
 
 
Deferred revenues
$
9.9

 
$
10.5

Accrued liabilities
$
68.8

 
$
75.7

Deferred tax liabilities
$
9.1

 
$
8.2

Other long-term liabilities
$
12.1

 
$
32.5

Retained earnings
$
77.7

 
$
74.4


 
Twelve Months Ended September 27, 2019
(In millions)
Balance without Adoption
 
As Reported
Revenues
781.2

 
780.6

Cost of revenues
524.7

 
523.9

Taxes on earnings
5.7

 
5.7

Net earnings attributable to Varex
15.3

 
15.5


Contracts and performance obligations
The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.
Revenue recognition
Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.
Product revenue is recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
Service revenue is recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.
Disaggregation of Revenue
Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15. Segment Information, included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and disaggregated by geographic region.    

F-40

Contract Balances
Contract assets are included within the prepaid expenses and other current assets, and other assets balances. Contract liabilities, which also includes refund obligations are included within the accrued liabilities, deferred revenues, and other long-term liabilities balances. The following table summarizes the changes in the contract assets and refund liabilities for the twelve months ended September 27, 2019:
(In millions)
Contact Assets
Balance at September 29, 2018
$
24.4

Costs recovered from product returns during the period
(6.4
)
Contract asset from shipments of products, subject to return during the period
5.7

Balance at September 27, 2019
$
23.7

(In millions)
Refund Liabilities
Balance at September 29, 2018
$
27.1

Recognition of revenue included in beginning of year refund liability
(7.0
)
Additions to refund liabilities
6.3

Balance at September 27, 2019
$
26.4


Remaining Performance Obligations
Remaining performance obligations represent the transaction price of firm orders for which revenue has not yet been recognized. As of September 27, 2019, total remaining performance obligations amounted to $265.2 million. The Company expects to recognize a majority of the remaining performance obligations over the next 12 months.
Costs to Obtain or Fulfill a Customer Contract
The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.
19. SUBSEQUENT EVENTS
On October 1, 2019, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of October 8, 2019, the Company was permanently reducing the revolving credit commitment under the Credit Agreement by $25.0 million to $125.0 million. The reduction in the revolving credit commitment will also reduce the fees paid by the Company in connection with such commitment.


F-41
 EX-4.1 2 exhibit41-10xk2019.htm EXHIBIT 4.1 Exhibit


Exhibit 4.1




DESCRIPTION OF VAREX’S CAPITAL STOCK
The following is a summary of the material terms of Varex’s capital stock contained in Varex’s amended and restated certificate of incorporation and bylaws and the in the Delaware General Corporation Law (“DGCL”). The summaries and descriptions below do not purport to be complete statements of the relevant provisions of the certificate of incorporation, bylaws or the DGCL.
General
Varex’s authorized capital stock consists of 150 million shares of common stock, par value $0.01 per share, and 20 million shares of preferred stock, par value $0.01 per share, all of which shares of preferred stock are undesignated. Varex’s board of directors may establish the rights and preferences of the preferred stock from time to time.
Common Stock
Each holder of Varex common stock is entitled to one vote for each share on all matters to be voted upon by the common stockholders, and there are no cumulative voting rights. Subject to any preferential rights of any outstanding preferred stock, holders of Varex common stock are entitled to receive ratably the dividends, if any, declared from time to time by Varex’s board of directors out of funds legally available for that purpose. If there is a liquidation, dissolution or winding up of Varex, holders of its common stock would be entitled to ratable distribution of its assets remaining after the payment in full of liabilities and any preferential rights of any then-outstanding preferred stock.
Holders of Varex common stock have no preemptive or conversion rights or other subscription rights, and there are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of Varex common stock are fully paid and non-assessable. The rights, preferences and privileges of the holders of Varex common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that Varex may designate and issue in the future.
Preferred Stock
Varex’s board of directors is authorized, subject to limitations prescribed by the DGCL and by Varex’s amended and restated certificate of incorporation, to issue up to 20 million shares of preferred stock in one or more series without further action by the holders of its common stock. Varex’s board of directors have the discretion, subject to limitations prescribed by the DGCL and by Varex’s amended and restated certificate of incorporation, to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.
Anti-Takeover Effects of Various Provisions of Delaware Law and Varex’s Certificate of Incorporation and Bylaws
Provisions of the DGCL and Varex’s amended and restated certificate of incorporation and bylaws could make it more difficult to acquire Varex by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized below, are expected to discourage certain types of coercive takeover practices and takeover bids that Varex’s board of directors may consider inadequate and to encourage persons seeking to acquire control of Varex to first negotiate with Varex’s board of directors. Varex believes that the benefits of increased protection of its ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure it outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of their terms.
Delaware Anti-Takeover Statute. Varex is subject to Section 203 of the DGCL, an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a “business

1


combination” with an “interested stockholder” for a period of three years following the time the person became an interested stockholder, unless (i) prior to such time, the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) the voting stock owned by directors who are also officers or held in employee benefit plans in which the employees do not have a confidential right to tender or vote stock held by the plan); or (iii) on or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock of such corporation not owned by the interested stockholder. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation’s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by Varex’s board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by Varex’s stockholders.
Classified Board. Varex’s amended and restated certificate of incorporation and bylaws provide that its board of directors was initially divided into three classes, two of which are comprised of two directors and one of which is comprised of three directors. In connection with the spin-off of Varex from Varian, directors of each class were initially elected for staggered three-year terms. In accordance with Varex’s certificate of incorporation, (i) commencing with the class of directors standing for election at the Company’s 2020 annual meeting, directors will stand for election for a two-year term; (ii) commencing with the class of directors standing for election at the Company’s 2021 annual meeting, directors will stand for election for a one-year term; and (iii) commencing with the Company’s 2022 annual meeting, and at each annual meeting thereafter, all directors will stand for election for a one-year term. Until the board is declassified, it would take at least two elections of directors for any individual or group to gain control of Varex’s board of directors. Accordingly, these provisions could discourage a third party from initiating a proxy contest, making a tender offer or otherwise attempting to gain control of Varex.
At any meeting of stockholders for the election of directors at which a quorum is present, the election will be determined by a majority of the votes cast by the stockholders entitled to vote in the election, with directors not receiving a majority of the votes cast required to tender their resignations for consideration by the board, except that in the case of a contested election, the election will be determined by a plurality of the votes cast by the stockholders entitled to vote in the election.
Removal of Directors. For so long as the Varex board of directors is classified, Varex’s amended and restated certificate of incorporation provides that its stockholders may remove its directors only for cause, by an affirmative vote of holders of at least a majority of Varex’s voting stock then-outstanding. Following the 2022 annual meeting, Varex’s stockholders may remove its directors with or without cause by an affirmative vote of at least a majority of Varex’s voting stock then-outstanding.
Amendments to Certificate of Incorporation. Varex’s amended and restated certificate of incorporation provide that the affirmative vote of the holders of at least 66 2/3% of its voting stock then-outstanding is required to amend certain provisions relating to the term and removal of its directors, the filling of its board vacancies, the calling of special meetings of stockholders, stockholder action by written consent, the elimination of liability of directors to the extent permitted by Delaware law and indemnification of directors and officers. The provisions of the amended and restated certificate of incorporation relating to the 66 2/3% voting threshold will be of no force and effect effective as of the completion of the 2021 annual meeting of stockholders and the amended and restated certificate of incorporation may thereafter be amended by the affirmative vote of the holders of at least a majority of the outstanding voting stock then-outstanding.
Amendments to Bylaws. Varex’s amended and restated bylaws provide that they may be amended by Varex’s board of directors or by the affirmative vote of holders of a majority of Varex’s voting stock then-outstanding.
Size of Board and Vacancies. Varex’s amended and restated bylaws provide that the number of directors on its board of directors will be fixed exclusively by its board of directors, except that the minimum number of

2


directors will be three. Any vacancies created in its board of directors resulting from any increase in the authorized number of directors or the death, resignation, retirement, disqualification, removal from office or other cause will be filled by a majority of the board of directors then in office, even if less than a quorum is present, or by a sole remaining director. Any director appointed to fill a vacancy on Varex’s board of directors will be appointed for a term expiring at the next election of the class for which such director has been appointed, and until his or her successor has been elected and qualified.
Special Stockholder Meetings. Varex’s amended and restated certificate of incorporation provides that only the board of directors, pursuant to a resolution adopted by the majority of the whole board, or the chairman of the board of directors may call special meetings of Varex stockholders. The majority of the board of directors must concur with the calling of the meeting by the chairman. Stockholders may not call special stockholder meetings.
Stockholder Action by Written Consent. Varex’s amended and restated certificate of incorporation expressly eliminates the right of its stockholders to act by written consent effective as of the distribution. Stockholder action must take place at the annual or a special meeting of Varex stockholders.
Requirements for Advance Notification of Stockholder Nominations and Proposals. Varex’s certificate of incorporation mandates that stockholder nominations for the election of directors will be given in accordance with the bylaws. The amended and restated bylaws will establish advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors as well as minimum qualification requirements for stockholders making the proposals or nominations. Additionally, the bylaws require that candidates for election as director disclose their qualifications and make certain representations.
No Cumulative Voting. The DGCL provides that stockholders are denied the right to cumulate votes in the election of directors unless the company’s certificate of incorporation provides otherwise. Varex’s amended and restated certificate of incorporation do not provide for cumulative voting.

Undesignated Preferred Stock. The authority of Varex’s board of directors to issue preferred stock could potentially be used to discourage attempts by third parties to obtain control of Varex’s company through a merger, tender offer, proxy contest or otherwise by making such attempts more difficult or more costly. Varex’s board of directors may be able to issue preferred stock with voting rights or conversion rights that, if exercised, could adversely affect the voting power of the holders of common stock.
Limitations on Liability, Indemnification of Officers and Directors and Insurance
The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties as directors, and Varex’s amended and restated certificate of incorporation includes such an exculpation provision. Varex’s amended and restated certificate of incorporation and bylaws include provisions that indemnify, to the fullest extent allowable under the DGCL, the personal liability of directors or officers for monetary damages for actions taken as a director or officer of Varex, or for serving at Varex’s request as a director or officer or another position at another corporation or enterprise, as the case may be. Varex’s amended and restated certificate of incorporation and bylaws also provide that Varex must indemnify and advance reasonable expenses to its directors and officers, subject to its receipt of an undertaking from the indemnified party as may be required under the DGCL. Varex’s amended and restated certificate of incorporation will expressly authorize Varex to carry directors’ and officers’ insurance to protect Varex, its directors, officers and certain employees for some liabilities.
The limitation of liability and indemnification provisions in Varex’s amended and restated certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against Varex’s directors and officers, even though such an action, if successful, might otherwise benefit Varex and its stockholders. However, these provisions do not limit or eliminate Varex’s rights, or those of any stockholder, to seek non-monetary relief such as injunction or rescission in the event of a breach of a director’s duty of care. The provisions do not alter the liability of directors under the federal securities laws.
Exclusive Forum
Varex’s amended and restated certificate of incorporation provide that unless the board of directors otherwise determines, the state courts located within the State of Delaware or, if no state court located in the State

3


of Delaware has jurisdiction, the federal court for the District of Delaware, will be the sole and exclusive forum for any derivative action or proceeding brought on behalf of Varex, any action asserting a claim of breach of a fiduciary duty owed by any director or officer of Varex to Varex or Varex’s stockholders, any action asserting a claim against Varex or any director or officer of Varex arising pursuant to any provision of the DGCL or Varex’s amended and restated certificate of incorporation or bylaws, or any action asserting a claim against Varex or any director or officer of Varex governed by the internal affairs doctrine.
Authorized but Unissued Shares
Varex’s authorized but unissued shares of common stock and preferred stock may be issued without stockholder approval. Varex may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of Varex by means of a proxy contest, tender offer, merger or otherwise.



4
 EX-10.18 3 exhibit1018-10xk2019.htm EXHIBIT 10.18 Exhibit


Exhibit 10.18



VAREX IMAGING CORPORATION
Grant Agreement - Deferred Stock Units
(For grants made after May 25, 2018)
GRANT AGREEMENT made effective as of ____________, 20__ (the “Grant Date”) between Varex Imaging Corporation, a Delaware corporation (the “Company”), and ____________ (the “Director”).
1.Grant of Deferred Stock Deferred Stock Units. The Company hereby grants to the Director ____________ Deferred Stock Units. Each Deferred Stock Unit shall be deemed to be the equivalent of one Share.

2.Subject to the Plan. The Agreement is subject to, and governed by, the provisions of the Varex Imaging Corporation 2017 Omnibus Stock Plan (the “Plan”) and, unless the context requires otherwise, terms used herein shall have the same meaning as in the Plan. In the event of a conflict between the provisions of the Plan and this Agreement, the Plan shall control.

3.Account. The Company shall credit to a bookkeeping account (the “Account”) maintained by the Company for the Director’s benefit the Deferred Stock Units. On each date that cash dividends are paid on the Shares, the Company will credit the Account with a number of additional Deferred Stock Units equal to the result of dividing (i) the product of the total number of Deferred Stock Units credited to the Account on the record date for such dividend and the per Share amount of such dividend by (ii) the Fair Market Value of one Share on the date such dividend is paid by the Company to stockholders. The additional Deferred Stock Units shall be or become vested to the same extent as the Deferred Stock Units that resulted in the crediting of such additional Deferred Stock Units.

4.Vesting. All of the Deferred Stock Units shall initially be unvested. 100% of the Deferred Stock Units shall become vested on the earlier of (i) the one-year anniversary of the [Grant Date/most recently completed Annual Meeting of Stockholders] and (ii) the next Annual Meeting of Stockholders that occurs after the Grant Date (the “Vesting Date”), provided the Director has continued on the Board until the end of such Vesting Date. All of the Deferred Stock Units credited to the Account shall become fully vested upon the occurrence of a Change in Control (as defined in Appendix A) or the Director’s death, provided the Director is then serving on the Board.

5.Termination of Service. In the event of the Director’s Termination of Service, other than as a result of death, Disability or Retirement (as defined in Appendix A), the Deferred Stock Units credited to the Account that were not vested on the date of such Termination of Service shall be immediately forfeited. In the event of the Director’s death, Disability or Retirement while serving on the Board, all of the Deferred Stock Units credited to the Account shall become fully vested. For Directors who are United States taxpayers, “Termination of Service” shall mean “separation from service” as that term is defined in Section 409A of the Code and the applicable guidance issued by the Secretary of the Treasury thereunder.

6.Forfeiture upon Engaging in Detrimental Activities. If, at any time within one (1) year after the Director’s Termination of Service for any reason, the Director engages in any activity in competition with any activity of the Company, or inimical, contrary or harmful to the interests of the Company, including, but not limited to: (i) conduct related to the Director’s service on the Board for which either criminal or civil penalties against the Director may be sought, (ii) violation of the Company’s policies, or (iii) disclosure or misuse of any confidential information or material concerning the Company, then subject to applicable laws, (A) the Deferred Stock Units shall be forfeited effective as of the date on which

1


the Director enters into such activity, and (B) the Director shall within ten (10) days after written notice from the Company return to the Company the Shares paid by the Company to the Director with respect to the Deferred Stock Units and, if the Director has previously sold all or a portion of the Shares paid to the Director by the Company, the Director shall pay the proceeds of such sale to the Company.

7.Service Acknowledgments. Nothing in this Agreement or the Plan shall confer upon the Director any right to continue service on the Board of the Company or its Subsidiaries or Affiliates (as the case may be). In addition, the Director acknowledges and agrees to the following:

(a)The Plan is discretionary in nature and the Company may amend, suspend, or terminate it at any time;

(b)The grant of the Deferred Stock Units is voluntary and occasional and does not create any contractual or other right to receive future grants of Deferred Stock Units, or benefits in lieu of the Deferred Stock Units even if the Deferred Stock Units have been granted repeatedly in the past;

(c)All determinations with respect to such future Deferred Stock Units, if any, including but not limited to, the times when the Deferred Stock Units shall be granted or when the Deferred Stock Units shall vest, will be at the sole discretion of the Board;

(d)The Director’s participation in the Plan is voluntary;

(e)The value of the Deferred Stock Units is an extraordinary item of compensation, which is outside the scope of the Director’s service contract (if any), except as may otherwise be explicitly provided in the Director’s service contract (if any);

(f)The Deferred Stock Units are not part of normal or expected compensation for any purpose, including, but not limited to, calculating termination, severance, resignation, redundancy, end of service, or similar payments, or bonuses, long-service awards, pension or retirement benefits;

(g)The future value of the Shares is unknown and cannot be predicted with certainty;

(h)No claim or entitlement to compensation or damages arises from the termination of the Deferred Stock Units or diminution in value of the Deferred Stock Units or Shares and the Director irrevocably release the Company and its Subsidiaries or Affiliates from any such claim that may arise;

(i)Neither the Plan nor the Deferred Stock Units shall be construed to create an employment or service relationship where any such relationship did not otherwise already exist.

(j)The Company is not obligated, and will have no liability for failure to issue or deliver any Shares upon vesting of the Deferred Stock Units unless such issuance or delivery would comply with the applicable laws, with such compliance determined by the Company in consultation with its legal counsel. Furthermore, the Director understands that the applicable laws of the country in which the Director is residing or serving on the Board at the time of grant and/or vesting of the Deferred Stock Units (including any rules or regulations governing securities, foreign exchange, tax, labor or other matters) may restrict or prevent the settlement of the Deferred Stock Units and neither the Company nor any Subsidiary or Affiliate assumes liability in relation to the Deferred Stock Units in such case. The Deferred Stock Units may not be settled if the issuance of such Shares would constitute a violation of any applicable laws, including any applicable U.S. federal or state securities laws or any other law or regulation. As a condition to the settlement of the Deferred Stock Units, the Company may require the Director to make any representation and warranty to the Company as may be required by the applicable laws.


2


8.Payment of Deferred Stock Units. The Company shall make a payment to the Director of the vested Deferred Stock Units credited to the Account as provided in Section 9 upon the earliest of (i) the Director’s Termination of Service for any reason, (ii) the third anniversary of the [Grant Date/most recently completed Annual Meeting of Stockholders], (iii) a Change in Control that qualifies as a change in control event under Section 409A of the Code and the Treasury Regulations promulgated thereunder, or (iv) the Director’s death (in accordance with the provisions of Section 10); provided that if payment is made pursuant to Section 8(i) and the Director is deemed at the time of such Termination of Service to be a “specified” employee under Section 409A of the Code, then payment shall not be made or commence until the earliest of (i) the expiration of the six (6)-month period measured from the date of Director’s Termination of Service; or (ii) the date of Director’s death following such Termination of Service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to Director, including (without limitation) the additional 20% tax for which Director would otherwise be liable under Section 409A(a)(1)(B) of the Code in the absence of such deferral.

9.Form of Payment. Payments pursuant to Section 8 shall be made in Shares equal to the number of vested Deferred Stock Units credited to the Account. Payment shall be made as soon as practicable after the applicable payment date, but in no event later than 30 days after the date established pursuant to Section 8. The Director understands and agrees that the Company is neither responsible for any foreign exchange fluctuations between the Director’s local currency and the United States Dollar that may affect the value of the Deferred Stock Units nor liable for any decrease in the value of this award or the underlying Shares.

10.Beneficiary. In the event of the Director’s death prior to payment of the Deferred Stock Units credited to the Account, payment shall be made to the last beneficiary designated in writing that is received by the Company prior to the Director’s death or, if no designated beneficiary survives the Director, such payment shall be made to the Director’s estate.

11.Source of Payments. The Director’s right to receive payment under this Agreement shall be an unfunded entitlement and shall be an unsecured claim against the general assets of the Company. The Director has only the status of a general unsecured creditor hereunder, and this Agreement constitutes only a promise by the Company to pay the value of the Account on the payment date.

12.Tax Liability. As a condition to the grant, vesting and settlement of the Deferred Stock Units, regardless of any action the Company takes with respect to any applicable taxes or tax withholdings, social contributions, required deductions, or other payments, if any (collectively, the “Tax-Related Items”), the Director hereby acknowledges and agrees that the ultimate liability for all Tax-Related Items legally due by the Director is and remains the Director’s responsibility and that the Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Deferred Stock Units, including the award of the Deferred Stock Units, the vesting of the Deferred Stock Units, the issuance of Shares in settlement of the Deferred Stock Units, the subsequent sale of Shares acquired at vesting and the receipt of and settlement of any dividend equivalents; and (b) does not commit to structure the terms of the Award or any aspect of the Deferred Stock Units to reduce or eliminate the Director’s liability for Tax-Related Items. The Director also agrees that he or she will not make any claim against the Company, or any of its Directors, Employees or Subsidiaries or Affiliates related to tax liabilities arising from the Deferred Stock Units. Prior to the relevant taxable event, the Director hereby acknowledges and agrees that the Company (and any Subsidiary or Affiliate) shall satisfy all its obligations related to the Tax-Related Items, if any, by withholding all or a portion of any Shares that otherwise would be issued to the Director upon settlement of the vested Deferred Stock Units. Such withheld Shares shall be valued based on the Fair Market Value as of the date the withholding obligations are satisfied. The Director must pay to the Company any amount of Tax-Related Items that the Company may be required to withhold that cannot be satisfied by the means previously described. The Company may refuse to deliver the Shares to the Director if the Director fails to comply with the Director’s obligations in connection with the Tax-Related Items. The Director further acknowledges and agrees that the Director

3


is solely responsible for filing all relevant documentation that may be required in relation to the Deferred Stock Units or any Tax-Related Items other than filings or documentation that is the specific obligation of the Company or any Subsidiary or Affiliate pursuant to applicable law, such as but not limited to personal income tax returns or reporting statements in relation to the grant or vesting of the Deferred Stock Units, the holding of Shares or any bank or brokerage account, the subsequent sale of Shares, and the receipt of any dividends. The Director also understands that applicable laws may require varying Share or Restricted Stock Unit valuation methods for purposes of calculating Tax-Related Items, and the Company assumes no responsibility or liability in relation to any such valuation or for any calculation or reporting of income or Tax-Related Items that may be required of the Director under applicable laws. Further, if the Director has become subject to Tax-Related Items in more than one jurisdiction, the Director acknowledges that the Company or any Subsidiary or Affiliate may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

13.Data Protection. The Director hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of his or her personal data by and among, as applicable, the Company and any Subsidiary or Affiliate for the exclusive purpose of implementing, administering and managing the Director’s participation in the Plan. The Director understands that the Company and its Subsidiaries or Affiliates may hold certain personal information about the Director including, but not limited to, the Director’s name, home address and telephone number, date of birth, social security number (or any other social or national identification number), salary, nationality, job title, number of Shares held and the details of the Deferred Stock Units or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding for the purpose of implementing, administering and managing the Director’s participation in the Plan (the “Data”). The Director understands that the Data may be transferred to the Company or any Subsidiaries or Affiliates, or to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the Director’s country or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than the Director’s country. The Director further acknowledges that withdrawal of consent may affect his or her ability to vest in, exercise or realize benefits from the Deferred Stock Units, and his or her ability to participate in the Plan.

14.Nontransferability. Except as otherwise permitted under the Plan, this Agreement shall not be assignable or transferable by the Director or by the Company (other than to successors of the Company) and no amounts payable under this Agreement, or any rights therein, shall be subject in any manner to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, levy, lien, attachment, garnishment, debt or other charge or disposition of any kind.

15.Notices. All notices required or permitted under this Agreement shall be in writing and shall be delivered personally or by mailing the same by registered or certified mail postage prepaid, to the other party. Notice given by mail shall be deemed delivered at the time and on the date the same is postmarked.

Notices to the Company should be addressed to:

Varex Imaging Corporation
1678 S. Pioneer Rd.
Salt Lake City, UT 84104
Attention: General Counsel






4




Notices to the Director should be addressed to the Director at the Director’s address as it appears on the Company’s records. The Company or the Director may by writing to the other party, designate a different address for notices.

16.Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the heirs, legatees, distributees, executors and administrators of the Director and the successors and assigns of the Company.

17.Governing Law and Forum. This Agreement shall be governed by, and interpreted in accordance with, the laws of the State of Delaware, other than its conflict of laws principles. The parties agree that any action or proceeding arising from or relating to this Agreement must be brought exclusively in a court of competent jurisdiction, federal or state, located in Utah and in no other jurisdiction.

18.Compliance with Laws and Regulations. The Director understands that the grant, vesting and payments of the Deferred Stock Units under the Plan and the issuance, transfer, assignment, sale, or other dealings of the Shares shall be subject to compliance by the Company (and its Subsidiaries or Affiliates) and the Director with all applicable laws, rules, and regulations. Furthermore, the Director agrees that he or she will not acquire Shares pursuant to the Plan except in compliance with all applicable laws, rules and regulations. Any cross-border remittance made to transfer proceeds received upon the sale of Shares must be made through a locally authorized financial institution or registered foreign exchange agency and may require the Director to provide such entity with certain information regarding the transaction. Moreover, the Director understands and agrees that the future value of the underlying Shares is unknown and cannot be predicted with certainty and may decrease in value, even below the fair market value of the Shares on the date that the Deferred Stock Units were granted. The Director understands that the Company is not responsible for any foreign exchange fluctuation between local currency and the United States Dollar or the selection by the Company in its sole discretion of an applicable foreign currency exchange rate that may affect the value of the Deferred Stock Units (or the calculation of income or Tax-Related Items thereunder). Notwithstanding anything else this Agreement, the Company reserves the right to impose other requirements on the Director’s participation in the Plan or on the Deferred Stock Units and any Shares acquired under the Plan, or take any other action, to the extent the Company determines it is necessary or advisable in order to comply with applicable law or to facilitate the administration of the Plan and to require the Director to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. The Director understands that the laws of the country in which he/she is residing at the time of grant, vesting or payment of the Deferred Stock Units (including any rules or regulations governing securities, foreign exchange, tax, labor or other matters) may restrict the Deferred Stock Units or may subject the Director to additional procedural or regulatory requirements he/she is solely responsible for and will have to independently fulfill in relation to the Deferred Stock Units. Such restrictions, procedures, requirements, terms, and conditions may be set forth (but are not limited to those) in the Country-Specific Addendum (the “Addendum”) attached hereto, which constitutes part of this Agreement. Notwithstanding any provision herein, the Director’s participation in the Plan shall be subject to any applicable special terms and conditions or disclosures as set forth in the Addendum. The Director also understands and agrees that if he serves on the Board, resides, moves to, or otherwise is or becomes subject to applicable laws or Company policies of another jurisdiction at any time, certain country-specific notices, disclaimers and/or terms and conditions may apply to him as from the date of grant, unless otherwise determined by the Company in its sole discretion

19.Entire Agreement; Modification. This Agreement and the Plan constitute the entire agreement between the parties relative to the subject matter hereof, and supersede all proposals, written or oral, and all other communications between the parties relating to the subject matter of this Agreement. This Agreement may be modified, amended or rescinded only by a written agreement executed by both parties.

5


20.Compliance with Section 409A of the Code. This Agreement is intended to comply and shall be administered in a manner that is intended to comply with section 409A of the Code and shall be construed and interpreted in accordance with such intent. Payment under this Agreement shall be made in a manner that will comply with section 409A of the Code, including regulations or other guidance issued with respect thereto, as determined by the Committee. Any provision of this Agreement that would cause the payment or settlement thereof to fail to satisfy section 409A of the Code shall be amended to comply with section 409A of the Code on a timely basis, which may be made on a retroactive basis, in accordance with regulations and other guidance issued under section 409A of the Code.

21.Severability. The invalidity, illegality or unenforceability of any provision of this Agreement shall in no way affect the validity, legality or enforceability of any other provision.

22.Communication, Electronic Delivery and Execution. The Company may, in its sole discretion, decide to deliver any documents related to Deferred Stock Units awarded under the Plan or future Deferred Stock Units that may be awarded under the Plan by electronic means or request Director’s consent to participate in the Plan by electronic means. By accepting this grant, whether electronically or otherwise, the Director hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. Electronic execution of this Agreement and/or other documents shall have the same binding effect as a written or hard copy signature and accordingly, shall bind the Director and the Company to all of the terms and conditions set forth in the Plan, this Agreement and/or such other documents. To the extent the Director has been provided with a copy of this Agreement, the Plan, or any other documentation relating to the option in a language other than English, the English language documents will prevail in case of ambiguities or divergences as a result of translation.
IN WITNESS WHEREOF, this Agreement has been executed by the Company and the Director, effective as of the date at the top of this Agreement.


6



Country-Specific Addendum

This Addendum includes additional country-specific notices, disclaimers, and/or terms and conditions that apply to individuals who serve of the Board or reside in the countries listed below and that may be material to the Director’s participation in the Plan. Such notices, disclaimers, and/or terms and conditions may also apply, as from the date of grant, if the Director moves to or otherwise is or becomes subject to the applicable laws or company policies of the country listed. However, because foreign exchange regulations and other local laws are subject to frequent change, the Director is advised to seek advice from his own personal legal and tax advisor prior to accepting or settling the Deferred Stock Units or holding or selling Shares acquired under the Plan. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Director’s acceptance of the Deferred Stock Units or participation in the Plan. Unless otherwise noted below, capitalized terms shall have the same meaning assigned to them under the Plan, the Agreement and Appendix A. This Addendum forms part of the Agreement and should be read in conjunction with the Agreement and the Plan.

Securities Law Notice: Unless otherwise noted, neither the Company nor the Shares are registered with any local stock exchange or under the control of any local securities regulator outside the United States. The Agreement (of which this Addendum is a part), the Plan, and any other communications or materials that the Director may receive regarding participation in the Plan do not constitute advertising or an offering of securities outside the United States, and the issuance of securities described in any Plan-related documents is not intended for public offering or circulation in your jurisdiction.


 
 
 
 
European Union
Data Privacy.  The following supplements Section 13 of the Agreement: The Director understands that Data will be held only as long as is necessary to implement, administer and manage the Director’s participation in the Plan. The Director understands that he or she may, at any time, view his or her Data, request additional information about the storage and processing of Data, require any necessary amendments to Data without cost or refuse or withdraw the consents herein by contacting in writing the Director’s local human resources representative.
 
 




7





APPENDIX A
“Change in Control” means and shall be deemed to have occurred as of the date of the first to occur of the following events:
(a)    Any Person or Group (other than a Person or Group who effectively controls the Company within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vi)) acquires stock of the Company that, together with stock held by such Person or Group, constitutes more than 50% of the total fair market value or total voting power of the stock of the Company. However, if any Person or Group is considered to own more than 50% of the total fair market value or total voting power of the stock of the Company, the acquisition of additional stock by the same Person or Group is not considered to cause a Change in Control. An increase in the percentage of stock owned by any Person or Group as a result of a transaction in which the Company acquires its stock in exchange for property will be treated as an acquisition of stock for purposes of this subsection. This subsection applies only when there is a transfer of stock of the Company (or issuance of stock of the Company) and stock in the Company remains outstanding after the transaction;
(b)    Any Person or Group acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such Person or Group) ownership of stock of the Company possessing 35% or more of the total voting power of the stock of the Company. However, if any Person or Group is considered to effectively control the Company within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vi), the acquisition of additional stock by the same Person or Group is not considered to cause a Change in Control;
(c)    A majority of members of the Company’s Board is replaced during any 12-month period by Directors whose appointment or election is not endorsed by a majority of the members of the Company’s Board prior to the date of the appointment or election; or
(d)    Any Person or Group acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such Person or Group) assets from the Company that have a total gross fair market value equal to or more than 40% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. However, no Change in Control shall be deemed to occur under this subsection (d) as a result of a transfer to an entity that is controlled by the stockholders of the Company immediately after the transfer as follows:
(i)    A stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to its stock;
(ii)    An entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company;
(iii)    A Person or Group that owns, directly or indirectly, 50% or more of the total value or voting power of all the outstanding stock of the Company; or
(iv)    An entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a person described in clause (iii) above.
For purposes of clauses (ii), (iii), and (iv) above, a Person’s or a Group’s status is determined immediately after the transfer of assets.



A-1


For these purposes, the term “Person” shall mean an individual, Company, association, joint stock company, business trust or other similar organization, partnership, limited liability company, joint venture, trust, unincorporated organization or government or agency, instrumentality or political subdivision thereof or any other person, in each case, to the extent consistent with Treasury Regulation Section 1.409A-3(i)(5). The term “Group” shall have the meaning set forth in Treasury Regulation Section 1.409A-3(i)(5), or any successor thereto in effect at the time a determination of whether a Change of Control has occurred is being made.  
“Retirement” means the Director has attained a minimum of 65 years of age and has provided a minimum of three (3) years of service as a member of the Board of Directors of the Company.


A-2
 EX-21.1 4 exhibit211-10xk2019.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1
VAREX IMAGING CORPORATION
LIST OF SUBSIDIARIES
 
 
 
 
Name
  
Jurisdiction of Incorporation
Varex Imaging Equipment (China) Co., Ltd.
  
China
MeVis Medical Solutions AG (73.7%)
  
Germany
Varex Imagens Brasil, Ltda.
  
Brazil
Varex Imaging Holdings, Inc.
  
Delaware, USA
Varex Imaging France SARL
  
France
Varex Imaging Deutschland AG
  
Germany
Varex Imaging Italia Srl
  
Italy
Varex Imaging Investments B.V.
  
Netherlands
Varex Imaging International Holdings B.V.
  
Netherlands
Varex Imaging UK Limited
  
United Kingdom
Varex Imaging Group Nederland B.V.
  
Netherlands
Claymount Switzerland AG
  
Switzerland
Clayberg International B.V.
  
Netherlands
Varex Imaging Philippines, Inc.
  
Philippines
Varex Imaging Technologies (Beijing) Co. Ltd.
  
China
Varex Imaging Nederland B.V.
  
Netherlands
Verax Imaging Americas Corporation
  
Illinois, USA
Varex Imaging International AG
 
Switzerland
Varex Imaging West Holdings, Inc.
 
Delaware, USA
Varex Imaging West, LLC
 
Delaware, USA
Varex Imaging Mexico, S. de R.L. de C.V.
 
Mexico
3901 Carnation Street, LLC
 
Delaware, USA
Varex Imaging Japan, K.K.
 
Japan
Dexela Limited
 
United Kingdom
Varex Imaging Equipment (China) Co., Ltd.
 
China
Virtual Media Integration, LLC
 
Delaware, USA
Varex Imaging Arabia, LLC (75%)
 
Saudi Arabia
Varex Imaging India Private Limited
 
India
Direct Conversion AB (publ) (~98%)
 
Sweden
Oy Ajat Ltd.
 
Finland
Direct Conversion Ltd
 
United Kingdom 
Direct Conversion GmbH
 
Germany 
Xcounter Securities AB
 
Sweden



 EX-23.1 5 exhibit231-10xk2019.htm EXHIBIT 23.1 Exhibit


Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S‑8 (No. 333-215770) of Varex Imaging Corporation of our report dated December 20, 2019 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.



/s/ PricewaterhouseCoopers LLP

Salt Lake City, Utah
December 20, 2019



EX-31.1 6 exhibit311-10xk2019.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Sunny S. Sanyal, certify that:

1.    I have reviewed this Annual Report on Form 10-K of Varex Imaging Corporation (the “registrant”);

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;    

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fiscal fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated:
December 20, 2019
By:
/s/ Sunny S. Sanyal
 
 
 
Sunny S. Sanyal
 
 
 
President, Chief Executive Officer
 
 
 
 



 EX-31.2 7 exhibit312-10xk2019.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Clarence R. Verhoef, certify that:

1.    I have reviewed this Annual Report on Form 10-K of Varex Imaging Corporation (the “registrant”);

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;    

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:    

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fiscal fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated:
December 20, 2019
By:
/s/ Clarence R. Verhoef
 
 
 
Clarence R. Verhoef
 
 
 
Senior Vice President, Chief Financial Officer
 
 
 
 



 EX-32.1 8 exhibit321-10xk2019.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Annual Report of Varex Imaging Corporation (the “Company”), on Form 10-K for the fiscal year ended September 27, 2019 (the “Report”), I, Sunny S. Sanyal, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:

1.
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated:
December 20, 2019
By:
/s/ Sunny S. Sanyal
 
 
 
Sunny S. Sanyal
 
 
 
President, Chief Executive Officer
 
 
 
 








 EX-32.2 9 exhibit322-10xk2019.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Annual Report of Varex Imaging Corporation (the “Company”), on Form 10-K for the fiscal year ended September 27, 2019 (the “Report”), I, Clarence R. Verhoef, Senior Vice President and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:

1.
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated:
December 20, 2019
By:
/s/ Clarence R. Verhoef
 
 
 
Clarence R. Verhoef
 
 
 
Senior Vice President, Chief Financial Officer
 
 
 
 



 EX-101.SCH 10 var-20190927.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2108100 - Disclosure - BORROWINGS link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - BORROWINGS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - BORROWINGS - Schedule of Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - BORROWINGS - Schedule of Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - BORROWINGS - Schedule of Short-Term and Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - BORROWINGS (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - BUSINESS COMBINATIONS link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - BUSINESS COMBINATIONS - Direct Conversion Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - BUSINESS COMBINATIONS - Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - BUSINESS COMBINATIONS - Intangibles Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - BUSINESS COMBINATIONS - PerkinElmer's Medical Imaging Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - BUSINESS COMBINATIONS - Pro Forma (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - BUSINESS COMBINATIONS - Revenues by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - BUSINESS COMBINATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - BUSINESS COMBINATIONS - Virtual Media Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - COMMITMENTS AND CONTINGENCIES - (Details) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1003001 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF EQUITY link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - EMPLOYEE BENEFIT PLANS - (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - EMPLOYEE STOCK PLANS link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - EMPLOYEE STOCK PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - EMPLOYEE STOCK PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - EMPLOYEE STOCK PLANS - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - FAIR VALUE - (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Foreign Currency Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Goowill (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - NET EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - NET EARNINGS PER SHARE - (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - NET EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - OTHER COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - OTHER COMPREHENSIVE INCOME - (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - OTHER COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - OTHER FINANCIAL INFORMATION link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - OTHER FINANCIAL INFORMATION - (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - OTHER FINANCIAL INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Summary of Changes in Redeemable Noncontrolling Interests & Noncontrolling INterets (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately Held Companies (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - RESTRUCTURING link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - RESTRUCTURING - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - RESTRUCTURING - Restructuring Charges Incurred (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - RESTRUCTURING (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 2418405 - Disclosure - REVENUE RECOGNITION - Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - REVENUE RECOGNITION - Schedule of ASC 606 Adoption Impact On Income Statement (Details) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - REVENUE RECOGNITION - Schedule of Balance Sheet Adjustment for ASC 606 Adoption (Details) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - REVENUE RECOGNITION - Schedule of Changes in Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - SEGMENT INFORMATION - Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - SEGMENT INFORMATION - Geographic (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - SEGMENT INFORMATION - Summary of Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - SUBSEQUENT EVENTS - (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2401415 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounting Standards Recently Adopted (Details) link:presentationLink link:calculationLink link:definitionLink 2401414 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2401408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2401411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2401412 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets, Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2401409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2401413 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) link:presentationLink link:calculationLink link:definitionLink 2401410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reclassification (Details) link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - TAXES ON EARNINGS link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - TAXES ON EARNINGS - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - TAXES ON EARNINGS - Income Tax Contingency (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - TAXES ON EARNINGS - Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - TAXES ON EARNINGS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - TAXES ON EARNINGS - Summary of Taxes by Jurisdiction and Classification (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - TAXES ON EARNINGS (Tables) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - TAXES ON EARNINGS - Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 var-20190927_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 var-20190927_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 var-20190927_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Noncontrolling Interest [Abstract] Changes in Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Table Text Block] Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Forecast Forecast [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] CETTEEN GmbH CETTEEN GmbH [Member] CETTEEN GmbH [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Fixed Cost Commitments Fixed Cost Commitments [Member] Fixed Cost Commitments [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] dpiX Holding dpiX Holding [Member] dpiX Holding [Member] dpiX LLC dpiX LLC [Member] dpiX LLC [Member] VEC Imaging VEC Imaging GmbH & Co. KG [Member] VEC Imaging GmbH & Co. KG [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Equity Method Investee Equity Method Investee [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Number of consortium members Equity Method Investments, Number of Full Ownership Members Equity Method Investments, Number of Full Ownership Members Income (loss) from equity method investments Income (Loss) from Equity Method Investments Equity method investments Equity Method Investments Purchases from related party Related Party Transaction, Purchases from Related Party Accounts payable, related parties Accounts Payable, Related Parties Percentage of manufacturing capacity Percentage Of Manufacturing Capacity The percentage of manufacturing capacity that the entity has the guaranteed right to purchase up to. Percentage of fixed costs Percentage Of Fixed Costs The percentage of fixed costs as defined in the agreement and determined at the beginning of each calendar year that the entity is required to pay. Related party transaction, expected fixed cost Related Party Transaction, Expected Fixed Cost Related Party Transaction, Expected Fixed Cost Contributions to equity method investments Payments to Acquire Equity Method Investments Debt Disclosure [Abstract] Schedule Of Short-Term And Long-Term Debt [Table] Schedule Of Short-Term And Long-Term Debt [Table] Schedule Of Short-Term And Long-Term Debt [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Secured Debt Secured Debt [Member] Revolving Credit Facility Revolving Credit Facility [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Other Debt Other Debt [Member] Other Debt [Member] Revolving Credit Facility Revolving Credit Facility May 2017 [Member] Revolving Credit Facility May 2017 [Member] Schedule Of Short-Term And Long-Term Debt [Line Items] Schedule Of Short-Term And Long-Term Debt [Line Items] [Line Items] for Schedule Of Short-Term And Long-Term Debt [Table] Current maturities of long-term debt Long-term Debt, Current Maturities [Abstract] Current maturities of long-term debt Long-term Debt, Current Maturities Non-current maturities of long-term debt: Long-term Debt, Excluding Current Maturities [Abstract] Long-term debt excluding current maturities, gross Long-term Debt Excluding Current Maturities, Gross Long-term Debt Excluding Current Maturities, Gross Debt issuance costs Debt Issuance Costs, Net Long-term debt outstanding Long-term Debt, Excluding Current Maturities Long-term Debt Long-term Debt Weighted-average interest rate, short-term debt Short-term Debt, Weighted Average Interest Rate, over Time Weighted-average interest rate, long-term debt Long-term Debt, Weighted Average Interest Rate, over Time Income Tax Disclosure [Abstract] Deferred Tax Assets: Deferred Tax Assets, Net [Abstract] Inventory adjustments Deferred Tax Assets, Inventory Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Product warranty Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves Deferred compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Accrued vacation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences Credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Foreign Other Deferred Tax Assets, Other Deferred tax assets, gross Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Liabilities: Deferred Tax Liabilities, Net [Abstract] Acquired intangibles Deferred Tax Liabilities, Intangible Assets Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Investments in privately held companies Deferred Tax Liabilities, Investment in Noncontrolled Affiliates Other Deferred Tax Liabilities, Other Total deferred tax liabilities Deferred Tax Liabilities, Gross Net deferred tax liabilities Deferred Tax Liabilities, Net Deferred tax assets Deferred Tax Assets, Jurisdictional Amount, Gross Deferred Tax Assets, Jurisdictional Amount, Gross Deferred tax liabilities Deferred Tax Liability, Jurisdictional Amount, Gross Deferred Tax Liability, Jurisdictional Amount, Gross Net deferred tax liabilities Deferred Income Tax Liabilities, Net Federal statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Deferred tax liabilities of undistributed foreign earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Operating loss carryforwards, that expire Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Operating loss carryforwards, that do not expire Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Operating loss carryforwards, valuation allowance increase (decrease) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Cash paid for income tax Income Taxes Paid Unrecognized tax benefits Unrecognized Tax Benefits Income tax penalties and interest expense Income Tax Examination, Penalties and Interest Expense Unrecognized tax benefits, income tax penalties and interest accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Segment Reporting [Abstract] SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] OTHER FINANCIAL INFORMATION Additional Financial Information Disclosure [Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Medical Medical [Member] Medical [Member] Industrial Industrial [Member] Industrial [Member] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Assets Assets Share-based Payment Arrangement [Abstract] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted Stock Units and Performance Stock Units, nonvested, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restricted Stock Units and Performance Stock Units, grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units and Performance Stock Units, vested in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted Stock Units and Performance Stock Units, forfeited in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Restricted Stock Units and Performance Stock Units, nonvested, ending balance (in shares) Weighted Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restricted Stock Units and Performance Stock Units, nonvested, beginning of period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restricted Stock Units and Performance Stock Units, grants in period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted Stock Units and Performance Stock Units, vested in period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Restricted Stock Units and Performance Stock Units, forfeitures, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Restricted Stock Units and Performance Stock Units, nonvested, end of period, weighted average grant date fair value (in USD per share) Accounting Policies [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Land Improvements Land Improvements [Member] Building Building [Member] Land Land [Member] Buildings and leasehold improvements Buildings and Leasehold Improvements [Member] Buildings and Leasehold Improvements [Member] Machinery Machinery and Equipment [Member] Construction in progress Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, plant and equipment, useful lives Property, Plant and Equipment, Useful Life Property, plant and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant, and equipment, net Property, Plant and Equipment, Net Depreciation Depreciation Accelerated depreciation Restructuring and Related Cost, Accelerated Depreciation Goodwill and Intangible Assets Disclosure [Abstract] GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Direct Conversion AB Direct Conversion AB [Member] Direct Conversion AB [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Net cash paid Payments to Acquire Businesses, Gross Debt assumed Noncash or Part Noncash Acquisition, Debt Assumed Deferred payment, value assigned Business Acquisition, Equity Interest Issued Or Issuable, Contingent Consideration, Value Assigned Business Acquisition, Equity Interest Issued Or Issuable, Contingent Consideration, Value Assigned Deferred payment (in shares) Business Acquisition, Equity Interest Issued or Issuable, Contingent Consideration Business Acquisition, Equity Interest Issued or Issuable, Contingent Consideration Revenue from Contract with Customer [Abstract] REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Derivatives designated as cash flow hedges Cash Flow Hedging [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Swap Contracts Interest Rate Swap [Member] Cross Currency Swap Contracts Cross Currency Interest Rate Contract [Member] Derivative [Line Items] Derivative [Line Items] Number of Instruments Derivative, Number of Instruments Held Notional Value Derivative, Notional Amount Commitments and Contingencies Disclosure [Abstract] Future minimum payments due, next twelve months Operating Leases, Future Minimum Payments Due, Next Twelve Months Future minimum payments, due in two years Operating Leases, Future Minimum Payments, Due in Two Years Future minimum payments, due in three years Operating Leases, Future Minimum Payments, Due in Three Years Future minimum payments, due in four years Operating Leases, Future Minimum Payments, Due in Four Years Future minimum payments, due in five years Operating Leases, Future Minimum Payments, Due in Five Years Future minimum payments, due thereafter Operating Leases, Future Minimum Payments, Due Thereafter Operating leases, rent expense Operating Leases, Rent Expense Environment liabilities Accrued Environmental Loss Contingencies, Noncurrent Amount of Gain or (Loss) Recognized in OCI on Derivative Fiscal Year Ended Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income Fiscal Year Ended Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options, outstanding, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options, forfeitures and expirations in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Options, exercises in period, value (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options, outstanding, ending balance (in shares) Options, exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Price Range Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price Range [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price Range [Roll Forward] Options, outstanding, price, beginning (in USD per share) Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price Options, grants in period, price (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Price Options, forfeitures and expirations in period, price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price Options, exercises in period, price (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Price Options, outstanding, price, ending (in USD per share) Options, exercisable, price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options, outstanding, weighted average exercise price, beginning (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options, grants in period, weighted average exercise price (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options, forfeitures and expirations in period, weighted average exercise price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options, exercises in period, weighted average exercise price (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options, outstanding, weighted average exercise price, ending (in USD per share) Options, exercisable, weighted average exercise price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Options, outstanding, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options, exercisable, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options, outstanding, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options, exercisable, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share price (in usd per share) Share Price Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Position [Axis] Position [Axis] Position [Domain] Position [Domain] Buy contracts Long [Member] Sell contract Short [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Japanese yen Japan, Yen Swiss franc Switzerland, Francs Chinese renminbi China, Yuan Renminbi Euro Euro Member Countries, Euro Foreign Exchange Contract Foreign Exchange Contract [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Revenues, net Revenues Gross margin Gross Profit Total operating expenses Operating Expenses Interest and other expenses, net Nonoperating Income (Expense) Earnings before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Taxes (benefit) on earnings Income Tax Expense (Benefit) Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net earnings attributable to Varex Net Income (Loss) Attributable to Parent Number of variable interest entities Number of Variable Interest Entities Number of Variable Interest Entities Virtual Media Integration, Ltd. Virtual Media Integration, Ltd. [Member] Virtual Media Integration, Ltd. [Member] Total cash consideration Business Combination, Consideration Transferred Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed technology Developed Technology Rights [Member] Patents, licenses and other Intellectual Property [Member] Customer contracts and supplier relationship Customer Contracts and Supplier Relationships [Member] Customer Contracts and Supplier Relationships [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net In-process R&D with indefinite lives Indefinite-lived Intangible Assets (Excluding Goodwill) Total intangible assets, gross Intangible Assets, Gross (Excluding Goodwill) Total intangible assets, net Intangible Assets, Net (Excluding Goodwill) Amortization of intangible assets Amortization of Intangible Assets Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Number of operating segments Number of Operating Segments Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Deferred Tax Assets Valuation Allowance [Roll Forward] Deferred Tax Assets Valuation Allowance [Roll Forward] Deferred Tax Assets Valuation Allowance [Roll Forward] Valuation allowance balance–beginning of fiscal year Increases resulting from business combinations Valuation Allowance, Deferred Tax Asset, Increase From Business Combination, Amount Valuation Allowance, Deferred Tax Asset, Increase From Business Combination, Amount Other increases Valuation Allowance, Deferred Tax Asset, Increase, Amount Valuation Allowance, Deferred Tax Asset, Increase, Amount Other decreases Valuation Allowance, Deferred Tax Asset, Decrease, Amount Valuation Allowance, Deferred Tax Asset, Decrease, Amount Valuation allowance balance—end of fiscal year Raw materials and parts Inventory, Raw Materials and Supplies, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total inventories Inventory, Net Fair Value Disclosures [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets: Assets, Fair Value Disclosure [Abstract] Cash equivalents - money market funds Cash and Cash Equivalents, Fair Value Disclosure Derivative assets Derivative Asset Total assets measured at fair value Assets, Fair Value Disclosure Liabilities: Liabilities, Fair Value Disclosure [Abstract] Derivative liabilities Derivative Liability Deferred consideration Business Combination, Contingent Consideration, Liability Total liabilities measured at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Long-term debt, fair value Long-term Debt, Fair Value Equity [Abstract] Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] BUSINESS COMBINATIONS Business Combination Disclosure [Text Block] Statement of Financial Position [Abstract] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Preferred stock, par value per share (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Common stock, par value per share (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares, issued (in shares) Common Stock, Shares, Issued Common stock, shares, outstanding (in shares) Common Stock, Shares, Outstanding Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Unrecognized tax benefits balance–beginning of fiscal year Subtractions based on tax positions related to a prior year Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized tax benefits balance—end of fiscal year Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Unrealized Gain (Loss) on Derivative Financial Instruments Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Unrealized Gain on Defined Benefit Obligations Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Income AOCI Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Changes In Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Balance at beginning of period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Other comprehensive loss before reclassifications Other Comprehensive Income (Loss), before Reclassifications, before Tax Income tax benefit Other Comprehensive Income (Loss), Tax Ending balance Amount reclassified out of accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Restructuring and Related Activities [Abstract] Other assets impairment charges Other Asset Impairment Charges Inventory write-down Inventory Write-down Intangible assets impairment Impairment of Intangible Assets, Finite-lived Severance costs Severance Costs Facility closure costs Business Exit Costs Total restructuring charges Restructuring Costs and Asset Impairment Charges Concentration Risk [Table] Concentration Risk [Table] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Canon Medical Systems Corporation Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member] Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Revenue, Net Revenue Benchmark [Member] Accounts Receivable Accounts Receivable [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk, percentage Concentration Risk, Percentage Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net earnings Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation expense Share-based Payment Arrangement, Noncash Expense Impairment of intangible assets Deferred taxes Deferred Income Tax Expense (Benefit) Excluding Portion to APIC Deferred Income Tax Expense (Benefit) Excluding Portion to APIC Amortization of deferred loan costs Amortization of Debt Issuance Costs Loss (gain) from equity method investments, net of dividends received Other, net Other Noncash Income (Expense) Changes in assets and liabilities, net of effects of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued operating liabilities and other long-term operating liabilities Increase (Decrease) in Accrued Liabilities Deferred revenues Increase (Decrease) in Deferred Revenue Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Investments in privately-held companies Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net transfers from parent Proceeds from Contributions from Parent Distributions to Varian Medical Systems, Inc. Payments of Distributions to Affiliates Taxes related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Borrowings under credit agreements Proceeds from Long-term Lines of Credit Repayments of borrowing under credit agreements Repayments of Long-term Lines of Credit Proceeds from exercise of stock options Proceeds from Stock Options Exercised Proceeds from shares issued under employee stock purchase plan Proceeds from Stock Plans Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Payment of debt issuance costs Payments of Debt Issuance Costs Contributions from noncontrolling partner Proceeds from Noncontrolling Interests Dividends paid to redeemable noncontrolling interest Payments of Ordinary Dividends, Noncontrolling Interest Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Effects of exchange rate changes on cash and cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net (decrease) increase in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents and restricted cash at end of period Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Supplemental non-cash activities: Noncash Investing and Financing Items [Abstract] Purchases of property, plant and equipment financed through accounts payable Capital Expenditures Incurred but Not yet Paid Transfers of property, plant and equipment from Varian Medical Systems, Inc. Receipt of Property Receipt of Property Other non-cash transfers to Varian Medical Systems, Inc. Noncash Transfers to Parent Noncash Transfers to Parent Earnings Per Share [Abstract] NET EARNINGS PER SHARE Earnings Per Share [Text Block] TAXES ON EARNINGS Income Tax Disclosure [Text Block] 2020 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 2021 Long-term Debt, Maturities, Repayments of Principal in Year Two 2022 Long-term Debt, Maturities, Repayments of Principal in Year Three Total debt outstanding Long-term Debt, Gross Less: current maturities of long-term debt Non-current portion of long -term debt FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five State and local taxes, net of federal tax benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Revaluation of deferred tax liabilities for US statutory change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Mandatory repatriation tax on foreign earnings Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Domestic production activities deduction Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent Research and development credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Prior year deferred tax adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Foreign Rate Difference Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent US Tax Reform - International Provisions Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Percent Other Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent Effective tax rate Effective Income Tax Rate Reconciliation, Percent PerkinElmer, Inc. PerkinElmer, Inc. [Member] PerkinElmer, Inc. [Member] Revenues Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] London Facility Closing London Facility Closing [Member] London Facility Closing [Member] Santa Clara Facility Relocation Santa Clara Facility Relocation [Member] Santa Clara Facility Relocation [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring charges Restructuring Charges Restructuring and impairment charges Expected additional costs to be incurred Restructuring and Related Cost, Expected Cost Remaining Other unrelated restructuring costs Other Restructuring Costs Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Balance without Adoption Calculated under Revenue Guidance in Effect before Topic 606 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Cost of revenues Cost of Revenue Net earnings attributable to Varex Revenue Business Acquisition, Pro Forma Revenue Operating earnings Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax Net earnings Business Acquisition, Pro Forma Net Income (Loss) Net earnings per share, basic (in USD per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Net earnings per share, diluted (in USD per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted EMPLOYEE STOCK PLANS Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Varian Majority Shareholder [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of revenues Cost of Sales [Member] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] General and administrative General and Administrative Expense [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Allocated share-based compensation expense Share-based Payment Arrangement, Expense Retirement Benefits [Abstract] Employer discretionary contribution amount Defined Contribution Plan, Cost Defined benefit pension plan liability Liability, Defined Benefit Pension Plan, Noncurrent Product Warranty Liability [Table] Product Warranty Liability [Table] Product Warranty Liability [Line Items] Product Warranty Liability [Line Items] Warranty term (in months) Warranty Term Warranty Term Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Accrued product warranty, at beginning of period Standard Product Warranty Accrual Charged to cost of revenues Standard Product Warranty Accrual, Increase for Warranties Issued Actual product warranty expenditures Standard Product Warranty Accrual, Decrease for Payments Accrued product warranty, at end of period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Consolidation Consolidation, Policy [Policy Text Block] Reclassification Reclassification, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Fiscal Year Fiscal Period, Policy [Policy Text Block] Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value Fair Value Measurement, Policy [Policy Text Block] Derivative instruments and hedging activities Derivatives, Policy [Policy Text Block] Concentration of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Property, Plant and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Investments Investment, Policy [Policy Text Block] Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Impairment of Long-lived Assets, Intangible Assets and Goodwill Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Loss Contingencies Commitments and Contingencies, Policy [Policy Text Block] Product Warranty Standard Product Warranty, Policy [Policy Text Block] Allowance for Doubtful Accounts Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Share-Based Compensation Expense Share-based Payment Arrangement [Policy Text Block] Research and Development Research and Development Expense, Policy [Policy Text Block] Software Development Costs Research, Development, and Computer Software, Policy [Policy Text Block] Taxes on Earnings Income Tax, Policy [Policy Text Block] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Accounting Standards Recently Adopted, Recent Accounting Standards Updates Not Yet Effective New Accounting Pronouncements, Policy [Policy Text Block] Revenue from Contract with Customer Revenue from Contract with Customer [Policy Text Block] Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Schedules of Concentration of Risk, by Risk Factor Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Intangible Assets Acquired as Part of Business Combination [Table] [Table] Intangible Assets Acquired as Part of Business Combination [Table] [Table] Intangible Assets Acquired as Part of Business Combination [Table] [Table] Favorable leasehold interests Lease Agreements [Member] Backlog Order or Production Backlog [Member] Trade names Trade Names [Member] Customer relationships Customer Relationships [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-process research and development In Process Research and Development [Member] Intangible Assets Acquired as Part of Business Combination [Table] [Line Items] Intangible Assets Acquired as Part of Business Combination [Table] [Line Items] [Line Items] for Intangible Assets Acquired as Part of Business Combination [Table] [Table] Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Estimated useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Income Statement [Abstract] Gross margin Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total operating expenses Operating earnings Operating Income (Loss) Interest income Investment Income, Interest Interest expense Interest Expense Other (expense) income, net Other Nonoperating Income (Expense) Interest and other expenses, net Net earnings per common share attributable to Varex Basic (in USD per share) Earnings Per Share, Basic Diluted (in USD per share) Earnings Per Share, Diluted Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2017 ESPP 2017 ESPP [Member] 2017 ESPP [Member] 2017 Omnibus Stock Plan 2017 Omnibus Stock Plan [Member] 2017 Omnibus Stock Plan [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Employee Stock Employee Stock [Member] Employee Stock Option Share-based Payment Arrangement, Option [Member] Purchase price of common stock, percent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Stock plan offering period (in months) Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Compensation cost not yet recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Compensation cost period for recognition (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Award vesting period (in months) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Award expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Options exercised, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Options, grants in period, grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value Grant-date fair value of shares granted in the period Share-based Compensation Arrangement By Share-Based Payment Award, Other Than Options, Grants In Period, Grant Date Fair Value Share-based Compensation Arrangement By Share-Based Payment Award, Other Than Options, Grants In Period, Grant Date Fair Value Shares outstanding, market value Share-based Compensation by Share-based Payment Award, Equity Instruments Other than Options, Shares Outstanding, Market Value Share-based Compensation by Share- based Payment Award, Shares Outstanding, Market Value Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Net Parent Investment Net Parent Investment [Member] Net Parent Investment [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Retained Earnings Retained Earnings [Member] Total Varex Equity Parent [Member] Noncontrolling Interests Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares outstanding, beginning of period (in shares) Effect of adoption of ASC 606 Cumulative Effect of New Accounting Principle in Period of Adoption Net earnings Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Net transfers to parent Net Transfers From (To) Parent Net Transfers from Parent Other Stockholders' Equity, Other Distribution to Varian Medical Systems Distributions to Parent Distributions to Parent Conversion of net parent investment into common stock (in shares) Stock Issued During Period, Shares, Conversion of Units Conversion of net parent investment into common stock Stock Issued During Period, Value, Conversion of Units Exercise of stock options (in shares) Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Common stock issued upon vesting of restricted shares (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Shares withheld on vesting of restricted stock (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Shares withheld on vesting of restricted stock Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Unrealized gain on interest rate swap contracts, net of tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Unrealized gain (loss) on defined benefit obligations Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Tax impacts to APIC related to share-based award activity Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Common stock issued under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Capital contribution by noncontrolling interest Noncontrolling Interest, Increase From Capital Contribution Noncontrolling Interest, Increase From Capital Contribution Noncontrolling interest acquired/consolidated Noncontrolling Interest, Increase from Sale of Parent Equity Interest Shares outstanding, end of period (in shares) RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Allocation of the purchase consideration: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounts Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Prepaids and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Other assets, non-current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Goodwill Goodwill Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets and Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets and Goodwill Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities Current maturities of long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Deferred revenues Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Revenue From Contract With Customer, Liability Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Revenue From Contract With Customer, Liability Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Other liabilities, non-current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Noncontrolling interest Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Net assets acquired, less noncontrolling interest Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Deferred consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Post-closing adjustments Goodwill, Purchase Accounting Adjustments Total cash consideration Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Other Noncurrent Liabilities Other Noncurrent Liabilities [Table Text Block] Schedule of Other Nonoperating Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] Balance at September 28, 2018 Business combination Goodwill, Acquired During Period Balance at September 27, 2019 Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Goodwill, impairment loss Goodwill, Impairment Loss Weighted average shares outstanding - basic (in shares) Dilutive effect of potential common shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted average shares outstanding - diluted (in shares) Net earnings per share attributable to Varex - basic (in USD per share) Net earnings per share attributable to Varex - diluted (in USD per share) Anti-dilutive employee shared based awards, excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Current provision: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State and local Current State and Local Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) Total current Current Income Tax Expense (Benefit) Deferred provision (benefit): Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State and local Deferred State and Local Income Tax Expense (Benefit) Foreign Deferred Foreign Income Tax Expense (Benefit) Total deferred Deferred Income Tax Expense (Benefit) Taxes on earnings United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS Noncontrolling Interest Disclosure [Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash Cash and cash equivalents and restricted cash as reported per statement of cash flows Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of $1.0 and $0.6 at September 27, 2019 and September 28, 2018, respectively Accounts Receivable, after Allowance for Credit Loss, Current Inventories Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Intangibles assets, net Investments in privately-held companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Other assets Other Assets, Noncurrent Total assets Liabilities, redeemable noncontrolling interests and stockholders' equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Deferred revenues Contract with Customer, Liability, Current Total current liabilities Liabilities, Current Long-term debt, net Deferred tax liabilities Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 11) Commitments and Contingencies Redeemable noncontrolling interests Redeemable Noncontrolling Interest, Equity, Carrying Amount Equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued Preferred Stock, Value, Issued Common stock, $.01 par value: 150,000,000 shares authorized, shares issued and outstanding: 38,371,305 and 38,026,597 at September 27, 2019 and September 28, 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Retained earnings Retained Earnings (Accumulated Deficit) Total Varex stockholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total stockholders' equity Total liabilities, redeemable noncontrolling interests and stockholders' equity Liabilities and Equity Noncontrolling Interest [Table] Noncontrolling Interest [Table] MeVis Medical Solutions AG (MeVis) MeVis Medical Solutions AG (MeVis) [Member] MeVis Medical Solutions AG (MeVis) [Member] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Joint Venture In Saudi Arabia Joint Venture In Saudi Arabia [Member] Joint Venture In Saudi Arabia [Member] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Noncontrolling interest, ownership percentage by parent Noncontrolling Interest, Ownership Percentage by Parent Noncontrolling interest, ownership percentage by noncontrolling owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Annual recurring compensation (in euros per share) Business Acquisition, Annual Recurring Compensation Business Acquisition, Annual Recurring Compensation Temporary equity, redemption price per share (in eur per share) Temporary Equity, Redemption Price Per Share Redeemable noncontrolling interest, equity, redemption value Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Temporary equity, shares outstanding (in shares) Temporary Equity, Shares Outstanding Accrued compensation and benefits Accrued Employee Benefits, Current Product warranty Standard Product Warranty Accrual, Current Income taxes payable Accrued Income Taxes, Current Payable to Varian Medical Systems Due to Related Parties, Current Right of return liability Contract with Customer, Refund Liability, Current Deferred consideration Business Combination, Contingent Consideration, Liability, Current Other Other Accrued Liabilities, Current Total accrued liabilities Long-term income tax payable Accrued Income Taxes, Noncurrent Defined benefit obligation liability Liability, Defined Benefit Plan, Noncurrent Long-term right of return liability Contract with Customer, Refund Liability, Noncurrent Long-term other Other Sundry Liabilities, Noncurrent Total other long-term liabilities Change in fair value of deferred consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Realized income (loss) on foreign currencies Foreign Currency Transaction Gain (Loss), before Tax Total other income (expense), net Statement of Comprehensive Income [Abstract] Other comprehensive (loss) earnings, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized (loss) gain on interest rate swap contracts Unrealized (loss) gain on defined benefit obligations Other comprehensive (loss) earnings, net of tax Other Comprehensive Income (Loss), Net of Tax Comprehensive earnings Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Less: Comprehensive earnings attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive earnings attributable to Varex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Summary of Valuation Allowance [Table Text Block] Summary of Valuation Allowance [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Schedule of Interest Rate Derivative Instruments Schedule of Interest Rate Derivatives [Table Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Permanent reduction in the revolving credit commitment Line of Credit Facility, Increase (Decrease), Net Revolving credit commitment Line of Credit Facility, Maximum Borrowing Capacity Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASU 2014-09 Accounting Standards Update 2014-09 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] (Decrease) increase to retained earnings for adoption of new accounting guidance Schedule of ASC 606 Adoption Impacts Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Schedule of Changes in Contract With Customer Assets And Liabilities Contract with Customer, Asset and Liability [Table Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Debt Repayment Period [Axis] Debt Repayment Period [Axis] Debt Repayment Period [Axis] Debt Repayment Period [Domain] Debt Repayment Period [Domain] [Domain] for Debt Repayment Period [Axis] Debt Instrument, Repayment, Period One Debt Instrument, Repayment, Period One [Member] Debt Instrument, Repayment, Period One [Member] Debt Instrument, Repayment, Period Two Debt Instrument, Repayment, Period Two [Member] Debt Instrument, Repayment, Period Two [Member] Debt Instrument, Repayment, Period Three Debt Instrument, Repayment, Period Three [Member] Debt Instrument, Repayment, Period Three [Member] Debt Instrument, Repayment, Period Four Debt Instrument, Repayment, Period Four [Member] Debt Instrument, Repayment, Period Four [Member] Debt Instrument, Repayment, Period Five Debt Instrument, Repayment, Period Five [Member] Debt Instrument, Repayment, Period Five [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Federal Funds Effective Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Base Rate Base Rate [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Maximum borrowing capacity Debt instrument, term Debt Instrument, Term Repayment percentage Debt Instrument, Periodic Payment, Percentage Debt Instrument, Periodic Payment, Percentage Proceeds from lines of credit Proceeds from Lines of Credit Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Used capacity, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Debt issuance costs Cover page. Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Smaller Reporting Company Entity Small Business Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Public Float Entity Public Float Entity common stock, shares outstanding (in shares) Entity Common Stock, Shares Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Recorded component of accumulated other comprehensive income (loss) that will be reclassified in the statements of comprehensive earnings over the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Loss on derivative instruments not designated as cash flow hedges Derivative Instruments Not Designated as Hedging Instruments, Loss BORROWINGS Debt Disclosure [Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Intangible Assets Acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] EMPLOYEE BENEFIT PLANS Compensation and Employee Benefit Plans [Text Block] Balance at beginning of period Net earnings attributable to noncontrolling interests Temporary Equity, Net Income Other Temporary Equity, Other Changes Balance at end of period Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest Contributions from noncontrolling interests Contributions from noncontrolling interests Balance at end of period Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Restatement Adjustment Restatement Adjustment [Member] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Reclassification of selling, general and administrative Schedule of Pro Rata Distribution [Table] Schedule of Pro Rata Distribution [Table] Schedule of Pro Rata Distribution [Table] Varian Medical Systems, Inc. Varian Medical Systems, Inc. [Member] Varian Medical Systems, Inc. [Member] Schedule of Pro Rata Distribution [Line Items] Schedule of Pro Rata Distribution [Line Items] [Line Items] for Schedule of Pro Rata Distribution [Table] Outstanding common stock, percentage distributed Outstanding Common Stock, Percentage Distributed Outstanding Common Stock, Percentage Distributed Schedule of Restructuring Charges Restructuring and Related Costs [Table Text Block] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Latin America Latin America [Member] EMEA EMEA [Member] APAC Asia Pacific [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Schedule of Short-Term and Long-Term Debt Schedule of Debt [Table Text Block] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] SUBSEQUENT EVENTS Subsequent Events [Text Block] Adjustment Due to ASC 606 Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected dividend Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Weighted average fair value at grant date (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other current assets Other Current Assets [Member] Other non-current assets Other Noncurrent Assets [Member] Other current liabilities Other Current Liabilities [Member] Other non-current liabilities Other Noncurrent Liabilities [Member] Derivative Assets Derivative Asset, Fair Value, Gross Asset Derivative Liabilities Derivative Liability, Fair Value, Gross Liability Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] FAIR VALUE Fair Value Disclosures [Text Block] Change in Contract with Customer, Asset [Abstract] Balance at September 29, 2018 Contract With Customer, Asset Contract With Customer, Asset Costs recovered from product returns during the period Increase (Decrease) In Contract with Customer, Asset, Costs Recovered From Product Returns Increase (Decrease) In Contract with Customer, Asset, Costs Recovered From Product Returns Contract asset from shipments of products, subject to return during the period Increase (Decrease) In Contract with Customer, Asset, Shipment Of Product Subject To Return Increase (Decrease) In Contract with Customer, Asset, Shipment Of Product Subject To Return Balance at September 27, 2019 Change in Contract with Customer, Liability [Abstract] Balance at September 29, 2018 Contract with Customer, Liability Recognition of revenue included in beginning of year refund liability Contract with Customer, Liability, Revenue Recognized Additions to refund liabilities Contract With Customer, Liability, Additions Contract With Customer, Liability, Additions Balance at September 27, 2019 Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Foreign Tax Authority Foreign Tax Authority [Member] Business combination, number of employees Business Combination, Number of Employees Business Combination, Number of Employees Goodwill expected tax deductible amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Deferred tax liabilities noncurrent Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] EX-101.PRE 14 var-20190927_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 chart-60e2d95fbd6683f2865.jpg begin 644 chart-60e2d95fbd6683f2865.jpg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end GRAPHIC 16 varex10k2017draft0image1a02.jpg begin 644 varex10k2017draft0image1a02.jpg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�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end XML 17 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS
 12 Months Ended
Sep. 27, 2019
Noncontrolling Interest [Abstract]  
REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS
In April 2019, a subsidiary of Varex completed the acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion. As the Company has majority voting rights it has consolidated Direct Conversion's operations in its consolidated financial statements and recorded the noncontrolling interest. The noncontrolling interest related to Direct Conversion is included in noncontrolling interest in the equity section of the Company's consolidated balance sheet. Earnings representing the noncontrolling interest's portion of Direct Conversion's income from operations is included in the Company's consolidated statements of earnings.
In September 2018, the Company entered into a partnership in Saudi Arabia. The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in our consolidated financial statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s 25% interest in the joint venture is included in noncontrolling interest in the equity section of the Company’s consolidated balance sheet. Earnings representing the noncontrolling partner's share of income from operations is included in the Company's consolidated statements of earnings.
In April 2015, the Company completed the acquisition of 73.5% of the then outstanding shares of MeVis Medical Solutions AG (“MeVis”), a public company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a domination and profit and loss transfer agreement (the “DPLTA”) with MeVis. In October 2015, the DPLTA became effective upon its registration at the local court of Bremen, Germany. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all of its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of €0.95 per MeVis share starting from January 1, 2015 and (2) a put right for their MeVis shares at €19.77 per MeVis share. Upon effectiveness of the DPLTA, the noncontrolling interests in MeVis became redeemable as a result of the put right and were reclassified to temporary equity. As of September 27, 2019, the redemption value of redeemable noncontrolling interests in MeVis was $10.5 million.
During fiscal year 2018, an immaterial number of MeVis’ shares were purchased under the put right. As of September 27, 2019, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares.
Changes in redeemable noncontrolling interests and noncontrolling interests were as follows: 
 
Fiscal Years
 
2019
 
2018
(In millions)
Redeemable
Noncontrolling
Interests
 
Noncontrolling
Interests
 
Redeemable
Noncontrolling
Interests
 
Noncontrolling Interest
Balance at beginning of period
$
11.1

 
$
2.1

 
$
11.2

 
$
—

Net earnings attributable to noncontrolling interests
0.5

 
(0.2
)
 
0.5

 
0.3

Contributions from noncontrolling interests
—

 
1.4

 
—

 
1.8

Dividend distributions
(0.5
)
 
—

 
(0.6
)
 
—

Other
(0.6
)
 
—

 
—

 
—

Balance at end of period
$
10.5

 
$
3.3

 
$
11.1

 
$
2.1
XML 18 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RESTRUCTURING
 12 Months Ended
Sep. 27, 2019
Restructuring and Related Activities [Abstract]  
RESTRUCTURING RESTRUCTURING
Following the acquisition of the medical imaging business from PKI in May of 2017, management began a multiyear program to consolidate the acquired operations, reduce costs, improve productivity and realize synergies.
In March 2018, the Company made the decision to transfer the complementary metal oxide semiconductor (“CMOS”) research and development capability from the U.K. to the U.S. and to permanently close the operation of the acquired detector business in London. The company will continue to develop the CMOS technology in the U.S. due to its competitive advantages, product differentiation and future economic benefit. In connection with this initiative, we recorded $1.7 million in restructuring charges during fiscal year 2018.
In July 2018, the Company committed to a plan to relocate the production of amorphous silicon glass for digital detectors, from its Santa Clara facility, to the jointly owned dpiX fabrication facility in Colorado. In July 2019, the Company committed to close its Santa Clara facility and to relocate the remaining production to its other existing facilities. The Company expects operations at the Santa Clara facility to cease by the end of December 2020 and all activities related to the closure of the facility to be complete by the end of March 2021. In connection with the relocation of the glass production and site closure the Company recorded $16.1 million and $14.2 million of restructuring and impairment charges during fiscal year 2019 and 2018, respectively. Fiscal year 2019 intangible asset impairment charges consisted of in-process research and development related to certain projects that were discontinued as a result of the Santa Clara facility closure. Fiscal year 2018 intangible asset impairment charges were related to a favorable leasehold interest that was impaired as a result of the amorphous silicon glass relocation. The Company expects to incur an additional $8.1 million to $12.1 million of restructuring charges through March 2021.
The Company also incurred approximately $2.8 million and $0.8 million of other unrelated restructuring expenses during fiscal years 2019 and 2018, respectively.
Cash outflows associated with these restructuring charges are limited to employee termination expenses, facility closure and equipment sales and disposals. Below is a detail of restructuring charges incurred during the 2019 and 2018 fiscal years, which predominately relate to the Company's Medical segment:
(In millions)
Location of Restructuring Charges in Consolidated Statements of Earnings
 
September 27, 2019
 
September 28, 2018
Other assets impairment charges
Selling, general and administrative
 
$
—

 
$
1.3

Inventory write downs
Cost of revenues
 
3.1

 
3.1

Intangible assets impairment
Impairment of intangible assets
 
4.8

 
3.0

Accelerated depreciation
Cost of revenues
 
4.5

 
4.2

Severance costs
Selling, general and administrative
 
6.2

 
4.3

Facility closure costs
Selling, general and administrative
 
0.3

 
0.8

Total restructuring charges
 
 
$
18.9

 
$
16.7
XML 19 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BORROWINGS
 12 Months Ended
Sep. 27, 2019
Debt Disclosure [Abstract]  
BORROWINGS BORROWINGS
The following table summarizes the Company's short-term and long-term debt:
 
September 27, 2019
 
September 28, 2018
(In millions, except for percentages)
Amount
 
Weighted-Average Interest Rate
 
Amount
 
Weighted-Average Interest Rate
Current maturities of long-term debt
 
 
 
 
 
 
 
Term facility
$
29.4

 
5.6
%
 
$
25.0

 
4.2
%
Other debt
1.3

 
 
 
—

 
 
Total current maturities of long-term debt
$
30.7

 
 
 
$
25.0

 
 
 
 
 
 
 
 
 
 
Non-current maturities of long-term debt:
 
 
 
 
 
 
 
Revolving credit facility
$
59.0

 
5.6
%
 
$
28.0

 
4.2
%
Term facility
308.6

 
5.6
%
 
345.0

 
4.2
%
Other debt
2.5

 
 
 
—

 
 
Debt issuance costs
(5.7
)
 
 
 
(8.2
)
 
 
Non-current maturities of long-term debt
364.4

 
 
 
364.8

 
 
Total long-term debt, net
$
395.1

 
 
 
$
389.8

 
 

Existing Credit Facility
On May 1, 2017 and in connection with the Acquired Detector Business, the Company entered into a new secured revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal amount of up to $200.0 million with a five-year term, and a secured term facility (the “Term Facility” and together with the Revolving Credit Facility, the “Credit Agreement”) in an aggregate principal amount of $400.0 million. The Term Facility will be repaid over five years, with 5.0% payable in quarterly installments
during each of the first two years of the term thereof, 7.5% payable in quarterly installments during the third and fourth years of the term thereof, and 10% payable in quarterly installments in the fifth year of the term thereof, with the remaining amount due at maturity. Varex used the net proceeds from the Term Facility, and the net proceeds from approximately $97.0 million drawn on the Revolving Credit Facility, to pay the purchase price for the Acquired Detector Business, plus related credit facility fees, and to repay all of Varex’s obligations under the Previous Credit Agreement. Both the Term Facility and Revolving Credit Facility expire on May 1, 2022.
The Credit Agreement contains various customary restrictive covenants that limits, among other things, the incurrence of indebtedness by Varex and its subsidiaries, the grant or incurrence of liens by Varex and its subsidiaries, the entry into sale and leaseback transactions by Varex and its subsidiaries, and the entry into certain fundamental change transactions by Varex and its subsidiaries. It also contains customary events of default and certain financial covenants. The Company agreed to maintain financial covenants, which include maximum consolidated total leverage ratio, maximum senior secured leverage ratio, maximum capital expenditures and a minimum consolidated fixed charge coverage ratio. The Company was in compliance with all financial covenants under the Credit Agreement as of September 27, 2019.
The Credit Agreement is secured by the stock and assets of Varex’s material subsidiaries. The Credit Agreement has several borrowing and interest rate options including the following indices: (a) LIBOR rate, or (b) the base rate (equal to the greater of the prime rate, the federal funds rate plus 0.50% or the LIBOR rate for a one-month period plus 1.00%). Loans under the Credit Agreement bear interest at a rate per annum using the applicable indices plus a varying interest rate margin of between 1.75% and 2.75% (for LIBOR rate loans) and 0.75%-1.75% (for base rate loans). The Credit Agreement also provides for fees applicable to amounts available to be drawn under outstanding letters of credit of 0.125%, and a fee on unused commitments which ranges from 0.25% to 0.40%.
On October 3, 2018, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of October 10, 2018, the Company had permanently reducing the revolving credit commitment under the Credit Agreement by $50.0 million to $150.0 million. The reduction in the revolving credit commitment reduced the fees paid by the Company in connection with such commitment.
Subsequent to fiscal year 2019, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of October 8, 2019, the Company was permanently reducing the revolving credit commitment under the Credit Agreement by $25.0 million to $125.0 million.
Subsequent to fiscal year 2019, the Company did not comply with the covenant under the Credit Agreement to timely deliver the Company's fiscal year 2019 annual financial statements. However, upon the filing of this Annual Report with the SEC, the Company will be able to deliver the fiscal year 2019 annual financial statements within the 30-day cure period set forth in the Credit Agreement and consequently no event of default will occur.
At September 27, 2019, the Company had $364.4 million in non-current maturities of long-term debt outstanding, net of deferred debt issuance costs of $5.7 million, and $30.7 million of current maturities of long-term debt outstanding.
Future principal payments of the long-term debt outstanding as of September 27, 2019 are as follows:
(In millions)
 
Fiscal years:
 
2020
$
30.7

2021
34.3

2022
335.8

Total debt outstanding
400.8

Less: current maturities of long-term debt
(30.7
)
Non-current portion of long -term debt
$
370.1
XML 20 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND INTANGIBLE ASSETS (Tables)
 12 Months Ended
Sep. 27, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table reflects goodwill by reportable operating segment:
(In millions)
Medical
 
Industrial
 
Total
Balance at September 28, 2018
$
147.0

 
$
96.6

 
$
243.6

Business combination
26.0

 
21.2

 
47.2

Balance at September 27, 2019
$
173.0

 
$
117.8

 
$
290.8
Schedule of Finite-Lived Intangible Assets
The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the consolidated balance sheets:
 
September 27, 2019
 
September 28, 2018
(In millions)
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Acquired existing technology
$
74.1

 
$
(28.4
)
 
$
45.7

 
$
57.9

 
$
(21.8
)
 
$
36.1

Patents, licenses and other
12.7

 
(8.4
)
 
4.3

 
9.9

 
(7.4
)
 
2.5

Customer contracts and supplier relationship
50.7

 
(17.2
)
 
33.5

 
42.6

 
(11.4
)
 
31.2

Total intangible assets with finite lives
137.5

 
(54.0
)
 
83.5

 
110.4

 
(40.6
)
 
69.8

In-process R&D with indefinite lives
2.8

 
0.0

 
2.8

 
4.0

 
0.0

 
4.0

Total intangible assets
$
140.3

 
$
(54.0
)
 
$
86.3

 
$
114.4

 
$
(40.6
)
 
$
73.8

 
 
 
 
 
 
 
 
 
 
 
 
Schedule of Indefinite-Lived Intangible Assets
The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the consolidated balance sheets:
 
September 27, 2019
 
September 28, 2018
(In millions)
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Acquired existing technology
$
74.1

 
$
(28.4
)
 
$
45.7

 
$
57.9

 
$
(21.8
)
 
$
36.1

Patents, licenses and other
12.7

 
(8.4
)
 
4.3

 
9.9

 
(7.4
)
 
2.5

Customer contracts and supplier relationship
50.7

 
(17.2
)
 
33.5

 
42.6

 
(11.4
)
 
31.2

Total intangible assets with finite lives
137.5

 
(54.0
)
 
83.5

 
110.4

 
(40.6
)
 
69.8

In-process R&D with indefinite lives
2.8

 
0.0

 
2.8

 
4.0

 
0.0

 
4.0

Total intangible assets
$
140.3

 
$
(54.0
)
 
$
86.3

 
$
114.4

 
$
(40.6
)
 
$
73.8

 
 
 
 
 
 
 
 
 
 
 
 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
As of September 27, 2019, the estimated future amortization expense of intangible assets with finite lives is as follows:
(In millions)
 
Fiscal years:
 
2020
$
17.2

2021
16.3

2022
14.7

2023
13.7

2024
9.1

Thereafter
12.5

Total
$
83.5
XML 21 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NET EARNINGS PER SHARE (Tables)
 12 Months Ended
Sep. 27, 2019
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per common share is as follows:
 
Fiscal Year
(In millions, except per share amounts)
2019
 
2018
 
2017
Net earnings attributable to Varex
$
15.5

 
$
27.5

 
$
51.6

Weighted average shares outstanding - basic
38.2

 
37.9

 
37.6

Dilutive effect of potential common shares
0.4

 
0.5

 
0.4

Weighted average shares outstanding - diluted
38.6

 
38.4

 
38

Net earnings per share attributable to Varex - basic
$
0.41

 
$
0.73

 
$
1.37

Net earnings per share attributable to Varex - diluted
$
0.40

 
$
0.72

 
$
1.36

Anti-dilutive employee shared based awards, excluded
1.9

 
1.2

 
1.0
XML 22 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Movement in Standard Product Warranty Accrual [Roll Forward]    
Accrued product warranty, at beginning of period $ 7.3 $ 7.0
Charged to cost of revenues 12.9 11.6
Actual product warranty expenditures (12.1) (11.3)
Accrued product warranty, at end of period $ 8.1 $ 7.3
Minimum    
Product Warranty Liability [Line Items]    
Warranty term (in months) 12 months  
Maximum    
Product Warranty Liability [Line Items]    
Warranty term (in months) 24 months  
XML 23 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATIONS - Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Apr. 29, 2019
Aug. 31, 2018
May 01, 2017
Sep. 27, 2019
Sep. 28, 2018
Allocation of the purchase consideration:          
Goodwill       $ 290.8 $ 243.6
Direct Conversion AB          
Allocation of the purchase consideration:          
Accounts Receivable $ 2.4        
Inventory 5.7        
Prepaids and other current assets 0.7        
Property, plant, and equipment 0.9        
Intangibles 32.9        
Goodwill 47.2        
Total assets acquired 89.8        
Accounts payable (1.0)        
Accrued liabilities (1.5)        
Current maturities of long-term debt (1.0)        
Deferred revenues (0.9)        
Long-term debt (3.5)        
Other liabilities, non-current (1.1)        
Total liabilities assumed (9.0)        
Noncontrolling interest (1.4)        
Net assets acquired, less noncontrolling interest 79.4        
Net cash paid 69.5        
Deferred consideration 9.9        
Total cash consideration $ 79.4        
Virtual Media Integration, Ltd.          
Allocation of the purchase consideration:          
Accounts Receivable   $ 0.2      
Inventory   1.0      
Other assets   0.2      
Intangibles   1.6      
Goodwill   1.5      
Other liabilities   (0.2)      
Net assets acquired   4.3      
Post-closing adjustments   0.5      
Total cash consideration   $ 4.8      
PerkinElmer, Inc.          
Allocation of the purchase consideration:          
Cash     $ 1.4    
Accounts Receivable     18.7    
Inventory     34.7    
Prepaids and other current assets     0.6    
Property, plant, and equipment     21.4    
Other assets, non-current     2.0    
Intangibles     81.1    
Goodwill     167.3    
Total assets acquired     327.2    
Current liabilities     (17.2)    
Other liabilities, non-current     (36.8)    
Total liabilities assumed     (54.0)    
Net assets acquired     273.2    
Net cash paid     277.4    
Total cash consideration     $ 273.2    
XML 24 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Allocated share-based compensation expense $ 11.7 $ 10.0 $ 8.4
Cost of revenues      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Allocated share-based compensation expense 1.2 1.3 0.9
Research and development      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Allocated share-based compensation expense 2.2 1.8 1.5
Selling, general and administrative      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Allocated share-based compensation expense $ 8.3 $ 6.9 6.0
Varian | General and administrative      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Allocated share-based compensation expense     $ 0.8
XML 25 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BORROWINGS - Narrative (Details) - USD ($)
Oct. 08, 2019
Oct. 10, 2018
May 01, 2017
Jan. 25, 2017
Sep. 27, 2019
Sep. 28, 2018
Line of Credit Facility [Line Items]            
Long-term debt, net         $ 364,400,000 $ 364,800,000
Debt issuance costs         5,700,000 8,200,000
Current maturities of long-term debt         30,700,000 25,000,000.0
Secured Debt            
Line of Credit Facility [Line Items]            
Current maturities of long-term debt         $ 29,400,000 $ 25,000,000.0
Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Maximum borrowing capacity     $ 400,000,000.0      
Revolving Credit Facility | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Maximum borrowing capacity   $ 150,000,000.0 $ 200,000,000.0      
Debt instrument, term     5 years      
Used capacity, commitment fee percentage     0.125%      
Permanent reduction in the revolving credit commitment   $ (50,000,000.0)        
Revolving Credit Facility | Secured Debt            
Line of Credit Facility [Line Items]            
Debt instrument, term     5 years      
Proceeds from lines of credit     $ 97,000,000.0      
Revolving Credit Facility | Federal Funds Effective Swap Rate | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Basis spread on variable rate     0.50%      
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Basis spread on variable rate     1.00%      
Revolving Credit Facility | Minimum | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Unused capacity, commitment fee percentage     0.25%      
Revolving Credit Facility | Minimum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Basis spread on variable rate     1.75%      
Revolving Credit Facility | Minimum | Base Rate | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Basis spread on variable rate     0.75%      
Revolving Credit Facility | Maximum | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Unused capacity, commitment fee percentage     0.40%      
Revolving Credit Facility | Maximum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Basis spread on variable rate     2.75%      
Revolving Credit Facility | Maximum | Base Rate | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Basis spread on variable rate     1.75%      
Revolving Credit Facility | Debt Instrument, Repayment, Period One | Secured Debt            
Line of Credit Facility [Line Items]            
Repayment percentage     5.00%      
Revolving Credit Facility | Debt Instrument, Repayment, Period Two | Secured Debt            
Line of Credit Facility [Line Items]            
Repayment percentage     5.00% 7.50%    
Revolving Credit Facility | Debt Instrument, Repayment, Period Three | Secured Debt            
Line of Credit Facility [Line Items]            
Repayment percentage     7.50%      
Revolving Credit Facility | Debt Instrument, Repayment, Period Four | Secured Debt            
Line of Credit Facility [Line Items]            
Repayment percentage     7.50% 10.00%    
Revolving Credit Facility | Debt Instrument, Repayment, Period Five | Secured Debt            
Line of Credit Facility [Line Items]            
Repayment percentage     10.00%      
Subsequent Event | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Maximum borrowing capacity $ 125,000,000.0          
Permanent reduction in the revolving credit commitment (25,000,000.0)          
Subsequent Event | Revolving Credit Facility | Revolving Credit Facility            
Line of Credit Facility [Line Items]            
Maximum borrowing capacity 125,000,000.0          
Permanent reduction in the revolving credit commitment $ 25,000,000.0          
XML 26 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) - Designated as Hedging Instrument - Derivatives designated as cash flow hedges - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Interest Rate Swap Contracts      
Derivative [Line Items]      
Amount of Gain or (Loss) Recognized in OCI on Derivative Fiscal Year Ended $ (6.3) $ 6.9 $ 0.6
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income Fiscal Year Ended 1.9 0.1 (0.3)
Cross Currency Swap Contracts      
Derivative [Line Items]      
Amount of Gain or (Loss) Recognized in OCI on Derivative Fiscal Year Ended (0.2) 0.0 0.0
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income Fiscal Year Ended $ 0.2 $ 0.0 $ 0.0
XML 27 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
COMMITMENTS AND CONTINGENCIES - (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Commitments and Contingencies Disclosure [Abstract]      
Future minimum payments due, next twelve months $ 7.5    
Future minimum payments, due in two years 5.4    
Future minimum payments, due in three years 4.7    
Future minimum payments, due in four years 1.8    
Future minimum payments, due in five years 0.9    
Future minimum payments, due thereafter 0.2    
Operating leases, rent expense 5.1 $ 5.3 $ 4.0
Environment liabilities $ 0.9 $ 1.3  
XML 28 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($)
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Finite-Lived Intangible Assets [Line Items]      
Gross Carrying Amount $ 137,500,000 $ 110,400,000  
Accumulated Amortization (54,000,000.0) (40,600,000)  
Net Carrying Amount 83,500,000 69,800,000  
In-process R&D with indefinite lives 2,800,000 4,000,000.0  
Total intangible assets, gross 140,300,000 114,400,000  
Total intangible assets, net 86,300,000 73,800,000  
Amortization of intangible assets 15,700,000 16,200,000 $ 10,500,000
Impairment of intangible assets 4,800,000 3,000,000.0 $ 0
Developed technology      
Finite-Lived Intangible Assets [Line Items]      
Gross Carrying Amount 74,100,000 57,900,000  
Accumulated Amortization (28,400,000) (21,800,000)  
Net Carrying Amount 45,700,000 36,100,000  
Patents, licenses and other      
Finite-Lived Intangible Assets [Line Items]      
Gross Carrying Amount 12,700,000 9,900,000  
Accumulated Amortization (8,400,000) (7,400,000)  
Net Carrying Amount 4,300,000 2,500,000  
Customer contracts and supplier relationship      
Finite-Lived Intangible Assets [Line Items]      
Gross Carrying Amount 50,700,000 42,600,000  
Accumulated Amortization (17,200,000) (11,400,000)  
Net Carrying Amount $ 33,500,000 $ 31,200,000  
XML 29 R88.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS - Summary of Taxes by Jurisdiction and Classification (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Current provision:      
Federal $ 9.2 $ (2.1) $ 24.8
State and local 1.3 (0.3) 1.6
Foreign 6.8 7.5 5.3
Total current 17.3 5.1 31.7
Deferred provision (benefit):      
Federal (10.0) (7.0) (7.0)
State and local (1.6) 0.7 (1.0)
Foreign 0.0 (1.4) (0.9)
Total deferred (11.6) (7.7) (8.9)
Taxes on earnings 5.7 (2.6) 22.8
United States 5.9 3.7 55.5
Foreign 15.6 22.0 19.3
Earnings before taxes $ 21.5 $ 25.7 $ 74.8
JSON 30 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "varex10k2019.htm": { "axisCustom": 1, "axisStandard": 39, "contextCount": 301, "dts": { "calculationLink": { "local": [ "var-20190927_cal.xml" ] }, "definitionLink": { "local": [ "var-20190927_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "varex10k2019.htm" ] }, "labelLink": { "local": [ "var-20190927_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "var-20190927_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "var-20190927.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 794, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 23, "http://www.vareximaging.com/20190927": 16, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 44 }, "keyCustom": 40, "keyStandard": 524, "memberCustom": 28, "memberStandard": 71, "nsprefix": "var", "nsuri": "http://www.vareximaging.com/20190927", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover", "role": "http://www.vareximaging.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - RELATED-PARTY TRANSACTIONS", "role": "http://www.vareximaging.com/role/RelatedPartyTransactions", "shortName": "RELATED-PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - REVENUE RECOGNITION - Schedule of Balance Sheet Adjustment for ASC 606 Adoption (Details)", "role": "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "shortName": "REVENUE RECOGNITION - Schedule of Balance Sheet Adjustment for ASC 606 Adoption (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2019Q1Sep29", "decimals": "-5", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418403 - Disclosure - REVENUE RECOGNITION - Schedule of ASC 606 Adoption Impact On Income Statement (Details)", "role": "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "shortName": "REVENUE RECOGNITION - Schedule of ASC 606 Adoption Impact On Income Statement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member", "decimals": "-5", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "var:ContractWithCustomerAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418404 - Disclosure - REVENUE RECOGNITION - Schedule of Changes in Contract Balances (Details)", "role": "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails", "shortName": "REVENUE RECOGNITION - Schedule of Changes in Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "var:ContractWithCustomerAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418405 - Disclosure - REVENUE RECOGNITION - Remaining Performance Obligations (Details)", "role": "http://www.vareximaging.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails", "shortName": "REVENUE RECOGNITION - Remaining Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2017Q2May1_us-gaap_DebtInstrumentAxis_var_RevolvingCreditFacilityMay2017Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419401 - Disclosure - SUBSEQUENT EVENTS - (Details)", "role": "http://www.vareximaging.com/role/SubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS - (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - RESTRUCTURING", "role": "http://www.vareximaging.com/role/Restructuring", "shortName": "RESTRUCTURING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - OTHER FINANCIAL INFORMATION", "role": "http://www.vareximaging.com/role/OtherFinancialInformation", "shortName": "OTHER FINANCIAL INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - NET EARNINGS PER SHARE", "role": "http://www.vareximaging.com/role/NetEarningsPerShare", "shortName": "NET EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES", "role": "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivities", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - BORROWINGS", "role": "http://www.vareximaging.com/role/Borrowings", "shortName": "BORROWINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - FAIR VALUE", "role": "http://www.vareximaging.com/role/FairValue", "shortName": "FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://www.vareximaging.com/role/GoodwillAndIntangibleAssets", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.vareximaging.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS", "role": "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterests", "shortName": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS", "role": "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "shortName": "CONSOLIDATED STATEMENTS OF EARNINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - EMPLOYEE STOCK PLANS", "role": "http://www.vareximaging.com/role/EmployeeStockPlans", "shortName": "EMPLOYEE STOCK PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - TAXES ON EARNINGS", "role": "http://www.vareximaging.com/role/TaxesOnEarnings", "shortName": "TAXES ON EARNINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - SEGMENT INFORMATION", "role": "http://www.vareximaging.com/role/SegmentInformation", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - EMPLOYEE BENEFIT PLANS", "role": "http://www.vareximaging.com/role/EmployeeBenefitPlans", "shortName": "EMPLOYEE BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - OTHER COMPREHENSIVE INCOME", "role": "http://www.vareximaging.com/role/OtherComprehensiveIncome", "shortName": "OTHER COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - REVENUE RECOGNITION", "role": "http://www.vareximaging.com/role/RevenueRecognition", "shortName": "REVENUE RECOGNITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.vareximaging.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - BUSINESS COMBINATIONS (Tables)", "role": "http://www.vareximaging.com/role/BusinessCombinationsTables", "shortName": "BUSINESS COMBINATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS", "role": "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - RESTRUCTURING (Tables)", "role": "http://www.vareximaging.com/role/RestructuringTables", "shortName": "RESTRUCTURING (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)", "role": "http://www.vareximaging.com/role/OtherFinancialInformationTables", "shortName": "OTHER FINANCIAL INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - NET EARNINGS PER SHARE (Tables)", "role": "http://www.vareximaging.com/role/NetEarningsPerShareTables", "shortName": "NET EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)", "role": "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesTables", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - BORROWINGS (Tables)", "role": "http://www.vareximaging.com/role/BorrowingsTables", "shortName": "BORROWINGS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - FAIR VALUE (Tables)", "role": "http://www.vareximaging.com/role/FairValueTables", "shortName": "FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables)", "role": "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsTables", "shortName": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - EMPLOYEE STOCK PLANS (Tables)", "role": "http://www.vareximaging.com/role/EmployeeStockPlansTables", "shortName": "EMPLOYEE STOCK PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SummaryOfValuationAllowanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - TAXES ON EARNINGS (Tables)", "role": "http://www.vareximaging.com/role/TaxesOnEarningsTables", "shortName": "TAXES ON EARNINGS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SummaryOfValuationAllowanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://www.vareximaging.com/role/SegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "lang": "en-US", "name": "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - OTHER COMPREHENSIVE INCOME (Tables)", "role": "http://www.vareximaging.com/role/OtherComprehensiveIncomeTables", "shortName": "OTHER COMPREHENSIVE INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - REVENUE RECOGNITION (Tables)", "role": "http://www.vareximaging.com/role/RevenueRecognitionTables", "shortName": "REVENUE RECOGNITION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2017Q1Jan28_srt_CounterpartyNameAxis_var_VarianMedicalSystemsInc.Member", "decimals": "INF", "first": true, "lang": null, "name": "var:OutstandingCommonStockPercentageDistributed", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesDescriptionOfBusinessDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2017Q1Jan28_srt_CounterpartyNameAxis_var_VarianMedicalSystemsInc.Member", "decimals": "INF", "first": true, "lang": null, "name": "var:OutstandingCommonStockPercentageDistributed", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reclassification (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reclassification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2018Q4YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "var:NumberofVariableInterestEntities", "reportCount": 1, "unique": true, "unitRef": "entity", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Variable Interest Entities (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesVariableInterestEntitiesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Variable Interest Entities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "var:NumberofVariableInterestEntities", "reportCount": 1, "unique": true, "unitRef": "entity", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_var_CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_var_CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003001 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)", "role": "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)", "subGroupType": "", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property Plant and Equipment (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401412 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets, Intangible Assets and Goodwill (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsIntangibleAssetsAndGoodwillDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets, Intangible Assets and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2017Q4YTD", "decimals": "INF", "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401413 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401414 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401415 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounting Standards Recently Adopted (Details)", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounting Standards Recently Adopted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2019Q3Apr302019_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - BUSINESS COMBINATIONS - Direct Conversion Narrative (Details)", "role": "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails", "shortName": "BUSINESS COMBINATIONS - Direct Conversion Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "D2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "-5", "lang": null, "name": "us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - BUSINESS COMBINATIONS - Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "BUSINESS COMBINATIONS - Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - BUSINESS COMBINATIONS - Intangibles Acquired (Details)", "role": "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails", "shortName": "BUSINESS COMBINATIONS - Intangibles Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "D2019Q4Apr30-Sep27_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - BUSINESS COMBINATIONS - Revenues by Segment (Details)", "role": "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "shortName": "BUSINESS COMBINATIONS - Revenues by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "D2019Q4Apr30-Sep27_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "D2018Q4Aug312018-Aug312018_us-gaap_BusinessAcquisitionAxis_var_VirtualMediaIntegrationLtd.Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - BUSINESS COMBINATIONS - Virtual Media Narrative (Details)", "role": "http://www.vareximaging.com/role/BusinessCombinationsVirtualMediaNarrativeDetails", "shortName": "BUSINESS COMBINATIONS - Virtual Media Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "D2017Q2May1_us-gaap_BusinessAcquisitionAxis_var_PerkinElmerInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402407 - Disclosure - BUSINESS COMBINATIONS - PerkinElmer's Medical Imaging Narrative (Details)", "role": "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails", "shortName": "BUSINESS COMBINATIONS - PerkinElmer's Medical Imaging Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "I2017Q2May1_us-gaap_BusinessAcquisitionAxis_var_PerkinElmerInc.Member", "decimals": "0", "lang": null, "name": "var:BusinessCombinationNumberofEmployees", "reportCount": 1, "unique": true, "unitRef": "employee", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_var_PerkinElmerInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402408 - Disclosure - BUSINESS COMBINATIONS - Pro Forma (Details)", "role": "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails", "shortName": "BUSINESS COMBINATIONS - Pro Forma (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_var_PerkinElmerInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately Held Companies (Details)", "role": "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails", "shortName": "RELATED-PARTY TRANSACTIONS - Investment in Privately Held Companies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_var_DpiXHoldingMember", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - RESTRUCTURING - Narrative (Details)", "role": "http://www.vareximaging.com/role/RestructuringNarrativeDetails", "shortName": "RESTRUCTURING - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherRestructuringCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherAssetImpairmentCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - RESTRUCTURING - Restructuring Charges Incurred (Details)", "role": "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails", "shortName": "RESTRUCTURING - Restructuring Charges Incurred (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - OTHER FINANCIAL INFORMATION - (Details)", "role": "http://www.vareximaging.com/role/OtherFinancialInformationDetails", "shortName": "OTHER FINANCIAL INFORMATION - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - NET EARNINGS PER SHARE - (Details)", "role": "http://www.vareximaging.com/role/NetEarningsPerShareDetails", "shortName": "NET EARNINGS PER SHARE - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unique": true, "unitRef": "derivative", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details)", "role": "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unique": true, "unitRef": "derivative", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details)", "role": "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF EQUITY", "role": "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details)", "role": "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details)", "role": "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_PositionAxis_us-gaap_LongMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407406 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Foreign Currency Contracts (Details)", "role": "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Foreign Currency Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_PositionAxis_us-gaap_LongMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - BORROWINGS - Schedule of Short-Term and Long-Term Debt (Details)", "role": "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "shortName": "BORROWINGS - Schedule of Short-Term and Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - BORROWINGS - Narrative (Details)", "role": "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "shortName": "BORROWINGS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "D2017Q2May1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_var_RevolvingCreditFacilityMay2017Member", "decimals": "INF", "lang": null, "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - BORROWINGS - Schedule of Debt Maturities (Details)", "role": "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails", "shortName": "BORROWINGS - Schedule of Debt Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - FAIR VALUE - (Details)", "role": "http://www.vareximaging.com/role/FairValueDetails", "shortName": "FAIR VALUE - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Goowill (Details)", "role": "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Summary of Goowill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "role": "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization Schedule (Details)", "role": "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Amortization Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - COMMITMENTS AND CONTINGENCIES - (Details)", "role": "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Narrative (Details)", "role": "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails", "shortName": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4_srt_OwnershipAxis_var_JointVentureInSaudiArabiaMember", "decimals": "2", "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Summary of Changes in Redeemable Noncontrolling Interests & Noncontrolling INterets (Details)", "role": "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails", "shortName": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Summary of Changes in Redeemable Noncontrolling Interests & Noncontrolling INterets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:TemporaryEquityNetIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - EMPLOYEE STOCK PLANS - Narrative (Details)", "role": "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "shortName": "EMPLOYEE STOCK PLANS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details)", "role": "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails", "shortName": "EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413404 - Disclosure - EMPLOYEE STOCK PLANS - Valuation Assumptions (Details)", "role": "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails", "shortName": "EMPLOYEE STOCK PLANS - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details)", "role": "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails", "shortName": "EMPLOYEE STOCK PLANS - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)", "role": "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails", "shortName": "EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - TAXES ON EARNINGS - Summary of Taxes by Jurisdiction and Classification (Details)", "role": "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails", "shortName": "TAXES ON EARNINGS - Summary of Taxes by Jurisdiction and Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - TAXES ON EARNINGS - Income Tax Rate Reconciliation (Details)", "role": "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails", "shortName": "TAXES ON EARNINGS - Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - BUSINESS COMBINATIONS", "role": "http://www.vareximaging.com/role/BusinessCombinations", "shortName": "BUSINESS COMBINATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - TAXES ON EARNINGS - Narrative (Details)", "role": "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails", "shortName": "TAXES ON EARNINGS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - TAXES ON EARNINGS - Deferred Tax Assets and Liabilities (Details)", "role": "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "TAXES ON EARNINGS - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - TAXES ON EARNINGS - Valuation Allowance (Details)", "role": "http://www.vareximaging.com/role/TaxesOnEarningsValuationAllowanceDetails", "shortName": "TAXES ON EARNINGS - Valuation Allowance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "var:ValuationAllowanceDeferredTaxAssetIncreaseFromBusinessCombinationAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - TAXES ON EARNINGS - Income Tax Contingency (Details)", "role": "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxContingencyDetails", "shortName": "TAXES ON EARNINGS - Income Tax Contingency (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - SEGMENT INFORMATION - Narrative (Details)", "role": "http://www.vareximaging.com/role/SegmentInformationNarrativeDetails", "shortName": "SEGMENT INFORMATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R95": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - SEGMENT INFORMATION - Summary of Segment Information (Details)", "role": "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails", "shortName": "SEGMENT INFORMATION - Summary of Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_var_MedicalMember", "decimals": "-5", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - SEGMENT INFORMATION - Assets (Details)", "role": "http://www.vareximaging.com/role/SegmentInformationAssetsDetails", "shortName": "SEGMENT INFORMATION - Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - SEGMENT INFORMATION - Geographic (Details)", "role": "http://www.vareximaging.com/role/SegmentInformationGeographicDetails", "shortName": "SEGMENT INFORMATION - Geographic (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD_srt_StatementGeographicalAxis_country_US", "decimals": "-5", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - EMPLOYEE BENEFIT PLANS - (Details)", "role": "http://www.vareximaging.com/role/EmployeeBenefitPlansDetails", "shortName": "EMPLOYEE BENEFIT PLANS - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - OTHER COMPREHENSIVE INCOME - (Details)", "role": "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails", "shortName": "OTHER COMPREHENSIVE INCOME - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10k2019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 100, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationGeographicDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Switzerland, Francs", "terseLabel": "Swiss franc" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "currency_CNY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "China, Yuan Renminbi", "terseLabel": "Chinese renminbi" } } }, "localname": "CNY", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "currency_JPY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Japan, Yen", "terseLabel": "Japanese yen" } } }, "localname": "JPY", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r576" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r575" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity common stock, shares outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r578" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r572" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r574" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "APAC" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationGeographicDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r181", "r193" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r67", "r132" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesDescriptionOfBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationGeographicDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r197", "r289", "r295", "r564" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.vareximaging.com/role/RestructuringNarrativeDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.vareximaging.com/role/RestructuringNarrativeDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.vareximaging.com/role/RestructuringNarrativeDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.vareximaging.com/role/RestructuringNarrativeDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesDescriptionOfBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r144", "r146", "r147", "r148" ], "lang": { "en-US": { "role": { "label": "Restatement Adjustment [Member]", "terseLabel": "Restatement Adjustment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationGeographicDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r196", "r289", "r294", "r563", "r566", "r570" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationGeographicDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r263", "r507" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "ASU 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r138", "r499", "r537", "r557" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties", "terseLabel": "Accounts payable, related parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r25", "r199", "r200", "r290" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $1.0 and $0.6 at September 27, 2019 and September 28, 2018, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r8", "r9", "r53" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent": { "auth_ref": [ "r56", "r250", "r251", "r262" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value of the obligation (known or estimated) arising from requirements to perform activities to remediate one or more sites, payable after twelve months or beyond the next operating cycle if longer.", "label": "Accrued Environmental Loss Contingencies, Noncurrent", "terseLabel": "Environment liabilities" } } }, "localname": "AccruedEnvironmentalLossContingenciesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails", "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r17", "r531", "r548" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r19", "r531", "r548" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Long-term income tax payable" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/OtherFinancialInformationDetails", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r70", "r76", "r77", "r306", "r433" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gain on Defined Benefit Obligations" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r46", "r245" ], "calculation": { "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r76", "r432" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gain (Loss) on Derivative Financial Instruments" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r73", "r75", "r76" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r72", "r76", "r77", "r433" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "OTHER FINANCIAL INFORMATION" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r26" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net", "terseLabel": "Tax impacts to APIC related to share-based award activity" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld on vesting of restricted stock" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r311", "r313", "r349", "r350" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r313", "r343", "r348" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Allocated share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r31", "r201", "r208" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r94", "r119", "r496" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred loan costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r119", "r225", "r234" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive employee shared based awards, excluded (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/NetEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r72", "r76", "r77", "r433" ], "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r186", "r529", "r547" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/SegmentInformationAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r63" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r478" ], "calculation": { "http://www.vareximaging.com/role/FairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r314", "r345" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r453", "r457" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails", "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails", "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/BusinessCombinationsVirtualMediaNarrativeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r397", "r398" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails", "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails", "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/BusinessCombinationsVirtualMediaNarrativeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails", "http://www.vareximaging.com/role/BusinessCombinationsVirtualMediaNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r395", "r396" ], "lang": { "en-US": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Net earnings per share, basic (in USD per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r395", "r396" ], "lang": { "en-US": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Net earnings per share, diluted (in USD per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r395", "r396" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business Acquisition, Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r417" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill expected tax deductible amount" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax": { "auth_ref": [ "r395", "r396" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax", "terseLabel": "Operating earnings" } } }, "localname": "BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r395", "r396" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net earnings" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r395", "r396" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r401" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "negatedLabel": "Noncontrolling interest" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r410", "r411", "r414" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total cash consideration", "totalLabel": "Total cash consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsVirtualMediaNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r410", "r411" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Deferred consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r118", "r418" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedTerseLabel": "Change in fair value of deferred consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r409", "r412", "r416" ], "calculation": { "http://www.vareximaging.com/role/FairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Deferred consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r409", "r413" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Deferred consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r419" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS COMBINATIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r394" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Revenues" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "Allocation of the purchase consideration:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 9.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaids and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts Receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "negatedLabel": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt", "negatedLabel": "Current maturities of long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r360", "r400" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities noncurrent" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "negatedLabel": "Long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedLabel": "Other liabilities, non-current" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets, non-current" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest", "totalLabel": "Net assets acquired, less noncontrolling interest" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r400" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r119", "r252", "r256", "r258" ], "calculation": { "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails": { "order": 6.0, "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Facility closure costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.", "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]", "terseLabel": "Balance without Adoption" } } }, "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r124", "r125", "r126" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property, plant and equipment financed through accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r42", "r121" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/FairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents - money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r13", "r122", "r128", "r528" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r114", "r121", "r127" ], "calculation": { "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash and cash equivalents and restricted cash as reported per statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r114", "r493" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Recorded component of accumulated other comprehensive income (loss) that will be reclassified in the statements of comprehensive earnings over the next 12 months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r450" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Derivatives designated as cash flow hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInContractWithCustomerAssetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Change in Contract with Customer, Asset [Abstract]" } } }, "localname": "ChangeInContractWithCustomerAssetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r57", "r262", "r538", "r556" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r261", "r264" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r128", "r267", "r567", "r568" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Loss Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r280" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Shares outstanding, end of period (in shares)", "periodStartLabel": "Shares outstanding, beginning of period (in shares)", "terseLabel": "Common stock, shares, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $.01 par value: 150,000,000 shares authorized, shares issued and outstanding: 38,371,305 and 38,026,597 at September 27, 2019 and September 28, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r299", "r300", "r310", "r352" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLANS" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r80", "r82", "r83" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive earnings attributable to Varex" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r80", "r82", "r424", "r425", "r440" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Comprehensive earnings attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r80", "r82", "r423", "r440" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive earnings" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "OTHER COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r172", "r173", "r487", "r488" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r172", "r173", "r487", "r488", "r565" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r172", "r173", "r487", "r488", "r565" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r167", "r544" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r172", "r173", "r487", "r488" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r170", "r172", "r173", "r174", "r487", "r489" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r172", "r173", "r487", "r488" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r128", "r427", "r442", "r444" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r128", "r435", "r436", "r437" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entities" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Schedule of Changes in Contract With Customer Assets And Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r284", "r285", "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Balance at September 27, 2019", "periodStartLabel": "Balance at September 29, 2018" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r284", "r285", "r290" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenues" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r291" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Recognition of revenue included in beginning of year refund liability" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r292" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Right of return liability" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityNoncurrent": { "auth_ref": [ "r292" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as noncurrent.", "label": "Contract with Customer, Refund Liability, Noncurrent", "terseLabel": "Long-term right of return liability" } } }, "localname": "ContractWithCustomerRefundLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r97" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r304", "r465" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross Currency Swap Contracts" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Effect of adoption of ASC 606" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r130", "r381", "r386" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r137", "r383" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r381", "r386" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current provision:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r130", "r381", "r386" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r405" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "BORROWINGS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Borrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r530", "r534", "r546" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r18", "r271", "r534", "r546" ], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Total debt outstanding" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r382", "r386" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r48", "r496" ], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Debt issuance costs", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r382", "r386" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r119", "r130", "r382", "r386" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred provision (benefit):" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r20", "r21", "r372", "r532", "r545" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r361", "r376" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities", "totalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r382", "r386" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r373" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Deferred tax assets, gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r355", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory adjustments" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r374" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred Tax Assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r354", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails", "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Operating loss carryforwards, that do not expire" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Operating loss carryforwards, that expire" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r355", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": { "auth_ref": [ "r378", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign", "terseLabel": "Credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": { "auth_ref": [ "r354", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences", "terseLabel": "Accrued vacation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r354", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "terseLabel": "Deferred compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r354", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": { "auth_ref": [ "r354", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves", "terseLabel": "Product warranty" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r375" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance", "periodEndLabel": "Valuation allowance balance\u2014end of fiscal year", "periodStartLabel": "Valuation allowance balance\u2013beginning of fiscal year" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails", "http://www.vareximaging.com/role/TaxesOnEarningsValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r361", "r376" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r355", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedTerseLabel": "Acquired intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": { "auth_ref": [ "r355", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.", "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates", "negatedTerseLabel": "Investments in privately held companies" } } }, "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "terseLabel": "Deferred Tax Liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r355", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r355", "r379", "r380" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r379" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "terseLabel": "Deferred tax liabilities of undistributed foreign earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": { "auth_ref": [ "r19", "r301", "r302", "r303" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.", "label": "Liability, Defined Benefit Pension Plan, Noncurrent", "terseLabel": "Defined benefit pension plan liability" } } }, "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Employer discretionary contribution amount" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r119", "r243" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r65", "r66", "r486" ], "calculation": { "http://www.vareximaging.com/role/FairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative assets" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r64", "r68", "r455", "r513" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative Assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r64", "r68", "r455", "r513" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedTerseLabel": "Derivative Liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r454", "r456", "r461", "r467" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r451", "r454", "r461" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r459", "r466" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income Fiscal Year Ended" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": { "auth_ref": [ "r460", "r462" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss", "terseLabel": "Loss on derivative instruments not designated as cash flow hedges" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r65", "r66", "r486" ], "calculation": { "http://www.vareximaging.com/role/FairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r447", "r449" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional Value" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r447", "r449" ], "lang": { "en-US": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative, Number of Instruments Held", "terseLabel": "Number of Instruments" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r139", "r446", "r448", "r449", "r451", "r452", "r458", "r461", "r469", "r471", "r474" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r128", "r140", "r446", "r448", "r451", "r452", "r470" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative instruments and hedging activities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r407" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606", "verboseLabel": "Adjustment Due to ASC 606" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "EMPLOYEE STOCK PLANS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r49", "r138", "r499" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Payable to Varian Medical Systems" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationGeographicDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net earnings per common share attributable to Varex" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r92", "r144", "r152", "r154", "r155", "r156", "r159", "r542", "r560" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in USD per share)", "verboseLabel": "Net earnings per share attributable to Varex - basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/NetEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r92", "r144", "r152", "r154", "r155", "r156", "r159", "r542", "r560" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in USD per share)", "verboseLabel": "Net earnings per share attributable to Varex - diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/NetEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/NetEarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r493" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effects of exchange rate changes on cash and cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r136", "r362", "r363" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails", "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Revaluation of deferred tax liabilities for US statutory change" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for qualified production activity.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent", "negatedTerseLabel": "Domestic production activities deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign Rate Difference" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Prior year deferred tax adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "terseLabel": "Mandatory repatriation tax on foreign earnings" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and local taxes, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r362", "r363", "r385" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Research and development credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent": { "auth_ref": [ "r362" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails": { "order": 11.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to increase (decrease) from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Percent", "terseLabel": "US Tax Reform - International Provisions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Compensation cost period for recognition (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity", "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvesteeMember": { "auth_ref": [ "r204", "r516", "r518", "r520", "r522", "r524", "r526" ], "lang": { "en-US": { "role": { "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.", "label": "Equity Method Investee [Member]", "terseLabel": "Equity Method Investee" } } }, "localname": "EquityMethodInvesteeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r43", "r187", "r205" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities": { "auth_ref": [ "r351" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities", "terseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r478", "r479", "r480", "r484" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r304", "r305", "r308", "r479", "r509" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r478", "r479", "r481", "r482", "r485" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r483" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r304", "r305", "r308", "r479", "r510" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r304", "r305", "r308", "r479", "r511" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r304", "r305", "r308", "r479", "r512" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r483", "r485" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r453", "r458", "r472" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r473" ], "lang": { "en-US": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Federal Funds Effective Swap Rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of Intangible Assets Acquired" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r233" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r235" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r235" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r235" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r235" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r235" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r226", "r229", "r233", "r237", "r514" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r233", "r514" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r226", "r232" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r233" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiscalPeriod": { "auth_ref": [ "r420", "r441", "r443" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.", "label": "Fiscal Period, Policy [Policy Text Block]", "terseLabel": "Fiscal Year" } } }, "localname": "FiscalPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r490", "r491", "r492" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Realized income (loss) on foreign currencies" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r128", "r492", "r494" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r304", "r464" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r93" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r215", "r217" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 8.0, "parentTag": "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "weight": 1.0 }, "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at September 27, 2019", "periodStartLabel": "Balance at September 28, 2018", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Business combination" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r128", "r221", "r230" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r119", "r216", "r219", "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r220", "r392" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "verboseLabel": "Post-closing adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r95" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross margin", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r451", "r468" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r119", "r238" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets", "verboseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsIntangibleAssetsAndGoodwillDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r119", "r238" ], "calculation": { "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "verboseLabel": "Intangible assets impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets, Intangible Assets and Goodwill" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r135" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r89", "r144", "r527", "r540", "r561" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails", "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r135" ], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r90", "r119", "r184", "r205", "r539", "r558" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Loss (gain) from equity method investments, net of dividends received", "terseLabel": "Income (loss) from equity method investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/OtherFinancialInformationDetails", "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "TAXES ON EARNINGS" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarnings" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Expense", "terseLabel": "Income tax penalties and interest expense" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r185", "r388" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes (benefit) on earnings", "totalLabel": "Taxes on earnings" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails", "http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r84", "r128", "r358", "r359", "r370", "r371", "r377", "r390", "r569" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Taxes on Earnings" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r116", "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income tax" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r118" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r118" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued operating liabilities and other long-term operating liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r118" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenues" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r118" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities, net of effects of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r118" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r153", "r158" ], "calculation": { "http://www.vareximaging.com/role/NetEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of potential common shares (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/NetEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r228", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r236" ], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "In-process R&D with indefinite lives" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r228", "r236" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Total intangible assets, gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r224", "r231" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangibles assets, net", "totalLabel": "Total intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r408" ], "lang": { "en-US": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Patents, licenses and other" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r87", "r183", "r495", "r496", "r543" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r112", "r115", "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r463" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap Contracts" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r33", "r214" ], "calculation": { "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r61", "r210" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r11", "r62", "r128", "r163", "r211", "r213" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "auth_ref": [ "r35", "r36", "r214" ], "calculation": { "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "terseLabel": "Raw materials and parts" } } }, "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r34", "r214" ], "calculation": { "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r212" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r99", "r182" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r43" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "terseLabel": "Investments in privately-held companies" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land Improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAgreementsMember": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.", "label": "Lease Agreements [Member]", "terseLabel": "Favorable leasehold interests" } } }, "localname": "LeaseAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Operating leases, rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r52" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r536", "r554" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable noncontrolling interests and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, redeemable noncontrolling interests and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r478" ], "calculation": { "http://www.vareximaging.com/role/FairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Used capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r134" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of the credit facility.", "label": "Line of Credit Facility, Increase (Decrease), Net", "negatedTerseLabel": "Permanent reduction in the revolving credit commitment" } } }, "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "verboseLabel": "Revolving credit commitment" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r50", "r133" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Buy contracts" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r18", "r272", "r534", "r550" ], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 }, "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less: current maturities of long-term debt", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Current Maturities [Abstract]", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "LongTermDebtCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Long-term debt, fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r141", "r270" ], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r141", "r270" ], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r141", "r270" ], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net", "totalLabel": "Long-term debt outstanding" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Excluding Current Maturities [Abstract]", "terseLabel": "Non-current maturities of long-term debt:" } } }, "localname": "LongTermDebtNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.", "label": "Long-term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Weighted-average interest rate, long-term debt" } } }, "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MajorityShareholderMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.", "label": "Majority Shareholder [Member]", "terseLabel": "Varian" } } }, "localname": "MajorityShareholderMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r60", "r535", "r553" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "verboseLabel": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterests" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r60", "r96", "r422", "r434" ], "lang": { "en-US": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInMinorityInterestRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]" } } }, "localname": "MovementInMinorityInterestRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r114", "r117", "r120" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r78", "r81", "r91", "r120", "r158", "r541", "r559" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net earnings attributable to Varex", "totalLabel": "Net earnings attributable to Varex" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/NetEarningsPerShareDetails", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r78", "r81", "r429", "r439" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "verboseLabel": "Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r277", "r429", "r430" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net earnings" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Standards Recently Adopted, Recent Accounting Standards Updates Not Yet Effective" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental non-cash activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1": { "auth_ref": [ "r124", "r125", "r126" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Debt Assumed", "terseLabel": "Debt assumed" } } }, "localname": "NoncashOrPartNoncashAcquisitionDebtAssumed1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": { "auth_ref": [ "r283", "r426", "r431" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.", "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest", "terseLabel": "Noncontrolling interest acquired/consolidated", "verboseLabel": "Contributions from noncontrolling interests" } } }, "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r100" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Interest and other expenses, net", "totalLabel": "Interest and other expenses, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationNarrativeDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Total operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating earnings" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r497", "r498" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Future minimum payments due, next twelve months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r497", "r498" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Future minimum payments, due in five years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r497", "r498" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Future minimum payments, due in four years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r497", "r498" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Future minimum payments, due in three years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r497", "r498" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Future minimum payments, due in two years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r497", "r498" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Future minimum payments, due thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r181", "r193" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrderOrProductionBacklogMember": { "auth_ref": [ "r404" ], "lang": { "en-US": { "role": { "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination.", "label": "Order or Production Backlog [Member]", "terseLabel": "Backlog" } } }, "localname": "OrderOrProductionBacklogMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r142", "r149", "r178", "r445" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r53" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetImpairmentCharges": { "auth_ref": [ "r119", "r247" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.", "label": "Other Asset Impairment Charges", "terseLabel": "Other assets impairment charges" } } }, "localname": "OtherAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other comprehensive loss before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": { "auth_ref": [ "r69" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax", "terseLabel": "Unrealized (loss) gain on interest rate swap contracts", "verboseLabel": "Unrealized gain on interest rate swap contracts, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings", "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r79", "r82", "r85", "r280" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive (loss) earnings, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) earnings, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r71", "r73" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Unrealized gain (loss) on defined benefit obligations", "negatedTerseLabel": "Unrealized (loss) gain on defined benefit obligations" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings", "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r74", "r387", "r389" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Income tax benefit" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r69", "r73", "r475" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Amount of Gain or (Loss) Recognized in OCI on Derivative Fiscal Year Ended" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r453", "r472" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Total other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/OtherFinancialInformationDetails", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r120" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other non-current assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r101" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r119", "r252", "r256", "r258" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other unrelated restructuring costs" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "auth_ref": [ "r19", "r533", "r549" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.", "label": "Other Sundry Liabilities, Noncurrent", "terseLabel": "Long-term other" } } }, "localname": "OtherSundryLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Varex Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r111" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDistributionsToAffiliates": { "auth_ref": [ "r109" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Payments of Distributions to Affiliates", "negatedTerseLabel": "Distributions to Varian Medical Systems, Inc." } } }, "localname": "PaymentsOfDistributionsToAffiliates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "auth_ref": [ "r109" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "negatedTerseLabel": "Dividends paid to redeemable noncontrolling interest" } } }, "localname": "PaymentsOfDividendsMinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r109" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Taxes related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r104", "r415" ], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Net cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r104" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisitions of businesses, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r104" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedLabel": "Investments in privately-held companies", "terseLabel": "Contributions to equity method investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r105" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r19", "r301", "r302", "r303" ], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "Defined benefit obligation liability" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r314", "r345" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r40", "r41" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromContributionsFromParent": { "auth_ref": [ "r108" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from parent as a source of financing that is recorded as additional paid in capital.", "label": "Proceeds from Contributions from Parent", "terseLabel": "Net transfers from parent" } } }, "localname": "ProceedsFromContributionsFromParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r107", "r134" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from lines of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r107" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Borrowings under credit agreements" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r108" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds from Noncontrolling Interests", "terseLabel": "Contributions from noncontrolling partner" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r106", "r346" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r106" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from shares issued under employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyLiabilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Warranty Liability [Line Items]", "terseLabel": "Product Warranty Liability [Line Items]" } } }, "localname": "ProductWarrantyLiabilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyLiabilityTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about product warranty liability, including, but not limited to, reductions in the liability for payments made under the warranty, changes in the liability for accruals related to product warranties issued, and changes in the liability for accruals related to preexisting warranties.", "label": "Product Warranty Liability [Table]", "terseLabel": "Product Warranty Liability [Table]" } } }, "localname": "ProductWarrantyLiabilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r78", "r81", "r113", "r186", "r194", "r423", "r428", "r430", "r439", "r440" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings", "totalLabel": "Net earnings" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings", "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r46", "r246" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r45", "r244" ], "calculation": { "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r246", "r555" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/SegmentInformationGeographicDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r44", "r128", "r246" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r244" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r32", "r128", "r202" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Allowance for Doubtful Accounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r76", "r77", "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Amount reclassified out of accumulated other comprehensive income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "Changes In Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r189", "r191" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxContingencyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r275", "r276", "r278", "r279" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "terseLabel": "Redeemable noncontrolling interests" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "terseLabel": "Changes in Redeemable Noncontrolling Interest" } } }, "localname": "RedeemableNoncontrollingInterestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails", "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r307", "r500", "r501" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Purchases from related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r307", "r500", "r501", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails", "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED-PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r110" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Repayments of borrowing under credit agreements" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r353", "r571" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r128", "r353" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r47", "r128", "r240", "r241", "r571" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Software Development Costs" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r127", "r528", "r551" ], "calculation": { "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "RESTRUCTURING" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expected cost remaining for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost Remaining", "terseLabel": "Expected additional costs to be incurred" } } }, "localname": "RestructuringAndRelatedCostExpectedCostRemaining1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r119", "r252", "r256", "r258" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "auth_ref": [ "r119" ], "calculation": { "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs and Asset Impairment Charges", "terseLabel": "Restructuring and impairment charges", "totalLabel": "Total restructuring charges" } } }, "localname": "RestructuringCostsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails", "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserveAcceleratedDepreciation": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails": { "order": 4.0, "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.", "label": "Restructuring and Related Cost, Accelerated Depreciation", "terseLabel": "Accelerated depreciation" } } }, "localname": "RestructuringReserveAcceleratedDepreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r282", "r552" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings", "verboseLabel": "(Decrease) increase to retained earnings for adoption of new accounting guidance" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r129", "r298" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contract with Customer" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE RECOGNITION" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, remaining performance obligation, amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r88", "r180", "r181", "r192" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues, net" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails", "http://www.vareximaging.com/role/SegmentInformationGeographicDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationGeographicDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales Revenue, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r397", "r398" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails", "http://www.vareximaging.com/role/BusinessCombinationsVirtualMediaNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Short-Term and Long-Term Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r139", "r446", "r448", "r449", "r451", "r452", "r458", "r461", "r469", "r471" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/NetEarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r313", "r342", "r348" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r313", "r342", "r348" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r146", "r147", "r148" ], "lang": { "en-US": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r478", "r479" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r226", "r232" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r226", "r232" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r221", "r223" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r221", "r223" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r236", "r239" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r461" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Schedule of Interest Rate Derivative Instruments" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r37", "r38", "r39" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r143", "r145", "r161", "r162", "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Schedule of ASC 606 Adoption Impacts" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of Other Nonoperating Income (Expense)" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r46", "r246" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r131", "r500", "r501", "r502", "r503", "r504" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r13", "r127", "r528", "r551" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restrictions on Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r254", "r255", "r257" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r254", "r255", "r257" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Schedule of Restructuring Charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r86", "r88", "r196" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformationGeographicDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r179", "r186", "r188", "r190", "r221" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/SegmentInformationAssetsDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r179", "r186", "r188", "r190", "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsTables", "http://www.vareximaging.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r314", "r345" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r320", "r331", "r334" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r369", "r384" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r170", "r172", "r173", "r174", "r487", "r489" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk, by Risk Factor" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails", "http://www.vareximaging.com/role/SegmentInformationAssetsDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/SegmentInformationAssetsDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r98", "r209" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "negatedLabel": "Reclassification of selling, general and administrative", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r119", "r252", "r256", "r258" ], "calculation": { "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails": { "order": 5.0, "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r118" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in months)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Restricted Stock Units and Performance Stock Units, forfeited in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted Stock Units and Performance Stock Units, forfeitures, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted Stock Units and Performance Stock Units, grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted Stock Units and Performance Stock Units, grants in period, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Restricted Stock Units and Performance Stock Units, nonvested, ending balance (in shares)", "periodStartLabel": "Restricted Stock Units and Performance Stock Units, nonvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Restricted Stock Units and Performance Stock Units, nonvested, end of period, weighted average grant date fair value (in USD per share)", "periodStartLabel": "Restricted Stock Units and Performance Stock Units, nonvested, beginning of period, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Restricted Stock Units and Performance Stock Units, vested in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted Stock Units and Performance Stock Units, vested in period, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options, exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options, exercisable, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options exercised, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options, forfeitures and expirations in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options, forfeitures and expirations in period, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options, grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value at grant date (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r345" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options, outstanding, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r322", "r345" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, outstanding, ending balance (in shares)", "periodStartLabel": "Options, outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options, outstanding, weighted average exercise price, ending (in USD per share)", "periodStartLabel": "Options, outstanding, weighted average exercise price, beginning (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r312", "r318" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails", "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options, exercises in period, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options, grants in period, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r128", "r314", "r319" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation Expense" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in usd per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Award expiration period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r337", "r347" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r345" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options, exercisable, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options, exercisable, weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options, outstanding, weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock, percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld on vesting of restricted stock (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Sell contract" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated over time.", "label": "Short-term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Weighted-average interest rate, short-term debt" } } }, "localname": "ShortTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Accrued product warranty, at end of period", "periodStartLabel": "Accrued product warranty, at beginning of period" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualCurrent": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/OtherFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual, Current", "terseLabel": "Product warranty" } } }, "localname": "StandardProductWarrantyAccrualCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/OtherFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Actual product warranty expenditures" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Charged to cost of revenues" } } }, "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r128", "r267" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Product Warranty" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r186", "r221", "r249", "r253", "r259", "r562" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails", "http://www.vareximaging.com/role/SegmentInformationAssetsDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r59", "r280" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity", "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r23", "r24", "r280", "r281", "r282" ], "lang": { "en-US": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Conversion of net parent investment into common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r23", "r24", "r280", "r282" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued under employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r280", "r282" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Common stock issued upon vesting of restricted shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r280", "r282", "r324" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options, exercises in period, value (in shares)", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity", "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r59", "r280", "r282" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "terseLabel": "Conversion of net parent investment into common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r23", "r24", "r280", "r282" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common stock issued under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r59", "r280", "r282" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r203" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Varex stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r421", "r422", "r438" ], "calculation": { "http://www.vareximaging.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedBalanceSheets", "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity", "http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r506" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r506" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r506" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r508" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Summary of Valuation Allowance [Table Text Block]" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Redeemable noncontrolling interest, equity, redemption value" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Net earnings attributable to noncontrolling interests" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityOtherChanges": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other.", "label": "Temporary Equity, Other Changes", "terseLabel": "Other" } } }, "localname": "TemporaryEquityOtherChanges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r12", "r274" ], "lang": { "en-US": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Temporary equity, redemption price per share (in eur per share)" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Temporary equity, shares outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails", "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r356", "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits balance\u2014end of fiscal year", "periodStartLabel": "Unrecognized tax benefits balance\u2013beginning of fiscal year", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxContingencyDetails", "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Subtractions based on tax positions related to a prior year" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxContingencyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r364" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxContingencyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r165", "r166", "r168", "r169", "r175", "r176", "r177" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r357" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Operating loss carryforwards, valuation allowance increase (decrease)" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r151", "r156" ], "calculation": { "http://www.vareximaging.com/role/NetEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/NetEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r150", "r156" ], "calculation": { "http://www.vareximaging.com/role/NetEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings", "http://www.vareximaging.com/role/NetEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "var_A2017ESPPMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 ESPP [Member]", "label": "2017 ESPP [Member]", "terseLabel": "2017 ESPP" } } }, "localname": "A2017ESPPMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_A2017OmnibusStockPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 Omnibus Stock Plan [Member]", "label": "2017 Omnibus Stock Plan [Member]", "terseLabel": "2017 Omnibus Stock Plan" } } }, "localname": "A2017OmnibusStockPlanMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_BuildingsandLeaseholdImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Buildings and Leasehold Improvements [Member]", "label": "Buildings and Leasehold Improvements [Member]", "terseLabel": "Buildings and leasehold improvements" } } }, "localname": "BuildingsandLeaseholdImprovementsMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "var_BusinessAcquisitionAnnualRecurringCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Annual Recurring Compensation", "label": "Business Acquisition, Annual Recurring Compensation", "terseLabel": "Annual recurring compensation (in euros per share)" } } }, "localname": "BusinessAcquisitionAnnualRecurringCompensation", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "var_BusinessAcquisitionEquityInterestIssuedOrIssuableContingentConsiderationValueAssigned": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued Or Issuable, Contingent Consideration, Value Assigned", "label": "Business Acquisition, Equity Interest Issued Or Issuable, Contingent Consideration, Value Assigned", "terseLabel": "Deferred payment, value assigned" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableContingentConsiderationValueAssigned", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "var_BusinessAcquisitionEquityInterestIssuedorIssuableContingentConsideration": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued or Issuable, Contingent Consideration", "label": "Business Acquisition, Equity Interest Issued or Issuable, Contingent Consideration", "terseLabel": "Deferred payment (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedorIssuableContingentConsideration", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "var_BusinessCombinationNumberofEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Number of Employees", "label": "Business Combination, Number of Employees", "terseLabel": "Business combination, number of employees" } } }, "localname": "BusinessCombinationNumberofEmployees", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails" ], "xbrltype": "integerItemType" }, "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities", "negatedLabel": "Accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRevenueFromContractWithCustomerLiability": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Revenue From Contract With Customer, Liability", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Revenue From Contract With Customer, Liability", "negatedLabel": "Deferred revenues" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRevenueFromContractWithCustomerLiability", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets and Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets and Goodwill", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsandGoodwill", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "var_CETTEENGmbHMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CETTEEN GmbH [Member]", "label": "CETTEEN GmbH [Member]", "terseLabel": "CETTEEN GmbH" } } }, "localname": "CETTEENGmbHMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "var_CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member]", "label": "Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member]", "terseLabel": "Canon Medical Systems Corporation" } } }, "localname": "CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "var_ContractWithCustomerAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Asset", "label": "Contract With Customer, Asset", "periodEndLabel": "Balance at September 27, 2019", "periodStartLabel": "Balance at September 29, 2018" } } }, "localname": "ContractWithCustomerAsset", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "var_ContractWithCustomerLiabilityAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Additions", "label": "Contract With Customer, Liability, Additions", "terseLabel": "Additions to refund liabilities" } } }, "localname": "ContractWithCustomerLiabilityAdditions", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "var_CustomerContractsandSupplierRelationshipsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer Contracts and Supplier Relationships [Member]", "label": "Customer Contracts and Supplier Relationships [Member]", "terseLabel": "Customer contracts and supplier relationship" } } }, "localname": "CustomerContractsandSupplierRelationshipsMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentPeriodicPaymentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment, Percentage", "label": "Debt Instrument, Periodic Payment, Percentage", "terseLabel": "Repayment percentage" } } }, "localname": "DebtInstrumentPeriodicPaymentPercentage", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "var_DebtInstrumentRepaymentPeriodFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period Five [Member]", "label": "Debt Instrument, Repayment, Period Five [Member]", "terseLabel": "Debt Instrument, Repayment, Period Five" } } }, "localname": "DebtInstrumentRepaymentPeriodFiveMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentRepaymentPeriodFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period Four [Member]", "label": "Debt Instrument, Repayment, Period Four [Member]", "terseLabel": "Debt Instrument, Repayment, Period Four" } } }, "localname": "DebtInstrumentRepaymentPeriodFourMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentRepaymentPeriodOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period One [Member]", "label": "Debt Instrument, Repayment, Period One [Member]", "terseLabel": "Debt Instrument, Repayment, Period One" } } }, "localname": "DebtInstrumentRepaymentPeriodOneMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentRepaymentPeriodThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period Three [Member]", "label": "Debt Instrument, Repayment, Period Three [Member]", "terseLabel": "Debt Instrument, Repayment, Period Three" } } }, "localname": "DebtInstrumentRepaymentPeriodThreeMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentRepaymentPeriodTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period Two [Member]", "label": "Debt Instrument, Repayment, Period Two [Member]", "terseLabel": "Debt Instrument, Repayment, Period Two" } } }, "localname": "DebtInstrumentRepaymentPeriodTwoMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtRepaymentPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Repayment Period [Axis]", "label": "Debt Repayment Period [Axis]", "terseLabel": "Debt Repayment Period [Axis]" } } }, "localname": "DebtRepaymentPeriodAxis", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "var_DebtRepaymentPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Debt Repayment Period [Axis]", "label": "Debt Repayment Period [Domain]", "terseLabel": "Debt Repayment Period [Domain]" } } }, "localname": "DebtRepaymentPeriodDomain", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DeferredIncomeTaxExpenseBenefitExcludingPortiontoAPIC": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Income Tax Expense (Benefit) Excluding Portion to APIC", "label": "Deferred Income Tax Expense (Benefit) Excluding Portion to APIC", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefitExcludingPortiontoAPIC", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "var_DeferredTaxAssetsJurisdictionalAmountGross": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Jurisdictional Amount, Gross", "label": "Deferred Tax Assets, Jurisdictional Amount, Gross", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsJurisdictionalAmountGross", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "var_DeferredTaxAssetsValuationAllowanceRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets Valuation Allowance [Roll Forward]", "label": "Deferred Tax Assets Valuation Allowance [Roll Forward]", "terseLabel": "Deferred Tax Assets Valuation Allowance [Roll Forward]" } } }, "localname": "DeferredTaxAssetsValuationAllowanceRollForward", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "var_DeferredTaxLiabilityJurisdictionalAmountGross": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Liability, Jurisdictional Amount, Gross", "label": "Deferred Tax Liability, Jurisdictional Amount, Gross", "negatedTerseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilityJurisdictionalAmountGross", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "var_DirectConversionABMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Direct Conversion AB [Member]", "label": "Direct Conversion AB [Member]", "terseLabel": "Direct Conversion AB" } } }, "localname": "DirectConversionABMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails", "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DistributionstoParent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Distributions to Parent", "label": "Distributions to Parent", "negatedTerseLabel": "Distribution to Varian Medical Systems" } } }, "localname": "DistributionstoParent", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "var_DpiXHoldingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "dpiX Holding [Member]", "label": "dpiX Holding [Member]", "terseLabel": "dpiX Holding" } } }, "localname": "DpiXHoldingMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "var_DpiXLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "dpiX LLC [Member]", "label": "dpiX LLC [Member]", "terseLabel": "dpiX LLC" } } }, "localname": "DpiXLLCMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "var_EquityMethodInvestmentsNumberofFullOwnershipMembers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investments, Number of Full Ownership Members", "label": "Equity Method Investments, Number of Full Ownership Members", "terseLabel": "Number of consortium members" } } }, "localname": "EquityMethodInvestmentsNumberofFullOwnershipMembers", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "integerItemType" }, "var_FixedCostCommitmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed Cost Commitments [Member]", "label": "Fixed Cost Commitments [Member]", "terseLabel": "Fixed Cost Commitments" } } }, "localname": "FixedCostCommitmentsMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "var_IncreaseDecreaseInContractwithCustomerAssetCostsRecoveredFromProductReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Contract with Customer, Asset, Costs Recovered From Product Returns", "label": "Increase (Decrease) In Contract with Customer, Asset, Costs Recovered From Product Returns", "terseLabel": "Costs recovered from product returns during the period" } } }, "localname": "IncreaseDecreaseInContractwithCustomerAssetCostsRecoveredFromProductReturns", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "var_IncreaseDecreaseInContractwithCustomerAssetShipmentOfProductSubjectToReturn": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Contract with Customer, Asset, Shipment Of Product Subject To Return", "label": "Increase (Decrease) In Contract with Customer, Asset, Shipment Of Product Subject To Return", "terseLabel": "Contract asset from shipments of products, subject to return during the period" } } }, "localname": "IncreaseDecreaseInContractwithCustomerAssetShipmentOfProductSubjectToReturn", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "var_IndustrialMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Industrial [Member]", "label": "Industrial [Member]", "terseLabel": "Industrial" } } }, "localname": "IndustrialMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails", "http://www.vareximaging.com/role/SegmentInformationAssetsDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "var_IntangibleAssetsAcquiredasPartofBusinessCombinationTableLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Intangible Assets Acquired as Part of Business Combination [Table] [Table]", "label": "Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]", "terseLabel": "Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]" } } }, "localname": "IntangibleAssetsAcquiredasPartofBusinessCombinationTableLineItems", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "stringItemType" }, "var_IntangibleAssetsAcquiredasPartofBusinessCombinationTableTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible Assets Acquired as Part of Business Combination [Table] [Table]", "label": "Intangible Assets Acquired as Part of Business Combination [Table] [Table]", "terseLabel": "Intangible Assets Acquired as Part of Business Combination [Table] [Table]" } } }, "localname": "IntangibleAssetsAcquiredasPartofBusinessCombinationTableTable", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails" ], "xbrltype": "stringItemType" }, "var_JointVentureInSaudiArabiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Joint Venture In Saudi Arabia [Member]", "label": "Joint Venture In Saudi Arabia [Member]", "terseLabel": "Joint Venture In Saudi Arabia" } } }, "localname": "JointVentureInSaudiArabiaMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_LondonFacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "London Facility Closing [Member]", "label": "London Facility Closing [Member]", "terseLabel": "London Facility Closing" } } }, "localname": "LondonFacilityClosingMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_LongtermDebtExcludingCurrentMaturitiesGross": { "auth_ref": [], "calculation": { "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 }, "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt Excluding Current Maturities, Gross", "label": "Long-term Debt Excluding Current Maturities, Gross", "terseLabel": "Long-term debt excluding current maturities, gross", "verboseLabel": "Non-current portion of long -term debt" } } }, "localname": "LongtermDebtExcludingCurrentMaturitiesGross", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "var_MeVisMedicalSolutionsAGMeVisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MeVis Medical Solutions AG (MeVis) [Member]", "label": "MeVis Medical Solutions AG (MeVis) [Member]", "terseLabel": "MeVis Medical Solutions AG (MeVis)" } } }, "localname": "MeVisMedicalSolutionsAGMeVisMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_MedicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical [Member]", "label": "Medical [Member]", "terseLabel": "Medical" } } }, "localname": "MedicalMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails", "http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails", "http://www.vareximaging.com/role/SegmentInformationAssetsDetails", "http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "var_NetParentInvestmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net Parent Investment [Member]", "label": "Net Parent Investment [Member]", "terseLabel": "Net Parent Investment" } } }, "localname": "NetParentInvestmentMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "var_NetTransfersFromToParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Transfers from Parent", "label": "Net Transfers From (To) Parent", "terseLabel": "Net transfers to parent" } } }, "localname": "NetTransfersFromToParent", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "var_NoncashTransferstoParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncash Transfers to Parent", "label": "Noncash Transfers to Parent", "terseLabel": "Other non-cash transfers to Varian Medical Systems, Inc." } } }, "localname": "NoncashTransferstoParent", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "var_NoncontrollingInterestIncreaseFromCapitalContribution": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Increase From Capital Contribution", "label": "Noncontrolling Interest, Increase From Capital Contribution", "terseLabel": "Capital contribution by noncontrolling interest", "verboseLabel": "Contributions from noncontrolling interests" } } }, "localname": "NoncontrollingInterestIncreaseFromCapitalContribution", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity", "http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails" ], "xbrltype": "monetaryItemType" }, "var_NumberofVariableInterestEntities": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Variable Interest Entities", "label": "Number of Variable Interest Entities", "terseLabel": "Number of variable interest entities" } } }, "localname": "NumberofVariableInterestEntities", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "integerItemType" }, "var_OtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Debt [Member]", "label": "Other Debt [Member]", "terseLabel": "Other Debt" } } }, "localname": "OtherDebtMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "var_OutstandingCommonStockPercentageDistributed": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding Common Stock, Percentage Distributed", "label": "Outstanding Common Stock, Percentage Distributed", "terseLabel": "Outstanding common stock, percentage distributed" } } }, "localname": "OutstandingCommonStockPercentageDistributed", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesDescriptionOfBusinessDetails" ], "xbrltype": "pureItemType" }, "var_PercentageOfFixedCosts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of fixed costs as defined in the agreement and determined at the beginning of each calendar year that the entity is required to pay.", "label": "Percentage Of Fixed Costs", "terseLabel": "Percentage of fixed costs" } } }, "localname": "PercentageOfFixedCosts", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "percentItemType" }, "var_PercentageOfManufacturingCapacity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of manufacturing capacity that the entity has the guaranteed right to purchase up to.", "label": "Percentage Of Manufacturing Capacity", "terseLabel": "Percentage of manufacturing capacity" } } }, "localname": "PercentageOfManufacturingCapacity", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "percentItemType" }, "var_PerkinElmerInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "PerkinElmer, Inc. [Member]", "label": "PerkinElmer, Inc. [Member]", "terseLabel": "PerkinElmer, Inc." } } }, "localname": "PerkinElmerInc.Member", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails", "http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails", "http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails", "http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails" ], "xbrltype": "domainItemType" }, "var_ReceiptofProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Receipt of Property", "label": "Receipt of Property", "terseLabel": "Transfers of property, plant and equipment from Varian Medical Systems, Inc." } } }, "localname": "ReceiptofProperty", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "var_RelatedPartyTransactionExpectedFixedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Related Party Transaction, Expected Fixed Cost", "label": "Related Party Transaction, Expected Fixed Cost", "terseLabel": "Related party transaction, expected fixed cost" } } }, "localname": "RelatedPartyTransactionExpectedFixedCost", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "var_RevolvingCreditFacilityMay2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revolving Credit Facility May 2017 [Member]", "label": "Revolving Credit Facility May 2017 [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMay2017Member", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsNarrativeDetails", "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails", "http://www.vareximaging.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "var_SantaClaraFacilityRelocationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Santa Clara Facility Relocation [Member]", "label": "Santa Clara Facility Relocation [Member]", "terseLabel": "Santa Clara Facility Relocation" } } }, "localname": "SantaClaraFacilityRelocationMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_ScheduleOfShortTermAndLongTermDebtLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule Of Short-Term And Long-Term Debt [Table]", "label": "Schedule Of Short-Term And Long-Term Debt [Line Items]", "terseLabel": "Schedule Of Short-Term And Long-Term Debt [Line Items]" } } }, "localname": "ScheduleOfShortTermAndLongTermDebtLineItems", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "var_ScheduleOfShortTermAndLongTermDebtTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Short-Term And Long-Term Debt [Table]", "label": "Schedule Of Short-Term And Long-Term Debt [Table]", "terseLabel": "Schedule Of Short-Term And Long-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermAndLongTermDebtTable", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "var_ScheduleofProRataDistributionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Pro Rata Distribution [Table]", "label": "Schedule of Pro Rata Distribution [Line Items]", "terseLabel": "Schedule of Pro Rata Distribution [Line Items]" } } }, "localname": "ScheduleofProRataDistributionLineItems", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesDescriptionOfBusinessDetails" ], "xbrltype": "stringItemType" }, "var_ScheduleofProRataDistributionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Pro Rata Distribution [Table]", "label": "Schedule of Pro Rata Distribution [Table]", "terseLabel": "Schedule of Pro Rata Distribution [Table]" } } }, "localname": "ScheduleofProRataDistributionTable", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesDescriptionOfBusinessDetails" ], "xbrltype": "stringItemType" }, "var_SharebasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Other Than Options, Grants In Period, Grant Date Fair Value", "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Other Than Options, Grants In Period, Grant Date Fair Value", "terseLabel": "Grant-date fair value of shares granted in the period" } } }, "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrantDateFairValue", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "var_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price", "periodEndLabel": "Options, outstanding, price, ending (in USD per share)", "periodStartLabel": "Options, outstanding, price, beginning (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingPrice", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period", "terseLabel": "Stock plan offering period (in months)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "var_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisablePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price", "terseLabel": "Options, exercisable, price (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisablePrice", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisePriceRangeRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price Range [Roll Forward]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price Range [Roll Forward]", "terseLabel": "Price Range" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisePriceRangeRollForward", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "var_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeituresandExpirationsinPeriodPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price", "terseLabel": "Options, forfeitures and expirations in period, price (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeituresandExpirationsinPeriodPrice", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value", "terseLabel": "Options, grants in period, grant date fair value" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodGrantDateFairValue", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "var_SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsExercisesinPeriodPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Price", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Price", "terseLabel": "Options, exercises in period, price (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsExercisesinPeriodPrice", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsGrantsinPeriodPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Price", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Price", "terseLabel": "Options, grants in period, price (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsGrantsinPeriodPrice", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_SharebasedCompensationbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSharesOutstandingMarketValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation by Share- based Payment Award, Shares Outstanding, Market Value", "label": "Share-based Compensation by Share-based Payment Award, Equity Instruments Other than Options, Shares Outstanding, Market Value", "terseLabel": "Shares outstanding, market value" } } }, "localname": "SharebasedCompensationbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSharesOutstandingMarketValue", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "var_VECImagingGmbHCo.KGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VEC Imaging GmbH & Co. KG [Member]", "label": "VEC Imaging GmbH & Co. KG [Member]", "terseLabel": "VEC Imaging" } } }, "localname": "VECImagingGmbHCo.KGMember", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails" ], "xbrltype": "domainItemType" }, "var_ValuationAllowanceDeferredTaxAssetDecreaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Decrease, Amount", "label": "Valuation Allowance, Deferred Tax Asset, Decrease, Amount", "negatedTerseLabel": "Other decreases" } } }, "localname": "ValuationAllowanceDeferredTaxAssetDecreaseAmount", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "var_ValuationAllowanceDeferredTaxAssetIncreaseAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Increase, Amount", "label": "Valuation Allowance, Deferred Tax Asset, Increase, Amount", "terseLabel": "Other increases" } } }, "localname": "ValuationAllowanceDeferredTaxAssetIncreaseAmount", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "var_ValuationAllowanceDeferredTaxAssetIncreaseFromBusinessCombinationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Increase From Business Combination, Amount", "label": "Valuation Allowance, Deferred Tax Asset, Increase From Business Combination, Amount", "terseLabel": "Increases resulting from business combinations" } } }, "localname": "ValuationAllowanceDeferredTaxAssetIncreaseFromBusinessCombinationAmount", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/TaxesOnEarningsValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "var_VarianMedicalSystemsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Varian Medical Systems, Inc. [Member]", "label": "Varian Medical Systems, Inc. [Member]", "terseLabel": "Varian Medical Systems, Inc." } } }, "localname": "VarianMedicalSystemsInc.Member", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesDescriptionOfBusinessDetails" ], "xbrltype": "domainItemType" }, "var_VirtualMediaIntegrationLtd.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Virtual Media Integration, Ltd. [Member]", "label": "Virtual Media Integration, Ltd. [Member]", "terseLabel": "Virtual Media Integration, Ltd." } } }, "localname": "VirtualMediaIntegrationLtd.Member", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.vareximaging.com/role/BusinessCombinationsVirtualMediaNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_WarrantyTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warranty Term", "label": "Warranty Term", "terseLabel": "Warranty term (in months)" } } }, "localname": "WarrantyTerm", "nsuri": "http://www.vareximaging.com/20190927", "presentation": [ "http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "durationItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5144-111524" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(1)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(3)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11374-113907" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5558-128473" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759068-111685" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02(b))", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03(b))", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r445": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=118875152&loc=SL5864739-113975" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r477": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r505": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r508": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r572": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r573": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r574": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r575": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r576": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r577": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r578": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" } }, "version": "2.1" } XML 31 R101.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION - Schedule of ASC 606 Adoption Impact On Income Statement (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Revenues, net $ 780.6 $ 773.4 $ 698.1
Cost of revenues 523.9 519.5 444.6
Taxes (benefit) on earnings 5.7 (2.6) 22.8
Net earnings attributable to Varex 15.5 $ 27.5 $ 51.6
Balance without Adoption      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Revenues, net 781.2    
Cost of revenues 524.7    
Taxes (benefit) on earnings 5.7    
Net earnings attributable to Varex $ 15.3    
XML 32 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
shares in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Income Statement [Abstract]      
Revenues, net $ 780,600,000 $ 773,400,000 $ 698,100,000
Cost of revenues 523,900,000 519,500,000 444,600,000
Gross margin 256,700,000 253,900,000 253,500,000
Operating expenses:      
Research and development 78,100,000 83,000,000.0 67,300,000
Selling, general and administrative 128,100,000 123,400,000 102,500,000
Impairment of intangible assets 4,800,000 3,000,000.0 0
Total operating expenses 211,000,000.0 209,400,000 169,800,000
Operating earnings 45,700,000 44,500,000 83,700,000
Interest income 100,000 200,000 200,000
Interest expense (21,100,000) (21,700,000) (12,300,000)
Other (expense) income, net (3,200,000) 2,700,000 3,200,000
Interest and other expenses, net (24,200,000) (18,800,000) (8,900,000)
Earnings before taxes 21,500,000 25,700,000 74,800,000
Taxes (benefit) on earnings 5,700,000 (2,600,000) 22,800,000
Net earnings 15,800,000 28,300,000 52,000,000.0
Less: Net earnings attributable to noncontrolling interests 300,000 800,000 400,000
Net earnings attributable to Varex $ 15,500,000 $ 27,500,000 $ 51,600,000
Net earnings per common share attributable to Varex      
Basic (in USD per share) $ 0.41 $ 0.73 $ 1.37
Diluted (in USD per share) $ 0.40 $ 0.72 $ 1.36
Weighted average common shares outstanding      
Basic (in shares) 38.2 37.9 37.6
Diluted (in shares) 38.6 38.4 38.0
XML 33 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Variable Interest Entities (Details)
 12 Months Ended
Sep. 27, 2019
entity
Accounting Policies [Abstract]  
Number of variable interest entities 2
XML 34 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION (Tables)
 12 Months Ended
Sep. 27, 2019
Revenue from Contract with Customer [Abstract]  
Schedule of ASC 606 Adoption Impacts
The beginning net cumulative-effect adjustment to the balance sheet for the adoption of ASC 606 is as follows:
 
Balance at
 
Adjustment Due to
 
Balance at
(In millions)
September 28, 2018
 
ASC 606
 
September 29, 2018
Assets:
 
 
 
 
 
Prepaid expenses and other current assets
$
17.1

 
$
6.4

 
$
23.5

Other assets
16.5

 
18.0

 
34.5

Liabilities and Equity:
 
 
 
 
 
Deferred revenues
13.2

 
0.3

 
13.5

Accrued liabilities
47.5

 
7.1

 
54.6

Deferred tax liabilities
23.2

 
(0.8
)
 
22.4

Other long-term liabilities
8.5

 
21.3

 
29.8

Retained earnings
62.4

 
(3.5
)
 
58.9


The following tables compare the reported consolidated balance sheet and statement of operations for fiscal year ended September 27, 2019, to the amounts that would have been reported if ASC 605 had been in effect:
 
September 27, 2019
(In millions)
Balance without Adoption
 
As Reported
Assets:
 
 
 
Prepaid expenses and other current assets
$
13.1

 
$
19.3

Other assets
$
10.0

 
$
27.5

Liabilities and equity:
 
 
 
Deferred revenues
$
9.9

 
$
10.5

Accrued liabilities
$
68.8

 
$
75.7

Deferred tax liabilities
$
9.1

 
$
8.2

Other long-term liabilities
$
12.1

 
$
32.5

Retained earnings
$
77.7

 
$
74.4


 
Twelve Months Ended September 27, 2019
(In millions)
Balance without Adoption
 
As Reported
Revenues
781.2

 
780.6

Cost of revenues
524.7

 
523.9

Taxes on earnings
5.7

 
5.7

Net earnings attributable to Varex
15.3

 
15.5
Schedule of Changes in Contract With Customer Assets And Liabilities The following table summarizes the changes in the contract assets and refund liabilities for the twelve months ended September 27, 2019:
(In millions)
Contact Assets
Balance at September 29, 2018
$
24.4

Costs recovered from product returns during the period
(6.4
)
Contract asset from shipments of products, subject to return during the period
5.7

Balance at September 27, 2019
$
23.7

(In millions)
Refund Liabilities
Balance at September 29, 2018
$
27.1

Recognition of revenue included in beginning of year refund liability
(7.0
)
Additions to refund liabilities
6.3

Balance at September 27, 2019
$
26.4
XML 35 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 36 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Cash flows from operating activities:      
Net earnings $ 15,800,000 $ 28,300,000 $ 52,000,000.0
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Share-based compensation expense 11,700,000 10,000,000.0 8,400,000
Depreciation 23,500,000 26,000,000.0 16,900,000
Amortization of intangible assets 15,700,000 16,200,000 10,500,000
Impairment of intangible assets 4,800,000 3,000,000.0 0
Other assets impairment charges 0 1,300,000 0
Inventory write-down 3,100,000 3,100,000 0
Deferred taxes (12,900,000) (7,700,000) (8,900,000)
Amortization of deferred loan costs 2,400,000 2,300,000 1,800,000
Loss (gain) from equity method investments, net of dividends received 2,300,000 (3,900,000) (1,300,000)
Other, net 800,000 700,000 1,800,000
Changes in assets and liabilities, net of effects of acquisitions:      
Accounts receivable 14,800,000 9,000,000.0 (23,100,000)
Inventories (11,100,000) (2,400,000) (4,200,000)
Prepaid expenses and other assets 4,300,000 2,000,000.0 (10,100,000)
Accounts payable (9,000,000.0) 5,200,000 4,900,000
Accrued operating liabilities and other long-term operating liabilities 10,900,000 (10,200,000) 28,100,000
Deferred revenues (5,200,000) 2,400,000 (1,600,000)
Net cash provided by operating activities 71,900,000 85,300,000 75,200,000
Cash flows from investing activities:      
Purchases of property, plant and equipment (19,800,000) (20,400,000) (20,200,000)
Acquisitions of businesses, net of cash acquired (69,500,000) (4,800,000) (271,800,000)
Investments in privately-held companies (3,900,000) 0 0
Net cash used in investing activities (93,200,000) (25,200,000) (292,000,000.0)
Cash flows from financing activities:      
Net transfers from parent 0 0 5,000,000.0
Distributions to Varian Medical Systems, Inc. 0 0 (227,100,000)
Taxes related to net share settlement of equity awards (2,100,000) (2,300,000) (1,900,000)
Borrowings under credit agreements 85,400,000 10,000,000.0 749,000,000.0
Repayments of borrowing under credit agreements (87,000,000.0) (106,000,000.0) (255,000,000.0)
Proceeds from exercise of stock options 800,000 3,800,000 2,800,000
Proceeds from shares issued under employee stock purchase plan 3,800,000 3,300,000 0
Excess tax benefits from share-based compensation 0 0 2,400,000
Payment of debt issuance costs (500,000) (400,000) (11,900,000)
Contributions from noncontrolling partner 0 1,800,000 0
Dividends paid to redeemable noncontrolling interest (500,000) (600,000) 0
Net cash (used in) provided by financing activities (100,000) (90,400,000) 263,300,000
Effects of exchange rate changes on cash and cash equivalents and restricted cash (700,000) (500,000) 900,000
Net (decrease) increase in cash and cash equivalents and restricted cash (22,100,000) (30,800,000) 47,400,000
Cash and cash equivalents and restricted cash at beginning of period 53,400,000 84,200,000 36,800,000
Cash and cash equivalents and restricted cash at end of period 31,300,000 53,400,000 84,200,000
Supplemental cash flow information:      
Cash paid for interest 19,900,000 19,300,000 9,800,000
Cash paid for income tax 8,200,000 13,800,000 6,000,000.0
Supplemental non-cash activities:      
Purchases of property, plant and equipment financed through accounts payable 1,800,000 2,000,000.0 4,000,000.0
Transfers of property, plant and equipment from Varian Medical Systems, Inc. 0 0 15,000,000.0
Other non-cash transfers to Varian Medical Systems, Inc. $ 0 $ 0 $ 1,600,000
XML 37 R99.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
OTHER COMPREHENSIVE INCOME - (Details) - USD ($)
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Changes In Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance at beginning of period $ 428,300,000 $ 379,000,000.0
Other comprehensive loss before reclassifications (10,200,000)  
Income tax benefit 2,700,000  
Ending balance 448,200,000 428,300,000
Amount reclassified out of accumulated other comprehensive income 0 0
Unrealized Gain (Loss) on Derivative Financial Instruments    
Changes In Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance at beginning of period 5,800,000  
Other comprehensive loss before reclassifications (8,300,000)  
Income tax benefit 2,100,000  
Ending balance (400,000) 5,800,000
Unrealized Gain on Defined Benefit Obligations    
Changes In Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance at beginning of period 0  
Other comprehensive loss before reclassifications (1,900,000)  
Income tax benefit 600,000  
Ending balance (1,300,000) 0
Accumulated Other Comprehensive Income    
Changes In Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance at beginning of period 5,800,000  
Ending balance $ (1,700,000) $ 5,800,000
XML 38 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details)
$ in Millions
 12 Months Ended
Sep. 27, 2019
USD ($)
Derivative [Line Items]  
Loss on derivative instruments not designated as cash flow hedges $ 1.5
Derivatives designated as cash flow hedges | Interest Rate Swap Contracts  
Derivative [Line Items]  
Recorded component of accumulated other comprehensive income (loss) that will be reclassified in the statements of comprehensive earnings over the next 12 months $ 0.1
XML 39 R91.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Sep. 27, 2019
Sep. 29, 2018
Sep. 28, 2018
Sep. 29, 2017
Sep. 30, 2016
Deferred Tax Assets:          
Inventory adjustments $ 5.6   $ 4.2    
Share-based compensation 3.1   0.8    
Product warranty 1.6   1.4    
Deferred compensation 1.1   0.9    
Net operating loss carryforwards 24.3   3.3    
Accrued vacation 1.0   1.3    
Credit carryforwards 1.9   1.8    
Other 7.5   4.7    
Deferred tax assets, gross 46.1   18.4    
Valuation allowance (18.8)   (4.0) $ (4.3) $ (2.5)
Total deferred tax assets 27.3   14.4    
Deferred Tax Liabilities:          
Acquired intangibles (19.3)   (15.2)    
Property, plant and equipment (10.6)   (14.3)    
Investments in privately held companies (3.3)   (4.1)    
Other (2.3)   (4.0)    
Total deferred tax liabilities (35.5)   (37.6)    
Net deferred tax liabilities (8.2)   (23.2)    
Deferred tax assets 27.3   14.4    
Deferred tax liabilities (35.5)   (37.6)    
Net deferred tax liabilities $ 8.2 $ 22.4 $ 23.2    
XML 40 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATIONS - PerkinElmer's Medical Imaging Narrative (Details) - PerkinElmer, Inc.
$ in Millions
May 01, 2017
USD ($)
employee
Business Acquisition [Line Items]  
Net cash paid $ 277.4
Total cash consideration $ 273.2
Business combination, number of employees | employee 280
Deferred tax liabilities noncurrent $ 31.0
Foreign Tax Authority  
Business Acquisition [Line Items]  
Goodwill expected tax deductible amount $ 35.0
XML 41 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RESTRUCTURING - Restructuring Charges Incurred (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Restructuring and Related Activities [Abstract]      
Other assets impairment charges $ 0.0 $ 1.3 $ 0.0
Inventory write-down 3.1 3.1 $ 0.0
Intangible assets impairment 4.8 3.0  
Accelerated depreciation 4.5 4.2  
Severance costs 6.2 4.3  
Facility closure costs 0.3 0.8  
Total restructuring charges $ 18.9 $ 16.7  
XML 42 R95.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION - Summary of Segment Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Segment Reporting Information [Line Items]      
Revenues, net $ 780.6 $ 773.4 $ 698.1
Gross margin 256.7 253.9 253.5
Total operating expenses 211.0 209.4 169.8
Interest and other expenses, net (24.2) (18.8) (8.9)
Earnings before taxes 21.5 25.7 74.8
Taxes (benefit) on earnings 5.7 (2.6) 22.8
Net earnings 15.8 28.3 52.0
Less: Net earnings attributable to noncontrolling interests 0.3 0.8 0.4
Net earnings attributable to Varex 15.5 27.5 51.6
Medical      
Segment Reporting Information [Line Items]      
Revenues, net 596.8 602.0 556.9
Gross margin 188.9 190.5 193.6
Industrial      
Segment Reporting Information [Line Items]      
Revenues, net 183.8 171.4 141.2
Gross margin $ 67.8 $ 63.4 $ 59.9
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE BENEFIT PLANS
 12 Months Ended
Sep. 27, 2019
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
Varex’s 401(k) plan became effective on January 1, 2017. Varex’s 401(k) plan is intended to be qualified under Section 401(a) of the Code with the 401(k) plan’s related trust intended to be tax exempt under Section 501(a) of the Code and intended for all full-time employees in the United States. This plan allows employees to contribute a portion of their pretax salary up to the maximum dollar limitation prescribed by the Internal Revenue Service. Prior to Varex's 401(k) plan becoming effective, Company employees participated in Varian's 401(k) plan. The Company made matching contributions to the plan totaling $6.7 million, $6.5 million and $4.3 million in fiscal years 2019, 2018 and 2017, respectively.
The Company also maintains defined benefit plans for employees located outside the US. The net pension liability is included in non-current liability on the Company's consolidated balance sheets and totaled $5.5 million and $3.3 million as of September 27, 2019 and September 28, 2018, respectively. The Company’s net periodic benefit costs for the Company’s defined benefit plans was not material for fiscal years 2019, 2018 and 2017.
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Sep. 27, 2019
Accounting Policies [Abstract]  
Basis of Presentation The accompanying consolidated financial statements are audited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Prior to January 28 2017, the date of separation and distribution, the financial statements were prepared on a stand-alone basis and were derived from Varian’s consolidated financial statements and records as it operated as part of Varian prior to the distribution, in conformity with GAAP.
Consolidation
All transactions between the Company and Varian prior to the separation have been included in the accompanying consolidated financial statements. All intercompany transactions while the Company operated as part of Varian were considered to be effectively settled for cash and are reflected as a component of financing activities as net transfers from (to) Varian in the consolidated statements of cash flows at the time the transactions were recorded.
Prior to the separation, the Company was dependent upon Varian for its working capital and financing requirements, as Varian uses a centralized approach to cash management and financing of its operations. Financial transactions relating to the Company were accounted for through the net parent investment account. Cash and cash equivalents held by Varian were not allocated to the Company.
Net parent investment in the consolidated statements of equity represents Varian’s historical investment in the Company, the net effect of transactions with and allocations from Varian and the Company’s accumulated earnings.
Reclassification
Reclassification
The Company has reclassified $3.0 million from selling, general and administrative expense to impairment of intangible assets for the year ended September 28, 2018, to conform to the current year's presentation. Such reclassifications had no impact on net earnings as previously reported.
Segment Reporting
Segment Reporting
The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its CEO, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance.
Fiscal Year
Fiscal Year
The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2019 was the 52-week period that ended on September 27, 2019. Fiscal year 2018 was the 52-week period that ended on September 28, 2018. Fiscal year 2017 was the 52-week period that ended on September 29, 2017.
Variable Interest Entities
Variable Interest Entities
For entities in which the Company has variable interests, the Company focuses on identifying which entity has the power to direct the activities that most significantly impact the variable interest entity’s economic performance and which enterprise has the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities and results of operations of the variable interest entity will be included in the Company’s consolidated financial statements. As of September 27, 2019, the Company had two variable interest entities neither of which were consolidated.
Use of Estimates Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.
Cash and Cash Equivalents and Restricted Cash
Cash and Cash Equivalents
The Company considers currency on hand, demand deposits, time deposits and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.
Restricted Cash
Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is
included in other assets on the consolidated balance sheet.
Fair Value
Fair Value
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. There is a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or, other inputs that are observable or can be corroborated by observable market data.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Derivative instruments and hedging activities
Derivative instruments and hedging activities
The Company records all derivatives on the balance sheet at fair value. Derivatives designated as a hedge are recorded on the Consolidated Balance Sheets at fair value as of the reporting date. For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss and reclassified from accumulated other comprehensive loss into earnings when the hedged transaction affects earnings.  For derivatives that are designated and qualify as net investment hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss. Time value is excluded and the cash payments are recognized as an adjustment to interest expense. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.
Concentration of Risk
Concentration of Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier.
Inventories
Inventories
Inventories are valued at the lower of cost or net realizable value. Costs include materials, labor and manufacturing overhead
and is computed using standard cost (which approximates actual cost) on a first-in-first-out basis. The Company evaluates the carrying
value of its inventories taking into consideration such factors as historical and anticipated future sales compared to quantities on hand
and the prices the Company expects to obtain for products in its various markets. The Company adjust excess and obsolete
inventories to net realizable value and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues.
Property, Plant and Equipment, net
Property, Plant and Equipment, net
Property, plant and equipment are stated at cost, net of accumulated depreciation. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation are computed using the straight-line method over the estimated useful lives of the assets. Land is not subject to depreciation, but land improvements are depreciated over fifteen years. Land leasehold rights and leasehold improvements are depreciated over the lesser of their estimated useful lives or remaining lease terms. Buildings are depreciated over twenty years. Machinery and equipment are depreciated over their estimated useful lives, which range from three years to seven years. Assets subject to lease are depreciated over the lesser of their estimated useful lives or remaining lease terms. Estimated useful lives are periodically reviewed and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted, and an impairment assessment may be performed on the recoverability of the carrying amounts. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts.
Investments
Investments
The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in these investments. Distributions received from an equity method investment are classified using the cumulative earnings approach. Under the cumulative earnings approach, distributions up to the amount of cumulative equity in earnings recognized will be treated as returns on investment as operating cash flows and those in excess of that amount will be treated as returns of investment as investing cash flows. The Company monitors these equity investments for impairment and makes appropriate reductions in carrying values if the Company determines that impairment charges are required based primarily on the financial condition and near-term prospects of these companies.
Goodwill and Intangible Assets
Goodwill and Intangible Assets
Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. Purchased intangible assets are carried at cost, net of accumulated amortization, and are included in intangible assets in the Company's consolidated balance sheets. Intangible assets with finite lives are amortized over their estimated useful lives of primarily two years to seven years using the straight-line method.
Impairment of Long-lived Assets, Intangible Assets and Goodwill
Impairment of Long-lived Assets, Intangible Assets and Goodwill
The Company reviews long-lived assets and identifiable intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. The Company assesses these assets for impairment based on their estimated undiscounted future cash flows. If the carrying value of the assets exceeds the estimated future undiscounted cash flows, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets.
The Company evaluates goodwill and indefinite lived intangible assets for impairment at least annually at the beginning of the fourth quarter of each fiscal year or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company performs a step one analysis, which consists of a comparison of the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit. The Company determines the fair value of its reporting units based on a combination of income and market approaches. The income approach is based on the present value of estimated future cash flows of the reporting units, and the market approach is based on a market multiple calculated for each reporting unit based on market data of other companies engaged in similar business. If the carrying amount of the reporting unit is in excess of its fair value, step two requires the comparison of the implied fair value of the reporting unit’s goodwill against the carrying amount of the reporting unit’s goodwill. Any excess of the carrying value of the reporting unit’s goodwill over the implied fair value of the reporting unit’s goodwill is recorded as an impairment loss. The impairment test for intangible assets with indefinite useful lives, if any, consists of a comparison of fair value to carrying value, with any excess of carrying value over fair value being recorded as an impairment loss.
Loss Contingencies
Loss Contingencies
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits and other loss contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent an unfavorable outcome is determined to be probable and the losses can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss.
Product Warranty
Product Warranty
The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
Allowance for Doubtful Accounts
Allowance for Doubtful Accounts
The Company evaluates the creditworthiness of customers prior to authorizing shipment for all major sale transactions. On a quarterly basis, the Company evaluates aged items in the accounts receivable aging report and provide an allowance in an amount deemed adequate for doubtful accounts. If the evaluation of customers’ financial conditions does not reflect a future ability to collect outstanding receivables, additional provisions may be needed.
Share-Based Compensation Expense
Share-Based Compensation Expense
The Company has an equity-based incentive plan that provides for the grant of nonqualified stock options and restricted stock units to directors, officers and other employees. The Company also permits employees to purchase shares under the Varex employee stock purchase plan. Prior to the separation, the Company’s employees historically participated in Varian’s equity-based incentive plans. Share-based compensation expense through the date of separation included allocations to the Company based on the awards and terms previously granted to its employees as well as an allocation of Varian’s corporate and shared functional employee expenses.
The Company values stock options granted and the option component of the shares of common stock purchased under the equity-based incentive plans and stock purchased under the employee stock purchase plan using the Black-Scholes option-pricing model. Share-based compensation expense for restricted stock units is measured using the fair value of the Company’s stock on the date of grant and is amortized over the award’s respective service period. The Black-Scholes option-pricing model requires the input of certain assumptions, and changes in the assumptions can materially affect the fair value estimates of share-based payment awards.
The Company measures and recognizes expense for all share-based payment awards based on their fair values. Share-based compensation expense recognized in the consolidated statements of earnings includes compensation expense for the share-based payment awards based on the grant date fair value estimated in accordance with the guidance on share-based compensation. Share-based compensation expense recognized is based on the value of the portion of share-based payment awards that is ultimately expected to vest. The Company attributes the value of share-based compensation to expense using the straight-line method. The Company considers only the direct tax impacts of share-based compensation awards when calculating the amount of tax windfalls or shortfalls.
Research and Development
Research and Development
Research and development costs have been expensed as incurred. These costs primarily include employees’ compensation, consulting fees and material costs.
Software Development Costs
Software Development Costs
Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized, as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility.
Taxes on Earnings
Taxes on Earnings
Current income tax expense is the amount of income taxes expected to be payable for the current year. Deferred income tax liabilities or assets are established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. In addition, we provide reserves for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance for accounting for income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense.
On December 22, 2017, the U.S. Government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (“U. S. Tax Reform”). U.S. Tax Reform significantly revised the U.S. corporate income tax structure including a lower corporate statutory rate and changes to the way foreign earnings are taxed. U.S. GAAP requires that the impact of tax legislation be recognized in the period in which the law is enacted. In accordance with these rules, we are including the impact of certain provisions of U.S. Tax Reform to the extent they are effective during the current reporting period.
Foreign Currency Translation
Foreign Currency Translation
The Company uses the U.S. Dollar predominately as the functional currency of its foreign operations. Gains and losses from remeasurement of foreign currency balances into U.S. Dollars are included in the consolidated statements of earnings. For the foreign subsidiary where the local currency is the functional currency, translation adjustments of foreign currency financial statements into U.S. dollars are recorded to a separate component of accumulated other comprehensive (loss) earnings.
Accounting Standards Recently Adopted, Recent Accounting Standards Updates Not Yet Effective
Accounting Standards Recently Adopted
In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which requires that the statement of cash flows explain the change in the total amount of restricted cash during the period and other additional disclosures. The Company adopted ASU 2016-18 in the first quarter of 2019 using the retrospective transition method and the Company's consolidated statements of cash flows have been retrospectively adjusted to reflect restricted cash balances. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-18.
The Company adopted ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which was issued to reduce the diversity in practice in how certain transactions are classified in the statement of cash flows. The Company adopted ASU 2016-15 in the first quarter of 2019 retrospectively. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-15.

The Company adopted ASC 606 as of September 29, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. The Company recorded a net reduction to retained earnings of $4.1 million, net of tax, as of September 29, 2018 due to the impact of adopting ASC 606. During the second quarter of 2019 the Company recorded an increase to retained earnings of $0.6 million, net of tax, to correct an error that was not quantitatively or qualitatively material to the current period, related to the adoption of ASC 606. The net cumulative impact of adopting ASC 606 was $3.5 million, net of tax. Refer to Note 18. Revenue Recognition, included in this report report for the detailed impact of adopting ASC 606.

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which amends the application of hedge accounting and improves financial reporting of hedging relationships to more accurately present the economic effects of risk management activities in the financial statements. The ASU is effective for public companies for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company early adopted the provisions of ASU 2017-12 during the quarter ended September 27, 2019, using the modified retrospective method. The adoption did not have an impact on the consolidated financial statements.
Recent Accounting Standards Updates Not Yet Effective
In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from U.S. federal tax legislation commonly referred to as the Tax Cuts and Jobs Act, which was enacted in December 2017 (the “2017 Tax Act”). ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021, and must be applied on a modified retrospective basis. The Company is currently evaluating the potential impact of this standard.
In February 2016, the FASB issued ASU 2016-02 on accounting for leases. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new standard will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of earnings. The new standard is required to be adopted using a modified retrospective method to each prior reporting period presented with various optional practical expedients. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2020 with early adoption permitted. The Company has not completed its assessment of the new standard, but anticipate that the most substantial change to its consolidated financial statements will be a gross-up of its total assets and liabilities. The adoption is not expected to materially impact our results of operations in the upcoming fiscal years and interim periods. The Company will continue to monitor the overall impact of adoption and update our disclosures as appropriate.
Revenue from Contract with Customer
Shipping and Handling Costs
Shipping and handling costs are included as a component of cost of revenues.
Revenue Recognition
Effective September 29, 2018, the Company adopted the requirements of Accounting Standards Update (“ASU”) 2014-09 and related amendments, Revenue from Contracts with Customers (“ASC 606”), which superseded all prior revenue recognition methods and industry-specific guidance. See “Recently Adopted Accounting Pronouncements” below.
The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts.
The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the
Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products.
The Company determines revenue recognition through the following steps:
•
Identification of the contract, or contracts, with a customer
•
Identification of the performance obligations in the contract
•
Determination of the transaction price
•
Allocation of the transaction price to the performance obligations in the contract
•
Recognition of revenue when, or as, a performance obligation is satisfied
Deferred Revenues
Deferred revenue primarily represents (i) the amount received applicable to non-software products for which parts
and services under the warranty contracts have not been delivered, and (ii) the amount received for service contracts for
which the services have not been rendered.
The Company adopted ASC 606 on September 29, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for fiscal year 2019 reflect the application of ASC 606 guidance while the reported results for fiscal year 2018 were prepared under the guidance of ASC 605, “Revenue Recognition.” The primary impacts of the adoption include: (1) recording a separate contract liability and contract asset related to the sale of X-ray tubes that were sold with an option for the customer to require the Company to repurchase specific parts of the X‑ray tube at a specific price; and (2) recording a liability related to the deferral of revenue for service type warranties that are provided to certain customers who purchase Linatron® X-ray accelerators.
The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component, if, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are included as a component of cost of revenues; and (5) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.
Transaction price and allocation to performance obligations
Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available.
The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.
XML 45 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Statement of Comprehensive Income [Abstract]      
Net earnings $ 15.8 $ 28.3 $ 52.0
Other comprehensive (loss) earnings, net of tax:      
Unrealized (loss) gain on interest rate swap contracts (6.2) 5.2 0.6
Unrealized (loss) gain on defined benefit obligations (1.3) (0.2) 0.2
Other comprehensive (loss) earnings, net of tax (7.5) 5.0 0.8
Comprehensive earnings 8.3 33.3 52.8
Less: Comprehensive earnings attributable to noncontrolling interests 0.3 0.8 0.4
Comprehensive earnings attributable to Varex $ 8.0 $ 32.5 $ 52.4
XML 46 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) - USD ($)
$ in Millions
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Sep. 30, 2016
Accounting Policies [Abstract]        
Cash and cash equivalents $ 29.9 $ 51.9 $ 83.3  
Restricted cash 1.4 1.5 0.9  
Cash and cash equivalents and restricted cash as reported per statement of cash flows $ 31.3 $ 53.4 $ 84.2 $ 36.8
XML 47 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)
Jan. 28, 2017
Varian Medical Systems, Inc.  
Schedule of Pro Rata Distribution [Line Items]  
Outstanding common stock, percentage distributed 1
XML 48 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Net Parent Investment
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Total Varex Equity
Noncontrolling Interests
Shares outstanding, beginning of period (in shares) at Sep. 30, 2016   0            
Balance at beginning of period at Sep. 30, 2016 $ 526.0 $ 0.0 $ 0.0 $ 526.0   $ 0.0 $ 526.0 $ 0.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net earnings 51.6     16.5   35.1 51.6  
Net transfers to parent 18.4     18.4     18.4  
Other (0.2)   (0.2)       (0.2)  
Distribution to Varian Medical Systems (227.1)     (227.1)     (227.1)  
Conversion of net parent investment into common stock (in shares)   37,400,000            
Conversion of net parent investment into common stock 0.0 $ 0.4 333.4 (333.8)        
Exercise of stock options (in shares)   100,000            
Exercise of stock options 2.8   2.8       2.8  
Common stock issued upon vesting of restricted shares (in shares)   200,000            
Shares withheld on vesting of restricted stock (in shares)   (100,000)            
Shares withheld on vesting of restricted stock (1.9)   (1.9)       (1.9)  
Share-based compensation 6.2   6.2       6.2  
Unrealized gain on interest rate swap contracts, net of tax 0.6       $ 0.6   0.6  
Unrealized gain (loss) on defined benefit obligations 0.2       0.2   0.2  
Tax impacts to APIC related to share-based award activity 2.4   2.4       2.4  
Shares outstanding, end of period (in shares) at Sep. 29, 2017   37,600,000            
Ending balance at Sep. 29, 2017 379.0 $ 0.4 342.7 0.0 0.8 35.1 379.0 0.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net earnings 27.8         27.5 27.5 0.3
Other (0.2)         (0.2) (0.2)  
Exercise of stock options (in shares)   200,000            
Exercise of stock options 3.8   3.8       3.8  
Common stock issued upon vesting of restricted shares (in shares)   200,000            
Shares withheld on vesting of restricted stock (in shares)   (100,000)            
Shares withheld on vesting of restricted stock (2.2)   (2.2)       (2.2)  
Share-based compensation 10.0   10.0       10.0  
Unrealized gain on interest rate swap contracts, net of tax 5.2       5.2   5.2  
Unrealized gain (loss) on defined benefit obligations (0.2)       (0.2)   (0.2)  
Common stock issued under employee stock purchase plan (in shares)   100,000            
Common stock issued under employee stock purchase plan 3.3   3.3       3.3  
Capital contribution by noncontrolling interest $ 1.8             1.8
Shares outstanding, end of period (in shares) at Sep. 28, 2018 38,026,597 38,000,000.0            
Ending balance at Sep. 28, 2018 $ 428.3 $ 0.4 357.6 0.0 5.8 62.4 426.2 2.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net earnings $ 15.3         15.5 15.5 (0.2)
Exercise of stock options (in shares) 35,000 0            
Exercise of stock options $ 0.8   0.8       0.8  
Common stock issued upon vesting of restricted shares (in shares)   200,000            
Shares withheld on vesting of restricted stock (in shares)   0            
Shares withheld on vesting of restricted stock (2.1)   (2.1)       (2.1)  
Share-based compensation 11.7   11.7       11.7  
Unrealized gain on interest rate swap contracts, net of tax (6.2)       (6.2)   (6.2)  
Unrealized gain (loss) on defined benefit obligations (1.3)       (1.3)   (1.3)  
Common stock issued under employee stock purchase plan (in shares)   200,000            
Common stock issued under employee stock purchase plan 3.8   3.8       3.8  
Noncontrolling interest acquired/consolidated $ 1.4             1.4
Shares outstanding, end of period (in shares) at Sep. 27, 2019 38,371,305 38,400,000            
Ending balance at Sep. 27, 2019 $ 448.2 $ 0.4 $ 371.8 $ 0.0 $ (1.7) 74.4 444.9 $ 3.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Effect of adoption of ASC 606 $ (3.5)         $ (3.5) $ (3.5)  
XML 49 R104.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUBSEQUENT EVENTS - (Details) - Revolving Credit Facility - USD ($)
Oct. 08, 2019
Oct. 10, 2018
May 01, 2017
Subsequent Event [Line Items]      
Revolving credit commitment     $ 400,000,000.0
Subsequent Event      
Subsequent Event [Line Items]      
Permanent reduction in the revolving credit commitment $ (25,000,000.0)    
Revolving credit commitment 125,000,000.0    
Revolving Credit Facility      
Subsequent Event [Line Items]      
Permanent reduction in the revolving credit commitment   $ (50,000,000.0)  
Revolving credit commitment   $ 150,000,000.0 $ 200,000,000.0
Revolving Credit Facility | Subsequent Event      
Subsequent Event [Line Items]      
Permanent reduction in the revolving credit commitment 25,000,000.0    
Revolving credit commitment $ 125,000,000.0    
XML 50 R100.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION - Schedule of Balance Sheet Adjustment for ASC 606 Adoption (Details) - USD ($)
$ in Millions
Sep. 27, 2019
Mar. 29, 2019
Dec. 28, 2018
Sep. 29, 2018
Sep. 28, 2018
Assets          
Prepaid expenses and other current assets $ 19.3     $ 23.5 $ 17.1
Other assets 27.5     34.5 16.5
Liabilities, redeemable noncontrolling interests and stockholders' equity          
Deferred revenues 10.5     13.5 13.2
Accrued liabilities 75.7     54.6 47.5
Deferred tax liabilities 8.2     22.4 23.2
Other long-term liabilities 32.5     29.8 8.5
Retained earnings 74.4     58.9 62.4
Balance without Adoption          
Assets          
Prepaid expenses and other current assets 13.1       17.1
Other assets 10.0       16.5
Liabilities, redeemable noncontrolling interests and stockholders' equity          
Deferred revenues 9.9       13.2
Accrued liabilities 68.8       47.5
Deferred tax liabilities 9.1       23.2
Other long-term liabilities 12.1       8.5
Retained earnings 77.7       $ 62.4
ASU 2014-09 | Adjustment Due to ASC 606          
Assets          
Prepaid expenses and other current assets       6.4  
Other assets       18.0  
Liabilities, redeemable noncontrolling interests and stockholders' equity          
Deferred revenues       0.3  
Accrued liabilities       7.1  
Deferred tax liabilities       (0.8)  
Other long-term liabilities       21.3  
Retained earnings $ (3.5) $ 0.6 $ (4.1) $ (3.5)  
XML 51 R90.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Income Tax Disclosure [Abstract]      
Federal statutory income tax rate 21.00% 24.50% 35.00%
Deferred tax liabilities of undistributed foreign earnings $ 0.1    
Net operating loss carryforwards 24.3 $ 3.3  
Operating loss carryforwards, that expire 4.4    
Operating loss carryforwards, that do not expire 19.9    
Operating loss carryforwards, valuation allowance increase (decrease) 14.8 (0.3)  
Cash paid for income tax 8.2 13.8 $ 6.0
Unrecognized tax benefits 0.6 0.6 $ 0.5
Income tax penalties and interest expense 0.1 0.0  
Unrecognized tax benefits, income tax penalties and interest accrued $ 0.1 $ 0.0  
XML 52 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATIONS - Virtual Media Narrative (Details)
$ in Millions
Aug. 31, 2018
USD ($)
Virtual Media Integration, Ltd.  
Business Acquisition [Line Items]  
Total cash consideration $ 4.8
XML 53 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RESTRUCTURING - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Restructuring Cost and Reserve [Line Items]    
Restructuring and impairment charges $ 18.9 $ 16.7
Other unrelated restructuring costs 2.8 0.8
London Facility Closing    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   1.7
Santa Clara Facility Relocation    
Restructuring Cost and Reserve [Line Items]    
Restructuring and impairment charges 16.1 $ 14.2
Minimum | Santa Clara Facility Relocation    
Restructuring Cost and Reserve [Line Items]    
Expected additional costs to be incurred 8.1  
Maximum | Santa Clara Facility Relocation    
Restructuring Cost and Reserve [Line Items]    
Expected additional costs to be incurred $ 12.1  
XML 54 R94.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION - Narrative (Details)
 12 Months Ended
Sep. 27, 2019
segment
Segment Reporting [Abstract]  
Number of operating segments 2
XML 55 R98.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE BENEFIT PLANS - (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Retirement Benefits [Abstract]      
Employer discretionary contribution amount $ 6.7 $ 6.5 $ 4.3
Defined benefit pension plan liability $ 5.5 $ 3.3  
XML 56 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) - Derivatives designated as cash flow hedges - Designated as Hedging Instrument
$ in Millions
Sep. 27, 2019
USD ($)
derivative
Interest Rate Swap Contracts  
Derivative [Line Items]  
Number of Instruments | derivative 6
Notional Value | $ $ 264.4
Cross Currency Swap Contracts  
Derivative [Line Items]  
Number of Instruments | derivative 4
Notional Value | $ $ 77.7
XML 57 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION
 12 Months Ended
Sep. 27, 2019
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company has two reportable operating segments Medical and Industrial. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, who is also its CODM, evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin. The operating and reportable segment structure provides alignment between business strategies and operating results.
Description of Segments
The Medical segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy and computer-aided detection. The Company provides a broad range of X-ray imaging components for Medical customers including X-ray tubes, digital flat panel detectors, generators, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys. The Company’s X-ray imaging components are primarily sold to imaging system OEM customers that incorporate them into their medical diagnostic, radiation therapy, dental, veterinary and industrial imaging systems. The Company also sells its X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.
The Industrial segment designs, manufactures, sells and services products for use in the security and industrial inspection applications, such as airport security, cargo screening at ports and borders and nondestructive examination in a variety of applications. The products include Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high voltage connectors and image processing software that we generally sell to OEM customers that incorporate these products into their inspection systems.
Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.
Information related to the Company’s segments is as follows:
 
Fiscal Year
(In millions)
2019
 
2018
 
2017
Revenues
 
 
 
 
 
Medical
$
596.8

 
$
602.0

 
$
556.9

Industrial
183.8

 
171.4

 
141.2

Total revenues
780.6

 
773.4

 
698.1

Gross margin
 
 
 
 
 
Medical
188.9

 
190.5

 
193.6

Industrial
67.8

 
63.4

 
59.9

Total gross margin
256.7

 
253.9

 
253.5

Total operating expenses
211.0

 
209.4

 
169.8

Interest and other expenses, net
(24.2
)
 
(18.8
)
 
(8.9
)
Earnings before taxes
21.5

 
25.7

 
74.8

Taxes (benefit) on earnings
5.7

 
(2.6
)
 
22.8

Net earnings
15.8

 
28.3

 
52.0

Less: Net earnings attributable to noncontrolling interests
0.3

 
0.8

 
0.4

Net earnings attributable to Varex
$
15.5

 
$
27.5

 
$
51.6


The following table summarizes the Company’s total assets by its reportable segments:
(In millions)
September 27, 2019
 
September 28, 2018
Identifiable assets:
 
 
 
Medical
$
794.3

 
$
770.6

Industrial
244.6

 
217.3

Total reportable segments
$
1,038.9

 
$
987.9


Geographic Information
 
Revenues
 
Property, plant and equipment, net
 
Fiscal Years
 
Fiscal Years
(In millions)
2019
 
2018
 
2017
 
2019
 
2018
United States
$
275.3

 
$
268.8

 
$
231.9

 
$
122.6

 
$
127.9

Latin America
7.3

 
7.0

 
7.9

 
—

 
—

EMEA
269.0

 
254.5

 
219.5

 
11.4

 
8.7

APAC
229.0

 
243.1

 
238.8

 
8.3

 
8.3

Total company
$
780.6

 
$
773.4

 
$
698.1

 
$
142.3

 
$
144.9


The Company operates various manufacturing and marketing operations outside the United States. Latin America includes Brazil and Mexico. EMEA includes Europe, Russia, the Middle East, India and Africa. APAC includes Asia and Australia. Revenues by region are based on the known final destination of products sold.
XML 58 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUBSEQUENT EVENTS
 12 Months Ended
Sep. 27, 2019
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
On October 1, 2019, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of October 8, 2019, the Company was permanently reducing the revolving credit commitment under the Credit Agreement by $25.0 million to $125.0 million. The reduction in the revolving credit commitment will also reduce the fees paid by the Company in connection with such commitment.
XML 59 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RELATED-PARTY TRANSACTIONS
 12 Months Ended
Sep. 27, 2019
Related Party Transactions [Abstract]  
RELATED-PARTY TRANSACTIONS RELATED-PARTY TRANSACTIONS
Investment in Privately-Held Companies
The Company has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a four-member consortium that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon based thin film transistor arrays for digital flat panel image detectors. In accordance with the dpiX Holding Agreement, net profits or losses are allocated to the members, in accordance with their ownership interests.
The equity investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated until realized by the Company. In fiscal years 2019, 2018 and 2017, the Company recorded (loss) and income on the equity investment in dpiX Holding of $(1.1) million, $3.4 million and $0.8 million, respectively. Income and loss on the equity investment in dpiX Holding is included in other (expense) income, net in the consolidated statements of earnings. The carrying value of the equity investment in dpiX Holding, which was included in investments in privately-held companies on the consolidated balance sheets, was $48.1 million and $48.9 million at September 27, 2019 and September 28, 2018, respectively.
In fiscal years 2019, 2018 and 2017, the Company purchased glass transistor arrays from dpiX totaling $23.5 million, $19.3 million and $24.7 million, respectively. These purchases of glass transistor arrays are included as a component of inventories on the consolidated balance sheets or cost of revenues in the consolidated statements of earnings for these fiscal years.
As of September 27, 2019 and September 28, 2018, the Company had accounts payable to dpiX totaling $3.6 million and $3.7 million, respectively.
In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides the Company with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires the Company to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of September 27, 2019, the Company estimated it has fixed cost commitments of $3.7 million related to this amended agreement through the remainder of calendar year 2019. The fixed cost commitment for future periods will be determined and approved by the dpiX board of directors at the beginning of each calendar year. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).
The Company has determined that dpiX is a variable interest entity because at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to direct the activities of dpiX and therefore is not the primary beneficiary of dpiX. The Company’s exposure to loss as a result of its involvement with dpiX is limited to the carrying value of the Company’s investment of $48.1 million and fixed cost commitments of $3.7 million.
In November 2018, the Company and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging Verwaltungsgesellschaft GmbH (“VEC”), a joint venture formed to develop technology to be used in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members, in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method. The Company has made contributions totaling $2.9 million, and has committed to contribute an additional $2.2 million, as milestones are achieved, and to provide certain full time employees to support prototyping and manufacturing activities in exchange for a 50% interest in VEC. CETTEEN made contributions of certain assets including intellectual property in exchange for a 50% interest in VEC. The Company's investment in VEC was $2.0 million as of September 27, 2019.
XML 60 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
 12 Months Ended
Sep. 27, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.
The Company records all derivatives on the consolidated balance sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.    The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. The Company does not offset fair value amounts recognized for derivative instruments in its consolidated balance sheets for presentation purposes.
Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.
Derivatives Designated as Hedging Instruments - Cash Flow Hedges
The Company uses interest rate swap contracts as cash flow hedges to manage its exposure to fluctuations in LIBOR interest rates. Interest rate swap contracts hedging variable rate debt effectively fix the LIBOR component of its interest rate for a specific period of time.
As of September 27, 2019, the Company had the following outstanding derivatives designated as cash flow hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Interest Rate Swap Contracts
6
 
$
264.4


The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for cash flow hedges:
 
Amount of Gain or (Loss) Recognized in OCI on Derivative
Fiscal Year Ended
 
Location of Gain or (Loss) Reclassified from Accumulated OCI into Income
 
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income
Fiscal Year Ended
(In millions)
2019
 
2018
 
2017
 
 
2019
 
2018
 
2017
Interest Rate Swap Contracts
$
(6.3
)
 
$
6.9

 
$
0.6

 
Interest expense
 
$
1.9

 
$
0.1

 
$
(0.3
)
The Company expects that $0.1 million of the accumulated other comprehensive (loss) income related to cash flow hedges will be realized in pre-tax earnings over the next 12 months, but the amount will vary depending on interest rates.
These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded.
 
Derivative Assets
 
Derivative Liabilities
(In millions)
 
 
September 27, 2019
 
September 28, 2018
 
 
 
September 27, 2019
 
September 28, 2018
Derivatives designated as cash flow hedges
Balance sheet location
 
 
 
 
 
Balance sheet location
 
 
 
 
Interest rate swap contracts
Other current assets
 
$
—

 
$
2.2

 
Other current liabilities
 
$
—

 
$
—

Interest rate swap contracts
Other non-current assets
 
—

 
5.5

 
Other non-current liabilities
 
(0.5
)
 
—

 
 
 
$
—

 
$
7.7

 
 
 
$
(0.5
)
 
$
—


Derivatives Designated as Hedging Instruments - Net Investment Hedges
The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly-owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive (loss) income along with the foreign currency translation adjustments on those investments. As of September 27, 2019, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Cross Currency Swap Contracts
4
 
$
77.7


The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
 
Amount of Gain or (Loss) Recognized in OCI on Derivative
Fiscal Year Ended
 
Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
 
Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
(In millions)
2019
 
2018
 
2017
 
 
2019
 
2018
 
2017
Cross Currency Swap Contracts
$
(0.2
)
 
$
—

 
$
—

 
Interest expense
 
$
0.2

 
$
—

 
$
—

These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:
 
Derivative Assets
 
Derivative Liabilities
(In millions)
 
 
September 27, 2019
 
September 28, 2018
 
 
 
September 27, 2019
 
September 28, 2018
Derivatives designated as net investment hedges
Balance sheet location
 
 
 
 
 
Balance sheet location
 
 
 
 
Cross currency swap contracts
Other current assets
 
—

 
—

 
Other current liabilities
 
(0.2
)
 
—

 
 
 
$
—

 
$
—

 
 
 
$
(0.2
)
 
$
—


Balance Sheet Hedges
The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily cash, third-party accounts receivable, accounts payable, and intercompany receivables and payables. These forward contracts expire within 30 days. These forward contracts are not designated for hedge accounting treatment, therefore, the change in fair value of these derivatives is recorded as a component of other income (expense) and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense). The effect of derivative instruments not designated as hedges for fiscal year 2019 was a loss of $1.5 million, which was primarily related to the purchase price hedge established following the announcement of the Company's planned acquisition of Direct Conversion. The Company does not, and does not intend to use derivative financial instruments for speculative or trading purposes.
The following table shows the notional amounts of outstanding foreign currency contracts entered into under its balance sheet hedge program as of September 27, 2019:
 
Notional Value of Derivatives not Designated as Hedging Instruments:
In millions
Buy contracts
 
Sell contract
Japanese yen
$
0.9

 
$
—

Swiss franc
—

 
(1.0
)
Chinese renminbi
1.8

 
—

Euro
8.8

 
—

 
$
11.5

 
$
(1.0
)
XML 61 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Sep. 27, 2019
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Lease Commitments
At September 27, 2019, the Company was committed to minimum rentals under non-cancelable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and thereafter, as follows: $7.5 million, $5.4 million, $4.7 million, $1.8 million, $0.9 million, and $0.2 million, respectively. Rental expenses were $5.1 million, $5.3 million, and $4.0 million for fiscal years 2019, 2018 and 2017, respectively.
Other Commitments
See Note 3. Related Party Transactions, included in this report, for additional information about the Company’s commitments to dpiX.
See Note 12. Redeemable Noncontrolling Interests & Noncontrolling Interests, included in this report, for additional information about the Company’s commitment to the noncontrolling shareholders of MeVis.
The Company has an environmental liability of approximately $0.9 million as of September 27, 2019.
 Contingencies
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duty audits, other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. The Company did not have any contingent liabilities as of September 27, 2019 and September 28, 2018. Legal expenses are expensed as incurred.
XML 62 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables)
 12 Months Ended
Sep. 27, 2019
Noncontrolling Interest [Abstract]  
Changes in Redeemable Noncontrolling Interest
Changes in redeemable noncontrolling interests and noncontrolling interests were as follows: 
 
Fiscal Years
 
2019
 
2018
(In millions)
Redeemable
Noncontrolling
Interests
 
Noncontrolling
Interests
 
Redeemable
Noncontrolling
Interests
 
Noncontrolling Interest
Balance at beginning of period
$
11.1

 
$
2.1

 
$
11.2

 
$
—

Net earnings attributable to noncontrolling interests
0.5

 
(0.2
)
 
0.5

 
0.3

Contributions from noncontrolling interests
—

 
1.4

 
—

 
1.8

Dividend distributions
(0.5
)
 
—

 
(0.6
)
 
—

Other
(0.6
)
 
—

 
—

 
—

Balance at end of period
$
10.5

 
$
3.3

 
$
11.1

 
$
2.1
XML 63 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)
 12 Months Ended
Sep. 27, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments
The following table shows the notional amounts of outstanding foreign currency contracts entered into under its balance sheet hedge program as of September 27, 2019:
 
Notional Value of Derivatives not Designated as Hedging Instruments:
In millions
Buy contracts
 
Sell contract
Japanese yen
$
0.9

 
$
—

Swiss franc
—

 
(1.0
)
Chinese renminbi
1.8

 
—

Euro
8.8

 
—

 
$
11.5

 
$
(1.0
)

As of September 27, 2019, the Company had the following outstanding derivatives designated as cash flow hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Interest Rate Swap Contracts
6
 
$
264.4


As of September 27, 2019, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Cross Currency Swap Contracts
4
 
$
77.7
Schedule of Interest Rate Derivative Instruments
The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for cash flow hedges:
 
Amount of Gain or (Loss) Recognized in OCI on Derivative
Fiscal Year Ended
 
Location of Gain or (Loss) Reclassified from Accumulated OCI into Income
 
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income
Fiscal Year Ended
(In millions)
2019
 
2018
 
2017
 
 
2019
 
2018
 
2017
Interest Rate Swap Contracts
$
(6.3
)
 
$
6.9

 
$
0.6

 
Interest expense
 
$
1.9

 
$
0.1

 
$
(0.3
)
The Company expects that $0.1 million of the accumulated other comprehensive (loss) income related to cash flow hedges will be realized in pre-tax earnings over the next 12 months, but the amount will vary depending on interest rates.
These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded.
 
Derivative Assets
 
Derivative Liabilities
(In millions)
 
 
September 27, 2019
 
September 28, 2018
 
 
 
September 27, 2019
 
September 28, 2018
Derivatives designated as cash flow hedges
Balance sheet location
 
 
 
 
 
Balance sheet location
 
 
 
 
Interest rate swap contracts
Other current assets
 
$
—

 
$
2.2

 
Other current liabilities
 
$
—

 
$
—

Interest rate swap contracts
Other non-current assets
 
—

 
5.5

 
Other non-current liabilities
 
(0.5
)
 
—

 
 
 
$
—

 
$
7.7

 
 
 
$
(0.5
)
 
$
—


The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
 
Amount of Gain or (Loss) Recognized in OCI on Derivative
Fiscal Year Ended
 
Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
 
Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
(In millions)
2019
 
2018
 
2017
 
 
2019
 
2018
 
2017
Cross Currency Swap Contracts
$
(0.2
)
 
$
—

 
$
—

 
Interest expense
 
$
0.2

 
$
—

 
$
—

These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:
 
Derivative Assets
 
Derivative Liabilities
(In millions)
 
 
September 27, 2019
 
September 28, 2018
 
 
 
September 27, 2019
 
September 28, 2018
Derivatives designated as net investment hedges
Balance sheet location
 
 
 
 
 
Balance sheet location
 
 
 
 
Cross currency swap contracts
Other current assets
 
—

 
—

 
Other current liabilities
 
(0.2
)
 
—

 
 
 
$
—

 
$
—

 
 
 
$
(0.2
)
 
$
—
XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 301 564 1 false 100 0 false 10 false false R1.htm 0001000 - Document - Cover Sheet http://www.vareximaging.com/role/Cover Cover Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS Sheet http://www.vareximaging.com/role/ConsolidatedStatementsOfEarnings CONSOLIDATED STATEMENTS OF EARNINGS Statements 2 false false R3.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS Sheet http://www.vareximaging.com/role/ConsolidatedStatementsOfComprehensiveEarnings CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS Statements 3 false false R4.htm 1003000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.vareximaging.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 4 false false R5.htm 1003001 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) Sheet http://www.vareximaging.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.vareximaging.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF EQUITY Sheet http://www.vareximaging.com/role/ConsolidatedStatementsOfEquity CONSOLIDATED STATEMENTS OF EQUITY Statements 7 false false R8.htm 2101100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 2102100 - Disclosure - BUSINESS COMBINATIONS Sheet http://www.vareximaging.com/role/BusinessCombinations BUSINESS COMBINATIONS Notes 9 false false R10.htm 2103100 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://www.vareximaging.com/role/RelatedPartyTransactions RELATED-PARTY TRANSACTIONS Notes 10 false false R11.htm 2104100 - Disclosure - RESTRUCTURING Sheet http://www.vareximaging.com/role/Restructuring RESTRUCTURING Notes 11 false false R12.htm 2105100 - Disclosure - OTHER FINANCIAL INFORMATION Sheet http://www.vareximaging.com/role/OtherFinancialInformation OTHER FINANCIAL INFORMATION Notes 12 false false R13.htm 2106100 - Disclosure - NET EARNINGS PER SHARE Sheet http://www.vareximaging.com/role/NetEarningsPerShare NET EARNINGS PER SHARE Notes 13 false false R14.htm 2107100 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Sheet http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivities FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Notes 14 false false R15.htm 2108100 - Disclosure - BORROWINGS Sheet http://www.vareximaging.com/role/Borrowings BORROWINGS Notes 15 false false R16.htm 2109100 - Disclosure - FAIR VALUE Sheet http://www.vareximaging.com/role/FairValue FAIR VALUE Notes 16 false false R17.htm 2110100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.vareximaging.com/role/GoodwillAndIntangibleAssets GOODWILL AND INTANGIBLE ASSETS Notes 17 false false R18.htm 2111100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.vareximaging.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 2112100 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS Sheet http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterests REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS Notes 19 false false R20.htm 2113100 - Disclosure - EMPLOYEE STOCK PLANS Sheet http://www.vareximaging.com/role/EmployeeStockPlans EMPLOYEE STOCK PLANS Notes 20 false false R21.htm 2114100 - Disclosure - TAXES ON EARNINGS Sheet http://www.vareximaging.com/role/TaxesOnEarnings TAXES ON EARNINGS Notes 21 false false R22.htm 2115100 - Disclosure - SEGMENT INFORMATION Sheet http://www.vareximaging.com/role/SegmentInformation SEGMENT INFORMATION Notes 22 false false R23.htm 2116100 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://www.vareximaging.com/role/EmployeeBenefitPlans EMPLOYEE BENEFIT PLANS Notes 23 false false R24.htm 2117100 - Disclosure - OTHER COMPREHENSIVE INCOME Sheet http://www.vareximaging.com/role/OtherComprehensiveIncome OTHER COMPREHENSIVE INCOME Notes 24 false false R25.htm 2118100 - Disclosure - REVENUE RECOGNITION Sheet http://www.vareximaging.com/role/RevenueRecognition REVENUE RECOGNITION Notes 25 false false R26.htm 2119100 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.vareximaging.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 26 false false R27.htm 2201201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 27 false false R28.htm 2301302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.vareximaging.com/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 2302301 - Disclosure - BUSINESS COMBINATIONS (Tables) Sheet http://www.vareximaging.com/role/BusinessCombinationsTables BUSINESS COMBINATIONS (Tables) Tables http://www.vareximaging.com/role/BusinessCombinations 29 false false R30.htm 2304301 - Disclosure - RESTRUCTURING (Tables) Sheet http://www.vareximaging.com/role/RestructuringTables RESTRUCTURING (Tables) Tables http://www.vareximaging.com/role/Restructuring 30 false false R31.htm 2305301 - Disclosure - OTHER FINANCIAL INFORMATION (Tables) Sheet http://www.vareximaging.com/role/OtherFinancialInformationTables OTHER FINANCIAL INFORMATION (Tables) Tables http://www.vareximaging.com/role/OtherFinancialInformation 31 false false R32.htm 2306301 - Disclosure - NET EARNINGS PER SHARE (Tables) Sheet http://www.vareximaging.com/role/NetEarningsPerShareTables NET EARNINGS PER SHARE (Tables) Tables http://www.vareximaging.com/role/NetEarningsPerShare 32 false false R33.htm 2307301 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) Sheet http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesTables FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) Tables http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivities 33 false false R34.htm 2308301 - Disclosure - BORROWINGS (Tables) Sheet http://www.vareximaging.com/role/BorrowingsTables BORROWINGS (Tables) Tables http://www.vareximaging.com/role/Borrowings 34 false false R35.htm 2309301 - Disclosure - FAIR VALUE (Tables) Sheet http://www.vareximaging.com/role/FairValueTables FAIR VALUE (Tables) Tables http://www.vareximaging.com/role/FairValue 35 false false R36.htm 2310301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.vareximaging.com/role/GoodwillAndIntangibleAssets 36 false false R37.htm 2312301 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables) Sheet http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsTables REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables) Tables http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterests 37 false false R38.htm 2313301 - Disclosure - EMPLOYEE STOCK PLANS (Tables) Sheet http://www.vareximaging.com/role/EmployeeStockPlansTables EMPLOYEE STOCK PLANS (Tables) Tables http://www.vareximaging.com/role/EmployeeStockPlans 38 false false R39.htm 2314301 - Disclosure - TAXES ON EARNINGS (Tables) Sheet http://www.vareximaging.com/role/TaxesOnEarningsTables TAXES ON EARNINGS (Tables) Tables http://www.vareximaging.com/role/TaxesOnEarnings 39 false false R40.htm 2315301 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.vareximaging.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) Tables http://www.vareximaging.com/role/SegmentInformation 40 false false R41.htm 2317301 - Disclosure - OTHER COMPREHENSIVE INCOME (Tables) Sheet http://www.vareximaging.com/role/OtherComprehensiveIncomeTables OTHER COMPREHENSIVE INCOME (Tables) Tables http://www.vareximaging.com/role/OtherComprehensiveIncome 41 false false R42.htm 2318301 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://www.vareximaging.com/role/RevenueRecognitionTables REVENUE RECOGNITION (Tables) Tables http://www.vareximaging.com/role/RevenueRecognition 42 false false R43.htm 2401403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesDescriptionOfBusinessDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details) Details 43 false false R44.htm 2401404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reclassification (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesReclassificationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reclassification (Details) Details 44 false false R45.htm 2401405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) Details 45 false false R46.htm 2401406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Variable Interest Entities (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesVariableInterestEntitiesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Variable Interest Entities (Details) Details 46 false false R47.htm 2401407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) Details 47 false false R48.htm 2401408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfRiskDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk (Details) Details 48 false false R49.htm 2401409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Details) Details 49 false false R50.htm 2401410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property Plant and Equipment (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property Plant and Equipment (Details) Details 50 false false R51.htm 2401411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) Details 51 false false R52.htm 2401412 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets, Intangible Assets and Goodwill (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsIntangibleAssetsAndGoodwillDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets, Intangible Assets and Goodwill (Details) Details 52 false false R53.htm 2401413 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) Details 53 false false R54.htm 2401414 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) Details 54 false false R55.htm 2401415 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounting Standards Recently Adopted (Details) Sheet http://www.vareximaging.com/role/SummaryOfSignificantAccountingPoliciesAccountingStandardsRecentlyAdoptedDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounting Standards Recently Adopted (Details) Details 55 false false R56.htm 2402402 - Disclosure - BUSINESS COMBINATIONS - Direct Conversion Narrative (Details) Sheet http://www.vareximaging.com/role/BusinessCombinationsDirectConversionNarrativeDetails BUSINESS COMBINATIONS - Direct Conversion Narrative (Details) Details 56 false false R57.htm 2402403 - Disclosure - BUSINESS COMBINATIONS - Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details) Sheet http://www.vareximaging.com/role/BusinessCombinationsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails BUSINESS COMBINATIONS - Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details) Details 57 false false R58.htm 2402404 - Disclosure - BUSINESS COMBINATIONS - Intangibles Acquired (Details) Sheet http://www.vareximaging.com/role/BusinessCombinationsIntangiblesAcquiredDetails BUSINESS COMBINATIONS - Intangibles Acquired (Details) Details 58 false false R59.htm 2402405 - Disclosure - BUSINESS COMBINATIONS - Revenues by Segment (Details) Sheet http://www.vareximaging.com/role/BusinessCombinationsRevenuesBySegmentDetails BUSINESS COMBINATIONS - Revenues by Segment (Details) Details 59 false false R60.htm 2402406 - Disclosure - BUSINESS COMBINATIONS - Virtual Media Narrative (Details) Sheet http://www.vareximaging.com/role/BusinessCombinationsVirtualMediaNarrativeDetails BUSINESS COMBINATIONS - Virtual Media Narrative (Details) Details 60 false false R61.htm 2402407 - Disclosure - BUSINESS COMBINATIONS - PerkinElmer's Medical Imaging Narrative (Details) Sheet http://www.vareximaging.com/role/BusinessCombinationsPerkinelmersMedicalImagingNarrativeDetails BUSINESS COMBINATIONS - PerkinElmer's Medical Imaging Narrative (Details) Details 61 false false R62.htm 2402408 - Disclosure - BUSINESS COMBINATIONS - Pro Forma (Details) Sheet http://www.vareximaging.com/role/BusinessCombinationsProFormaDetails BUSINESS COMBINATIONS - Pro Forma (Details) Details 62 false false R63.htm 2403401 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately Held Companies (Details) Sheet http://www.vareximaging.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesDetails RELATED-PARTY TRANSACTIONS - Investment in Privately Held Companies (Details) Details 63 false false R64.htm 2404402 - Disclosure - RESTRUCTURING - Narrative (Details) Sheet http://www.vareximaging.com/role/RestructuringNarrativeDetails RESTRUCTURING - Narrative (Details) Details 64 false false R65.htm 2404403 - Disclosure - RESTRUCTURING - Restructuring Charges Incurred (Details) Sheet http://www.vareximaging.com/role/RestructuringRestructuringChargesIncurredDetails RESTRUCTURING - Restructuring Charges Incurred (Details) Details 65 false false R66.htm 2405402 - Disclosure - OTHER FINANCIAL INFORMATION - (Details) Sheet http://www.vareximaging.com/role/OtherFinancialInformationDetails OTHER FINANCIAL INFORMATION - (Details) Details http://www.vareximaging.com/role/OtherFinancialInformationTables 66 false false R67.htm 2406402 - Disclosure - NET EARNINGS PER SHARE - (Details) Sheet http://www.vareximaging.com/role/NetEarningsPerShareDetails NET EARNINGS PER SHARE - (Details) Details http://www.vareximaging.com/role/NetEarningsPerShareTables 67 false false R68.htm 2407402 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) Sheet http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) Details 68 false false R69.htm 2407403 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details) Sheet http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details) Details 69 false false R70.htm 2407404 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) Sheet http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) Details 70 false false R71.htm 2407405 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) Sheet http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) Details 71 false false R72.htm 2407406 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Foreign Currency Contracts (Details) Sheet http://www.vareximaging.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfForeignCurrencyContractsDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Foreign Currency Contracts (Details) Details 72 false false R73.htm 2408402 - Disclosure - BORROWINGS - Schedule of Short-Term and Long-Term Debt (Details) Sheet http://www.vareximaging.com/role/BorrowingsScheduleOfShortTermAndLongTermDebtDetails BORROWINGS - Schedule of Short-Term and Long-Term Debt (Details) Details 73 false false R74.htm 2408403 - Disclosure - BORROWINGS - Narrative (Details) Sheet http://www.vareximaging.com/role/BorrowingsNarrativeDetails BORROWINGS - Narrative (Details) Details 74 false false R75.htm 2408404 - Disclosure - BORROWINGS - Schedule of Debt Maturities (Details) Sheet http://www.vareximaging.com/role/BorrowingsScheduleOfDebtMaturitiesDetails BORROWINGS - Schedule of Debt Maturities (Details) Details 75 false false R76.htm 2409402 - Disclosure - FAIR VALUE - (Details) Sheet http://www.vareximaging.com/role/FairValueDetails FAIR VALUE - (Details) Details http://www.vareximaging.com/role/FairValueTables 76 false false R77.htm 2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Goowill (Details) Sheet http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsSummaryOfGoowillDetails GOODWILL AND INTANGIBLE ASSETS - Summary of Goowill (Details) Details 77 false false R78.htm 2410403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Sheet http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Details 78 false false R79.htm 2410404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization Schedule (Details) Sheet http://www.vareximaging.com/role/GoodwillAndIntangibleAssetsAmortizationScheduleDetails GOODWILL AND INTANGIBLE ASSETS - Amortization Schedule (Details) Details 79 false false R80.htm 2411401 - Disclosure - COMMITMENTS AND CONTINGENCIES - (Details) Sheet http://www.vareximaging.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES - (Details) Details http://www.vareximaging.com/role/CommitmentsAndContingencies 80 false false R81.htm 2412402 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Narrative (Details) Sheet http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNarrativeDetails REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Narrative (Details) Details http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsTables 81 false false R82.htm 2412403 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Summary of Changes in Redeemable Noncontrolling Interests & Noncontrolling INterets (Details) Sheet http://www.vareximaging.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsSummaryOfChangesInRedeemableNoncontrollingInterestsNoncontrollingInteretsDetails REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Summary of Changes in Redeemable Noncontrolling Interests & Noncontrolling INterets (Details) Details 82 false false R83.htm 2413402 - Disclosure - EMPLOYEE STOCK PLANS - Narrative (Details) Sheet http://www.vareximaging.com/role/EmployeeStockPlansNarrativeDetails EMPLOYEE STOCK PLANS - Narrative (Details) Details 83 false false R84.htm 2413403 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) Sheet http://www.vareximaging.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) Details 84 false false R85.htm 2413404 - Disclosure - EMPLOYEE STOCK PLANS - Valuation Assumptions (Details) Sheet http://www.vareximaging.com/role/EmployeeStockPlansValuationAssumptionsDetails EMPLOYEE STOCK PLANS - Valuation Assumptions (Details) Details 85 false false R86.htm 2413405 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details) Sheet http://www.vareximaging.com/role/EmployeeStockPlansStockOptionActivityDetails EMPLOYEE STOCK PLANS - Stock Option Activity (Details) Details 86 false false R87.htm 2413406 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) Sheet http://www.vareximaging.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) Details 87 false false R88.htm 2414402 - Disclosure - TAXES ON EARNINGS - Summary of Taxes by Jurisdiction and Classification (Details) Sheet http://www.vareximaging.com/role/TaxesOnEarningsSummaryOfTaxesByJurisdictionAndClassificationDetails TAXES ON EARNINGS - Summary of Taxes by Jurisdiction and Classification (Details) Details 88 false false R89.htm 2414403 - Disclosure - TAXES ON EARNINGS - Income Tax Rate Reconciliation (Details) Sheet http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxRateReconciliationDetails TAXES ON EARNINGS - Income Tax Rate Reconciliation (Details) Details 89 false false R90.htm 2414404 - Disclosure - TAXES ON EARNINGS - Narrative (Details) Sheet http://www.vareximaging.com/role/TaxesOnEarningsNarrativeDetails TAXES ON EARNINGS - Narrative (Details) Details 90 false false R91.htm 2414405 - Disclosure - TAXES ON EARNINGS - Deferred Tax Assets and Liabilities (Details) Sheet http://www.vareximaging.com/role/TaxesOnEarningsDeferredTaxAssetsAndLiabilitiesDetails TAXES ON EARNINGS - Deferred Tax Assets and Liabilities (Details) Details 91 false false R92.htm 2414406 - Disclosure - TAXES ON EARNINGS - Valuation Allowance (Details) Sheet http://www.vareximaging.com/role/TaxesOnEarningsValuationAllowanceDetails TAXES ON EARNINGS - Valuation Allowance (Details) Details 92 false false R93.htm 2414407 - Disclosure - TAXES ON EARNINGS - Income Tax Contingency (Details) Sheet http://www.vareximaging.com/role/TaxesOnEarningsIncomeTaxContingencyDetails TAXES ON EARNINGS - Income Tax Contingency (Details) Details 93 false false R94.htm 2415402 - Disclosure - SEGMENT INFORMATION - Narrative (Details) Sheet http://www.vareximaging.com/role/SegmentInformationNarrativeDetails SEGMENT INFORMATION - Narrative (Details) Details 94 false false R95.htm 2415403 - Disclosure - SEGMENT INFORMATION - Summary of Segment Information (Details) Sheet http://www.vareximaging.com/role/SegmentInformationSummaryOfSegmentInformationDetails SEGMENT INFORMATION - Summary of Segment Information (Details) Details 95 false false R96.htm 2415404 - Disclosure - SEGMENT INFORMATION - Assets (Details) Sheet http://www.vareximaging.com/role/SegmentInformationAssetsDetails SEGMENT INFORMATION - Assets (Details) Details 96 false false R97.htm 2415405 - Disclosure - SEGMENT INFORMATION - Geographic (Details) Sheet http://www.vareximaging.com/role/SegmentInformationGeographicDetails SEGMENT INFORMATION - Geographic (Details) Details 97 false false R98.htm 2416401 - Disclosure - EMPLOYEE BENEFIT PLANS - (Details) Sheet http://www.vareximaging.com/role/EmployeeBenefitPlansDetails EMPLOYEE BENEFIT PLANS - (Details) Details http://www.vareximaging.com/role/EmployeeBenefitPlans 98 false false R99.htm 2417402 - Disclosure - OTHER COMPREHENSIVE INCOME - (Details) Sheet http://www.vareximaging.com/role/OtherComprehensiveIncomeDetails OTHER COMPREHENSIVE INCOME - (Details) Details http://www.vareximaging.com/role/OtherComprehensiveIncomeTables 99 false false R100.htm 2418402 - Disclosure - REVENUE RECOGNITION - Schedule of Balance Sheet Adjustment for ASC 606 Adoption (Details) Sheet http://www.vareximaging.com/role/RevenueRecognitionScheduleOfBalanceSheetAdjustmentForAsc606AdoptionDetails REVENUE RECOGNITION - Schedule of Balance Sheet Adjustment for ASC 606 Adoption (Details) Details 100 false false R101.htm 2418403 - Disclosure - REVENUE RECOGNITION - Schedule of ASC 606 Adoption Impact On Income Statement (Details) Sheet http://www.vareximaging.com/role/RevenueRecognitionScheduleOfAsc606AdoptionImpactOnIncomeStatementDetails REVENUE RECOGNITION - Schedule of ASC 606 Adoption Impact On Income Statement (Details) Details 101 false false R102.htm 2418404 - Disclosure - REVENUE RECOGNITION - Schedule of Changes in Contract Balances (Details) Sheet http://www.vareximaging.com/role/RevenueRecognitionScheduleOfChangesInContractBalancesDetails REVENUE RECOGNITION - Schedule of Changes in Contract Balances (Details) Details 102 false false R103.htm 2418405 - Disclosure - REVENUE RECOGNITION - Remaining Performance Obligations (Details) Sheet http://www.vareximaging.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails REVENUE RECOGNITION - Remaining Performance Obligations (Details) Details 103 false false R104.htm 2419401 - Disclosure - SUBSEQUENT EVENTS - (Details) Sheet http://www.vareximaging.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS - (Details) Details http://www.vareximaging.com/role/SubsequentEvents 104 false false All Reports Book All Reports varex10k2019.htm exhibit1018-10xk2019.htm exhibit211-10xk2019.htm exhibit231-10xk2019.htm exhibit311-10xk2019.htm exhibit312-10xk2019.htm exhibit321-10xk2019.htm exhibit322-10xk2019.htm exhibit41-10xk2019.htm var-20190927.xsd var-20190927_cal.xml var-20190927_def.xml var-20190927_lab.xml var-20190927_pre.xml chart-60e2d95fbd6683f2865.jpg varex10k2017draft0image1a02.jpg http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/currency/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 65 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets, Intangible Assets and Goodwill (Details) - USD ($)
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Accounting Policies [Abstract]      
Impairment of intangible assets $ 4,800,000 $ 3,000,000.0 $ 0
Goodwill, impairment loss   $ 0 $ 0
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATIONS - Direct Conversion Narrative (Details) - Direct Conversion AB - USD ($)
$ in Millions
Apr. 29, 2019
Apr. 30, 2019
Business Acquisition [Line Items]    
Percentage of voting interests acquired   98.20%
Net cash paid $ 69.5  
Debt assumed 4.5  
Deferred payment, value assigned $ 9.9  
Deferred payment (in shares) 300,000  
XML 67 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND INTANGIBLE ASSETS - Amortization Schedule (Details) - USD ($)
$ in Millions
Sep. 27, 2019
Sep. 28, 2018
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]    
2020 $ 17.2  
2021 16.3  
2022 14.7  
2023 13.7  
2024 9.1  
Thereafter 12.5  
Net Carrying Amount $ 83.5 $ 69.8
XML 68 R89.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS - Income Tax Rate Reconciliation (Details)
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Income Tax Disclosure [Abstract]      
Federal statutory income tax rate 21.00% 24.50% 35.00%
State and local taxes, net of federal tax benefit (0.90%) 1.10% 1.30%
Revaluation of deferred tax liabilities for US statutory change 0.00% (41.80%) 0.00%
Mandatory repatriation tax on foreign earnings 1.90% 13.00% 0.00%
Domestic production activities deduction 0.00% (0.80%) (2.40%)
Research and development credit (10.20%) (11.10%) (2.60%)
Prior year deferred tax adjustments 4.70% 1.90% (4.00%)
Foreign Rate Difference 6.00% 0.80% 0.00%
Change in valuation allowance 11.20% (1.90%) 3.80%
US Tax Reform - International Provisions (0.047) 0 0
Other (2.50%) 4.20% (0.60%)
Effective tax rate 26.50% (10.10%) 30.50%
XML 69 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE STOCK PLANS - Valuation Assumptions (Details) - $ / shares
 3 Months Ended 12 Months Ended
Dec. 28, 2018
Dec. 29, 2017
Sep. 27, 2019
Employee Stock Option      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 4 years 9 months 18 days 4 years 2 months 12 days 4 years 7 months 6 days
Risk-free interest rate 2.60% 1.60% 2.50%
Expected volatility 31.80% 23.60% 33.90%
Expected dividend 0.00% 0.00% 0.00%
Weighted average fair value at grant date (in USD per share) $ 11.57 $ 8.08 $ 10.19
Employee Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 6 months 6 months 6 months
Risk-free interest rate 2.00% 1.00% 2.50%
Expected volatility 34.10% 28.00% 43.90%
Expected dividend 0.00% 0.00% 0.00%
Weighted average fair value at grant date (in USD per share) $ 8.92 $ 7.81 $ 7.81
XML 70 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BORROWINGS - Schedule of Debt Maturities (Details) - USD ($)
$ in Millions
Sep. 27, 2019
Sep. 28, 2018
Debt Disclosure [Abstract]    
2020 $ 30.7  
2021 34.3  
2022 335.8  
Total debt outstanding 400.8  
Less: current maturities of long-term debt (30.7) $ (25.0)
Non-current portion of long -term debt $ 370.1  
XML 71 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) - Derivatives designated as cash flow hedges - Designated as Hedging Instrument - USD ($)
$ in Millions
Sep. 27, 2019
Sep. 28, 2018
Interest Rate Swap Contracts    
Derivative [Line Items]    
Derivative Assets $ 0.0 $ 7.7
Derivative Liabilities (0.5) 0.0
Cross Currency Swap Contracts    
Derivative [Line Items]    
Derivative Assets 0.0 0.0
Derivative Liabilities (0.2) 0.0
Other current assets | Interest Rate Swap Contracts    
Derivative [Line Items]    
Derivative Assets 0.0 2.2
Other current assets | Cross Currency Swap Contracts    
Derivative [Line Items]    
Derivative Assets 0.0 0.0
Other non-current assets | Interest Rate Swap Contracts    
Derivative [Line Items]    
Derivative Assets 0.0 5.5
Other current liabilities | Interest Rate Swap Contracts    
Derivative [Line Items]    
Derivative Liabilities 0.0 0.0
Other current liabilities | Cross Currency Swap Contracts    
Derivative [Line Items]    
Derivative Liabilities (0.2) 0.0
Other non-current liabilities | Interest Rate Swap Contracts    
Derivative [Line Items]    
Derivative Liabilities $ (0.5) $ 0.0
XML 72 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Narrative (Details)
shares in Millions, $ in Millions
 1 Months Ended
Oct. 31, 2015
€ / shares
Sep. 27, 2019
USD ($)
shares
Apr. 30, 2019
Sep. 28, 2018
USD ($)
Sep. 29, 2017
USD ($)
Apr. 30, 2015
Noncontrolling Interest [Line Items]            
Redeemable noncontrolling interest, equity, redemption value | $   $ 10.5   $ 11.1 $ 11.2  
Joint Venture In Saudi Arabia            
Noncontrolling Interest [Line Items]            
Noncontrolling interest, ownership percentage by parent       75.00%    
Noncontrolling interest, ownership percentage by noncontrolling owners       25.00%    
Direct Conversion AB            
Noncontrolling Interest [Line Items]            
Percentage of voting interests acquired     98.20%      
MeVis Medical Solutions AG (MeVis)            
Noncontrolling Interest [Line Items]            
Percentage of voting interests acquired           73.50%
Annual recurring compensation (in euros per share) | € / shares € 0.95          
Temporary equity, redemption price per share (in eur per share) | € / shares € 19.77          
Redeemable noncontrolling interest, equity, redemption value | $   $ 10.5        
Temporary equity, shares outstanding (in shares) | shares   0.5        
MeVis Medical Solutions AG (MeVis) | MeVis Medical Solutions AG (MeVis)            
Noncontrolling Interest [Line Items]            
Noncontrolling interest, ownership percentage by noncontrolling owners   26.30%        
XML 73 R92.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS - Valuation Allowance (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Deferred Tax Assets Valuation Allowance [Roll Forward]      
Valuation allowance balance–beginning of fiscal year $ 4.0 $ 4.3 $ 2.5
Increases resulting from business combinations 12.0 0.0 0.0
Other increases 2.8 2.2 2.5
Other decreases 0.0 (2.5) (0.7)
Valuation allowance balance—end of fiscal year $ 18.8 $ 4.0 $ 4.3
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATIONS - Pro Forma (Details) - PerkinElmer, Inc.
$ / shares in Units, $ in Millions
 12 Months Ended
Sep. 29, 2017
USD ($)
$ / shares
Business Acquisition [Line Items]  
Revenue $ 777.8
Operating earnings 84.7
Net earnings $ 43.1
Net earnings per share, basic (in USD per share) | $ / shares $ 1.15
Net earnings per share, diluted (in USD per share) | $ / shares $ 1.13
XML 75 varex10k2019_htm.xml IDEA: XBRL DOCUMENT 0001681622 2018-09-29 2019-09-27 0001681622 2019-11-18 0001681622 2019-03-29 0001681622 2017-09-30 2018-09-28 0001681622 2016-10-01 2017-09-29 0001681622 2018-09-28 0001681622 2019-09-27 0001681622 2017-09-29 0001681622 2016-09-30 0001681622 us-gaap:CommonStockMember 2018-09-29 2019-09-27 0001681622 us-gaap:CommonStockMember 2017-09-30 2018-09-28 0001681622 us-gaap:CommonStockMember 2017-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-09-29 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2017-09-30 2018-09-28 0001681622 us-gaap:ParentMember 2017-09-30 2018-09-28 0001681622 us-gaap:RetainedEarningsMember 2017-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2017-09-29 0001681622 us-gaap:CommonStockMember 2016-10-01 2017-09-29 0001681622 us-gaap:NoncontrollingInterestMember 2018-09-29 2019-09-27 0001681622 us-gaap:ParentMember 2016-10-01 2017-09-29 0001681622 var:NetParentInvestmentMember 2016-09-30 0001681622 us-gaap:RetainedEarningsMember 2016-10-01 2017-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 2018-09-28 0001681622 us-gaap:CommonStockMember 2016-09-30 0001681622 us-gaap:RetainedEarningsMember 2017-09-30 2018-09-28 0001681622 var:NetParentInvestmentMember 2016-10-01 2017-09-29 0001681622 var:NetParentInvestmentMember 2018-09-28 0001681622 us-gaap:RetainedEarningsMember 2018-09-29 2019-09-27 0001681622 us-gaap:AdditionalPaidInCapitalMember 2017-09-29 0001681622 var:NetParentInvestmentMember 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:ParentMember 2016-09-30 0001681622 us-gaap:RetainedEarningsMember 2019-09-27 0001681622 us-gaap:CommonStockMember 2018-09-28 0001681622 us-gaap:ParentMember 2018-09-29 2019-09-27 0001681622 us-gaap:ParentMember 2018-09-28 0001681622 us-gaap:ParentMember 2019-09-27 0001681622 us-gaap:RetainedEarningsMember 2016-09-30 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 2018-09-28 0001681622 us-gaap:AdditionalPaidInCapitalMember 2016-10-01 2017-09-29 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-10-01 2017-09-29 0001681622 us-gaap:RetainedEarningsMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-29 2019-09-27 0001681622 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:CommonStockMember 2019-09-27 0001681622 var:NetParentInvestmentMember 2017-09-29 0001681622 us-gaap:NoncontrollingInterestMember 2016-09-30 0001681622 us-gaap:ParentMember 2017-09-29 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-29 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-09-30 2018-09-28 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-09-29 2019-09-27 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2016-10-01 2017-09-29 0001681622 srt:MinimumMember 2018-09-29 2019-09-27 0001681622 us-gaap:LandImprovementsMember 2018-09-29 2019-09-27 0001681622 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2018-09-29 2019-09-27 0001681622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-28 0001681622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-03-29 0001681622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-09-27 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-09-30 2018-09-28 0001681622 var:VarianMedicalSystemsInc.Member 2017-01-28 0001681622 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2018-09-29 2019-09-27 0001681622 srt:MaximumMember 2018-09-29 2019-09-27 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-09-29 2019-09-27 0001681622 us-gaap:BuildingMember 2018-09-29 2019-09-27 0001681622 srt:RestatementAdjustmentMember 2017-09-30 2018-09-28 0001681622 us-gaap:MachineryAndEquipmentMember 2019-09-27 0001681622 us-gaap:MachineryAndEquipmentMember 2018-09-28 0001681622 var:BuildingsandLeaseholdImprovementsMember 2019-09-27 0001681622 us-gaap:ConstructionInProgressMember 2019-09-27 0001681622 us-gaap:LandMember 2019-09-27 0001681622 var:BuildingsandLeaseholdImprovementsMember 2018-09-28 0001681622 us-gaap:LandMember 2018-09-28 0001681622 us-gaap:ConstructionInProgressMember 2018-09-28 0001681622 var:PerkinElmerInc.Member 2017-05-01 0001681622 var:PerkinElmerInc.Member 2017-05-01 2017-05-01 0001681622 var:DirectConversionABMember us-gaap:DevelopedTechnologyRightsMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:CustomerRelationshipsMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:CustomerRelationshipsMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:DevelopedTechnologyRightsMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:TradeNamesMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:OrderOrProductionBacklogMember 2019-04-29 0001681622 var:DirectConversionABMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:OrderOrProductionBacklogMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:TradeNamesMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:InProcessResearchAndDevelopmentMember 2019-04-29 0001681622 var:DirectConversionABMember 2019-04-29 2019-04-29 0001681622 var:PerkinElmerInc.Member 2016-10-01 2017-09-29 0001681622 var:PerkinElmerInc.Member var:IndustrialMember 2017-05-01 2017-09-29 0001681622 var:PerkinElmerInc.Member 2017-05-01 2017-09-29 0001681622 var:PerkinElmerInc.Member var:MedicalMember 2017-05-01 2017-09-29 0001681622 var:VirtualMediaIntegrationLtd.Member 2018-08-31 2018-08-31 0001681622 var:PerkinElmerInc.Member us-gaap:ForeignCountryMember 2017-05-01 0001681622 var:DirectConversionABMember 2019-04-30 0001681622 var:PerkinElmerInc.Member us-gaap:LeaseAgreementsMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:OrderOrProductionBacklogMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:LeaseAgreementsMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:TradeNamesMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:OrderOrProductionBacklogMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:CustomerRelationshipsMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:DevelopedTechnologyRightsMember 2017-05-01 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:DevelopedTechnologyRightsMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:TradeNamesMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:CustomerRelationshipsMember 2017-05-01 0001681622 var:PerkinElmerInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2017-05-01 0001681622 var:VirtualMediaIntegrationLtd.Member 2018-08-31 0001681622 var:DirectConversionABMember 2019-04-30 2019-09-27 0001681622 var:DirectConversionABMember var:IndustrialMember 2019-04-30 2019-09-27 0001681622 var:DirectConversionABMember var:MedicalMember 2019-04-30 2019-09-27 0001681622 var:VECImagingGmbHCo.KGMember 2018-11-01 2019-09-27 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2019-09-27 0001681622 var:VECImagingGmbHCo.KGMember srt:ScenarioForecastMember 2019-12-17 2019-12-17 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2018-09-29 2019-09-27 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2013-10-01 2013-10-31 0001681622 var:DpiXHoldingMember 2019-09-27 0001681622 var:DpiXHoldingMember 2018-09-29 2019-09-27 0001681622 var:DpiXLLCMember 2019-09-27 0001681622 var:CETTEENGmbHMember var:VECImagingGmbHCo.KGMember 2019-09-27 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2018-09-28 0001681622 var:DpiXHoldingMember 2016-10-01 2017-09-29 0001681622 var:DpiXHoldingMember 2017-09-30 2018-09-28 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2016-10-01 2017-09-29 0001681622 var:VECImagingGmbHCo.KGMember 2019-09-27 0001681622 var:DpiXHoldingMember var:FixedCostCommitmentsMember 2018-09-29 2019-09-27 0001681622 var:DpiXHoldingMember 2018-09-28 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2017-09-30 2018-09-28 0001681622 var:LondonFacilityClosingMember 2017-09-30 2018-09-28 0001681622 var:SantaClaraFacilityRelocationMember 2017-09-30 2018-09-28 0001681622 var:SantaClaraFacilityRelocationMember 2018-09-29 2019-09-27 0001681622 srt:MinimumMember var:SantaClaraFacilityRelocationMember 2019-09-27 0001681622 srt:MaximumMember var:SantaClaraFacilityRelocationMember 2019-09-27 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 currency:CHF us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 currency:CHF us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-27 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-27 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-10-01 2017-09-29 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 2018-09-28 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-29 2019-09-27 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-29 2019-09-27 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 2018-09-28 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-10-01 2017-09-29 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2018-09-29 2019-09-27 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-28 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-10-10 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:BaseRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodOneMember 2017-05-01 2017-05-01 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:BaseRateMember 2017-05-01 2017-05-01 0001681622 var:RevolvingCreditFacilityMay2017Member 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodThreeMember 2017-05-01 2017-05-01 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 var:RevolvingCreditFacilityMay2017Member us-gaap:SubsequentEventMember 2019-10-08 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodFiveMember 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 var:RevolvingCreditFacilityMay2017Member us-gaap:SubsequentEventMember 2019-10-08 2019-10-08 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-10-10 2018-10-10 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:FederalFundsEffectiveSwapRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember 2019-09-27 0001681622 var:OtherDebtMember 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-09-29 2019-09-27 0001681622 us-gaap:SecuredDebtMember 2018-09-29 2019-09-27 0001681622 us-gaap:SecuredDebtMember 2018-09-28 0001681622 us-gaap:SecuredDebtMember 2017-09-30 2018-09-28 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-09-30 2018-09-28 0001681622 var:OtherDebtMember 2018-09-28 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-09-28 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodTwoMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodFourMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodFourMember 2017-01-25 2017-01-25 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodTwoMember 2017-01-25 2017-01-25 0001681622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-27 0001681622 us-gaap:FairValueMeasurementsRecurringMember 2019-09-27 0001681622 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-27 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-27 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-28 0001681622 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-28 0001681622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-28 0001681622 us-gaap:FairValueMeasurementsRecurringMember 2018-09-28 0001681622 var:MedicalMember 2018-09-29 2019-09-27 0001681622 var:IndustrialMember 2018-09-29 2019-09-27 0001681622 var:IndustrialMember 2019-09-27 0001681622 var:MedicalMember 2018-09-28 0001681622 var:IndustrialMember 2018-09-28 0001681622 var:MedicalMember 2019-09-27 0001681622 us-gaap:IntellectualPropertyMember 2018-09-28 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2019-09-27 0001681622 us-gaap:DevelopedTechnologyRightsMember 2018-09-28 0001681622 us-gaap:IntellectualPropertyMember 2019-09-27 0001681622 us-gaap:DevelopedTechnologyRightsMember 2019-09-27 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2018-09-28 0001681622 var:JointVentureInSaudiArabiaMember 2018-09-28 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-04-30 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2019-09-27 0001681622 var:MeVisMedicalSolutionsAGMeVisMember var:MeVisMedicalSolutionsAGMeVisMember 2019-09-27 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-10-31 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-10-01 2015-10-31 0001681622 us-gaap:CostOfSalesMember 2016-10-01 2017-09-29 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2017-09-30 2018-09-28 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-09-29 2019-09-27 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-10-01 2017-09-29 0001681622 us-gaap:CostOfSalesMember 2018-09-29 2019-09-27 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-09-30 2018-09-28 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2016-10-01 2017-09-29 0001681622 us-gaap:CostOfSalesMember 2017-09-30 2018-09-28 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2018-09-29 2019-09-27 0001681622 us-gaap:EmployeeStockMember 2018-09-29 2018-12-28 0001681622 us-gaap:EmployeeStockMember 2018-09-29 2019-09-27 0001681622 us-gaap:EmployeeStockOptionMember 2018-09-29 2019-09-27 0001681622 us-gaap:EmployeeStockOptionMember 2017-09-30 2017-12-29 0001681622 us-gaap:EmployeeStockOptionMember 2018-09-29 2018-12-28 0001681622 us-gaap:EmployeeStockMember 2017-09-30 2017-12-29 0001681622 us-gaap:EmployeeStockMember var:A2017ESPPMember 2017-01-01 2017-01-31 0001681622 us-gaap:EmployeeStockOptionMember var:A2017ESPPMember 2019-09-27 0001681622 us-gaap:EmployeeStockOptionMember var:A2017OmnibusStockPlanMember 2019-09-27 0001681622 us-gaap:EmployeeStockOptionMember 2019-09-27 0001681622 us-gaap:EmployeeStockMember var:A2017ESPPMember 2018-09-29 2019-09-27 0001681622 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-09-29 2019-09-27 0001681622 us-gaap:EmployeeStockMember var:A2017ESPPMember 2017-01-31 0001681622 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:MajorityShareholderMember 2016-10-01 2017-09-29 0001681622 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-09-29 2019-09-27 0001681622 srt:MaximumMember 2019-09-27 0001681622 srt:MinimumMember 2019-09-27 0001681622 srt:MaximumMember 2018-09-28 0001681622 srt:MinimumMember 2018-09-28 0001681622 us-gaap:OperatingSegmentsMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2018-09-28 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2018-09-28 0001681622 us-gaap:OperatingSegmentsMember 2018-09-28 0001681622 srt:LatinAmericaMember 2018-09-29 2019-09-27 0001681622 us-gaap:EMEAMember 2018-09-29 2019-09-27 0001681622 us-gaap:EMEAMember 2018-09-28 0001681622 srt:LatinAmericaMember 2017-09-30 2018-09-28 0001681622 srt:AsiaPacificMember 2018-09-29 2019-09-27 0001681622 srt:AsiaPacificMember 2016-10-01 2017-09-29 0001681622 srt:AsiaPacificMember 2019-09-27 0001681622 country:US 2019-09-27 0001681622 us-gaap:EMEAMember 2019-09-27 0001681622 country:US 2018-09-29 2019-09-27 0001681622 srt:LatinAmericaMember 2018-09-28 0001681622 country:US 2016-10-01 2017-09-29 0001681622 srt:LatinAmericaMember 2016-10-01 2017-09-29 0001681622 srt:LatinAmericaMember 2019-09-27 0001681622 us-gaap:EMEAMember 2016-10-01 2017-09-29 0001681622 country:US 2018-09-28 0001681622 country:US 2017-09-30 2018-09-28 0001681622 srt:AsiaPacificMember 2018-09-28 0001681622 us-gaap:EMEAMember 2017-09-30 2018-09-28 0001681622 srt:AsiaPacificMember 2017-09-30 2018-09-28 0001681622 var:IndustrialMember 2017-09-30 2018-09-28 0001681622 var:MedicalMember 2017-09-30 2018-09-28 0001681622 var:IndustrialMember 2016-10-01 2017-09-29 0001681622 var:MedicalMember 2016-10-01 2017-09-29 0001681622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-29 2019-09-27 0001681622 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-09-29 2019-09-27 0001681622 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-28 0001681622 2018-09-29 0001681622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-09-29 0001681622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-29 2019-09-27 0001681622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-09-27 0001681622 2019-09-28 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:SubsequentEventMember 2019-10-08 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:SubsequentEventMember 2019-10-08 2019-10-08 var:derivative iso4217:USD iso4217:USD shares pure var:member shares var:entity var:employee var:segment iso4217:EUR shares false --09-27 FY 2019 0001681622 0.01 0.01 150000000 150000000 38026597 38371305 38026597 38371305 P5Y 0 0 3000000 0 0.01 0.01 20000000 20000000 0 0 0 P12M 0 100000 0.1 0.075 0.075 0.05 37.60 22.63 37.60 22.63 37.60 22.63 31.08 31.08 27.77 22.84 31.42 31.42 10-K true 2019-09-27 false 001-37860 VAREX IMAGING CORPORATION DE 81-3434516 1678 S. Pioneer Road Salt Lake City UT 84104 (801) 972-5000 Common Stock VREX NASDAQ No No Yes Yes Large Accelerated Filer false false false 1160400000 38494349 <div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Documents Incorporated by Reference</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Portions of registrant’s proxy statement relating to registrant’s </span><span style="font-family:inherit;font-size:9pt;">2020</span><span style="font-family:inherit;font-size:9pt;"> annual meeting of stockholders have been incorporated by reference in Part III of this annual report on Form 10-K.</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div> 780600000 773400000 698100000 523900000 519500000 444600000 256700000 253900000 253500000 78100000 83000000.0 67300000 128100000 123400000 102500000 4800000 3000000.0 0 211000000.0 209400000 169800000 45700000 44500000 83700000 100000 200000 200000 21100000 21700000 12300000 -3200000 2700000 3200000 -24200000 -18800000 -8900000 21500000 25700000 74800000 5700000 -2600000 22800000 15800000 28300000 52000000.0 300000 800000 400000 15500000 27500000 51600000 0.41 0.73 1.37 0.40 0.72 1.36 38200000 37900000 37600000 38600000 38400000 38000000.0 15800000 28300000 52000000.0 -6200000 5200000 600000 1300000 200000 -200000 -7500000 5000000.0 800000 8300000 33300000 52800000 300000 800000 400000 8000000.0 32500000 52400000 29900000 51900000 141000000.0 154000000.0 248200000 235100000 19300000 17100000 438400000 458100000 142300000 144900000 290800000 243600000 86300000 73800000 53600000 51000000.0 27500000 16500000 1038900000 987900000 58200000 66300000 75700000 47500000 30700000 25000000.0 10500000 13200000 175100000 152000000.0 364400000 364800000 8200000 23200000 32500000 8500000 580200000 548500000 10500000 11100000 0 0 400000 400000 371800000 357600000 -1700000 5800000 74400000 62400000 444900000 426200000 3300000 2100000 448200000 428300000 1038900000 987900000 15800000 28300000 52000000.0 11700000 10000000.0 8400000 23500000 26000000.0 16900000 15700000 16200000 10500000 4800000 3000000.0 0 0 1300000 0 3100000 3100000 0 -12900000 -7700000 -8900000 2400000 2300000 1800000 -2300000 3900000 1300000 -800000 -700000 -1800000 -14800000 -9000000.0 23100000 11100000 2400000 4200000 -4300000 -2000000.0 10100000 -9000000.0 5200000 4900000 10900000 -10200000 28100000 -5200000 2400000 -1600000 71900000 85300000 75200000 19800000 20400000 20200000 69500000 4800000 271800000 3900000 0 0 -93200000 -25200000 -292000000.0 0 0 5000000.0 0 0 227100000 2100000 2300000 1900000 85400000 10000000.0 749000000.0 87000000.0 106000000.0 255000000.0 800000 3800000 2800000 3800000 3300000 0 0 0 2400000 500000 400000 11900000 0 1800000 0 500000 600000 0 -100000 -90400000 263300000 -700000 -500000 900000 -22100000 -30800000 47400000 53400000 84200000 36800000 31300000 53400000 84200000 19900000 19300000 9800000 8200000 13800000 6000000.0 1800000 2000000.0 4000000.0 0 0 15000000.0 0 0 1600000 0 0 0 526000000.0 0 0 526000000.0 0 526000000.0 16500000 35100000 51600000 51600000 18400000 18400000 18400000 227100000 227100000 227100000 37400000 400000 333400000 -333800000 0 100000 2800000 2800000 2800000 200000 100000 1900000 1900000 1900000 6200000 6200000 6200000 600000 600000 600000 -200000 -200000 -200000 2400000 2400000 2400000 200000 200000 200000 37600000 400000 342700000 0 800000 35100000 379000000.0 0 379000000.0 27500000 27500000 300000 27800000 200000 3800000 3800000 3800000 200000 100000 2200000 2200000 2200000 100000 3300000 3300000 3300000 10000000.0 10000000.0 10000000.0 5200000 5200000 5200000 200000 200000 200000 1800000 1800000 200000 200000 200000 38000000.0 400000 357600000 0 5800000 62400000 426200000 2100000 428300000 -3500000 -3500000 -3500000 15500000 15500000 -200000 15300000 0 800000 800000 800000 200000 0 2100000 2100000 2100000 200000 3800000 3800000 3800000 11700000 11700000 11700000 -6200000 -6200000 -6200000 1300000 1300000 1300000 1400000 1400000 38400000 400000 371800000 0 -1700000 74400000 444900000 3300000 448200000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varex Imaging Corporation (the “Company,” “Varex” or “Varex Imaging”) designs, manufactures, sells and services a broad range of Medical products, which include X-ray imaging components, including X-ray tubes, digital detectors and accessories, high voltage connectors, image processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys, for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, computed tomography, oncology and computer-aided detection. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary, to independent service companies, distributors and directly to end-users for replacement purposes.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also designs, manufacturers, sells and services industrial products, which include Linatron</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> X-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection systems. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varex Imaging Corporation was incorporated in Delaware on July 18, 2016 for the purpose of holding the assets and liabilities associated with the Company's business and separated from Varian Medical Systems, Inc. (“Varian”) on January 28, 2017, upon which Varian completed the distribution of </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding common stock of Varex to Varian stockholders. Following the separation and distribution, Varex became an independent publicly-traded company and is listed on the NASDAQ Global Select Market under the ticker “VREX.”</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principle of Consolidation</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements are audited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Prior to January 28 2017, the date of separation and distribution, the financial statements were prepared on a stand-alone basis and were derived from Varian’s consolidated financial statements and records as it operated as part of Varian prior to the distribution, in conformity with GAAP. Prior to the separation and distribution, the consolidated financial statements included allocations of certain Varian corporate expenses these costs were allocated to the Company on the basis of direct usage when identifiable or other systematic measures that reflect utilization of services provided to or benefits received by the Company.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All transactions between the Company and Varian prior to the separation have been included in the accompanying consolidated financial statements. All intercompany transactions while the Company operated as part of Varian were considered to be effectively settled for cash and are reflected as a component of financing activities as net transfers from (to) Varian in the consolidated statements of cash flows at the time the transactions were recorded.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the separation, the Company was dependent upon Varian for its working capital and financing requirements, as Varian uses a centralized approach to cash management and financing of its operations. Financial transactions relating to the Company were accounted for through the net parent investment account. Cash and cash equivalents held by Varian were not allocated to the Company.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net parent investment in the consolidated statements of equity represents Varian’s historical investment in the Company, the net effect of transactions with and allocations from Varian and the Company’s accumulated earnings.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassification</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> from selling, general and administrative expense to impairment of intangible assets for the year ended September 28, 2018, to conform to the current year's presentation. Such reclassifications had no impact on net earnings as previously reported.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its CEO, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. See Note </span><span style="font-family:inherit;font-size:10pt;">15</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information, </span><span style="font-family:inherit;font-size:10pt;">included in this report, for further information on the Company’s segments.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fiscal Year</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2019 was the 52-week period that ended on September 27, 2019. Fiscal year 2018 was the 52-week period that ended on September 28, 2018. Fiscal year 2017 was the 52-week period that ended on September 29, 2017. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Interest Entities</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For entities in which the Company has variable interests, the Company focuses on identifying which entity has the power to direct the activities that most significantly impact the variable interest entity’s economic performance and which enterprise has the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities and results of operations of the variable interest entity will be included in the Company’s consolidated financial statements. As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> variable interest entities neither of which were consolidated. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers currency on hand, demand deposits, time deposits and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"/><span style="font-family:inherit;font-size:10pt;">Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">included in other assets on the consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the consolidated statements of cash flows consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:382px;"/><td style="width:6px;"/><td style="width:69px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:69px;"/><td style="width:4px;"/><td style="width:6px;"/><td style="width:6px;"/><td style="width:69px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:69px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Twelve Months Ended September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Twelve Months Ended September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">End of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents and restricted cash as reported per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>84.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. There is a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:102px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;text-align:left;padding-left:102px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2—Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or, other inputs that are observable or can be corroborated by observable market data.</span></div><div style="line-height:120%;text-align:left;padding-left:102px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative instruments and hedging activities</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records all derivatives on the balance sheet at fair value. Derivatives designated as a hedge are recorded on the Consolidated Balance Sheets at fair value as of the reporting date. For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss and reclassified from accumulated other comprehensive loss into earnings when the hedged transaction affects earnings.  For derivatives that are designated and qualify as net investment hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss. Time value is excluded and the cash payments are recognized as an adjustment to interest expense. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, which is as follows:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canon Medical Systems Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canon Medical Systems Corporation accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>10.1%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>9.8%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s accounts receivable as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are valued at the lower of cost or net realizable value. Costs include materials, labor and manufacturing overhead</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and is computed using standard cost (which approximates actual cost) on a first-in-first-out basis. The Company evaluates the carrying</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">value of its inventories taking into consideration such factors as historical and anticipated future sales compared to quantities on hand</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and the prices the Company expects to obtain for products in its various markets. The Company adjust excess and obsolete</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inventories to net realizable value and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s inventories, net:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and parts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Plant and Equipment, net</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment are stated at cost, net of accumulated depreciation. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation are computed using the straight-line method over the estimated useful lives of the assets. Land is not subject to depreciation, but land improvements are depreciated over </span><span style="font-family:inherit;font-size:10pt;"><span>fifteen years</span></span><span style="font-family:inherit;font-size:10pt;">. Land leasehold rights and leasehold improvements are depreciated over the lesser of their estimated useful lives or remaining lease terms. Buildings are depreciated over </span><span style="font-family:inherit;font-size:10pt;"><span>twenty years</span></span><span style="font-family:inherit;font-size:10pt;">. Machinery and equipment are depreciated over their estimated useful lives, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>seven years</span></span><span style="font-family:inherit;font-size:10pt;">. Assets subject to lease are depreciated over the lesser of their estimated useful lives or remaining lease terms. Estimated useful lives are periodically reviewed and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted, and an impairment assessment may be performed on the recoverability of the carrying amounts. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s property, plant and equipment, net:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Buildings and leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>134.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>138.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Machinery</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>170.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>166.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>341.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>335.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(199.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(190.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant, and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>142.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>144.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded depreciation expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$26.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$16.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, in fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. During fiscal year 2019 the company recorded accelerated depreciation of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the machinery and equipment used in the fabrication of amorphous silicon glass at its facility in Santa Clara, CA. See Note </span><span style="font-family:inherit;font-size:10pt;">4</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring, </span><span style="font-family:inherit;font-size:10pt;">included in this report, for further information. During fiscal year 2018 the company recorded accelerated depreciation of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the machinery and equipment used in the fabrication of amorphous silicon glass at its facility in Santa Clara, CA. See Note </span><span style="font-family:inherit;font-size:10pt;">4</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring, </span><span style="font-family:inherit;font-size:10pt;">included in this report, for further information.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in these investments. Distributions received from an equity method investment are classified using the cumulative earnings approach. Under the cumulative earnings approach, distributions up to the amount of cumulative equity in earnings recognized will be treated as returns on investment as operating cash flows and those in excess of that amount will be treated as returns of investment as investing cash flows. The Company monitors these equity investments for impairment and makes appropriate reductions in carrying values if the Company determines that impairment charges are required based primarily on the financial condition and near-term prospects of these companies.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Intangible Assets</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. Purchased intangible assets are carried at cost, net of accumulated amortization, and are included in intangible assets in the Company's consolidated balance sheets. Intangible assets with finite lives are amortized over their estimated useful lives of primarily </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>seven years</span></span><span style="font-family:inherit;font-size:10pt;"> using the straight-line method.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-lived Assets, Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews long-lived assets and identifiable intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. The Company assesses these assets for impairment based on their estimated undiscounted future cash flows. If the carrying value of the assets exceeds the estimated future undiscounted cash flows, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates goodwill and indefinite lived intangible assets for impairment at least annually at the beginning of the fourth quarter of each fiscal year or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company performs a step one analysis, which consists of a comparison of the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit. The Company determines the fair value of its reporting units based on a combination of income and market approaches. The income approach is based on the present value of estimated future cash flows of the reporting units, and the market approach is based on a market multiple calculated for each reporting unit based on market data of other companies engaged in similar business. If the carrying amount of the reporting unit is in excess of its fair value, step two requires the comparison of the implied fair value of the reporting unit’s goodwill against the carrying amount of the reporting unit’s goodwill. Any excess of the carrying value of the reporting unit’s goodwill over the implied fair value of the reporting unit’s goodwill is recorded as an impairment loss. The impairment test for intangible assets with indefinite useful lives, if any, consists of a comparison of fair value to carrying value, with any excess of carrying value over fair value being recorded as an impairment loss.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of impairments of intangible assets related to the restructuring activities see Note </span><span style="font-family:inherit;font-size:10pt;">4</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring</span><span style="font-family:inherit;font-size:10pt;">, included in this report. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> goodwill impairment charges were recognized for any of the prior periods presented. No impairment charges were recognized in fiscal year </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss Contingencies</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits and other loss contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent an unfavorable outcome is determined to be probable and the losses can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Warranty</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company warrants most of its products for a specific period of time, usually </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>24</span></span><span style="font-family:inherit;font-size:10pt;"> months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table reflects the changes in the Company’s accrued product warranty:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued product warranty, at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Charged to cost of revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actual product warranty expenditures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued product warranty, at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective September 29, 2018, the Company adopted the requirements of Accounting Standards Update (“ASU”) 2014-09 and related amendments, Revenue from Contracts with Customers (“ASC 606”), which superseded all prior revenue recognition methods and industry-specific guidance. See “Recently Adopted Accounting Pronouncements” below.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines revenue recognition through the following steps:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification of the contract, or contracts, with a customer</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification of the performance obligations in the contract</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Determination of the transaction price</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocation of the transaction price to the performance obligations in the contract</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of revenue when, or as, a performance obligation is satisfied</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenues</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue primarily represents (i) the amount received applicable to non-software products for which parts</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and services under the warranty contracts have not been delivered, and (ii) the amount received for service contracts for</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">which the services have not been rendered.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Allowance for Doubtful Accounts</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates the creditworthiness of customers prior to authorizing shipment for all major sale transactions. On a quarterly basis, the Company evaluates aged items in the accounts receivable aging report and provide an allowance in an amount deemed adequate for doubtful accounts. If the evaluation of customers’ financial conditions does not reflect a future ability to collect outstanding receivables, additional provisions may be needed. We had an allowance for doubtful accounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an equity-based incentive plan that provides for the grant of nonqualified stock options and restricted stock units to directors, officers and other employees. The Company also permits employees to purchase shares under the Varex employee stock purchase plan. Prior to the separation, the Company’s employees historically participated in Varian’s equity-based incentive plans. Share-based compensation expense through the date of separation included allocations to the Company based on the awards and terms previously granted to its employees as well as an allocation of Varian’s corporate and shared functional employee expenses.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company values stock options granted and the option component of the shares of common stock purchased under the equity-based incentive plans and stock purchased under the employee stock purchase plan using the Black-Scholes option-pricing model. Share-based compensation expense for restricted stock units is measured using the fair value of the Company’s stock on the date of grant and is amortized over the award’s respective service period. The Black-Scholes option-pricing model requires the input of certain assumptions, and changes in the assumptions can materially affect the fair value estimates of share-based payment awards.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company measures and recognizes expense for all share-based payment awards based on their fair values. Share-based compensation expense recognized in the consolidated statements of earnings includes compensation expense for the share-based payment awards based on the grant date fair value estimated in accordance with the guidance on share-based compensation. Share-based compensation expense recognized is based on the value of the portion of share-based payment awards that is ultimately expected to vest. The Company attributes the value of share-based compensation to expense using the straight-line method. The Company considers only the direct tax impacts of share-based compensation awards when calculating the amount of tax windfalls or shortfalls. For additional information, see Note </span><span style="font-family:inherit;font-size:10pt;">13</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Plans</span><span style="font-family:inherit;font-size:10pt;">, included in this report.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shipping and Handling Costs</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and handling costs are included as a component of cost of revenues.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs have been expensed as incurred. These costs primarily include employees’ compensation, consulting fees and material costs. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Software Development Costs</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized, as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Taxes on Earnings</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">Current income tax expense is the amount of income taxes expected to be payable for the current year. Deferred income tax liabilities or assets are established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. In addition, we provide reserves for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance for accounting for income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. Government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (“U. S. Tax Reform”). U.S. Tax Reform significantly revised the U.S. corporate income tax structure including a lower corporate statutory rate and changes to the way foreign earnings are taxed. U.S. GAAP requires that the impact of tax legislation be recognized in the period in which the law is enacted. In accordance with these rules, we are including the impact of certain provisions of U.S. Tax Reform to the extent they are effective during the current reporting period. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the U.S. Dollar predominately as the functional currency of its foreign operations. Gains and losses from remeasurement of foreign currency balances into U.S. Dollars are included in the consolidated statements of earnings. For the foreign subsidiary where the local currency is the functional currency, translation adjustments of foreign currency financial statements into U.S. dollars are recorded to a separate component of accumulated other comprehensive (loss) earnings. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Standards Recently Adopted</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which requires that the statement of cash flows explain the change in the total amount of restricted cash during the period and other additional disclosures. The Company adopted ASU 2016-18 in the first quarter of 2019 using the retrospective transition method and the Company's consolidated statements of cash flows have been retrospectively adjusted to reflect restricted cash balances. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-18.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which was issued to reduce the diversity in practice in how certain transactions are classified in the statement of cash flows. The Company adopted ASU 2016-15 in the first quarter of 2019 retrospectively. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-15.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 as of September 29, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. The Company recorded a net reduction to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax, as of September 29, 2018 due to the impact of adopting ASC 606. During the second quarter of 2019 the Company recorded an increase to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax, to correct an error that was not quantitatively or qualitatively material to the current period, related to the adoption of ASC 606. The net cumulative impact of adopting ASC 606 was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax. Refer to Note </span><span style="font-weight:normal;">18.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, included in this report report for the detailed impact of adopting ASC 606.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which amends the application of hedge accounting and improves financial reporting of hedging relationships to more accurately present the economic effects of risk management activities in the financial statements. The ASU is effective for public companies for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company early adopted the provisions of ASU 2017-12 during the quarter ended September 27, 2019, using the modified retrospective method. The adoption did not have an impact on the consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Standards Updates Not Yet Effective</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from U.S. federal tax legislation commonly referred to as the Tax Cuts and Jobs Act, which was enacted in December 2017 (the “2017 Tax Act”). ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021, and must be applied on a modified retrospective basis. The Company is currently evaluating the potential impact of this standard.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02 on accounting for leases. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new standard will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of earnings. The new standard is required to be adopted using a modified retrospective method to each prior reporting period presented with various optional practical expedients. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2020 with early adoption permitted. The Company has not completed its assessment of the new standard, but anticipate that the most substantial change to its consolidated financial statements will be a gross-up of its total assets and liabilities. The adoption is not expected to materially impact our results of operations in the upcoming fiscal years and interim periods. The Company will continue to monitor the overall impact of adoption and update our disclosures as appropriate.</span></div> 1 The accompanying consolidated financial statements are audited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Prior to January 28 2017, the date of separation and distribution, the financial statements were prepared on a stand-alone basis and were derived from Varian’s consolidated financial statements and records as it operated as part of Varian prior to the distribution, in conformity with GAAP. <div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All transactions between the Company and Varian prior to the separation have been included in the accompanying consolidated financial statements. All intercompany transactions while the Company operated as part of Varian were considered to be effectively settled for cash and are reflected as a component of financing activities as net transfers from (to) Varian in the consolidated statements of cash flows at the time the transactions were recorded.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the separation, the Company was dependent upon Varian for its working capital and financing requirements, as Varian uses a centralized approach to cash management and financing of its operations. Financial transactions relating to the Company were accounted for through the net parent investment account. Cash and cash equivalents held by Varian were not allocated to the Company.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net parent investment in the consolidated statements of equity represents Varian’s historical investment in the Company, the net effect of transactions with and allocations from Varian and the Company’s accumulated earnings.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassification</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> from selling, general and administrative expense to impairment of intangible assets for the year ended September 28, 2018, to conform to the current year's presentation. Such reclassifications had no impact on net earnings as previously reported.</span></div> -3000000.0 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</span></div><span style="font-family:inherit;font-size:10pt;">The Company has </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span> reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its CEO, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. 2 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fiscal Year</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2019 was the 52-week period that ended on September 27, 2019. Fiscal year 2018 was the 52-week period that ended on September 28, 2018. Fiscal year 2017 was the 52-week period that ended on September 29, 2017. </span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Interest Entities</span></div><span style="font-family:inherit;font-size:10pt;">For entities in which the Company has variable interests, the Company focuses on identifying which entity has the power to direct the activities that most significantly impact the variable interest entity’s economic performance and which enterprise has the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities and results of operations of the variable interest entity will be included in the Company’s consolidated financial statements. As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span> variable interest entities neither of which were consolidated. 2 <span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers currency on hand, demand deposits, time deposits and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"/><span style="font-family:inherit;font-size:10pt;">Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is</span></div>included in other assets on the consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the consolidated statements of cash flows consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:382px;"/><td style="width:6px;"/><td style="width:69px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:69px;"/><td style="width:4px;"/><td style="width:6px;"/><td style="width:6px;"/><td style="width:69px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:69px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Twelve Months Ended September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Twelve Months Ended September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">End of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents and restricted cash as reported per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>84.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 51900000 29900000 83300000 51900000 1500000 1400000 900000 1500000 53400000 31300000 84200000 53400000 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. There is a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:102px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;text-align:left;padding-left:102px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2—Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or, other inputs that are observable or can be corroborated by observable market data.</span></div><div style="line-height:120%;text-align:left;padding-left:102px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative instruments and hedging activities</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records all derivatives on the balance sheet at fair value. Derivatives designated as a hedge are recorded on the Consolidated Balance Sheets at fair value as of the reporting date. For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss and reclassified from accumulated other comprehensive loss into earnings when the hedged transaction affects earnings.  For derivatives that are designated and qualify as net investment hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss. Time value is excluded and the cash payments are recognized as an adjustment to interest expense. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</span></div>Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. <div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, which is as follows:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canon Medical Systems Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.173 0.181 0.193 0.101 0.098 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are valued at the lower of cost or net realizable value. Costs include materials, labor and manufacturing overhead</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and is computed using standard cost (which approximates actual cost) on a first-in-first-out basis. The Company evaluates the carrying</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">value of its inventories taking into consideration such factors as historical and anticipated future sales compared to quantities on hand</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and the prices the Company expects to obtain for products in its various markets. The Company adjust excess and obsolete</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inventories to net realizable value and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues.</span></div> <div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s inventories, net:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and parts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 160100000 149900000 27900000 25400000 60200000 59800000 248200000 235100000 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Plant and Equipment, net</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment are stated at cost, net of accumulated depreciation. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation are computed using the straight-line method over the estimated useful lives of the assets. Land is not subject to depreciation, but land improvements are depreciated over </span><span style="font-family:inherit;font-size:10pt;"><span>fifteen years</span></span><span style="font-family:inherit;font-size:10pt;">. Land leasehold rights and leasehold improvements are depreciated over the lesser of their estimated useful lives or remaining lease terms. Buildings are depreciated over </span><span style="font-family:inherit;font-size:10pt;"><span>twenty years</span></span><span style="font-family:inherit;font-size:10pt;">. Machinery and equipment are depreciated over their estimated useful lives, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>seven years</span></span><span style="font-family:inherit;font-size:10pt;">. Assets subject to lease are depreciated over the lesser of their estimated useful lives or remaining lease terms. Estimated useful lives are periodically reviewed and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted, and an impairment assessment may be performed on the recoverability of the carrying amounts. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts.</span></div> P15Y P20Y P3Y P7Y <div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s property, plant and equipment, net:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Buildings and leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>134.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>138.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Machinery</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>170.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>166.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>341.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>335.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(199.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(190.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant, and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>142.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>144.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8300000 8300000 134400000 138100000 170700000 166100000 28500000 23100000 341900000 335600000 199600000 190700000 142300000 144900000 23500000 26000000.0 16900000 4500000 4200000 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in these investments. Distributions received from an equity method investment are classified using the cumulative earnings approach. Under the cumulative earnings approach, distributions up to the amount of cumulative equity in earnings recognized will be treated as returns on investment as operating cash flows and those in excess of that amount will be treated as returns of investment as investing cash flows. The Company monitors these equity investments for impairment and makes appropriate reductions in carrying values if the Company determines that impairment charges are required based primarily on the financial condition and near-term prospects of these companies.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Intangible Assets</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. Purchased intangible assets are carried at cost, net of accumulated amortization, and are included in intangible assets in the Company's consolidated balance sheets. Intangible assets with finite lives are amortized over their estimated useful lives of primarily </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>seven years</span></span><span style="font-family:inherit;font-size:10pt;"> using the straight-line method.</span></div> P2Y P7Y <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-lived Assets, Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews long-lived assets and identifiable intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. The Company assesses these assets for impairment based on their estimated undiscounted future cash flows. If the carrying value of the assets exceeds the estimated future undiscounted cash flows, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates goodwill and indefinite lived intangible assets for impairment at least annually at the beginning of the fourth quarter of each fiscal year or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company performs a step one analysis, which consists of a comparison of the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit. The Company determines the fair value of its reporting units based on a combination of income and market approaches. The income approach is based on the present value of estimated future cash flows of the reporting units, and the market approach is based on a market multiple calculated for each reporting unit based on market data of other companies engaged in similar business. If the carrying amount of the reporting unit is in excess of its fair value, step two requires the comparison of the implied fair value of the reporting unit’s goodwill against the carrying amount of the reporting unit’s goodwill. Any excess of the carrying value of the reporting unit’s goodwill over the implied fair value of the reporting unit’s goodwill is recorded as an impairment loss. The impairment test for intangible assets with indefinite useful lives, if any, consists of a comparison of fair value to carrying value, with any excess of carrying value over fair value being recorded as an impairment loss.</span></div> 4800000 3000000.0 0 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss Contingencies</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits and other loss contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent an unfavorable outcome is determined to be probable and the losses can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Warranty</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company warrants most of its products for a specific period of time, usually </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>24</span></span><span style="font-family:inherit;font-size:10pt;"> months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.</span></div> P12M P24M <div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table reflects the changes in the Company’s accrued product warranty:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued product warranty, at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Charged to cost of revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actual product warranty expenditures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued product warranty, at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 7300000 7000000.0 12900000 11600000 12100000 11300000 8100000 7300000 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Allowance for Doubtful Accounts</span></div>The Company evaluates the creditworthiness of customers prior to authorizing shipment for all major sale transactions. On a quarterly basis, the Company evaluates aged items in the accounts receivable aging report and provide an allowance in an amount deemed adequate for doubtful accounts. If the evaluation of customers’ financial conditions does not reflect a future ability to collect outstanding receivables, additional provisions may be needed. 1000000.0 600000 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an equity-based incentive plan that provides for the grant of nonqualified stock options and restricted stock units to directors, officers and other employees. The Company also permits employees to purchase shares under the Varex employee stock purchase plan. Prior to the separation, the Company’s employees historically participated in Varian’s equity-based incentive plans. Share-based compensation expense through the date of separation included allocations to the Company based on the awards and terms previously granted to its employees as well as an allocation of Varian’s corporate and shared functional employee expenses.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company values stock options granted and the option component of the shares of common stock purchased under the equity-based incentive plans and stock purchased under the employee stock purchase plan using the Black-Scholes option-pricing model. Share-based compensation expense for restricted stock units is measured using the fair value of the Company’s stock on the date of grant and is amortized over the award’s respective service period. The Black-Scholes option-pricing model requires the input of certain assumptions, and changes in the assumptions can materially affect the fair value estimates of share-based payment awards.</span></div>The Company measures and recognizes expense for all share-based payment awards based on their fair values. Share-based compensation expense recognized in the consolidated statements of earnings includes compensation expense for the share-based payment awards based on the grant date fair value estimated in accordance with the guidance on share-based compensation. Share-based compensation expense recognized is based on the value of the portion of share-based payment awards that is ultimately expected to vest. The Company attributes the value of share-based compensation to expense using the straight-line method. The Company considers only the direct tax impacts of share-based compensation awards when calculating the amount of tax windfalls or shortfalls. <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shipping and Handling Costs</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and handling costs are included as a component of cost of revenues.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective September 29, 2018, the Company adopted the requirements of Accounting Standards Update (“ASU”) 2014-09 and related amendments, Revenue from Contracts with Customers (“ASC 606”), which superseded all prior revenue recognition methods and industry-specific guidance. See “Recently Adopted Accounting Pronouncements” below.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines revenue recognition through the following steps:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification of the contract, or contracts, with a customer</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification of the performance obligations in the contract</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Determination of the transaction price</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocation of the transaction price to the performance obligations in the contract</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of revenue when, or as, a performance obligation is satisfied</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenues</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue primarily represents (i) the amount received applicable to non-software products for which parts</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and services under the warranty contracts have not been delivered, and (ii) the amount received for service contracts for</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">which the services have not been rendered.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 on September 29, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for fiscal year 2019 reflect the application of ASC 606 guidance while the reported results for fiscal year 2018 were prepared under the guidance of ASC 605, “Revenue Recognition.” The primary impacts of the adoption include: (1) recording a separate contract liability and contract asset related to the sale of X-ray tubes that were sold with an option for the customer to require the Company to repurchase specific parts of the X‑ray tube at a specific price; and (2) recording a liability related to the deferral of revenue for service type warranties that are provided to certain customers who purchase Linatron</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> X-ray accelerators.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component, if, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are included as a component of cost of revenues; and (5) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transaction price and allocation to performance obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div>Research and development costs have been expensed as incurred. These costs primarily include employees’ compensation, consulting fees and material costs. <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Software Development Costs</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized, as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Taxes on Earnings</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">Current income tax expense is the amount of income taxes expected to be payable for the current year. Deferred income tax liabilities or assets are established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. In addition, we provide reserves for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance for accounting for income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. Government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (“U. S. Tax Reform”). U.S. Tax Reform significantly revised the U.S. corporate income tax structure including a lower corporate statutory rate and changes to the way foreign earnings are taxed. U.S. GAAP requires that the impact of tax legislation be recognized in the period in which the law is enacted. In accordance with these rules, we are including the impact of certain provisions of U.S. Tax Reform to the extent they are effective during the current reporting period. </span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</span></div>The Company uses the U.S. Dollar predominately as the functional currency of its foreign operations. Gains and losses from remeasurement of foreign currency balances into U.S. Dollars are included in the consolidated statements of earnings. For the foreign subsidiary where the local currency is the functional currency, translation adjustments of foreign currency financial statements into U.S. dollars are recorded to a separate component of accumulated other comprehensive (loss) earnings. <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Standards Recently Adopted</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which requires that the statement of cash flows explain the change in the total amount of restricted cash during the period and other additional disclosures. The Company adopted ASU 2016-18 in the first quarter of 2019 using the retrospective transition method and the Company's consolidated statements of cash flows have been retrospectively adjusted to reflect restricted cash balances. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-18.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which was issued to reduce the diversity in practice in how certain transactions are classified in the statement of cash flows. The Company adopted ASU 2016-15 in the first quarter of 2019 retrospectively. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-15.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 as of September 29, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. The Company recorded a net reduction to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax, as of September 29, 2018 due to the impact of adopting ASC 606. During the second quarter of 2019 the Company recorded an increase to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax, to correct an error that was not quantitatively or qualitatively material to the current period, related to the adoption of ASC 606. The net cumulative impact of adopting ASC 606 was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax. Refer to Note </span><span style="font-weight:normal;">18.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, included in this report report for the detailed impact of adopting ASC 606.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which amends the application of hedge accounting and improves financial reporting of hedging relationships to more accurately present the economic effects of risk management activities in the financial statements. The ASU is effective for public companies for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company early adopted the provisions of ASU 2017-12 during the quarter ended September 27, 2019, using the modified retrospective method. The adoption did not have an impact on the consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Standards Updates Not Yet Effective</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from U.S. federal tax legislation commonly referred to as the Tax Cuts and Jobs Act, which was enacted in December 2017 (the “2017 Tax Act”). ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021, and must be applied on a modified retrospective basis. The Company is currently evaluating the potential impact of this standard.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02 on accounting for leases. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new standard will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of earnings. The new standard is required to be adopted using a modified retrospective method to each prior reporting period presented with various optional practical expedients. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2020 with early adoption permitted. The Company has not completed its assessment of the new standard, but anticipate that the most substantial change to its consolidated financial statements will be a gross-up of its total assets and liabilities. The adoption is not expected to materially impact our results of operations in the upcoming fiscal years and interim periods. The Company will continue to monitor the overall impact of adoption and update our disclosures as appropriate.</span></div> -4100000 600000 -3500000 BUSINESS COMBINATIONS<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Direct Conversion AB (publ)</span></div><div style="line-height:120%;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">April 29, 2019</span><span style="font-family:inherit;font-size:10pt;">, Varex completed the acquisition of </span><span style="font-family:inherit;font-size:10pt;"><span>98.2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of common stock of Direct Conversion AB (publ) (“Direct Conversion”) for $</span><span style="font-family:inherit;font-size:10pt;"><span>69.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, net of cash acquired, the assumption of Direct Conversion's debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and deferred consideration equal to </span><span style="font-family:inherit;font-size:10pt;"><span>$9.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;"><span>0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (subject to reduction to settle indemnity claims) to be paid on the first anniversary of the closing with a mixture of cash and shares of Varex common stock. The acquisition of Direct Conversion expands our detector product portfolio to include photon counting technology.  This technology will allow Varex to expand its range of imaging applications and offer new solutions to both Medical and Industrial customers.</span></div><div style="line-height:120%;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary purchase price allocation:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocation of the purchase consideration:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>89.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net assets acquired, less noncontrolling interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>79.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>79.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded the assets acquired and liabilities assumed at their preliminary estimated fair values. Intangibles were valued primarily using a discounted cash flow, which included estimated revenue growth and discount rate. Due to the complexity of this transaction as of September 27, 2019, the Company had not finalized the determination of the fair values allocated to various assets and liabilities, including, but not limited to, inventory; deferred tax assets and liabilities; intangible assets and the residual amount allocated to goodwill. The fair value assigned to goodwill is primarily attributable to expected synergies. The goodwill related to the Direct Conversion acquisition is not tax deductible.</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Weighted Average <br/>Useful Life<br/>(In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Backlog</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">indefinite</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent revenues by reporting segment from Direct Conversion from the acquisition date of </span><span style="font-family:inherit;font-size:10pt;">April 29, 2019</span><span style="font-family:inherit;font-size:10pt;">, through September 27, 2019:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Direct Conversion Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Direct Conversion revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The acquisition of Direct Conversion did not have a significant impact on our consolidated results of operations on a pro forma basis for the current or prior years.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Virtual Media Integration </span></div><div style="line-height:120%;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 31, 2018, the Company completed the acquisition of Virtual Media Integration, Ltd. (“VMI”) from MISTRAS Group, Inc for </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. VMI is a provider of computed and digital radiography and X-ray film digitizer systems for industrial non-destructive testing. The acquired assets and liabilities of the VMI business were allocated to the Industrial reporting segment. The acquisition related costs were included in the consolidated statements of earnings under selling, general and administrative expenses.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the purchase price allocation:</span></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocation of the purchase consideration:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts Receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Post-closing adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total cash consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of PerkinElmer’s Medical Imaging Business</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 1, 2017, the Company completed the acquisition of the medical imaging business (“Acquired Detector Business”) of PerkinElmer, Inc. (“PKI”) for </span><span style="font-family:inherit;font-size:10pt;"><span>$277.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;"><span>$273.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> after post-closing working capital adjustments. The acquisition consisted of PerkinElmer Medical Holdings, Inc. and Dexela Limited, together with certain assets of PKI and its direct and indirect subsidiaries relating to digital flat panel X-ray detectors that serve as components for industrial, medical, dental and veterinary X-ray imaging systems. The Acquired Detector Business included about </span><span style="font-family:inherit;font-size:10pt;"><span>280</span></span><span style="font-family:inherit;font-size:10pt;"> employees, with operations in Santa Clara, California as well as operations in Germany, the Netherlands, China and the United Kingdom. The acquisition of the Acquired Detector Business was pursuant to the Master Purchase and Sale Agreement, dated December 21, 2016 (the “Purchase Agreement”), by and between PKI and Varian and the subsequent Assignment and Assumption Agreement, dated January 27, 2017, by and between Varian and Varex, pursuant to which Varian assigned and conveyed all of its rights, obligations, title and interest in the Purchase Agreement to Varex.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent the determination of the fair value of identifiable assets acquired and liabilities for the Acquired Detector Business:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total cash consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>273.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocation of the purchase consideration:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts Receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaids and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant, and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>167.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>327.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other liabilities, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>273.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value assigned to goodwill is attributable to expected cost synergy opportunities. Included in the goodwill recorded for the Acquired Detector Business is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$35 million</span></span><span style="font-family:inherit;font-size:10pt;"> that will be deductible for income tax purposes in Germany, China and the Netherlands. The remaining goodwill related to the stock acquisition in the United States is not tax deductible. Also, as a result of the acquisition, non-current deferred income tax liability increased by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$31 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to basis differences for both tangible and intangible assets acquired as part of the stock purchases in the United States and the United Kingdom, and asset purchases in Germany, the Netherlands and China.</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent the determination of the fair value of identifiable intangible assets for the Acquired Detector Business, which are amortized straight-line:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated <br/>Useful Life<br/>(In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Favorable leasehold interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Backlog</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">indefinite</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent revenues by reporting segment from the Acquired Detector Business from the acquisition date of May 1, 2017 through September 29, 2017:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">May 1, 2017 through September 29, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired Detector Business</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Acquired Detector Business revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>61.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Unaudited Pro Forma Information </span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited pro-forma amounts presented below for the fiscal year 2017 are presented for informational purposes only. In addition to the Company's results for the periods presented, the amounts below also include effects of the Acquired Detector Business as if it had been consummated on October 1, 2016. These unaudited pro-forma results include effects that are directly attributable to the acquisition which include the amortization of intangible assets, interest expense, and other adjustments, including estimated tax effects. The unaudited pro-forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the Acquired Detector Business and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations or results that might have been achieved had the acquisition been consummated as of October 3, 2015.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>777.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>84.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share, basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share, diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.982 69500000 4500000 9900000 300000 2400000 5700000 700000 900000 47200000 32900000 89800000 1000000.0 1500000 1000000.0 900000 3500000 1100000 9000000.0 1400000 79400000 69500000 9900000 79400000 200000 P1Y 2500000 P5Y 18400000 P10Y 2800000 9000000.0 P10Y 32900000 <div style="line-height:120%;padding-bottom:9px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent revenues by reporting segment from Direct Conversion from the acquisition date of </span><span style="font-family:inherit;font-size:10pt;">April 29, 2019</span><span style="font-family:inherit;font-size:10pt;">, through September 27, 2019:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Direct Conversion Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Direct Conversion revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent revenues by reporting segment from the Acquired Detector Business from the acquisition date of May 1, 2017 through September 29, 2017:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">May 1, 2017 through September 29, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired Detector Business</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Acquired Detector Business revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>61.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information related to the Company’s segments is as follows:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>596.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>602.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>556.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>183.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>171.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>141.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>780.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>773.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>698.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross margin</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>188.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>190.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>193.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>67.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>63.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>256.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>253.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>253.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>211.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>209.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>169.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest and other expenses, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(24.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(18.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings before taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Taxes (benefit) on earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4500000 1800000 6300000 4800000 <div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the purchase price allocation:</span></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocation of the purchase consideration:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts Receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Post-closing adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total cash consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary purchase price allocation:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocation of the purchase consideration:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>89.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net assets acquired, less noncontrolling interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>79.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>79.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent the determination of the fair value of identifiable assets acquired and liabilities for the Acquired Detector Business:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total cash consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>273.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocation of the purchase consideration:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts Receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaids and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant, and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>167.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>327.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:20px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other liabilities, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>273.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 200000 1000000.0 200000 1600000 1500000 200000 4300000 500000 4800000 277400000 273200000 280 273200000 1400000 18700000 34700000 600000 21400000 2000000.0 81100000 167300000 327200000 17200000 36800000 54000000.0 273200000 35000000 31000000 <div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent the determination of the fair value of identifiable intangible assets for the Acquired Detector Business, which are amortized straight-line:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated <br/>Useful Life<br/>(In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Favorable leasehold interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Backlog</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">indefinite</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Weighted Average <br/>Useful Life<br/>(In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Backlog</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">indefinite</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3800000 P16Y 1200000 P1Y 1400000 P5Y 37700000 P7Y 4000000.0 33000000.0 P7Y 81100000 41100000 20200000 61300000 The unaudited pro-forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the Acquired Detector Business and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations or results that might have been achieved had the acquisition been consummated as of October 3, 2015.<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>777.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>84.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share, basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share, diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span> 777800000 84700000 43100000 1.15 1.13 RELATED-PARTY TRANSACTIONS<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment in Privately-Held Companies </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in dpiX Holding LLC (“dpiX Holding”), a </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;">-member consortium that has a </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon based thin film transistor arrays for digital flat panel image detectors. In accordance with the dpiX Holding Agreement, net profits or losses are allocated to the members, in accordance with their ownership interests.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The equity investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated until realized by the Company. In fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded (loss) and income on the equity investment in dpiX Holding of </span><span style="font-family:inherit;font-size:10pt;"><span>$(1.1) million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Income and loss on the equity investment in dpiX Holding is included in other (expense) income, net in the consolidated statements of earnings. The carrying value of the equity investment in dpiX Holding, which was included in investments in privately-held companies on the consolidated balance sheets, was </span><span style="font-family:inherit;font-size:10pt;"><span>$48.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$48.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company purchased glass transistor arrays from dpiX totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$23.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$19.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. These purchases of glass transistor arrays are included as a component of inventories on the consolidated balance sheets or cost of revenues in the consolidated statements of earnings for these fiscal years.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had accounts payable to dpiX totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides the Company with the right to </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires the Company to pay for </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company estimated it has fixed cost commitments of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this amended agreement through the remainder of calendar year </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. The fixed cost commitment for future periods will be determined and approved by the dpiX board of directors at the beginning of each calendar year. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has determined that dpiX is a variable interest entity because at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to direct the activities of dpiX and therefore is not the primary beneficiary of dpiX. The Company’s exposure to loss as a result of its involvement with dpiX is limited to the carrying value of the Company’s investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$48.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and fixed cost commitments of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the Company and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging Verwaltungsgesellschaft GmbH (“VEC”), a joint venture formed to develop technology to be used in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members, in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method. The Company has made contributions totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and has committed to contribute an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, as milestones are achieved, and to provide certain full time employees to support prototyping and manufacturing activities in exchange for a </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> interest in VEC. CETTEEN made contributions of certain assets including intellectual property in exchange for a </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> interest in VEC. The Company's investment in VEC was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 0.40 4 1 -1100000 3400000 800000 48100000 48900000 23500000 19300000 24700000 3600000 3700000 0.50 0.50 3700000 48100000 3700000 2900000 2200000 0.50 0.50 2000000.0 RESTRUCTURING<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">Following the acquisition of the medical imaging business from PKI in May of 2017, management began a multiyear program to consolidate the acquired operations, reduce costs, improve productivity and realize synergies.</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2018, the Company made the decision to transfer the complementary metal oxide semiconductor (“CMOS”) research and development capability from the U.K. to the U.S. and to permanently close the operation of the acquired detector business in London. The company will continue to develop the CMOS technology in the U.S. due to its competitive advantages, product differentiation and future economic benefit. In connection with this initiative, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in restructuring charges during fiscal year 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"/><span style="font-family:inherit;font-size:10pt;">In July 2018, the Company committed to a plan to relocate the production of amorphous silicon glass for digital detectors, from its Santa Clara facility, to the jointly owned dpiX fabrication facility in Colorado. In July 2019, the Company committed to close its Santa Clara facility and to relocate the remaining production to its other existing facilities. The Company expects operations at the Santa Clara facility to cease by the end of December 2020 and all activities related to the closure of the facility to be complete by the end of March 2021. In connection with the relocation of the glass production and site closure the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$16.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$14.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of restructuring and impairment charges during fiscal year 2019 and 2018, respectively. Fiscal year 2019 intangible asset impairment charges consisted of in-process research and development related to certain projects that were discontinued as a result of the Santa Clara facility closure. Fiscal year 2018 intangible asset impairment charges were related to a favorable leasehold interest that was impaired as a result of the amorphous silicon glass relocation. The Company expects to incur an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$12.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of restructuring charges through March 2021.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of other unrelated restructuring expenses during fiscal years 2019 and 2018, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash outflows associated with these restructuring charges are limited to employee termination expenses, facility closure and equipment sales and disposals. Below is a detail of restructuring charges incurred during the 2019 and 2018 fiscal years, which predominately relate to the Company's Medical segment:</span></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:214px;"/><td style="width:273px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:99px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:99px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Location of Restructuring Charges in Consolidated Statements of Earnings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets impairment charges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventory write downs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets impairment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment of intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accelerated depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Severance costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Facility closure costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total restructuring charges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1700000 16100000 14200000 8100000 12100000 2800000 800000 Below is a detail of restructuring charges incurred during the 2019 and 2018 fiscal years, which predominately relate to the Company's Medical segment:<div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:214px;"/><td style="width:273px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:99px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:99px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Location of Restructuring Charges in Consolidated Statements of Earnings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets impairment charges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventory write downs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets impairment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment of intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accelerated depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Severance costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Facility closure costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total restructuring charges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 1300000 3100000 3100000 4800000 3000000.0 4500000 4200000 6200000 4300000 300000 800000 18900000 16700000 OTHER FINANCIAL INFORMATION<div style="line-height:120%;padding-top:12px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;background-color:#ffffff;">     </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s accrued liabilities:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Product warranty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Payable to Varian Medical Systems</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Right of return liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>75.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s other long-term liabilities:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term income tax payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Environment liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Defined benefit obligation liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term right of return liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total other long-term liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s other income (expense), net:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income (loss) from equity method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in fair value of deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Realized income (loss) on foreign currencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s accrued liabilities:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Product warranty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Payable to Varian Medical Systems</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Right of return liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>75.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span> 32100000 27000000.0 8100000 7300000 10700000 1400000 0 2300000 6900000 0 8900000 0 9000000.0 9500000 75700000 47500000 <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s other long-term liabilities:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term income tax payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Environment liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Defined benefit obligation liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term right of return liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total other long-term liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 3900000 3500000 900000 1300000 5500000 3300000 19500000 0 2700000 400000 32500000 8500000 <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table summarizes the Company’s other income (expense), net:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income (loss) from equity method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in fair value of deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Realized income (loss) on foreign currencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -2300000 3900000 1300000 -1000000.0 0 0 -1900000 -1200000 1900000 -3200000 2700000 3200000 NET EARNINGS PER SHARE<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net earnings per common share is computed by dividing the net earnings for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net earnings per common share reflects the effects of potentially dilutive securities, which is computed by dividing net earnings by the sum of the weighted average number of common shares outstanding and dilutive common shares, which consists of stock options and unvested restricted stock.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per common share is as follows:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:22px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Dilutive effect of potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share attributable to Varex - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share attributable to Varex - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Anti-dilutive employee shared based awards, excluded</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company excludes potentially dilutive common shares (consisting of shares underlying stock options and the employee stock purchase plan) from the computation of diluted weighted average shares outstanding if the inclusion of the shares underlying these stock awards would be anti-dilutive to earnings per share.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per common share is as follows:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:22px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Dilutive effect of potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share attributable to Varex - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share attributable to Varex - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:2px;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Anti-dilutive employee shared based awards, excluded</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 15500000 27500000 51600000 38200000 37900000 37600000 400000 500000 400000 38600000 38400000 38000000 0.41 0.73 1.37 0.40 0.72 1.36 1900000 1200000 1000000.0 FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records all derivatives on the consolidated balance sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.    The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. The Company does not offset fair value amounts recognized for derivative instruments in its consolidated balance sheets for presentation purposes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives Designated as Hedging Instruments - Cash Flow Hedges</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses interest rate swap contracts as cash flow hedges to manage its exposure to fluctuations in LIBOR interest rates. Interest rate swap contracts hedging variable rate debt effectively fix the LIBOR component of its interest rate for a specific period of time.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had the following outstanding derivatives designated as cash flow hedging instruments:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions, except for number of instruments)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest Rate Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>264.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for cash flow hedges:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain or (Loss) Recognized in OCI on Derivative<br/>Fiscal Year Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income<br/>Fiscal Year Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest Rate Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expects that </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the accumulated other comprehensive (loss) income related to cash flow hedges will be realized in pre-tax earnings over the next 12 months, but the amount will vary depending on interest rates.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded. </span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:20%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Derivatives designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Balance sheet location</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Balance sheet location</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;">Other non-current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other non-current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives Designated as Hedging Instruments - Net Investment Hedges</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly-owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive (loss) income along with the foreign currency translation adjustments on those investments. As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had the following outstanding derivatives designated as net investment hedging instruments:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions, except for number of instruments)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain or (Loss) Recognized in OCI on Derivative<br/>Fiscal Year Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:20%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Derivatives designated as net investment hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Balance sheet location</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Balance sheet location</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross currency swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Hedges</span></div><div style="line-height:120%;padding-top:12px;padding-left:4px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily cash, third-party accounts receivable, accounts payable, and intercompany receivables and payables. These forward contracts expire within 30 days. These forward contracts are not designated for hedge accounting treatment, therefore, the change in fair value of these derivatives is recorded as a component of other income (expense) and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense). The effect of derivative instruments not designated as hedges for fiscal year 2019 was a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was primarily related to the purchase price hedge established following the announcement of the Company's planned acquisition of Direct Conversion. The Company does not, and does not intend to use derivative financial instruments for speculative or trading purposes.</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the notional amounts of outstanding foreign currency contracts entered into under its balance sheet hedge program as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Value of Derivatives not Designated as Hedging Instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">In millions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Buy contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Sell contract</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Chinese renminbi</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Euro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6 264400000 <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for cash flow hedges:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain or (Loss) Recognized in OCI on Derivative<br/>Fiscal Year Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income<br/>Fiscal Year Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest Rate Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expects that </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the accumulated other comprehensive (loss) income related to cash flow hedges will be realized in pre-tax earnings over the next 12 months, but the amount will vary depending on interest rates.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded. </span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:20%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Derivatives designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Balance sheet location</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Balance sheet location</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;">Other non-current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other non-current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain or (Loss) Recognized in OCI on Derivative<br/>Fiscal Year Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:20%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Derivatives designated as net investment hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Balance sheet location</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Balance sheet location</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross currency swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -6300000 6900000 600000 1900000 100000 -300000 100000 0 2200000 0 0 0 5500000 500000 0 0 7700000 500000 0 4 77700000 -200000 0 0 200000 0 0 0 0 200000 0 0 0 200000 0 1500000 <div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the notional amounts of outstanding foreign currency contracts entered into under its balance sheet hedge program as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Value of Derivatives not Designated as Hedging Instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">In millions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Buy contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Sell contract</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Chinese renminbi</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Euro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had the following outstanding derivatives designated as cash flow hedging instruments:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions, except for number of instruments)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest Rate Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>264.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> As of <span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had the following outstanding derivatives designated as net investment hedging instruments:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions, except for number of instruments)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 900000 0 0 -1000000.0 1800000 0 8800000 0 11500000 -1000000.0 BORROWINGS<div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's short-term and long-term debt:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except for percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Interest Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current maturities of long-term debt</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Term facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current maturities of long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current maturities of long-term debt:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revolving credit facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Term facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>308.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>345.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>364.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>364.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>395.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>389.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Existing Credit Facility</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 1, 2017 and in connection with the Acquired Detector Business, the Company entered into a new secured revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> with a </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year term, and a secured term facility (the “Term Facility” and together with the Revolving Credit Facility, the “Credit Agreement”) in an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$400.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Term Facility will be repaid over </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, with </span><span style="font-family:inherit;font-size:10pt;"><span>5.0%</span></span><span style="font-family:inherit;font-size:10pt;"> payable in quarterly installments </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">during each of the first two years of the term thereof, </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;"> payable in quarterly installments during the third and fourth years of the term thereof, and </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> payable in quarterly installments in the fifth year of the term thereof, with the remaining amount due at maturity. Varex used the net proceeds from the Term Facility, and the net proceeds from approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$97.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> drawn on the Revolving Credit Facility, to pay the purchase price for the Acquired Detector Business, plus related credit facility fees, and to repay all of Varex’s obligations under the Previous Credit Agreement. Both the Term Facility and Revolving Credit Facility expire on May 1, 2022.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement contains various customary restrictive covenants that limits, among other things, the incurrence of indebtedness by Varex and its subsidiaries, the grant or incurrence of liens by Varex and its subsidiaries, the entry into sale and leaseback transactions by Varex and its subsidiaries, and the entry into certain fundamental change transactions by Varex and its subsidiaries. It also contains customary events of default and certain financial covenants. The Company agreed to maintain financial covenants, which include maximum consolidated total leverage ratio, maximum senior secured leverage ratio, maximum capital expenditures and a minimum consolidated fixed charge coverage ratio. The Company was in compliance with all financial covenants under the Credit Agreement as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement is secured by the stock and assets of Varex’s material subsidiaries. The Credit Agreement has several borrowing and interest rate options including the following indices: (a) LIBOR rate, or (b) the base rate (equal to the greater of the prime rate, the federal funds rate plus </span><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span><span style="font-family:inherit;font-size:10pt;"> or the LIBOR rate for a one-month period plus </span><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span><span style="font-family:inherit;font-size:10pt;">). Loans under the Credit Agreement bear interest at a rate per annum using the applicable indices plus a varying interest rate margin of between </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2.75%</span></span><span style="font-family:inherit;font-size:10pt;"> (for LIBOR rate loans) and </span><span style="font-family:inherit;font-size:10pt;"><span>0.75%</span></span><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> (for base rate loans). The Credit Agreement also provides for fees applicable to amounts available to be drawn under outstanding letters of credit of </span><span style="font-family:inherit;font-size:10pt;"><span>0.125%</span></span><span style="font-family:inherit;font-size:10pt;">, and a fee on unused commitments which ranges from </span><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>0.40%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 3, 2018, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of October 10, 2018, the Company had permanently reducing the revolving credit commitment under the Credit Agreement by </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The reduction in the revolving credit commitment reduced the fees paid by the Company in connection with such commitment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to fiscal year 2019, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of </span><span style="font-family:inherit;font-size:10pt;">October 8, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was permanently reducing the revolving credit commitment under the Credit Agreement by </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to fiscal year 2019, the Company did not comply with the covenant under the Credit Agreement to timely deliver the Company's fiscal year 2019 annual financial statements. However, upon the filing of this Annual Report with the SEC, the Company will be able to deliver the fiscal year 2019 annual financial statements within the 30-day cure period set forth in the Credit Agreement and consequently no event of default will occur. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$364.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in non-current maturities of long-term debt outstanding, net of deferred debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$30.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of current maturities of long-term debt outstanding.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future principal payments of the long-term debt outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal years:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>335.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total debt outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>400.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(30.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current portion of long -term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>370.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's short-term and long-term debt:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except for percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Interest Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current maturities of long-term debt</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Term facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current maturities of long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current maturities of long-term debt:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revolving credit facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Term facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>308.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>345.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>364.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>364.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>395.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>389.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 29400000 0.056 25000000.0 0.042 1300000 0 30700000 25000000.0 59000000.0 0.056 28000000.0 0.042 308600000 0.056 345000000.0 0.042 2500000 0 5700000 8200000 364400000 364800000 395100000 389800000 200000000.0 400000000.0 P5Y 0.050 0.075 0.10 97000000.0 0.0050 0.0100 0.0175 0.0275 0.0075 0.0175 0.00125 0.0025 0.0040 50000000.0 150000000.0 25000000.0 125000000.0 364400000 5700000 30700000 <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future principal payments of the long-term debt outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal years:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>335.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total debt outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>400.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(30.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current portion of long -term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>370.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 30700000 34300000 335800000 400800000 30700000 370100000 FAIR VALUE<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets/Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements at September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents - money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the total outstanding borrowings under the Company's credit agreement were </span><span style="font-family:inherit;font-size:10pt;"><span>$395.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of deferred loan costs, which approximated its fair value because it is carried at a market observable interest rate that resets periodically and is categorized as Level 2 in the fair value hierarchy. The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable and accounts payable, also approximate their fair values due to their short maturities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no financial assets or liabilities measured on a recurring basis using significant unobservable inputs (Level 3) and there were no transfers in or out of Level 1, 2 or 3 during fiscal year 2018. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company determined the following levels of inputs for the following assets or liabilities:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:714px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:298px;"/><td style="width:9px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements at September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other<br/>Observable Inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs <br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents - Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 8800000 0 8800000 0 8800000 0 8800000 0 700000 0 700000 8900000 0 0 8900000 8900000 700000 0 9600000 395100000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company determined the following levels of inputs for the following assets or liabilities:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:714px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:298px;"/><td style="width:9px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements at September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other<br/>Observable Inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs <br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents - Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements at September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents - money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 18400000 0 18400000 0 7700000 0 7700000 0 26100000 0 26100000 0 0 0 0 GOODWILL AND INTANGIBLE ASSETS<div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects goodwill by reportable operating segment: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Industrial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>147.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>96.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>243.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Business combination</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>173.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>290.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the consolidated balance sheets: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired existing technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>36.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Patents, licenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer contracts and supplier relationship</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>42.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets with finite lives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>110.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(40.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process R&amp;D with indefinite lives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>86.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>114.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(40.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>73.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense for intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$15.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$16.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company recognized an impairment loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. These impairment costs were included in the consolidated statements of earnings under impairment of intangible assets.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">As of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, the estimated future amortization expense of intangible assets with finite lives is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal years:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects goodwill by reportable operating segment: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Industrial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>147.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>96.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>243.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Business combination</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>173.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>290.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 147000000.0 96600000 243600000 26000000.0 21200000 47200000 173000000.0 117800000 290800000 <div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the consolidated balance sheets: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired existing technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>36.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Patents, licenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer contracts and supplier relationship</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>42.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets with finite lives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>110.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(40.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process R&amp;D with indefinite lives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>86.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>114.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(40.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>73.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the consolidated balance sheets: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired existing technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>36.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Patents, licenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer contracts and supplier relationship</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>42.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets with finite lives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>110.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(40.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process R&amp;D with indefinite lives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>86.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>114.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(40.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>73.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 74100000 28400000 45700000 57900000 21800000 36100000 12700000 8400000 4300000 9900000 7400000 2500000 50700000 17200000 33500000 42600000 11400000 31200000 137500000 54000000.0 83500000 110400000 40600000 69800000 2800000 2800000 4000000.0 4000000.0 140300000 54000000.0 86300000 114400000 40600000 73800000 15700000 16200000 10500000 4800000 3000000.0 <div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">As of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, the estimated future amortization expense of intangible assets with finite lives is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal years:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 17200000 16300000 14700000 13700000 9100000 12500000 83500000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;font-weight:bold;">Lease Commitments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">At </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, the Company was committed to minimum rentals under non-cancelable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and therea</span><span style="font-family:inherit;font-size:10pt;">fter, as follows: </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Ren</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">tal expenses were</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">,</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, and</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">for fiscal years</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;font-weight:bold;">Other Commitments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 3. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Related Party Transactions, </span><span style="font-family:inherit;font-size:10pt;">included in this report, for additional information about the Company’s commitments to dpiX.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 12. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Redeemable Noncontrolling Interests &amp; Noncontrolling Interests, </span><span style="font-family:inherit;font-size:10pt;">included in this report, for additional information about the Company’s commitment to the noncontrolling shareholders of MeVis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an environmental liability of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duty audits, other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. The Company did not have any contingent liabilities as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">. Legal expenses are expensed as incurred.</span></div> 7500000 5400000 4700000 1800000 900000 200000 5100000 5300000 4000000.0 900000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">REDEEMABLE NONCONTROLLING INTERESTS &amp; </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">NONCONTROLLING INTERESTS</span><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In </span><span style="font-family:inherit;font-size:10pt;">April 2019, a subsidiary of Varex completed the acquisition of </span><span style="font-family:inherit;font-size:10pt;"><span>98.2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of common stock of Direct Conversion. As the Company has majority voting rights it has consolidated Direct Conversion's operations in its consolidated financial statements and recorded the noncontrolling interest. The noncontrolling interest related to Direct Conversion is included in noncontrolling interest in the equity section of the Company's consolidated balance sheet. Earnings representing the noncontrolling interest's portion of Direct Conversion's income from operations is included in the Company's consolidated statements of earnings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In September 2018, the Company entered into a partnership in Saudi Arabia. </span><span style="font-family:inherit;font-size:10pt;">The Company has majority voting rights with an approximate </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in our consolidated financial statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> interest in the joint venture is included in noncontrolling interest in the equity section of the Company’s consolidated balance sheet. Earnings representing the noncontrolling partner's share of income from operations is included in the Company's consolidated statements of earnings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In April 2015, the Company completed the acquisition of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>73.5%</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> of the then outstanding shares of MeVis Medical Solutions AG (“MeVis”), a public company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a domination and profit and loss transfer agreement (the “DPLTA”) with MeVis. In October 2015, the DPLTA became effective upon its registration at the local court of Bremen, Germany. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all of its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>€0.95</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> per MeVis share starting from January 1, 2015 and (2) a put right for their MeVis shares at </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>€19.77</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> per MeVis share. Upon effectiveness of the DPLTA, the noncontrolling interests in MeVis became redeemable as a result of the put right and were reclassified to temporary equity. As of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, the redemption value of redeemable noncontrolling interests in MeVis was </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">During fiscal year 2018, an immaterial number of MeVis’ shares were purchased under the put right. As of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, noncontrolling shareholders together held approximately </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>0.5 million</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> shares of MeVis, representing </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>26.3%</span></span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> of the outstanding shares.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Changes in redeemable noncontrolling interests and noncontrolling interests were as follows:</span><span style="font-family:inherit;font-size:12pt;background-color:#ffffff;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.77777777777777%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Redeemable <br/>Noncontrolling <br/>Interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling <br/>Interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Redeemable <br/>Noncontrolling <br/>Interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling Interest</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contributions from noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Dividend distributions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.982 0.75 0.25 0.735 0.95 19.77 10500000 500000 0.263 <div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Changes in redeemable noncontrolling interests and noncontrolling interests were as follows:</span><span style="font-family:inherit;font-size:12pt;background-color:#ffffff;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.77777777777777%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Redeemable <br/>Noncontrolling <br/>Interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling <br/>Interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Redeemable <br/>Noncontrolling <br/>Interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling Interest</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contributions from noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Dividend distributions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11100000 2100000 11200000 0 500000 -200000 500000 300000 1400000 1800000 500000 600000 -600000 0 10500000 3300000 11100000 2100000 EMPLOYEE STOCK PLANS<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Plans</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's employees participate in Varex Imaging Corporation 2017 Omnibus Stock Plan (the “2017 Stock Plan”) and Varex Imaging Corporation 2017 Employee Stock Purchase Plan (the “2017 ESPP”) which allows the grants of stock options, restricted stock units and performance shares among other types of awards. </span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, Varex stockholders approved the 2017 ESPP, which provides eligible employees with an opportunity to purchase shares of Varex common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the lower of its fair market value at the start and end of a </span><span style="font-family:inherit;font-size:10pt;"><span>six months</span></span><span style="font-family:inherit;font-size:10pt;"> purchase period. The 2017 ESPP provides for the purchase of up to </span><span style="font-family:inherit;font-size:10pt;"><span>one million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Varex common stock.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense recognized in the consolidated statements of earnings is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees. Prior to the separation, Varian also charged the Company for the allocated share-based compensation costs of certain employees of Varian who provided selling, general and administrative services on the Company’s behalf.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the effect of recording share-based compensation expense and for the option component of the employee stock purchase plan shares:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total share-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:8pt;">Includes allocated share-based compensation of </span><span style="font-family:inherit;font-size:8pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:8pt;"> for fiscal year 2017 and represents charges by Varian to the Company for certain Varian employees who provided general and administrative services on the Company’s behalf.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrecognized share-based compensation cost as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$23.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, and is expected to be recognized in the next </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>4</span></span><span style="font-family:inherit;font-size:10pt;"> fiscal years. As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock available for future issuances under the 2017 Stock Plan and the 2017 ESPP, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of ESPP grants. The Company calculated the fair value of option grants and option component of ESPP grants on the respective dates of grant using the following weighted average assumptions:</span></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:29%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Stock Option Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Stock Purchase Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Expected volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Weighted average fair value at grant date</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$10.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$11.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$8.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$7.81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$8.92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$7.81</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risk-Free Interest Rate</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The interest rates used are based on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Expected Term</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options granted generally vest over a period of </span><span style="font-family:inherit;font-size:10pt;"><span>36</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>48</span></span><span style="font-family:inherit;font-size:10pt;"> months and expire </span><span style="font-family:inherit;font-size:10pt;"><span>7</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years from date of grant. Employee stock purchase plan offering periods are </span><span style="font-family:inherit;font-size:10pt;"><span>6 months</span></span><span style="font-family:inherit;font-size:10pt;"> and provides eligible employees with an opportunity to purchase shares of Varex common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the lower of its fair market value at the start and end of a six-month purchase period.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Expected Dividend Yield</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The dividend rate used is zero as the Company has never paid any cash dividends on its common stock and does not anticipate doing so in the foreseeable future. The Company is also restricted from paying dividends on common stock under its credit facility.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Expected Volatility</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Authoritative accounting guidance on stock-based compensation indicates that companies should consider volatility over a period generally commensurate with the expected or contractual term of the stock option. Adequate Company-specific data does not exist for this time period as the Company began trading in January 2017. The volatility variable used is a blended approach by using the Company's historic data for the years it has been publicly traded and a benchmark of other comparable companies’ volatility rates for the prior years.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Activity</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company’s employees:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:40%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands, except per share amounts and the remaining term)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Price range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average <br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (1)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outstanding at September 28, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$22.63 — $37.60</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$31.42 — $31.42</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canceled, expired or forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$31.08 — $31.08</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$22.84 — $27.77</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outstanding at September 27, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$22.63 — $37.60</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.60</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,220.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercisable at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$22.63 — $37.60</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,220.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of </span><span style="font-family:inherit;font-size:8pt;"><span>$28.28</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">September 27, 2019</span><span style="font-family:inherit;font-size:8pt;">, the last trading date of the Company's respective fiscal years, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average grant-date fair value of options granted during fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively. The total intrinsic value of the options exercised during the years ended </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 29, 2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units, Restricted Stock Awards and Deferred Stock Units</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for restricted stock units, restricted stock awards and deferred stock units under Varex’s employee incentive plans for the Company’s employees:</span></div><div style="line-height:120%;padding-top:10px;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:63%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average <br/>Grant-Date Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(201)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canceled or expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(50)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total grant-date fair value of shares granted in fiscal year was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$11.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Shares outstanding at </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 29, 2017</span><span style="font-family:inherit;font-size:10pt;"> had an estimated market value of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$18.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$17.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 0.85 P6M 1000000000000 <div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the effect of recording share-based compensation expense and for the option component of the employee stock purchase plan shares:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total share-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:8pt;">Includes allocated share-based compensation of </span><span style="font-family:inherit;font-size:8pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:8pt;"> for fiscal year 2017 and represents charges by Varian to the Company for certain Varian employees who provided general and administrative services on the Company’s behalf.</span></div> 1200000 1300000 900000 2200000 1800000 1500000 8300000 6900000 6000000.0 11700000 10000000.0 8400000 800000 23100000 P3Y P4Y 1200000 700000 <div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of ESPP grants. The Company calculated the fair value of option grants and option component of ESPP grants on the respective dates of grant using the following weighted average assumptions:</span></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:29%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Stock Option Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Stock Purchase Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Expected volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Weighted average fair value at grant date</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$10.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$11.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$8.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$7.81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$8.92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>$7.81</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P4Y7M6D P4Y9M18D P4Y2M12D P0Y6M P0Y6M P0Y6M 0.025 0.026 0.016 0.025 0.020 0.010 0.339 0.318 0.236 0.439 0.341 0.280 0.000 0.000 0.000 0.000 0.000 0.000 10.19 11.57 8.08 7.81 8.92 7.81 P36M P48M P7Y P10Y P6M 0.85 <div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company’s employees:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:40%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands, except per share amounts and the remaining term)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Price range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average <br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (1)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outstanding at September 28, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$22.63 — $37.60</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$31.42 — $31.42</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canceled, expired or forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$31.08 — $31.08</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$22.84 — $27.77</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outstanding at September 27, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$22.63 — $37.60</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.60</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,220.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercisable at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$22.63 — $37.60</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,220.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of </span><span style="font-family:inherit;font-size:8pt;"><span>$28.28</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">September 27, 2019</span><span style="font-family:inherit;font-size:8pt;">, the last trading date of the Company's respective fiscal years, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.</span></div> 2011000 30.35 297000 31.42 4000 31.08 35000 23.38 2269000 30.60 P4Y1M6D 1220300 1477000 29.67 P3Y4M24D 1220300 28.28 3000000.0 3100000 9200000 200000 1700000 1400000 <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for restricted stock units, restricted stock awards and deferred stock units under Varex’s employee incentive plans for the Company’s employees:</span></div><div style="line-height:120%;padding-top:10px;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:63%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average <br/>Grant-Date Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(201)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canceled or expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(50)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 641000 33.60 288000 31.29 201000 31.56 50000 34.13 678000 33.18 9000000.0 10100000 11400000 19200000 18400000 17800000 TAXES ON EARNINGS<div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense is based on reported income or loss before income taxes. Deferred income taxes reflect the effect of temporary differences between asset and liability amounts that are recognized for financial reporting purposes and the amounts that are recognized for income tax purposes. These deferred taxes are measured by applying currently enacted tax laws. Valuation allowances are recognized to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Taxes on earnings were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current provision:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State and local</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred provision (benefit):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State and local</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total deferred</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Taxes on earnings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Earnings before taxes are generated from the following geographic areas:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings before taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The effective tax rate differs from the U.S. federal statutory tax rate as a result of the following:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal statutory income tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State and local taxes, net of federal tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revaluation of deferred tax liabilities for US statutory change</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Mandatory repatriation tax on foreign earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Domestic production activities deduction</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Prior year deferred tax adjustments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign Rate Difference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">US Tax Reform - International Provisions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (U.S. Tax Reform) was enacted in the U.S. which significantly revised the U.S. corporate income tax structure. Among the revisions impacting our effective tax rate are a lower U.S. corporate statutory rate going from </span><span style="font-family:inherit;font-size:10pt;">35%</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;"> effective January 1, 2018 and changes to the way foreign earnings are taxed. As a September fiscal year filer, the lower corporate income tax rate is phased in from a U.S. statutory federal rate of </span><span style="font-family:inherit;font-size:10pt;"><span>24.5%</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal year ending September 28, 2018 to a rate of </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;"> for the fiscal year ending September 27, 2019. </span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During fiscal year 2019, the Company’s effective tax rate varied from the U.S. federal statutory rate of </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;"> primarily because of the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform, and U.S. research and development tax credits. These favorable U.S. tax items are offset by losses in certain foreign jurisdictions for which no benefit is recognized and earnings in other foreign jurisdictions that are taxed at higher rates.</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During fiscal year 2018, the Company’s effective tax rate varied from the U.S. federal statutory rate primarily because the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform. During fiscal years 2018 and 2017, the effective tax rate also differs from the U.S. federal statutory rate due to increases resulting from U.S. state income tax expense, losses in certain foreign jurisdictions for which no benefit is recognized, earnings in other foreign jurisdictions that are taxed at higher rates, and limitations on the deductibility of officers' compensation. These are offset by decreases due to U.S. research and development credits, tax windfalls for share-based compensation, and the release of a valuation allowance against loss carryforwards in certain foreign jurisdictions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) that allows for reasonable estimated amounts to be recorded and a measurement period of up to one year from the date of enactment to revise these provisional amounts as new information is obtained and additional guidance is issued. During the three months ended December 28, 2018, the Company completed its analysis of U.S. Tax Reform, and the accounting for the income tax effects has been finalized for the measurement period under SAB 118, with no significant adjustments from the provisional amounts. During fiscal year 2019, additional U.S. Tax Reform provisions, including GILTI (global intangible low-taxed income), BEAT (base-erosion anti-abuse tax), FDII (foreign-derived intangible income), limitations on interest expense deductions (if certain conditions apply), and other components became effective for the Company and, if applicable, have been included in the calculation of the fiscal year 2019 tax provision. The determination of the tax effects of U.S. Tax Reform may change following future legislation or further interpretation of U.S. Tax Reform from U.S. Federal and state tax authorities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The guidance for accounting for U.S. Tax Reform requires taxpayers to make an election regarding the accounting for GILTI. This policy election is to either: (1) treat GILTI as a period cost if and when incurred, or (2) recognize deferred taxes for basis differences that are expected to reverse as GILTI in future years. During the first quarter of fiscal year 2019, the Company has made the accounting policy election to account for GILTI under the period cost method.</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant components of deferred tax assets and liabilities are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Deferred Tax Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventory adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Product warranty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net operating loss carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued vacation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>46.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(18.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(19.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Investments in privately held companies</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Reported As:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the changes to the U.S. taxation of foreign earnings included in U.S. Tax Reform, the Company reevaluated its previous indefinite reinvestment assertion with respect to these earnings during fiscal year 2018, which resulted in the Company revoking its assertion for current and future earnings for all countries, while maintaining the assertion that historic earnings are </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">indefinitely reinvested outside the U.S. The Company has modified this prior assertion for the year ended September 27, 2019 with respect to the acquisition of Direct Conversion. The modification was to assert that all earnings for Direct Conversion, located primarily in Sweden and Finland, are indefinitely reinvested in those countries. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable U.S. tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. This estimated liability is for U.S. State income taxes and foreign withholding taxes that would apply if the foreign earnings were actually repatriated in the form of a dividend.</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of September 27, 2019, the Company has net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$24.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> with </span><span style="font-family:inherit;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> expiring between 2020 and 2030 and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> carried forward indefinitely. </span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The valuation allowance relates primarily to net operating losses in certain foreign jurisdictions where, based on the weight of available evidence, it is more likely than not that the tax benefit of the net operating losses will not be realized. The valuation allowance increased by </span><span style="font-family:inherit;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> during fiscal year 2019 and decreased by </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> during fiscal year 2018. The increase during the current year was primarily related to the acquisition of Direct Conversion that included deferred tax assets subject to a valuation allowance as of acquisition. Changes in the Company's valuation allowance for deferred tax assets were as follows:</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance balance–beginning of fiscal year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Increases resulting from business combinations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other increases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other decreases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance balance—end of fiscal year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During fiscal year 2019, the Company paid U.S and foreign taxes of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$8.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. In fiscal year 2018, the Company paid U.S. and foreign taxes of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$13.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for uncertainty in income taxes following a two-step approach for recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether the weight of available evidence indicates that it is more likely than not that, based on the technical merits, the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Changes in the Company’s unrecognized tax benefits were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits balance–beginning of fiscal year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Subtractions based on tax positions related to a prior year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions based on tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits balance—end of fiscal year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, the total amount of gross unrecognized tax benefits was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, all of which would affect the effective tax rate if recognized. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company includes interest and penalties related to income taxes within taxes on earnings on the Combined Statements of Earnings. For the year ended </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> interest and penalties have been included for this period. For the year ended </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;"> any interest or penalties related to unrecognized tax benefits are minimal and have been included in the balance for that period.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"/><span style="font-family:inherit;font-size:10pt;">The Company files U.S. Federal and state income tax returns and non-U.S. income tax returns in various jurisdictions. All of these returns are subject to examination by their respective taxing jurisdictions from the date of filing through each applicable statute of limitation period. The Company’s significant operations up to the date of separation have historically been included in Varian’s U.S. federal and state income tax returns and non-U.S. jurisdiction tax returns. Material liabilities arising related to the pre-spin operations </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">would be the responsibility of Varian. Other periods for entities acquired are still open and subject to examination. Generally, periods prior to 2009 are no longer subject to examination.</span></div> <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Taxes on earnings were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current provision:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State and local</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred provision (benefit):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State and local</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total deferred</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Taxes on earnings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 9200000 -2100000 24800000 1300000 -300000 1600000 6800000 7500000 5300000 17300000 5100000 31700000 -10000000.0 -7000000.0 -7000000.0 -1600000 700000 -1000000.0 0 -1400000 -900000 -11600000 -7700000 -8900000 5700000 -2600000 22800000 <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Earnings before taxes are generated from the following geographic areas:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings before taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5900000 3700000 55500000 15600000 22000000.0 19300000 21500000 25700000 74800000 <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The effective tax rate differs from the U.S. federal statutory tax rate as a result of the following:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal statutory income tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State and local taxes, net of federal tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revaluation of deferred tax liabilities for US statutory change</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Mandatory repatriation tax on foreign earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Domestic production activities deduction</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Prior year deferred tax adjustments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign Rate Difference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">US Tax Reform - International Provisions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.210 0.245 0.350 -0.009 0.011 0.013 0 -0.418 0 0.019 0.130 0 0 0.008 0.024 0.102 0.111 0.026 0.047 0.019 -0.040 0.06 0.008 0 0.112 -0.019 0.038 -0.047 0 0 -0.025 0.042 -0.006 0.265 -0.101 0.305 0.245 <div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant components of deferred tax assets and liabilities are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Deferred Tax Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventory adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Product warranty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net operating loss carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued vacation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>46.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(18.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(19.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Investments in privately held companies</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:80px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Reported As:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5600000 4200000 3100000 800000 1600000 1400000 1100000 900000 24300000 3300000 1000000.0 1300000 1900000 1800000 7500000 4700000 46100000 18400000 18800000 4000000.0 27300000 14400000 19300000 15200000 10600000 14300000 3300000 4100000 2300000 4000000.0 35500000 37600000 8200000 23200000 27300000 14400000 35500000 37600000 8200000 23200000 100000 24300000 4400000 19900000 14800000 -300000 Changes in the Company's valuation allowance for deferred tax assets were as follows:<div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance balance–beginning of fiscal year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Increases resulting from business combinations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other increases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other decreases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance balance—end of fiscal year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4000000.0 4300000 2500000 12000000.0 0 0 2800000 2200000 2500000 0 2500000 700000 18800000 4000000.0 4300000 8200000 13800000 <div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Changes in the Company’s unrecognized tax benefits were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits balance–beginning of fiscal year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Subtractions based on tax positions related to a prior year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions based on tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits balance—end of fiscal year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 600000 500000 200000 0 200000 100000 600000 600000 600000 600000 100000 SEGMENT INFORMATION<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> reportable operating segments Medical and Industrial. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, who is also its CODM, evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin. The operating and reportable segment structure provides alignment between business strategies and operating results.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Segments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Medical segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy and computer-aided detection. The Company provides a broad range of X-ray imaging components for Medical customers including X-ray tubes, digital flat panel detectors, generators, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys. The Company’s X-ray imaging components are primarily sold to imaging system OEM customers that incorporate them into their medical diagnostic, radiation therapy, dental, veterinary and industrial imaging systems. The Company also sells its X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Industrial segment designs, manufactures, sells and services products for use in the security and industrial inspection applications, such as airport security, cargo screening at ports and borders and nondestructive examination in a variety of applications. The products include Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high voltage connectors and image processing software that we generally sell to OEM customers that incorporate these products into their inspection systems.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information related to the Company’s segments is as follows:</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>596.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>602.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>556.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>183.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>171.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>141.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>780.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>773.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>698.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross margin</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>188.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>190.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>193.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>67.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>63.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>256.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>253.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>253.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>211.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>209.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>169.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest and other expenses, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(24.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(18.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings before taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Taxes (benefit) on earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s total assets by its reportable segments: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Identifiable assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>794.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>770.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>244.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>217.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>987.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Geographic Information</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Property, plant and equipment, net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>275.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>268.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>231.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>122.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>127.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EMEA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>269.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>254.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>219.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">APAC</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>229.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>243.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>238.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total company</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>780.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>773.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>698.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>142.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>144.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates various manufacturing and marketing operations outside the United States. Latin America includes Brazil and Mexico. EMEA includes Europe, Russia, the Middle East, India and Africa. APAC includes Asia and Australia. Revenues by region are based on the known final destination of products sold.</span></div> 2 596800000 602000000.0 556900000 183800000 171400000 141200000 780600000 773400000 698100000 188900000 190500000 193600000 67800000 63400000 59900000 256700000 253900000 253500000 211000000.0 209400000 169800000 -24200000 -18800000 -8900000 21500000 25700000 74800000 5700000 -2600000 22800000 15800000 28300000 52000000.0 300000 800000 400000 15500000 27500000 51600000 <div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s total assets by its reportable segments: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Identifiable assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>794.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>770.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>244.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>217.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>987.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 794300000 770600000 244600000 217300000 1038900000 987900000 <div style="line-height:120%;padding-bottom:9px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Geographic Information</span></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Property, plant and equipment, net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>275.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>268.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>231.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>122.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>127.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EMEA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>269.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>254.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>219.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">APAC</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>229.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>243.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>238.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total company</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>780.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>773.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>698.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>142.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>144.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 275300000 268800000 231900000 122600000 127900000 7300000 7000000.0 7900000 0 0 269000000.0 254500000 219500000 11400000 8700000 229000000.0 243100000 238800000 8300000 8300000 780600000 773400000 698100000 142300000 144900000 EMPLOYEE BENEFIT PLANS<div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varex’s 401(k) plan became effective on January 1, 2017. Varex’s 401(k) plan is intended to be qualified under Section 401(a) of the Code with the 401(k) plan’s related trust intended to be tax exempt under Section 501(a) of the Code and intended for all full-time employees in the United States. This plan allows employees to contribute a portion of their pretax salary up to the maximum dollar limitation prescribed by the Internal Revenue Service. Prior to Varex's 401(k) plan becoming effective, Company employees participated in Varian's 401(k) plan. The Company made matching contributions to the plan totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also maintains defined benefit plans for employees located outside the US. The net pension liability is included in non-current liability on the Company's consolidated balance sheets and totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company’s net periodic benefit costs for the Company’s defined benefit plans was not material for fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 6700000 6500000 4300000 5500000 3300000 OTHER COMPREHENSIVE INCOME<div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the changes in the accumulated balances for each component of other comprehensive income (loss):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:721px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:429px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gain (Loss) on Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gain on Defined Benefit Obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income tax benefit </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> amounts were reclassified out of accumulated other comprehensive income during fiscal years 2019 and 2018.</span></div> <div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the changes in the accumulated balances for each component of other comprehensive income (loss):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:721px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:429px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gain (Loss) on Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gain on Defined Benefit Obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income tax benefit </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5800000 0 5800000 -8300000 -1900000 -10200000 -2100000 -600000 -2700000 -400000 -1300000 -1700000 0 REVENUE RECOGNITION<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 on September 29, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for fiscal year 2019 reflect the application of ASC 606 guidance while the reported results for fiscal year 2018 were prepared under the guidance of ASC 605, “Revenue Recognition.” The primary impacts of the adoption include: (1) recording a separate contract liability and contract asset related to the sale of X-ray tubes that were sold with an option for the customer to require the Company to repurchase specific parts of the X‑ray tube at a specific price; and (2) recording a liability related to the deferral of revenue for service type warranties that are provided to certain customers who purchase Linatron</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> X-ray accelerators.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component, if, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are included as a component of cost of revenues; and (5) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transaction price and allocation to performance obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The beginning net cumulative-effect adjustment to the balance sheet for the adoption of ASC 606 is as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustment Due to</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 29, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities and Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>62.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>58.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables compare the reported consolidated balance sheet and statement of operations for fiscal year ended September 27, 2019, to the amounts that would have been reported if ASC 605 had been in effect:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance without Adoption</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities and equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>68.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>75.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Retained earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Twelve Months Ended September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance without Adoption</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>781.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>780.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>524.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>523.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Taxes on earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contracts and performance obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue is recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service revenue is recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Disaggregation of Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note </span><span style="font-family:inherit;font-size:10pt;">15</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information, </span><span style="font-family:inherit;font-size:10pt;">included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and disaggregated by geographic region.    </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Balances</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract assets are included within the prepaid expenses and other current assets, and other assets balances. Contract liabilities, which also includes refund obligations are included within the accrued liabilities, deferred revenues, and other long-term liabilities balances. The following table summarizes the changes in the contract assets and refund liabilities for the twelve months ended September 27, 2019:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Contact Assets</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 29, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Costs recovered from product returns during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contract asset from shipments of products, subject to return during the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Refund Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 29, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognition of revenue included in beginning of year refund liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions to refund liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Remaining Performance Obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining performance obligations represent the transaction price of firm orders for which revenue has not yet been recognized. As of September 27, 2019, total remaining performance obligations amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$265.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company expects to recognize a majority of the remaining performance obligations over the next 12 months.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs to Obtain or Fulfill a Customer Contract</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.</span></div> <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The beginning net cumulative-effect adjustment to the balance sheet for the adoption of ASC 606 is as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustment Due to</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 29, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities and Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>62.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>58.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables compare the reported consolidated balance sheet and statement of operations for fiscal year ended September 27, 2019, to the amounts that would have been reported if ASC 605 had been in effect:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance without Adoption</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities and equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>68.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>75.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Retained earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Twelve Months Ended September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance without Adoption</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>781.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>780.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>524.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>523.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Taxes on earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 17100000 6400000 23500000 16500000 18000000.0 34500000 13200000 300000 13500000 47500000 7100000 54600000 23200000 -800000 22400000 8500000 21300000 29800000 62400000 -3500000 58900000 13100000 19300000 10000000.0 27500000 9900000 10500000 68800000 75700000 9100000 8200000 12100000 32500000 77700000 74400000 781200000 780600000 524700000 523900000 5700000 5700000 15300000 15500000 The following table summarizes the changes in the contract assets and refund liabilities for the twelve months ended September 27, 2019:<div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Contact Assets</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 29, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Costs recovered from product returns during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contract asset from shipments of products, subject to return during the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Refund Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 29, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognition of revenue included in beginning of year refund liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions to refund liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 24400000 -6400000 5700000 23700000 27100000 -7000000.0 6300000 26400000 265200000 SUBSEQUENT EVENTS<div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 1, 2019, the Company, in accordance with the terms of the Credit Agreement, provided notice to the administrative agent that effective as of October 8, 2019, the Company was permanently reducing the revolving credit commitment under the Credit Agreement by </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The reduction in the revolving credit commitment will also reduce the fees paid by the Company in connection with such commitment.</span></div> -25000000.0 125000000.0 XML 76 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
OTHER FINANCIAL INFORMATION - (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Sep. 29, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Accrued compensation and benefits $ 32.1 $ 27.0    
Product warranty 8.1 7.3    
Income taxes payable 10.7 1.4    
Payable to Varian Medical Systems 0.0 2.3    
Right of return liability 6.9 0.0    
Deferred consideration 8.9 0.0    
Other 9.0 9.5    
Total accrued liabilities 75.7 47.5   $ 54.6
Long-term income tax payable 3.9 3.5    
Environment liabilities 0.9 1.3    
Defined benefit obligation liability 5.5 3.3    
Long-term right of return liability 19.5 0.0    
Long-term other 2.7 0.4    
Total other long-term liabilities 32.5 8.5   $ 29.8
Income (loss) from equity method investments (2.3) 3.9 $ 1.3  
Change in fair value of deferred consideration 1.0 0.0 0.0  
Realized income (loss) on foreign currencies (1.9) (1.2) 1.9  
Total other income (expense), net $ (3.2) $ 2.7 $ 3.2  
XML 77 R96.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION - Assets (Details) - USD ($)
$ in Millions
Sep. 27, 2019
Sep. 28, 2018
Segment Reporting Information [Line Items]    
Assets $ 1,038.9 $ 987.9
Operating Segments    
Segment Reporting Information [Line Items]    
Assets 1,038.9 987.9
Medical | Operating Segments    
Segment Reporting Information [Line Items]    
Assets 794.3 770.6
Industrial | Operating Segments    
Segment Reporting Information [Line Items]    
Assets $ 244.6 $ 217.3
XML 78 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover - USD ($)
$ in Millions
 12 Months Ended
Sep. 27, 2019
Nov. 18, 2019
Mar. 29, 2019
Cover page.      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Sep. 27, 2019    
Document Transition Report false    
Entity File Number 001-37860    
Entity Registrant Name VAREX IMAGING CORPORATION    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 81-3434516    
Entity Address, Address Line One 1678 S. Pioneer Road    
Entity Address, City or Town Salt Lake City    
Entity Address, State or Province UT    
Entity Address, Postal Zip Code 84104    
City Area Code (801)    
Local Phone Number 972-5000    
Title of 12(b) Security Common Stock    
Trading Symbol VREX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Smaller Reporting Company false    
Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 1,160.4
Entity common stock, shares outstanding (in shares)   38,494,349  
Documents Incorporated by Reference
Documents Incorporated by Reference

Portions of registrant’s proxy statement relating to registrant’s 2020 annual meeting of stockholders have been incorporated by reference in Part III of this annual report on Form 10-K.

    
Entity Central Index Key 0001681622    
Current Fiscal Year End Date --09-27    
Amendment Flag false    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
XML 79 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)
 12 Months Ended
Sep. 27, 2019
segment
Accounting Policies [Abstract]  
Number of operating segments 2
XML 80 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
OTHER COMPREHENSIVE INCOME (Tables)
 12 Months Ended
Sep. 27, 2019
Equity [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)
The following table presents the changes in the accumulated balances for each component of other comprehensive income (loss):
(In millions)
Unrealized Gain (Loss) on Derivative Financial Instruments
 
Unrealized Gain on Defined Benefit Obligations
 
Accumulated Other Comprehensive Income
Balance at September 28, 2018
$
5.8

 
$
—

 
$
5.8

Other comprehensive loss before reclassifications
(8.3
)
 
(1.9
)
 
(10.2
)
Income tax benefit
2.1

 
0.6

 
2.7

Balance at September 27, 2019
$
(0.4
)
 
$
(1.3
)
 
$
(1.7
)
 
 
 
 
 
 
XML 81 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($)
$ in Millions
Sep. 27, 2019
Sep. 28, 2018
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 1.0 $ 0.6
Preferred stock, par value per share (usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value per share (usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares, issued (in shares) 38,371,305 38,026,597
Common stock, shares, outstanding (in shares) 38,371,305 38,026,597
XML 82 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Details) - USD ($)
$ in Millions
Sep. 27, 2019
Sep. 28, 2018
Accounting Policies [Abstract]    
Raw materials and parts $ 160.1 $ 149.9
Work-in-process 27.9 25.4
Finished goods 60.2 59.8
Total inventories $ 248.2 $ 235.1
XML 83 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATIONS
 12 Months Ended
Sep. 27, 2019
Business Combinations [Abstract]  
BUSINESS COMBINATIONS BUSINESS COMBINATIONS
Acquisition of Direct Conversion AB (publ)
On April 29, 2019, Varex completed the acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion AB (publ) (“Direct Conversion”) for $69.5 million in cash, net of cash acquired, the assumption of Direct Conversion's debt of $4.5 million and deferred consideration equal to $9.9 million or 0.3 million shares of the Company’s common stock (subject to reduction to settle indemnity claims) to be paid on the first anniversary of the closing with a mixture of cash and shares of Varex common stock. The acquisition of Direct Conversion expands our detector product portfolio to include photon counting technology.  This technology will allow Varex to expand its range of imaging applications and offer new solutions to both Medical and Industrial customers.
The following table summarizes the preliminary purchase price allocation:
(In millions)
Fair Value
Allocation of the purchase consideration:
 
Accounts receivable
$
2.4

Inventories
5.7

Prepaid expenses and other current assets
0.7

Property, plant, and equipment
0.9

Goodwill
47.2

Intangible assets
32.9

Total assets acquired
89.8

Accounts payable
(1.0
)
Accrued liabilities
(1.5
)
Current maturities of long-term debt
(1.0
)
Deferred revenues
(0.9
)
Long-term debt
(3.5
)
Other long-term liabilities
(1.1
)
Total liabilities assumed
(9.0
)
Noncontrolling interest
(1.4
)
Net assets acquired, less noncontrolling interest
$
79.4

Net cash paid
$
69.5

Deferred consideration
9.9

Total consideration
$
79.4



The Company recorded the assets acquired and liabilities assumed at their preliminary estimated fair values. Intangibles were valued primarily using a discounted cash flow, which included estimated revenue growth and discount rate. Due to the complexity of this transaction as of September 27, 2019, the Company had not finalized the determination of the fair values allocated to various assets and liabilities, including, but not limited to, inventory; deferred tax assets and liabilities; intangible assets and the residual amount allocated to goodwill. The fair value assigned to goodwill is primarily attributable to expected synergies. The goodwill related to the Direct Conversion acquisition is not tax deductible.
The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:
(In millions)
Fair Value
 
Estimated Weighted Average
Useful Life
(In Years)
Backlog
$
0.2

 
1
Trade names
2.5

 
5
Developed technology
18.4

 
10
In-process research and development
2.8

 
indefinite
Customer relationships
9.0

 
10
Total intangible assets acquired
$
32.9

 
 

The following amounts represent revenues by reporting segment from Direct Conversion from the acquisition date of April 29, 2019, through September 27, 2019:
(In millions)
Direct Conversion Revenue
Medical
$
4.5

Industrial
1.8

Total Direct Conversion revenues
$
6.3



The acquisition of Direct Conversion did not have a significant impact on our consolidated results of operations on a pro forma basis for the current or prior years.
Acquisition of Virtual Media Integration
On August 31, 2018, the Company completed the acquisition of Virtual Media Integration, Ltd. (“VMI”) from MISTRAS Group, Inc for $4.8 million. VMI is a provider of computed and digital radiography and X-ray film digitizer systems for industrial non-destructive testing. The acquired assets and liabilities of the VMI business were allocated to the Industrial reporting segment. The acquisition related costs were included in the consolidated statements of earnings under selling, general and administrative expenses.
The following table summarizes the purchase price allocation:
(In millions)
Fair Value
Allocation of the purchase consideration:
 
Accounts Receivable
$
0.2

Inventories
1.0

Other assets
0.2

Intangibles
1.6

Goodwill
1.5

Other liabilities
(0.2
)
Net assets acquired
4.3

Post-closing adjustments
0.5

Total cash consideration
$
4.8


Acquisition of PerkinElmer’s Medical Imaging Business
On May 1, 2017, the Company completed the acquisition of the medical imaging business (“Acquired Detector Business”) of PerkinElmer, Inc. (“PKI”) for $277.4 million, or $273.2 million after post-closing working capital adjustments. The acquisition consisted of PerkinElmer Medical Holdings, Inc. and Dexela Limited, together with certain assets of PKI and its direct and indirect subsidiaries relating to digital flat panel X-ray detectors that serve as components for industrial, medical, dental and veterinary X-ray imaging systems. The Acquired Detector Business included about 280 employees, with operations in Santa Clara, California as well as operations in Germany, the Netherlands, China and the United Kingdom. The acquisition of the Acquired Detector Business was pursuant to the Master Purchase and Sale Agreement, dated December 21, 2016 (the “Purchase Agreement”), by and between PKI and Varian and the subsequent Assignment and Assumption Agreement, dated January 27, 2017, by and between Varian and Varex, pursuant to which Varian assigned and conveyed all of its rights, obligations, title and interest in the Purchase Agreement to Varex.
The following amounts represent the determination of the fair value of identifiable assets acquired and liabilities for the Acquired Detector Business:
(In millions)
Fair Value
Total cash consideration
$
273.2

Allocation of the purchase consideration:
 
Cash
1.4

Accounts Receivable
18.7

Inventory
34.7

Prepaids and other current assets
0.6

Property, plant, and equipment
21.4

Other assets, non-current
2.0

Intangibles
81.1

Goodwill
167.3

Total assets acquired
$
327.2


 
 
Current liabilities
$
(17.2
)
Other liabilities, non-current
(36.8
)
Total liabilities assumed
(54.0
)
Net assets acquired
$
273.2


The fair value assigned to goodwill is attributable to expected cost synergy opportunities. Included in the goodwill recorded for the Acquired Detector Business is approximately $35 million that will be deductible for income tax purposes in Germany, China and the Netherlands. The remaining goodwill related to the stock acquisition in the United States is not tax deductible. Also, as a result of the acquisition, non-current deferred income tax liability increased by approximately $31 million related to basis differences for both tangible and intangible assets acquired as part of the stock purchases in the United States and the United Kingdom, and asset purchases in Germany, the Netherlands and China.
The following amounts represent the determination of the fair value of identifiable intangible assets for the Acquired Detector Business, which are amortized straight-line:
(In millions)
Fair Value
 
Estimated
Useful Life
(In Years)
Favorable leasehold interests
$
3.8

 
16
Backlog
1.2

 
1
Trade names
1.4

 
5
Developed technology
37.7

 
7
In-process research and development
4.0

 
indefinite
Customer relationships
33.0

 
7
Total intangible assets acquired
$
81.1

 
 

The following amounts represent revenues by reporting segment from the Acquired Detector Business from the acquisition date of May 1, 2017 through September 29, 2017:
(In millions)
May 1, 2017 through September 29, 2017
Acquired Detector Business
 
Medical
$
41.1

Industrial
20.2

Total Acquired Detector Business revenues
$
61.3


Unaudited Pro Forma Information
The unaudited pro-forma amounts presented below for the fiscal year 2017 are presented for informational purposes only. In addition to the Company's results for the periods presented, the amounts below also include effects of the Acquired Detector Business as if it had been consummated on October 1, 2016. These unaudited pro-forma results include effects that are directly attributable to the acquisition which include the amortization of intangible assets, interest expense, and other adjustments, including estimated tax effects. The unaudited pro-forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the Acquired Detector Business and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations or results that might have been achieved had the acquisition been consummated as of October 3, 2015.
 
Fiscal Year
(In millions)
2017
Revenue
$
777.8

Operating earnings
$
84.7

Net earnings
$
43.1

Net earnings per share, basic
$
1.15

Net earnings per share, diluted
$
1.13
XML 84 R102.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION - Schedule of Changes in Contract Balances (Details)
$ in Millions
 12 Months Ended
Sep. 27, 2019
USD ($)
Change in Contract with Customer, Asset [Abstract]  
Balance at September 29, 2018 $ 24.4
Costs recovered from product returns during the period (6.4)
Contract asset from shipments of products, subject to return during the period 5.7
Balance at September 27, 2019 23.7
Change in Contract with Customer, Liability [Abstract]  
Balance at September 29, 2018 27.1
Recognition of revenue included in beginning of year refund liability (7.0)
Additions to refund liabilities 6.3
Balance at September 27, 2019 $ 26.4
ZIP 85 0001681622-19-000083-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001681622-19-000083-xbrl.zip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Έ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�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end XML 86 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Accounting Policies [Abstract]  
    Restrictions on Cash and Cash Equivalents Cash and cash equivalents and restricted cash as reported within
    the consolidated statements of cash flows consisted of the following:
     
    Twelve Months Ended September 27, 2019
     
    Twelve Months Ended September 28, 2018
     
    Beginning of Period
     
    End of Period
     
    Beginning of Period
     
    End of Period
    Cash and cash equivalents
    $
    51.9

     
    $
    29.9

     
    $
    83.3

     
    $
    51.9

    Restricted cash
    1.5

     
    1.4

     
    0.9

     
    1.5

    Cash and cash equivalents and restricted cash as reported per statement of cash flows
    $
    53.4

     
    $
    31.3

     
    $
    84.2

     
    $
    53.4
    Schedules of Concentration of Risk, by Risk Factor
    Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, which is as follows:
     
    Fiscal Year
     
    2019
     
    2018
     
    2017
    Canon Medical Systems Corporation
    17.3
    %
     
    18.1
    %
     
    19.3
    %
    Schedule of Inventory, Current
    The following table summarizes the Company’s inventories, net:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Raw materials and parts
    $
    160.1

     
    $
    149.9

    Work-in-process
    27.9

     
    25.4

    Finished goods
    60.2

     
    59.8

    Total inventories
    $
    248.2

     
    $
    235.1
    Property, Plant and Equipment
    The following table summarizes the Company’s property, plant and equipment, net:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Land
    $
    8.3

     
    $
    8.3

    Buildings and leasehold improvements
    134.4

     
    138.1

    Machinery
    170.7

     
    166.1

    Construction in progress
    28.5

     
    23.1

     
    $
    341.9

     
    $
    335.6

    Accumulated depreciation and amortization
    (199.6
    )
     
    (190.7
    )
    Property, plant, and equipment, net
    $
    142.3

     
    $
    144.9
    Schedule of Product Warranty Liability
    The following table reflects the changes in the Company’s accrued product warranty:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
    Accrued product warranty, at beginning of period
    $
    7.3

     
    $
    7.0

    Charged to cost of revenues
    12.9

     
    11.6

    Actual product warranty expenditures
    (12.1
    )
     
    (11.3
    )
    Accrued product warranty, at end of period
    $
    8.1

     
    $
    7.3

    XML 87 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    EMPLOYEE STOCK PLANS
    		 12 Months Ended
    Sep. 27, 2019
    Share-based Payment Arrangement [Abstract]  
    EMPLOYEE STOCK PLANS EMPLOYEE STOCK PLANS
    Employee Stock Plans
    The Company's employees participate in Varex Imaging Corporation 2017 Omnibus Stock Plan (the “2017 Stock Plan”) and Varex Imaging Corporation 2017 Employee Stock Purchase Plan (the “2017 ESPP”) which allows the grants of stock options, restricted stock units and performance shares among other types of awards.
    In January 2017, Varex stockholders approved the 2017 ESPP, which provides eligible employees with an opportunity to purchase shares of Varex common stock at 85% of the lower of its fair market value at the start and end of a six months purchase period. The 2017 ESPP provides for the purchase of up to one million shares of Varex common stock.
    Share-Based Compensation Expense
    Share-based compensation expense recognized in the consolidated statements of earnings is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees. Prior to the separation, Varian also charged the Company for the allocated share-based compensation costs of certain employees of Varian who provided selling, general and administrative services on the Company’s behalf.
    The table below summarizes the effect of recording share-based compensation expense and for the option component of the employee stock purchase plan shares:
     
    Fiscal Year
    (In millions)
    2019
     
    2018
     
    2017
    Cost of revenues
    $
    1.2

     
    $
    1.3

     
    $
    0.9

    Research and development
    2.2

     
    1.8

     
    1.5

    Selling, general and administrative (1)
    8.3

     
    6.9

     
    6.0

    Total share-based compensation expense
    $
    11.7

     
    $
    10.0

     
    $
    8.4

    (1) Includes allocated share-based compensation of $0.8 million for fiscal year 2017 and represents charges by Varian to the Company for certain Varian employees who provided general and administrative services on the Company’s behalf.
    The unrecognized share-based compensation cost as of September 27, 2019 was $23.1 million, and is expected to be recognized in the next 3 to 4 fiscal years. As of September 27, 2019, there were approximately 1.2 million and 0.7 million shares of common stock available for future issuances under the 2017 Stock Plan and the 2017 ESPP, respectively.
    The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of ESPP grants. The Company calculated the fair value of option grants and option component of ESPP grants on the respective dates of grant using the following weighted average assumptions:
     
    Employee Stock Option Plan
     
    Employee Stock Purchase Plans
     
    Fiscal Year
     
    Fiscal Year
     
    2019
     
    2018
     
    2017
     
    2019
     
    2018
     
    2017
    Expected term (in years)
    4.6

     
    4.8

     
    4.2

     
    0.5

     
    0.5

     
    0.5

    Risk-free interest rate
    2.5
    %
     
    2.6
    %
     
    1.6
    %
     
    2.5
    %
     
    2.0
    %
     
    1.0
    %
    Expected volatility
    33.9
    %
     
    31.8
    %
     
    23.6
    %
     
    43.9
    %
     
    34.1
    %
     
    28.0
    %
    Expected dividend
    0.0
    %
     
    0.0
    %
     
    0.0
    %
     
    0.0
    %
     
    0.0
    %
     
    0.0
    %
    Weighted average fair value at grant date
    $10.19
     
    $11.57
     
    $8.08
     
    $7.81
     
    $8.92
     
    $7.81

    Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.
    Risk-Free Interest Rate
    The interest rates used are based on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award.
    Expected Term
    Options granted generally vest over a period of 36 to 48 months and expire 7 to 10 years from date of grant. Employee stock purchase plan offering periods are 6 months and provides eligible employees with an opportunity to purchase shares of Varex common stock at 85% of the lower of its fair market value at the start and end of a six-month purchase period.
    Expected Dividend Yield
    The dividend rate used is zero as the Company has never paid any cash dividends on its common stock and does not anticipate doing so in the foreseeable future. The Company is also restricted from paying dividends on common stock under its credit facility.
    Expected Volatility
    Authoritative accounting guidance on stock-based compensation indicates that companies should consider volatility over a period generally commensurate with the expected or contractual term of the stock option. Adequate Company-specific data does not exist for this time period as the Company began trading in January 2017. The volatility variable used is a blended approach by using the Company's historic data for the years it has been publicly traded and a benchmark of other comparable companies’ volatility rates for the prior years.
    Stock Option Activity
    The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company’s employees:
    (In thousands, except per share amounts and the remaining term)
    Options
     
    Price range
     
    Weighted Average
    Exercise Price
     
    Weighted Average Remaining Term (in years)
     
    Aggregate Intrinsic Value (1)
    Outstanding at September 28, 2018
    2,011
     
    $22.63 — $37.60
     
    $
    30.35

     
     
     
     
    Granted
    297
     
    $31.42 — $31.42
     
    31.42

     
     
     
     
    Canceled, expired or forfeited
    (4)
     
    $31.08 — $31.08
     
    31.08

     
     
     
     
    Exercised
    (35)
     
    $22.84 — $27.77
     
    23.38

     
     
     
     
    Outstanding at September 27, 2019
    2,269
     
    $22.63 — $37.60
     
    $
    30.60

     
    4.1
     
    $
    1,220.3

    Exercisable at September 27, 2019
    1,477
     
    $22.63 — $37.60
     
    $
    29.67

     
    3.4
     
    $
    1,220.3

    (1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $28.28 as of September 27, 2019, the last trading date of the Company's respective fiscal years, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
    The weighted-average grant-date fair value of options granted during fiscal years 2019, 2018 and 2017 was $3.0 million, $3.1 million and $9.2 million respectively. The total intrinsic value of the options exercised during the years ended September 27, 2019, September 28, 2018 and September 29, 2017 was $0.2 million, $1.7 million and $1.4 million respectively
    Restricted Stock Units, Restricted Stock Awards and Deferred Stock Units
    The following table summarizes the activity for restricted stock units, restricted stock awards and deferred stock units under Varex’s employee incentive plans for the Company’s employees:
    (In thousands, except per share amounts)
    Number of Shares
     
    Weighted Average
    Grant-Date Fair
    Value
    Balance at September 28, 2018
    641
     
    $
    33.60

    Granted
    288
     
    31.29

    Vested
    (201)
     
    31.56

    Canceled or expired
    (50)
     
    34.13

    Balance at September 27, 2019
    678
     
    $
    33.18

    The total grant-date fair value of shares granted in fiscal year was $9.0 million, $10.1 million and $11.4 million for fiscal years 2019, 2018 and 2017, respectively. Shares outstanding at September 27, 2019, September 28, 2018 and September 29, 2017 had an estimated market value of $19.2 million, $18.4 million and $17.8 million, respectively.
    XML 88 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    OTHER COMPREHENSIVE INCOME
    		 12 Months Ended
    Sep. 27, 2019
    Equity [Abstract]  
    OTHER COMPREHENSIVE INCOME OTHER COMPREHENSIVE INCOME
    The following table presents the changes in the accumulated balances for each component of other comprehensive income (loss):
    (In millions)
    Unrealized Gain (Loss) on Derivative Financial Instruments
     
    Unrealized Gain on Defined Benefit Obligations
     
    Accumulated Other Comprehensive Income
    Balance at September 28, 2018
    $
    5.8

     
    $
    —

     
    $
    5.8

    Other comprehensive loss before reclassifications
    (8.3
    )
     
    (1.9
    )
     
    (10.2
    )
    Income tax benefit
    2.1

     
    0.6

     
    2.7

    Balance at September 27, 2019
    $
    (0.4
    )
     
    $
    (1.3
    )
     
    $
    (1.7
    )
     
     
     
     
     
     

    No amounts were reclassified out of accumulated other comprehensive income during fiscal years 2019 and 2018.
    XML 90 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    FAIR VALUE (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Fair Value Disclosures [Abstract]  
    Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
    At September 28, 2018, the Company determined the following levels of inputs for the following assets or liabilities:
    (In millions)
    Fair Value Measurements at September 28, 2018
     
    Quoted Prices in Active Markets for Identical Assets and Liabilities
    (Level 1)
     
    Significant Other
    Observable Inputs
    (Level 2)
     
    Significant Unobservable Inputs
    (Level 3)
     
    Total
    Assets:
     
     
     
     
     
     
     
    Cash equivalents - Money market funds
    $
    —

     
    $
    18.4

     
    $
    —

     
    $
    18.4

    Derivative assets
    —

     
    7.7

     
    —

     
    7.7

    Total assets measured at fair value
    $
    —

     
    $
    26.1

     
    $
    —

     
    $
    26.1

    Liabilities:
     
     
     
     
     
     
     
    Derivative liabilities
    $
    —

     
    $
    —

     
    $
    —

     
    $
    —


    In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
    (In millions)
    Fair Value Measurements at September 27, 2019
     
    Quoted Prices in Active Markets for Identical Assets and Liabilities
    (Level 1)
     
    Significant Other
    Observable Inputs
    (Level 2)
     
    Significant Unobservable Inputs
    (Level 3)
     
    Total
    Assets:
     
     
     
     
     
     
     
    Cash equivalents - money market funds
    $
    —

     
    $
    8.8

     
    $
    —

     
    $
    8.8

    Total assets measured at fair value
    $
    —

     
    $
    8.8

     
    $
    —

     
    $
    8.8

    Liabilities:
     
     
     
     
     
     
     
    Derivative liabilities
    $
    —

     
    $
    0.7

     
    $
    —

     
    $
    0.7

    Deferred consideration
    8.9

     
    —

     
    —

     
    8.9

    Total liabilities measured at fair value
    $
    8.9

     
    $
    0.7

     
    $
    —

     
    $
    9.6
    XML 91 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    OTHER FINANCIAL INFORMATION (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Schedule of Accrued Liabilities The following table summarizes the Company’s accrued liabilities:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Accrued compensation and benefits
    $
    32.1

     
    $
    27.0

    Product warranty
    8.1

     
    7.3

    Income taxes payable
    10.7

     
    1.4

    Payable to Varian Medical Systems
    —

     
    2.3

    Right of return liability
    6.9

     
    —

    Deferred consideration
    8.9

     
    —

    Other
    9.0

     
    9.5

    Total accrued liabilities
    $
    75.7

     
    $
    47.5
    Other Noncurrent Liabilities
    The following table summarizes the Company’s other long-term liabilities:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Long-term income tax payable
    $
    3.9

     
    $
    3.5

    Environment liabilities
    0.9

     
    1.3

    Defined benefit obligation liability
    5.5

     
    3.3

    Long-term right of return liability
    19.5

     
    —

    Long-term other
    2.7

     
    0.4

    Total other long-term liabilities
    $
    32.5

     
    $
    8.5
    Schedule of Other Nonoperating Income (Expense)
    The following table summarizes the Company’s other income (expense), net:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
    Income (loss) from equity method investments
    $
    (2.3
    )
     
    $
    3.9

     
    $
    1.3

    Change in fair value of deferred consideration
    1.0

     
    —

     
    —

    Realized income (loss) on foreign currencies
    (1.9
    )
     
    (1.2
    )
     
    1.9

    Total other income (expense), net
    $
    (3.2
    )
     
    $
    2.7

     
    $
    3.2
    EXCEL 92 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !B+E$\?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ &(N43R?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " 8BY1/WU266^X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!:L,P#(9?9?B>*':@8R;-I:.G#@8K;.QF;+4UBQUC:R1]^SE9 MFS*V!]C1TN]/GT"-#E+W$9]C'S"2Q70WNLXGJ<.:G8B"!$CZA$ZE,B=\;A[Z MZ!3E9SQ"4/I#'1%$5:W (2FC2,$$+,)"9&UCM-01%?7Q@C=ZP8?/V,TPHP$[ M=.@I 2\YL'::&,YCU\ -,,$(HTO?!30+<:[^B9T[P"[),=DE-0Q#.=1S+N_ MX>UI]S*O6UB?2'F-^5>RDLX!U^PZ^;7>/.ZWK!45?RBX*$2UY_=2U)*OWB?7 M'WXW8=<;>[#_V/@JV#;PZR[:+U!+ P04 " 8BY1/F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( !B+E$^TW:MQ>0, "H1 8 >&PO=V]R:W-H965T&ULC5AM;YLP&/PKB!]0\ LDJ9)(3:-IDS:IZK3M,TVRZ)J5N')F/-M%#6[DRJSYD:? M567_.>BZS(R]K(]13-L0K9?G[*B^*_/C_%#;JVBLLL]+536YKH):'5;A M';O=BK0E=(B?N;HVD_.@'R@:CIHM<7K^5OU3-W@[F*>L4?>Z^)7OS6D5SL-@KP[9I3"/^OI9#0-*PF 8 M_5?UH@H+;WMB-7:Z:+K?8'=IC"Z'*K8K9?;:'_.J.U[[?Q(^T#"!#P0^$N;Q MAP0Q$,1(8/)#@AP(TB%$_5"Z>[/-3+9>UOH:U+V]YZR=1>Q6VKN_:QN[F]W] M9V]/8UM?UO$R>FG+#(A-C^ 3!!L1D:T]"G DL.&$SM\+W%.$>(_84H3$71!P MC**CBPD]P70)Z;*CRPD]=6X11)B6L'U&V$\CC-/ MKAFIP$FR <9C.H/AOF.<5G!M1QB/[PSGEPE:P74>83S6,QQS1E/,7?,1QN<^ MSCJC4>;$?8#QN8\#SVB$%*XQO? MBRC.OZ#93MS7X0&33I3$7"ZDD)Y50.!50-"$)VYR$,8W(KP*")KPQ$T.PJ0> M%<\;/$UX,G-5 &;N4<&K@* )3]PY#3"^V2;P*B!HPE-W3B.,9]T4>!40-.&I MNSHCC#N6:+*1+%5][#;I3;#3EZK[0C!I'3\$W'5[X^@?O/^*\"VKCWG5!$_: MV.ULM^D\:&V4[4I\8P=\4ME^O"C4P;2G,WM>][OW_L+H\_!E(AH_CZS_ E!+ M P04 " 8BY1/-<]-\24$ !@% & 'AL+W=OUEO+SIZD=]4JIQ?A9Y6:_<4]-7+059$UYK8Z>O6E4MF^"RIRC_M^[!79N737RZ[LM5HO];7)SZ5ZK9SZ M6A19]6NC?=:]N="E?59ETZE M#BOWA3VG7+0!'?'MK&[UZ-II4WG3^D=[\_=^Y?JM(I6K7=-6D9F?=[55>=[6 M9'3\-U3JWMML \?7'[5_ZI(WR;QEM=KJ_/MYWYQ6KG2=O3IDU[SYHF]_J2&A MR'6&[/]1[RHW>*O$M+'3>=W]=W;7NM'%4(N14F0_^]]SV?W>^B=Q-(3A #X$ M\'L BV<#@B$@^!T0S@:$0T!H!7A]*EW?I%F3K9>5OCE5_WHO63N*V'-H>G_7 M%G:=W3TSW5.;TO=U'"Z]][:> =GT"!\A[$YXIO)["QRUL.$DG#\VL*5$'#TB M*4!B+"* :09=?#".%S@^A/%A%Q^.XZ7533TB.J3L$"']V&__K'P!*8(0D"DE MXT2R1_)!?0351U1]8JGOD7C44L2#!*D')$LBI)Z281C&,^ICJ#XFZH75TB8F M+?$H%D@](F&>*22C&?4"JA=DY(F)Z2-AO*396_-G(XE280^2/GD*RL!'N5,P M%L%,Z@F4GE#I@24](0TQCK4C$D\:0/I\[L4Q'R^-/M5/UD:?CG&)Y ,0=ST MIV1/K.B,RHYLV8P.;L:0GBU"_01V/$"96:_F>AY:Q@OC-(783H'3GH_@E$=D M"!;8=3DG6U4Y\9'%L>]QZGO2]KV!D>/]S2)D=O:(LG>/*:#8(ICXL./8\3AU M/&D[WL!8FFW)"++WZBF@C.2I;L8.QR/ZHI*)&K#+<.HRB>TR Y.,)YEST MM6S:XXI1Z?V8[(6WQS16^88]I_UAU^]J^K.WSUEU/)>U\Z:;1A?=4&PO=V]R:W-H965T&UL?99= M;]L@%(;_BN7[V>!O5TFD)M:T29L4=>IV31*26+6-!R3I_OWX<%T*I+VH ;_O MX3G'!%C<"'UA9XQY\-IW UN&9\['ASAF^S/N$8O(B ?QYDAHC[CHTE/,1HK1 M09GZ+DX *.(>M4.X6JBQ+5TMR(5W[8"W-&"7OD?TWQIWY+8,8?@V\-2>SEP. MQ*O%B$[X%^;/XY:*7CQ'.;0]'EA+AH#BXS)\A \-5 :E^-WB&S/:@4QE1\B+ M['P_+$,@B7"']UR&0.)QQ1O<=3*2X/@[!0WG.:71;+]%_ZJ2%\GL$,,;TOUI M#_R\#*LP.. CNG3\B=R^X2FA/ RF['_@*^Z$7)*(.?:D8^I_L+\P3OHIBD#I MT:M^MH-ZWO2;,IML?D,R&9+9 (M/#>ED2-\-G\^038;,,L0Z%56;!G&T6E!R M"ZC^O".2JP@^9*+Z>SFHBJW>B?(P,7I=U519J;JBI(JL2(T6E88H3_RPN1ZRUI#80OQ21_5U= M46YK&E<#HCM?MO3"EBYL8<&6+BRTB[[QB(!#ZXI,S0?:RDM;N;2E15NY(&5D MU7^C18596@O5#0.,U?@!M?:BUBZJM9K7M3.'6,S _(,6M^M(4V?]NZ(\N<<. M@7]; RY];>]KP%,B>UEX158=&J_HSD\.WMF'H0,, ;")H;,SV!O,)#%WF#2Q MET_C48D2V\2Q<8CTF)[4 !4E4B*--MKDF;%[QM:" M<8 9;_Y] #,65)T>/]B 3U>?OGU=]/I:-S_:H[7=ZF=5GMN-=^RZRT,0M/NC MK8K6KR_VW/_S4C=5T?6WS6O07AI;',9"51EP&"9!59S.WG8]/GMJMNOZK2M/ M9_O4K-JWJBJ:_QYM65\W'GD?#[Z=7H_=\"#8KB_%J_W+=M\O3TU_%]RC'$Z5 M/;>G^KQJ[,O&^T(/.Q,/!4;%WR=[;6?7JZ$ISW7]8[CY_;#QPL&1+>V^&T(4 M_<^[W=FR'"+U/OZ=@GKW.H>"\^N/Z+^.C>\;\URT=E>7_YP.W7'C9=[J8%^* MM[+[5E]_LU.#8F\UM?X/^V[+7CXXZ>O8UV4[?J_V;VU75U.4WDI5_+S]GL[C M[W6*_U$,%^"I -\+4/1I 3,5,*) <',V-O5KT17;=5-?5\UMM"[%,"GHP?2= MN1\>CGTW_M>WMNV?OF\II'7P/@2:-(\W#<\TO%3LM"*)[Y*@-W!WP= %C^7- MP@7C 8&,&. :!' B&;<-/&H.=^:D?NY:(D6Q303+:Q$T$H$K$3"RDV3S&JA M2/3Z#FCB"!N)H9$8&(F%D9LFG_=)E/ER>('*Q#YA,PDTDP SB3"3J&HH]\4H M[H H=5E)H9446$F%E535$IG,%\.X ZHXA@A"216Y#F*L,TEN6Z2T4J=[Y7+0T@PG-@- LD9E*)OSF61I!!.5 5%9(HPU*T--C,]% M2S.8IPQX:A3 -$]-2BHS1;(X=:6F!A/5 *(:"3"C4?D+JSCYRZP%%$G8-G<$X-0"G1KV9:U!&BW>7R0^0<>+BNW&<% "B M&@DPHU%IU$L%$+&+& ;3U &&IEB3J)E[^@<$\DXW_4$L#!!0 ( !B+E$\':&AC1@( +P' M 8 >&PO=V]R:W-H965T&ULC97;CILP%$5_!?$!8X.Y M)2)(3:JJE5HIFJKMLY,X 8W!U';"]._K"X/ L6:2A_BVSS[K8+#+@?$741,B M@]>6=F(3UE+V:P#$L28M%D^L)YU:.3/>8JF&_ )$SPD^F:"6@AC"#+2XZ<*J M-'-[7I7L*FG3D3T/Q+5M,?^W)90-FS *WR:>FTLM]02HRAY?R$\B?_5[KD9@ ME$P[J D_,F_!2M=Q'4 4;QNR&#F/4#7/(J##_P?$J)&M'%X72XE?;-IUI![N2%6.8/R > M ^(I($K>#4!C '("@"4SI7[&$E0ENVFC4;*TFGFGBI6)WK\C220(4P$01>REB$X\6%(7? 'D-D#%(%@8K MIPRKR8VFLQJG#*M(9PKXE/DQ$B]&E-2#XF39 M6DTVRZ*^?_-SI&UVE\EE>4^Q@,B]$+D' CD0^2-;](%H M@5)X40H/2N*@%'?51JE_CQY1+J!67JB5!RIUH%9WJ5"!\@A!1[CS"6&IO$HO%I@=H_I>^X'YI>E$<&!2G[$DP7=O4?4$L#!!0 ( !B+E$]I4BH& M)08 ' E 8 >&PO=V]R:W-H965T&ULC9I=;Z,X%(;_ M2I3[3/ 7F*JMU 2M=J5=J9K5[EXS+6VC24(6:#O[[Q<(S03[P>E<3!+ZVGZ/ MP7Z.C:_?R^I[_5(4S>S';KNO;^8O37.X6B[KAY=BE]=?RD.Q;__R5%:[O&E_ M5L_+^E 5^6-?:+==RBB*E[M\LY_?7O?7[JO;Z_*UV6[VQ7TUJU]WN[SZ;U5L MR_>;N9A_7/BZ>7YIN@O+V^M#_ES\631_'>ZK]M?R5,OC9E?LZTVYGU7%T\W\ M3EQE1G8%>L7?F^*]/OL^ZT+Y5I;?NQ^_/=[,H\Y1L2T>FJZ*O/UX*];%=MO5 MU/KX=ZAT?FJS*WC^_:/V7_K@VV"^Y76Q+K?_;!Z;EYNYG<\>BZ?\==M\+=]_ M+8: S'PV1/][\59L6WGGI&WCH=S6_?^SA]>Z*7=#+:V57?[C^+G9]Y_O0_T? MQ;B ' K(4P$1!PNHH8#Z64 '"^BA@/Y9P/2]=0RE[YLL;_+;ZZI\GU7'VWO( MNZ=(7.FV]Q^ZBWUG]W]KNZ=NK[[="IU<+]^ZB@;-ZJB1YYJ38MG6?FI"4A,K MZ167XP;6OB(V8TD&DIA-*(Q3]>75*$[+%6BL0/<5Z+,*K'+ZZ2A)>LG^V(:Q M4??/B=<72JM F/E"(Z.Q<&3=H'4#L:=<08P5Q%[LPCA65T=-?!Z\2"AX$$81 M!>\+K0[$GJ#U!*P+QWKB-225(>L@C-&Z+Q1Q&O!NT;L%[\[065F_)8/=#L)8 MDG<01B;@/47OJ><]T8[UU&M(XVCQ=0H[W==-.!813X41]+<[Q@<1MW+T"Q*! MHSM8U]CQQ.0MP+';S8-HU'^"^OFSP@R$4[Z1"'="@F_C^I9>*PLA4W0.TH1& M049*&QJ9@G$B%$00NQ$H?[[0Z!^$_,3X0F%#[IEEPH=9.VNX[O7G3*U!N%!T MGS)2ND-C[)^!)@SXMZY_X_,#[?LZ?G1\7;COF:4B]FEL)F@LF&D"H!:[/!; M()Y?09GB! O"A72GB'$ ##8!9(N\\>^#:"$$SUP@Q9&6D5++4 2,-^'S3<1N M7B& <#R"?*&;Y@WV?>%"1*$[()EU$E@GW#L@?3XM\,E8@])@<@%"'9I^)8-/ M OAB-S62/J9$A/P 9=NM'( OE39X QB!$A HW"E, JVP7]>@Y % 58HXY)\! M* & L9LL21]7B> [X"NM0012G6Z?C -@!DKMS\.QGJB",20!0^["=25];"Q$ MBA,Q267$MQ&EP6Y@'$E8V\5N(B/]I=@B3G&)1%+$3D9*F021*IF'$G@HW,E8 M KPP2UF#TO,>DHPM,P$E$#!V,S )L$H5CW\BX,043-(TN*T@&8(RA2$TL:FB MF$,*.!2G3C^HRVNNRY(,)"84M&+T*$!/XB9?*K1"&AQ?E&0@6?D:< >=[&COKDR@MT"E$!0AGBA&+6 M*6!=XO):^5A"4VL2\ACPA5.^F6\*^):XC%87J;6^+,E XN:18\>,-P5X2UR\ M*0 1YA0DQ*R(A"(\W3#9%"SO$C<[5Z$-Q\&Y+W$3G,'YIS=,U\C TP \ZP)/^WBRN)H#H>#,")1N M"CBVS[S3L)*S$RLYPP R "#K LC JS%,KD#(.Z(@U*$.,(PA QA*70R9RZNZ MRY(,)"*8BAOFC@'NI"YW!E$2LGQ1DH&$]PR79\=.=D7UW!_IJ6    N^Z4YO MG%T]'1NZZT\-.==7XBH['O[Y6?6\V=>S;V73E+O^Z,I3639%ZS/Z MTDYH+T7^>/JQ+9Z:[FO2?J^.9X"./YKR,)QO6IX.6=W^#U!+ P04 " 8 MBY1/M^,ZK9 & !/)P & 'AL+W=O>Q$G0 &;!26;??FW30^BJ'[LW M%PF0K[JK#ZZ_JIO;C_+PX_A:%-7@YW:S.]X-7ZMJ?S.9'!]?BVU^')?[8E?_ MY[D\;/.J?GMXF1SWAR)_:HVVFXF,HGBRS=>[X?UM^]F7P_UM^59MUKOBRV%P M?-MN\\._TV)3?MP-Q?#7!U_7+Z]5\\'D_G:?OQ3?BNK/_9=#_6YR;N5IO2UV MQW6Y&QR*Y[OA;^)F971CT!)_K8N/X\7K03.4[V7YHWFS>KH;1HU'Q:9XK)HF M\OK/>S$K-INFI=J/?URCPW.?C>'EZU^M+]K!UX/YGA^+6;GY>_U4O=X-T^'@ MJ7C.WS;5U_+#%FY 9CAPH_^]>"\V-=YX4O?Q6&Z.[>_!X]NQ*K>NE=J5;?[S M]'>]:_]^G/X39\X,&TAG(,\&(NHT4,Y ?1JH3@/M#/390":=!L89F$\#V6D0 M.X/X;*#C3H/$&22?8T@[#5)GD'X:=$]KY@RRSS&8=HN73$359ON-.28Z8F1'J-\9L89 M97QDCIK1/O. &-+. C&QSRP1D_B,14SJ,RO$9&=F4D_M>7XEG%_9-J O&J@# M$9F[$Q.WS*YE(MR%@ETHT(4@2WABDHLNC"1S-N,,<73>2SP$]+/L;<4&M++J M:L6;- TG3;?FRILTB1LPL '#9CTES\3TA&27PQ!C,HX'#HEX3+;\DD/*C,D: MVY[NO#'%<$PQV$ET4#'W-QW3QS@$LCV0YV\"_4V OZ27:<)Z&45C$N'F(9#M M@3Q_4^AO"OPE2SU->2]2)G2Q'\(PVXMY7F?0ZPQX36-'QD*82G34_.">ZA0 MJE$$^B)Q>^H@'"^=&IT0&=D5G15@9"EU6["1 MB:Y)Q)(CD.9D=!(E&Y48P430,($6U/%)D=V30Z.^T*#K@3M M2K.N1IT+@25"<(V0@B57/&R/Q#BC*Q%"V3[*=QIK@ B(*@("!Z[8Q940R#; M _D>8Q400 8$E0'!HW=$M7CA(-,%V9Z6?(^Q#@@@!((*@>"QFVG2(@2R/9#O M,=8 41 Q-3C#$0"%G4#(-L#^7DWEA()I$00*9E)+B4JB3N>=(FCNP3179! M.94\NJLDHQZ) .5RD*=<6H[)Z!Y AR2H+D!+$8WP2]0=3S]#AK?J=,F?Z2OU ME Q/W"56&\G5AJ7NCO$V8,(G!E*&3DP(M0)4-%97!H:U30)M8_FP@[ISW640 M9?LHWVDLDA*()$N,'!2J_1)+FT3U#4V,)!V0W+,4(@VP/Y'N/0KD#=PK(BQ:L-'I@6093M MHWRGKQR^H=*%BKKBI4O74Z-P>%<@O,N(S@\/R6JLZ X,@&P/Y'N,8[L"L5VR MHTG#,AY!8^E*@6.R:[%4X>BO0/27-.@XR$MBTDC&AIX>SS#9M:HXQ"L0XB4+ M*[PPT3*E2S8#&$\>%:]?E$G8N:3BJD*31]"283D2@&*>\ -*2U8MK@ FKQUF M*:QS*@U/(!66+\7EBR60CO%VM:$+ME1HNF:#JAR; _D>XP53",%8_/"KWNZTC6- M=4PC$WSN,T+SA#(]D#^I286 ,$0-)M M:/CMBJ"*OC+\VD1<.\(S6 ,$ !)MYNH@+V/3*7T*9P#C&1N Z@'2Y7]P6,?%^@*T-&+Q;&EX793H\6FFW ^[>^8F M6FMZ0;%"([GV^!HL?$:%YV\&JYI!A12]9720-U6*7\R'4+:/.CD]N?C.3O-5 MLS_RP\MZ=QQ\+ZNJW+9?TGDNRZJH6XS&=5NO1?YT?K,IGJOF95*_/IR^XG5Z M4Y5[]_6UR?D[=/?_ 5!+ P04 " 8BY1/@7:W2;0! #2 P & 'AL M+W=OUKFT7>Q96Y&KV0/%TO< MJ+6P/\^@S%30 WUQ/,JV\\'!RGP0+7P!_W6X6+38RE)+#;V3IB<6FH+>'T[G M+,3'@&\2)K4;(4_PENH# \*,$_P>=H_"]O*WI&K\?BRL?^-,1Y02G*'(]3A!UL-!8T/QS=XMO.8S88W MP_*#V/J-RU]02P,$% @ &(N43]0;3NZS 0 T@, !@ !X;"]W;W)K M<.3,>YZ-U3[X#".19*^,+VH70'QGS50=: M^!O;@\&;QCHM IJN9;YW(.H$THKQW>XMTT(:6N;)=W9E;H>@I(&S(W[06KB? M)U!V+.B>OC@>9-N%Z&!EWHL6OD+XUI\=6FQAJ:4&XZ4UQ$%3T+O]\72(\2G@ MNX31K\XD5G*Q]BD:G^J"[J(@4%"%R"!PN\(]*!6)4,:/F9,N*2-P?7YA_Y!J MQUHNPL.]58^R#EU!;RFIH1&#"@]V_ AS/6\HF8O_#%=0&!Z58([**I]64@T^ M6#VSH!0MGJ==FK2/TTV6S;!M )\!? '#:-$V>5'8P:9)7WF5@[WAZD]?P M:=J_"-=*X\G%!GS9U/_&V@ H97>#(]3A!UL,!4V(QW=X=M.834:P_?R#V/*- MRU]02P,$% @ &(N43Y_K1VJU 0 T@, !D !X;"]W;W)K&UL?5-A;]P@#/TKB!]0[DC:G4Y)I%ZK:9,VZ=1IZV^C\ M38U&"^=-TS#;&Q!5!&G%^&YWQ[20'2VRZ#N;(L/!*=G!V1 [:"W,KQ,H''.Z MIV^.)]FT+CA8D?6B@6_@OO=GXRVVL%120V6DKGX+W %Y<.#$I^C1&7C2LK!.M0SBY>B MQ>NTRR[NXW23'&;8-H#/ +X #C$/FQ)%Y8_"B2(S.!(S];X7X8GW1^Y[4P9G M;$6\\^*M]UX+GJ09NP:B.>8TQ?!5S'Z)8)Y]2<&W4ISX/W"^#4\V%281GORA M\':;(-TD2"-!^M\2MV+N_DK"5CW58)HX39:4.'1QDE?>96#O>7R3]_!IVK\* MT\C.D@LZ_[*Q_S6B R]E=^-'J/4?;#$4U"X&UL?5-A;]L@$/TKB!]0$N*U661;:CI5F[1)4:>UGXE]ME'!>(#C M[M_OP*[KK5:_ '?<>_?N.-+!V&?7 'CRHE7K,MIXWQT8)!UXX.#Y6DG:O@)_E=WLFBQF:64&EHG34LL5!F]W1Z.28B/ 8\2!K M9.F;C.XI*:$2O?(/9O@*4SV?*)F*_PX74!@>E&".PB@75U+TSAL]L: 4+5[& M7;9Q'\:;9#_!U@%\ O 9L(]YV)@H*O\BO,A3:P9BQ]YW(CSQ]L"Q-T5PQE;$ M.Q3OT'O)^>XF99= -,4$NPG?_*-RO M$R2K!$DD2#XL<2WF\W])V**G&FP=I\F1PO1MG.2%=Q[86Q[?Y"U\G/8?PM:R M=>1L/+YL[']EC >4LKG"$6KP@\V&@LJ'XPV>[3AFH^%--_T@-G_C_"]02P,$ M% @ &(N43_1R*HRO 0 T@, !D !X;"]W;W)K&UL?5-A;YPP#/TK47Y P^585YT J==IVJ1-.G7:]CD'!J(FF";A:/_] MDL QUK%](;;Q>WYVG&Q$\V1; $=>M.IL3EOG^@-CMFQ!"WN#/73^3XU&"^== MTS#;&Q!5!&G%>)+<,BUD1XLLQDZFR'!P2G9P,L0.6@OS>@2%8TYW]!IXE$WK M0H 562\:^ ;N>W\RWF,+2R4U=%9B1PS4.;W?'8YIR(\)/R2,=F63T,D9\2DX MGZN<)D$0*"A=8!#^N, #*!6(O(SGF9,N)0-P;5_9/\;>?2]G8>$!U4]9N3:G M=Y144(M!N4<&UL?5/; M;MP@$/T5Q >$7>RTTP-]J#]38U&">=-TS#;&Q!5!"G) M^&[W@2G1:5IDT7T+CA8D?6B@6_@ MOO&8AO@8\*.#T:[.)%1R1GP)QF.5TUT0!!)* M%QB$WR[P %(&(B_C=>:D2\H 7)^O[)]C[;Z6L[#P@/)G5[DVIW>45%"+0;IG M'+_ 7,\M)7/Q7^$"TH<')3Y'B=+&E92#=:AF%B]%B;=I[W3+*I,(GPY ^%Z39!NDF01H+TOR5NQ=S^ ME82M>JK -'&:+"EQT'&25]YE8.]Y?)/?X=.T/PG3=-J2,SK_LK'_-:(#+V5W MXT>H]1]L,234+AP_^K.9QFPR'/;S#V++-RY^ 5!+ P04 " 8BY1/4!0W MO+4! #2 P &0 'AL+W=O=J*&1W _N[/Q M%IM92JFAM1);8J#*Z-WV>$I"? SX)6&PBS,)E5P0GX/QK$>U9,L79/1 R4E5*)7[@&'KS#5 M\XF2J?CO< 7EPX,2GZ- 9>-*BMXZU!.+EZ+%R[C+-N[#>+,_3+!U )\ ? 8< M8AXV)HK*/PLG\M3@0,S8^TZ$)]X>N>]-$9RQ%?'.B[?>>\UYLD_9-1!-,:&;#3V MQ;4 GKQJU;FSO$R@SYG1'WQQ/LFE]<+ BZT4#W\'_Z,\6+;:H M5%)#YZ3IB(4ZI_>[XRD-^ AXEC"ZU9F$2B[&O 3C2Y73)"0$"DH?% 1N5W@ MI8(0IO%KUJ1+R$!)*RL%YHV<53$6+UVF77=S'Z8;?SK1M I\)?"'%)DU([%3[WL1GGAWY-B;,CAC*^(=)N_0>RUX^C%CUR T8TX3AJ\P MNP7!4'T)P;="G/A_=+Y-WV]FN(_T_9I^2+8%TDV!- JD[Y:X@3G\6R1;]52# M;>(T.5*:H8N3O/(N WO/XYO\A4_3_DW81G:.7(S'EXW]KXWQ@*DD-SA"+7ZP MQ5!0^W"\Q;.=QFPRO.GG'\26;US\ 5!+ P04 " 8BY1/\L189[0! #2 M P &0 'AL+W=O'B %ZG?]\!.Z[;6GD!9IASYLPP9*.Q+ZX% M\.1-2>URVGK?'QAS90M*N"O3@\:;VE@E/)JV8:ZW(*H(4I+QW>Z&*=%I6F31 M=[)%9@8O.PTG2]R@E+"_CB#-F-,]?7<\=TWK@X,562\:^ ;^>W^R:+&%I>H4 M:-<932S4.;W;'XYIB(\!/SH8W>I,0B5G8UZ"\53E=!<$@832!P:!VP7N09TZZI S ]?F=_7.L'6LY"P?W1O[L*M_F]):2"FHQ2/]LQD>8Z[FF9"[^ M"UQ 8GA0@CE*(UU<23DX;]3,@E*4>)OV3L=]G&Z2=(9M _@,X O@-N9A4Z*H M_$%X4636C,1.O>]%>.+]@6-ORN",K8AW*-ZA]U+P:YZQ2R":8XY3#%_%[)<( MANQ+"KZ5XLC_@_-M>+*I,(GPY"^%R39!NDF01H+TPQ*W8M)_DK!53Q78)DZ3 M(Z49=)SDE7<9V#L>W^1/^#3M7X5M.NW(V7A\V=C_VA@/*&5WA2/4X@=;# FU M#\=/>+;3F$V&-_W\@]CRC8O?4$L#!!0 ( !B+E$\& ^W:M@$ -(# 9 M >&PO=V]R:W-H965T0-DAIUOZ[GB131NB@Q59)QKX N%K=W9HL9FEDAJ,E]80 M!W5.'[;'TS[&IX!O$@:_.)-8R<7:UVA\K'*ZB8) 01DB@\#M"H^@5"1"&3\F M3CJGC,#E^9W].=6.M5R$AT>KOLLJM#F]IZ2"6O0JO-CA TSU'"B9BO\$5U 8 M'I5@CM(JGU92]CY8/;&@%"W>QEV:M _CS6$WP=8!? +P&7"?\K Q45+^)((H M,F<'XL;>=R(^\?;(L3=E=*96I#L4[]%[+?CAD+%K))IB3F,,7\1LYPB&[',* MOI;BQ/^!\W7X;E7A+L%W?RB\72?8KQ+L$\'^OR6NQ=S]E80M>JK!-6F:/"EM M;](D+[SSP#[P]":_P\=I_RQ<(XTG%QOP95/_:VL#H)3-#8Y0BQ]L-A34(1[O M\.S&,1N-8+OI!['Y&Q>_ %!+ P04 " 8BY1/$*\MF+8! #2 P &0 M 'AL+W=O/*J5>LR MVGC?'1ES10-:N!O308LWE;%:>#1MS5QG0901I!7C27++M) MS=/H.]L\-;U7 MLH6S):[76MBW$R@S9'1#WQW/LFY\<+ \[40-7\%_Z\X6+3:SE%)#ZZ1IB84J MH_>;XVD7XF/ =PF#6YQ)J.1BS$LPOI0938(@4%#XP"!PN\(#*!6(4,;/B9/. M*0-P>7YG_Q1KQUHNPL+]DZ9N,'B@IH1*]\L]F^ Q3/7M*IN(?X0H*PX,2 MS%$8Y>)*BMYYHR<6E*+%Z[C+-N[#>+/G$VP=P"< GP&'F(>-B:+RC\*+/+5F M(';L?2?"$V^.''M3!&=L1;Q#\0Z]UYSO#RF[!J(IYC3&\$7,9HY@R#ZGX&LI M3OP?.%^';U<5;B-\^X?"#^L$NU6"7238_;?$E9C;Y*\D;-%3#;:.T^1(8?HV M3O+".P_L?7Q$]CM\G/8G86O9.G(Q'E\V]K\RQ@-*26YPA!K\8+.AH/+A>(=G M.X[9:'C333^(S=\X_P502P,$% @ &(N43[@(&UL?5-A;]L@$/TKB!]0$IQE561;:CI5 MK;1)4:=MGXE]ME'!N(#C[M_OP*[K;6Z_ '?<>_?N.-+!V"?7 'CRHE7K,MIX MWQT8R>6IZKV0+ M)TM M; _'78B/ 3\E#&YQ)J&2LS%/P7@H,[H)@D!!X0.#P.T"MZ!4($(9SQ,GG5,& MX/+\RGX7:\=:SL+!K5&_9.F;C%Y34D(E>N4?S7 /4SV?*)F*_PH74!@>E&". MPB@75U+TSAL]L: 4+5[&7;9Q'\:;?3+!U@%\ O 9)&GU@S$ MCKWO1'CB[8%C;XK@C*V(=RC>H?>2\_TV99= -,4K"I,(3_Y2^ [!;I5@%PEV'Y:X%I/\DX0M>JK!UG&:'"E,W\9)7GCG M@;WA\4W>PL=I_R9L+5M'SL;CR\;^5\9X0"F;*QRA!C_8;"BH?#A^QK,=QVPT MO.FF'\3F;YS_ 5!+ P04 " 8BY1/N<:HVK4! #2 P &0 'AL+W=O MV=$U&;RDIH1*]=$\X?(6IGFM*IN(?X0+2AP!TL:5 M%+UUJ"86+T6)]W%O==R'\2;93;!U )\ ? ;N.]-$9RQ%?'.B[?>>\GY/DG9)1!-,<QTG>>&=!_:. MQS?Y#!^G_;LP=:LM.:/S+QO[7R$Z\%(V5WZ$&O_!9D-"Y<+QQI_-.&:CX;"; M?A";OW'^&U!+ P04 " 8BY1/R%#F#K4! #2 P &0 'AL+W=OUUKX =]Q[]^XXT@'-LVT ''G1JK49;9SK#HS9H@$M M[!5VT/J;"HT6SINF9K8S(,H(THKQS>:::2%;FJ?1=S)YBKU3LH63(;;76IC7 M(R@<,KJE;XXG63=J*&[^!^="?C+3:SE%)#:R6VQ$"5T=OMX;@+\3'@ MIX3!+LXD5')&? [&?9G131 $"@H7&(3?+G '2@4B+^/WQ$GGE &X/+^Q?XVU M^UK.PL(=JE^R=$U&]Y244(E>N2<!RL:5%+UU MJ"<6+T6+EW&7;=R'\29))M@Z@$\ /@/V,0\;$T7E7X03>6IP(&;L?2?"$V\/ MW/>F",[8BGCGQ5OOO>3\^B9EET TQ1S'&+Z(V,ZW; M1IM+2=+I\O-S?.PX^6C=D^\ GG6ROB"=B'T1\9\U8$6_L;V M8/"FL4Z+@*9KF>\=B#J!M&(\RUXS+:2A99Y\9U?F=@A*&C@[X@>MA?MQ F7' M@N[HB^-1MEV(#E;FO6CA,X0O_=FAQ1:66FHP7EI#'#0%O=\=3X<8GP*^2AC] MZDQB)1=KGZ+QH2YH%@6!@BI$!H';%1Y J4B$,K[/G'1)&8'K\PO[NU0[UG(1 M'AZL^B;KT!7TCI(:&C&H\&C']S#7\XJ2N?B/< 6%X5$)YJBL\FDEU>"#U3,+ M2M'B>=JE2?LXW? W,VP;P&< 7P!W*0^;$B7E;T409>[L2-S4^U[$)]X=.?:F MBL[4BG2'XCUZKR6_S7)VC41SS&F*X:N8W1+!D'U)P;=2G/A?<+X-WV\JW"?X M_C>%_\A_V"0X)(+#?TO>9>!O>?I37Z%3]/^ M2;A6&D\N-N#+IOXWU@9 *=D-CE"''VPQ%#0A'F_Q[*8QFXQ@^_D'L>4;ES\! M4$L#!!0 ( !B+E$^BU'%\M $ -(# 9 >&PO=V]R:W-H965T,>TD#TM\^@[VS(WHU>RA[,E;M1:V)\G4&8J:$+? M'$^R[7QPL#(?1 M?P7\;SA8MMK+44D/OI.F)A::@#\GQE(7X&/!=PN0V9Q(J MN1CS$HQ/=4$/01 HJ'Q@$+A=X1&4"D0HX\?"2=>4 ;@]O[%_B+5C+1?AX-&H M9UG[KJ#WE-30B%'Y)S-]A*6>6TJ6XC_#%12&!R68HS+*Q954H_-&+RPH18O7 M>9=]W*?Y)DT6V#Z +P"^ NYC'C8GBLK?"R_*W)J)V+GW@PA/G!PY]J8*SMB* M>(?B'7JO);]+RE._!\XWX>GNPK3"$__4)CM M$V2[!%DDR/Y;XE[,[5])V*:G&FP;I\F1RHQ]G.2-=QW8!Q[?Y'?X/.U?A&UE M[\C%>'S9V/_&& \HY7"#(]3A!UL-!8T/QSL\VWG,9L.;8?E!;/W&Y2]02P,$ M% @ &(N43Q!Z-_BU 0 T@, !D !X;"]W;W)K&UL?5-A;]L@$/TKB!]0$I(U461;:CI-F[1)4:>MGXE]ME&!\P#'W;\? M8-?S-FM?@#ONO7MW'-F ]L6U )Z\:F5<3EOONQ-CKFQ!"W>''9AP4Z/5P@?3 M-LQU%D250%HQOMG<,RVDH466?!=;9-A[)0U<+'&]UL+^/(/"(:=;^N9XDDWK MHX,562<:^ K^6W>QP6(S2R4U&"?1$ MU3A^VI_,^QJ> [Q(&MSB36,D5\24: MGZJ<;J(@4%#ZR"#"=H-'4"H2!1D_)DXZIXS Y?F-_4.J/=1R%0X>43W+RK\HF8K_##=0(3PJ"3E*5"ZMI.R=1SVQ!"E:O(Z[-&D? MQAM^F&#K #X!^ PXICQL3)24OQ=>%)G%@=BQ]YV(3[P]\=";,CI3*])=$.^" M]U;PPWW&;I%HBCF/,7P1LYTC6&"?4_"U%&?^#YROPW>K"G<)OOM#X6&=8+]* ML$\$^_^6N!9S_"L)6_14@VW2-#E28F_2)"^\\\ ^\/0FO\/':?\B;".-(U?T MX653_VM$#T'*YBZ,4!L^V&PHJ'T\'L+9CF,V&AZ[Z0>Q^1L7OP!02P,$% M @ &(N43X1(-9:U 0 T@, !D !X;"]W;W)K&UL?5/MCIP@%'T5P@,L#F,[TXF:[&S3M$F;3+9I^YO1JY(%L8#C]NU[0=>: MKMD_P+V<<^X'EVPT]LFU )X\:]6YG+;>]R?&7-F"%N[.]-#A36VL%AY-VS#7 M6Q!5)&G%>)*\9UK(CA99]%ULD9G!*]G!Q1(W:"WLGS,H,^9T1U\DZ8B%.J?WN],Y#?@(^"EA=*LS"9553 5+9ZG779Q'Z>; M]##3M@E\)O"%<(QQV!0H9OY1>%%DUHS$3KWO17CBW8EC;\K@C*V(=YB\0^^M MX(+,7]'Y-GV_F>$^TO=K^C'9%D@W!=(H MD+Y9X@;F^'^1;-53#;:)T^1(:88N3O+*NPSL/8]O\@\^3?LW81O9.7(U'E\V M]K\VQ@.FDMSA"+7XP19#0>W#\8!G.XW99'C3SS^(+=^X^ M02P,$% @ M&(N43X.CPQBT 0 T@, !D !X;"]W;W)K&UL M?5-AC]0@$/TKA!]P[+)5UTW;Y/:,T423S1GU,]M.6W+ 5*#;\]\+M%>K-GX! M9ICWYLTPY"/:)]/*LE7$%[;SO3XRYJ@,MW!WV8,)-@U8+'TS;,M=;$'4" M:<7X;O>::2$-+?/DN]@RQ\$K:>!BB1NT%O;G&12.!=W3%\>C;#L?':S,>]'" M%_!?^XL-%EM8:JG!.(F&6&@*>K\_G;,8GP*^21C=ZDQB)5?$IVA\K NZBX) M0>4C@PC;#1Y J4@49/R8.>F2,@+7YQ?V]ZGV4,M5.'A ]5W6OBOHD9(:&C$H M_XCC!YCK>47)7/PGN($*X5%)R%&A \ZIDE2-'B>=JE2?LXW?"W,VP; MP&< 7P#'E(=-B9+R=\*+,K_ %!+ P04 " 8BY1/ MKJ"E8P$# #L#0 &0 'AL+W=OOZ/DF:S4&467,G:U&9?W92E9DV3;5/FEJ) M;&L'E45":3I)RBROXM7"]CVIU4(>=9%7XDE%S;$L,_5W+0IY7L8LOG0\Y_N# M;CN2U:+.]N*'T#_K)V5:R<"RS4M1-;FL(B5VR_B!W:]IW@ZPB%^Y.#=7[U&[ ME!8 MW9/Y-INVTWX*^Y^9?&-Z3RN:C1?)J27J,>L.0U<8-B 2PSY($))8DS><\' . M9\CM<'X]G.:88 0)1I9@=+/$B;-$A)EBD3$4&0."F2.",(&53*#(Q">8IXX( MP@2V:PI%IH" '!&$X5AD!D5F@&#DB"#,&(O,H<@<$+@;CS"!C68GG*>>WQ HY#=[Y#8%\>YZAVN,@]D#^O_X=T]Z'NF]GG5 M1"]2FR._/9COI-3"S"6],UXYF*O7T"C$3K>O4_.NNOM'U]"R[N]6R7#!6_T# M4$L#!!0 ( !B+E$^P(/I=[P$ &8% 9 >&PO=V]R:W-H965T0/B%D#NW0%2-E$42NUTBI5VVM6)/I!0Y^A^=SRE%N\ /SL8U6H? MV$HN0KQ8XTN5H] F! Q*;1FH66[P (Q9(I/&[YD3+9(V<+U_8W]RM9M:+E3! M@V"_NDJW.4I14$%-KTP_B_$SS/4D*)B+_PHW8 9N,S$:I6#*?8/RJK3@,XM) MA=/7:>UZMX[324+F,'\ F0/($I Z'3P)N'>3.,7'BT M#B>?_ 2QER!V!/%_)<:;$GV8Q"^2>$42#\%^(^+#'/PB>Z_(WD.0;D1\F ^N MZ^ 5.;PGB,.-B _SP3^1>D52#P'9B/@PT48$K_YS#K)Q':Z"4EQ[-UU6WF6( MW+O&PO_@TP3Z1F73]2JX"&VZS?5$+80&DTIX9YZN-4-O,1C4VFX/9B^GUI\, M+89YJN%EM!9_ 5!+ P04 " 8BY1/YW,%K=\! !!0 &0 'AL+W=O M KZ&_#59J(K"I5QZ%7G>B1A#K'CX?S);5X M!_C>P:0VKE1!4^"_>@JW>;XA%$%-1V9?A;31UCZ23!:FO\,=V &;BLQ'J5@RGU1 M.2HM^*)B2N'T=1Z[WHW3O)+&"\U/"!="N!).SH?,1J[R]U33(I-B0G+>^X': M7WPXAV9O2IMT6^'63/'*9.]%%,<9N5NA!7.9,>$&3HT98>_4<@]@K$3B#^J\5DUZ(/<_2;)%Z3Q".0[DQ\F)/?Y.@U.7H$ MWNU,/)@D\)ND7I/4(W#8F?@P^W]"-D>0@VSQJ:]ZC-6!0:SM-S5S.MW(.M!B6!X>L MKU[Q&U!+ P04 " 8BY1/[#MT^;E! MXTUCK.(>3=LRUUO@=20IR9+=[@-37&A:YM%WL65N!B^%AHLE;E"*V]]GD&8L MZ)Z^.9Y%V_G@8&7>\Q:^@?_>7RQ:;%&IA0+MA-'$0E/0^_WIG 5\!/P0,+K5 MF81*KL:\!.-S7=!=2 @D5#XH<-QN\ !2!B%,X]>L29>0@;@^OZD_Q=JQEBMW M\&#D3U'[KJ!'2FIH^"#]LQD_P5S/@9*Y^"]P XGPD G&J(QT<275X+Q1LPJF MHOCKM L=]W&ZR8XS;9N0S(1D(1QC'#8%BID_MP6R38$L"F3_E)B]*W$+&PO=V]R:W-H965T M?;0ACS/L2^X[?GSO'YVR4ZDVW :]"][I'+?&]$="=-F"H/I.]M#9 M+[54@AH;JH;H7@&M/$EPDD112@1E'2XRGSNK(I.#X:R#LT)Z$(*J7R?@9[)"".L>/\?&4.KP'?& MN4XN4KZYX%.5X\@5!!Q*XQ2H7:[P!)P[(5O&SUD3+Y:.N-[?U%]\[[:7"]7P M)/D/5IDVQP\855#3@9M7.7Z$N9\#1G/SG^$*W,)=)=:CE%S[7U0.VD@QJ]A2 M!'V?5M;Y=9SU;[0P(9D)R89 )B-?^3,UM,B4')&:SKZG[B^.CXD]F](E_5'X M;[9X;;/78G=(,W)U0C/F-&&2%29>$,2J+Q9)R.*4_$-/PO1=L,*=I^_6]/U_ M_/=!@;T7V/_5XOVFQ1#F(6QR")H< @(?-B8!3!J%3=*@21H0B#Y_4)5PSJ-+M+8.^IO4BVE 5M*=&<; M;NU3L00<:N.V]W:OIH&9 B/[^2T@RX-4_ 902P,$% @ &(N43[ =W]ZV M 0 T@, !D !X;"]W;W)K&UL;5/;;MP@$/T5 MQ >$7>Q-HY5M*9NJ:J566J5J^\S:8QL%C MXG?Y]!^QUW-0OP SGG+DP9*.Q M+ZX%\.15J\[EM/6^/S+FRA:T<'>FAPYO:F.U\&C:AKG>@J@B22O&=[M[IH7L M:)%%W]D6F1F\DAV<+7&#UL+^.8$R8T[W].9XEDWK@X,562\:^ [^1W^V:+%% MI9(:.B=-1RS4.7W<'T]IP$? 3PFC6YU)J.1BS$LPOE0YW86$0$'I@X+ [0I/ MH%00PC1^SYIT"1F(Z_--_5.L'6NY" =/1OV2E6]S^D!)!;48E'\VXV>8ZSE0 M,A?_%:Z@$!XRP1BE42ZNI!R<-WI6P52T>)UVV<5]G&X.-]HV@<\$OA >(H%- M@6+F'X4716;-2.S4^UZ$)]X?.?:F#,[8BGB'R3OT7HOD/LG8-0C-F-.$X2O, M?D$P5%]"\*T0)_X?G6_3D\T,DTA/UO0TW19(-P72*)#^4V+ZKL0MS.%=$+;J MJ0;;Q&ERI#1#%R=YY5T&]I''-WF#3]/^3=A&=HY7C?VOC?& J>SN<(1: M_&"+H:#VX?@!SW8:L\GPII]_$%N^&PO=V]R:W-H965T^"2Y/CUMKN2(@I6Q#4W*D.I-NIE1;4NJ5NB.DTT"J0!"=IDNR(H$SB(@NQ MLRXRU5O.))PU,KT05/\Y 5=#CE?X(_#$FM;Z "FRCC;P"^SO[JS=BLPJ%1,@ M#5,2::AS?+\ZGK8>'P#/# :SF"-?R46I5[_X7N4X\0D!A])Z!>J&*SP YU[( MI?$V:>+9TA.7\P_U;Z%V5\N%&GA0_(55MLWQ :,*:MIS^Z2&1YCJV6(T%?\# MKL =W&?B/$K%3?BBLC=6B4G%I2+H^S@R&<9AW-D=)EJK?+R-4+39C3B$D7F-6, M($Y]MDAC%J?T/WH:IZ^C&:X#?;VD;_9Q@4U48!,$-O^4N+\I,88YQ$VV49-M M1.#+C4D$LT]N3,CBX@3H)CQ9@TK5R] NB^C<%?=IN/A/^-A2/ZENF#3HHJQ[ M/N&2:Z4LN%22.Y=+Z[IX7G"HK9_NW5R/;WE<6-5-;4KF?T7Q%U!+ P04 M" 8BY1/UQ@3N,(! W! &0 'AL+W=O9[=\ M$1A^?V: L9B5?C$]@$6O4@RFQ+VUXY$04_<@F;E3(PQNIU5:,NN6NB-FU,": M0)*"T"3Y0"3C ZZ*$#OKJE"3%7R LT9FDI+I/R<0:B[Q ;\%GGG76Q\@53&R M#KZ#_3&>M5N13:7A$@;#U8 TM"5^/!Q/N<<'P$\.L]G-D:_DHM2+7WQI2ISX MA$! ;;T"<\,5GD (+^32^+UJXLW2$_?S-_5/H797RX49>%+B%V]L7^('C!IH MV23LLYH_PUI/CM%:_%>X@G!PGXGSJ)4PX8OJR5@E5Q67BF2OR\B',,[+3D97 M6IQ 5P+=" _!ARQ&(?./S+*JT&I&>CG[D?DK/ARI.YO:!\-1A#V7O''1:Y7> M'PIR]4(KYK1@Z [SCB!.?;.@,8L3_8].X_0TFF$:Z.F>GB=Q@2PJD 6![)\2 MZ4V),4P:-\FC)GE$(+LQB6'R&Q.RNS@)N@M/UJ!:34-HEUUTZXK'\%+(.WQI MJ6],=WPPZ**L>S[ADENE++A4DCN72^^Z>%L(:*V?WKNY7M[RLK!J7-N4;/^* MZB]02P,$% @ &(N43RZ;]Q6X 0 T@, !D !X;"]W;W)K&UL;5/M;ML@%'T5Q .4Q$Z:*+(M-:VJ3=JDJ-.VW\2^ME&! MZP&.N[:>*2XT+;+HNY@BP]Y)H>%BB.V5XN;W&20..=W2 M=\>+:%H7'*S(.M[ -W#?NXOQ%IM5*J% 6X&:&*AS^K ]G7]-&9RQ M%?'.)V^]]U:DA_N,W8+0A#F/F&2!VK&::1GB[I M^W1=8+>6 ?DO@F?^'C MM'_EIA':DBLZ_[*Q_S6B Y_*YLZ/4.L_V&Q(J%TX^H$@9ARST7#833^(S=^X M^ -02P,$% @ &(N43^PT0=O? 0 04 !D !X;"]W;W)K&UL=53KCIP@%'X5P@,L#H[C=*(F.]LT;=(FDVW:_F;T>,F" M6&#&[=L7T+7&LG^$<_@NYR"0C5*]Z!; H%?!>YWCUICA1(@N6Q!,/\@!>KM2 M2R68L:%JB!X4L,J3!"9S%U5D\F9XU\-%(7T3@JD_9^!RS/$. MOR6>NZ8U+D&*;& -? ?S8[@H&Y%%I>H$]+J3/5)0Y_AQ=SJG#N\!/SL8]6J. M7"=7*5]<\*7*<>0* @ZE<0K,#G=X LZ=D"WC]ZR)%TM'7,_?U#_YWFTO5Z;A M2?)?767:'!\QJJ!F-VZ>Y?@9YGX2C.;FO\(=N(6[2JQ'*;GV7U3>M)%B5K&E M"/8ZC5WOQW%:2>E,"Q/H3* +X>A]R&3D*__(#"LR)4>DIKT?F/O%NQ.U>U.Z MI-\*OV:+US9[+^+T0T;N3FC&G"<,76%V"X)8]<6"ABS.]#\Z#=/C8(6QI\=K M>G(("^R# GLOL%^W>(PV+88P[S29!$V2@ #=F(0P<=CD$#0Y! 3V&Y,0YAV3 M-&B2!@22C4D(L_TG9'4$!:C&7SZ-2GGK_<5?99?[_>C///D'GQZ';TPU7:_1 M51I[$?QQK:4T8$N)'NRNMO8]6@(.M7'3U,[5="NGP,AA?G#(\NH5?P%02P,$ M% @ &(N43\]R:\6X 0 T@, !D !X;"]W;W)K&UL=5/M;ML@%'T5Q .4Q$F;++(M-9VF3MJDJ-/:W\2^ME&!ZP*.N[W1/-L&P)%7);7-:.-<>V#,%@TH;J^P!>UO*C2*.V^: MFMG6 "\C24F6K%8W3'&A:9Y&W\GD*79."@TG0VRG%#=_CB"QS^B:OCD>1-VX MX&!YVO(:?H'[W9Z,M]BD4@H%V@K4Q$"5T=OUX;@-^ AX%-#;V9F$2LZ(S\'X M7F9T%1(""84+"MQO%[@#*8.03^-EU*13R$"QCKN:9D+/X'7$!Z>,C$QRA0VKB2HK,.U:CB4U'\==B%CGL_ MW.R2D;9,2$9",A'V,0X; L7,OW+'\]1@3\S0^Y:')UX?$M^;(CAC*^*=3]YZ M[R7?['&UL=51MCYP@$/XKA!]PN+KJ=:,FM]%&9^7&98AFX1\52V 1F^<]2K'K=;#B1!5ML"I>A #].9++22GVH2R M(6J00"M'XHR$09 03KL>%YG+7621B5&SKH>+1&KDG,I?9V!BRO$!WQ,O7=-J MFR!%-M &OH+^-ERDBM6)'DFH<_QT.)U3BW> [QU,:K-'MI.K$*\V M^%3E.+ % 8-26P5JEAL\ V-6R)3Q<]'$JZ4E;O=W]0^N=]/+E2IX%NQ'5^DV MQX\855#3D>D7,7V$I9\8HZ7YSW #9N"V$N-1"J;<+RI'I05?5$PIG+[-:]>[ M=5KT[S0_(5P(X8Y 9B-7^7NJ:9%),2$YG_U [5]\.(7F;$J;=$?AOIGBE MBNA=D)&;%5HPYQD3;C"'%4&,^FH1^BS.X3_TT$^/O!5&CAYMZ4GL%SAZ!8Y. MX/A7BX==BS[,?ZJ,O2:Q1R#:F?@P1[])XC5)/ +QSL2'2?PFJ=QLRQS,6C6=G"6GAHXI_+/"9@8"S_TWP//[:W1-D#*O*+5+K[6A1_8A(!! MI:T"-<,=GH Q*V32^#UK^HNE):[G[^J?7>VFE@M5\"38K[;63>&GOE?#E0Y, M/XOQ"\SU['UO+OX;W($9N,W$>%2"*??UJD%IP6<5DPJG;]/8=FX25B=[+.,MR MK^E)B@OL4(&=$]BM!'9! ML"D1P_RGR#UJLD<$HHT)AHEQDP0U21"!W<8$P^QQDP-JWA7(3285(('\W\TIK,N"P97;:<',Y=3?YD66O1S MZR1+_R[_ E!+ P04 " 8BY1/(C[0Y=4! ")]:@EU_Z+ZHLV M4JPJMA3!7I=Q&/TX+RM9NM+"!+H2Z$9X\#YD,?*5?V2&5862,U++WD_,_>+X M0.W>U"[IM\*OV>*US5ZK-*8%N3JA%7-<,'2'B3<$L>J;!0U9'.D[.@W3DV"% MB:_K]?_S3H$#J!=*=0))^N&DQ@,FBL$D6-,G>":1Q:%3+R^COY"Z[7;U'ZD_7/_AR;[\QU0VC1F=I[!GU M)ZF5TH M);JS#??VJ=@"#JUQTWL[5\N%60(CI_4M(-N#5/T%4$L#!!0 ( M !B+E$].XV0JN $ -(# 9 >&PO=V]R:W-H965TDAV\PU7.-T53\#[B \/"0B8]1:F'CBLK>.BTG%9^*9&_CSE72C!-G":+2MVK.,D+[SRP=S2^R5_X..T_F6FXLNBLG7_9 MV/]::P<^E&PO=V]R:W-H965T"]1*7>8B==9FKT?)>PEDC,PK!]*\3<#45.,5O@:>^[:P/D#(? M6 O?P'X?SMJMR*I2]P*DZ95$&IH"/Z3'T][C ^"YA\ELYLA7+_ MP.>6^LITVTN#+LJZYQ,NN5'*@K.2W#DOG>OB=<&AL7[ZSLWU_);GA57#TJ9D M_5>4OP%02P,$% @ &(N43Y> >+>F 0 F0, !D !X;"]W;W)K&UL;9/;;J,P$(9?Q?(#U('0I(T :9-5M2NU4M35MM<. M#,&*#]1V0O?M=VPH2BINL&?\SS<'[+PW]N1: $\^E=2NH*WWW88Q5[6@N+LS M'6@\:8Q5W*-IC\QU%G@=@Y1DZ6*Q8HH+3B/9+/-@CX*W@3T M[FI/0B<'8T[!^%T7=!$* @F5#P2.RP5V(&4 81D?(Y-.*4/@]?Z+_A1[QUX. MW,'.R'=1^[:@#Y34T/"S]*^F_P5C/_>4C,T_PP4DRD,EF*,RTL4OJ<[.&S52 ML!3%/X=5Z+CVP\GZ<0R;#TC'@'0*2.)PV) H5OZ3>U[FUO3$#K/O>/C%R2;% MV53!&4<1S[!XA]Y+F:7W.;L$T*C9#IKT1K.:- SY4Y)T-DD: =D-8#T/6,X" MEA&PO $\S .R64 V4\'CMS8'S2IJ=-0DWU*PJZF&2_O"[5%H1P[&XP^*8VR, M\8"TQ1W>A!;?R61(:'S8KG%OA]LR&-YTXT-@TVLL_P-02P,$% @ &(N4 M3RNHV)@] @ ] 8 !D !X;"]W;W)K&ULC55= MCYLP$/PKB/>>^3"$1 3IDJAJI58Z7=7VV2&;@,Y@:COA^N]K&\)!\%V:AV!O M9F9WUF&=MHR_B ) .J\5K<7:+:1L5@B)O("*B ?60*U^.3)>$:FV_(1$PX$< M#*FB*/"\&%6DK-TL-;$GGJ7L+&E9PQ-WQ+FJ"/^[ N[U\!S>2JD#J L M;<@)?H#\V3QQM4.#RJ&LH!8EJQT.Q[7[Z*]V2XTW@%\EM&*T=K23/6,O>O/U ML'8]71!0R*56(.IQ@2U0JH54&7]Z37=(J8GC]57]L_&NO.R)@"VCO\N#+-9N MXCH'.)(SE<^L_0*]G\AU>O/?X )4P74E*D?.J##?3GX6DE6]BBJE(J_=LZS- ML^WUKS0[(>@)P4#PXP\)84\(WPCX0P+N"?B&@#HKIC<[(DF6X2*7C(<>BFZ:*$>L^DPP0CC#PBDU(<4@2W%)IC1@VF" M[1P11U/(S@*)[46$5I^AX8<3G^^XP%8!; 3P1.#&QZ;#+ RF-IA/?I#XGO[< M6+9"0VR![FQ0+XBFT(F#R.H@FCE8X!L#T2P53FS5=[AXA L]6^ESO7AW:!A55@\?^GGE@%DONGODWN-F.2:&E-M+Q[.-OEK)GV/&CT[E? 3V:N M"B=GYUKJ5V@4'4;W8Z!GQTU\HT9Z-X'?9+K[X#OAI[(6SIY)-9G,_#@R)D&5 MZ3VH0R_4%31L*!RE7B[4FG>#N-M(UO1W#!HNNNP?4$L#!!0 ( !B+E$\6 M?"@]O0$ -(# 9 >&PO=V]R:W-H965T)W^?;DXKIOX!9CAS)DS MPU!,VCS;'L"A%RF4+7'OW' DQ-8]2&9O] #*W[3:2.:\:3IB!P.LB4%2$+K; M'8AD7.&JB+ZSJ0H].L$5G VRHY3,_#F!T%.)]_C5\<2[W@4'J8J!=? =W(_A M;+Q%%I:&2U"6:X4,M"6^WQ]/>T*#R!$(/(R?L^<>$D9 M?G5_9/L79?RX59>-#B%V]<7^(/FLE&X)SU] MAKF>6XSFXK_"%82'!R4^1ZV%C2NJ1^NTG%F\%,E>TLY5W*=T511?M_,O& M_K=:._!"=C=^A'K_P19#0.O"\&UL M;5/;CIPP#/V5*!^PF0ET+R- VMFJ:J56&FW5[7,&#$2;"TW"L/W[YL)0NN6% MV.;X^-AQBDF;5]L#./0FA;(E[IT;#H38N@?)[(T>0/D_K3:2.>^:CMC! &MB MDA2$[G:W1#*N<%7$V,E4A1Z=X I.!ME12F9^'T'HJ<1[? T\\ZYW(4"J8F = M? ?W8S@9[Y&%I>$2E.5:(0-MB1_WAV,>\!'PPF&R*QN%3LY:OP;G2U/B71 $ M FH7&)@_+O $0@0B+^/7S(F7DB%Q;5_9/\7>?2]G9N%)BY^\<7V)[S%JH&6C M<,]Z^@QS/Q\PFIO_"A<0'AZ4^!JU%C9^43U:I^7,XJ5(]I9.KN(YS?S7M.T$ M.B?0)8'&!)(*1>4?F6-58?2$3)K]P,(5[P_4SZ8.P3B*^,^+MSYZJ?+LKB"7 M0#1CC@E#5YC]@B">?2E!MTH7:_39!M:LPB0;8BH/1AFR#?),@C0?Z/ M@H=W32;,;<2H5.1=";*:J033Q6VRJ-:CBIN\BBX+^TCCG?R%IVW_QDS'E45G M[?S-QOFW6COP0G8W?H5Z_\ 61T#K@GGG;9/6+#E.#_,+(LLSKOX 4$L#!!0 M ( !B+E$_M/"&S& ( "(& 9 >&PO=V]R:W-H965TK:AB* [#!:IH6?MY:N<.(D_Y3;&RAH/PY*VJJ/BS <;;S(_\Q\1+ M>2V4F4!YVM K? ?UHSD(/4*#R[FLH)8EKST!E\S_&*WWQ/ 6^%E"*T=]SV1R MY/S5#+Z<,S\T 0&#DS(.5#=WV )CQDB'\;OW](?H8^'^)[??)?X0Y,XR82O<:),VF?WNDF%:]Z%QU* M1=^ZMJQMV_;^#]F\(.X%\2"(\'\%22](WBO O0"_5T!Z 7$$J,O=%G-'%DH]>\\Q#E-T-T8]L^F8>,3$S\1V2BS( M,[*;01;/R'Z*8!P-#-)Y#,G$L\G$UB 9!QJOY@V268/$&N"1010F3C4ZAEBF M[A99!2NG(%.(1"ZTFT++)$CFX\6S\>))O!@[>[/IF-5HE2C 3KASC+N!4R8, M_E%<,ALLF0G6+2Z9E"2) @?:3B&2N"GMIM 2!TYM]C/++8*EDQ0:G25S>WZC MXEK6TCMRI8^E/3P7SA5HPS#07H6^L(&PO=V]R:W-H965T%JR7I&EAQSW14XKYOS40-JS\ MT+\$'IM3+74 E46'3_ ;Y)]NQ]4*32J'AD(K&M9Z'(XK_SY<;G.--X"G!@9Q M-?=T)GO&GO7BQV'E!]H0$*BD5L!J.,,&"-%"RL:+U?2G+37Q>GY1_VYR5[GL ML8 -(W^;@ZQ7?NY[!SCBGLA'-CR S2?U/9O\3S@#47#M1.U1,2+,KU?U0C)J M5905BE_'L6G-.%C]"\U-B"PAF@AA]BDAMH3XC9!\2D@L(9D1T)B*J'T^WP_H2A)V)EG;/C)39ZI6R!Q"B1&(+X1^,!!ZA1( M'0X6LTJ[,/FL6"[,MUFU')@T<)O-G&8SA\ 'A[YP"BR^7J[<*9!_H5P.3#J_ M6RY,/#."KEX+!7XRG4AX%>M;J2_=571J=O>1?FVS^%HUP;%GOF M%=Z>2?66S8L[,B9!60SNU''5JFE/"P)'J:<+->=CZQH7DG6V*Z/IKZ'\#U!+ M P04 " 8BY1/0T,OVOT! !W!0 &0 'AL+W=O 'B%\Y'U&1W-DV;M,EDF[:_&3V.9E$L,./V M[@OH&%=I_P@'W_.>YX"2#HR_B1I .N\M[43FUE+V1X1$44-+A,=ZZ-2;BO&6 M2!7R*Q(]!U*:I):BT/<3U)*F<_/4K)UYGK*;I$T'9^Z(6]L2_N<9*!LR-W ? M"Z_-M99Z >5I3Z[P'>2/_LQ5A&:7LFFA$PWK' Y5YCX%QU.B]4;PLX%!+.:. M[N3"V)L.OI29ZVL@H%!([4#4<(<34*J-%,;OR=.=2^K$Y?SA_LGTKGJY$ $G M1G\UI:PS=^\Z)53D1N4K&S[#U ]VG:GYKW 'JN2:1-4H&!7FZ10W(5D[N2B4 MEKR/8].9<9C\'VGVA'!*".>$(/YO0C0E1*L$-)*95E^()'G*V>#P\;!ZHK^) MX!BIS2STHMD[\TYU*]3J/8]QG**[-IHTSZ,F7&C"CXK35I'@68(4P$P16BE" MDQ\M*X0'NT%D-8B,0?RA#;QJ8]1@H^F,)DA\+UBU8E'%!^\?,+$5)K; )"N8 M47-8E EWBRHCBT6$O=B.@JTHV(*R6Z'@316U+>L3WHKPP=O;41(K2F)!V:]0 MDLWFA_%^PV)117AQD",,6OP"^DKZ1OBUZ81S85+]3>:;KQB3H!Q]3YG5ZA:< M PJ5U-.=FO/Q+A@#R?KIFD/S79O_!5!+ P04 " 8BY1/M,.3!F,# V M#P &0 'AL+W=OP%? MP&251-H05:W42JM6;9_9Q$G0 D[!2;9_7V-8EMCC59*' ,Z9F3.#SS@SOXCF MI3UP+KW7JJS;A7^0\O@0ANWFP*N\#<21U^J7G6BJ7*K'9A^VQX;G6VU4E2&. MHB2L\J+VEW.]]M0LY^(DRZ+F3XW7GJHJ;_ZM>"DN"Q_Y;PL_BOU!=@OA\Y9GHOQ3 M;.5AX:>^M^6[_%3*'^+RA0\)Q;XW9/^-GWFIX!T3%6,CRE9_>YM3*T4U>%%4 MJORUOQ:UOEX&_V]FL $>#/!H@)(/#L]YMTN0@]457_3+>IBZ]]4>5JU>E[2>#8/SYVC ;/J,7B"02,B5-[' M$!@*L<*6.;X.D-F()+Z&K %( I,@8)Y$VY-IGDD$.Z"@ ZH=T"L'R"A4CXDU MIM880E%@E#,#4"0.'-G$()D8(&,4==5C9I,PG]!L-HG3LP%A43H1@A@D9CM M" (Y]BL"6](CPH"+U.$";BCHCHZ"X):"H)YB90N!'%L,P=T" >V"N:C""D?) M'=G"ND2V,.T.BFQ%I0&)IA_#)$.VF-TFUT1A22) D\SE A83FMU>+@RK"44118A1@ZT\S^"H&8X^ CL%0)(%7F^G<*BXN@V[,EL+@(=*:9V4(@ M9IZ=X61XJ'BSUX-9ZVW$J9;=?_#)ZCC\/>K9SUA?J:&P'^'>W?03Y?>\V1=U MZST+J48;/8#LA)!<<8P"M?4.:H@='TJ^D]TM4_=-/\GU#U( 0 ^@0 !D !X;"]W;W)K&ULC53;;IPP$/T5RQ\0 WN!K@ IFZI*I59:I6KR[(7AHMB8V&9) M_[ZV80E-7"DOV#,^<^;,X'$Z"OFL&@"-7CGK5(8;K?L#(:IH@%-U(WKHS$DE M)*?:F+(FJI= 2Q?$&8F"8$\X;3NVI+W60XP:B$B@Y,/XCQ'N9Z=AC-Q?^ "S #MTI,CD(PY;ZH&)06?&8Q4CA] MG=:V<^LX\U_#_ '1'! M >'>U3(E%=;I6 MN#,C7AGO)=_&24HNEFC&'"=,M,*$"X(8]B5%Y$MQC#Z$1_[PC5?AQH5O_U'X MQ4^P]1)L'<%F39 $?H*=EV#W44$2ONN1#_.?,O?>)'L/P<9/$'L)XL^7F7@) MDD^4Z<'$\;LD9'7W.,C:39U"A1@Z-_$K[S+8MY&[NV_PZ57X267==@J=A383 MX.YI)80&(R6X,2UOS$.T& PJ;;>QVNOH4'E5#-H9,V;0, Y#Y\7FWUJ\!;P6D,O1^O 5'+D_,UL MOI_R,#*&@$*IC +1CROL@%(CI&W\]9KAD-(0Q^N;^E=;NZ[E2"3L./U3GU25 MA^LP.,&9=%2]\/X;^'K2,/#%_X K4 TW3G2.DE-I_X.RDXHSKZ*M,/+NGG5C MG[W7O]'F";$GQ -AL7Q(2#PA^2#@AP3L"7A"0*X4VYL]4:3(!.\#X;YN2\PA M6FRP[GYI@K;9]IUNC]31:X'7.$-7(^0Q6X>)1YC%@$!:?4@1SZ78QG?T^'." MW3UBF7Z&[&<@RWD3R6R=B>4G8Q/QEWD!/"N K0 >":RF?7*0E84TOI>1^4W* MO<X]E4/*N4>:3 MC:+#J'B.S5F=Q+=ZA+@;_R'CYL]/(BYU(X,C5_HFV/-ZYER!-A@]:8>5'GG# MAL)9F>5*KX6[^&ZC>.MG&AH&:_$?4$L#!!0 ( !B+E$_FI/L59 ( -H' M 9 >&PO=V]R:W-H965TR9M&7\5>0 MTGJKREJL[5S*9N4XXI!#1<6"-5"K+R?&*RK5EI\=T7"@1^-4E8[GNJ%3T:*V ML]38GGB6LHLLBQJ>N"4N547Y[RV4K%W;Q+X9GHMS+K7!R=*&GN$[R)?FB:N= M,[ L*.RA+S:1T_.I)[2&F=ARO;^R?3/(JF3T5L&/ES^(H\[4=V]813O12RF?6 M?H8^H:5M]=E_A2N4"JZ5J!@'5@KSM X7(5G5LR@I%7WKWD5MWFW/?W/#';S> MP1L<2/A7![]W\-\= I-\I\RD^I%*FJ6 0?3<(W_OY= M$A%.$* $@2$([@CB214ZS-)@:H.)%OXDD0X3C3&XC"4J8XG(2"8R.DPR"D&\ MQ02T0T!D$>)20E1*.)>2N!,IX2S*!Z6%3+1@*#*JW)V8"!43(6(F8;;1[/?$ M,RES3/1(2(P*B>="H@0G2%""9'Y2$P\G("Y^85VD&/[TQF*@X$&O$WQ/N/;/&;3?Q_R18#31N(,^J(%?"S&1[".K!++77O&5F' ;7Q=$>= MV+=Z<)E.^T[33;UOE)^+6EA[)E6_-EWUQ)@$I=%=J%.7JT$[;$HX2;V,U)IW MTZ;;2-;TD]09QGGV!U!+ P04 " 8BY1/+_^#B;(! #. P &0 'AL M+W=O.> M$-,.(*A9J1&D6^F5%M2Z4I^)&370+I $)T66;8F@3.*F"KVC;BIUL9Q).&ID M+D)0_?L9N)IJG.-;XX6=!^L;I*E&>H9O8+^/1^TJ,JMT3( T3$FDH:_Q^WQ_ M*#T^ 'XPF,QBCGR2DU*OOOC'&K_#J(.>7KA]4=,G2'DV&*7P7^ *W,&]$[='J[@) M7]1>C%4BJ3@K@K[%D8K6^&LPMK+JUQW6NSWFTK D1%S%R,B-@M$MMK> MV2"+D_4W_2O59R8-.BGK?E(XREXI"TXO6SFIP3VNN>#06S]]%_GH"R=NW/_-O :WDNI!Y >=:0,[R!_-'LN(I0KW(L*ZA%R6J/PVGM?YZM MMJG&&\#/$EHQZ'O:R9ZQ=QU\/:[]4"<$% Y2*Q#57&$#E&HAE<9OJ^GW4VKB ML']3WQKORLN>"-@P^JL\RF+M+WSO""=RH?*5M5_ ^DE\SYK_!E>@"JXS47,< M&!7F[1TN0K+*JJA4*O+1M65MVM;JWVAN0F0)44^8X7\28DN('R5@2\"/$A)+ M2!XEI):0C@BH*Y:I_C.1),\X:SW>[9^&Z&TZ6Z5J?0]ZT"RG^:860*C1:XZ7 M\PQ=M9#%/'68:(")[A&;*0+?(YX=B.7B'O/BPBSO,=LI)DUZ"%)6>[^1TV]D M^/& GX2A6R!V"L1& -\)S$8%ZS")P=0&,\G_,UOG M"0W.D[YROQ-^+FOA[9E41],&UL?53M;ILP%'T5Q /$?%,B0&I339NT25&G=;\= MN 14&S/;"=W;SS8$$>J.']CW=*QW.#2%^^CO#ZG& M&\!K!Z-8S1W=R8FQ-QU\JPO7TX: 0"4U U;#%0Y B"92-O[,G.XBJ0O7\QO[ M%].[ZN6$!1P8^=W5LBWIH<$7(E_8^!7F?F+7F9O_#E<@"JZ=*(V*$6'> M3G41DM&915FA^'T:N]Z,X\Q_*[,7!'-!L!3XT7\+PKD@W!2@R9EI]1E+7.:< MC0Z??M: ]9[P]Z%:S$HGS=J9;ZI;H;+7,O;"'%TUT8QYFC#!'2:ZQQQLF'C! M(.5A,1)8C02&(+PC2.P$H94@- 31'4&Z<6G#/-A%(JM(9"'(-LLU86*#Z0TF MR7:?K$5L58D_JOC>1F7"9"N5Z#.1Q"J26$3\C4CRH95LE]E%4JM(:A$)-B(3 M)EF)A)Y^-CIHM:7U%?,#\W/7"^?$I#H=9@\WC$E0E-Y.66[5K;8$!!JIIZF: M\^EL3X%DPWQMH>7N+/\!4$L#!!0 ( !B+E$]@X%;SH 0 P8 9 M>&PO=V]R:W-H965TS)+EJ:J_-COG MVMFWLC@T#\&N;8_W8=@\[UR9-_/JZ [=+R]57>9M=UN_ALVQ=OEV<"J+D*(H M#LM\?PA6R^'9IWJUK-[:8G]PG^I9\U:6>?W/VA75Z2%0P<>#S_O77=L_"%?+ M8_[JOKCVC^.GNKL++U&V^](=FGUUF-7NY2'X2=T_6NH=!HL_]^[43*YG?2I/ M5?6UO_EU^Q!$_8A?;V[C2N*/E(WCK_'H,$%LW><7G]$?QR2[Y)Y MRANWJ8J_]MMV]Q L@MG6O>1O1?NY.OWBQH1L,!NS_\V]NZ(S[T?283Q713/\ MG3V_-6U5CE&ZH93YM_/W_C!\G\;X'V[8@48'NC@H\T,'/3KH6QW,Z&"^.^@? M.MC1P=Z*$(\.L><0GB=KF/TL;_/5LJY.L_J\@8YYOT_5?=RM[W/_<%C.X;=N M 9KNZ?O**KT,W_M H\WZ;$-3F\A+O0<(N MV4O&!#.FP5]?C2+& 30,H(< 9A) 1:F7QMG&#C:'#HIYHG.#01((DH TO=EAR -) 4B*052$:1T!&']51J,ICB812- /]=]L M6(]&4R"3S$D PK15!#(B'X@8T"*=T.X:"--; 7[[,K4>C>()T)T28#!Q%6>N MFA!OA#$LGSLU%^1.88(K"X 2'\C>G@^6 <5U0#&*CD97^X4N2CH*HO9*,QP_4-57^C.<.5U'-J3'!] M0]'?:$YPL71I3&D-**U9/IS2=_+$"2T]H+3V%TAS2INY%G PI36@M-8^#B_Z MD3AQF,0:D-B7CLUH9*_R$7HEC9FN>=&W6B@6&C-=)__C/(9)K &)M5<_L]'( M7FU'::B8QIK3F(E2ICF-U4(Z(AC,8P-X[*M29D#W;D0@3&0#*K5_Y,D,)W(D M'E(QD0UJWB,?AQ.9Q"4RF,@&$3GV@7CS+LB%$0[=J#+[&\%P&B_4/$JG'P$5 MD]J 1MY7W6PTNMI^<2+)E,&T-H#6_EDK,[R7UR2>Z@QFOP'-O$Y\)-#,*QD) MBX2YH9O/#.CF=2R)HL$R86YHYS,#VGDK['6+5<("E?"+5F:Y2E"BI;FS6"8L MD FV\RR7"4H2B;\6"X5%0L&0B$DYRBFO^T,S>ZK:MBJ'EYXO M5=6Z+F177X/9SN7;RTWA7MK^,NFNZ_/[Z?--6QW'=^_AY1\ JW\!4$L#!!0 M ( !B+E$\=MAJPA0, ,(2 9 >&PO=V]R:W-H965T,#BR+35452NU4I2J[6]BKVT48%U8Q^G;EUM< M',Y42WZ$B\^>V1GXV('515?/]5$IX[P6>5FOW:,QISO?K[='5:2UIT^J;'[9 MZZI(37-8'?SZ5*ETUPTJFSR;-2/51.?2Z*M/IS MKW)]6;O,?3OQF!V.ICWA;U:G]*"^*_/C]% U1_[599<5JJPS73J5VJ_=#^PN MDM'YN#[[LUF[0SDCE:FM:B[39O*A$Y7GKU,SC]V#J M7F.V \?[;^Z?NN2;9)[26B4Z_Y7MS''MQJZS4_OTG)M'??FLAH1"UQFR_ZI> M5-[(VYDT,;8ZK[O_SO9<&UT,+LU4BO2UWV9EM[T,_F_#\ ^#.#7 4S^=X 8 M!HA_ T27?#^S+M6/J4DWJTI?G*J_6J>TO2G8G6B*N6U/=K7K?FNRK9NS+YM0 MQ"O_I34:-/>]AH\U@;S5)$##PJO&;^9PG0B'$^&=@;PQB+"!@ :B,Q WF2RQ M@80&$G:;L-()[1)001@FG462 #1;08&&?9P0-(HL\>\URE"?W M8APDAD%BD";#!DMHL+1/DP7XU@XL$AU$XRL:>)R(0R#$0*[\?1PD$D0<3 @# MB$A)6&!&V Q(&*:$V6#"IIQPCW@<,,P)0Z!,JHI$5!R,$UL BP5A@8%BT8RJ M8EP8X&5:U7A2519[U!V L6)+F[(B$?$PYA@^#N"3Q!.$8ZXXLR\K)Q85@,RD MK(,H&I65BH*IXL*BIE!$U12CQP%Z@KC\'%/%PQDUQS\@=T\,!&-/<>]%BE#MQD01F1P!V0J)'$)@=,8,= M@=D1%NPD@^BF(:(:!4'T;1;T)$@4$OV$P/0(0$](K/0"TR-FT",P/<*&'C&E MAU%-B<"\",3+I*I(1#0E D,EP,(54A88*C&CU9.8&&G1ZB5RVNHQ:O64&"MI MT>HE4$0T)1*S)P%[(355C)6<\SY$O!!9M'J)!*]$D4T\:6-TT7T]V&MM5&,8>,U5.JIT=SW(U=ZTNU&S7_5?5?H#HT_#%R/_ M^MEJ\Q=02P,$% @ &(N43X!<4S2 @ (@D !D !X;"]W;W)K&ULE5;;CILP$/T5Q < -KUO8& MK7;8TP[&XKF@-S&86UK*@;$7O?AZ7-N>CHB6-),:@JCA2G>T+#62BN-W!VKW MG-IQ.']#_VS$*S$'(NB.E;^*H\S7]L*VCO1$+J5\8K_'/S.P7]W M"(SX-C(C]1.1)$TXNUF\O:V&Z*1 *U\=9J8WS=F9;TJM4+O7- RCQ+UJH,YF MV]K@.YNXMW$5?D^"(9(M'@'@>XK=V"**8 8?E.$;_V 8(IH(,0 ! @/@WVE< MP A"!".(PB7#P?9VH3&IFY5.CY,$H$DT9@D\F" & 2(Y\M<@ "+&3);F^5 M9N"$,,D2)%D",A$,@#PXK;WY0M%$9: 94CNCX94B9XH'+(X-PF,>/YB @+,? M^1]0"^<_"OZO=M<9W24PFLI@!-<) @HEPA,0?+Q7 Y8&^&W,YH>+O8UL Y,JKYGNM.),4E5D)ZCPLO5 M@Z5?E/0D]316<]YV[78A6=.]2-S^693^!5!+ P04 " 8BY1/I4IJ8:@! M "; P &0 'AL+W=OD>E#]IM9',>=.T-L"8&24%HENV(9%SA MJHB^HZD*?7&"*S@:9"]2,O-^ *&'$J_QA^.)GSL7'*0J>G:&W^#^]$?C+3)1 M&BY!6:X5,M"6^/MZ?\B#/@J>.0QVMD>ADY/6K\'XV90X"P6!@-H% O/+%>Y MB #R9?P=F7A*&0+G^P_Z0^S=]W)B%NZT>.&-ZTI\BU$#+;L(]Z2''S#VL\5H M;/X77$%X>:C$YZBUL/&+ZHMU6HX47XID;VGE*JY#.KFA8]AR !T#Z!1 4R\I M4:S\GCE6%48/R*39]RQ<\7I/_6SJX(RCB&>^>.N]UVJ[RPMR#:!1V7)&0VU_#;/C)SYLJBDW;^BN(@6ZT=>%ZV\JC.OY3)$-"ZL+WQ>Y/^EV0X MW8]/@4SOL?H'4$L#!!0 ( !B+E$\2:D2(\ $ '(% 9 >&PO=V]R M:W-H965TY&[C93# 2%1 M-M 1L6,#].I-S7A'I KY!8F! ZE,4D<1]KP8=:3MW2(S:R=>9.PJ:=O#B3OB MVG6$_SD"96/N^NY]X;6]-%(OH"(;R 6^@_PQG+B*T.)2M1WTHF6]PZ'.W2?_ M<-QKO1'\;&$4J[FC.SDS]J:#+U7N>KH@H%!*[4#4<(-GH%0;J3)^SY[N@M2) MZ_G=_9/I7?5R)@*>&?W55K+)W=1U*JC)E;FO\(-J)+K2A2C M9%28IU->A63=[*)*ZBBB.,W331K/F.&GP!TVR:)#R7R#8"L'& M(%@;>+'=(+ :!,8@_&"PWU0Y:2*CZ8T&)\DNM&-"*R9\Q. M)K1@@AVV8R(K M)GK$Q.D&,VGB-2;U[)#8"HDMD&TODR9900+?SDBLC.21D?RCR-1JD/[_C[&W M&NPM%?B;+O>/748;!EH=%WT;?2/\TO;".3.I3IXY'S5C$I2=MU.?IE$7X!)0 MJ*6>)FK.IVM@"B0;YAL.+==L\1=02P,$% @ &(N43_^8P#H$ @ ; 4 M !D !X;"]W;W)K&UL=53;CILP$/T5Q =@[M"( M(&VVJEJIE:*MNGUVR"2@M3&U3=C^?7TAE!+W!7O&9\Z9&>.I)L;?1 L@O7=* M>K'W6RF''4*B:8%B$; !>G5R89QBJ4Q^16+@@,\FB!(4AV&.*.YZOZZ,[\CK MBHV2=#T&2YX)/*%39]AKB?SO;GX MKW #HN Z$Z71,"+,UVM&(1F=650J%+_;M>O-.LW\]S!W0#P'Q$M 8FNQ0B;S MCUCBNN)L\KCM_8#U%4>[6/6FT4[3"G.FDA?*>ZNS(J[031/-F(/%Q"M,M""0 M8E\D8I?$(7X(SXK$39 XHD2 U!^D\&Z:9(B\D,IC>8HBB" MTBV3.66R!YDBWZA8R(>52ID&A5LD=XKD#R)ELA')'TI)D^ _5U8X10I'P[*- MBL64*Y4HB#*W2NE4*1TJVX:5+I7MWX-6?SL%?C7O7'@-&WLS8U;>990\Q>:U M_(7;.?0-\VO7"^_$I'ISYF5<&).@<@D#U=)6C;[%('"1>ENH/;<#P!J2#?-L M0\N K?\ 4$L#!!0 ( !B+E$^U?]]\DP, *P1 9 >&PO=V]R:W-H M965T=94M M-@>:)Y7#CK00_^Q8F2=<7)9[MSJ6--DV07GF8L\+W3Q)"WL^;>X]E_,I._$L M+>AS:56G/$_*OX\T8Y>9C>R/&R_I_L#K&^Y\>DSV] ?E/X_/I;AR.Y9MFM.B M2EEAE70WLS^CAS4A=4"#^)722W5U;M6IO#+V5E]\WZ MH%E6,PD=?R2IW3VS#KP^_V!?-VWVF#O&.!6$ MGB.H#C39=A<9W?'Z-!+G9?O]H+W@["B_C;C=!YKY/U!+ P04 " 8BY1/ M48,E(WT" #%" &0 'AL+W=O4%+F?/2$?2T=-=HL46)";"(7SF]R\Z]8ZSL.7\U MBZ_'I1L81931@S(41%]N=$L9,TQ:QY^&U&USFL#N_8/]LS6OS>R)I%O.?N=' M=5FZJ>L/XD?87 ;@)P&X#B_P:$34#X'A!9\[4R:_434625"7YW1/VV*F(. M!5J$NI@'LVEK9Y]IMU+OWE9Q$&7^S1 UF$V-P1T,:A&^9F]38"C%!H_"<3_! M=HR(9W"&$#01VOBP9V*"( ()(DL0]0CB015JS,QBRKH*J3-HHDN1$\
    XML 94 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    OTHER FINANCIAL INFORMATION
    		 12 Months Ended
    Sep. 27, 2019
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    OTHER FINANCIAL INFORMATION OTHER FINANCIAL INFORMATION
         The following table summarizes the Company’s accrued liabilities:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Accrued compensation and benefits
    $
    32.1

     
    $
    27.0

    Product warranty
    8.1

     
    7.3

    Income taxes payable
    10.7

     
    1.4

    Payable to Varian Medical Systems
    —

     
    2.3

    Right of return liability
    6.9

     
    —

    Deferred consideration
    8.9

     
    —

    Other
    9.0

     
    9.5

    Total accrued liabilities
    $
    75.7

     
    $
    47.5


    The following table summarizes the Company’s other long-term liabilities:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Long-term income tax payable
    $
    3.9

     
    $
    3.5

    Environment liabilities
    0.9

     
    1.3

    Defined benefit obligation liability
    5.5

     
    3.3

    Long-term right of return liability
    19.5

     
    —

    Long-term other
    2.7

     
    0.4

    Total other long-term liabilities
    $
    32.5

     
    $
    8.5

    The following table summarizes the Company’s other income (expense), net:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
    Income (loss) from equity method investments
    $
    (2.3
    )
     
    $
    3.9

     
    $
    1.3

    Change in fair value of deferred consideration
    1.0

     
    —

     
    —

    Realized income (loss) on foreign currencies
    (1.9
    )
     
    (1.2
    )
     
    1.9

    Total other income (expense), net
    $
    (3.2
    )
     
    $
    2.7

     
    $
    3.2
    XML 95 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    FAIR VALUE
    		 12 Months Ended
    Sep. 27, 2019
    Fair Value Disclosures [Abstract]  
    FAIR VALUE FAIR VALUE
    Assets/Liabilities Measured at Fair Value on a Recurring Basis
    In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
    (In millions)
    Fair Value Measurements at September 27, 2019
     
    Quoted Prices in Active Markets for Identical Assets and Liabilities
    (Level 1)
     
    Significant Other
    Observable Inputs
    (Level 2)
     
    Significant Unobservable Inputs
    (Level 3)
     
    Total
    Assets:
     
     
     
     
     
     
     
    Cash equivalents - money market funds
    $
    —

     
    $
    8.8

     
    $
    —

     
    $
    8.8

    Total assets measured at fair value
    $
    —

     
    $
    8.8

     
    $
    —

     
    $
    8.8

    Liabilities:
     
     
     
     
     
     
     
    Derivative liabilities
    $
    —

     
    $
    0.7

     
    $
    —

     
    $
    0.7

    Deferred consideration
    8.9

     
    —

     
    —

     
    8.9

    Total liabilities measured at fair value
    $
    8.9

     
    $
    0.7

     
    $
    —

     
    $
    9.6


    As of September 27, 2019, the total outstanding borrowings under the Company's credit agreement were $395.1 million, net of deferred loan costs, which approximated its fair value because it is carried at a market observable interest rate that resets periodically and is categorized as Level 2 in the fair value hierarchy. The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable and accounts payable, also approximate their fair values due to their short maturities.
    There were no financial assets or liabilities measured on a recurring basis using significant unobservable inputs (Level 3) and there were no transfers in or out of Level 1, 2 or 3 during fiscal year 2018.
    At September 28, 2018, the Company determined the following levels of inputs for the following assets or liabilities:
    (In millions)
    Fair Value Measurements at September 28, 2018
     
    Quoted Prices in Active Markets for Identical Assets and Liabilities
    (Level 1)
     
    Significant Other
    Observable Inputs
    (Level 2)
     
    Significant Unobservable Inputs
    (Level 3)
     
    Total
    Assets:
     
     
     
     
     
     
     
    Cash equivalents - Money market funds
    $
    —

     
    $
    18.4

     
    $
    —

     
    $
    18.4

    Derivative assets
    —

     
    7.7

     
    —

     
    7.7

    Total assets measured at fair value
    $
    —

     
    $
    26.1

     
    $
    —

     
    $
    26.1

    Liabilities:
     
     
     
     
     
     
     
    Derivative liabilities
    $
    —

     
    $
    —

     
    $
    —

     
    $
    —
    XML 97 R87.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)
    shares in Thousands
    		 12 Months Ended
    Sep. 27, 2019
    $ / shares
    shares
    Number of Shares  
    Restricted Stock Units and Performance Stock Units, nonvested, beginning balance (in shares) | shares 641
    Restricted Stock Units and Performance Stock Units, grants in period (in shares) | shares 288
    Restricted Stock Units and Performance Stock Units, vested in period (in shares) | shares (201)
    Restricted Stock Units and Performance Stock Units, forfeited in period (in shares) | shares (50)
    Restricted Stock Units and Performance Stock Units, nonvested, ending balance (in shares) | shares 678
    Weighted Average Grant-Date Fair Value  
    Restricted Stock Units and Performance Stock Units, nonvested, beginning of period, weighted average grant date fair value (in USD per share) | $ / shares $ 33.60
    Restricted Stock Units and Performance Stock Units, grants in period, weighted average grant date fair value (in USD per share) | $ / shares 31.29
    Restricted Stock Units and Performance Stock Units, vested in period, weighted average grant date fair value (in USD per share) | $ / shares 31.56
    Restricted Stock Units and Performance Stock Units, forfeitures, weighted average grant date fair value (in USD per share) | $ / shares 34.13
    Restricted Stock Units and Performance Stock Units, nonvested, end of period, weighted average grant date fair value (in USD per share) | $ / shares $ 33.18
    XML 98 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    GOODWILL AND INTANGIBLE ASSETS - Summary of Goowill (Details)
    $ in Millions
    		 12 Months Ended
    Sep. 27, 2019
    USD ($)
    Goodwill [Roll Forward]  
    Balance at September 28, 2018 $ 243.6
    Business combination 47.2
    Balance at September 27, 2019 290.8
    Medical  
    Goodwill [Roll Forward]  
    Balance at September 28, 2018 147.0
    Business combination 26.0
    Balance at September 27, 2019 173.0
    Industrial  
    Goodwill [Roll Forward]  
    Balance at September 28, 2018 96.6
    Business combination 21.2
    Balance at September 27, 2019 $ 117.8
    XML 99 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    BORROWINGS - Schedule of Short-Term and Long-Term Debt (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Sep. 27, 2019
    Sep. 28, 2018
    Current maturities of long-term debt    
    Current maturities of long-term debt $ 30.7 $ 25.0
    Non-current maturities of long-term debt:    
    Long-term debt excluding current maturities, gross 370.1  
    Debt issuance costs (5.7) (8.2)
    Long-term debt outstanding 364.4 364.8
    Long-term Debt 395.1 389.8
    Other Debt    
    Current maturities of long-term debt    
    Current maturities of long-term debt 1.3 0.0
    Non-current maturities of long-term debt:    
    Long-term debt excluding current maturities, gross 2.5 0.0
    Secured Debt    
    Current maturities of long-term debt    
    Current maturities of long-term debt 29.4 25.0
    Non-current maturities of long-term debt:    
    Long-term debt excluding current maturities, gross $ 308.6 $ 345.0
    Weighted-average interest rate, short-term debt 5.60% 4.20%
    Weighted-average interest rate, long-term debt 5.60% 4.20%
    Revolving Credit Facility | Revolving Credit Facility    
    Non-current maturities of long-term debt:    
    Long-term debt excluding current maturities, gross $ 59.0 $ 28.0
    Weighted-average interest rate, long-term debt 5.60% 4.20%
    XML 100 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    EMPLOYEE STOCK PLANS - Narrative (Details) - USD ($)
    $ in Millions
    		 1 Months Ended 12 Months Ended
    Jan. 31, 2017
    Sep. 27, 2019
    Sep. 28, 2018
    Sep. 29, 2017
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Options exercised, intrinsic value   $ 0.2 $ 1.7 $ 1.4
    Options, grants in period, grant date fair value   3.0 3.1 9.2
    Grant-date fair value of shares granted in the period   9.0 10.1 11.4
    Shares outstanding, market value   19.2 $ 18.4 $ 17.8
    Employee Stock Option        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Compensation cost not yet recognized   $ 23.1    
    2017 ESPP | Employee Stock        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Purchase price of common stock, percent 85.00% 85.00%    
    Stock plan offering period (in months) 6 months 6 months    
    Number of shares authorized (in shares) 1,000,000,000,000      
    2017 ESPP | Employee Stock Option        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares available for grant (in shares)   700,000    
    2017 Omnibus Stock Plan | Employee Stock Option        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares available for grant (in shares)   1,200,000    
    Minimum        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Award vesting period (in months)   36 months    
    Award expiration period (in years)   7 years    
    Minimum | Employee Stock Option        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Compensation cost period for recognition (in years)   3 years    
    Maximum        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Award vesting period (in months)   48 months    
    Award expiration period (in years)   10 years    
    Maximum | Employee Stock Option        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Compensation cost period for recognition (in years)   4 years    
    XML 101 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    BUSINESS COMBINATIONS - Intangibles Acquired (Details) - USD ($)
    $ in Millions
    Apr. 29, 2019
    May 01, 2017
    Direct Conversion AB    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles $ 32.9  
    Direct Conversion AB | In-process research and development    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles 2.8  
    Direct Conversion AB | Backlog    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles $ 0.2  
    Estimated useful life 1 year  
    Direct Conversion AB | Trade names    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles $ 2.5  
    Estimated useful life 5 years  
    Direct Conversion AB | Developed technology    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles $ 18.4  
    Estimated useful life 10 years  
    Direct Conversion AB | Customer relationships    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles $ 9.0  
    Estimated useful life 10 years  
    PerkinElmer, Inc.    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles   $ 81.1
    PerkinElmer, Inc. | In-process research and development    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles   4.0
    PerkinElmer, Inc. | Favorable leasehold interests    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles   $ 3.8
    Estimated useful life   16 years
    PerkinElmer, Inc. | Backlog    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles   $ 1.2
    Estimated useful life   1 year
    PerkinElmer, Inc. | Trade names    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles   $ 1.4
    Estimated useful life   5 years
    PerkinElmer, Inc. | Developed technology    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles   $ 37.7
    Estimated useful life   7 years
    PerkinElmer, Inc. | Customer relationships    
    Intangible Assets Acquired as Part of Business Combination [Table] [Line Items]    
    Intangibles   $ 33.0
    Estimated useful life   7 years
    XML 102 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property Plant and Equipment (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Sep. 27, 2019
    Sep. 28, 2018
    Sep. 29, 2017
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, gross $ 341.9 $ 335.6  
    Accumulated depreciation and amortization (199.6) (190.7)  
    Property, plant, and equipment, net 142.3 144.9  
    Depreciation 23.5 26.0 $ 16.9
    Accelerated depreciation $ 4.5 4.2  
    Land Improvements      
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, useful lives 15 years    
    Building      
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, useful lives 20 years    
    Land      
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, gross $ 8.3 8.3  
    Buildings and leasehold improvements      
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, gross 134.4 138.1  
    Machinery      
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, gross 170.7 166.1  
    Construction in progress      
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, gross $ 28.5 $ 23.1  
    Minimum | Machinery      
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, useful lives 3 years    
    Maximum | Machinery      
    Property, Plant and Equipment [Line Items]      
    Property, plant and equipment, useful lives 7 years    
    XML 103 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) - USD ($)
    $ in Millions
    Sep. 27, 2019
    Sep. 28, 2018
    Accounting Policies [Abstract]    
    Allowance for doubtful accounts $ 1.0 $ 0.6
    XML 104 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    EMPLOYEE STOCK PLANS (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Share-based Payment Arrangement [Abstract]  
    Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs
    The table below summarizes the effect of recording share-based compensation expense and for the option component of the employee stock purchase plan shares:
     
    Fiscal Year
    (In millions)
    2019
     
    2018
     
    2017
    Cost of revenues
    $
    1.2

     
    $
    1.3

     
    $
    0.9

    Research and development
    2.2

     
    1.8

     
    1.5

    Selling, general and administrative (1)
    8.3

     
    6.9

     
    6.0

    Total share-based compensation expense
    $
    11.7

     
    $
    10.0

     
    $
    8.4

    (1) Includes allocated share-based compensation of $0.8 million for fiscal year 2017 and represents charges by Varian to the Company for certain Varian employees who provided general and administrative services on the Company’s behalf.
    Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions
    The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of ESPP grants. The Company calculated the fair value of option grants and option component of ESPP grants on the respective dates of grant using the following weighted average assumptions:
     
    Employee Stock Option Plan
     
    Employee Stock Purchase Plans
     
    Fiscal Year
     
    Fiscal Year
     
    2019
     
    2018
     
    2017
     
    2019
     
    2018
     
    2017
    Expected term (in years)
    4.6

     
    4.8

     
    4.2

     
    0.5

     
    0.5

     
    0.5

    Risk-free interest rate
    2.5
    %
     
    2.6
    %
     
    1.6
    %
     
    2.5
    %
     
    2.0
    %
     
    1.0
    %
    Expected volatility
    33.9
    %
     
    31.8
    %
     
    23.6
    %
     
    43.9
    %
     
    34.1
    %
     
    28.0
    %
    Expected dividend
    0.0
    %
     
    0.0
    %
     
    0.0
    %
     
    0.0
    %
     
    0.0
    %
     
    0.0
    %
    Weighted average fair value at grant date
    $10.19
     
    $11.57
     
    $8.08
     
    $7.81
     
    $8.92
     
    $7.81
    Schedule of Share-based Compensation, Stock Options, Activity
    The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company’s employees:
    (In thousands, except per share amounts and the remaining term)
    Options
     
    Price range
     
    Weighted Average
    Exercise Price
     
    Weighted Average Remaining Term (in years)
     
    Aggregate Intrinsic Value (1)
    Outstanding at September 28, 2018
    2,011
     
    $22.63 — $37.60
     
    $
    30.35

     
     
     
     
    Granted
    297
     
    $31.42 — $31.42
     
    31.42

     
     
     
     
    Canceled, expired or forfeited
    (4)
     
    $31.08 — $31.08
     
    31.08

     
     
     
     
    Exercised
    (35)
     
    $22.84 — $27.77
     
    23.38

     
     
     
     
    Outstanding at September 27, 2019
    2,269
     
    $22.63 — $37.60
     
    $
    30.60

     
    4.1
     
    $
    1,220.3

    Exercisable at September 27, 2019
    1,477
     
    $22.63 — $37.60
     
    $
    29.67

     
    3.4
     
    $
    1,220.3

    (1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $28.28 as of September 27, 2019, the last trading date of the Company's respective fiscal years, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
    Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
    The following table summarizes the activity for restricted stock units, restricted stock awards and deferred stock units under Varex’s employee incentive plans for the Company’s employees:
    (In thousands, except per share amounts)
    Number of Shares
     
    Weighted Average
    Grant-Date Fair
    Value
    Balance at September 28, 2018
    641
     
    $
    33.60

    Granted
    288
     
    31.29

    Vested
    (201)
     
    31.56

    Canceled or expired
    (50)
     
    34.13

    Balance at September 27, 2019
    678
     
    $
    33.18
    XML 105 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    BORROWINGS (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Debt Disclosure [Abstract]  
    Schedule of Short-Term and Long-Term Debt
    The following table summarizes the Company's short-term and long-term debt:
     
    September 27, 2019
     
    September 28, 2018
    (In millions, except for percentages)
    Amount
     
    Weighted-Average Interest Rate
     
    Amount
     
    Weighted-Average Interest Rate
    Current maturities of long-term debt
     
     
     
     
     
     
     
    Term facility
    $
    29.4

     
    5.6
    %
     
    $
    25.0

     
    4.2
    %
    Other debt
    1.3

     
     
     
    —

     
     
    Total current maturities of long-term debt
    $
    30.7

     
     
     
    $
    25.0

     
     
     
     
     
     
     
     
     
     
    Non-current maturities of long-term debt:
     
     
     
     
     
     
     
    Revolving credit facility
    $
    59.0

     
    5.6
    %
     
    $
    28.0

     
    4.2
    %
    Term facility
    308.6

     
    5.6
    %
     
    345.0

     
    4.2
    %
    Other debt
    2.5

     
     
     
    —

     
     
    Debt issuance costs
    (5.7
    )
     
     
     
    (8.2
    )
     
     
    Non-current maturities of long-term debt
    364.4

     
     
     
    364.8

     
     
    Total long-term debt, net
    $
    395.1

     
     
     
    $
    389.8

     
     
    Schedule of Maturities of Long-term Debt
    Future principal payments of the long-term debt outstanding as of September 27, 2019 are as follows:
    (In millions)
     
    Fiscal years:
     
    2020
    $
    30.7

    2021
    34.3

    2022
    335.8

    Total debt outstanding
    400.8

    Less: current maturities of long-term debt
    (30.7
    )
    Non-current portion of long -term debt
    $
    370.1
    XML 106 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    RESTRUCTURING (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Restructuring and Related Activities [Abstract]  
    Schedule of Restructuring Charges Below is a detail of restructuring charges incurred during the 2019 and 2018 fiscal years, which predominately relate to the Company's Medical segment:
    (In millions)
    Location of Restructuring Charges in Consolidated Statements of Earnings
     
    September 27, 2019
     
    September 28, 2018
    Other assets impairment charges
    Selling, general and administrative
     
    $
    —

     
    $
    1.3

    Inventory write downs
    Cost of revenues
     
    3.1

     
    3.1

    Intangible assets impairment
    Impairment of intangible assets
     
    4.8

     
    3.0

    Accelerated depreciation
    Cost of revenues
     
    4.5

     
    4.2

    Severance costs
    Selling, general and administrative
     
    6.2

     
    4.3

    Facility closure costs
    Selling, general and administrative
     
    0.3

     
    0.8

    Total restructuring charges
     
     
    $
    18.9

     
    $
    16.7
    XML 107 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    NET EARNINGS PER SHARE
    		 12 Months Ended
    Sep. 27, 2019
    Earnings Per Share [Abstract]  
    NET EARNINGS PER SHARE NET EARNINGS PER SHARE
    Basic net earnings per common share is computed by dividing the net earnings for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net earnings per common share reflects the effects of potentially dilutive securities, which is computed by dividing net earnings by the sum of the weighted average number of common shares outstanding and dilutive common shares, which consists of stock options and unvested restricted stock.
    A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per common share is as follows:
     
    Fiscal Year
    (In millions, except per share amounts)
    2019
     
    2018
     
    2017
    Net earnings attributable to Varex
    $
    15.5

     
    $
    27.5

     
    $
    51.6

    Weighted average shares outstanding - basic
    38.2

     
    37.9

     
    37.6

    Dilutive effect of potential common shares
    0.4

     
    0.5

     
    0.4

    Weighted average shares outstanding - diluted
    38.6

     
    38.4

     
    38

    Net earnings per share attributable to Varex - basic
    $
    0.41

     
    $
    0.73

     
    $
    1.37

    Net earnings per share attributable to Varex - diluted
    $
    0.40

     
    $
    0.72

     
    $
    1.36

    Anti-dilutive employee shared based awards, excluded
    1.9

     
    1.2

     
    1.0


    The Company excludes potentially dilutive common shares (consisting of shares underlying stock options and the employee stock purchase plan) from the computation of diluted weighted average shares outstanding if the inclusion of the shares underlying these stock awards would be anti-dilutive to earnings per share.
    XML 108 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    GOODWILL AND INTANGIBLE ASSETS
    		 12 Months Ended
    Sep. 27, 2019
    Goodwill and Intangible Assets Disclosure [Abstract]  
    GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
    The following table reflects goodwill by reportable operating segment:
    (In millions)
    Medical
     
    Industrial
     
    Total
    Balance at September 28, 2018
    $
    147.0

     
    $
    96.6

     
    $
    243.6

    Business combination
    26.0

     
    21.2

     
    47.2

    Balance at September 27, 2019
    $
    173.0

     
    $
    117.8

     
    $
    290.8


    The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the consolidated balance sheets:
     
    September 27, 2019
     
    September 28, 2018
    (In millions)
    Gross Carrying Amount
     
    Accumulated Amortization
     
    Net Carrying Amount
     
    Gross Carrying Amount
     
    Accumulated Amortization
     
    Net Carrying Amount
    Acquired existing technology
    $
    74.1

     
    $
    (28.4
    )
     
    $
    45.7

     
    $
    57.9

     
    $
    (21.8
    )
     
    $
    36.1

    Patents, licenses and other
    12.7

     
    (8.4
    )
     
    4.3

     
    9.9

     
    (7.4
    )
     
    2.5

    Customer contracts and supplier relationship
    50.7

     
    (17.2
    )
     
    33.5

     
    42.6

     
    (11.4
    )
     
    31.2

    Total intangible assets with finite lives
    137.5

     
    (54.0
    )
     
    83.5

     
    110.4

     
    (40.6
    )
     
    69.8

    In-process R&D with indefinite lives
    2.8

     
    0.0

     
    2.8

     
    4.0

     
    0.0

     
    4.0

    Total intangible assets
    $
    140.3

     
    $
    (54.0
    )
     
    $
    86.3

     
    $
    114.4

     
    $
    (40.6
    )
     
    $
    73.8

     
     
     
     
     
     
     
     
     
     
     
     

    Amortization expense for intangible assets was $15.7 million, $16.2 million and $10.5 million in fiscal years 2019, 2018 and 2017, respectively. The Company recognized an impairment loss of $4.8 million and $3.0 million in fiscal years 2019 and 2018, respectively. These impairment costs were included in the consolidated statements of earnings under impairment of intangible assets.
    As of September 27, 2019, the estimated future amortization expense of intangible assets with finite lives is as follows:
    (In millions)
     
    Fiscal years:
     
    2020
    $
    17.2

    2021
    16.3

    2022
    14.7

    2023
    13.7

    2024
    9.1

    Thereafter
    12.5

    Total
    $
    83.5
    XML 109 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    EMPLOYEE STOCK PLANS - Stock Option Activity (Details)
    $ / shares in Units, shares in Thousands
    		 12 Months Ended
    Sep. 27, 2019
    USD ($)
    $ / shares
    shares
    Options  
    Options, outstanding, beginning balance (in shares) | shares 2,011
    Options, grants in period (in shares) | shares 297
    Options, forfeitures and expirations in period (in shares) | shares (4)
    Options, exercises in period, value (in shares) | shares (35)
    Options, outstanding, ending balance (in shares) | shares 2,269
    Options, exercisable (in shares) | shares 1,477
    Weighted Average Exercise Price  
    Options, outstanding, weighted average exercise price, beginning (in USD per share) $ 30.35
    Options, grants in period, weighted average exercise price (in USD per share) 31.42
    Options, forfeitures and expirations in period, weighted average exercise price (in USD per share) 31.08
    Options, exercises in period, weighted average exercise price (in USD per share) 23.38
    Options, outstanding, weighted average exercise price, ending (in USD per share) 30.60
    Options, exercisable, weighted average exercise price (in USD per share) $ 29.67
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
    Options, outstanding, weighted average remaining contractual term (in years) 4 years 1 month 6 days
    Options, exercisable, weighted average remaining contractual term (in years) 3 years 4 months 24 days
    Options, outstanding, intrinsic value | $ $ 1,220,300
    Options, exercisable, intrinsic value | $ $ 1,220,300
    Share price (in usd per share) $ 28.28
    Minimum  
    Price Range  
    Options, outstanding, price, beginning (in USD per share) 22.63
    Options, grants in period, price (in USD per share) 31.42
    Options, forfeitures and expirations in period, price (in USD per share) 31.08
    Options, exercises in period, price (in USD per share) 22.84
    Options, outstanding, price, ending (in USD per share) 22.63
    Options, exercisable, price (in USD per share) 22.63
    Maximum  
    Price Range  
    Options, outstanding, price, beginning (in USD per share) 37.60
    Options, grants in period, price (in USD per share) 31.42
    Options, forfeitures and expirations in period, price (in USD per share) 31.08
    Options, exercises in period, price (in USD per share) 27.77
    Options, outstanding, price, ending (in USD per share) 37.60
    Options, exercisable, price (in USD per share) $ 37.60
    XML 110 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    FAIR VALUE - (Details) - USD ($)
    $ in Millions
    Sep. 27, 2019
    Sep. 28, 2018
    Liabilities:    
    Long-term debt, fair value $ 395.1  
    Fair Value, Measurements, Recurring    
    Assets:    
    Cash equivalents - money market funds 8.8 $ 18.4
    Derivative assets   7.7
    Total assets measured at fair value 8.8 26.1
    Liabilities:    
    Derivative liabilities 0.7 0.0
    Deferred consideration 8.9  
    Total liabilities measured at fair value 9.6  
    Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)    
    Assets:    
    Cash equivalents - money market funds 0.0 0.0
    Derivative assets   0.0
    Total assets measured at fair value 0.0 0.0
    Liabilities:    
    Derivative liabilities 0.0 0.0
    Deferred consideration 8.9  
    Total liabilities measured at fair value 8.9  
    Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)    
    Assets:    
    Cash equivalents - money market funds 8.8 18.4
    Derivative assets   7.7
    Total assets measured at fair value 8.8 26.1
    Liabilities:    
    Derivative liabilities 0.7 0.0
    Deferred consideration 0.0  
    Total liabilities measured at fair value 0.7  
    Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)    
    Assets:    
    Cash equivalents - money market funds 0.0 0.0
    Derivative assets   0.0
    Total assets measured at fair value 0.0 0.0
    Liabilities:    
    Derivative liabilities 0.0 $ 0.0
    Deferred consideration 0.0  
    Total liabilities measured at fair value $ 0.0  
    XML 111 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Foreign Currency Contracts (Details) - Foreign Exchange Contract - Designated as Hedging Instrument
    $ in Millions
    Sep. 27, 2019
    USD ($)
    Buy contracts  
    Derivatives, Fair Value [Line Items]  
    Notional Value $ 11.5
    Buy contracts | Japanese yen  
    Derivatives, Fair Value [Line Items]  
    Notional Value 0.9
    Buy contracts | Swiss franc  
    Derivatives, Fair Value [Line Items]  
    Notional Value 0.0
    Buy contracts | Chinese renminbi  
    Derivatives, Fair Value [Line Items]  
    Notional Value 1.8
    Buy contracts | Euro  
    Derivatives, Fair Value [Line Items]  
    Notional Value 8.8
    Sell contract  
    Derivatives, Fair Value [Line Items]  
    Notional Value (1.0)
    Sell contract | Japanese yen  
    Derivatives, Fair Value [Line Items]  
    Notional Value 0.0
    Sell contract | Swiss franc  
    Derivatives, Fair Value [Line Items]  
    Notional Value (1.0)
    Sell contract | Chinese renminbi  
    Derivatives, Fair Value [Line Items]  
    Notional Value 0.0
    Sell contract | Euro  
    Derivatives, Fair Value [Line Items]  
    Notional Value $ 0.0
    XML 112 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Summary of Changes in Redeemable Noncontrolling Interests & Noncontrolling INterets (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Sep. 27, 2019
    Sep. 28, 2018
    Sep. 29, 2017
    Noncontrolling Interest [Line Items]      
    Balance at beginning of period $ 11.1 $ 11.2  
    Net earnings attributable to noncontrolling interests 0.5 0.5  
    Dividends paid to redeemable noncontrolling interest (0.5) (0.6) $ 0.0
    Other (0.6) 0.0  
    Balance at end of period 10.5 11.1 11.2
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]      
    Balance at beginning of period 428.3 379.0 526.0
    Contributions from noncontrolling interests 1.4    
    Contributions from noncontrolling interests   1.8  
    Balance at end of period 3.3 2.1  
    Noncontrolling Interests      
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]      
    Balance at beginning of period 2.1 0.0 $ 0.0
    Net earnings attributable to noncontrolling interests (0.2) 0.3  
    Contributions from noncontrolling interests $ 1.4    
    Contributions from noncontrolling interests   $ 1.8  
    XML 113 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details)
    		 12 Months Ended
    Sep. 27, 2019
    Minimum  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 2 years
    Maximum  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 7 years
    XML 114 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounting Standards Recently Adopted (Details) - USD ($)
    $ in Millions
    Sep. 27, 2019
    Mar. 29, 2019
    Dec. 28, 2018
    Sep. 29, 2018
    Sep. 28, 2018
    Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
    (Decrease) increase to retained earnings for adoption of new accounting guidance $ 74.4     $ 58.9 $ 62.4
    ASU 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606          
    Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
    (Decrease) increase to retained earnings for adoption of new accounting guidance $ (3.5) $ 0.6 $ (4.1) $ (3.5)  
    XML 115 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    BUSINESS COMBINATIONS - Revenues by Segment (Details) - USD ($)
    $ in Millions
    		 5 Months Ended
    Sep. 27, 2019
    Sep. 29, 2017
    Direct Conversion AB    
    Segment Reporting Information [Line Items]    
    Revenues $ 6.3  
    Direct Conversion AB | Medical    
    Segment Reporting Information [Line Items]    
    Revenues 4.5  
    Direct Conversion AB | Industrial    
    Segment Reporting Information [Line Items]    
    Revenues $ 1.8  
    PerkinElmer, Inc.    
    Segment Reporting Information [Line Items]    
    Revenues   $ 61.3
    PerkinElmer, Inc. | Medical    
    Segment Reporting Information [Line Items]    
    Revenues   41.1
    PerkinElmer, Inc. | Industrial    
    Segment Reporting Information [Line Items]    
    Revenues   $ 20.2
    XML 116 R93.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    TAXES ON EARNINGS - Income Tax Contingency (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Sep. 27, 2019
    Sep. 28, 2018
    Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
    Unrecognized tax benefits balance–beginning of fiscal year $ 0.6 $ 0.5
    Subtractions based on tax positions related to a prior year (0.2) 0.0
    Additions based on tax positions related to the current year 0.2 0.1
    Unrecognized tax benefits balance—end of fiscal year $ 0.6 $ 0.6
    XML 117 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    RELATED-PARTY TRANSACTIONS - Investment in Privately Held Companies (Details)
    $ in Millions
    		 1 Months Ended 11 Months Ended 12 Months Ended
    Dec. 17, 2019
    USD ($)
    Oct. 31, 2013
    Sep. 27, 2019
    USD ($)
    member
    Sep. 27, 2019
    USD ($)
    member
    Sep. 28, 2018
    USD ($)
    Sep. 29, 2017
    USD ($)
    Related Party Transaction [Line Items]            
    Income (loss) from equity method investments       $ (2.3) $ 3.9 $ 1.3
    Contributions to equity method investments       $ 3.9 0.0 0.0
    dpiX Holding            
    Related Party Transaction [Line Items]            
    Equity method investment, ownership percentage     40.00% 40.00%    
    Number of consortium members | member     4 4    
    Income (loss) from equity method investments       $ (1.1) 3.4 0.8
    Equity method investments     $ 48.1 48.1 48.9  
    dpiX Holding | Equity Method Investee            
    Related Party Transaction [Line Items]            
    Purchases from related party       23.5 19.3 $ 24.7
    Accounts payable, related parties     $ 3.6 $ 3.6 $ 3.7  
    Percentage of manufacturing capacity   50.00%        
    Percentage of fixed costs   50.00%        
    dpiX LLC            
    Related Party Transaction [Line Items]            
    Equity method investment, ownership percentage     100.00% 100.00%    
    VEC Imaging            
    Related Party Transaction [Line Items]            
    Equity method investment, ownership percentage     50.00% 50.00%    
    Equity method investments     $ 2.0 $ 2.0    
    Contributions to equity method investments     $ 2.9      
    Fixed Cost Commitments | dpiX Holding            
    Related Party Transaction [Line Items]            
    Related party transaction, expected fixed cost       $ 3.7    
    CETTEEN GmbH | VEC Imaging            
    Related Party Transaction [Line Items]            
    Equity method investment, ownership percentage     50.00% 50.00%    
    Forecast | VEC Imaging            
    Related Party Transaction [Line Items]            
    Contributions to equity method investments $ 2.2          
    XML 118 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    NET EARNINGS PER SHARE - (Details) - USD ($)
    $ / shares in Units, shares in Millions, $ in Millions
    		 12 Months Ended
    Sep. 27, 2019
    Sep. 28, 2018
    Sep. 29, 2017
    Earnings Per Share [Abstract]      
    Net earnings attributable to Varex $ 15.5 $ 27.5 $ 51.6
    Weighted average shares outstanding - basic (in shares) 38.2 37.9 37.6
    Dilutive effect of potential common shares (in shares) 0.4 0.5 0.4
    Weighted average shares outstanding - diluted (in shares) 38.6 38.4 38.0
    Net earnings per share attributable to Varex - basic (in USD per share) $ 0.41 $ 0.73 $ 1.37
    Net earnings per share attributable to Varex - diluted (in USD per share) $ 0.40 $ 0.72 $ 1.36
    Anti-dilutive employee shared based awards, excluded (in shares) 1.9 1.2 1.0
    XML 119 R97.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SEGMENT INFORMATION - Geographic (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Sep. 27, 2019
    Sep. 28, 2018
    Sep. 29, 2017
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Revenues, net $ 780.6 $ 773.4 $ 698.1
    Property, plant and equipment, net 142.3 144.9  
    United States      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Revenues, net 275.3 268.8 231.9
    Property, plant and equipment, net 122.6 127.9  
    Latin America      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Revenues, net 7.3 7.0 7.9
    Property, plant and equipment, net 0.0 0.0  
    EMEA      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Revenues, net 269.0 254.5 219.5
    Property, plant and equipment, net 11.4 8.7  
    APAC      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Revenues, net 229.0 243.1 $ 238.8
    Property, plant and equipment, net $ 8.3 $ 8.3  
    XML 120 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk (Details) - Canon Medical Systems Corporation - Customer Concentration Risk
    		 12 Months Ended
    Sep. 27, 2019
    Sep. 28, 2018
    Sep. 29, 2017
    Sales Revenue, Net      
    Concentration Risk [Line Items]      
    Concentration risk, percentage 17.30% 18.10% 19.30%
    Accounts Receivable      
    Concentration Risk [Line Items]      
    Concentration risk, percentage 10.10% 9.80%  
    XML 121 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    		 12 Months Ended
    Sep. 27, 2019
    Accounting Policies [Abstract]  
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    Description of Business
    Varex Imaging Corporation (the “Company,” “Varex” or “Varex Imaging”) designs, manufactures, sells and services a broad range of Medical products, which include X-ray imaging components, including X-ray tubes, digital detectors and accessories, high voltage connectors, image processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys, for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, computed tomography, oncology and computer-aided detection. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary, to independent service companies, distributors and directly to end-users for replacement purposes.
    The Company also designs, manufacturers, sells and services industrial products, which include Linatron® X-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection systems. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.
    Varex Imaging Corporation was incorporated in Delaware on July 18, 2016 for the purpose of holding the assets and liabilities associated with the Company's business and separated from Varian Medical Systems, Inc. (“Varian”) on January 28, 2017, upon which Varian completed the distribution of 100% of the outstanding common stock of Varex to Varian stockholders. Following the separation and distribution, Varex became an independent publicly-traded company and is listed on the NASDAQ Global Select Market under the ticker “VREX.”
    Basis of Presentation and Principle of Consolidation
    The accompanying consolidated financial statements are audited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Prior to January 28 2017, the date of separation and distribution, the financial statements were prepared on a stand-alone basis and were derived from Varian’s consolidated financial statements and records as it operated as part of Varian prior to the distribution, in conformity with GAAP. Prior to the separation and distribution, the consolidated financial statements included allocations of certain Varian corporate expenses these costs were allocated to the Company on the basis of direct usage when identifiable or other systematic measures that reflect utilization of services provided to or benefits received by the Company.
    All transactions between the Company and Varian prior to the separation have been included in the accompanying consolidated financial statements. All intercompany transactions while the Company operated as part of Varian were considered to be effectively settled for cash and are reflected as a component of financing activities as net transfers from (to) Varian in the consolidated statements of cash flows at the time the transactions were recorded.
    Prior to the separation, the Company was dependent upon Varian for its working capital and financing requirements, as Varian uses a centralized approach to cash management and financing of its operations. Financial transactions relating to the Company were accounted for through the net parent investment account. Cash and cash equivalents held by Varian were not allocated to the Company.
    Net parent investment in the consolidated statements of equity represents Varian’s historical investment in the Company, the net effect of transactions with and allocations from Varian and the Company’s accumulated earnings.
    Reclassification
    The Company has reclassified $3.0 million from selling, general and administrative expense to impairment of intangible assets for the year ended September 28, 2018, to conform to the current year's presentation. Such reclassifications had no impact on net earnings as previously reported.
    Segment Reporting
    The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its CEO, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. See Note 15. Segment Information, included in this report, for further information on the Company’s segments.
    Fiscal Year
    The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2019 was the 52-week period that ended on September 27, 2019. Fiscal year 2018 was the 52-week period that ended on September 28, 2018. Fiscal year 2017 was the 52-week period that ended on September 29, 2017.
    Variable Interest Entities
    For entities in which the Company has variable interests, the Company focuses on identifying which entity has the power to direct the activities that most significantly impact the variable interest entity’s economic performance and which enterprise has the obligation to absorb losses or the right to receive benefits from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities and results of operations of the variable interest entity will be included in the Company’s consolidated financial statements. As of September 27, 2019, the Company had two variable interest entities neither of which were consolidated.
     Use of Estimates
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.
    Cash and Cash Equivalents
    The Company considers currency on hand, demand deposits, time deposits and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.
    Restricted Cash
    Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is
    included in other assets on the consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within
    the consolidated statements of cash flows consisted of the following:
     
    Twelve Months Ended September 27, 2019
     
    Twelve Months Ended September 28, 2018
     
    Beginning of Period
     
    End of Period
     
    Beginning of Period
     
    End of Period
    Cash and cash equivalents
    $
    51.9

     
    $
    29.9

     
    $
    83.3

     
    $
    51.9

    Restricted cash
    1.5

     
    1.4

     
    0.9

     
    1.5

    Cash and cash equivalents and restricted cash as reported per statement of cash flows
    $
    53.4

     
    $
    31.3

     
    $
    84.2

     
    $
    53.4


    Fair Value
    Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. There is a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
    Level 1—Quoted prices in active markets for identical assets or liabilities.
    Level 2—Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or, other inputs that are observable or can be corroborated by observable market data.
    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
    Derivative instruments and hedging activities
    The Company records all derivatives on the balance sheet at fair value. Derivatives designated as a hedge are recorded on the Consolidated Balance Sheets at fair value as of the reporting date. For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss and reclassified from accumulated other comprehensive loss into earnings when the hedged transaction affects earnings.  For derivatives that are designated and qualify as net investment hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss. Time value is excluded and the cash payments are recognized as an adjustment to interest expense. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.
    Concentration of Risk
    Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.
    Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, which is as follows:
     
    Fiscal Year
     
    2019
     
    2018
     
    2017
    Canon Medical Systems Corporation
    17.3
    %
     
    18.1
    %
     
    19.3
    %

    Canon Medical Systems Corporation accounted for 10.1% and 9.8% of the Company’s accounts receivable as of September 27, 2019 and September 28, 2018, respectively.
    Inventories
    Inventories are valued at the lower of cost or net realizable value. Costs include materials, labor and manufacturing overhead
    and is computed using standard cost (which approximates actual cost) on a first-in-first-out basis. The Company evaluates the carrying
    value of its inventories taking into consideration such factors as historical and anticipated future sales compared to quantities on hand
    and the prices the Company expects to obtain for products in its various markets. The Company adjust excess and obsolete
    inventories to net realizable value and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues.
    The following table summarizes the Company’s inventories, net:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Raw materials and parts
    $
    160.1

     
    $
    149.9

    Work-in-process
    27.9

     
    25.4

    Finished goods
    60.2

     
    59.8

    Total inventories
    $
    248.2

     
    $
    235.1


    Property, Plant and Equipment, net
    Property, plant and equipment are stated at cost, net of accumulated depreciation. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation are computed using the straight-line method over the estimated useful lives of the assets. Land is not subject to depreciation, but land improvements are depreciated over fifteen years. Land leasehold rights and leasehold improvements are depreciated over the lesser of their estimated useful lives or remaining lease terms. Buildings are depreciated over twenty years. Machinery and equipment are depreciated over their estimated useful lives, which range from three years to seven years. Assets subject to lease are depreciated over the lesser of their estimated useful lives or remaining lease terms. Estimated useful lives are periodically reviewed and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted, and an impairment assessment may be performed on the recoverability of the carrying amounts. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts.
    The following table summarizes the Company’s property, plant and equipment, net:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Land
    $
    8.3

     
    $
    8.3

    Buildings and leasehold improvements
    134.4

     
    138.1

    Machinery
    170.7

     
    166.1

    Construction in progress
    28.5

     
    23.1

     
    $
    341.9

     
    $
    335.6

    Accumulated depreciation and amortization
    (199.6
    )
     
    (190.7
    )
    Property, plant, and equipment, net
    $
    142.3

     
    $
    144.9


    The Company recorded depreciation expense of $23.5 million, $26.0 million and $16.9 million, in fiscal years 2019, 2018 and 2017, respectively. During fiscal year 2019 the company recorded accelerated depreciation of $4.5 million on the machinery and equipment used in the fabrication of amorphous silicon glass at its facility in Santa Clara, CA. See Note 4. Restructuring, included in this report, for further information. During fiscal year 2018 the company recorded accelerated depreciation of $4.2 million on the machinery and equipment used in the fabrication of amorphous silicon glass at its facility in Santa Clara, CA. See Note 4. Restructuring, included in this report, for further information.
    Investments
    The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in these investments. Distributions received from an equity method investment are classified using the cumulative earnings approach. Under the cumulative earnings approach, distributions up to the amount of cumulative equity in earnings recognized will be treated as returns on investment as operating cash flows and those in excess of that amount will be treated as returns of investment as investing cash flows. The Company monitors these equity investments for impairment and makes appropriate reductions in carrying values if the Company determines that impairment charges are required based primarily on the financial condition and near-term prospects of these companies.
    Goodwill and Intangible Assets
    Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. Purchased intangible assets are carried at cost, net of accumulated amortization, and are included in intangible assets in the Company's consolidated balance sheets. Intangible assets with finite lives are amortized over their estimated useful lives of primarily two years to seven years using the straight-line method.
    Impairment of Long-lived Assets, Intangible Assets and Goodwill
    The Company reviews long-lived assets and identifiable intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. The Company assesses these assets for impairment based on their estimated undiscounted future cash flows. If the carrying value of the assets exceeds the estimated future undiscounted cash flows, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets.
    The Company evaluates goodwill and indefinite lived intangible assets for impairment at least annually at the beginning of the fourth quarter of each fiscal year or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company performs a step one analysis, which consists of a comparison of the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit. The Company determines the fair value of its reporting units based on a combination of income and market approaches. The income approach is based on the present value of estimated future cash flows of the reporting units, and the market approach is based on a market multiple calculated for each reporting unit based on market data of other companies engaged in similar business. If the carrying amount of the reporting unit is in excess of its fair value, step two requires the comparison of the implied fair value of the reporting unit’s goodwill against the carrying amount of the reporting unit’s goodwill. Any excess of the carrying value of the reporting unit’s goodwill over the implied fair value of the reporting unit’s goodwill is recorded as an impairment loss. The impairment test for intangible assets with indefinite useful lives, if any, consists of a comparison of fair value to carrying value, with any excess of carrying value over fair value being recorded as an impairment loss.
    During the fiscal year ended September 27, 2019 and 2018, the Company recognized $4.8 million and $3.0 million of impairments of intangible assets related to the restructuring activities see Note 4. Restructuring, included in this report. No goodwill impairment charges were recognized for any of the prior periods presented. No impairment charges were recognized in fiscal year 2017.
    Loss Contingencies
    From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits and other loss contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent an unfavorable outcome is determined to be probable and the losses can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss.
    Product Warranty
    The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
    The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
    The following table reflects the changes in the Company’s accrued product warranty:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
    Accrued product warranty, at beginning of period
    $
    7.3

     
    $
    7.0

    Charged to cost of revenues
    12.9

     
    11.6

    Actual product warranty expenditures
    (12.1
    )
     
    (11.3
    )
    Accrued product warranty, at end of period
    $
    8.1

     
    $
    7.3


    Revenue Recognition
    Effective September 29, 2018, the Company adopted the requirements of Accounting Standards Update (“ASU”) 2014-09 and related amendments, Revenue from Contracts with Customers (“ASC 606”), which superseded all prior revenue recognition methods and industry-specific guidance. See “Recently Adopted Accounting Pronouncements” below.
    The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts.
    The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the
    Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products.
    The Company determines revenue recognition through the following steps:
    •
    Identification of the contract, or contracts, with a customer
    •
    Identification of the performance obligations in the contract
    •
    Determination of the transaction price
    •
    Allocation of the transaction price to the performance obligations in the contract
    •
    Recognition of revenue when, or as, a performance obligation is satisfied
    Deferred Revenues
    Deferred revenue primarily represents (i) the amount received applicable to non-software products for which parts
    and services under the warranty contracts have not been delivered, and (ii) the amount received for service contracts for
    which the services have not been rendered.
    Allowance for Doubtful Accounts
    The Company evaluates the creditworthiness of customers prior to authorizing shipment for all major sale transactions. On a quarterly basis, the Company evaluates aged items in the accounts receivable aging report and provide an allowance in an amount deemed adequate for doubtful accounts. If the evaluation of customers’ financial conditions does not reflect a future ability to collect outstanding receivables, additional provisions may be needed. We had an allowance for doubtful accounts of $1.0 million and $0.6 million as of September 27, 2019 and September 28, 2018, respectively.
    Share-Based Compensation Expense
    The Company has an equity-based incentive plan that provides for the grant of nonqualified stock options and restricted stock units to directors, officers and other employees. The Company also permits employees to purchase shares under the Varex employee stock purchase plan. Prior to the separation, the Company’s employees historically participated in Varian’s equity-based incentive plans. Share-based compensation expense through the date of separation included allocations to the Company based on the awards and terms previously granted to its employees as well as an allocation of Varian’s corporate and shared functional employee expenses.
    The Company values stock options granted and the option component of the shares of common stock purchased under the equity-based incentive plans and stock purchased under the employee stock purchase plan using the Black-Scholes option-pricing model. Share-based compensation expense for restricted stock units is measured using the fair value of the Company’s stock on the date of grant and is amortized over the award’s respective service period. The Black-Scholes option-pricing model requires the input of certain assumptions, and changes in the assumptions can materially affect the fair value estimates of share-based payment awards.
    The Company measures and recognizes expense for all share-based payment awards based on their fair values. Share-based compensation expense recognized in the consolidated statements of earnings includes compensation expense for the share-based payment awards based on the grant date fair value estimated in accordance with the guidance on share-based compensation. Share-based compensation expense recognized is based on the value of the portion of share-based payment awards that is ultimately expected to vest. The Company attributes the value of share-based compensation to expense using the straight-line method. The Company considers only the direct tax impacts of share-based compensation awards when calculating the amount of tax windfalls or shortfalls. For additional information, see Note 13. Employee Stock Plans, included in this report.
    Shipping and Handling Costs
    Shipping and handling costs are included as a component of cost of revenues.
    Research and Development
    Research and development costs have been expensed as incurred. These costs primarily include employees’ compensation, consulting fees and material costs.
    Software Development Costs
    Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized, as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility.
    Taxes on Earnings
    Current income tax expense is the amount of income taxes expected to be payable for the current year. Deferred income tax liabilities or assets are established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. In addition, we provide reserves for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance for accounting for income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense.
    On December 22, 2017, the U.S. Government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (“U. S. Tax Reform”). U.S. Tax Reform significantly revised the U.S. corporate income tax structure including a lower corporate statutory rate and changes to the way foreign earnings are taxed. U.S. GAAP requires that the impact of tax legislation be recognized in the period in which the law is enacted. In accordance with these rules, we are including the impact of certain provisions of U.S. Tax Reform to the extent they are effective during the current reporting period.
    Foreign Currency Translation
    The Company uses the U.S. Dollar predominately as the functional currency of its foreign operations. Gains and losses from remeasurement of foreign currency balances into U.S. Dollars are included in the consolidated statements of earnings. For the foreign subsidiary where the local currency is the functional currency, translation adjustments of foreign currency financial statements into U.S. dollars are recorded to a separate component of accumulated other comprehensive (loss) earnings.
    Accounting Standards Recently Adopted
    In November 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which requires that the statement of cash flows explain the change in the total amount of restricted cash during the period and other additional disclosures. The Company adopted ASU 2016-18 in the first quarter of 2019 using the retrospective transition method and the Company's consolidated statements of cash flows have been retrospectively adjusted to reflect restricted cash balances. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-18.
    The Company adopted ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which was issued to reduce the diversity in practice in how certain transactions are classified in the statement of cash flows. The Company adopted ASU 2016-15 in the first quarter of 2019 retrospectively. Net cash flows for fiscal years 2019, 2018 and 2017 did not change as a result of adopting ASU 2016-15.

    The Company adopted ASC 606 as of September 29, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. The Company recorded a net reduction to retained earnings of $4.1 million, net of tax, as of September 29, 2018 due to the impact of adopting ASC 606. During the second quarter of 2019 the Company recorded an increase to retained earnings of $0.6 million, net of tax, to correct an error that was not quantitatively or qualitatively material to the current period, related to the adoption of ASC 606. The net cumulative impact of adopting ASC 606 was $3.5 million, net of tax. Refer to Note 18. Revenue Recognition, included in this report report for the detailed impact of adopting ASC 606.

    In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which amends the application of hedge accounting and improves financial reporting of hedging relationships to more accurately present the economic effects of risk management activities in the financial statements. The ASU is effective for public companies for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company early adopted the provisions of ASU 2017-12 during the quarter ended September 27, 2019, using the modified retrospective method. The adoption did not have an impact on the consolidated financial statements.
    Recent Accounting Standards Updates Not Yet Effective
    In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from U.S. federal tax legislation commonly referred to as the Tax Cuts and Jobs Act, which was enacted in December 2017 (the “2017 Tax Act”). ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.
    In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements.
    In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021, and must be applied on a modified retrospective basis. The Company is currently evaluating the potential impact of this standard.
    In February 2016, the FASB issued ASU 2016-02 on accounting for leases. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new standard will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of earnings. The new standard is required to be adopted using a modified retrospective method to each prior reporting period presented with various optional practical expedients. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2020 with early adoption permitted. The Company has not completed its assessment of the new standard, but anticipate that the most substantial change to its consolidated financial statements will be a gross-up of its total assets and liabilities. The adoption is not expected to materially impact our results of operations in the upcoming fiscal years and interim periods. The Company will continue to monitor the overall impact of adoption and update our disclosures as appropriate.
    XML 122 R103.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    REVENUE RECOGNITION - Remaining Performance Obligations (Details)
    $ in Millions
    Sep. 27, 2019
    USD ($)
    Revenue from Contract with Customer [Abstract]  
    Revenue, remaining performance obligation, amount $ 265.2
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-09-28  
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
    Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months
    XML 123 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reclassification (Details) - USD ($)
    		 12 Months Ended
    Sep. 27, 2019
    Sep. 28, 2018
    Sep. 29, 2017
    Error Corrections and Prior Period Adjustments Restatement [Line Items]      
    Reclassification of selling, general and administrative $ (128,100,000) $ (123,400,000) $ (102,500,000)
    Impairment of intangible assets $ 4,800,000 3,000,000.0 $ 0
    Restatement Adjustment      
    Error Corrections and Prior Period Adjustments Restatement [Line Items]      
    Reclassification of selling, general and administrative   3,000,000.0  
    Impairment of intangible assets   $ 3,000,000  
    XML 124 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    SEGMENT INFORMATION (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Segment Reporting [Abstract]  
    Schedule of Segment Reporting Information, by Segment
    The following amounts represent revenues by reporting segment from Direct Conversion from the acquisition date of April 29, 2019, through September 27, 2019:
    (In millions)
    Direct Conversion Revenue
    Medical
    $
    4.5

    Industrial
    1.8

    Total Direct Conversion revenues
    $
    6.3


    The following amounts represent revenues by reporting segment from the Acquired Detector Business from the acquisition date of May 1, 2017 through September 29, 2017:
    (In millions)
    May 1, 2017 through September 29, 2017
    Acquired Detector Business
     
    Medical
    $
    41.1

    Industrial
    20.2

    Total Acquired Detector Business revenues
    $
    61.3


    Information related to the Company’s segments is as follows:
     
    Fiscal Year
    (In millions)
    2019
     
    2018
     
    2017
    Revenues
     
     
     
     
     
    Medical
    $
    596.8

     
    $
    602.0

     
    $
    556.9

    Industrial
    183.8

     
    171.4

     
    141.2

    Total revenues
    780.6

     
    773.4

     
    698.1

    Gross margin
     
     
     
     
     
    Medical
    188.9

     
    190.5

     
    193.6

    Industrial
    67.8

     
    63.4

     
    59.9

    Total gross margin
    256.7

     
    253.9

     
    253.5

    Total operating expenses
    211.0

     
    209.4

     
    169.8

    Interest and other expenses, net
    (24.2
    )
     
    (18.8
    )
     
    (8.9
    )
    Earnings before taxes
    21.5

     
    25.7

     
    74.8

    Taxes (benefit) on earnings
    5.7

     
    (2.6
    )
     
    22.8

    Net earnings
    15.8

     
    28.3

     
    52.0

    Less: Net earnings attributable to noncontrolling interests
    0.3

     
    0.8

     
    0.4

    Net earnings attributable to Varex
    $
    15.5

     
    $
    27.5

     
    $
    51.6
    Reconciliation of Assets from Segment to Consolidated
    The following table summarizes the Company’s total assets by its reportable segments:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Identifiable assets:
     
     
     
    Medical
    $
    794.3

     
    $
    770.6

    Industrial
    244.6

     
    217.3

    Total reportable segments
    $
    1,038.9

     
    $
    987.9
    Revenue from External Customers by Geographic Areas
    Geographic Information
     
    Revenues
     
    Property, plant and equipment, net
     
    Fiscal Years
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
     
    2019
     
    2018
    United States
    $
    275.3

     
    $
    268.8

     
    $
    231.9

     
    $
    122.6

     
    $
    127.9

    Latin America
    7.3

     
    7.0

     
    7.9

     
    —

     
    —

    EMEA
    269.0

     
    254.5

     
    219.5

     
    11.4

     
    8.7

    APAC
    229.0

     
    243.1

     
    238.8

     
    8.3

     
    8.3

    Total company
    $
    780.6

     
    $
    773.4

     
    $
    698.1

     
    $
    142.3

     
    $
    144.9
    XML 125 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    CONSOLIDATED BALANCE SHEETS - USD ($)
    $ in Millions
    Sep. 27, 2019
    Sep. 28, 2018
    Current assets:    
    Cash and cash equivalents $ 29.9 $ 51.9
    Accounts receivable, net of allowance for doubtful accounts of $1.0 and $0.6 at September 27, 2019 and September 28, 2018, respectively 141.0 154.0
    Inventories 248.2 235.1
    Prepaid expenses and other current assets 19.3 17.1
    Total current assets 438.4 458.1
    Property, plant and equipment, net 142.3 144.9
    Goodwill 290.8 243.6
    Intangibles assets, net 86.3 73.8
    Investments in privately-held companies 53.6 51.0
    Other assets 27.5 16.5
    Total assets 1,038.9 987.9
    Current liabilities:    
    Accounts payable 58.2 66.3
    Accrued liabilities 75.7 47.5
    Current maturities of long-term debt 30.7 25.0
    Deferred revenues 10.5 13.2
    Total current liabilities 175.1 152.0
    Long-term debt, net 364.4 364.8
    Deferred tax liabilities 8.2 23.2
    Other long-term liabilities 32.5 8.5
    Total liabilities 580.2 548.5
    Commitments and contingencies (Note 11)
    Redeemable noncontrolling interests 10.5 11.1
    Equity:    
    Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued 0.0 0.0
    Common stock, $.01 par value: 150,000,000 shares authorized, shares issued and outstanding: 38,371,305 and 38,026,597 at September 27, 2019 and September 28, 2018, respectively 0.4 0.4
    Additional paid-in capital 371.8 357.6
    Accumulated other comprehensive (loss) income (1.7) 5.8
    Retained earnings 74.4 62.4
    Total Varex stockholders' equity 444.9 426.2
    Noncontrolling interests 3.3 2.1
    Total stockholders' equity 448.2 428.3
    Total liabilities, redeemable noncontrolling interests and stockholders' equity $ 1,038.9 $ 987.9
    XML 126 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    TAXES ON EARNINGS
    		 12 Months Ended
    Sep. 27, 2019
    Income Tax Disclosure [Abstract]  
    TAXES ON EARNINGS TAXES ON EARNINGS
    Income tax expense is based on reported income or loss before income taxes. Deferred income taxes reflect the effect of temporary differences between asset and liability amounts that are recognized for financial reporting purposes and the amounts that are recognized for income tax purposes. These deferred taxes are measured by applying currently enacted tax laws. Valuation allowances are recognized to reduce deferred tax assets to the amount that is more likely than not to be realized.
    Taxes on earnings were as follows:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
    Current provision:
     
     
     
     
     
    Federal
    $
    9.2

     
    $
    (2.1
    )
     
    $
    24.8

    State and local
    1.3

     
    (0.3
    )
     
    1.6

    Foreign
    6.8

     
    7.5

     
    5.3

    Total current
    17.3

     
    5.1

     
    31.7

    Deferred provision (benefit):
     
     
     
     
     
    Federal
    (10.0
    )
     
    (7.0
    )
     
    (7.0
    )
    State and local
    (1.6
    )
     
    0.7

     
    (1.0
    )
    Foreign
    —

     
    (1.4
    )
     
    (0.9
    )
    Total deferred
    (11.6
    )
     
    (7.7
    )
     
    (8.9
    )
    Taxes on earnings
    $
    5.7

     
    $
    (2.6
    )
     
    $
    22.8


    Earnings before taxes are generated from the following geographic areas:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
    United States
    $
    5.9

     
    $
    3.7

     
    $
    55.5

    Foreign
    15.6

     
    22.0

     
    19.3

    Earnings before taxes
    $
    21.5

     
    $
    25.7

     
    $
    74.8


    The effective tax rate differs from the U.S. federal statutory tax rate as a result of the following:
     
    Fiscal Years
     
    2019
     
    2018
     
    2017
    Federal statutory income tax rate
    21.0
     %
     
    24.5
     %
     
    35.0
     %
    State and local taxes, net of federal tax benefit
    (0.9
    )%
     
    1.1
     %
     
    1.3
     %
    Revaluation of deferred tax liabilities for US statutory change
    —
     %
     
    (41.8
    )%
     
    —
     %
    Mandatory repatriation tax on foreign earnings
    1.9
     %
     
    13.0
     %
     
    —
     %
    Domestic production activities deduction
    —
     %
     
    (0.8
    )%
     
    (2.4
    )%
    Research and development credit
    (10.2
    )%
     
    (11.1
    )%
     
    (2.6
    )%
    Prior year deferred tax adjustments
    4.7
     %
     
    1.9
     %
     
    (4.0
    )%
    Foreign Rate Difference
    6
     %
     
    0.8
     %
     
    —
     %
    Change in valuation allowance
    11.2
     %
     
    (1.9
    )%
     
    3.8
     %
    US Tax Reform - International Provisions
    (4.7
    )%
     
    —
     %
     
    —
     %
    Other
    (2.5
    )%
     
    4.2
     %
     
    (0.6
    )%
    Effective tax rate
    26.5
     %
     
    (10.1
    )%
     
    30.5
     %

    On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (U.S. Tax Reform) was enacted in the U.S. which significantly revised the U.S. corporate income tax structure. Among the revisions impacting our effective tax rate are a lower U.S. corporate statutory rate going from 35% to 21% effective January 1, 2018 and changes to the way foreign earnings are taxed. As a September fiscal year filer, the lower corporate income tax rate is phased in from a U.S. statutory federal rate of 24.5% in fiscal year ending September 28, 2018 to a rate of 21% for the fiscal year ending September 27, 2019.
    During fiscal year 2019, the Company’s effective tax rate varied from the U.S. federal statutory rate of 21% primarily because of the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform, and U.S. research and development tax credits. These favorable U.S. tax items are offset by losses in certain foreign jurisdictions for which no benefit is recognized and earnings in other foreign jurisdictions that are taxed at higher rates.
    During fiscal year 2018, the Company’s effective tax rate varied from the U.S. federal statutory rate primarily because the favorable impact of changes to the U.S. corporate tax structure resulting from U.S. Tax Reform. During fiscal years 2018 and 2017, the effective tax rate also differs from the U.S. federal statutory rate due to increases resulting from U.S. state income tax expense, losses in certain foreign jurisdictions for which no benefit is recognized, earnings in other foreign jurisdictions that are taxed at higher rates, and limitations on the deductibility of officers' compensation. These are offset by decreases due to U.S. research and development credits, tax windfalls for share-based compensation, and the release of a valuation allowance against loss carryforwards in certain foreign jurisdictions.
    The SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) that allows for reasonable estimated amounts to be recorded and a measurement period of up to one year from the date of enactment to revise these provisional amounts as new information is obtained and additional guidance is issued. During the three months ended December 28, 2018, the Company completed its analysis of U.S. Tax Reform, and the accounting for the income tax effects has been finalized for the measurement period under SAB 118, with no significant adjustments from the provisional amounts. During fiscal year 2019, additional U.S. Tax Reform provisions, including GILTI (global intangible low-taxed income), BEAT (base-erosion anti-abuse tax), FDII (foreign-derived intangible income), limitations on interest expense deductions (if certain conditions apply), and other components became effective for the Company and, if applicable, have been included in the calculation of the fiscal year 2019 tax provision. The determination of the tax effects of U.S. Tax Reform may change following future legislation or further interpretation of U.S. Tax Reform from U.S. Federal and state tax authorities.
    The guidance for accounting for U.S. Tax Reform requires taxpayers to make an election regarding the accounting for GILTI. This policy election is to either: (1) treat GILTI as a period cost if and when incurred, or (2) recognize deferred taxes for basis differences that are expected to reverse as GILTI in future years. During the first quarter of fiscal year 2019, the Company has made the accounting policy election to account for GILTI under the period cost method.
    Significant components of deferred tax assets and liabilities are as follows:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Deferred Tax Assets:
     
     
     
    Inventory adjustments
    $
    5.6

     
    $
    4.2

    Share-based compensation
    3.1

     
    0.8

    Product warranty
    1.6

     
    1.4

    Deferred compensation
    1.1

     
    0.9

    Net operating loss carryforwards
    24.3

     
    3.3

    Accrued vacation
    1.0

     
    1.3

    Credit carryforwards
    1.9

     
    1.8

    Other
    7.5

     
    4.7

     
    46.1

     
    18.4

    Valuation allowance
    (18.8
    )
     
    (4.0
    )
    Total deferred tax assets
    27.3

     
    14.4

    Deferred Tax Liabilities:
     
     
     
    Acquired intangibles
    (19.3
    )
     
    (15.2
    )
    Property, plant and equipment
    (10.6
    )
     
    (14.3
    )
    Investments in privately held companies
    (3.3
    )
     
    (4.1
    )
    Other
    (2.3
    )
     
    (4.0
    )
    Total deferred tax liabilities
    (35.5
    )
     
    (37.6
    )
    Net deferred tax liabilities
    $
    (8.2
    )
     
    $
    (23.2
    )
    Reported As:
     
     
     
    Deferred tax assets
    $
    27.3

     
    $
    14.4

    Deferred tax liabilities
    (35.5
    )
     
    (37.6
    )
    Net deferred tax liabilities
    $
    (8.2
    )
     
    $
    (23.2
    )

    As a result of the changes to the U.S. taxation of foreign earnings included in U.S. Tax Reform, the Company reevaluated its previous indefinite reinvestment assertion with respect to these earnings during fiscal year 2018, which resulted in the Company revoking its assertion for current and future earnings for all countries, while maintaining the assertion that historic earnings are
    indefinitely reinvested outside the U.S. The Company has modified this prior assertion for the year ended September 27, 2019 with respect to the acquisition of Direct Conversion. The modification was to assert that all earnings for Direct Conversion, located primarily in Sweden and Finland, are indefinitely reinvested in those countries. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable U.S. tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for U.S. State income taxes and foreign withholding taxes that would apply if the foreign earnings were actually repatriated in the form of a dividend.
    As of September 27, 2019, the Company has net operating loss carryforwards of approximately $24.3 million with $4.4 million expiring between 2020 and 2030 and $19.9 million carried forward indefinitely.
    The valuation allowance relates primarily to net operating losses in certain foreign jurisdictions where, based on the weight of available evidence, it is more likely than not that the tax benefit of the net operating losses will not be realized. The valuation allowance increased by $14.8 million during fiscal year 2019 and decreased by $0.3 million during fiscal year 2018. The increase during the current year was primarily related to the acquisition of Direct Conversion that included deferred tax assets subject to a valuation allowance as of acquisition. Changes in the Company's valuation allowance for deferred tax assets were as follows:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
    Valuation allowance balance–beginning of fiscal year
    $
    4.0

     
    $
    4.3

     
    $
    2.5

    Increases resulting from business combinations
    12.0

     
    —

     
    —

    Other increases
    2.8

     
    2.2

     
    2.5

    Other decreases
    —

     
    (2.5
    )
     
    (0.7
    )
    Valuation allowance balance—end of fiscal year
    $
    18.8

     
    $
    4.0

     
    $
    4.3


    During fiscal year 2019, the Company paid U.S and foreign taxes of approximately $8.2 million. In fiscal year 2018, the Company paid U.S. and foreign taxes of approximately $13.8 million.
    The Company accounts for uncertainty in income taxes following a two-step approach for recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether the weight of available evidence indicates that it is more likely than not that, based on the technical merits, the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.
    Changes in the Company’s unrecognized tax benefits were as follows:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
    Unrecognized tax benefits balance–beginning of fiscal year
    $
    0.6

     
    $
    0.5

    Subtractions based on tax positions related to a prior year
    (0.2
    )
     
    —

    Additions based on tax positions related to the current year
    0.2

     
    0.1

    Unrecognized tax benefits balance—end of fiscal year
    $
    0.6

     
    $
    0.6


    As of September 27, 2019 and September 28, 2018, the total amount of gross unrecognized tax benefits was $0.6 million and $0.6 million, respectively, all of which would affect the effective tax rate if recognized.
    The Company includes interest and penalties related to income taxes within taxes on earnings on the Combined Statements of Earnings. For the year ended September 27, 2019, $0.1 million interest and penalties have been included for this period. For the year ended September 28, 2018 any interest or penalties related to unrecognized tax benefits are minimal and have been included in the balance for that period.
    The Company files U.S. Federal and state income tax returns and non-U.S. income tax returns in various jurisdictions. All of these returns are subject to examination by their respective taxing jurisdictions from the date of filing through each applicable statute of limitation period. The Company’s significant operations up to the date of separation have historically been included in Varian’s U.S. federal and state income tax returns and non-U.S. jurisdiction tax returns. Material liabilities arising related to the pre-spin operations
    would be the responsibility of Varian. Other periods for entities acquired are still open and subject to examination. Generally, periods prior to 2009 are no longer subject to examination.
    XML 127 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    REVENUE RECOGNITION
    		 12 Months Ended
    Sep. 27, 2019
    Revenue from Contract with Customer [Abstract]  
    REVENUE RECOGNITION REVENUE RECOGNITION
    The Company adopted ASC 606 on September 29, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for fiscal year 2019 reflect the application of ASC 606 guidance while the reported results for fiscal year 2018 were prepared under the guidance of ASC 605, “Revenue Recognition.” The primary impacts of the adoption include: (1) recording a separate contract liability and contract asset related to the sale of X-ray tubes that were sold with an option for the customer to require the Company to repurchase specific parts of the X‑ray tube at a specific price; and (2) recording a liability related to the deferral of revenue for service type warranties that are provided to certain customers who purchase Linatron® X-ray accelerators.
    The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component, if, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are included as a component of cost of revenues; and (5) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.
    Transaction price and allocation to performance obligations
    Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available.
    The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.
    If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.
    The beginning net cumulative-effect adjustment to the balance sheet for the adoption of ASC 606 is as follows:
     
    Balance at
     
    Adjustment Due to
     
    Balance at
    (In millions)
    September 28, 2018
     
    ASC 606
     
    September 29, 2018
    Assets:
     
     
     
     
     
    Prepaid expenses and other current assets
    $
    17.1

     
    $
    6.4

     
    $
    23.5

    Other assets
    16.5

     
    18.0

     
    34.5

    Liabilities and Equity:
     
     
     
     
     
    Deferred revenues
    13.2

     
    0.3

     
    13.5

    Accrued liabilities
    47.5

     
    7.1

     
    54.6

    Deferred tax liabilities
    23.2

     
    (0.8
    )
     
    22.4

    Other long-term liabilities
    8.5

     
    21.3

     
    29.8

    Retained earnings
    62.4

     
    (3.5
    )
     
    58.9


    The following tables compare the reported consolidated balance sheet and statement of operations for fiscal year ended September 27, 2019, to the amounts that would have been reported if ASC 605 had been in effect:
     
    September 27, 2019
    (In millions)
    Balance without Adoption
     
    As Reported
    Assets:
     
     
     
    Prepaid expenses and other current assets
    $
    13.1

     
    $
    19.3

    Other assets
    $
    10.0

     
    $
    27.5

    Liabilities and equity:
     
     
     
    Deferred revenues
    $
    9.9

     
    $
    10.5

    Accrued liabilities
    $
    68.8

     
    $
    75.7

    Deferred tax liabilities
    $
    9.1

     
    $
    8.2

    Other long-term liabilities
    $
    12.1

     
    $
    32.5

    Retained earnings
    $
    77.7

     
    $
    74.4


     
    Twelve Months Ended September 27, 2019
    (In millions)
    Balance without Adoption
     
    As Reported
    Revenues
    781.2

     
    780.6

    Cost of revenues
    524.7

     
    523.9

    Taxes on earnings
    5.7

     
    5.7

    Net earnings attributable to Varex
    15.3

     
    15.5


    Contracts and performance obligations
    The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.
    Revenue recognition
    Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.
    Product revenue is recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
    Service revenue is recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.
    Disaggregation of Revenue
    Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15. Segment Information, included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and disaggregated by geographic region.    
    Contract Balances
    Contract assets are included within the prepaid expenses and other current assets, and other assets balances. Contract liabilities, which also includes refund obligations are included within the accrued liabilities, deferred revenues, and other long-term liabilities balances. The following table summarizes the changes in the contract assets and refund liabilities for the twelve months ended September 27, 2019:
    (In millions)
    Contact Assets
    Balance at September 29, 2018
    $
    24.4

    Costs recovered from product returns during the period
    (6.4
    )
    Contract asset from shipments of products, subject to return during the period
    5.7

    Balance at September 27, 2019
    $
    23.7

    (In millions)
    Refund Liabilities
    Balance at September 29, 2018
    $
    27.1

    Recognition of revenue included in beginning of year refund liability
    (7.0
    )
    Additions to refund liabilities
    6.3

    Balance at September 27, 2019
    $
    26.4


    Remaining Performance Obligations
    Remaining performance obligations represent the transaction price of firm orders for which revenue has not yet been recognized. As of September 27, 2019, total remaining performance obligations amounted to $265.2 million. The Company expects to recognize a majority of the remaining performance obligations over the next 12 months.
    Costs to Obtain or Fulfill a Customer Contract
    The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.
    XML 128 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    BUSINESS COMBINATIONS (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Business Combinations [Abstract]  
    Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
    The following table summarizes the purchase price allocation:
    (In millions)
    Fair Value
    Allocation of the purchase consideration:
     
    Accounts Receivable
    $
    0.2

    Inventories
    1.0

    Other assets
    0.2

    Intangibles
    1.6

    Goodwill
    1.5

    Other liabilities
    (0.2
    )
    Net assets acquired
    4.3

    Post-closing adjustments
    0.5

    Total cash consideration
    $
    4.8


    The following table summarizes the preliminary purchase price allocation:
    (In millions)
    Fair Value
    Allocation of the purchase consideration:
     
    Accounts receivable
    $
    2.4

    Inventories
    5.7

    Prepaid expenses and other current assets
    0.7

    Property, plant, and equipment
    0.9

    Goodwill
    47.2

    Intangible assets
    32.9

    Total assets acquired
    89.8

    Accounts payable
    (1.0
    )
    Accrued liabilities
    (1.5
    )
    Current maturities of long-term debt
    (1.0
    )
    Deferred revenues
    (0.9
    )
    Long-term debt
    (3.5
    )
    Other long-term liabilities
    (1.1
    )
    Total liabilities assumed
    (9.0
    )
    Noncontrolling interest
    (1.4
    )
    Net assets acquired, less noncontrolling interest
    $
    79.4

    Net cash paid
    $
    69.5

    Deferred consideration
    9.9

    Total consideration
    $
    79.4


    The following amounts represent the determination of the fair value of identifiable assets acquired and liabilities for the Acquired Detector Business:
    (In millions)
    Fair Value
    Total cash consideration
    $
    273.2

    Allocation of the purchase consideration:
     
    Cash
    1.4

    Accounts Receivable
    18.7

    Inventory
    34.7

    Prepaids and other current assets
    0.6

    Property, plant, and equipment
    21.4

    Other assets, non-current
    2.0

    Intangibles
    81.1

    Goodwill
    167.3

    Total assets acquired
    $
    327.2


     
     
    Current liabilities
    $
    (17.2
    )
    Other liabilities, non-current
    (36.8
    )
    Total liabilities assumed
    (54.0
    )
    Net assets acquired
    $
    273.2
    Schedule of Intangible Assets Acquired
    The following amounts represent the determination of the fair value of identifiable intangible assets for the Acquired Detector Business, which are amortized straight-line:
    (In millions)
    Fair Value
     
    Estimated
    Useful Life
    (In Years)
    Favorable leasehold interests
    $
    3.8

     
    16
    Backlog
    1.2

     
    1
    Trade names
    1.4

     
    5
    Developed technology
    37.7

     
    7
    In-process research and development
    4.0

     
    indefinite
    Customer relationships
    33.0

     
    7
    Total intangible assets acquired
    $
    81.1

     
     

    The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:
    (In millions)
    Fair Value
     
    Estimated Weighted Average
    Useful Life
    (In Years)
    Backlog
    $
    0.2

     
    1
    Trade names
    2.5

     
    5
    Developed technology
    18.4

     
    10
    In-process research and development
    2.8

     
    indefinite
    Customer relationships
    9.0

     
    10
    Total intangible assets acquired
    $
    32.9

     
     
    Schedule of Segment Reporting Information, by Segment
    The following amounts represent revenues by reporting segment from Direct Conversion from the acquisition date of April 29, 2019, through September 27, 2019:
    (In millions)
    Direct Conversion Revenue
    Medical
    $
    4.5

    Industrial
    1.8

    Total Direct Conversion revenues
    $
    6.3


    The following amounts represent revenues by reporting segment from the Acquired Detector Business from the acquisition date of May 1, 2017 through September 29, 2017:
    (In millions)
    May 1, 2017 through September 29, 2017
    Acquired Detector Business
     
    Medical
    $
    41.1

    Industrial
    20.2

    Total Acquired Detector Business revenues
    $
    61.3


    Information related to the Company’s segments is as follows:
     
    Fiscal Year
    (In millions)
    2019
     
    2018
     
    2017
    Revenues
     
     
     
     
     
    Medical
    $
    596.8

     
    $
    602.0

     
    $
    556.9

    Industrial
    183.8

     
    171.4

     
    141.2

    Total revenues
    780.6

     
    773.4

     
    698.1

    Gross margin
     
     
     
     
     
    Medical
    188.9

     
    190.5

     
    193.6

    Industrial
    67.8

     
    63.4

     
    59.9

    Total gross margin
    256.7

     
    253.9

     
    253.5

    Total operating expenses
    211.0

     
    209.4

     
    169.8

    Interest and other expenses, net
    (24.2
    )
     
    (18.8
    )
     
    (8.9
    )
    Earnings before taxes
    21.5

     
    25.7

     
    74.8

    Taxes (benefit) on earnings
    5.7

     
    (2.6
    )
     
    22.8

    Net earnings
    15.8

     
    28.3

     
    52.0

    Less: Net earnings attributable to noncontrolling interests
    0.3

     
    0.8

     
    0.4

    Net earnings attributable to Varex
    $
    15.5

     
    $
    27.5

     
    $
    51.6
    Business Acquisition, Pro Forma Information The unaudited pro-forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the Acquired Detector Business and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations or results that might have been achieved had the acquisition been consummated as of October 3, 2015.
     
    Fiscal Year
    (In millions)
    2017
    Revenue
    $
    777.8

    Operating earnings
    $
    84.7

    Net earnings
    $
    43.1

    Net earnings per share, basic
    $
    1.15

    Net earnings per share, diluted
    $
    1.13
    XML 129 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }

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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    TAXES ON EARNINGS (Tables)
    		 12 Months Ended
    Sep. 27, 2019
    Income Tax Disclosure [Abstract]  
    Summary of Valuation Allowance [Table Text Block] Changes in the Company's valuation allowance for deferred tax assets were as follows:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
    Valuation allowance balance–beginning of fiscal year
    $
    4.0

     
    $
    4.3

     
    $
    2.5

    Increases resulting from business combinations
    12.0

     
    —

     
    —

    Other increases
    2.8

     
    2.2

     
    2.5

    Other decreases
    —

     
    (2.5
    )
     
    (0.7
    )
    Valuation allowance balance—end of fiscal year
    $
    18.8

     
    $
    4.0

     
    $
    4.3
    Schedule of Components of Income Tax Expense (Benefit)
    Taxes on earnings were as follows:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
    Current provision:
     
     
     
     
     
    Federal
    $
    9.2

     
    $
    (2.1
    )
     
    $
    24.8

    State and local
    1.3

     
    (0.3
    )
     
    1.6

    Foreign
    6.8

     
    7.5

     
    5.3

    Total current
    17.3

     
    5.1

     
    31.7

    Deferred provision (benefit):
     
     
     
     
     
    Federal
    (10.0
    )
     
    (7.0
    )
     
    (7.0
    )
    State and local
    (1.6
    )
     
    0.7

     
    (1.0
    )
    Foreign
    —

     
    (1.4
    )
     
    (0.9
    )
    Total deferred
    (11.6
    )
     
    (7.7
    )
     
    (8.9
    )
    Taxes on earnings
    $
    5.7

     
    $
    (2.6
    )
     
    $
    22.8
    Schedule of Income before Income Tax, Domestic and Foreign
    Earnings before taxes are generated from the following geographic areas:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
     
    2017
    United States
    $
    5.9

     
    $
    3.7

     
    $
    55.5

    Foreign
    15.6

     
    22.0

     
    19.3

    Earnings before taxes
    $
    21.5

     
    $
    25.7

     
    $
    74.8
    Schedule of Effective Income Tax Rate Reconciliation
    The effective tax rate differs from the U.S. federal statutory tax rate as a result of the following:
     
    Fiscal Years
     
    2019
     
    2018
     
    2017
    Federal statutory income tax rate
    21.0
     %
     
    24.5
     %
     
    35.0
     %
    State and local taxes, net of federal tax benefit
    (0.9
    )%
     
    1.1
     %
     
    1.3
     %
    Revaluation of deferred tax liabilities for US statutory change
    —
     %
     
    (41.8
    )%
     
    —
     %
    Mandatory repatriation tax on foreign earnings
    1.9
     %
     
    13.0
     %
     
    —
     %
    Domestic production activities deduction
    —
     %
     
    (0.8
    )%
     
    (2.4
    )%
    Research and development credit
    (10.2
    )%
     
    (11.1
    )%
     
    (2.6
    )%
    Prior year deferred tax adjustments
    4.7
     %
     
    1.9
     %
     
    (4.0
    )%
    Foreign Rate Difference
    6
     %
     
    0.8
     %
     
    —
     %
    Change in valuation allowance
    11.2
     %
     
    (1.9
    )%
     
    3.8
     %
    US Tax Reform - International Provisions
    (4.7
    )%
     
    —
     %
     
    —
     %
    Other
    (2.5
    )%
     
    4.2
     %
     
    (0.6
    )%
    Effective tax rate
    26.5
     %
     
    (10.1
    )%
     
    30.5
     %
    Schedule of Deferred Tax Assets and Liabilities
    Significant components of deferred tax assets and liabilities are as follows:
    (In millions)
    September 27, 2019
     
    September 28, 2018
    Deferred Tax Assets:
     
     
     
    Inventory adjustments
    $
    5.6

     
    $
    4.2

    Share-based compensation
    3.1

     
    0.8

    Product warranty
    1.6

     
    1.4

    Deferred compensation
    1.1

     
    0.9

    Net operating loss carryforwards
    24.3

     
    3.3

    Accrued vacation
    1.0

     
    1.3

    Credit carryforwards
    1.9

     
    1.8

    Other
    7.5

     
    4.7

     
    46.1

     
    18.4

    Valuation allowance
    (18.8
    )
     
    (4.0
    )
    Total deferred tax assets
    27.3

     
    14.4

    Deferred Tax Liabilities:
     
     
     
    Acquired intangibles
    (19.3
    )
     
    (15.2
    )
    Property, plant and equipment
    (10.6
    )
     
    (14.3
    )
    Investments in privately held companies
    (3.3
    )
     
    (4.1
    )
    Other
    (2.3
    )
     
    (4.0
    )
    Total deferred tax liabilities
    (35.5
    )
     
    (37.6
    )
    Net deferred tax liabilities
    $
    (8.2
    )
     
    $
    (23.2
    )
    Reported As:
     
     
     
    Deferred tax assets
    $
    27.3

     
    $
    14.4

    Deferred tax liabilities
    (35.5
    )
     
    (37.6
    )
    Net deferred tax liabilities
    $
    (8.2
    )
     
    $
    (23.2
    )
    Schedule of Unrecognized Tax Benefits Roll Forward
    Changes in the Company’s unrecognized tax benefits were as follows:
     
    Fiscal Years
    (In millions)
    2019
     
    2018
    Unrecognized tax benefits balance–beginning of fiscal year
    $
    0.6

     
    $
    0.5

    Subtractions based on tax positions related to a prior year
    (0.2
    )
     
    —

    Additions based on tax positions related to the current year
    0.2

     
    0.1

    Unrecognized tax benefits balance—end of fiscal year
    $
    0.6

     
    $
    0.6

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